0000899923-24-00005710-Q MYRIAD GENETICS INC 20241108202411080818170818170818170818170 0 0000899923-24-000057 10-Q 92 20240930 20241108 20241108 MYRIAD GENETICS INC 0000899923 2835 870494517 DE 1231 10-Q 34 000-26642 241438078 322 NORTH 2200 WEST SALT LAKE CITY UT 84116 801-584-3600 322 NORTH 2200 WEST SALT LAKE CITY UT 84116 10-Q 1 mygn-20240930.htm 10-Q mygn-20240930false000089992312/312024Q3http://www.myriad.com/20240930#TestingMemberhttp://www.myriad.com/20240930#TestingMemberhttp://www.myriad.com/20240930#TestingMember01-012024-09-3000008999232024-11-0400008999232024-09-3000008999232023-12-3100008999232023-01-012023-09-3000008999232023-07-012023-09-3000008999232024-07-012024-09-300000899923us-gaap:CommonStockMember2022-12-310000899923us-gaap:AdditionalPaidInCapitalMember2022-12-310000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000899923us-gaap:RetainedEarningsMember2022-12-310000899923us-gaap:AdditionalPaidInCapitalMember2023-01-012023-03-310000899923us-gaap:RetainedEarningsMember2023-01-012023-03-310000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-03-310000899923us-gaap:CommonStockMember2023-03-310000899923us-gaap:AdditionalPaidInCapitalMember2023-03-310000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-310000899923us-gaap:RetainedEarningsMember2023-03-310000899923us-gaap:AdditionalPaidInCapitalMember2023-04-012023-06-3000008999232023-04-012023-06-300000899923us-gaap:RetainedEarningsMember2023-04-012023-06-300000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300000899923us-gaap:CommonStockMember2023-06-300000899923us-gaap:AdditionalPaidInCapitalMember2023-06-300000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300000899923us-gaap:RetainedEarningsMember2023-06-3000008999232023-06-300000899923us-gaap:AdditionalPaidInCapitalMember2023-07-012023-09-300000899923us-gaap:RetainedEarningsMember2023-07-012023-09-300000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-012023-09-300000899923us-gaap:CommonStockMember2023-09-300000899923us-gaap:AdditionalPaidInCapitalMember2023-09-3000008999232023-09-300000899923us-gaap:CommonStockMember2023-12-310000899923us-gaap:AdditionalPaidInCapitalMember2023-12-310000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000899923us-gaap:RetainedEarningsMember2023-12-310000899923us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-3100008999232024-01-012024-03-310000899923us-gaap:RetainedEarningsMember2024-01-012024-03-310000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000899923us-gaap:CommonStockMember2024-03-310000899923us-gaap:AdditionalPaidInCapitalMember2024-03-310000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310000899923us-gaap:RetainedEarningsMember2024-03-3100008999232024-03-310000899923us-gaap:AdditionalPaidInCapitalMember2024-04-012024-06-3000008999232024-04-012024-06-300000899923us-gaap:RetainedEarningsMember2024-04-012024-06-300000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300000899923us-gaap:CommonStockMember2024-06-300000899923us-gaap:AdditionalPaidInCapitalMember2024-06-300000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300000899923us-gaap:RetainedEarningsMember2024-06-3000008999232024-06-300000899923us-gaap:AdditionalPaidInCapitalMember2024-07-012024-09-300000899923us-gaap:RetainedEarningsMember2024-07-012024-09-300000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-07-012024-09-300000899923us-gaap:CommonStockMember2024-09-300000899923us-gaap:AdditionalPaidInCapitalMember2024-09-300000899923us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-09-300000899923us-gaap:RetainedEarningsMember2024-09-300000899923country:USmygn:HereditaryCancerTestingMember2024-07-012024-09-300000899923us-gaap:NonUsMembermygn:HereditaryCancerTestingMember2024-07-012024-09-300000899923country:USmygn:HereditaryCancerTestingMember2023-07-012023-09-300000899923us-gaap:NonUsMembermygn:HereditaryCancerTestingMember2023-07-012023-09-300000899923mygn:HereditaryCancerTestingMember2023-07-012023-09-300000899923country:USmygn:TumorProfilingMember2024-07-012024-09-300000899923us-gaap:NonUsMembermygn:TumorProfilingMember2024-07-012024-09-300000899923mygn:TumorProfilingMember2024-07-012024-09-300000899923country:USmygn:TumorProfilingMember2023-07-012023-09-300000899923us-gaap:NonUsMembermygn:TumorProfilingMember2023-07-012023-09-300000899923mygn:TumorProfilingMember2023-07-012023-09-300000899923country:USmygn:PrenatalTestingMember2024-07-012024-09-300000899923us-gaap:NonUsMembermygn:PrenatalTestingMember2024-07-012024-09-300000899923country:USmygn:PrenatalTestingMember2023-07-012023-09-300000899923us-gaap:NonUsMembermygn:PrenatalTestingMember2023-07-012023-09-300000899923mygn:PrenatalTestingMember2023-07-012023-09-300000899923country:USmygn:PharmacogenomicsMember2024-07-012024-09-300000899923us-gaap:NonUsMembermygn:PharmacogenomicsMember2024-07-012024-09-300000899923country:USmygn:PharmacogenomicsMember2023-07-012023-09-300000899923us-gaap:NonUsMembermygn:PharmacogenomicsMember2023-07-012023-09-300000899923mygn:PharmacogenomicsMember2023-07-012023-09-300000899923country:US2024-07-012024-09-300000899923us-gaap:NonUsMember2024-07-012024-09-300000899923country:US2023-07-012023-09-300000899923us-gaap:NonUsMember2023-07-012023-09-300000899923country:USmygn:HereditaryCancerTestingMember2024-01-012024-09-300000899923us-gaap:NonUsMembermygn:HereditaryCancerTestingMember2024-01-012024-09-300000899923mygn:HereditaryCancerTestingMember2024-01-012024-09-300000899923country:USmygn:HereditaryCancerTestingMember2023-01-012023-09-300000899923us-gaap:NonUsMembermygn:HereditaryCancerTestingMember2023-01-012023-09-300000899923mygn:HereditaryCancerTestingMember2023-01-012023-09-300000899923country:USmygn:TumorProfilingMember2024-01-012024-09-300000899923us-gaap:NonUsMembermygn:TumorProfilingMember2024-01-012024-09-300000899923country:USmygn:TumorProfilingMember2023-01-012023-09-300000899923us-gaap:NonUsMembermygn:TumorProfilingMember2023-01-012023-09-300000899923mygn:TumorProfilingMember2023-01-012023-09-300000899923country:USmygn:PrenatalTestingMember2024-01-012024-09-300000899923us-gaap:NonUsMembermygn:PrenatalTestingMember2024-01-012024-09-300000899923country:USmygn:PrenatalTestingMember2023-01-012023-09-300000899923us-gaap:NonUsMembermygn:PrenatalTestingMember2023-01-012023-09-300000899923mygn:PrenatalTestingMember2023-01-012023-09-300000899923country:USmygn:PharmacogenomicsMember2024-01-012024-09-300000899923us-gaap:NonUsMembermygn:PharmacogenomicsMember2024-01-012024-09-300000899923country:USmygn:PharmacogenomicsMember2023-01-012023-09-300000899923us-gaap:NonUsMembermygn:PharmacogenomicsMember2023-01-012023-09-300000899923mygn:PharmacogenomicsMember2023-01-012023-09-300000899923country:US2024-01-012024-09-300000899923us-gaap:NonUsMember2024-01-012024-09-300000899923country:US2023-01-012023-09-300000899923us-gaap:NonUsMember2023-01-012023-09-300000899923mygn:MedicareMembergaap:GovernmentContractsConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-01-012024-09-300000899923mygn:MedicareMembergaap:GovernmentContractsConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2024-07-012024-09-300000899923mygn:MedicareMembergaap:GovernmentContractsConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-07-012023-09-300000899923mygn:MedicareMembergaap:GovernmentContractsConcentrationRiskMemberus-gaap:RevenueFromContractWithCustomerMember2023-01-012023-09-300000899923mygn:MedicareMembergaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2024-01-012024-09-300000899923mygn:MedicareMembergaap:CustomerConcentrationRiskMemberus-gaap:AccountsReceivableMember2023-01-012023-12-310000899923us-gaap:CashMember2023-12-310000899923us-gaap:CashEquivalentsMember2023-12-310000899923us-gaap:CorporateDebtSecuritiesMember2023-12-310000899923us-gaap:MunicipalBondsMember2023-12-310000899923us-gaap:FairValueInputsLevel2Member2024-09-300000899923us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2023-12-310000899923us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember2023-12-310000899923us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember2023-12-310000899923us-gaap:MoneyMarketFundsMember2023-12-310000899923us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember2023-12-310000899923us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember2023-12-310000899923us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMember2023-12-310000899923us-gaap:FairValueInputsLevel1Memberus-gaap:MunicipalBondsMember2023-12-310000899923us-gaap:FairValueInputsLevel2Memberus-gaap:MunicipalBondsMember2023-12-310000899923us-gaap:FairValueInputsLevel3Memberus-gaap:MunicipalBondsMember2023-12-310000899923mygn:ContingentConsiderationMemberus-gaap:FairValueInputsLevel1Member2023-12-310000899923mygn:ContingentConsiderationMemberus-gaap:FairValueInputsLevel2Member2023-12-310000899923mygn:ContingentConsiderationMemberus-gaap:FairValueInputsLevel3Member2023-12-310000899923mygn:ContingentConsiderationMember2023-12-310000899923us-gaap:FairValueInputsLevel1Member2023-12-310000899923us-gaap:FairValueInputsLevel2Member2023-12-310000899923us-gaap:FairValueInputsLevel3Member2023-12-310000899923mygn:GatewayGenomicsLLCMember2024-09-300000899923us-gaap:LeaseholdImprovementsMember2024-09-300000899923us-gaap:LeaseholdImprovementsMember2023-12-310000899923us-gaap:EquipmentMember2024-09-300000899923us-gaap:EquipmentMember2023-12-310000899923us-gaap:LeaseholdImprovementsMember2023-01-012023-09-300000899923mygn:PharmacogenomicsMember2024-09-300000899923mygn:PharmacogenomicsMember2020-10-010000899923us-gaap:DevelopedTechnologyRightsMembermygn:EndoPredictMemberus-gaap:DiscontinuedOperationsDisposedOfBySaleMember2024-09-300000899923us-gaap:DevelopedTechnologyRightsMember2024-09-300000899923us-gaap:ComputerSoftwareIntangibleAssetMember2024-09-300000899923mygn:ComputerSoftwareInProcessIntangibleAssetMember2024-09-300000899923us-gaap:CustomerRelationshipsMember2024-09-300000899923us-gaap:TrademarksMember2024-09-300000899923us-gaap:DevelopedTechnologyRightsMember2023-12-310000899923us-gaap:ComputerSoftwareIntangibleAssetMember2023-12-310000899923mygn:ComputerSoftwareInProcessIntangibleAssetMember2023-12-310000899923us-gaap:CustomerRelationshipsMember2023-12-310000899923us-gaap:TrademarksMember2023-12-310000899923mygn:ABLFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2023-06-300000899923mygn:ABLFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2023-10-310000899923mygn:ABLFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2024-09-300000899923mygn:ABLFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember2023-12-310000899923mygn:ABLFacilityMembermygn:VariableRateScenarioOneMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMembermygn:NewYorkFederalReserveBankRateMember2024-01-012024-09-300000899923mygn:ABLFacilityMembermygn:VariableRateScenarioOneMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrMember2024-01-012024-09-300000899923mygn:ABLFacilityMembermygn:VariableRateScenarioOneMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrMembersrt:MinimumMember2024-01-012024-09-300000899923mygn:ABLFacilityMembermygn:VariableRateScenarioOneMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrMembersrt:MaximumMember2024-01-012024-09-300000899923mygn:ABLFacilityMembermygn:VariableRateScenarioTwoMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrMember2024-01-012024-09-300000899923mygn:ABLFacilityMembermygn:VariableRateScenarioTwoMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrMembersrt:MinimumMember2024-01-012024-09-300000899923mygn:ABLFacilityMembermygn:VariableRateScenarioTwoMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrMembersrt:MaximumMember2024-01-012024-09-300000899923mygn:ABLFacilityMembermygn:VariableRateScenarioTwoMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMembermygn:ABRFloorMember2024-01-012024-09-300000899923mygn:ABLFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMembersrt:MinimumMember2024-01-012024-09-300000899923mygn:ABLFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMembersrt:MaximumMember2024-01-012024-09-300000899923mygn:ABLFacilityMemberus-gaap:LineOfCreditMember2024-01-012024-09-300000899923mygn:ABLFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMembersrt:MaximumMember2024-09-300000899923mygn:ABLFacilityMemberus-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMembersrt:MinimumMember2024-09-300000899923mygn:RaygenIncVersusMyriadWomensHealthIncMembermygn:SettledLitigationContingentPaymentsMember2023-10-232023-10-230000899923mygn:SettledLitigationContingentPaymentsMembermygn:FirstInstallmentMembermygn:RaygenIncVersusMyriadWomensHealthIncMember2023-10-232023-10-230000899923mygn:SettledLitigationContingentPaymentsMembermygn:SecondInstallmentMembermygn:RaygenIncVersusMyriadWomensHealthIncMember2023-10-232023-10-230000899923mygn:SettledLitigationContingentPaymentsMembermygn:ThirdInstallmentMembermygn:RaygenIncVersusMyriadWomensHealthIncMember2023-10-232023-10-230000899923mygn:SettledLitigationContingentPaymentsMembermygn:FourthInstallmentMembermygn:RaygenIncVersusMyriadWomensHealthIncMember2023-10-232023-10-230000899923mygn:SettledLitigationContingentPaymentsMembermygn:FifthInstallmentMembermygn:RaygenIncVersusMyriadWomensHealthIncMember2023-10-232023-10-230000899923mygn:RaygenIncVersusMyriadWomensHealthIncMembermygn:SettledLitigationNonContingentPaymentsMember2023-10-232023-10-230000899923mygn:RaygenIncVersusMyriadWomensHealthIncMembermygn:SettledLitigationNonContingentPaymentsMember2023-10-230000899923mygn:RaygenIncVersusMyriadWomensHealthIncMembermygn:SettledLitigationNonContingentPaymentsMember2024-09-300000899923mygn:SettledLitigationNonContingentPaymentsMembermygn:FirstInstallmentMembermygn:RaygenIncVersusMyriadWomensHealthIncMember2023-10-232023-10-230000899923mygn:SettledLitigationNonContingentPaymentsMembermygn:SecondInstallmentMembermygn:RaygenIncVersusMyriadWomensHealthIncMember2023-10-232023-10-230000899923mygn:RaygenIncVersusMyriadWomensHealthIncMember2024-09-300000899923mygn:TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember2023-06-010000899923mygn:TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember2024-09-300000899923us-gaap:RestrictedStockUnitsRSUMembersrt:MinimumMember2024-01-012024-09-300000899923us-gaap:RestrictedStockUnitsRSUMembersrt:MaximumMember2024-01-012024-09-300000899923mygn:OptionsAndRestrictedStockUnitsMembermygn:NonEmployeeDirectorMember2024-01-012024-09-300000899923us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember2024-01-012024-09-300000899923us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember2024-01-012024-09-300000899923us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember2024-01-012024-09-300000899923us-gaap:RestrictedStockUnitsRSUMember2024-01-012024-09-300000899923us-gaap:RestrictedStockUnitsRSUMember2023-12-310000899923us-gaap:RestrictedStockUnitsRSUMember2024-09-300000899923mygn:EmployeeStockPurchasePlanTwentyTwelveMember2021-09-232021-09-230000899923mygn:EmployeeStockPurchasePlanTwentyTwelveMember2024-01-012024-09-300000899923mygn:EmployeeStockPurchasePlanTwentyTwelveMember2024-07-012024-09-300000899923mygn:EmployeeStockPurchasePlanTwentyTwelveMember2023-07-012023-09-300000899923mygn:EmployeeStockPurchasePlanTwentyTwelveMember2023-01-012023-09-300000899923us-gaap:CostOfSalesMember2024-07-012024-09-300000899923us-gaap:CostOfSalesMember2023-07-012023-09-300000899923us-gaap:CostOfSalesMember2024-01-

012024-09-300000899923us-gaap:CostOfSalesMember2023-01-012023-09-300000899923us-gaap:ResearchAndDevelopmentExpenseMember2024-07-012024-09-300000899923us-gaap:ResearchAndDevelopmentExpenseMember2023-07-012023-09-300000899923us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-09-300000899923us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-09-300000899923us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-07-012024-09-300000899923us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-07-012023-09-300000899923us-gaap:SellingGeneralAndAdministrativeExpensesMember2024-01-012024-09-300000899923us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-09-300000899923srt:MaximumMemberus-gaap:PendingLitigationMember2024-05-032024-05-030000899923us-gaap:PendingLitigationMember2024-09-300000899923srt:MinimumMember2024-09-300000899923srt:MaximumMember2024-09-300000899923mygn:WestSaltLakeCityMember2023-09-300000899923mygn:WestSaltLakeCityMember2024-09-300000899923us-gaap:AccumulatedTranslationAdjustmentMember2023-12-310000899923us-gaap:AccumulatedTranslationAdjustmentMember2024-01-012024-09-300000899923us-gaap:AccumulatedTranslationAdjustmentMember2024-09-300000899923us-gaap:DiscontinuedOperationsDisposedOfBySaleMembermygn:EndoPredictMember2024-08-010000899923us-gaap:DiscontinuedOperationsDisposedOfBySaleMembermygn:EndoPredictMember2024-01-012024-09-30UNITED STATESSECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549_____FORM 10-Q_____(Mark One)â˜’QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the quarterly period ended September 30, 2024ORâ˜TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934For the transition period from Â Â Â Â Â Â Â Â Â Â Â Â to Â Â Â Â Â Â Â Â Â Â Â Â Commission file number:Â Â 0-26642_____MYRIAD GENETICS, INC.(Exact name of registrant as specified in its charter)_____Delaware(State or other jurisdictionof incorporation or organization)322 North 2200 West, Salt Lake City, UT(Address of principal executive offices)87-0494517(I.R.S. Employer Identification No.)84116(Zip Code)Registrant's telephone number, including area code: (801) 584-3600Not applicable(Former name or former address, if changed since last report)_____Securities registered pursuant to SectionÂ 12(b) of the Act:Title of each classTrading Symbol(s)Name of each exchange on which registeredCommon Stock, $0.01 par valueMYGNNasdaq Global Select MarketIndicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.Â Â Â Â Â YesÂ Â xÂ Â Â Â NoÂ Â Â¨Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (Â§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).Â Â Â Â Â YesÂ Â xÂ Â Â Â NoÂ Â Â¨Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of â€œlarge accelerated filer,â€ â€œaccelerated filer,â€ â€œsmaller reporting company,â€ and â€œemerging growth companyâ€ in Rule 12b-2 of the Exchange Act.Large accelerated filerxAccelerated filerâ˜Non-accelerated filerâ˜Smaller reporting companyâ˜Emerging growth companyâ˜If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Â¨Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).Â Â Â Â YesÂ Â â˜Â Â Â Â NoÂ Â xAs of NovemberÂ 4, 2024, the registrant had 91,035,230 shares of $0.01 par value common stock outstanding.MYRIAD GENETICS, INC.INDEX TO FORM 10-QPagePART I - Financial InformationItem 1.Financial StatementsCondensed Consolidated Balance Sheets as of September 30, 2024 and December 31, 2023 (unaudited)4Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2024 and 2023 (unaudited)5Condensed Consolidated Statements of Comprehensive Loss for the three and nine months ended September 30, 2024 and 2023 (unaudited)6Condensed Consolidated Statements of Stockholdersâ€™ Equity for the three and nine months ended September 30, 2024 and 2023 (unaudited)7Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2024 and 2023 (unaudited)8Notes to Condensed Consolidated Financial Statements (unaudited)9Item 2.Management's Discussion and Analysis of Financial Condition and Results of Operations24Item 3.Quantitative and Qualitative Disclosures About Market Risk33Item 4.Controls and Procedures33PART II - Other InformationItem 1.Legal Proceedings34Item 1A.Risk Factors34Item 2.Unregistered Sales of Equity Securities and Use of Proceeds36Item 3.Defaults Upon Senior Securities36Item 4.Mine Safety Disclosures36Item 5.Other Information37Item 6.Exhibits37Signatures383Table of ContentsPART I - Financial InformationItem 1.Â Â Â Â Financial Statements.MYRIAD GENETICS, INC.AND SUBSIDIARIESCondensed Consolidated Balance Sheets (unaudited)(in millions)September 30,2024December 31,2023ASSETSCurrent assets:Cash and cash equivalents$99.9Â $132.1Â Marketable investment securitiesâ€Â 8.8Â Trade accounts receivable125.7Â 114.3Â Inventory26.2Â 22.0Â Prepaid taxes17.0Â 17.0Â Prepaid expenses and other current assets24.4Â 19.4Â Total current assets293.2Â 313.6Â Operating lease right-of-use assets57.4Â 61.6Â Property, plant, and equipment, net115.4Â 119.0Â Intangibles, net312.5Â 349.5Â Goodwill286.3Â 287.4Â Other assets16.5Â 15.4Â Total assets$1,081.3Â $1,146.5Â LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:Accounts payable$29.6Â $25.8Â Accrued liabilities111.2Â 113.9Â Current maturities of operating lease liabilities13.5Â 16.2Â Total current liabilities154.3Â 155.9Â Unrecognized tax benefits31.4Â 30.2Â Long-term debt39.0Â 38.5Â Noncurrent operating lease liabilities90.6Â 97.4Â Other long-term liabilities34.3Â 41.3Â Total liabilities349.6Â 363.3Â Commitments and contingenciesStockholdersâ€™ equity:Common stock, 91.0 and 89.9 shares outstanding at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, respectively0.9Â 0.9Â Additional paid-in capital1,445.2Â 1,415.5Â Accumulated other comprehensive loss(0.1)(3.7)Accumulated deficit(714.3)(629.5)Total stockholders' equity731.7Â 783.2Â Total liabilities and stockholdersâ€™ equity$1,081.3Â $1,146.5Â See accompanying notes to Condensed Consolidated Financial Statements.4Table of ContentsMYRIAD GENETICS, INC.AND SUBSIDIARIESCondensed Consolidated Statements of Operations (unaudited)(in millions, except per share amounts)Three months endedSeptember 30,Nine months endedSeptember 30,2024202320242023Testing revenue$213.3Â $191.9Â $627.0Â $556.6Â Costs and expenses:Cost of testing revenue63.5Â 57.6Â 192.5Â 174.6Â Research and development expense28.5Â 24.0Â 81.2Â 67.7Â Selling, general, and administrative expense139.1Â 136.1Â 424.0Â 428.5Â Legal settlementsâ€Â 34.3Â â€”Â 111.8Â Goodwill and long-lived asset impairment charges2.2Â â€”Â 13.8Â â€”Â Total costs and expenses233.3Â 252.0Â 711.5Â 782.6Â Operating loss(20.0)(60.1)(84.5)(226.0)Other income (expense):Interest income0.4Â 0.6Â 1.4Â 1.8Â Interest expense(0.8)(1.0)(2.1)(2.0)Other(0.8)(0.7)0.8Â (3.7)Total other income (expense), net(1.2)(1.1)0.1Â (3.9)Loss before income tax(21.2)(61.2)(84.4)(229.9)Income tax expense0.9Â 0.1Â 0.4Â 2.2Â Net loss(22.1)(61.3)(84.8)(232.1)Net loss per share:Basic and diluted(0.24)(0.75)(0.94)(2.84)Weighted average shares outstanding:Basic and diluted90.9Â 81.9Â 90.5Â 81.6Â See accompanying notes to Condensed Consolidated Financial Statements.5Table of Contents MYRIAD GENETICS, INC.AND SUBSIDIARIESCondensed Consolidated Statements of Comprehensive Loss (unaudited)(in millions)Three months endedSeptember 30,Nine months endedSeptember 30,20242023202420232023Net loss(22.1)(61.3)(84.8)(232.1)Change in unrealized loss on available-for-sale debt securities, net of taxâ€Â 0.3Â 0.1Â 2.5Â Change in foreign currency translation adjustment, net of tax(0.5)(0.1)(1.5)0.7Â Reclassification adjustments for losses included in net loss, net of taxâ€Â 0.1Â â€Â 1.5Â Reclassification of cumulative translation adjustment to income upon sale or liquidation of certain foreign entities, net of tax4.4Â (0.1)5.1Â 0.4Â Comprehensive loss(18.2)(61.1)(81.1)(227.0)See accompanying notes to Condensed Consolidated Financial Statements.6Table of ContentsMYRIAD GENETICS, INC.AND SUBSIDIARIESCondensed Consolidated Statements of Stockholdersâ€™ Equity (unaudited)(in millions)CommonstockAdditionalpaid-incapitalAccumulatedothercomprehensivelossAccumulateddeficitMyriad Genetics, Inc.Stockholdersâ€™equityBALANCES AT DECEMBER 31, 2022$0.8Â $1,260.1Â (8.9)(366.2)$885.8Â Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding taxâ€Â (4.9)â€Â â€Â (4.9)Stock-based compensation expenseâ€Â 7.5Â â€Â â€Â 7.5Â Net lossâ€Â â€Â â€Â (54.7)(54.7)Other comprehensive income, net of taxâ€Â â€Â 1.5Â â€Â 1.5Â BALANCES AT MARCH 31, 2023$0.8Â $1,262.7Â (7.4)(420.9)$835.2Â Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding taxâ€Â 2.9Â â€Â â€Â 2.9Â Stock-based compensation expenseâ€Â 11.2Â â€Â â€Â 11.2Â Net lossâ€Â â€Â â€Â (116.1)(116.1)Other comprehensive income, net of taxâ€Â â€Â 2.0Â â€Â 2.0Â BALANCES AT JUNE 30, 2023$0.8Â $1,276.8Â (5.4)(537.0)$735.2Â Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding taxâ€Â (2.2)â€Â â€Â (2.2)Stock-based compensation expenseâ€Â 11.6Â â€Â â€Â 11.6Â Net lossâ€Â â€Â â€Â (61.3)(61.3)Other comprehensive income, net of taxâ€Â â€Â 0.1Â â€Â 0.1Â BALANCES AT SEPTEMBER 30, 2023$0.8Â $1,286.2Â (5.3)(598.3)$683.4Â BALANCES AT DECEMBER 31, 2023$0.9Â $1,415.5Â (3.7)(629.5)$783.2Â Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding taxâ€Â (8.7)â€Â â€Â (8.7)Stock-based compensation expenseâ€Â 12.0Â â€Â â€Â 12.0Â Net lossâ€Â â€Â â€Â (26.0)(26.0)Other comprehensive loss, net of taxâ€Â â€Â (0.5)â€Â (0.5)BALANCES AT MARCH 31, 2024$0.9Â $1,418.8Â (4.2)(655.5)$760.0Â Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding taxâ€Â 2.5Â â€Â â€Â 2.5Â Stock-based compensation expenseâ€Â 14.5Â â€Â â€Â 14.5Â Net lossâ€Â â€Â â€Â (36.7)(36.7)Other comprehensive income, net of taxâ€Â â€Â 0.2Â â€Â 0.2Â BALANCES AT JUNE 30, 2024$0.9Â $1,435.8Â (4.0)(692.2)$740.5Â Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding taxâ€Â (3.0)â€Â â€Â (3.0)Stock-based compensation expenseâ€Â 12.4Â â€Â â€Â 12.4Â Net lossâ€Â â€Â â€Â (22.1)(22.1)Other comprehensive income, net of taxâ€Â â€Â 3.9Â â€Â 3.9Â BALANCES AT SEPTEMBER 30, 2024$0.9Â $1,445.2Â (0.1)(714.3)$731.7Â See accompanying notes to Condensed Consolidated Financial Statements.7Table of ContentsMYRIAD GENETICS, INC.AND SUBSIDIARIESCondensed Consolidated Statements of Cash Flows (unaudited)(in millions)Nine months endedSeptember 30,20242023CASH FLOWS FROM OPERATING ACTIVITIES:Net loss(84.8)(232.1)Adjustments to reconcile net loss to net cash used in operating activities:Depreciation and amortization46.4Â 46.8Â Non-cash lease expense6.7Â 8.6Â Stock-based compensation expense38.9Â 30.3Â Deferred income taxes(3.0)(1.7)Unrecognized tax benefits1.2Â 2.8Â Bad debt expense(0.8)â€Â Net realized losses on marketable investment securitiesâ€Â 1.5Â Impairment of goodwill and long-lived assets13.6Â â€Â Gain on termination of lease(3.1)â€Â Gain on acquisition(2.2)â€Â Other non-cash adjustments2.0Â 3.0Â Changes in assets and liabilities:Prepaid expenses and other current assets(4.6)(1.8)Trade accounts receivable(12.7)(13.7)Inventory(4.9)(5.0)Prepaid taxes(0.1)0.2Â Other assets(0.2)(0.2)Tenant improvement allowance receivedâ€Â 16.3Â Accounts payable5.8Â 2.2Â Accrued liabilities(13.5)86.6Â Net cash used in operating activities(15.3)(56.2)CASH FLOWS FROM INVESTING ACTIVITIES:Capital expenditures(15.4)(53.2)Capitalization of internal-use software costs(8.4)(6.6)Proceeds from the sale of business, net cash sold8.8Â â€Â Proceeds from maturities and sales of marketable investment securities9.0Â 103.7Â Net cash provided by (used in) investing activities(6.0)43.9Â CASH FLOWS FROM FINANCING ACTIVITIES:Proceeds from common stock issued under stock-based compensation plans3.0Â â€Â Payment of tax withheld for common stock issued under stock-based compensation plans(12.2)(7.3)Proceeds from revolving credit facility100.0Â 40.0Â Repayment of revolving credit facility(100.0)â€Â Fees associated with issuance and refinancing of revolving credit facilityâ€Â (1.6)Payment on finance leases(0.3)(0.1)Net cash provided by (used in) financing activities(9.5)31.0Â Effect of foreign exchange rates on cash, cash equivalents, and restricted cash(0.3)(0.1)Net (decrease) increase in cash, cash equivalents, and restricted cash(31.1)18.6Â Cash, cash equivalents, and restricted cash at beginning of the period140.9Â 66.4Â Cash, cash equivalents, and restricted cash at end of the period$109.8Â $85.0Â See accompanying notes to Condensed Consolidated Financial Statements.8Table of ContentsNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)1.BASIS OF PRESENTATIONMyriad Genetics, Inc. (together with its subsidiaries, the â€œCompanyâ€ or â€œMyriadâ€) is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower health care costs. Myriad provides insights that help people take control of their health and enable healthcare providers to better detect, treat, and prevent disease. The Company currently operates as a single reporting segment. The Companyâ€™s principal executive office is located in Salt Lake City, Utah.The accompanying Condensed Consolidated Financial Statements for the Company have been prepared in accordance with United States ("U.S.") generally accepted accounting principles (â€œGAAPâ€) for interim financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (â€œSECâ€).Â All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. The accompanying Condensed Consolidated Financial Statements should be read in conjunction with the Companyâ€™s audited Consolidated Financial Statements and notes thereto included in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023 (the â€œForm 10-Kâ€). The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. The Company has historically experienced seasonality in its business. The quarters ending March 31 and September 30 are typically weaker due to the annual reset of patient deductibles in the beginning of each calendar year and vacation schedules in the summer. The quarter ending December 31 is typically stronger due to increased demand as patients meet their deductibles throughout the year. Seasonal patterns were disrupted in recent years as a result of the COVID pandemic and certain other factors, but the Company believes it has experienced the impacts of seasonality in the third quarter 2024. Additionally, operating results for the three and nine months ended SeptemberÂ 30, 2024 may not necessarily be indicative of results to be expected for any other interim period or for the full year. Recent Accounting PronouncementsIn November 2023, the Financial Accounting Standards Board ("FASB") issued accounting standards update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which enhances the disclosures required for reportable segments in annual and interim consolidated financial statements. ASU 2023-07 is effective for the Company for annual reporting periods beginning after December 15, 2023 and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2023-07 on its segment disclosures.In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires enhanced income tax disclosures, including disaggregation of information on the rate reconciliation table and disaggregated information related to income taxes paid. The amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact of ASU 2023-09 on its income tax disclosures.ReclassificationsCertain prior period amounts have been reclassified to conform with the current period presentation. The reclassifications have no impact on the Company's total assets, total liabilities, stockholders' equity, or cash flows from operations.9Table of Contents2.REVENUEThe Company primarily generates revenue by performing genetic testing. Testing revenues are primarily derived from the following categories of products: Hereditary Cancer (MyRisk, BRACAnalysis, BRACAnalysis CDx), Tumor Profiling (MyChoice CDx, Prolaris, Precise Tumor, and EndoPredict), Prenatal (Foresight, Prequel, and SneakPeek), and Pharmacogenomics (GeneSight). Revenue is recorded at the estimated transaction price. The Company has determined that the communication of test results indicates transfer of control for revenue recognition purposes.The following table presents detail regarding the composition of the Companyâ€™s total revenue by product type and by geographical region, either U.S. or rest of world (â€œRoWâ€):Three months ended September 30,20242023(in millions)U.S.RoWTotalU.S.RoWTotalTesting revenues:Hereditary Cancer$78.4Â $12.1Â $90.5Â $75.1Â $11.4Â $86.5Â Tumor Profiling26.5Â 5.1Â 31.6Â 22.0Â 8.2Â 30.2Â Prenatal43.4Â 0.1Â 43.5Â 39.4Â 0.1Â 39.5Â Pharmacogenomics47.7Â â€Â 47.7Â 35.7Â â€Â 35.7Â Total revenue$196.0Â $17.3Â $213.3Â $172.2Â $19.7Â $191.9Â Nine months ended September 30,20242023(in millions)U.S.RoWTotalU.S.RoWTotalTesting revenues:Hereditary Cancer$235.6Â $34.5Â $270.1Â $203.6Â $35.3Â $238.9Â Tumor Profiling77.1Â 18.0Â 95.1Â 78.1Â 25.4Â 103.5Â Prenatal131.7Â 0.5Â 132.2Â 110.8Â 0.5Â 111.3Â Pharmacogenomics129.6Â â€Â 129.6Â 102.9Â â€Â 102.9Â Total revenue$574.0Â $53.0Â $627.0Â $495.4Â $61.2Â $556.6Â Under Accounting Standards Codification ("ASC") 606: Revenue from Contracts with Customers, an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company performs its obligation under a contract with a customer by processing tests and communicating the test results to customers in exchange for consideration from the customer. The Company has the right to bill its customers upon the completion of performance obligations and thus does not record contract assets. Occasionally, customers make payments prior to the Companyâ€™s performance of its contractual obligations. When this occurs, the Company records a contract liability as Deferred revenue, which is included in Accrued liabilities in the Condensed Consolidated Balance Sheets. In accordance with ASC 606, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining

performance obligations for its contracts that are one year or less, as the revenue is expected to be recognized within the next year. Furthermore, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts wherein the Companyâ€™s right to payment is in an amount that directly corresponds with the value of the Companyâ€™s performance to date. In determining the transaction price, the Company includes an estimate of the expected amount of consideration to be received. The Company applies this method consistently for similar contracts when estimating the effect of any uncertainty on an amount of variable consideration to which it will be entitled. An estimate of transaction price does not include any estimated amount of variable consideration that is constrained. In addition, the Company considers all the information (historical, current, and forecast) that is reasonably available to identify possible consideration amounts. In determining the expected value, the Company considers the probability of the variable consideration for each possible scenario. The Company also has significant experience with historical discount patterns and uses this experience to estimate transaction prices. 10Table of ContentsThe estimate of revenue is affected by, among other factors, assumptions for changes in payor mix, payor collections, current customer contractual requirements, experience with collections from third-party payors, and changes in medical policies. When assessing the total consideration for insurance carriers and patients, revenues are further constrained for estimated refunds. The Company reserves certain amounts in Accrued liabilities in the Companyâ€™s Condensed Consolidated Balance Sheets in anticipation of requests for refunds of payments made previously by insurance carriers, which are accounted for as reductions in revenues in the Condensed Consolidated Statements of Operations and Comprehensive Income/Loss.Cash collections for certain tests delivered may differ from rates estimated due to changes in the estimated transaction price for contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met, settlements with third-party payors, or as a result of third-party payors disputing our bills or denying payment for tests that we have performed, among other reasons. As a result of this new information, the Company updates its estimate of the amounts to be recognized for previously delivered tests. During the three and nine months ended September 30, 2024, the Company recognized $8.6Â million and $17.3Â million, respectively, which resulted in $0.09 and $0.19 impact to earnings per share, respectively, for testing in which the performance obligation was met in prior periods, primarily due to a changes in the estimated transaction price. Additionally, during the nine months ended September 30, 2024, the Company recognized $3.0 million in revenue due to a retroactive coverage change by a payor for one of its prenatal products. For the three and nine months ended SeptemberÂ 30, 2023, the Company recognized $7.1Â million and $6.2Â million in revenue, respectively, which resulted in a $0.07 and $0.06, respectively, impact to earnings per share for tests in which the performance obligation was met in prior periods, primarily driven by changes in the estimated transaction price. The Company applies the practical expedient related to costs to obtain or fulfill a contract since the amortization period for such costs will be one year or less. Accordingly, no costs incurred to obtain or fulfill a contract have been capitalized. The Company also applies the practical expedient for not adjusting revenue recognized for the effects of the time value of money. This practical expedient has been elected because the Company collects very little cash from customers under payment terms and the vast majority of payment terms have a payback period of less than one year. Concentration of Credit RiskFinancial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company limits its exposure to loss by placing its cash in financial institutions with high credit ratings. The Company's cash may consist of deposits held with banks that may at times exceed federally insured limits of $250,000 per customer. Substantially all of the Companyâ€™s accounts receivable are with companies in the healthcare industry, U.S. and state governmental agencies, and individuals. The Company does not believe that receivables due from U.S. and state governmental agencies, such as Medicare, represent a credit risk since the related healthcare programs are funded by the U.S. and state governments. The Company only has one payor, Medicare, that represents greater than 10% of its revenues. Revenues received from Medicare represented 11% of total revenue for both of the three and nine months ended SeptemberÂ 30, 2024 and 12% of total revenue for both of the three and nine months ended SeptemberÂ 30, 2023. Concentrations of credit risk are mitigated due to the number of the Companyâ€™s customers as well as their dispersion across many geographic regions. The Company has one payor that accounted for more than 10% of accounts receivable at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023. The balance of accounts receivable from this one payor represented 19% and 12% of the total accounts receivable balance as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, respectively. The Company does not require collateral from its customers.11Table of Contents3.MARKETABLE INVESTMENT SECURITIESAt SeptemberÂ 30, 2024, the Company had no investment securities outstanding. The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for debt securities classified as available-for-sale securities by major security type and class of security at DecemberÂ 31, 2023 were as follows:(in millions)AmortizedcostGrossunrealizedholdinggainsGrossunrealizedholdinglossesEstimatedfair valueDecember 31, 2023Cash and cash equivalents:Cash$129.9Â $â€”Â $â€”Â $129.9Â Cash equivalents2.2Â â€”Â â€”Â 2.2Â Total cash and cash equivalents132.1Â â€”Â â€”Â 132.1Â Available-for-sale:Corporate bonds and notes8.4Â â€”Â (0.1)8.3Â Municipal bonds0.5Â â€”Â â€”Â 0.5Â Total$141.0Â $â€”Â (0.1)140.9Â The cost of a security sold, or amount reclassified out of Accumulated other comprehensive income or loss into Net loss, is determined based on the specific identification method. Additional information relating to fair value of marketable investment securities can be found in Note 4.4.FAIR VALUE MEASUREMENTSThe fair value of the Companyâ€™s financial instruments reflects the amounts that the Company estimates it will receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels:Level 1â€“quoted prices in active markets for identical assets and liabilities.Level 2â€“observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.Â Â Some of the Companyâ€™s marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities.Level 3â€“unobservable inputs.All of the Companyâ€™s financial instruments are valued using quoted prices in active markets or based on other observable inputs.Â For Level 2 securities, the Company uses a third-party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application, and corroborative information. The fair value of the Companyâ€™s long-term debt, which it considers a Level 2 measurement, is estimated using discounted cash flow analyses based on the Companyâ€™s current estimated incremental borrowing rates for similar borrowing arrangements.Â The fair value of the Companyâ€™s long-term debt is estimated to be $39.7Â million at SeptemberÂ 30, 2024.12Table of ContentsAt SeptemberÂ 30, 2024, the Company did not have any financial assets requiring fair value re-measurement. The following table sets forth the fair value of the financial assets and liabilities that the Company re-measures on a regular basis as of December 31, 2023:(in millions)Level 1Level 2Level 3TotalDecember 31, 2023Money market funds(a)$2.2Â $â€”Â $â€”Â $2.2Â Corporate bonds and notesâ€”Â 8.3Â â€”Â 8.3Â Municipal bondsâ€”Â 0.5Â â€”Â 0.5Â Contingent considerationâ€”Â â€”Â (5.4)(5.4)Total$2.2Â $8.8Â (5.4)5.6Â (a)Money market funds are primarily comprised of exchange traded funds and accrued interest.The following table reconciles the change in the fair value of the contingent consideration during the periods presented:(in millions)CarryingAmountBalance at December 31, 2023$5.4Â Change in fair value recognized in the Statements of Operations0.5Â Payment of contingent consideration(5.8)Translation adjustments recognized in Other comprehensive loss(0.1)Ending balance at SeptemberÂ 30, 2024$â€”Â For the Level 2 contingent consideration related to the acquisition of Gateway Genomics, LLC ("Gateway"), the Company reassesses the fair value of expected contingent consideration and the corresponding liability each reporting period using current financial or operating projections. As of SeptemberÂ 30, 2024, the Company has estimated a fair value of $0 related to the Gateway contingent consideration as the achievement of the contingent consideration targets is not considered probable.5.PROPERTY, PLANT, AND EQUIPMENT, NETThe property, plant and equipment at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023 were as follows:(in millions)September 30,2024December 31,2023Leasehold improvements$78.2Â $91.3Â Equipment154.5Â 147.6Â Property, plant and equipment, gross232.7Â 238.9Â Less accumulated depreciation(117.3)(119.9)Property, plant and equipment, net$115.4Â $119.0Â The Company recorded depreciation during the respective periods as follows:Three months endedSeptember 30,Nine months endedSeptember 30,(in millions)2024202320242023Depreciation expense$4.8Â $3.4Â $14.5Â $14.8Â During the nine months ended September 30, 2023, the Company incurred $5.7Â million of accelerated depreciation of leasehold improvements and equipment in connection with the Company's decision to cease the use of its former corporate headquarters in Salt Lake City, Utah, and transition corporate support operations to its new facility in west Salt Lake City. The Company formally assigned the previous corporate headquarters lease to a third party as of DecemberÂ 31, 2023. See Note 15 for further discussion. 13Table of Contents6.GOODWILL AND INTANGIBLE ASSETSGoodwillThe changes in the carrying amount of goodwill for the nine months ended September 30, 2024 were as follows:(in millions)TotalBeginning balance$287.4Â Goodwill impairment(0.8)Translation adjustments(0.3)Ending balance$286.3Â The Company recognized a goodwill impairment charge of $0.8 million during the nine months ended September 30, 2024 related to the goodwill allocated to the Myriad International reporting unit. The goodwill impairment charge is reflected in Goodwill and long-lived asset impairment charges in the Condensed Consolidated Statements of Operations. See Note 18 for further discussion.As of September 30, 2024, goodwill for the Pharmacogenomics reporting unit (formerly referred to as Mental Health) was approximately $121.0Â million, which represents approximately 42.3% of total recorded goodwill. On November 1, 2024, UnitedHealthcare updated its medical policy for pharmacogenetic testing to no longer provide coverage for certain multi-gene panel pharmacogenetic tests, including the Company's GeneSight test, under its commercial and individual exchange benefit plans, effective January 1, 2025. The Company is still assessing the full impact of this policy change on its long-term forecasts; however, goodwill recorded in connection with this reporting unit may be at risk of impairment. The reporting unit was last quantitatively tested for goodwill impairment as of October 1, 2020, at which time the fair value of the reporting unit was in excess of the carrying value by 12%. As more information becomes available about the impact of the coverage decision by UnitedHealthcare, or if other adverse events occur, the Company may be required to record a goodwill impairment charge, which could have a material impact on the financial statements. See Item 2. Business Updates and Item 1A. Risk Factors for additional information. Intangible AssetsIntangible assets consist of amortizable assets of developed technologies, internal-use software, customer relationships, and trademarks, as well as in-process internal-use software that is not yet being amortized. During the nine months ended SeptemberÂ 30, 2024, the Company completed the sale of its EndoPredict business, including certain developed technologies with a net book value of approximately $13.1Â million. See Note 18 for further discussion about the sale of the EndoPredict business.The following summarizes the amounts reported as intangible assets:(in millions)GrossCarryingAmountAccumulatedAmortizationNetAt September 30, 2024Developed technologies$603.3Â (316.9)286.4Â Internal-use software1.6Â (0.5)1.1Â Internal-use software (in-process)18.8Â â€”Â 18.8Â Customer relationships1.6Â (0.3)1.3Â Trademarks6.1Â (1.2)4.9Â Total intangible assets631.4Â $(318.9)312.5Â 14Table of Contents(in millions)GrossCarryingAmountAccumulatedAmortizationNetAt December 31, 2023Developed technologies$626.1Â (295.3)330.8Â Internal-use software0.8Â (0.1)0.7Â Internal-use software (in-process)11.2Â â€”Â 11.2Â Customer relationships1.6Â (0.2)1.4Â Trademarks6.1Â (0.7)5.4Â Total intangible assets$645.8Â (296.3)349.5Â The Company recorded amortization expense during the respective periods for these intangible assets as follows:Three months endedSeptember 30,Nine months endedSeptember 30,(in millions)2024202320242023Amortization of intangible assets$10.5Â $10.7Â $31.9Â $32.0Â 7.ACCRUED LIABILITIESThe Company's accrued liabilities at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023 were as follows:(in millions)September 30,2024December 31,2023Employee compensation and benefits$51.4Â $49.7Â Accrued taxes payable4.2Â 4.6Â Refunds payable and reserves19.2Â 20.1Â Short-term contingent considerationâ€”Â 3.1Â Accrued royalties6.6Â 5.3Â Legal settlements6.0Â 6.0Â Lease termination accrual 4.3Â 4.4Â Other accrued liabilities19.5Â 20.7Â Total accrued liabilities$111.2Â $113.9Â 8.LONG-TERM DEBTOn June 30, 2023, the Company entered into an asset-based revolving credit facility (the â€œABL Facilityâ€) with an initial maximum principal amount of $90.0 million, with JPMorgan Chase Bank, N.A., as administrative agent and issuing bank, the other lender parties thereto, and certain of the Company's domestic subsidiaries (the "Guarantors"). On October 31, 2023, the Company entered into an amendment to the ABL Facility to increase the maximum principal amount of the available revolving line of credit by $25.0Â million for a total maximum principal commitment of $115.0Â million under the ABL Facility, which was effected through a new commitment provided by a new lender, Goldman Sachs Bank USA. The ABL Facility matures on June 30, 2026. The obligations of the Company are guaranteed by the Guarantors and the ABL Facility is secured by substantially all of the assets of the Company and the Guarantors. The Company had long-term debt of $40.0 million under the ABL Facility at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, net of $1.0 million and $1.5 million of debt issuance costs, respectively. Proceeds from the ABL Facility were or will be used for the working capital needs and general corporate purposes of the Company and its subsidiaries.Availability under the ABL Facility is subject to a borrowing base, which is the lesser of (a) 85% of the Company's and the Guarantors' eligible accounts receivable plus certain cash held in a segregated and fully-blocked account with the administrative agent in an amount up to $20.0Â million ("Eligible Cash") minus any reserves established by the administrative agent in accordance with the ABL Facility, and (b) the aggregate amount of cash collections from eligible accounts of the Company and the Guarantors for the 60 consecutive days most recently ended. Subject to certain conditions, the Company can freely withdraw cash from the Eligible Cash account, provided that any reduction in the Eligible Cash amount will have a corresponding reduction in the borrowing base under the ABL Facility. 15Table of ContentsLoans outstanding under the ABL Facility will bear interest at a rate per annum equal to, at the option of the Company, either (a) the greatest of (i) the daily Prime Rate, (ii) the daily NYFRB Rate plus 0.5%, and (iii) the monthly Adjusted Term SOFR Rate (as defined below) plus 1.0% (the â€œABRâ€) plus an applicable margin ranging from 1.0% to 1.5% depending on the aggregate average unused availability under the ABL Facility during the prior quarter or (b) term Secured Overnight Financing Rate ("SOFR") for a tenor of one, three or six months (at the Companyâ€™s election) plus 0.1% (the â€œAdjusted Term SOFR Rateâ€) plus an applicable margin ranging from 2.0% to 2.5% depending on the average unused availability under the ABL Facility during the prior quarter, with an ABR floor of 1.0% and an Adjusted Term SOFR Rate floor of 0.0%. Under the ABL Facility, the undrawn fee ranges from 37.5 to 50 basis points based on the daily amount of the available revolving commitment. The weighted average interest rate for borrowings under the ABL Facility as of SeptemberÂ 30, 2024 was 8.4%.The Company may elect to prepay all or any portion of the amounts owed prior to the maturity date without premium or penalty. The ABL Facility is also subject to customary mandatory prepayments with the proceeds of unpermitted indebtedness and upon the occurrence of an over-advance. Voluntary and mandatory prepayments and all other payments of the ABL Facility must be accompanied by payment of accrued interest on the principal amount repaid or prepaid.The ABL Facility contains customary loan terms, interest rates, representations and warranties and affirmative and negative covenants, in each case, subject to customary limitations, exceptions and exclusions. Covenants under the ABL Facility limit or restrict the Company and its subsidiaries' ability to incur liens, incur indebtedness, dispose of assets, make investments, make certain restricted payments, merge or consolidate, and enter into certain speculative hedging arrangements. The ABL Facility requires the Company and the Guarantors, on a consolidated basis, to maintain minimum liquidity of $60.0Â million and minimum availability of $25.0Â million at all times before achieving a fixed charge coverage ratio of 1.0 to 1.0 and thereafter, to maintain a fixed charge coverage ratio of 1.0 to 1.0 until achieving availability under the ABL Facility of greater than the greater of (a) $10.6 million and (b) 12.5% of the lesser of the maximum commitment amount and the borrowing base for a period of 30 consecutive days. As of SeptemberÂ 30, 2024, availability under the ABL Facility was $48.8 million. In addition, the ABL Facility includes a number of customary events of default. If any event of default occurs (subject, in certain instances, to specified grace periods), the principal, premium, if any, interest, and any other monetary obligations on all the then-outstanding amounts under the ABL Facility may become due and payable immediately.Under the terms of the ABL Facility, if (i) an event of default has occurred and is continuing or (ii) availability under the ABL Facility is less than the greater of (a) $12.5Â million and (b) 15% of the lesser of the maximum commitment amount and the borrowing base, the Company will become subject to cash dominion, upon which the administrative agent will apply funds credited to a collection account to first prepay any outstanding protective advances, second to prepay any revolving loans and third, to cash collateralize any outstanding letter of credit exposure. Such cash dominion period will end when availability has remained in excess of the greater of (i) $12.5Â million and (ii) 15% of the lesser of the maximum commitment amount and the borrowing base for a period of 45 consecutive days and no event of default is continuing.9.OTHER LONG-TERM LIABILITIESThe Company's other long-term liabilities at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023 were as follows:(in millions)September 30,2024December 31,2023Contingent consideration$â€”Â $2.3Â Escrow liability7.5Â 7.5Â Legal settlements24.0Â 24.0Â Other2.8Â 7.5Â Total other long-term liabilities$34.3Â $41.3Â 16Table of ContentsOn October 23, 2023 (the "Effective Date"), the Company and Ravgen, Inc. ("Ravgen") entered into a settlement agreement pursuant to which the parties agreed to settle a pending lawsuit. Subject to the terms of the settlement agreement, the Company agreed to pay Ravgen a contingent payment of $21.25Â million payable in five annual installments, with (1) the first installment of $5.0Â million payable on the later of (a) 30 days after notification in writing by Ravgen of the successful conclusion in favor of Ravgen of all of Ravgen's litigations and patent reexaminations pending as of the Effective Date and (b) January 1, 2026

(the "Contingent Payment Date"); (2) the second installment of $5.0Â million on the first anniversary of the Contingent Payment Date; (3) the third installment of $5.0Â million on the second anniversary of the Contingent Payment Date; (4) the fourth installment of $5.0Â million on the third anniversary of the Contingent Payment Date; and (5) $1.25Â million on the fourth anniversary of the Contingent Payment Date. Additionally, the Company agreed to pay Ravgen a minimum of $12.75Â million in three installment payments of which $7.75Â million is outstanding as of SeptemberÂ 30, 2024. The remaining payments will be made in two installments: (1) $5.0Â million on or before October 31, 2024 and (2) $2.75Â million on or before October 31, 2025. The Company has accrued $5.0Â million in Accrued liabilities and $24.0Â million in Other long-term liabilities for these payments in the Company's Condensed Consolidated Balance Sheet as of SeptemberÂ 30, 2024. 10.PREFERRED AND COMMON STOCKHOLDERS' EQUITYThe Company is authorized to issue up to 5.0 million shares of preferred stock, par value $0.01 per share. There were no shares of preferred stock outstanding at SeptemberÂ 30, 2024.The Company is authorized to issue up to 150.0 million shares of common stock, par value $0.01 per share. There were 91.0 million shares of common stock issued and outstanding at SeptemberÂ 30, 2024.Shares of common stock issued and outstandingNine months endedSeptember 30,(in millions)20242023Beginning common stock issued and outstanding89.9Â 81.2Â Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plan1.1Â 0.9Â Common stock issued and outstanding at end of period91.0Â 82.1Â Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding. Diluted earnings per share is computed based on the weighted-average number of shares of common stock, including the dilutive effect of common stock equivalents, outstanding. In periods when the Company has a net loss, stock awards are excluded from the calculation of diluted net loss per share as their inclusion would have an antidilutive effect.The following is a reconciliation of the denominators of the basic and diluted earnings per share (â€œEPSâ€) computations:Three months endedSeptember 30,Nine months endedSeptember 30,(in millions)2024202320242023Denominator:Weighted-average shares outstanding used to compute basic EPS90.9Â 81.9Â 90.5Â 81.6Â Effect of dilutive sharesâ€”Â â€”Â â€”Â â€”Â Weighted-average shares outstanding and dilutive securities used to compute diluted EPS90.9Â 81.9Â 90.5Â 81.6Â Certain outstanding options and restricted stock units (â€œRSUsâ€) were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. These potential dilutive shares of common stock, which may be dilutive to future diluted earnings per share, are as follows:Three months endedSeptember 30,Nine months endedSeptember 30,(in millions)2024202320242023Anti-dilutive options and RSUs excluded from EPS computation5.9Â 5.3Â 5.9Â 5.3Â 17Table of Contents11.STOCK-BASED COMPENSATIONOn November 30, 2017, the Companyâ€™s stockholders approved the adoption of the 2017 Employee, Director and Consultant Equity Incentive Plan (as amended, the â€œ2017 Planâ€). The 2017 Plan allows the Company, under the direction of the Compensation and Human Capital Committee (the "CHCC") of the Board of Directors, to make grants of restricted stock and restricted stock unit awards to employees, consultants, and directors. Stockholders have subsequently approved amendments to the 2017 Plan increasing the shares available to grant thereunder, including most recently at the Company's annual meeting of stockholders held on June 1, 2023, when stockholders approved an amendment to the 2017 Plan to increase the aggregate number of shares of common stock available thereunder for the granting of awards by an additional 4.8Â million shares. As of SeptemberÂ 30, 2024, the Company had 2.3Â million shares of common stock available for grant under the 2017 Plan. If an RSU awarded under the 2017 Plan is cancelled or forfeited without the issuance of shares of common stock, the unissued shares that were subject to the RSU will again be available for issuance pursuant to the 2017 Plan. The number of shares, terms, and vesting periods are generally determined by the Companyâ€™s Board of Directors or the CHCC on an award-by-award basis. RSUs granted to employees generally vest either ratably over three or four years or as cliff vesting after three years either on the anniversary of the date on which the RSUs were granted or during the month in which such anniversary dates occur. The number of performance-based RSUs ("PSUs") awarded to certain employees may be increased or reduced based on certain additional performance and market metrics. RSUs granted to non-employee directors generally vest in full upon the earlier of the completion of one year of service following the date of the grant or the date of the next annual meeting of stockholders following such grant. Options granted to the Company's President and Chief Executive Officer as an inducement to his employment expire on August 13, 2027.The performance and market conditions associated with PSU awards granted during the nine months ended September 30, 2024 include vesting that is based on revenue targets (34% weighting), adjusted earnings per share targets (33% weighting), and relative total stockholder return (33% weighting) measured against the Nasdaq Health Care Index (IXHC) using the 20-trading day averages at the beginning and end of the measurement period. The measurement period for the relative total stockholder return metric is January 1, 2024 through December 31, 2026, and the revenue and adjusted earnings per share metrics will be measured based on fiscal year 2026 results. The Company estimates the likelihood of achievement of performance conditions for all PSU awards at the end of each period. To the extent those awards or portions thereof are considered probable of being achieved, such awards or portions thereof are expensed over the performance period. The portion of the awards pertaining to relative total stockholder return represent market conditions and, accordingly, the estimated fair value of such awards is recognized over the performance period. Stock OptionsA summary of the stock option activity for the nine months ended SeptemberÂ 30, 2024 is as follows:(number of shares in millions)NumberofSharesWeightedAverageExercisePriceOptions outstanding at December 31, 20230.7Â $13.38Â Options outstanding at September 30, 20240.7Â $13.38Â Options exercisable at September 30, 20240.5Â $13.38Â As of SeptemberÂ 30, 2024, there was no unrecognized stock-based compensation expense. There were no options granted during the nine months ended SeptemberÂ 30, 2024.18Table of ContentsRestricted Stock UnitsA summary of the RSU awards activity under the Companyâ€™s equity plan and inducement awards, including PSU awards, for the nine months ended SeptemberÂ 30, 2024 is as follows:(number of shares in millions)NumberofSharesWeightedAverageGrant DateFair ValueRSUs unvested and outstanding at December 31, 20234.4Â $24.37Â RSUs granted2.5Â $22.46Â Less:RSUs vested(1.5)$23.77Â RSUs canceled(0.2)$23.62Â RSUs unvested and outstanding at September 30, 20245.2Â $23.63Â Employee Stock Purchase PlanThe Company also has an Employee Stock Purchase Plan that was initially approved by stockholders in 2012 and was amended and approved by the Board of Directors of the Company on September 23, 2021 and the stockholders on June 2, 2022 (the "Amended and Restated 2012 Purchase Plan"), under which 4.0Â million shares of common stock were authorized for issuance under the Amended and Restated 2012 Purchase Plan.Â Shares are issued under the Amended and Restated 2012 Purchase Plan twice yearly at the end of each offering period and the number of shares that may be purchased by any participant during an offering period is limited to 5,000 shares.Â The first offering period of 2024 started on December 1, 2023 and ended on May 31, 2024. The second offering period of 2024 began on June 1, 2024 and will end on November 30, 2024. As of SeptemberÂ 30, 2024, 1.1Â million shares of common stock were available for issuance under the Amended and Restated 2012 Purchase Plan. Shares purchased under, and compensation expense associated with, the Amended and Restated 2012 Purchase Plan for the nine months ended September 30, 2024 and 2023 are as follows:Three months endedSeptember 30,Nine months endedSeptember 30,(in millions)2024202320242023Shares purchased under the planâ€”Â â€”Â 0.2Â 0.2Plan compensation expense$0.5Â $0.5Â $1.6Â $1.7Â Stock-Based Compensation ExpenseStock-based compensation expense recognized and included in the Condensed Consolidated Statements of Operations and Comprehensive Loss was allocated as follows:Three months endedSeptember 30,Nine months endedSeptember 30,(in millions)20242023202420232Cost of testing revenue$0.3Â $0.4Â $1.0Â $1.1Â Research and development expense1.6Â 1.2Â 4.4Â 2.9Â Selling, general, and administrative expense10.5Â 10.0Â 33.5Â 26.3Â Â Â Â Â Â Total stock-based compensation expense$12.4Â $11.6Â $38.9Â $30.3Â As of SeptemberÂ 30, 2024, there was $81.7 million of total unrecognized stock-based compensation expense related to RSUs that is expected to be recognized over a weighted-average period of 2.2 years.Â The Company recognizes forfeitures as they occur. In the event that a PSU is determined to be improbable of vesting, the Company records an adjustment to reverse all previously recognized expense associated with the equity award in the current period. 19Table of Contents12.INCOME TAXESIn order to determine the Companyâ€™s quarterly provision for income taxes, the Company used an estimated annual effective tax rate that is based on expected annual income and statutory tax rates in the various jurisdictions in which the Company operates.Â Certain significant or unusual items are separately recognized in the quarter during which they occur and can be a source of variability in the effective tax rate from quarter to quarter.For the three months ended SeptemberÂ 30, 2024, there was $0.9 million in income tax expense, or approximately (4.2)% of pre-tax loss, compared to $0.1 million income tax expense, or approximately (0.2)% of pre-tax loss, for the three months ended SeptemberÂ 30, 2023. Income tax expense for the nine months ended September 30, 2024 was $0.4 million, or approximately (0.5)% of pre-tax loss, compared to an income tax expense of $2.2Â million, or approximately (1.0)% of pre-tax loss, for the nine months ended September 30, 2023. For the three and nine months ended September 30, 2024 and 2023, the Companyâ€™s effective tax rate differs from the U.S. federal statutory rate primarily due to the recognition of valuation allowances. Due to the Company's cumulative loss and the exhaustion of future taxable income from the reversal of taxable temporary differences, the Company's estimated annual effective tax rate for the current year includes a valuation allowance against the majority of the current year increase in deferred tax assets.13.COMMITMENTS AND CONTINGENCIESThe Company is involved from time to time in various disputes, claims and legal actions, including class actions and other litigation, including the matters described below, arising in the ordinary course of business. Such actions may include allegations of negligence, product or professional liability or other legal claims, and could involve claims for substantial compensatory and punitive damages or claims for indeterminate amounts of damages. The Company is also involved, from time to time, in investigations by governmental agencies regarding its business which may result in adverse judgments, settlements, fines, penalties, injunctions or other relief. In addition, certain federal and state statutes, including the qui tam provisions of the federal False Claims Act, allow private individuals to bring lawsuits against healthcare companies on behalf of the government or private payors. The Company has received subpoenas from time to time related to billing or other practices based on the False Claims Act or other federal and state statutes, regulations or other laws.The Company intends to defend its current litigation matters, but cannot provide any assurance as to the ultimate outcome or that an adverse resolution would not have a material adverse effect on its financial condition, results of operations or cash flows.The Company assesses legal contingencies to determine the degree of probability and range of possible loss for potential accrual in its financial statements. When evaluating legal contingencies, the Company may be unable to provide a meaningful estimate due to a number of factors, including the proceedings may be in early stages, there may be uncertainty as to the outcome of pending appeals or motions, there may be significant factual issues to be resolved, and there may be complex or novel legal theories to be presented. In addition, damages may not be specified or the damage amounts claimed may be unsupported, exaggerated or unrelated to possible outcomes, and therefore, such amounts are not a reliable indicator of potential liability. As of SeptemberÂ 30, 2024, except as noted below, the Company has not recorded any material accrual for loss contingencies associated with legal proceedings or other matters or determined that an unfavorable outcome is probable and reasonably estimable in accordance with ASC 450, Contingencies. However, it is possible that the ultimate resolution of legal proceedings or other matters, if unfavorable, may be material to the Company's results of operations, financial condition or cash flows. Further, in the event that damages from an unfavorable resolution of one or more of these proceedings exceed the aggregate amount of the coverage limits of the Companyâ€™s insurance, or if the Companyâ€™s insurance carriers disclaim coverage, the amounts payable by the Company could also have a material adverse impact on the Companyâ€™s results of operations, financial condition or cash flows.20Table of ContentsStockholder Derivative ActionsOn August 9, 2021, a stockholder derivative complaint was filed in the Delaware Court of Chancery against the Company's former President and Chief Executive Officer, Mark C. Capone, its former Chief Financial Officer, R. Bryan Riggsbee, its former Executive Vice President of Clinical Development, Bryan M. Dechairo, and certain of the Company's current and former directors, Lawrence C. Best, Walter Gilbert, John T. Henderson, Heiner Dreismann, Dennis Langer, Lee N. Newcomer, S. Louise Phanstiel, and Colleen F. Reitan (collectively, the "Individual Defendants"), and the Company, as nominal defendant. The complaint is premised upon similar allegations that were set forth in the securities class action lawsuit that was settled and then dismissed by the U.S. District Court for the District of Utah in December 2023 (the "Securities Class Action"), including that the Individual Defendants made false and misleading statements regarding the Company's business and operations. The plaintiff, Donna Hickock, asserts breach of fiduciary duty and unjust enrichment claims against the Individual Defendants and seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged breaches, or disgorgement or restitution, from each of the Individual Defendants, plus interest. Plaintiff Hickock also seeks legal and other costs and fees relating to this action. On November 19, 2021, this action was stayed by the Delaware Court of Chancery pending the resolution of the Securities Class Action. On January 18, 2022, a stockholder derivative complaint was filed in the Delaware Court of Chancery against the Individual Defendants and the Company, as nominal defendant. The action is premised upon similar allegations as set forth in the Securities Class Action and the Hickock stockholder derivative action. The plaintiff, Esther Kogus, asserts that the Individual Defendants breached their fiduciary duties and also asserts unjust enrichment and aiding and abetting breaches of fiduciary duty claims against the Individual Defendants. Plaintiff Kogus seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged breaches and claims, and restitution from the Individual Defendants. On behalf of herself, plaintiff Kogus seeks legal and other costs and fees relating to this action. On March 3, 2022, the Delaware Court of Chancery consolidated the Hickock and Kogus derivative actions and stayed the consolidated action. On April 19, 2024, the Court of Chancery ordered that Leo Shumacher be substituted for Ms. Kogus as a plaintiff in this consolidated action.On September 17, 2021, a stockholder derivative complaint was filed in the U.S. District Court in the District of Delaware against the Individual Defendants and the Company, as nominal defendant. The action is premised upon similar allegations as set forth in the Securities Class Action and Hickock stockholder derivative action. The plaintiff, Karen Marcey, asserts that the Individual Defendants violated U.S. securities laws and breached their fiduciary duties, and also asserts unjust enrichment, waste of corporate assets and insider trading claims against all or some of the Individual Defendants. Plaintiff Marcey seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged violations and restitution from the Individual Defendants, plus interest and, on behalf of herself, legal and other costs and fees relating to this action. On January 4, 2022, this action was stayed by the U.S. District Court for the District of Delaware pending the resolution of the Securities Class Action. On April 30, 2024, the parties across all of the foregoing stockholder derivative actions entered into a global stipulation of settlement to resolve the actions (the "Settlement"). On May 3, 2024, the parties submitted the Settlement to the Delaware Court of Chancery for approval. As part of the Settlement, (i) the Company agreed to adopt or implement certain corporate governance reforms; and (ii) the parties agreed that plaintiffs' counsel will apply to the court for an award of attorneys' fees and expenses not to exceed $0.95 million to be paid by the Company, and that the Individual Defendants and the Company will not oppose or object to the requested fee award. The Settlement contains no admission of liability, wrongdoing or responsibility by any of the parties. On August 6, 2024, the Delaware Court of Chancery held a hearing to consider the Settlement. The parties expect a ruling on or about November 26, 2024. The Company has accrued $0.95 million for the settlement of the stockholder derivative actions, which is included in Accrued liabilities in the Companyâ€™s Condensed Consolidated Balance Sheet as of SeptemberÂ 30, 2024.Other Legal ProceedingsFrom time to time, the Company receives recoupment requests from third-party payors for alleged overpayments. The Company disagrees with the contentions of the pending requests or has recorded an estimated reserve for the alleged overpayments. 21Table of Contents14.SUPPLEMENTAL CASH FLOW INFORMATIONThe Company's supplemental cash flow information for the nine months ended SeptemberÂ 30, 2024 and 2023 are as follows:Nine Months Ended September 30,(in millions)20242023Cash paid for income taxes$1.8Â $1.3Â Cash paid for interest1.3Â 0.8Â Non-cash investing and financing activities: Change in operating lease right-of-use assets and lease liabilitiesOperating lease right-of-use assets(0.3)8.7Â Operating lease liabilities(3.1)9.2Â Non-cash adjustment to right-of-use assets and lease liabilities from lease modifications3.1Â â€”Â Purchases of property, plant and equipment and capitalization of internal-use software in accounts payable and accrued liabilities2.5Â 9.1Â The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported on the Condensed Consolidated Balance Sheets that agrees to the amounts included in the Condensed Consolidated Statements of Cash Flows.September 30,(in millions)20242023Cash and cash equivalents$99.9Â $76.0Â Restricted cash9.9Â 9.0Â Total cash, cash equivalents, and restricted cash$109.8Â $85.0Â 15.LEASESThe Company leases certain office spaces and research and development laboratory facilities, vehicles, and office equipment with remaining lease terms ranging from approximately one to fourteen years. Operating leases are included in Operating lease right-of-use assets, Noncurrent operating lease liabilities, and Current maturities of operating lease liabilities in the Condensed Consolidated Balance Sheets. Finance leases are included in Other assets, Accrued liabilities, and Other long-term liabilities in the Condensed Consolidated Balance Sheets. Due to the increase in remote and hybrid work and the Company's need to ensure its facilities are designed to handle future growth, the Company has been executing on a multi-year strategy to reset its real estate footprint. As part of that strategy, during the nine months ended SeptemberÂ 30, 2023, the Company took full possession of the remaining phases of the west Salt Lake City, Utah facility and recognized an additional $5.9 million right-of-use asset and corresponding lease liability, net of tenant improvement allowance not yet received. Also during the nine months ended SeptemberÂ 30, 2023, the Company decided to cease the use of its former corporate headquarters in Salt Lake City and transition corporate support operations to its new facility in west Salt Lake City, and as of December 31, 2023, the Company had formally assigned the lease for its previous corporate headquarters in Salt Lake City to a third party.During the nine months ended SeptemberÂ 30, 2024, the Company terminated the lease for one of its Salt Lake City, Utah facilities. As

a result of the termination, the short-term lease liability of $3.1Â million associated with the lease was removed from the Company's Condensed Consolidated Balance Sheets. The total net gain recognized in connection with the termination of the lease was $1.2Â million, which is included in Selling, general, and administrative expense in the Condensed Consolidated Statements of Operations.During the nine months ended SeptemberÂ 30, 2024, the Company also amended the lease for its west Salt Lake City, Utah headquarters to include approximately 63,000 additional square feet in anticipation of future operating needs. The lease has a term of 12 years, which is expected to commence in fiscal year 2026. Total future rent payments for the additional space are approximately $18.2Â million.22Table of Contents16. ACCUMULATED OTHER COMPREHENSIVE LOSSThe functional currency of the Companyâ€™s international subsidiaries is the local currency. For those subsidiaries, expenses denominated in the functional currency are translated into U.S. dollars using average exchange rates in effect during the period and assets and liabilities are translated using period-end exchange rates. The foreign currency translation adjustments are included in Accumulated other comprehensive loss as a separate component of Stockholdersâ€™ equity.The following table shows the cumulative translation adjustments included in Accumulated other comprehensive loss (in millions):Ending balance December 31, 2023$(3.7)Period translation adjustments(1.5)Reclassification of cumulative translation adjustment to income upon sale or liquidation of certain foreign entities5.1Â Ending balance September 30, 2024$(0.1)17.ACQUISITIONOn February 1, 2024, the Company acquired from Intermountain Health select assets from its Intermountain Precision Genomics ("IPG") laboratory business, including the Precise Tumor Test, the Precise Liquid Test, and IPG's CLIA-certified laboratory in St. George, Utah for an immaterial amount (the "Precise acquisition"). In connection with the Precise acquisition, the Company recognized a gain of $2.2Â million, which is included in Other income in the Company's Condensed Consolidated Statements of Operations.18.DIVESTITUREOn August 1, 2024, the Company completed the sale of its EndoPredict business to Eurobio Scientific ("Eurobio") for net cash consideration of $10.0Â million, subject to customary closing adjustments, plus contingent consideration subject to certain earn-out conditions. The transaction was accounted for as a sale of business. The Company recognized a total net loss, including transaction expenses, of $12.4Â million during the nine months ended SeptemberÂ 30, 2024 in connection with this sale. The loss is included in Goodwill and long-lived asset impairment charges on the Companyâ€™s Condensed Consolidated Statements of Operations. The recognized loss included the release of $4.4Â million of foreign currency translation adjustments previously included in Accumulated other comprehensive income (loss). As part of the transaction, the Company licensed the rights from Eurobio to continue to sell EndoPredict as a laboratory developed test outside of the European Union and licensed to Eurobio the right to sell Prolaris in vitro diagnostic kits outside the U.S.23Table of ContentsItem 2.Â Â Â Â Managementâ€™s Discussion and Analysis of Financial Condition and Results of OperationsThe following Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations should be read in conjunction with the unaudited Condensed Consolidated Financial Statements and the related notes thereto included in this Quarterly Report on Form 10-Q and the audited Consolidated Financial Statements and notes thereto and Managementâ€™s Discussion and Analysis of Financial Condition and Results of Operations for the year ended DecemberÂ 31, 2023 included in our Annual Report on Form 10-K filed with the SEC on February 28, 2024. â€œWe,â€ â€œus,â€ â€œour,â€ â€œMyriadâ€ and the â€œCompanyâ€ as used in this Quarterly Report on Form 10â€’Q refer to Myriad Genetics, Inc., a Delaware corporation, and its subsidiaries.Myriad, the Myriad logo, BRACAnalysis, BRACAnalysis CDx, Colaris, MyRisk, Myriad myRisk, MyRisk Hereditary Cancer, myChoice, Tumor BRACAnalysis CDx, MyChoice CDx, Prequel, Prequel with Amplify, Amplify, Foresight, Foresight Universal Plus, Precise Tumor, Precise Oncology Solutions, Precise Liquid, Precise MRD, FirstGene, SneakPeek, SneakPeek Early Gender DNA Test, SneakPeek Snap, Urosuite, Mygenehistory, Health.Illuminated., RiskScore, Prolaris, and GeneSight are registered trademarks or trademarks of Myriad. Solely for convenience, trademarks, trade names and service marks referred to in this Quarterly Report on Form 10-Q may appear without the Â®, â„¢ or SM symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable licensor to these trademarks, trade names and service marks.Cautionary Statement Regarding Forward-Looking StatementsThe SEC encourages companies to disclose forward-looking information so that investors can better understand a companyâ€™s future prospects and make informed investment decisions. This Quarterly Report on Form 10â€’Q contains such â€œforward-looking statementsâ€ within the meaning of the Private Securities Litigation Reform Act of 1995.Words such as â€œmay,â€ â€œanticipate,â€ â€œestimate,â€ â€œexpects,â€ â€œprojects,â€ â€œintends,â€ â€œplans,â€ â€œbelieves,â€ â€œseek,â€ â€œcould,â€ â€œcontinue,â€ â€œlikely,â€ â€œwill,â€ â€œstrategyâ€ and â€œgoalâ€ and words and terms of similar substance used in connection with any discussion of future operating or financial performance identify forward-looking statements. All forward-looking statements are managementâ€™s present expectations of future events and are subject to a number of known and unknown risks and uncertainties that could cause actual results, conditions, and events to differ materially and adversely from those anticipated. These risks include, but are not limited to: â€¢the risk that sales and profit margins of our existing tests may decline;â€¢the risk that we may not be able to operate our business on a profitable basis; â€¢risks related to our ability to achieve certain revenue growth targets and generate sufficient revenue from our existing product portfolio or in launching and commercializing new tests to be profitable; â€¢risks related to changes in governmental or private insurersâ€™ coverage and reimbursement levels for our tests or our ability to obtain reimbursement for new tests at comparable levels to our existing tests, including risks to our business and financial results associated with UnitedHealthcare's recent update to its medical policy for pharmacogenetic testing to no longer provide coverage for certain multi-gene panel pharmacogenetic tests, such as GeneSight, under its commercial and individual exchange benefit plans, effective January 1, 2025, and our pursuit of a resolution with respect thereto that may benefit the company and patients that could benefit from GeneSight; â€¢risks related to increased competition and the development of new competing tests; â€¢the risk that we may be unable to develop or achieve commercial success for additional tests in a timely manner, or at all; â€¢the risk that we may not successfully develop new markets or channels for our tests; â€¢the risk that licenses to the technology underlying our tests and any future tests are terminated or cannot be maintained on satisfactory terms; â€¢risks related to delays or other problems with operating our laboratory testing facilities and the transition of such facilities to our new laboratory testing facilities;â€¢risks related to public concern over genetic testing in general or our tests in particular;â€¢risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; â€¢risks related to our ability to obtain new corporate collaborations or licenses and acquire or develop new technologies or businesses on satisfactory terms, if at all; 24Table of Contentsâ€¢risks related to our ability to successfully integrate and derive benefits from any technologies or businesses that we license, acquire, or develop; â€¢the risk that we are not able to secure additional financing to fund our business, if needed, in a timely manner or on favorable terms, if it all;â€¢risks related to our projections or estimates about the potential market opportunity for our current and future products;â€¢the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests;â€¢the risk of patent-infringement claims or challenges to the validity of our patents;â€¢risks related to changes in intellectual property laws covering our tests, or patents or enforcement, in the United States and foreign countries; â€¢risks related to security breaches, loss of data and other disruptions, including from cyberattacks;â€¢risks of new, changing and competitive technologies in the United States and internationally, and that we may not be able to keep pace with the rapid technology changes in our industry, or properly leverage new technologies to achieve or sustain competitive advantages in our products; â€¢the risk that we may be unable to comply with financial or operating covenants under our credit or lending agreements; â€¢the risk that we may not be able to maintain effective disclosure controls and procedures and internal control over financial reporting;â€¢risks related to current and future investigations, claims or lawsuits, including derivative claims, product or professional liability claims, and risks related to the amount of our insurance coverage limits and scope of insurance coverage with respect thereto; andâ€¢other factors discussed under the heading "Risk Factors" contained in Part I, Item 1A of our Annual Report on Form 10-K filed with the SEC on February 28, 2024, as updated in Part II, Item 1A of our Quarterly Report on Form 10-Q filed with the SEC on May 8, 2024, and subsequent filings we make with the SEC.In light of these assumptions, risks and uncertainties, the results and events discussed in the forward-looking statements contained in this Quarterly Report on Form 10-Q, or in any document incorporated by reference might not occur. Stockholders are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this Quarterly Report on Form 10-Q. We are not under any obligation, and we expressly disclaim any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise except as required by law. All forward-looking statements in this Quarterly Report on Form 10-Q attributable to us or to any person acting on our behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this section.GeneralWe are a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. We develop and offer tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower health care costs. Our genetic tests provide insights that help people take control of their health and enable healthcare providers to better detect, treat, and prevent disease. Personalized genetic data and digital and virtual consumer trends are converging to change traditional models of care. We believe significant growth opportunities exist to help patient populations with pressing health care needs through innovative genetic and precision medicine solutions and services. Our focus is on innovation and growth in three key areas where we have specialized products, capabilities, and expertise: Oncology, Women's Health, and Pharmacogenomics. The pillars of our long-term growth strategy are founded on investments in science and innovation, technology-enabled operations, an elevated customer experience, strong commercial execution, and scalable operations. We believe our path to continued growth is driven by articulating our clinical differentiation, raising awareness with patients who we believe would benefit from our testing products, and innovation that improves clinical outcomes, ease of use, and access. By investing in technology-enabled commercial tools, new laboratory facilities, advanced automation, and standardized processes and technology, we believe we will be able to reduce complexity and cost while enhancing our ability to scale and grow. In June 2024, we launched the Universal Plus Panel to our Foresight Carrier Screen or the Foresight Universal Plus Test, which is an expanded carrier screening test. We also plan to launch new products, such as FirstGene, Precise Liquid, and Precise minimal residual disease, or MRD, which we expect will help accelerate our growth. We intend to develop and enhance our products and services to support growth, improve patient and provider experience, and reach more patients of all backgrounds. We are committed to disciplined management of a key set of initiatives to fulfill our mission and drive long-term growth and profitability.25Table of ContentsBusiness UpdatesOur recent significant business updates and financial highlights include the following: â€¢Revenue growth of 11% year-over-year for the quarter ended SeptemberÂ 30, 2024.â€¢Third quarter 2024 testing volumes grew 6% year-over-year, driven by 10% growth year-over-year in Pharmacogenomics test volumes, 5% growth year-over-year in Hereditary Cancer test volumes, and 3% growth year-over-year in Prenatal test volumes.â€¢In October 2024, we announced five research collaborations to study the use of MRD testing in Breast Cancer.â€¢In October 2024, we announced a joint effort with Ultima Genomics to explore the UG 100TM sequencing platform and its ppmSeqTM technology to advance clinical testing.â€¢In October 2024, we announced a third patent granted for MRD with an early priority date. â€¢In August 2024, Peach State Health Plan, a managed Medicaid plan in Georgia, added GeneSight to its medical policy. The Peach State Plan is part of the Centene network of managed Medicaid plans. On November 1, 2024, UnitedHealthcare updated its medical policy for pharmacogenetic testing to no longer provide coverage for certain multi-gene panel pharmacogenetic tests, including our GeneSight test, under its commercial and individual exchange benefit plans, effective January 1, 2025. We recognized approximately $40.0 million in revenue for GeneSight volume from UnitedHealthcare under these commercial and individual exchange plans during the last twelve months ended September 30, 2024. We do not believe that the updated policy affects coverage of GeneSight by UnitedHealthcare under Medicare Advantage and managed Medicaid plans. While we are still assessing the full impact of UnitedHealthcare's change in its GeneSight coverage policy, including our ability to offset the loss in GeneSight coverage, we anticipate that this change will negatively impact revenue in fiscal year 2025 and thereafter. In addition, please refer to Note 6, "Goodwill and Intangible Assets" in the notes to the Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q and Item 1A, "Risk Factors" in Part II of this Quarterly Report on Form 10-Q for potential impacts of UnitedHealthcare's change on goodwill in our Pharmacogenomics reporting unit.Results of Operations for the Three Months Ended September 30, 2024 and 2023The results of operations for the three months ended September 30, 2024 and 2023 are discussed below. RevenueThe following table summarizes year-over-year revenue changes in our core product categories:Three months ended September 30,% of Total Revenue(in millions)20242023Change20242023Testing revenues:Hereditary Cancer$90.5Â $86.5Â $4.0Â 43%45%Tumor Profiling31.6Â 30.2Â 1.4Â 15%16%Prenatal43.5Â 39.5Â 4.0Â 20%20%Pharmacogenomics47.7Â 35.7Â 12.0Â 22%19%Total revenue$213.3Â $191.9Â $21.4Â 100%100%The following table summarizes testing volume changes in our core product categories:Three months ended September 30,(in thousands)20242023% ChangeProduct volumes:Hereditary Cancer74Â 71Â 5Â %Tumor Profiling13Â 13Â â€”Â %Prenatal162Â 156Â 3Â %Pharmacogenomics127Â 116Â 10Â %Total376Â 356Â 6Â %26Table of ContentsTest revenues increased $21.4Â million for the three months ended September 30, 2024 compared to the same period in the prior year primarily due to both an increase in testing volumes and an increase in the average revenue per test, due in part to changes in contracted price and operational improvements. Pharmacogenomics revenues increased $12.0Â million for the three months ended September 30, 2024 compared to the same period in the prior year due to a 22% increase in the average revenue per test and a 10% increase in testing volume. Average revenue per test increased primarily due to a change in estimate. We expect that Pharmacogenomics revenues in fiscal year 2025 and thereafter will be negatively impacted by UnitedHealthcare's recent change in GeneSight test coverage under its commercial and individual exchange benefits plans. Hereditary Cancer revenues increased $4.0Â million for the three months ended September 30, 2024 compared to the same period in the prior year primarily due to a 5% increase in testing volume. Prenatal revenues increased $4.0Â million for the three months ended September 30, 2024 compared to the same period in the prior year due to a 6% increase in average revenue per test and a 3% increase in testing volume. Cost of SalesThree months ended September 30,(in millions)20242023ChangeCost of testing revenue$63.5Â $57.6Â $5.9Cost of testing revenue as a % of total revenue29.8Â %30.0Â %Cost of testing revenue for the three months ended SeptemberÂ 30, 2024 increased $5.9 million compared to the same period in the prior year primarily due to an increase in testing volumes in Pharmacogenomics, Hereditary Cancer, and Prenatal tests. Research and Development ExpenseThree months ended September 30,(in millions)20242023ChangeResearch and development expense$28.5Â $24.0Â $4.5Research and development expense as a % of total revenue13.4Â %12.5Â %Â Research and development expense for the three months ended SeptemberÂ 30, 2024 increased by $4.5 million compared to the same period in the prior year primarily due to additional investments in research and development related to increased headcount and laboratory expenses.Selling, General, and Administrative ExpenseThree months ended September 30,(in millions)20242023ChangeSelling, general, and administrative expense$139.1Â $136.1Â $3.0Selling, general, and administrative expense as a % of total revenue65.2Â %70.9Â %Selling, general, and administrative expense in the current period was generally consistent with the expenses incurred in the same period of the prior year. Legal SettlementsThree months ended September 30,(in millions)20242023ChangeLegal settlements$â€”Â $34.3Â $(34.3)Legal settlements as a % of total revenueâ€”Â %17.9Â %There were no legal settlements in the three months ended SeptemberÂ 30, 2024. Legal settlements in the three months ended SeptemberÂ 30, 2023 consisted of $34.3Â million in connection with accruals for pending settlements.27Table of ContentsGoodwill and Long-lived Asset Impairment ChargesThree months ended September 30,Change(in millions)20242023Goodwill and long-lived asset impairment charges$2.2Â $â€”Â $2.2Â Goodwill and long-lived asset impairment charges as a % of total revenue1.0Â %â€”Â %Goodwill and long-lived asset impairment charges in the three months ended SeptemberÂ 30, 2024 consisted of $2.2 million of losses in connection with the sale of the EndoPredict business. There were no corresponding impairment charges in the same period of the prior year.Other Income (Expense), NetThree months ended September 30,(in millions)20242023ChangeOther income (expense), net(1.2)(1.1)$(0.1)Other income (expense), net remained consistent for the three months ended SeptemberÂ 30, 2024 as compared to the same period in the prior year. Income Tax ExpenseThree months ended September 30,(in millions)20242023ChangeIncome tax expense$0.9Â $0.1Â $0.8Effective tax rate(4.2)%(0.2)%Â Our tax rate is the product of a U.S. federal effective rate of 21.0% and a blended state income tax rate of approximately 3.4%. Certain significant or unusual items are separately recognized during the period in which they occur and can be a source of variability in the effective tax rates from period to period.For the three months ended SeptemberÂ 30, 2024, there was $0.9 million income tax expense and our effective tax rate was (4.2)%.Â For the three months ended SeptemberÂ 30, 2023, there was $0.1 million income tax expense and our effective tax rate was (0.2)%. For the three months ended SeptemberÂ 30, 2024 and 2023, our effective tax rate differs from the U.S. federal statutory rate primarily due to the recognition of valuation allowances. Due to our cumulative loss and the exhaustion of future taxable income from the reversal of taxable temporary differences, our estimated annual effective tax rate for the current year includes a valuation allowance against the majority of the current year increase in deferred tax assets. Results of Operations for the Nine Months Ended September 30, 2024 and 2023 The results of operations for the nine months ended September 30, 2024 and 2023 are discussed below. RevenueThe following table summarizes year-over-year revenue changes in our core product categories:Nine months ended September 30,% of Total Revenue(in millions)20242023Change20242023Testing

revenues:Hereditary Cancer$270.1Â $238.9Â $31.2Â 43%43%Tumor Profiling95.1Â 103.5Â (8.4)15%19%Prenatal132.2Â 111.3Â 20.9Â 21%20%Pharmacogenomics129.6Â 102.9Â 26.7Â 21%18%Total revenue$627.0Â $556.6Â $70.4Â 100%100%28Table of ContentsThe following table summarizes testing volume changes in our core product categories:Nine months ended September 30,(in thousands)20242023% ChangeProduct volumes:Hereditary Cancer219Â 207Â 5%Tumor Profiling41Â 45Â (9)%Prenatal506Â 469Â 8%Pharmacogenomics380Â 343Â 11%Total1,146Â 1,064Â 8%Test revenues increased $70.4 million for the nine months ended September 30, 2024 compared to the same period in the prior year primarily due to an increase in the average revenue per test across the majority of our products, due in part to changes in contracted price and operational improvements, as well as an increase in testing volumes. For the nine months ended September 30, 2024, we recorded $17.3Â million of revenue as a change of estimate related to previously delivered tests, as compared to the nine months ended September 30, 2023, in which we recorded a $6.2Â million decrease in revenue as a change of estimate related to previously delivered tests.Hereditary Cancer revenues increased $31.2Â million for the nine months ended September 30, 2024 compared to the same period in the prior year due to an 8% increase in average revenue per test and a 5% increase in testing volume. Pharmacogenomics revenues increased $26.7Â million for the nine months ended September 30, 2024 compared to the same period in the prior year due primarily to a 13% increase in the average revenue per test, which was partially due to changes in the estimated revenue per test related to prior periods, and an 11% increase in testing volume. We expect that Pharmacogenomics revenues in fiscal year 2025 and thereafter will be negatively impacted by UnitedHealthcare's recent change in GeneSight test coverage under its commercial and individual exchange benefits plans. Prenatal revenues increased $20.9Â million for the nine months ended September 30, 2024 compared to the same period in the prior year due to a 10% increase in average revenue per test and an 8% increase in testing volume. Tumor Profiling revenues decreased $8.4Â million for the nine months ended September 30, 2024 compared to the same period in the prior year due primarily to a decrease in testing volume for MyChoice CDx, which was largely driven by MyChoice CDx studies that occurred in the prior year period. Cost of SalesNine months ended September 30,(in millions)20242023ChangeCost of testing revenue$192.5Â $174.6Â $17.9Cost of testing revenue as a % of total revenue30.7Â %31.4Â %Cost of testing revenue for the nine months ended September 30, 2024 increased $17.9 million compared to the same period in the prior year primarily due to an increase in testing volumes in Pharmacogenomics, Hereditary Cancer, and Prenatal tests. Research and Development ExpenseNine months ended September 30,(in millions)20242023ChangeResearch and development expense$81.2Â $67.7Â $13.5Â Research and development expense as a % of total revenue13.0Â %12.2Â %Research and development expense for the nine months ended September 30, 2024 increased by $13.5Â million compared to the same period in the prior year primarily due to additional investments in research and development, consisting of an $8.1 million increase in compensation costs and $4.5 million increase in laboratory expenses. Compensation expense increased in part due to an increase in the average cost per employee for the current period compared to the same period in the prior year. 29Table of ContentsSelling, General, and Administrative ExpenseNine months ended September 30,(in millions)20242023ChangeSelling, general, and administrative expense$424.0Â $428.5Â $(4.5)Selling, general, and administrative expense as a % of total revenue67.6Â %77.0Â %Selling, general, and administrative expense decreased $4.5 million for the nine months ended September 30, 2024 primarily due to a decrease in facility costs associated with our real estate optimization strategy.Legal SettlementsNine months ended September 30,(in millions)20242023ChangeLegal settlements$â€”Â $111.8Â $(111.8)Legal settlements as a % of total revenueâ€”Â %20.1Â %There were no legal settlements in the nine months ended September 30, 2024. Legal settlements for the nine months ended September 30, 2023 consisted of $111.8Â million in connection with accruals for pending settlements.Goodwill and Long-lived Asset Impairment ChargesNine months ended September 30,Change(in millions)20242023Goodwill and long-lived asset impairment charges$13.8Â $â€”Â $13.8Â Goodwill and long-lived asset impairment charges as a % of total revenue2.2Â %â€”Â %Goodwill and long-lived asset impairment charges in the nine months ended SeptemberÂ 30, 2024 included $12.4Â million of losses in connection with the sale of the EndoPredict business. There were no corresponding impairment charges in the same period of the prior year.Other Income (Expense), NetNine months ended September 30,(in millions)20242023ChangeOther income (expense), net$0.1Â (3.9)4.0Other income (expense), net increased for the nine months ended September 30, 2024 compared to the same period in the prior year due primarily to the $2.2 million gain recognized on the February 2024 acquisition of Precise assets and laboratory from Intermountain Health in the current period, an additional $1.3 million loss due to foreign currency fluctuations in the current period and the prior period including an additional $1.4 million in expense from the sale of investments.Income Tax Expense Nine months ended September 30,(in millions)20242023ChangeIncome tax expense $0.4Â $2.2Â $(1.8)Effective tax rate(0.5)%(1.0)%Our tax rate is the product of a blended U.S. federal effective rate of 21.0% and a blended state income tax rate of approximately 3.4%. Certain significant or unusual items are separately recognized during the period in which they occur and can be a source of variability in the effective tax rates from period to period.Income tax expense for the nine months ended September 30, 2024 was $0.4 million and our effective tax rate was (0.5)%.Â Income tax expense for the nine months ended September 30, 2023 was $2.2 million and our effective tax rate was (1.0)%. For the nine months ended September 30, 2024 and 2023, our recognized effective tax rate differs from the U.S. federal statutory rate primarily due to the recognition of valuation allowances. Due to our cumulative loss and the exhaustion of future taxable income from the reversal of taxable temporary differences, our estimated annual effective tax rate for the current year includes a valuation allowance against the majority of the current year increase in deferred tax assets.30Table of ContentsLiquidity and Capital ResourcesOur primary sources of liquidity are our cash and cash equivalents, our expected cash flows from operations, and, in certain circumstances as discussed below, amounts available for borrowing under our asset-based revolving credit facility with JPMorgan Chase Bank, N.A., as administrative agent and issuing bank, and the other lender parties thereto, or the ABL Facility. As of SeptemberÂ 30, 2024, we had cash and cash equivalents of $99.9Â million and availability under the ABL Facility was $48.8 million, subject to the minimum availability requirement under the ABL Facility. Our capital deployment strategy focuses on use of resources in the key areas of research and development, technology and acquisitions. We believe that investing organically through research and development and new product development or acquisitively to support our business strategy provides the best return on invested capital. Our ABL Facility has a total maximum principal commitment of $115.0Â million. The ABL Facility requires that we and our subsidiaries guaranteeing the indebtedness, on a consolidated basis, maintain minimum liquidity of $60.0Â million and minimum availability of $25.0Â million at all times before achieving a fixed charge coverage ratio of 1.0 to 1.0 and, thereafter, to maintain a fixed charge coverage ratio of 1.0 to 1.0 until achieving availability under the ABL Facility of greater of (a) $10.6Â million and (b) 12.5% of the lesser of the maximum commitment amount and the borrowing base for a period of 30 consecutive days. As of SeptemberÂ 30, 2024, we had $40.0 million outstanding under the ABL Facility and availability under the ABL Facility was $48.8 million, subject to the minimum availability requirement under the ABL Facility.We believe that our existing capital resources will be sufficient to meet our projected operating requirements for at least the next 12 months. Our available capital resources, however, may be consumed more rapidly than currently expected, or may be insufficient for our business needs for many reasons, including as a result of our operational cash needs, capital expenditures, and litigation related costs not covered by, or above the limits set forth in, our insurance. In addition, we are subject to covenants under our ABL Facility which could limit our ability to incur additional indebtedness or impact our ability to pursue other financing. If we do not generate sufficient cash from operations, if our capital resources are consumed more rapidly than expected, or if we no longer have access to additional funds under our ABL Facility and we are unable to secure additional funds on acceptable terms, or at all, we may be forced to delay, scale back or eliminate some of our sales and marketing efforts, research and development activities, or other operations; or delay development of our tests in an effort to provide sufficient funds to continue our operations. If any of these events occurs, our ability to achieve our development and commercialization goals could be adversely affected.From time to time, we enter into purchase commitments or other agreements that may materially impact our liquidity position in future periods. In April 2024, we entered into an amendment of our lease in west Salt Lake City, Utah to include approximately 63,000 additional square feet. The lease has a term of 12 years, which is expected to commence in the second half of 2026. Total future rent payments for the additional space are approximately $18.2 million.Because of the technical nature of our business and our focus on science, research, and development, we are highly dependent upon our ability to attract and retain highly qualified and experienced management, scientific, and technical personnel. Loss of the services of or failure to recruit additional key management, scientific, and technical personnel and other qualified personnel who are necessary to operate our business would adversely affect our business, and it may have a material adverse effect on our business as a whole. Additionally, disruptions to our supply chain could cause shortages of critical materials required to conduct our business, which may have a material adverse effect on our business as a whole. In addition, as discussed below, inflation has had, and may continue to have, an impact on the costs we incur to attract and retain qualified personnel, costs to generate sales and produce testing results, and costs of laboratory supplies.Third-party payors, including state and federal health care programs such as Medicare, managed care organizations, and other private health insurers, are increasingly attempting to contain health care costs by limiting or denying coverage for certain tests and reducing reimbursement rates for both new and existing tests. We have experienced and may continue to experience coverage limitations or denials for many of our products. For example, on November 1, 2024, UnitedHealthcare updated its medical policy for pharmacogenetic testing to no longer provide coverage for certain multi-gene panel pharmacogenetic tests, including our GeneSight test, under its commercial and individual exchange benefit plans, effective January 1, 2025. We recognized approximately $40.0 million in revenue for GeneSight volume from UnitedHealthcare under these commercial and individual exchange plans during the last twelve months ended September 30, 2024. While we are still assessing the full impact of UnitedHealthcare's change in its GeneSight coverage policy, including our ability to offset the loss in GeneSight coverage, we anticipate that this change would negatively impact our revenue, profitability and cash flow in fiscal year 2025 and thereafter.31Table of ContentsThe following table represents the balances of cash, cash equivalents and marketable investment securities as of the dates set forth in the table below:Â (in millions)September 30,2024December 31,2023ChangeCash and cash equivalents$99.9Â $132.1Â $(32.2)Marketable investment securitiesâ€”Â 8.8Â (8.8)Cash, cash equivalents and marketable investment securities$99.9Â $140.9Â $(41.0)The decrease in cash, cash equivalents and marketable investment securities as of SeptemberÂ 30, 2024 as compared to December 31, 2023 was primarily driven by $15.3 million in cash used by operations, $15.4 million in cash used for capital expenditures, $8.4 million in cash used for the capitalization of internal-use software, and $9.2 million in cash used for the payment of withholding tax for the issuance of common stock, net of proceeds from the issuance of common stock. The decrease in cash was partially offset by $8.8 million in cash received from the sale of our EndoPredict business. The following table represents the Condensed Consolidated Cash Flow Statement:Nine Months Ended September 30,(in millions)20242023ChangeCash flows used in operating activities(15.3)(56.2)$40.9Â Cash flows provided by (used in) investing activities(6.0)43.9Â (49.9)Cash flows provided by (used in) financing activities(9.5)31.0Â (40.5)Effect of foreign exchange rates on cash, cash equivalents, and restricted cash(0.3)(0.1)(0.2)Net increase (decrease) in cash, cash equivalents, and restricted cash(31.1)18.6Â (49.7)Cash, cash equivalents, and restricted cash at the beginning of the period140.9Â 66.4Â 74.5Â Cash, cash equivalents, and restricted cash at the end of the period$109.8Â $85.0Â $24.8Â Cash Flows from Operating ActivitiesWe used less cash for operating activities for the nine months ended September 30, 2024 compared to the same period in the prior year, primarily due to an improvement in core operations which drove a 13% increase in revenues and an 8% decrease in expenses as a percentage of revenue, excluding non-cash expenses for goodwill and long-lived asset impairment charges and accrued legal settlements. In the nine months ended September 30, 2023, we received $16.3Â million in tenant improvement allowance reimbursements that did not reoccur during the nine months ended September 30, 2024.Cash Flows from Investing ActivitiesThe decrease in cash flows used in investing activities for the nine months ended September 30, 2024 compared to the same period in the prior year was primarily due to the $94.7Â million decrease in cash flows from maturities and sales of marketable investment securities in the current period, partially offset by a $37.8Â million decrease in capital expenditures in the current period in connection with the completion of the build-out of new facilities in the prior year. Cash Flows from Financing ActivitiesThe decrease in cash flows used in financing activities for the nine months ended September 30, 2024 compared to the same period in the prior year was primarily due to proceeds of $40.0Â million under the ABL Facility in the prior year period.Effects of InflationWhile inflation continues to return to more moderate levels in 2024, inflation has had, and may continue to have, an impact on the labor costs we incur to attract and retain qualified personnel, costs to generate sales and produce testing results, and costs of laboratory supplies. Inflationary costs have impacted our profitability and may continue to adversely affect our business, financial condition and results of operations. In addition, increased inflation has had, and may continue to have, an effect on interest rates. An increase in interest rates in the future may adversely affect our borrowing rate and our ability to obtain, or the terms under which we can obtain, additional funding. 32Table of ContentsCritical Accounting EstimatesCritical accounting estimates are those policies which are both important to the presentation of a companyâ€™s financial condition and results and require managementâ€™s most difficult, subjective or complex judgments, often as a result of the need to make estimates about the effect of matters that are inherently uncertain. For a further discussion of our critical accounting estimates, see our Annual Report on FormÂ 10-K filed with the SEC on February 28, 2024. No significant changes to our accounting policies took place during the three months ended SeptemberÂ 30, 2024.Item 3.Â Â Â Â Â Quantitative and Qualitative Disclosures About Market RiskWe are exposed to market risks in the ordinary course of our business. These risks primarily relate to interest rates and foreign currency exchange risks.We are exposed to interest rate risk primarily through borrowings under our ABL Facility. Our ABL Facility has a variable interest rate based on the Prime Rate, the NYFRB Rate, or the Secured Overnight Financing Rate (SOFR). An incremental change in the borrowing rate of 100 basis points would increase or decrease our annual interest expense by $0.4 million based on our $40.0 million debt outstanding on our ABL Facility as of SeptemberÂ 30, 2024.We have been and may continue to be exposed to fluctuations in foreign currencies with regard to certain agreements with service providers. While our expenses are predominantly denominated in U.S. dollars, approximately 8% of our revenues for the nine months ended September 30, 2024 are denominated in other currencies, primarily in Japanese yen. A hypothetical 10% change in the value of the Japanese yen relative to the U.S. dollar would result in a 1% change in our revenues. Although we also have certain operations denominated in euros and Swiss francs, among other currencies, those operations are subject to less overall market risk due to the revenues and expenses being denominated in the same currency. We do not currently utilize hedging strategies to mitigate foreign currency risk.Item 4.Â Â Â Â Controls and ProceduresEvaluation of Disclosure Controls and ProceduresÂ Â We maintain disclosure controls and procedures, or Disclosure Controls, within the meaning of Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Our Disclosure Controls are designed to ensure that information required to be disclosed by us in the reports we file or submit under the Exchange Act, such as this Quarterly Report on Form 10-Q, is recorded, processed, summarized, and reported within the time periods specified in the SECâ€™s rules and forms. Our Disclosure Controls are also designed to ensure that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating our Disclosure Controls, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, and management necessarily applied its judgment in evaluating and implementing possible controls and procedures.As of the end of the period covered by this Quarterly Report on Form 10-Q, we evaluated the effectiveness of the design and operation of our Disclosure Controls, which was done under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer. Based on the evaluation of our Disclosure Controls, our Chief Executive Officer and Chief Financial Officer have concluded that, as of SeptemberÂ 30, 2024, our Disclosure Controls were effective to provide reasonable assurance that information required to be disclosed by us in the reports we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time period specified in the SEC's rules and forms and is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.Changes in Internal ControlsÂ Â There were no changes in our internal control over financial reporting that occurred during the three months ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.33Table of ContentsPART II - Other InformationItem 1.Â Â Â Â Legal Proceedings.For information regarding certain current legal proceedings, see Note 13, "Commitments and Contingencies" in the notes to Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q. Item 1A. Risk Factors.In addition to the other information set forth in this Quarterly Report on Form 10-Q, you should carefully consider the risk factors and other cautionary statements described under the heading â€œItem 1A. Risk Factorsâ€ included in Part I of our Annual Report on Form 10-K filed with the SEC on February 28, 2024, "Item 1A. Risk Factors" included in Part II of our Quarterly Report on Form 10-Q filed with the SEC on May 8, 2024 and this Quarterly Report on Form 10-Q, which could materially affect our business, financial condition or future results. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially and adversely affect our business, financial condition or future results. There have been no material changes in our risk factors from those described in our Annual Report on Form 10-K filed with the SEC on February 28, 2024 and our Quarterly Report on Form 10-Q filed with the SEC on May

8, 2024, other than the updates to the risk factors set forth below. We may disclose changes to risk factors or additional risk factors from time to time in our future filings with the SEC.If the government and other third-party payors fail to provide coverage and adequate payment for our existing and future tests, if any, our revenue and prospects for profitability will be harmed.In both domestic and foreign markets, sales of our tests or any future tests will depend in large part upon the availability of reimbursement from third-party payors. Such third-party payors include state and federal health care programs such as Medicare, managed care organizations, other private health insurers and other organizations. These third-party payors are increasingly attempting to contain health care costs by demanding price discounts and limiting both coverage regarding which tests they will pay for and the amounts that they will pay for existing and new tests. We have experienced coverage limitations and price reductions for many of our products, including for our GeneSight Psychotropic Mental Health Medication Test, and we may continue to experience future coverage limitations and price reductions from the Centers for Medicare & Medicaid Services, managed care organizations, and other third-party payors. We do not receive reimbursement from third-party payers or payment from patients for many of the tests we perform. The fact that a test has been approved for reimbursement in the past, for any particular indication or in any particular jurisdiction, does not guarantee that such a test will be approved or remain approved for reimbursement, that the reimbursement amount approved for such test will not be reduced in the future, or that similar or additional tests will be approved for reimbursement in the future. For example, on November 1, 2024, UnitedHealthcare updated its medical policy for pharmacogenetic testing to no longer provide coverage for certain multi-gene panel pharmacogenetic tests, including our GeneSight test, under its commercial and individual exchange benefit plans, effective January 1, 2025. We recognized approximately $40.0 million in revenue for GeneSight volume from UnitedHealthcare under these commercial and individual exchange plans during the last twelve months ended September 30, 2024. While we are still assessing the full impact of UnitedHealthcare's change in its GeneSight coverage policy, including our ability to offset the loss in GeneSight coverage, we anticipate that this change will negatively impact revenue in fiscal year 2025 and thereafter. While we intend to continue our engagement with UnitedHealthcare regarding its decision to change its GeneSight coverage policy, there is no guarantee that our efforts will be successful or that our GeneSight test will be covered by UnitedHealthcare in the future. If unchanged, UnitedHealthcare's updated medical policy for these plans will prevent us from sustaining previous GeneSight revenue or profitability levels and may materially and adversely affect our business and financial results as a whole and could lead to coverage changes in other UnitedHealthcare plans and at other payors. Moreover, there can be no assurance that any new tests we have launched or may launch will be reimbursed at rates that are comparable to the rates that we historically obtained for our existing product portfolio. As a result, third-party payors may not cover or provide adequate payment for our current or future tests to enable us to maintain past levels of revenue or profitability with respect to such tests. Further, third-party reimbursement might not be available to enable us to maintain price levels sufficient to realize an appropriate return on investment in product development.34Table of ContentsIn addition, under the Protecting Access to Medicare Act of 2014 (PAMA), Medicare reimbursement for any given test is based on the weighted-median of the payments made by private payors for such test, rendering private payor payment levels even more significant. As a result, future Medicare payments may fluctuate more often and become subject to the willingness of private payors to recognize the value of tests generally and any given test individually. Since December 2019, Congress has passed a series of laws to modify PAMAâ€™s statutory requirements related to the data reporting period and phase-in of payment reductions under the Medicareâ€™s Clinical Laboratory Fee Schedule (CLFS) for clinical diagnostic laboratory tests (CDLTs) that are not advanced diagnostic laboratory tests (ADLT). Most recently, the Further Continuing Appropriations and Other Extensions Act of 2024 (Pub.L. 118-22, enacted on November, 16, 2023) further delayed the reporting requirement as well as the application of the 15% phase-in reduction. Under these statutory provisions, the next data reporting period for CDLTs that are not ADLTs will be January 1, 2025 through March 31, 2025. The same series of laws modified the phase-in of payment reductions resulting from private payor rate implementation so that a 0.0 percent reduction limit was applied for calendar years 2021 through 2023, as compared to the payment amounts for a test the preceding year. The Further Continuing Appropriations and Other Extensions Act of 2024 further applied a 0.0 percent reduction limit for calendar year 2024. Consequently, payment may not be reduced by more than 15 percent per year for calendar years 2025 through 2027 as compared to payment amount established for a test the prior year. Any declines in average selling prices of our products due to pricing pressures may have an adverse impact on our business, results of operations and financial condition.Third-party payors may also impose prior authorization requirements, dispute our billing or coding and may decide to deny payment or recoup payment for testing that they contend to have been not medically necessary, against their coverage determinations, or for which they have otherwise overpaid, and we may be required to change our revenue estimates for previously delivered tests or refund reimbursements already received. We have also experienced delays or denials of coverage for failure to adequately comply with procedural requirements imposed by third-party payors to obtain reimbursement. When a third-party payor denies payment for testing, we often are not able to collect payment from the patient, and therefore, we do not receive any payment from our testing. We also periodically receive and respond to requests for recoupment from third-party payors in the ordinary course of business. If a third-party payor successfully proves that payment for prior testing was in breach of contract or otherwise contrary to law, they may recoup payment, which amounts could be significant and would impact our results of operations. We may also continue to negotiate and settle with third-party payers in order to resolve allegations of overpayment.As part of our revenue recognition process, we estimate the expected amount of consideration to be received from our tests using all the information (historical, current, and forecast) that is reasonably available to identify possible consideration amounts. The estimate of revenue is affected by, among other factors, changes in payor mix, payor collections, current customer contractual requirements, experience with collections from third-party payors, and changes in medical policies. We have experienced, and may continue to experience, positive and negative changes in our revenue estimates for previously delivered tests as a result of third-party payors disputing our bills or denying payment for tests that we have performed or from changes in the estimated transaction price due to contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met and settlements with third-party payors. While we believe our revenue recognition process is reasonable and performed in accordance with applicable accounting standards, we cannot guarantee that our revenue estimates for our tests will be accurate or equal the amount of cash actually collected or that we will not continue to recognize positive or negative changes in our revenues for tests performed in prior periods. For example, we have one third-party payor that represents 19% and 12% of our total accounts receivable balance as of September 30, 2024 and December 31, 2023. If the actual amount of cash collected differs from our current estimates, our revenue may be materially impacted. 35Table of ContentsThird-party payors, such as commercial health insurers and government payors and programs, may also adopt requirements, programs or policies that may restrict or adversely affect our business. For example, in September 2022, the California Department of Public Health (CDPH) promulgated certain regulatory amendments to the California Prenatal Screening (PNS) Program that made the PNS Program the exclusive means of obtaining cfDNA trisomy screening in California. These regulatory amendments set a price that participating laboratories would receive for each cfDNA test that was substantially lower than laboratories had previously charged, and prohibited laboratories that did not contract with CDPH from participating in the PNS Program and from offering or performing cfDNA trisomy screening in California. As we are not a participating laboratory under the PNS Program, we would have been prohibited from offering or performing our Prequel screening test in California. On September 16, 2022, we filed jointly with Laboratory Corporation of America Holdings (Labcorp) a writ petition in the Superior Court of the State of California, County of San Francisco, against the CDPH and its Director challenging CDPHâ€™s ability to make the PNS Program the exclusive means of obtaining cfDNA trisomy screening in California. On September 16, 2022, we also moved jointly with Labcorp for a preliminary injunction to enjoin the implementation and enforcement of the new exclusivity regulation. On November 2, 2022, the Superior Court granted our motion for a preliminary injunction, which allowed us to continue to offer our Prequel screening test in California. On December 17, 2022, we filed jointly with Labcorp a motion for judgment on our writ, through which we sought a permanent injunction to enjoin the implementation and enforcement of the new exclusivity regulation. On April 28, 2023, the Superior Court issued an order granting our motion for a permanent injunction to enjoin the implementation and enforcement of the new exclusivity regulation. On June 1, 2023, the Superior Court issued a final judgment and writ of mandate enjoining the implementation and enforcement of the new exclusivity regulation. The CDPH did not file a notice of appeal. As a result of the foregoing, we expect to continue to be able to offer and perform our Prequel screening test in California. However, the possibility that we might not be able to continue to offer our Prequel screening test in California had a chilling effect on sales of our Prequel screening test in California.U.S. and foreign governments continue to propose and pass legislation designed to reduce the cost of health care. For example, in some foreign markets, the government controls the pricing of many health care products. We expect that there will continue to be federal and state proposals to implement governmental controls or impose health care requirements. In addition, the Medicare program and increasing emphasis on managed care in the United States will continue to put pressure on product pricing. Cost control initiatives could decrease the price that we would receive for any tests in the future, which would limit our revenue and profitability.Impairment in the value of our goodwill or other intangible assets could have a material adverse effect on our operating results and financial condition.We record goodwill and intangible assets at fair value upon the acquisition of a business. Goodwill represents the excess of amounts paid for acquiring businesses over the fair value of the net assets acquired. Goodwill and indefinite-lived intangible assets are evaluated for impairment annually, or more frequently if conditions warrant, by comparing the carrying value of a reporting unit to its estimated fair value. Intangible assets with definite lives are reviewed for impairment when events or circumstances indicate that their carrying value may not be recoverable. Declines in operating results, divestitures, sustained market declines and other factors that impact the fair value of a reporting unit, such as the anticipated loss of future revenue from our Pharmacogenomics reporting unit, which unit accounted for approximately 42.3% of our total recorded goodwill at September 30, 2024, as a result of UnitedHealthcare's decision to no longer provide coverage for our GeneSight test under its commercial and individual exchange benefit plans, could result in an impairment of goodwill or intangible assets and, in turn, a charge to net income. Any such charges could have a material adverse effect on our results of operations or financial condition.Item 2.Â Â Â Â Unregistered Sales of Equity Securities and Use of Proceeds.Issuer Purchases of Equity SecuritiesNone.Item 3.Â Â Â Â Defaults Upon Senior Securities.None.Item 4.Â Â Â Â Mine Safety Disclosures.Not applicable.36Table of ContentsItem 5.Â Â Â Â Other Information.Rule 10b5-1 Trading PlansDuring the quarter ended September 30, 2024, none of our directors or executive officers adopted, modified or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any â€œnon-Rule 10b5-1 trading arrangementâ€ (as defined in Item 408 of Regulation S-K).Item 6.Â Â Â Â Exhibits.31.1Certification of Chief Executive Officer pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002.31.2Certification of Chief Financial Officer pursuant to Section 302(a) of the Sarbanes-Oxley Act of 2002.32.1Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Furnished).101.INSInline XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.101.SCHInline XBRL Taxonomy Extension Schema Document.101.CALInline XBRL Taxonomy Extension Calculation Linkbase Document.101.DEFInline XBRL Taxonomy Extension Definition Linkbase Document.101.LABInline XBRL Taxonomy Extension Label Linkbase Document.101.PREInline XBRL Taxonomy Extension Presentation Linkbase Document.104The cover page from the Company's Quarterly Report on Form 10-Q for the quarter ended SeptemberÂ 30, 2024 has been formatted in Inline XBRL.37Table of ContentsSIGNATURESPursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.MYRIAD GENETICS, INC.Date: November 8, 2024By:/s/ Paul J. DiazPaul J. DiazPresident and Chief Executive Officer(Principal executive officer)Date: November 8, 2024By:/s/ Scott J. LefflerScott J. LefflerChief Financial Officer(Principal financial officer)Date: November 8, 2024By:/s/ Natalie MunkNatalie MunkChief Accounting Officer(Principal accounting officer)38 EX-31.1 2 exhibit311-certificationof.htm EX-31.1 DocumentExhibit 31.1SARBANES-OXLEY SECTION 302(a) CERTIFICATIONI, Paul J. Diaz, certify that:1.I have reviewed this quarterly report on Form 10-Q of Myriad Genetics, Inc.;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;c)evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andd)disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and5.The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; andb)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.Date: November 8, 2024By:/s/ Paul J. DiazPaul J. DiazPresident and Chief Executive Officer(Principal Executive Officer) EX-31.2 3 exhibit312-certificationof.htm EX-31.2 DocumentExhibit 31.2SARBANES-OXLEY SECTION 302(a) CERTIFICATIONI, Scott J. Leffler, certify that:1.I have reviewed this quarterly report on Form 10-Q of Myriad Genetics, Inc.;2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;4.The registrantâ€™s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:a)designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;b)designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;c)evaluated the effectiveness of the registrantâ€™s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; andd)disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and5.The registrantâ€™s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrantâ€™s auditors and the audit committee of the registrantâ€™s board of directors (or persons performing the equivalent functions):a)all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrantâ€™s ability to record, process, summarize and report financial information; andb)any fraud, whether or not material, that involves management or other employees who have a significant role in the registrantâ€™s internal control over financial reporting.Date: November 8, 2024By:/s/ Scott J. LefflerScott J. LefflerChief Financial Officer(Principal Financial Officer) EX-32.1 4 exhibit321-certificationpu.htm EX-32.1 DocumentExhibit 32.1CertificationPursuant to Section 906 of the Sarbanes-Oxley Act of 2002(Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code)Pursuant to section 906 of the Sarbanes-Oxley Act of 2002 (subsections (a) and (b) of section 1350, chapter 63 of title 18, United States

Code), each of the undersigned officers of Myriad Genetics, Inc., a Delaware corporation (the â€œCompanyâ€), does hereby certify, to such officerâ€™s knowledge, that:The Quarterly Report on Form 10-Q for the quarter ended SeptemberÂ 30, 2024 (the â€œForm 10-Qâ€) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and the information contained in the Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of the Company.Date: November 8, 2024Date: November 8, 2024By:/s/ Paul J. DiazBy:/s/ Scott J. LefflerPaul J. DiazScott J. LefflerPresident and Chief Executive OfficerChief Financial OfficerPrincipal Executive OfficerPrincipal Financial Officer EX-101.SCH 5 mygn-20240930.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink 9952151 - Statement - Condensed Consolidated Balance Sheets (unaudited) link:presentationLink link:calculationLink link:definitionLink 9952152 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 9952153 - Statement - Condensed Consolidated Statements of Operations (unaudited) link:presentationLink link:calculationLink link:definitionLink 9952154 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited) link:presentationLink link:calculationLink link:definitionLink 9952155 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited) link:presentationLink link:calculationLink link:definitionLink 9952156 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited) link:presentationLink link:calculationLink link:definitionLink 9952157 - Disclosure - BASIS OF PRESENTATION link:presentationLink link:calculationLink link:definitionLink 9952158 - Disclosure - REVENUE link:presentationLink link:calculationLink link:definitionLink 9952159 - Disclosure - MARKETABLE INVESTMENT SECURITIES link:presentationLink link:calculationLink link:definitionLink 9952160 - Disclosure - FAIR VALUE MEASUREMENTS link:presentationLink link:calculationLink link:definitionLink 9952161 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET link:presentationLink link:calculationLink link:definitionLink 9952162 - Disclosure - GOODWILL AND INTANGIBLE ASSETS link:presentationLink link:calculationLink link:definitionLink 9952163 - Disclosure - ACCRUED LIABILITIES link:presentationLink link:calculationLink link:definitionLink 9952164 - Disclosure - LONG-TERM DEBT link:presentationLink link:calculationLink link:definitionLink 9952165 - Disclosure - OTHER LONG-TERM LIABILITIES link:presentationLink link:calculationLink link:definitionLink 9952166 - Disclosure - PREFERRED AND COMMON STOCKHOLDERS' EQUITY link:presentationLink link:calculationLink link:definitionLink 9952167 - Disclosure - STOCK-BASED COMPENSATION link:presentationLink link:calculationLink link:definitionLink 9952168 - Disclosure - INCOME TAXES link:presentationLink link:calculationLink link:definitionLink 9952169 - Disclosure - COMMITMENTS AND CONTINGENCIES link:presentationLink link:calculationLink link:definitionLink 9952170 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION link:presentationLink link:calculationLink link:definitionLink 9952171 - Disclosure - LEASES link:presentationLink link:calculationLink link:definitionLink 9952172 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) link:presentationLink link:calculationLink link:definitionLink 9952173 - Disclosure - ACQUISITION link:presentationLink link:calculationLink link:definitionLink 9952174 - Disclosure - DIVESTITURE link:presentationLink link:calculationLink link:definitionLink 9954471 - Disclosure - BASIS OF PRESENTATION (Policies) link:presentationLink link:calculationLink link:definitionLink 9954472 - Disclosure - REVENUE (Tables) link:presentationLink link:calculationLink link:definitionLink 9954473 - Disclosure - MARKETABLE INVESTMENT SECURITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954474 - Disclosure - FAIR VALUE MEASUREMENTS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954475 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET (Tables) link:presentationLink link:calculationLink link:definitionLink 9954476 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables) link:presentationLink link:calculationLink link:definitionLink 9954477 - Disclosure - ACCRUED LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954478 - Disclosure - OTHER LONG-TERM LIABILITIES (Tables) link:presentationLink link:calculationLink link:definitionLink 9954479 - Disclosure - PREFERRED AND COMMON STOCKHOLDERS' EQUITY (Tables) link:presentationLink link:calculationLink link:definitionLink 9954480 - Disclosure - STOCK-BASED COMPENSATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9954481 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION (Tables) link:presentationLink link:calculationLink link:definitionLink 9954482 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables) link:presentationLink link:calculationLink link:definitionLink 9954483 - Disclosure - BASIS OF PRESENTATION (Details) link:presentationLink link:calculationLink link:definitionLink 9954484 - Disclosure - REVENUE - Schedule of Total Revenue by Type and by U.S versus Rest of World (Details) link:presentationLink link:calculationLink link:definitionLink 9954485 - Disclosure - REVENUE - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954486 - Disclosure - MARKETABLE INVESTMENT SECURITIES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954487 - Disclosure - MARKETABLE INVESTMENT SECURITIES - Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Details) link:presentationLink link:calculationLink link:definitionLink 9954488 - Disclosure - FAIR VALUE MEASUREMENTS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954489 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Fair Value of Financial Assets and Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954490 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Change in Fair Value of Contingent Consideration (Details) link:presentationLink link:calculationLink link:definitionLink 9954491 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET - Schedule of Property, Plant and Equipment, Net (Details) link:presentationLink link:calculationLink link:definitionLink 9954492 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET - Schedule of Depreciation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954493 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954494 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Goodwill (Details) link:presentationLink link:calculationLink link:definitionLink 9954495 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954496 - Disclosure - GOODWILL AND INTANGIBLE ASSETS- Schedule of Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954497 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Schedule of Recorded Amortization Expense for Intangible Assets (Details) link:presentationLink link:calculationLink link:definitionLink 9954498 - Disclosure - ACCRUED LIABILITIES (Details) link:presentationLink link:calculationLink link:definitionLink 9954499 - Disclosure - LONG-TERM DEBT (Details) link:presentationLink link:calculationLink link:definitionLink 9954500 - Disclosure - OTHER LONG-TERM LIABILITIES - Schedule of Other Long-Term Liabilities (Details) link:presentationLink link:calculationLink link:definitionLink 9954501 - Disclosure - OTHER LONG-TERM LIABILITIES - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954502 - Disclosure - PREFERRED AND COMMON STOCKHOLDERS' EQUITY - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954503 - Disclosure - PREFERRED AND COMMON STOCKHOLDERS' EQUITY - Schedule of Common Stock Issued and Outstanding (Details) link:presentationLink link:calculationLink link:definitionLink 9954504 - Disclosure - PREFERRED AND COMMON STOCKHOLDERS' EQUITY - Schedule of Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations (Details) link:presentationLink link:calculationLink link:definitionLink 9954505 - Disclosure - PREFERRED AND COMMON STOCKHOLDERS' EQUITY - Schedule of Potential Dilutive Common Shares (Details) link:presentationLink link:calculationLink link:definitionLink 9954506 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details) link:presentationLink link:calculationLink link:definitionLink 9954507 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954508 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Restricted Stock Unit Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954509 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Share-Based Compensation, Employee Stock Purchase Plan, Activity (Details) link:presentationLink link:calculationLink link:definitionLink 9954510 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense (Details) link:presentationLink link:calculationLink link:definitionLink 9954511 - Disclosure - INCOME TAXES (Details) link:presentationLink link:calculationLink link:definitionLink 9954512 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details) link:presentationLink link:calculationLink link:definitionLink 9954513 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION - Schedule of Supplemental Cash Flow Information (Details) link:presentationLink link:calculationLink link:definitionLink 9954514 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION - Schedule of Cash and Cash Equivalents and Restricted Cash (Details) link:presentationLink link:calculationLink link:definitionLink 9954515 - Disclosure - LEASES (Details) link:presentationLink link:calculationLink link:definitionLink 9954516 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Details) link:presentationLink link:calculationLink link:definitionLink 9954517 - Disclosure - ACQUISITION (Details) link:presentationLink link:calculationLink link:definitionLink 9954518 - Disclosure - DIVESTITURE (Details) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 6 mygn-20240930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 7 mygn-20240930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 8 mygn-20240930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Debt instrument, covenant, liquidity amount, minimum Debt Instrument, Covenant, Liquidity Amount, Minimum Debt Instrument, Covenant, Liquidity Amount, Minimum First Installment First Installment [Member] First Installment Adjustments to reconcile net loss to net cash used in operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Prepaid taxes Prepaid Taxes Statistical Measurement [Domain] Statistical Measurement [Domain] Gross unrealized holding losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax Cover [Abstract] Cover [Abstract] Net (decrease) increase in cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Fourth Installment Fourth Installment [Member] Fourth Installment Trading Symbol Trading Symbol All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-NEOs Non-NEOs [Member] Service period for award vesting (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Disposal Group Name [Domain] Disposal Group Name [Domain] Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Cash equivalents Cash Equivalents [Member] Trade accounts receivable Increase (Decrease) in Accounts Receivable Escrow liability Escrow Liability, Noncurrent Escrow Liability, Noncurrent Costs and expenses: Operating Costs and Expenses [Abstract] BASIS OF PRESENTATION Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] FAIR VALUE MEASUREMENTS Fair Value Disclosures [Text Block] Change in unrealized loss on available-for-sale debt securities, net of tax OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax Award Timing Disclosures [Line Items] ABL Facility ABL Facility [Member] ABL Facility Other Performance Measure, Amount Other Performance Measure, Amount Total Investments and Cash [Abstract] LEASES Lessee, Operating Leases [Text Block] Common stock, shares outstanding (shares) Common stock outstanding (shares) Beginning common stock outstanding (shares) Ending common stock outstanding (shares) Common Stock, Shares, Outstanding Proceeds from maturities and sales of marketable investment securities Proceeds from Sale and Maturity of Marketable Securities Shares available for grant (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Noncurrent operating lease liabilities Operating Lease, Liability, Noncurrent Revenue from Contract with Customer [Abstract] Revenue from Contract with Customer [Abstract] Plan Name [Domain] Plan Name [Domain] U.S. UNITED STATES Effect of dilutive shares Weighted Average Number of Shares Outstanding, Diluted, Adjustment Borrowing base period Line Of Credit Facility, Commitment Fee, Borrowing Base, Period Line Of Credit Facility, Commitment Fee, Borrowing Base, Period Other assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Leases [Abstract] Gross Carrying Amount Finite-Lived Intangible Assets, Gross Foreign currency translation Disposal Group, Including Discontinued Operation, Foreign Currency Translation Gains (Losses) Money market funds Money Market Funds [Member] Selling, general, and administrative expense Selling, General and Administrative Expenses [Member] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Accrued taxes payable Taxes Payable, Current Schedule of Cumulative Translation Adjustments in Accumulated Other Comprehensive Income (Loss) Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block] Pharmacogenomics Pharmacogenomics [Member] Pharmacogenomics Installment [Axis] Litigation Installments [Axis] Litigation Installments Plan Name [Axis] Plan Name [Axis] Equity Components Equity Components [Axis] Share-Based Compensation Expense [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Award Timing Method Award Timing Method [Text Block] Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Variable Rate, Scenario Two Variable Rate, Scenario Two [Member] Variable Rate, Scenario Two Estimated fair value Debt Securities, Available-for-Sale Line of credit facility, borrowing base, percent of eligible accounts receivable plus certain cash held Line Of Credit Facility, Borrowing Base, Percent Of Eligible Accounts Receivable Plus Certain Cash Held Line Of Credit Facility, Borrowing Base, Percent Of Eligible Accounts Receivable Plus Certain Cash Held Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Insider Trading Policies and Procedures [Line Items] Proceeds from the sale of business, net cash sold Proceeds from Divestiture of Businesses, Net of Cash Divested Total costs and expenses Costs and Expenses Business Acquisition, Acquiree [Domain] Business Acquisition, Acquiree [Domain] Adjustment to Compensation, Amount Adjustment to Compensation Amount Additional paid-in capital Additional Paid in Capital, Common Stock Payables and Accruals [Abstract] Payables and Accruals [Abstract] Compensation Amount Outstanding Recovery Compensation Amount Reclassification of cumulative translation adjustment to income upon sale or liquidation of certain foreign entities, net of tax Reclassification of cumulative translation adjustment to income upon sale or liquidation of certain foreign entities Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax Disposal Group Classification [Axis] Disposal Group Classification [Axis] Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Entity Small Business Entity Small Business Developed technologies Developed Technology Rights [Member] ACCRUED LIABILITIES Accounts Payable and Accrued Liabilities Disclosure [Text Block] Company Selected Measure Amount Company Selected Measure Amount Geographical [Axis] Geographical [Axis] Tabular List, Table Tabular List [Table Text Block] Accrual, current Loss Contingency, Accrual, Current Level 3 Fair Value, Inputs, Level 3 [Member] Share-Based Compensation [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Estimated fair value Investments and Cash Change in operating lease right-of-use assets and lease liabilities Cash Flow, Operating Activities, Lessee [Abstract] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Short-term contingent consideration Business Combination, Contingent Consideration, Liability, Current Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Schedule of Available-for-sale Securities [Line Items] Debt Securities, Available-for-Sale [Line Items] Accrued liabilities Total accrued liabilities Accrued Liabilities, Current Anti-dilutive options and RSUs excluded from EPS computation (shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Achievement Levels Based on EPS Targets Share-Based Payment Arrangement, Tranche One [Member] Credit Facility [Domain] Credit Facility [Domain] Cash, cash equivalents, and restricted cash at beginning of the period Cash, cash equivalents, and restricted cash at end of the period Total cash, cash equivalents, and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Interest rate, weighted average percentage Debt, Weighted Average Interest Rate Tumor Profiling Tumor Profiling [Member] Tumor Profiling Current assets: Assets, Current [Abstract] Goodwill Beginning balance Ending balance Goodwill Final Installment Fifth Installment [Member] Fifth Installment Payment of tax withheld for common stock issued under stock-based compensation plans Payment, Tax Withholding, Share-Based Payment Arrangement Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Product and Service Product and Service [Domain] Employee Stock Option Share-Based Payment Arrangement, Option [Member] Debt Securities, Available-for-Sale [Table] Debt Securities, Available-for-Sale [Table] RSUs vested (dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Goodwill [Roll Forward] Goodwill [Roll Forward] Depreciation expense Depreciation Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Marketable investment securities Marketable Securities, Current Lease termination accrual Lease Termination Accrual, Current Lease Termination Accrual, Current Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Preferred stock outstanding (shares) Preferred Stock, Shares Outstanding Repayment of revolving credit facility Repayments of Lines of Credit Municipal bonds Municipal bonds Municipal Bonds [Member] Hereditary Cancer Hereditary Cancer Testing [Member] Molecular diagnostic hereditary cancer testing. Security Exchange Name Security Exchange Name Basis spread on rate (percent) Debt Instrument, Basis Spread on Variable Rate Award Type [Axis] Award Type [Axis] Availability threshold, percentage of maximum commitment amount Debt Instrument, Debt Default, Availability Threshold, Percentage Of Maximum Commitment Amount Debt Instrument, Debt Default,

Availability Threshold, Percentage Of Maximum Commitment Amount Corporate bonds and notes Corporate bonds and notes Corporate Debt Securities [Member] Gross unrealized holding losses Investments And Cash, Accumulated Gross Unrealized Loss, before Tax Investments And Cash, Accumulated Gross Unrealized Loss, before Tax Translation adjustments Goodwill, Foreign Currency Translation Gain (Loss) Percentage of goodwill Goodwill, Percentage Of Record Goodwill Goodwill, Percentage Of Record Goodwill Capital expenditures Payments to Acquire Other Productive Assets Translation adjustments recognized in Other comprehensive loss Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss) Number of Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Property, plant, and equipment, net Property, plant and equipment, net Property, Plant and Equipment, Net Total liabilities Liabilities Schedule of Cash and Cash Equivalents Schedule of Cash and Cash Equivalents [Table Text Block] Options exercisable at end of period (dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Common stock, par value (dollars per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Research and development expense Research and Development Expense Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Revolving Credit Facility Revolving Credit Facility [Member] Expiration Date Trading Arrangement Expiration Date CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Current maturities of operating lease liabilities Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Common stock issued (shares) Beginning common stock issued (shares) Ending common stock issued (shares) Common Stock, Shares, Issued Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Maximum aggregate principal commitment Line of Credit Facility, Maximum Borrowing Capacity Concentration risk (percent) Concentration Risk, Percentage Settled Litigation, Contingent Payments Settled Litigation, Contingent Payments [Member] Settled Litigation, Contingent Payments Equipment Equipment [Member] Line of credit facility, commitment fee amount Line of Credit Facility, Commitment Fee Amount Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Less accumulated depreciation Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Property, plant and equipment, gross Property, Plant and Equipment, Gross Debt Instrument [Line Items] Debt Instrument [Line Items] Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Research and development expense Research and Development Expense [Member] Common stock authorized (shares) Common Stock, Shares Authorized Goodwill and long-lived asset impairment charges Goodwill and Intangible Asset Impairment Cash Cash [Member] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Diluted (shares) Weighted-average shares outstanding and dilutive securities used to compute diluted EPS Weighted Average Number of Shares Outstanding, Diluted MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] AOCI Attributable to Parent, Net of Tax [Roll Forward] AOCI Attributable to Parent, Net of Tax [Roll Forward] Long-Term Debt, Type [Axis] Long-Term Debt, Type [Axis] Prepaid taxes Increase (Decrease) in Prepaid Taxes Total stockholders' equity Beginning balance Ending balance Equity, Attributable to Parent Schedule of Supplemental Cash Flow Information Schedule of Cash Flow, Supplemental Disclosures [Table Text Block] Third Installment Third Installment [Member] Third Installment Litigation Case [Axis] Litigation Case [Axis] Interest expense Interest Expense, Nonoperating Schedule of Changes in Carrying Amount of Goodwill Schedule of Goodwill [Table Text Block] PROPERTY, PLANT AND EQUIPMENT, NET Property, Plant and Equipment Disclosure [Text Block] Concentration Risk Type [Domain] Concentration Risk Type [Domain] Selling, general, and administrative expense Selling, General and Administrative Expense Other comprehensive income (loss), net of tax Period translation adjustments Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent Trade accounts receivable Accounts Receivable, after Allowance for Credit Loss, Current Maximum number of shares per participant per offering period (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee Cost of testing revenue Cost of Sales [Member] Options granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Government Contracts Concentration Risk Government Contracts Concentration Risk [Member] Impairment of goodwill and long-lived assets Asset Impairment Charges Change in foreign currency translation adjustment, net of tax Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax Long-term debt Long-Term Debt Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Schedule of Fair Value of Financial Assets and Liabilities Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Document Fiscal Period Focus Document Fiscal Period Focus Legal settlements Pending settlement accrued Estimated Litigation Liability, Current Gain on acquisition Gain on acquisition Asset Acquisition, Gain (Loss) Asset Acquisition, Gain (Loss) All Executive Categories All Executive Categories [Member] Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] ASSETS Assets [Abstract] Fair Value, by Balance Sheet Grouping [Table] Fair Value, by Balance Sheet Grouping [Table] Document Type Document Type Line of credit facility, commitment fee percentage Line of Credit Facility, Commitment Fee Percentage Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Internal-use software Computer Software, Intangible Asset [Member] Contingent consideration Business Combination, Contingent Consideration, Liability, Noncurrent RSUs vested (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Amortized cost Debt Securities, Available-for-Sale, Amortized Cost Maximum Maximum [Member] Amortization of intangible assets Amortization of Intangible Assets Available-for-sale: Debt Securities, Available-for-Sale [Abstract] Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Net Finite-Lived Intangible Assets, Net RoW Non-US [Member] Accounts payable Accounts Payable, Current Refunds payable and reserves Refunds Payable And Reserve, Current Refunds Payable And Reserve, Current Leasehold improvements Leasehold Improvements [Member] Medicare Medicare [Member] Medicare Fair Value Measurements Fair Value Measurement, Policy [Policy Text Block] Capitalized costs incurred to obtain or fulfill contract Capitalized Contract Cost, Gross Current Fiscal Year End Date Current Fiscal Year End Date Statistical Measurement [Axis] Statistical Measurement [Axis] PEO Name PEO Name Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Loss before income tax Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Shares issued under the plan (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Vesting [Axis] Vesting [Axis] Award Type [Domain] Award Type [Domain] Name Outstanding Recovery, Individual Name Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Goodwill impairment Goodwill impairment charge Goodwill, Impairment Loss Schedule of Potential Dilutive Common Shares Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Non-PEO NEO Non-PEO NEO [Member] Title of Individual [Axis] Title and Position [Axis] Additional paid-in capital Additional Paid-in Capital [Member] Award Timing Predetermined Award Timing Predetermined [Flag] Customer relationships Customer Relationships [Member] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Second Installment Second Installment [Member] Second Installment Diluted (dollars per share) Earnings Per Share, Diluted Title of Individual [Domain] Title and Position [Domain] Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Schedule of Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations Schedule of Weighted Average Number of Shares [Table Text Block] Revenue Revenue from Contract with Customer [Policy Text Block] Schedule of Recorded Amortization Expense for Intangible Assets Finite-Lived Intangible Assets Amortization Expense [Table Text Block] Non-cash lease expense Operating Lease, Right-of-Use Asset, Periodic Reduction Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Vesting weight (percent) Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage Number of reporting segments Number of Operating Segments Cash paid for income taxes Income Taxes Paid Pending Litigation Pending Litigation [Member] Customer [Axis] Customer [Axis] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Stock-based compensation expense Total stock-based compensation expense Share-Based Payment Arrangement, Noncash Expense Contingent Consideration Type [Domain] Contingent Consideration Type [Domain] Performance Based on Nasdaq Healthcare Provider Index Share-Based Payment Arrangement, Tranche Two [Member] Operating lease right-of-use assets Change In Operating Lease, Right-Of-Use Asset Change In Operating Lease, Right-Of-Use Asset Income tax expense Income Tax Expense (Benefit) Other income (expense): Nonoperating Income (Expense) [Abstract] EndoPredict EndoPredict [Member] EndoPredict Availability threshold amount Line Of Credit Facility, Debt Default, Availability Threshold Line Of Credit Facility, Debt Default, Availability Threshold Weighted-average period for recognition (in years) Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Testing revenue Total revenue Revenue from Contract with Customer, Excluding Assessed Tax Total other income (expense), net Nonoperating Income (Expense) Statement of Comprehensive Income [Abstract] Statement of Comprehensive Income [Abstract] Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] West Salt Lake City West Salt Lake City [Member] West Salt Lake City Approximate tax rate Effective Income Tax Rate Reconciliation, Percent Net cash provided by (used in) investing activities Net Cash Provided by (Used in) Investing Activities Operating loss Operating Income (Loss) Number of additional shares authorized (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized Variable Rate [Domain] Variable Rate [Domain] Total liabilities and stockholdersâ€™ equity Liabilities and Equity Other non-cash adjustments Other Operating Activities, Cash Flow Statement SOFR floor (percent) Debt Instrument, Floor Percentage Debt Instrument, Floor Percentage Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] All Adjustments to Compensation All Adjustments to Compensation [Member] Employee compensation and benefits Employee-related Liabilities, Current Fair Value Hierarchy and NAV [Axis] Fair Value Hierarchy and NAV [Axis] Accumulated Other Comprehensive Income (Loss) [Line Items] Accumulated Other Comprehensive Income (Loss) [Line Items] Total net loss, including transaction expenses Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Interest income Investment Income, Interest Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Individual: Individual [Axis] Gateway Gateway Genomics, LLC [Member] Gateway Genomics, LLC Accumulated other comprehensive loss AOCI Attributable to Parent [Member] Restricted cash Restricted Cash Inventory Inventory, Net Schedule of Shares Purchased and Compensation Expense Schedule of Share-Based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block] Long-Term Debt, Type [Domain] Long-Term Debt, Type [Domain] Product and Service Product and Service [Axis] Entity Address, State or Province Entity Address, State or Province Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Statement [Line Items] Statement [Line Items] Prenatal Prenatal Testing [Member] Molecular diagnostic Prenatal testing. Unrecognized tax benefits Increase (Decrease) In Unrecognized Tax Benefits Increase (decrease) in unrecognized tax benefits. Line of credit, increase in maximum principal upon request Line Of Credit Facility, Accordion Feature, Increase Limit Line Of Credit Facility, Accordion Feature, Increase Limit Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Sale of business for net cash consideration Disposal Group, Including Discontinued Operation, Consideration Schedule of Property, Plant and Equipment, Net Property, Plant and Equipment [Table Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Non-Employee Director Non Employee Director [Member] Non employee director. Financial Instruments [Domain] Financial Instruments [Domain] Vesting [Domain] Vesting [Domain] RSUs unvested and outstanding, beginning balance (dollars per share) RSUs unvested and outstanding, ending balance (dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value LIABILITIES AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Beginning balance Ending balance Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value Non-cash adjustment to right-of-use assets and lease liabilities from lease modifications Non-Cash Adjustment To Right-Of-Use Assets And Lease Liabilities From Lease Modifications Non-Cash Adjustment To Right-Of-Use Assets And Lease Liabilities From Lease Modifications Minimum Minimum [Member] Restatement Determination Date Restatement Determination Date Fees associated with issuance and refinancing of revolving credit facility Payments of Debt Restructuring Costs Adoption Date Trading Arrangement Adoption Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security Schedule of Available-for-Sale Securities Reconciliation [Table Text Block] Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Gross unrealized holding gains Investments And Cash, Accumulated Gross Unrealized Gain, before Tax Investments And Cash, Accumulated Gross Unrealized Gain, before Tax Options outstanding (dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Concentration Risk [Table] Concentration Risk [Table] Operating lease right-of-use assets Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Options outstanding (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Bad debt expense Accounts Receivable, Credit Loss Expense (Reversal) Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Exercise Price Award Exercise Price Arrangement Duration Trading Arrangement Duration GOODWILL AND INTANGIBLE ASSETS Goodwill and Intangible Assets Disclosure [Text Block] Stockholdersâ€™ equity: Equity, Attributable to Parent [Abstract] RSUs granted (dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Gain on termination of lease Gain on termination of lease Gain (Loss) on Termination of Lease Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] All Individuals All Individuals [Member] Proceeds from revolving credit facility Proceeds from Lines of Credit Reporting Unit [Axis] Reporting Unit [Axis] Change in earnings per share (dollars per share) Increase (Decrease) In Earnings Loss Per Share Increase decrease in earnings (loss) per share. PEO PEO [Member] Variable Rate [Axis] Variable Rate [Axis] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Name Trading Arrangement, Individual Name Other Other Nonoperating Income (Expense) Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Intangibles, net Intangible Assets, Net (Excluding Goodwill) Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Disposal Group Name [Axis] Disposal Group Name [Axis] Number of annual installments Litigation Settlement, Number Of Installments Litigation Settlement, Number Of Installments Gross unrealized holding gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax Other assets Increase (Decrease) in Other Noncurrent Assets Remaining lease terms (in years) Lessee, Operating Lease, Remaining Lease Term Proceeds from common stock issued under stock-based compensation plans Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised Unrecognized stock-based compensation expense related to RSUs Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Undrawn fee (percent) Line of Credit Facility, Unused Capacity, Commitment Fee Percentage Divestitures [Line Items] Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items] Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Prepaid expenses and other current assets Increase (Decrease) in Prepaid Expenses, Other Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Relative Total Stockholders Return Share-Based Payment Arrangement, Tranche Three [Member] Disposal Groups, Including Discontinued Operations [Table] Disposal Groups, Including Discontinued Operations [Table] Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Estimated fair value Cash and Cash Equivalents, Fair Value Disclosure Percentage of fair value in excess of carrying value Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Local Phone Number Local Phone Number Cash and cash equivalents: Cash and Cash Equivalents, at Carrying Value [Abstract] Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Schedule of Restricted Stock Unit Activity Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Changes in assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Secured Overnight Financing Rate (SOFR) Secured Overnight Financing Rate

(SOFR) [Member] PEO Total Compensation Amount PEO Total Compensation Amount Raygen, Inc vs. Myriad Women's Health, Inc. Raygen, Inc Versus Myriad Women's Health, Inc. [Member] Raygen, Inc Versus Myriad Women's Health, Inc. Reconciliation of change in fair value of contingent consideration Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward] Variable Rate Scenario [Domain] Variable Rate Scenario [Domain] Variable Rate Scenario [Domain] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Schedule of Accrued Liabilities Schedule of Accrued Liabilities [Table Text Block] Income Statement Location [Axis] Statement of Income Location, Balance [Axis] COMMITMENTS AND CONTINGENCIES Commitments and Contingencies Disclosure [Text Block] Debt Disclosure [Abstract] Debt Disclosure [Abstract] Intangible Assets [Line Items] Intangible Assets [Line Items] Intangible assets. Common stock Common Stock [Member] Measure: Measure [Axis] 2012 Purchase Plan Employee Stock Purchase Plan Twenty Twelve [Member] Employee Stock Purchase Plan Twenty Twelve [Member] Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture Preferred stock authorized (shares) Preferred Stock, Shares Authorized Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Schedule of Change in Fair Value of Contingent Consideration Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] 2017 Plan Two Thousand Seventeen Employee Director And Consultant Equity Incentive Plan [Member] Two Thousand Seventeen Employee Director And Consultant Equity Incentive Plan Line of Credit Line of Credit [Member] Entity Emerging Growth Company Entity Emerging Growth Company Financial liabilities Liabilities, Fair Value Disclosure Entity Central Index Key Entity Central Index Key Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Contingent consideration Contingent Consideration [Member] Contingent consideration. Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Accumulated Foreign Currency Adjustment Attributable to Parent Accumulated Foreign Currency Adjustment Attributable to Parent [Member] Amortized cost Investments And Cash, Amortized Cost Investments And Cash, Amortized Cost Discontinued Operations and Disposal Groups [Abstract] Discontinued Operations and Disposal Groups [Abstract] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount PREFERRED AND COMMON STOCKHOLDERS' EQUITY Equity [Text Block] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Preferred stock, par value (dollars per share) Preferred Stock, Par or Stated Value Per Share Equity Component Equity Component [Domain] Financial Instrument [Axis] Financial Instrument [Axis] Litigation settlement, outstanding Litigation Settlement, Remaining Amount Awarded To Other Party Litigation Settlement, Remaining Amount Awarded To Other Party Change in fair value recognized in the Statements of Operations Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings Revenue recognized Contract with Customer, Asset, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Stock-based compensation expense APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Title Trading Arrangement, Individual Title Statement [Table] Statement [Table] City Area Code City Area Code Current liabilities: Liabilities, Current [Abstract] Cash paid for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Contingent consideration liability Business Combination, Contingent Consideration, Liability Disposal Group Classification [Domain] Disposal Group Classification [Domain] Fixed charge ratio, minimum Debt Instrument, Covenant, Fixed Charge Ratio, Minimum Debt Instrument, Covenant, Fixed Charge Ratio, Minimum Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Level 1 Fair Value, Inputs, Level 1 [Member] Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Accrued liabilities Increase (Decrease) in Accrued Liabilities Options exercisable at end of period (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Revenue recognized due to retroactive coverage change Contract with Customer, Asset, Cumulative Catch-up Adjustment to Revenue, Modification of Contract Schedule of Long-term Debt Instruments [Table] Schedule of Long-Term Debt Instruments [Table] Long-term debt Long-Term Debt, Excluding Current Maturities Weighted Average Grant Date Fair Value Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Accumulated Other Comprehensive Income (Loss) [Table] Accumulated Other Comprehensive Income (Loss) [Table] INCOME TAXES Income Tax Disclosure [Text Block] Equity [Abstract] Equity [Abstract] Accumulated deficit Retained Earnings (Accumulated Deficit) Revenues Revenue from Contract with Customer Benchmark [Member] Inventory Increase (Decrease) in Inventories Supplemental Cash Flow Elements [Abstract] Supplemental Cash Flow Elements [Abstract] Deferred income taxes Deferred Income Taxes and Tax Credits Settlement agreement Litigation Settlement, Amount Awarded to Other Party Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Operating lease liability Operating Lease, Liability Net cash provided by (used in) financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount MARKETABLE INVESTMENT SECURITIES Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] NYFRB New York Federal Reserve Bank Rate [Member] New York Federal Reserve Bank Rate Credit Facility [Axis] Credit Facility [Axis] Accelerated depreciation Restructuring and Related Cost, Accelerated Depreciation Legal settlements Legal Fees Amendment Flag Amendment Flag Estimated fair value of long-term debt Long-Term Debt, Fair Value Entity Registrant Name Entity Registrant Name Short term lease liability Operating Lease, Liability, Current, Terminated Operating Lease, Liability, Current, Terminated Options and RSUs Options And Restricted Stock Units [Member] Options and Restricted Stock Units. Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Schedule of Restrictions on Cash and Cash Equivalents Restrictions on Cash and Cash Equivalents [Table Text Block] Fair Value as of Grant Date Award Grant Date Fair Value Vesting rights, average trading days Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Average Trading Days Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Average Trading Days Financial assets requiring fair value re-measurement Total Fair Value, Net Asset (Liability) Customer concentration Customer Concentration Risk [Member] Revenue from contract with customer, product and service, extensible enumeration Revenue from Contract with Customer, Product and Service [Extensible Enumeration] SUPPLEMENTAL CASH FLOW INFORMATION Cash Flow, Supplemental Disclosures [Text Block] Debt issuance costs Debt Issuance Costs, Net Level 2 Fair Value, Inputs, Level 2 [Member] LONG-TERM DEBT Debt Disclosure [Text Block] Fair Value Hierarchy and NAV [Domain] Fair Value Hierarchy and NAV [Domain] Operating lease liabilities Change In Operating Lease Liability Change In Operating Lease Liability Geographical Geographical [Domain] Schedule of Non-amortizable Intangible Assets Schedule of Indefinite-Lived Intangible Assets [Table Text Block] Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Schedule of Total Revenue by Type and by U.S versus Rest of World Disaggregation of Revenue [Table Text Block] Intangible, net Disposal Group, Including Discontinued Operation, Intangible Assets Payment of contingent consideration Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements Entity Address, Postal Zip Code Entity Address, Postal Zip Code Schedule of Stock-Based Compensation Expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Net loss per share: Earnings Per Share, Basic And Diluted EPS [Abstract] Earnings Per Share, Basic And Diluted EPS Restatement Determination Date: Restatement Determination Date [Axis] Title of 12(b) Security Title of 12(b) Security Concentration Risk Type [Axis] Concentration Risk Type [Axis] Common stock, 91.0 and 89.9 shares outstanding at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, respectively Common Stock, Value, Issued Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] Cash and cash equivalents Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Tenant improvement allowance received Payments for (Proceeds from) Tenant Allowance Litigation Status [Axis] Litigation Status [Axis] Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] RSUs canceled (dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Schedule of Common Stock Issued and Outstanding Schedule of Common Stock Outstanding Roll Forward [Table Text Block] CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Revenue and Concentration Risk [Line Items] Concentration Risk [Line Items] Purchases of property, plant and equipment and capitalization of internal-use software in accounts payable and accrued liabilities Purchases Of Property, Plant And Equipment And Capitalization Of Internal-use Software In Accounts Payable And Accrued Liabilities Purchases Of Property, Plant And Equipment And Capitalization Of Internal-use Software In Accounts Payable And Accrued Liabilities Reporting Unit [Domain] Reporting Unit [Domain] Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Basic (dollars per share) Earnings Per Share, Basic Accounts payable Increase (Decrease) in Accounts Payable Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Other Liabilities Disclosure [Abstract] Other Liabilities Disclosure [Abstract] Trademarks Trademarks [Member] Payment on finance leases Finance Lease, Principal Payments Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Unrecognized stock-based compensation expense related to stock options Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount OTHER LONG-TERM LIABILITIES Other Liabilities Disclosure [Text Block] Total assets Assets Concentration of Credit Risk Concentration Risk, Credit Risk, Policy [Policy Text Block] Line of credit facility, borrowing base, eligible cash collections, period Line Of Credit Facility, Borrowing Base, Eligible Cash Collections, Period Line Of Credit Facility, Borrowing Base, Eligible Cash Collections, Period Cost of testing revenue Cost of Goods and Services Sold RSUs granted (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Schedule Of Intangible Assets [Line Items] Schedule Of Intangible Assets [Line Items] Schedule Of Intangible Assets [Line Items] Other long-term liabilities Total other long-term liabilities Other Liabilities, Noncurrent Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Plan compensation expense Share-Based Payment Arrangement, Expensed and Capitalized, Amount Commitments and contingencies Commitments and Contingencies Accrued royalties Accrued Royalties, Current Other Other Sundry Liabilities, Noncurrent Reclassification adjustments for losses included in net loss, net of tax Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax ACQUISITION Asset Acquisition [Text Block] Variable Rate Scenario [Axis] Variable Rate Scenario [Axis] Variable Rate Scenario Termination Date Trading Arrangement Termination Date ABR Floor ABR Floor [Member] ABR Floor Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Unrecognized tax benefits Unrecognized Tax Benefits, Net Unrecognized Tax Benefits, Net STOCK-BASED COMPENSATION Share-Based Payment Arrangement [Text Block] Entity Address, City or Town Entity Address, City or Town Debt instrument, maximum amount borrowing base period Debt Instrument, Maximum Amount Borrowing Base Period Debt Instrument, Maximum Amount Borrowing Base Period Debt Instrument [Axis] Debt Instrument [Axis] Schedule of Stock Option Activity Share-Based Payment Arrangement, Option, Activity [Table Text Block] DIVESTITURE Disposal Groups, Including Discontinued Operations, Disclosure [Text Block] Net loss Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) Comprehensive Income (Loss) Note [Text Block] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Loss Contingencies [Table] Loss Contingencies [Table] RSUs canceled (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Business Acquisition [Axis] Business Acquisition [Axis] Schedule of Amortizable Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Increase principal commitment Line of Credit Facility, Current Borrowing Capacity Area of real estate property Area of Real Estate Property Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Shares purchased under the plan Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Entity File Number Entity File Number Legal settlements Legal Charges Pending Settlement, Noncurrent Legal Charges Pending Settlement, Noncurrent Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Net realized losses on marketable investment securities Marketable Security, Realized Gain (Loss) Variable Rate, Scenario One Variable Rate, Scenario One [Member] Variable Rate, Scenario One REVENUE Revenue from Contract with Customer [Text Block] Document Fiscal Year Focus Document Fiscal Year Focus Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Effect of foreign exchange rates on cash, cash equivalents, and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Weighted average shares outstanding: Weighted Average Number of Shares Outstanding, Basic [Abstract] Lease term (in years) Lessee, Operating Lease, Term of Contract Other accrued liabilities Other Accrued Liabilities, Current Financial assets Assets, Fair Value Disclosure Name Forgone Recovery, Individual Name Document Period End Date Document Period End Date Level 3 Contingent Consideration by Type [Axis] Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Lease payments due Lessee, Operating Lease, Liability, to be Paid RSUs unvested and outstanding, beginning balance (shares) RSUs unvested and outstanding, ending balance (shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Insider Trading Arrangements [Line Items] Schedule Of Intangible Assets [Table] Schedule Of Intangible Assets [Table] Schedule of Intangible Assets [Table] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Settled Litigation, Non-Contingent Payments Settled Litigation, Non-Contingent Payments [Member] Settled Litigation, Non-Contingent Payments Discontinued Operations, Disposed of by Sale Discontinued Operations, Disposed of by Sale [Member] Line of credit facility, borrowing base, eligible cash held Line Of Credit Facility, Borrowing Base, Eligible Cash Held Line Of Credit Facility, Borrowing Base, Eligible Cash Held Cost, product and service, extensible enumeration Cost, Product and Service [Extensible Enumeration] Adjustment to Compensation: Adjustment to Compensation [Axis] Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Accounts receivable Accounts Receivable [Member] Reclassifications Reclassification, Comparability Adjustment [Policy Text Block] Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Litigation Case [Domain] Litigation Case [Domain] Fair Value, Recurring and Nonrecurring [Table] Fair Value, Recurring and Nonrecurring [Table] Customer [Domain] Customer [Domain] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Accumulated deficit Retained Earnings [Member] Schedule of Other Long-Term Liabilities Other Noncurrent Liabilities [Table Text Block] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Litigation Status [Domain] Litigation Status [Domain] Internal-use software (in-process) Computer Software, In-Process, Intangible Asset [Member] Computer Software, In-Process, Intangible Asset Basic (shares) Weighted-average shares outstanding used to compute basic EPS Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Capitalization of internal-use software costs Payments for Software Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plan (shares) Stock Issued During Period, Shares, Share-Based Payment Arrangement And Employee Stock Purchase Plans Stock Issued During Period, Shares, Share-Based Payment Arrangement And Employee Stock Purchase Plans Debt instrument, covenant, availability amount, minimum Debt Instrument, Covenant, Availability Amount, Minimum Debt Instrument, Covenant, Availability Amount, Minimum RSUs Restricted Stock Units (RSUs) [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Common shares issued and outstanding Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] Name Awards Close in Time to MNPI Disclosures, Individual Name Entity Filer Category Entity Filer Category Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Company Selected Measure Name Company Selected Measure Name Litigation Installments [Domain] Litigation Installments [Domain] Litigation Installments [Domain] Testing [Member] Testing Revenue EX-101.PRE 9 mygn-20240930_pre.xml XBRL

TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 11 R1.htm IDEA: XBRL DOCUMENT v3.24.3 Cover - shares 9 Months Ended Sep. 30, 2024 Nov. 04, 2024 Cover [Abstract] Â Â Document Type 10-Q Â Document Quarterly Report true Â Document Period End Date Sep. 30, 2024 Â Document Transition Report false Â Entity File Number 0-26642 Â Entity Registrant Name MYRIAD GENETICS, INC. Â Entity Incorporation, State or Country Code DE Â Entity Tax Identification Number 87-0494517 Â Entity Address, Address Line One 322 North 2200 West Â Entity Address, City or Town Salt Lake City Â Entity Address, State or Province UT Â Entity Address, Postal Zip Code 84116 Â City Area Code 801 Â Local Phone Number 584-3600 Â Title of 12(b) Security Common Stock, $0.01 par value Â Trading Symbol MYGN Â Security Exchange Name NASDAQ Â Entity Current Reporting Status Yes Â Entity Interactive Data Current Yes Â Entity Filer Category Large Accelerated Filer Â Entity Small Business false Â Entity Emerging Growth Company false Â Entity Shell Company false Â Entity Common Stock, Shares Outstanding Â 91,035,230 Amendment Flag false Â Entity Central Index Key 0000899923 Â Current Fiscal Year End Date --12-31 Â Document Fiscal Year Focus 2024 Â Document Fiscal Period Focus Q3 Â X - DefinitionBoolean flag that is true when the XBRL content amends previously-filed or accepted submission. + ReferencesNo definition available. + Details Name: dei_AmendmentFlag Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionArea code of city + ReferencesNo definition available. + Details Name: dei_CityAreaCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCover page. + ReferencesNo definition available. + Details Name: dei_CoverAbstract Namespace Prefix: dei_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionEnd date of current fiscal year in the format --MM-DD. + ReferencesNo definition available. + Details Name: dei_CurrentFiscalYearEndDate Namespace Prefix: dei_ Data Type: xbrli:gMonthDayItemType Balance Type: na Period Type: duration X - DefinitionFiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalPeriodFocus Namespace Prefix: dei_ Data Type: dei:fiscalPeriodItemType Balance Type: na Period Type: duration X - DefinitionThis is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006. + ReferencesNo definition available. + Details Name: dei_DocumentFiscalYearFocus Namespace Prefix: dei_ Data Type: xbrli:gYearItemType Balance Type: na Period Type: duration X - DefinitionFor the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD. + ReferencesNo definition available. + Details Name: dei_DocumentPeriodEndDate Namespace Prefix: dei_ Data Type: xbrli:dateItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as an quarterly report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Form 10-Q -Number 240 -Section 308 -Subsection a + Details Name: dei_DocumentQuarterlyReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true only for a form used as a transition report. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Forms 10-K, 10-Q, 20-F -Number 240 -Section 13 -Subsection a-1 + Details Name: dei_DocumentTransitionReport Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'. + ReferencesNo definition available. + Details Name: dei_DocumentType Namespace Prefix: dei_ Data Type: dei:submissionTypeItemType Balance Type: na Period Type: duration X - DefinitionAddress Line 1 such as Attn, Building Name, Street Name + ReferencesNo definition available. + Details Name: dei_EntityAddressAddressLine1 Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the City or Town + ReferencesNo definition available. + Details Name: dei_EntityAddressCityOrTown Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionCode for the postal or zip code + ReferencesNo definition available. + Details Name: dei_EntityAddressPostalZipCode Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionName of the state or province. + ReferencesNo definition available. + Details Name: dei_EntityAddressStateOrProvince Namespace Prefix: dei_ Data Type: dei:stateOrProvinceItemType Balance Type: na Period Type: duration X - DefinitionA unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityCentralIndexKey Namespace Prefix: dei_ Data Type: dei:centralIndexKeyItemType Balance Type: na Period Type: duration X - DefinitionIndicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument. + ReferencesNo definition available. + Details Name: dei_EntityCommonStockSharesOutstanding Namespace Prefix: dei_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionIndicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesNo definition available. + Details Name: dei_EntityCurrentReportingStatus Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionIndicate if registrant meets the emerging growth company criteria. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityEmergingGrowthCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionCommission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen. + ReferencesNo definition available. + Details Name: dei_EntityFileNumber Namespace Prefix: dei_ Data Type: dei:fileNumberItemType Balance Type: na Period Type: duration X - DefinitionIndicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityFilerCategory Namespace Prefix: dei_ Data Type: dei:filerCategoryItemType Balance Type: na Period Type: duration X - DefinitionTwo-character EDGAR code representing the state or country of incorporation. + ReferencesNo definition available. + Details Name: dei_EntityIncorporationStateCountryCode Namespace Prefix: dei_ Data Type: dei:edgarStateCountryItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-T -Number 232 -Section 405 + Details Name: dei_EntityInteractiveDataCurrent Namespace Prefix: dei_ Data Type: dei:yesNoItemType Balance Type: na Period Type: duration X - DefinitionThe exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityRegistrantName Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionBoolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityShellCompany Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionIndicates that the company is a Smaller Reporting Company (SRC). + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntitySmallBusiness Namespace Prefix: dei_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - DefinitionThe Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b-2 + Details Name: dei_EntityTaxIdentificationNumber Namespace Prefix: dei_ Data Type: dei:employerIdItemType Balance Type: na Period Type: duration X - DefinitionLocal phone number for entity. + ReferencesNo definition available. + Details Name: dei_LocalPhoneNumber Namespace Prefix: dei_ Data Type: xbrli:normalizedStringItemType Balance Type: na Period Type: duration X - DefinitionTitle of a 12(b) registered security. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection b + Details Name: dei_Security12bTitle Namespace Prefix: dei_ Data Type: dei:securityTitleItemType Balance Type: na Period Type: duration X - DefinitionName of the Exchange on which a security is registered. + ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Exchange Act -Number 240 -Section 12 -Subsection d1-1 + Details Name: dei_SecurityExchangeName Namespace Prefix: dei_ Data Type: dei:edgarExchangeCodeItemType Balance Type: na Period Type: duration X - DefinitionTrading symbol of an instrument as listed on an exchange. + ReferencesNo definition available. + Details Name: dei_TradingSymbol Namespace Prefix: dei_ Data Type: dei:tradingSymbolItemType Balance Type: na Period Type: duration XML 12 R2.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (unaudited) - USD ($) $ in Millions Sep. 30, 2024 Dec. 31, 2023 Current assets: Â Â Cash and cash equivalents $ 99.9 $ 132.1 Marketable investment securities 0.0 8.8 Trade accounts receivable 125.7 114.3 Inventory 26.2 22.0 Prepaid taxes 17.0 17.0 Prepaid expenses and other current assets 24.4 19.4 Total current assets 293.2 313.6 Operating lease right-of-use assets 57.4 61.6 Property, plant, and equipment, net 115.4 119.0 Intangibles, net 312.5 349.5 Goodwill 286.3 287.4 Other assets 16.5 15.4 Total assets 1,081.3 1,146.5 Current liabilities: Â Â Accounts payable 29.6 25.8 Accrued liabilities 111.2 113.9 Current maturities of operating lease liabilities 13.5 16.2 Total current liabilities 154.3 155.9 Unrecognized tax benefits 31.4 30.2 Long-term debt 39.0 38.5 Noncurrent operating lease liabilities 90.6 97.4 Other long-term liabilities 34.3 41.3 Total liabilities 349.6 363.3 Commitments and contingencies Stockholdersâ€™ equity: Â Â Common stock, 91.0 and 89.9 shares outstanding at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, respectively 0.9 0.9 Additional paid-in capital 1,445.2 1,415.5 Accumulated other comprehensive loss (0.1) (3.7) Accumulated deficit (714.3) (629.5) Total stockholders' equity 731.7 783.2 Total liabilities and stockholdersâ€™ equity $ 1,081.3 $ 1,146.5 X - DefinitionUnrecognized Tax Benefits, Net + ReferencesNo definition available. + Details Name: mygn_UnrecognizedTaxBenefitsNet Namespace Prefix: mygn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10 + Details Name: us-gaap_AccountsPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2 + Details Name: us-gaap_AccountsReceivableNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionValue received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AdditionalPaidInCapitalCommonStock Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section

50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 12: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 13: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Assets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset recognized for present right to economic benefit, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_AssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AssetsCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionRepresents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommitmentsAndContingencies Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_CommonStockValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-1 + Details Name: us-gaap_IntangibleAssetsNetExcludingGoodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_InventoryNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -

Paragraph 1 -Subparagraph (SX 210.5-02(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 15: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 18: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 29: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30 + Details Name: us-gaap_Liabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LiabilitiesAndStockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 20: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7 + Details Name: us-gaap_LiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_LiabilitiesCurrentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LongTermDebtNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of investment in marketable security, classified as current. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_MarketableSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as current. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAssetsNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_PrepaidExpenseAndOtherAssetsCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (g)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 340 -SubTopic 10 -Name Accounting Standards Codification -Section 05 -Paragraph 5 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5 + Details Name: us-gaap_PrepaidTaxes Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of accumulated undistributed earnings (deficit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting

Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(17)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1 + Details Name: us-gaap_RetainedEarningsAccumulatedDeficit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StockholdersEquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 13 R3.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Balance Sheets (unaudited) (Parenthetical) - shares shares in Millions Sep. 30, 2024 Dec. 31, 2023 Sep. 30, 2023 Dec. 31, 2022 Statement of Financial Position [Abstract] Â Â Â Â Common stock, shares outstanding (shares) 91.0 89.9 82.1 81.2 X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfFinancialPositionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 14 R4.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Operations (unaudited) - USD ($) shares in Millions, $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Income Statement [Abstract] Â Â Â Â Testing revenue $ 213.3 $ 191.9 $ 627.0 $ 556.6 Costs and expenses: Â Â Â Â Cost of testing revenue 63.5 57.6 192.5 174.6 Research and development expense 28.5 24.0 81.2 67.7 Selling, general, and administrative expense 139.1 136.1 424.0 428.5 Legal settlements 0.0 34.3 0.0 111.8 Goodwill and long-lived asset impairment charges 2.2 0.0 13.8 0.0 Total costs and expenses 233.3 252.0 711.5 782.6 Operating loss (20.0) (60.1) (84.5) (226.0) Other income (expense): Â Â Â Â Interest income 0.4 0.6 1.4 1.8 Interest expense (0.8) (1.0) (2.1) (2.0) Other (0.8) (0.7) 0.8 (3.7) Total other income (expense), net (1.2) (1.1) 0.1 (3.9) Loss before income tax (21.2) (61.2) (84.4) (229.9) Income tax expense 0.9 0.1 0.4 2.2 Net loss $ (22.1) $ (61.3) $ (84.8) $ (232.1) Net loss per share: Â Â Â Â Basic (dollars per share) $ (0.24) $ (0.75) $ (0.94) $ (2.84) Diluted (dollars per share) $ (0.24) $ (0.75) $ (0.94) $ (2.84) Weighted average shares outstanding: Â Â Â Â Basic (shares) 90.9 81.9 90.5 81.6 Diluted (shares) 90.9 81.9 90.5 81.6 Revenue from contract with customer, product and service, extensible enumeration Testing [Member] Testing [Member] Testing [Member] Testing [Member] Cost, product and service, extensible enumeration Testing [Member] Testing [Member] Testing [Member] Testing [Member] X - DefinitionEarnings Per Share, Basic And Diluted EPS + ReferencesNo definition available. + Details Name: mygn_EarningsPerShareBasicAndDilutedEPSAbstract Namespace Prefix: mygn_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(2)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1 + Details Name: us-gaap_CostOfGoodsAndServicesSold Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionTotal costs of sales and operating expenses for the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_CostsAndExpenses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareBasic Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 52 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (e)(4) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(27)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7 + Details Name: us-gaap_EarningsPerShareDiluted Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionTotal loss recognized during the period from the impairment of goodwill plus the

loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill. + ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetImpairment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(11)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 9: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 235 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-05(b)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(10)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of interest expense classified as nonoperating. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_InterestExpenseNonoperating Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32 + Details Name: us-gaap_InvestmentIncomeInterest Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(6)) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_LegalFees Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_NonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OperatingCostsAndExpensesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe net result for the period of deducting operating expenses from operating revenues. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic

280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 31 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31 + Details Name: us-gaap_OperatingIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of income (expense) related to nonoperating activities, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_OtherNonoperatingIncomeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details Name: us-gaap_ResearchAndDevelopmentExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIndicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: duration X - DefinitionThe aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_SellingGeneralAndAdministrativeExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionIndicates type of cost from product sold and service rendered. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap_TypeOfCostGoodOrServiceExtensibleList Namespace Prefix: us-gaap_ Data Type: enum2:enumerationSetItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 15 R5.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Comprehensive Loss (unaudited) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Statement of Comprehensive Income [Abstract] Â Â Â Â Net loss $ (22.1) $ (61.3) $ (84.8) $ (232.1) Change in unrealized loss on available-for-sale debt securities, net of tax 0.0 0.3 0.1 2.5 Change in foreign currency translation adjustment, net of tax (0.5) (0.1) (1.5) 0.7 Reclassification adjustments for losses included in net loss, net of tax 0.0 0.1 0.0 1.5 Reclassification of cumulative translation adjustment to income upon sale or liquidation of certain foreign entities, net of tax 4.4 (0.1) 5.1 0.4 Comprehensive loss $ (18.2) $ (61.1) $ (81.1) $ (227.0) X - DefinitionAmount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(26)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5 + Details Name: us-gaap_ComprehensiveIncomeNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB

-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (a) -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481839/830-10-45-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 20 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482014/830-20-35-3Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-12 + Details Name: us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 40 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481724/830-30-40-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-17AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 16 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-16 + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-17A + Details Name: us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10AReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11 + Details Name: us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 16 R6.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Stockholders' Equity (unaudited) - USD ($) $ in Millions Total Common stock Additional paid-in capital Accumulated other comprehensive loss Accumulated deficit Beginning balance at Dec. 31, 2022 $ 885.8 $ 0.8 $ 1,260.1 $ (8.9) $ (366.2) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax (4.9) Â (4.9) Â Â Stock-based compensation expense 7.5 Â 7.5 Â Â Net loss (54.7) Â Â Â (54.7) Other comprehensive income (loss), net of tax 1.5 Â Â 1.5 Â Ending balance at Mar. 31, 2023 835.2 0.8 1,262.7 (7.4) (420.9) Beginning balance at Dec. 31, 2022 885.8 0.8 1,260.1 (8.9) (366.2) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Net loss (232.1) Â Â Â Â Ending balance at Sep. 30, 2023 683.4 0.8 1,286.2 (5.3) (598.3) Beginning balance at Mar. 31, 2023 835.2 0.8 1,262.7 (7.4) (420.9) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax 2.9 Â 2.9 Â Â Stock-based compensation expense 11.2 Â 11.2 Â Â Net loss (116.1) Â Â Â (116.1) Other comprehensive income (loss), net of tax 2.0 Â Â 2.0 Â Ending balance at Jun. 30, 2023 735.2 0.8 1,276.8 (5.4) (537.0) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax (2.2) Â (2.2) Â Â Stock-based compensation expense 11.6 Â 11.6 Â Â Net loss (61.3) Â Â Â (61.3) Other comprehensive income (loss), net of tax 0.1 Â Â 0.1 Â Ending balance at Sep. 30, 2023 683.4 0.8 1,286.2 (5.3) (598.3) Beginning balance at Dec. 31, 2023 783.2 0.9 1,415.5 (3.7) (629.5) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax (8.7) Â (8.7) Â Â Stock-based compensation expense 12.0 Â 12.0 Â Â Net loss (26.0) Â Â Â (26.0) Other comprehensive income (loss), net of tax (0.5) Â Â (0.5) Â Ending balance at Mar. 31, 2024 760.0 0.9 1,418.8 (4.2) (655.5) Beginning balance at Dec. 31, 2023 783.2 0.9 1,415.5 (3.7) (629.5) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Net loss (84.8) Â Â Â Â Ending balance at Sep. 30, 2024 731.7 0.9 1,445.2 (0.1) (714.3) Beginning balance at Mar. 31, 2024 760.0 0.9 1,418.8 (4.2) (655.5) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax 2.5 Â 2.5 Â Â Stock-based compensation expense 14.5 Â 14.5 Â Â Net loss (36.7) Â Â Â (36.7) Other comprehensive income (loss), net of tax 0.2 Â Â 0.2 Â Ending balance at Jun. 30, 2024 740.5 0.9 1,435.8 (4.0) (692.2) Increase (Decrease) in Stockholders' Equity [Roll Forward] Â Â Â Â Â Issuance of common stock under stock-based compensation plans, net of shares exchanged for withholding tax (3.0) Â (3.0) Â Â Stock-based compensation expense 12.4 Â 12.4 Â Â Net loss (22.1) Â Â Â (22.1) Other comprehensive income (loss), net of tax 3.9 Â Â 3.9 Â Ending balance at Sep. 30, 2024 $ 731.7 $ 0.9 $ 1,445.2 $ (0.1) $ (714.3) X - DefinitionAmount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 20 -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12 + Details Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34:

http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionValue, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 17 R7.htm IDEA: XBRL DOCUMENT v3.24.3 Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Millions 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 CASH FLOWS FROM OPERATING ACTIVITIES: Â Â Net loss $ (84.8) $ (232.1) Adjustments to reconcile net loss to net cash used in operating activities: Â Â Depreciation and amortization 46.4 46.8 Non-cash lease expense 6.7 8.6 Stock-based compensation expense 38.9 30.3 Deferred income taxes (3.0) (1.7) Unrecognized tax benefits 1.2 2.8 Bad debt expense (0.8) 0.0 Net realized losses on marketable investment securities 0.0 1.5 Impairment of goodwill and long-lived assets 13.6 0.0 Gain on termination of lease (3.1) 0.0 Gain on acquisition (2.2) 0.0 Other non-cash adjustments 2.0 3.0 Changes in assets and liabilities: Â Â Prepaid expenses and other current assets (4.6) (1.8) Trade accounts receivable (12.7) (13.7) Inventory (4.9) (5.0) Prepaid taxes (0.1) 0.2 Other assets (0.2) (0.2) Tenant improvement allowance received 0.0 16.3 Accounts payable 5.8 2.2 Accrued liabilities (13.5) 86.6 Net cash used in operating activities (15.3) (56.2) CASH FLOWS FROM INVESTING ACTIVITIES: Â Â Capital expenditures (15.4) (53.2) Capitalization of internal-use software costs (8.4) (6.6) Proceeds from the sale of business, net cash sold 8.8 0.0 Proceeds from maturities and sales of marketable investment securities 9.0 103.7 Net cash provided by (used in) investing activities (6.0) 43.9 CASH FLOWS FROM FINANCING ACTIVITIES: Â Â Proceeds from common stock issued under stock-based compensation plans 3.0 0.0 Payment of tax withheld for common stock issued under stock-based compensation plans (12.2) (7.3) Proceeds from revolving credit facility 100.0 40.0 Repayment of revolving credit facility (100.0) 0.0 Fees associated with issuance and refinancing of revolving credit facility 0.0 (1.6) Payment on finance leases (0.3) (0.1) Net cash provided by (used in) financing activities (9.5) 31.0 Effect of foreign exchange rates on cash, cash equivalents, and restricted cash (0.3) (0.1) Net (decrease) increase in cash, cash equivalents, and restricted cash (31.1) 18.6 Cash, cash equivalents, and restricted cash at beginning of the period 140.9 66.4 Cash, cash equivalents, and restricted cash at end of the period $ 109.8 $ 85.0 X - DefinitionAsset Acquisition, Gain (Loss) + ReferencesNo definition available. + Details Name: mygn_AssetAcquisitionGainLoss Namespace Prefix: mygn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionIncrease (decrease) in unrecognized tax benefits. + ReferencesNo definition available. + Details Name: mygn_IncreaseDecreaseInUnrecognizedTaxBenefits Namespace Prefix: mygn_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4 + Details Name: us-gaap_AssetImpairmentCharges Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 1 -SubTopic 230 -Topic 830 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of deferred income tax expense (benefit) and income tax credits. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_DeferredIncomeTaxesAndTaxCredits Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_DepreciationAndAmortization Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 230 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1 + Details Name: us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow for principal payment on finance lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (g)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 5 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5 + Details Name: us-gaap_FinanceLeasePrincipalPayments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of gain (loss) on termination of lease before expiration of lease term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 40 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479092/842-20-40-1 + Details Name: us-gaap_GainLossOnTerminationOfLease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsPayable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccountsReceivable Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInAccruedLiabilities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInInventories Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInOperatingCapitalAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in noncurrent assets classified as other. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInOtherNoncurrentAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType

Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidExpensesOther Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) of consideration paid in advance for income and other taxes that provide economic benefits in future periods. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_IncreaseDecreaseInPrepaidTaxes Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of realized gain (loss) on investment in marketable security. + ReferencesNo definition available. + Details Name: us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24 + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25 + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionOther cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities). + ReferencesNo definition available. + Details Name: us-gaap_OtherOperatingActivitiesCashFlowStatement Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNet cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_PaymentsForProceedsFromTenantAllowance Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsForSoftware Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThe cash outflow for cost incurred in the modification of term of existing debt agreement in order for the entity to achieve some advantage. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsOfDebtRestructuringCosts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15 + Details Name: us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 13 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13 + Details Name: us-gaap_PaymentsToAcquireOtherProductiveAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionThis element represents the cash inflow during the period from the sale of a component of the entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12 + Details Name: us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 14 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Subparagraph (a) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A + Details Name: us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14 + Details Name: us-gaap_ProceedsFromLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period. + ReferencesNo definition available. + Details Name: us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of expense (reversal of expense) for expected credit loss on accounts receivable. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479319/326-20-50-13Reference 2:

http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2 + Details Name: us-gaap_ProvisionForDoubtfulAccounts Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 15 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_RepaymentsOfLinesOfCredit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 18 R8.htm IDEA: XBRL DOCUMENT v3.24.3 BASIS OF PRESENTATION 9 Months Ended Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â BASIS OF PRESENTATION BASIS OF PRESENTATIONMyriad Genetics, Inc. (together with its subsidiaries, the â€œCompanyâ€ or â€œMyriadâ€) is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower health care costs. Myriad provides insights that help people take control of their health and enable healthcare providers to better detect, treat, and prevent disease. The Company currently operates as a single reporting segment. The Companyâ€™s principal executive office is located in Salt Lake City, Utah.The accompanying Condensed Consolidated Financial Statements for the Company have been prepared in accordance with United States ("U.S.") generally accepted accounting principles (â€œGAAPâ€) for interim financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (â€œSECâ€).Â All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. The accompanying Condensed Consolidated Financial Statements should be read in conjunction with the Companyâ€™s audited Consolidated Financial Statements and notes thereto included in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023 (the â€œForm 10-Kâ€). The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. The Company has historically experienced seasonality in its business. The quarters ending March 31 and September 30 are typically weaker due to the annual reset of patient deductibles in the beginning of each calendar year and vacation schedules in the summer. The quarter ending December 31 is typically stronger due to increased demand as patients meet their deductibles throughout the year. Seasonal patterns were disrupted in recent years as a result of the COVID pandemic and certain other factors, but the Company believes it has experienced the impacts of seasonality in the third quarter 2024. Additionally, operating results for the three and nine months ended SeptemberÂ 30, 2024 may not necessarily be indicative of results to be expected for any other interim period or for the full year. Recent Accounting PronouncementsIn November 2023, the Financial Accounting Standards Board ("FASB") issued accounting standards update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which enhances the disclosures required for reportable segments in annual and interim consolidated financial statements. ASU 2023-07 is effective for the Company for annual reporting periods beginning after December 15, 2023 and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2023-07 on its segment disclosures.In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires enhanced income tax disclosures, including disaggregation of information on the rate reconciliation table and disaggregated information related to income taxes paid. The amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact of ASU 2023-09 on its income tax disclosures.ReclassificationsCertain prior period amounts have been reclassified to conform with the current period presentation. The reclassifications have no impact on the Company's total assets, total liabilities, stockholders' equity, or cash flows from operations. X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480424/946-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/810/tableOfContentReference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205/tableOfContent + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 19 R9.htm IDEA: XBRL DOCUMENT v3.24.3 REVENUE 9 Months Ended Sep. 30, 2024 Revenue from Contract with Customer [Abstract] Â REVENUE REVENUEThe Company primarily generates revenue by performing genetic testing. Testing revenues are primarily derived from the following categories of products: Hereditary Cancer (MyRisk, BRACAnalysis, BRACAnalysis CDx), Tumor Profiling (MyChoice CDx, Prolaris, Precise Tumor, and EndoPredict), Prenatal (Foresight, Prequel, and SneakPeek), and Pharmacogenomics (GeneSight). Revenue is recorded at the estimated transaction price. The Company has determined that the communication of test results indicates transfer of control for revenue recognition purposes.The following table presents detail regarding the composition of the Companyâ€™s total revenue by product type and by geographical region, either U.S. or rest of world (â€œRoWâ€):Three months ended September 30,20242023(in millions)U.S.RoWTotalU.S.RoWTotalTesting revenues:Hereditary Cancer$78.4Â $12.1Â $90.5Â $75.1Â $11.4Â $86.5Â Tumor Profiling26.5Â 5.1Â 31.6Â 22.0Â 8.2Â 30.2Â Prenatal43.4Â 0.1Â 43.5Â 39.4Â 0.1Â 39.5Â Pharmacogenomics47.7Â â€”Â 47.7Â 35.7Â â€”Â 35.7Â Total revenue$196.0Â $17.3Â $213.3Â $172.2Â $19.7Â $191.9Â Nine months ended September 30,20242023(in millions)U.S.RoWTotalU.S.RoWTotalTesting revenues:Hereditary Cancer$235.6Â $34.5Â $270.1Â $203.6Â $35.3Â $238.9Â Tumor Profiling77.1Â 18.0Â 95.1Â 78.1Â 25.4Â 103.5Â Prenatal131.7Â 0.5Â 132.2Â 110.8Â 0.5Â 111.3Â Pharmacogenomics129.6Â â€”Â 129.6Â 102.9Â â€”Â 102.9Â Total revenue$574.0Â $53.0Â $627.0Â $495.4Â $61.2Â $556.6Â Under Accounting Standards Codification ("ASC") 606: Revenue from Contracts with Customers, an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company performs its obligation under a contract with a customer by processing tests and communicating the test results to customers in exchange for consideration from the customer. The Company has the right to bill its customers upon the completion of performance obligations and thus does not record contract assets. Occasionally, customers make payments prior to the Companyâ€™s performance of its contractual obligations. When this occurs, the Company records a contract liability as Deferred revenue, which is included in Accrued liabilities in the Condensed Consolidated Balance Sheets. In accordance with ASC 606, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts that are one year or less, as the revenue is expected to be recognized within the next year. Furthermore, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts wherein the Companyâ€™s right to payment is in an amount that directly corresponds with the value of the Companyâ€™s performance to date. In determining the transaction price, the Company includes an estimate of the expected amount of consideration to be received. The Company applies this method consistently for similar contracts when estimating the effect of any uncertainty on an amount of variable consideration to which it will be entitled. An estimate of transaction price does not include any estimated amount of variable consideration that is constrained. In addition, the Company considers all the information (historical, current, and forecast) that is reasonably available to identify possible consideration amounts. In determining the expected value, the Company considers the probability of the variable consideration for each possible scenario. The Company also has significant experience with historical discount patterns and uses this experience to estimate transaction prices. The estimate of revenue is affected by, among other factors, assumptions for changes in payor mix, payor collections, current customer contractual requirements, experience with collections from third-party payors, and changes in medical policies. When assessing the total consideration for insurance carriers and patients, revenues are further constrained for estimated refunds. The Company reserves certain amounts in Accrued liabilities in the Companyâ€™s Condensed Consolidated Balance Sheets in anticipation of requests for refunds of payments made previously by insurance carriers, which are accounted for as reductions in revenues in the Condensed Consolidated Statements of Operations and Comprehensive Income/Loss.Cash collections for certain tests delivered may differ from rates estimated due to changes in the estimated transaction price for contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met, settlements with third-party payors, or as a result of third-party payors disputing our bills or denying payment for tests that we have performed, among other reasons. As a result of this new information, the Company updates its estimate of the amounts to be recognized for previously delivered tests. During the three and nine months ended September 30, 2024, the Company recognized $8.6Â million and $17.3Â million, respectively, which resulted in $0.09 and $0.19 impact to earnings per share, respectively, for testing in which the performance obligation was met in prior periods, primarily due to a changes in the estimated transaction price. Additionally, during the nine months ended September 30, 2024, the Company recognized $3.0 million in revenue due to a retroactive coverage change by a payor for one of its prenatal products. For the three and nine months ended SeptemberÂ 30, 2023, the Company recognized $7.1Â million and $6.2Â million in revenue, respectively, which resulted in a $0.07 and $0.06, respectively, impact to earnings per share for tests in which the performance obligation was met in prior periods, primarily driven by changes in the estimated transaction price. The Company applies the practical expedient related to costs to obtain or fulfill a contract since the amortization period for such costs will be one year or less. Accordingly, no costs incurred to obtain or fulfill a contract have been capitalized. The Company also applies the practical expedient for not adjusting revenue recognized for the effects of the time value of money. This practical expedient has been elected because the Company collects very little cash from customers under payment terms and the vast majority of payment terms have a payback period of less than one year. Concentration of Credit RiskFinancial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company limits its exposure to loss by placing its cash in financial institutions with high credit ratings. The Company's cash may consist of deposits held with banks that may at times exceed federally insured limits of $250,000 per customer. Substantially all of the Companyâ€™s accounts receivable are with companies in the healthcare industry, U.S. and state governmental agencies, and individuals. The Company does not believe that receivables due from U.S. and state governmental agencies, such as Medicare, represent a credit risk since the related healthcare programs are funded by the U.S. and state governments. The Company only has one payor, Medicare, that represents greater than 10% of its revenues. Revenues received from Medicare represented 11% of total revenue for both of the three and nine months ended SeptemberÂ 30, 2024 and 12% of total revenue for both of the three and nine months ended SeptemberÂ 30, 2023. Concentrations of credit risk are mitigated due to the number of the Companyâ€™s customers as well as their dispersion across many geographic regions. The Company has one payor that accounted for more than 10% of accounts receivable at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023. The balance of accounts receivable from this one payor represented 19% and 12% of the total accounts receivable balance as of SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, respectively. The Company does not require collateral from its customers. X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 15 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 20 R10.htm IDEA: XBRL DOCUMENT v3.24.3 MARKETABLE INVESTMENT SECURITIES 9 Months Ended Sep. 30, 2024 Investments, Debt and Equity Securities [Abstract] Â MARKETABLE INVESTMENT SECURITIES MARKETABLE INVESTMENT SECURITIESAt SeptemberÂ 30, 2024, the Company had no investment securities outstanding. The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for debt securities classified as available-for-sale securities by major security type and class of security at DecemberÂ 31, 2023 were as follows:(in millions)AmortizedcostGrossunrealizedholdinggainsGrossunrealizedholdinglossesEstimatedfair valueDecember 31, 2023Cash and cash equivalents:Cash$129.9Â $â€”Â $â€”Â $129.9Â Cash equivalents2.2Â â€”Â â€”Â 2.2Â Total cash and cash equivalents132.1Â â€”Â â€”Â 132.1Â Available-for-sale:Corporate bonds and notes8.4Â â€”Â (0.1)8.3Â Municipal bonds0.5Â â€”Â â€”Â 0.5Â Total$141.0Â $â€”Â (0.1)140.9Â The cost of a security sold, or amount reclassified out of Accumulated other comprehensive income or loss into Net loss, is determined based on the specific identification method. Additional information relating to fair value of marketable investment securities can be found in Note 4. X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for investments in certain debt and equity securities. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 940 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/940-320/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Regulation S-K (SK) -Number 229 -Section 1403 -Paragraph b -Publisher SECReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/320/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6BReference 6:

http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6BReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 320 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/942-320/tableOfContent + Details Name: us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 21 R11.htm IDEA: XBRL DOCUMENT v3.24.3 FAIR VALUE MEASUREMENTS 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â FAIR VALUE MEASUREMENTS FAIR VALUE MEASUREMENTSThe fair value of the Companyâ€™s financial instruments reflects the amounts that the Company estimates it will receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels:Level 1â€”quoted prices in active markets for identical assets and liabilities.Level 2â€”observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.Â Â Some of the Companyâ€™s marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities.Level 3â€”unobservable inputs.All of the Companyâ€™s financial instruments are valued using quoted prices in active markets or based on other observable inputs.Â For Level 2 securities, the Company uses a third-party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application, and corroborative information. The fair value of the Companyâ€™s long-term debt, which it considers a Level 2 measurement, is estimated using discounted cash flow analyses based on the Companyâ€™s current estimated incremental borrowing rates for similar borrowing arrangements.Â The fair value of the Companyâ€™s long-term debt is estimated to be $39.7Â million at SeptemberÂ 30, 2024.At SeptemberÂ 30, 2024, the Company did not have any financial assets requiring fair value re-measurement. The following table sets forth the fair value of the financial assets and liabilities that the Company re-measures on a regular basis as of December 31, 2023:(in millions)Level 1Level 2Level 3TotalDecember 31, 2023Money market funds(a)$2.2Â $â€”Â $â€”Â $2.2Â Corporate bonds and notesâ€”Â 8.3Â â€”Â 8.3Â Municipal bondsâ€”Â 0.5Â â€”Â 0.5Â Contingent considerationâ€”Â â€”Â (5.4)(5.4)Total$2.2Â $8.8Â (5.4)5.6Â (a)Money market funds are primarily comprised of exchange traded funds and accrued interest.The following table reconciles the change in the fair value of the contingent consideration during the periods presented:(in millions)CarryingAmountBalance at December 31, 2023$5.4Â Change in fair value recognized in the Statements of Operations0.5Â Payment of contingent consideration(5.8)Translation adjustments recognized in Other comprehensive loss(0.1)Ending balance at SeptemberÂ 30, 2024$â€”Â For the Level 2 contingent consideration related to the acquisition of Gateway Genomics, LLC ("Gateway"), the Company reassesses the fair value of expected contingent consideration and the corresponding liability each reporting period using current financial or operating projections. As of SeptemberÂ 30, 2024, the Company has estimated a fair value of $0 related to the Gateway contingent consideration as the achievement of the contingent consideration targets is not considered probable. X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 107 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2E -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2EReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6A -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6AReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 940 -SubTopic 820 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1 + Details Name: us-gaap_FairValueDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 22 R12.htm IDEA: XBRL DOCUMENT v3.24.3 PROPERTY, PLANT AND EQUIPMENT, NET 9 Months Ended Sep. 30, 2024 Property, Plant and Equipment [Abstract] Â PROPERTY, PLANT AND EQUIPMENT, NET PROPERTY, PLANT, AND EQUIPMENT, NETThe property, plant and equipment at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023 were as follows:(in millions)September 30,2024December 31,2023Leasehold improvements$78.2Â $91.3Â Equipment154.5Â 147.6Â Property, plant and equipment, gross232.7Â 238.9Â Less accumulated depreciation(117.3)(119.9)Property, plant and equipment, net$115.4Â $119.0Â The Company recorded depreciation during the respective periods as follows:Three months endedSeptember 30,Nine months endedSeptember 30,(in millions)2024202302024202 3Depreciation expense$4.8Â $3.4Â $14.5Â $14.8Â During the nine months ended September 30, 2023, the Company incurred $5.7Â million of accelerated depreciation of leasehold improvements and equipment in connection with the Company's decision to cease the use of its former corporate headquarters in Salt Lake City, Utah, and transition corporate support operations to its new facility in west Salt Lake City. The Company formally assigned the previous corporate headquarters lease to a third party as of DecemberÂ 31, 2023. See Note 15 for further discussion. X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 6 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 7 -SubTopic 360 -Topic 958 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7 + Details Name: us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 23 R13.htm IDEA: XBRL DOCUMENT v3.24.3 GOODWILL AND INTANGIBLE ASSETS 9 Months Ended Sep. 30, 2024 Goodwill and Intangible Assets Disclosure [Abstract] Â GOODWILL AND INTANGIBLE ASSETS GOODWILL AND INTANGIBLE ASSETSGoodwillThe changes in the carrying amount of goodwill for the nine months ended September 30, 2024 were as follows:(in millions)TotalBeginning balance$287.4Â Goodwill impairment(0.8)Translation adjustments(0.3)Ending balance$286.3Â The Company recognized a goodwill impairment charge of $0.8 million during the nine months ended September 30, 2024 related to the goodwill allocated to the Myriad International reporting unit. The goodwill impairment charge is reflected in Goodwill and long-lived asset impairment charges in the Condensed Consolidated Statements of Operations. See Note 18 for further discussion.As of September 30, 2024, goodwill for the Pharmacogenomics reporting unit (formerly referred to as Mental Health) was approximately $121.0Â million, which represents approximately 42.3% of total recorded goodwill. On November 1, 2024, UnitedHealthcare updated its medical policy for pharmacogenetic testing to no longer provide coverage for certain multi-gene panel pharmacogenetic tests, including the Company's GeneSight test, under its commercial and individual exchange benefit plans, effective January 1, 2025. The Company is still assessing the full impact of this policy change on its long-term forecasts; however, goodwill recorded in connection with this reporting unit may be at risk of impairment. The reporting unit was last quantitatively tested for goodwill impairment as of October 1, 2020, at which time the fair value of the reporting unit was in excess of the carrying value by 12%. As more information becomes available about the impact of the coverage decision by UnitedHealthcare, or if other adverse events occur, the Company may be required to record a goodwill impairment charge, which could have a material impact on the financial statements. See Item 2. Business Updates and Item 1A. Risk Factors for additional information. Intangible AssetsIntangible assets consist of amortizable assets of developed technologies, internal-use software, customer relationships, and trademarks, as well as in-process internal-use software that is not yet being amortized. During the nine months ended SeptemberÂ 30, 2024, the Company completed the sale of its EndoPredict business, including certain developed technologies with a net book value of approximately $13.1Â million. See Note 18 for further discussion about the sale of the EndoPredict business.The following summarizes the amounts reported as intangible assets:(in millions)GrossCarryingAmountAccumulatedAmortizationNetAt September 30, 2024Developed technologies$603.3Â (316.9)286.4Â Internal-use software1.6Â (0.5)1.1Â Internal-use software (in-process)18.8Â â€”Â 18.8Â Customer relationships1.6Â (0.3)1.3Â Trademarks6.1Â (1.2)4.9Â Total intangible assets631.4Â $(318.9)312.5Â (in millions)GrossCarryingAmountAccumulatedAmortizationNetAt December 31, 2023Developed technologies$626.1Â (295.3)330.8Â Internal-use software0.8Â (0.1)0.7Â Internal-use software (in-process)11.2Â â€”Â 11.2Â Customer relationships1.6Â (0.2)1.4Â Trademarks6.1Â (0.7)5.4Â Total intangible assets$645.8Â (296.3)349.5Â The Company recorded amortization expense during the respective periods for these intangible assets as follows:Three months endedSeptember 30,Nine months endedSeptember 30,(in millions)2024202302024202 3Amortization of intangible assets$10.5Â $10.7Â $31.9Â $32.0Â X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for goodwill and intangible assets. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-30/tableOfContentReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/350-20/tableOfContent + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 24 R14.htm IDEA: XBRL DOCUMENT v3.24.3 ACCRUED LIABILITIES 9 Months Ended Sep. 30, 2024 Payables and Accruals [Abstract] Â ACCRUED LIABILITIES ACCRUED LIABILITIESThe Company's accrued liabilities at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023 were as follows:(in millions)September 30,2024December 31,2023Employee compensation and benefits$51.4Â $49.7Â Accrued taxes payable4.2Â 4.6Â Refunds payable and reserves19.2Â 20.1Â Short-term contingent considerationâ€”Â 3.1Â Accrued royalties6.6Â 5.3Â Legal settlements6.0Â 6.0Â Lease termination accrual 4.3Â 4.4Â Other accrued liabilities19.5Â 20.7Â Total accrued liabilities$111.2Â $113.9Â X - DefinitionThe entire disclosure for accounts payable and accrued liabilities at the end of the reporting period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 720 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 25 R15.htm IDEA: XBRL DOCUMENT v3.24.3 LONG-TERM DEBT 9 Months Ended Sep. 30, 2024 Debt Disclosure [Abstract] Â LONG-TERM DEBT LONG-TERM DEBTOn June 30, 2023, the Company entered into an asset-based revolving credit facility (the â€œABL Facilityâ€) with an initial maximum principal amount of $90.0 million, with JPMorgan Chase Bank, N.A., as administrative agent and issuing bank, the other lender parties thereto, and certain of the Company's domestic subsidiaries (the "Guarantors"). On October 31, 2023, the Company entered into an amendment to the ABL Facility to increase the maximum principal amount of the available revolving line of credit by $25.0Â million for a total maximum principal commitment of $115.0Â million under the ABL Facility, which was effected through a new commitment provided by a new lender, Goldman Sachs Bank USA. The ABL Facility matures on June 30, 2026. The obligations of the Company are guaranteed by the Guarantors and the ABL Facility is secured by substantially all of the assets of the Company and the Guarantors. The Company had long-term debt of $40.0 million under the ABL Facility at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023, net of $1.0 million and $1.5 million of debt issuance costs, respectively. Proceeds from the ABL Facility were or will be used for the working capital needs and general corporate purposes of the Company and its subsidiaries.Availability under the ABL Facility is subject to a borrowing base, which is the lesser of (a) 85% of the Company's and the Guarantors' eligible accounts receivable plus certain cash held in a segregated and fully-blocked account with the administrative agent in an amount up to $20.0Â million ("Eligible Cash") minus any reserves established by the administrative agent in accordance with the ABL Facility, and (b) the aggregate amount of cash collections from eligible accounts of the Company and the Guarantors for the 60 consecutive days most recently ended. Subject to certain conditions, the Company can freely withdraw cash from the Eligible Cash account, provided that any reduction in the Eligible Cash amount will have a corresponding reduction in the borrowing base under the ABL Facility. Loans outstanding under the ABL Facility will bear interest at a rate per annum equal to, at the option of the Company, either (a) the greatest of (i) the daily Prime Rate, (ii) the daily NYFRB Rate plus 0.5%, and (iii) the monthly Adjusted Term SOFR Rate (as defined below) plus 1.0% (the â€œABRâ€) plus an applicable margin ranging from 1.0% to 1.5% depending on the aggregate average unused availability under the ABL Facility during the prior quarter or (b) term Secured Overnight Financing Rate ("SOFR") for a tenor of one, three or six months (at the Companyâ€™s election) plus 0.1% (the â€œAdjusted Term SOFR Rateâ€) plus an applicable margin ranging from 2.0% to 2.5% depending on the average unused availability under the ABL Facility during the prior quarter, with an ABR floor of 1.0% and an Adjusted Term SOFR Rate floor of 0.0%. Under the ABL Facility, the undrawn fee ranges from 37.5 to 50 basis points based on the daily amount of the

available revolving commitment. The weighted average interest rate for borrowings under the ABL Facility as of SeptemberÂ 30, 2024 was 8.4%.The Company may elect to prepay all or any portion of the amounts owed prior to the maturity date without premium or penalty. The ABL Facility is also subject to customary mandatory prepayments with the proceeds of unpermitted indebtedness and upon the occurrence of an over-advance. Voluntary and mandatory prepayments and all other payments of the ABL Facility must be accompanied by payment of accrued interest on the principal amount repaid or prepaid.The ABL Facility contains customary loan terms, interest rates, representations and warranties and affirmative and negative covenants, in each case, subject to customary limitations, exceptions and exclusions. Covenants under the ABL Facility limit or restrict the Company and its subsidiaries' ability to incur liens, incur indebtedness, dispose of assets, make investments, make certain restricted payments, merge or consolidate, and enter into certain speculative hedging arrangements. The ABL Facility requires the Company and the Guarantors, on a consolidated basis, to maintain minimum liquidity of $60.0Â million and minimum availability of $25.0Â million at all times before achieving a fixed charge coverage ratio of 1.0 to 1.0 and thereafter, to maintain a fixed charge coverage ratio of 1.0 to 1.0 until achieving availability under the ABL Facility of greater than the greater of (a) $10.6 million and (b) 12.5% of the lesser of the maximum commitment amount and the borrowing base for a period of 30 consecutive days. As of SeptemberÂ 30, 2024, availability under the ABL Facility was $48.8 million. In addition, the ABL Facility includes a number of customary events of default. If any event of default occurs (subject, in certain instances, to specified grace periods), the principal, premium, if any, interest, and any other monetary obligations on all the then-outstanding amounts under the ABL Facility may become due and payable immediately.Under the terms of the ABL Facility, if (i) an event of default has occurred and is continuing or (ii) availability under the ABL Facility is less than the greater of (a) $12.5Â million and (b) 15% of the lesser of the maximum commitment amount and the borrowing base, the Company will become subject to cash dominion, upon which the administrative agent will apply funds credited to a collection account to first prepay any outstanding protective advances, second to prepay any revolving loans and third, to cash collateralize any outstanding letter of credit exposure. Such cash dominion period will end when availability has remained in excess of the greater of (i) $12.5Â million and (ii) 15% of the lesser of the maximum commitment amount and the borrowing base for a period of 45 consecutive days and no event of default is continuing. X - ReferencesNo definition available. + Details Name: us-gaap_DebtDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 405 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(c)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 470 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/470/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1C -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1CReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I + Details Name: us-gaap_DebtDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 26 R16.htm IDEA: XBRL DOCUMENT v3.24.3 OTHER LONG-TERM LIABILITIES 9 Months Ended Sep. 30, 2024 Other Liabilities Disclosure [Abstract] Â OTHER LONG-TERM LIABILITIES OTHER LONG-TERM LIABILITIESThe Company's other long-term liabilities at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023 were as follows:(in millions)September 30,2024December 31,2023Contingent consideration$â€”Â $2.3Â Escrow liability7.5Â 7.5Â Legal settlements24.0Â 24.0Â Other2.8Â 7.5Â Total other long-term liabilities$34.3Â $41.3Â On October 23, 2023 (the "Effective Date"), the Company and Ravgen, Inc. ("Ravgen") entered into a settlement agreement pursuant to which the parties agreed to settle a pending lawsuit. Subject to the terms of the settlement agreement, the Company agreed to pay Ravgen a contingent payment of $21.25Â million payable in five annual installments, with (1) the first installment of $5.0Â million payable on the later of (a) 30 days after notification in writing by Ravgen of the successful conclusion in favor of Ravgen of all of Ravgen's litigations and patent reexaminations pending as of the Effective Date and (b) January 1, 2026 (the "Contingent Payment Date"); (2) the second installment of $5.0Â million on the first anniversary of the Contingent Payment Date; (3) the third installment of $5.0Â million on the second anniversary of the Contingent Payment Date; (4) the fourth installment of $5.0Â million on the third anniversary of the Contingent Payment Date; and (5) $1.25Â million on the fourth anniversary of the Contingent Payment Date. Additionally, the Company agreed to pay Ravgen a minimum of $12.75Â million in three installment payments of which $7.75Â million is outstanding as of SeptemberÂ 30, 2024. The remaining payments will be made in two installments: (1) $5.0Â million on or before October 31, 2024 and (2) $2.75Â million on or before October 31, 2025. The Company has accrued $5.0Â million in Accrued liabilities and $24.0Â million in Other long-term liabilities for these payments in the Company's Condensed Consolidated Balance Sheet as of SeptemberÂ 30, 2024. X - ReferencesNo definition available. + Details Name: us-gaap_OtherLiabilitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for other liabilities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405/tableOfContent + Details Name: us-gaap_OtherLiabilitiesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 27 R17.htm IDEA: XBRL DOCUMENT v3.24.3 PREFERRED AND COMMON STOCKHOLDERS' EQUITY 9 Months Ended Sep. 30, 2024 Equity [Abstract] Â PREFERRED AND COMMON STOCKHOLDERS' EQUITY PREFERRED AND COMMON STOCKHOLDERS' EQUITYThe Company is authorized to issue up to 5.0 million shares of preferred stock, par value $0.01 per share. There were no shares of preferred stock outstanding at SeptemberÂ 30, 2024.The Company is authorized to issue up to 150.0 million shares of common stock, par value $0.01 per share. There were 91.0 million shares of common stock issued and outstanding at SeptemberÂ 30, 2024.Shares of common stock issued and outstandingNine months endedSeptember 30,(in millions)20242023Beginning common stock issued and outstanding89.9Â 81.2Â Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plan1.1Â 0.9Â Common stock issued and outstanding at end of period91.0Â 82.1Â Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding. Diluted earnings per share is computed based on the weighted-average number of shares of common stock, including the dilutive effect of common stock equivalents, outstanding. In periods when the Company has a net loss, stock awards are excluded from the calculation of diluted net loss per share as their inclusion would have an antidilutive effect.The following is a reconciliation of the denominators of the basic and diluted earnings per share (â€œEPSâ€) computations:Three months endedSeptember 30,Nine months endedSeptember 30,(in millions)20242023202420232Denominator:Weighted-average shares outstanding used to compute basic EPS90.9Â 81.9Â 90.5Â 81.6Â Effect of dilutive sharesâ€”Â â€”Â â€”Â â€”Â Weighted-average shares outstanding and dilutive securities used to compute diluted EPS90.9Â 81.9Â 90.5Â 81.6Â Certain outstanding options and restricted stock units (â€œRSUsâ€) were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. These potential dilutive shares of common stock, which may be dilutive to future diluted earnings per share, are as follows:Three months endedSeptember 30,Nine months endedSeptember 30,(in millions)20242023202420232Anti-dilutive options and RSUs excluded from EPS computation5.9Â 5.3Â 5.9Â 5.3Â X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for equity. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 235 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477968/946-235-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 505 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478448/946-505-50-6Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480237/815-40-50-6Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.3-04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(e)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 505 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/505/tableOfContentReference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 16 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-16Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18 + Details Name: us-gaap_StockholdersEquityNoteDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 28 R18.htm IDEA: XBRL DOCUMENT v3.24.3 STOCK-BASED COMPENSATION 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] Â STOCK-BASED COMPENSATION STOCK-BASED COMPENSATIONOn November 30, 2017, the Companyâ€™s stockholders approved the adoption of the 2017 Employee, Director and Consultant Equity Incentive Plan (as amended, the â€œ2017 Planâ€). The 2017 Plan allows the Company, under the direction of the Compensation and Human Capital Committee (the "CHCC") of the Board of Directors, to make grants of restricted stock and restricted stock unit awards to employees, consultants, and directors. Stockholders have subsequently approved amendments to the 2017 Plan increasing the shares available to grant thereunder, including most recently at the Company's annual meeting of stockholders held on June 1, 2023, when stockholders approved an amendment to the 2017 Plan to increase the aggregate number of shares of common stock available thereunder for the granting of awards by an additional 4.8Â million shares. As of SeptemberÂ 30, 2024, the Company had 2.3Â million shares of common stock available for grant under the 2017 Plan. If an RSU awarded under the 2017 Plan is cancelled or forfeited without the issuance of shares of common stock, the unissued shares that were subject to the RSU will again be available for issuance pursuant to the 2017 Plan. The number of shares, terms, and vesting periods are generally determined by the Companyâ€™s Board of Directors or the CHCC on an award-by-award basis. RSUs granted to employees generally vest either ratably over three or four years or as cliff vesting after three years either on the anniversary of the date on which the RSUs were granted or during the month in which such anniversary dates occur. The number of performance-based RSUs ("PSUs") awarded to certain employees may be increased or reduced based on certain additional performance and market metrics. RSUs granted to non-employee directors generally vest in full upon the earlier of the completion of one year of service following the date of the grant or the date of the next annual meeting of stockholders following such grant. Options granted to the Company's President and Chief Executive Officer as an inducement to his employment expire on August 13, 2027.The performance and market conditions associated with PSU awards granted during the nine months ended September 30, 2024 include vesting that

is based on revenue targets (34% weighting), adjusted earnings per share targets (33% weighting), and relative total stockholder return (33% weighting) measured against the Nasdaq Health Care Index (IXHC) using the 20-trading day averages at the beginning and end of the measurement period. The measurement period for the relative total stockholder return metric is January 1, 2024 through December 31, 2026, and the revenue and adjusted earnings per share metrics will be measured based on fiscal year 2026 results. The Company estimates the likelihood of achievement of performance conditions for all PSU awards at the end of each period. To the extent those awards or portions thereof are considered probable of being achieved, such awards or portions thereof are expensed over the performance period. The portion of the awards pertaining to relative total stockholder return represent market conditions and, accordingly, the estimated fair value of such awards is recognized over the performance period. Stock OptionsA summary of the stock option activity for the nine months ended SeptemberÂ 30, 2024 is as follows:(number of shares in millions)NumberofSharesWeightedAverageExercisePriceOptions outstanding at December 31, 20230.7Â $13.38Â Options outstanding at September 30, 20240.7Â $13.38Â Options exercisable at September 30, 20240.5Â $13.38Â As of SeptemberÂ 30, 2024, there was no unrecognized stock-based compensation expense. There were no options granted during the nine months ended SeptemberÂ 30, 2024.Restricted Stock UnitsA summary of the RSU awards activity under the Companyâ€™s equity plan and inducement awards, including PSU awards, for the nine months ended SeptemberÂ 30, 2024 is as follows:(number of shares in millions)NumberofSharesWeightedAverageGrant DateFair ValueRSUs unvested and outstanding at December 31, 20234.4Â $24.37Â RSUs granted2.5Â $22.46Â Less:RSUs vested(1.5)$23.77Â RSUs canceled(0.2)$23.62Â RSUs unvested and outstanding at September 30, 20245.2Â $23.63Â Employee Stock Purchase PlanThe Company also has an Employee Stock Purchase Plan that was initially approved by stockholders in 2012 and was amended and approved by the Board of Directors of the Company on September 23, 2021 and the stockholders on June 2, 2022 (the "Amended and Restated 2012 Purchase Plan"), under which 4.0Â million shares of common stock were authorized for issuance under the Amended and Restated 2012 Purchase Plan.Â Shares are issued under the Amended and Restated 2012 Purchase Plan twice yearly at the end of each offering period and the number of shares that may be purchased by any participant during an offering period is limited to 5,000 shares.Â The first offering period of 2024 started on December 1, 2023 and ended on May 31, 2024. The second offering period of 2024 began on June 1, 2024 and will end on November 30, 2024. As of SeptemberÂ 30, 2024, 1.1Â million shares of common stock were available for issuance under the Amended and Restated 2012 Purchase Plan. Shares purchased under, and compensation expense associated with, the Amended and Restated 2012 Purchase Plan for the nine months ended September 30, 2024 and 2023 are as follows:Three months endedSeptember 30,Nine months endedSeptember 30,(in millions)20242023202420232024Shares purchased under the planâ€”Â â€”Â 0.2Â 0.2Plan compensation expense$0.5Â $0.5Â $1.6Â $1.7Â Stock-Based Compensation ExpenseStock-based compensation expense recognized and included in the Condensed Consolidated Statements of Operations and Comprehensive Loss was allocated as follows:Three months endedSeptember 30,Nine months endedSeptember 30,(in millions)20242023202420232024Cost of testing revenue$0.3Â $0.4Â $1.0Â $1.1Â Research and development expense1.6Â 1.2Â 4.4Â 2.9Â Selling, general, and administrative expense10.5Â 10.0Â 33.5Â 26.3Â Â Â Â Â Â Â Total stock-based compensation expense$12.4Â $11.6Â $38.9Â $30.3Â As of SeptemberÂ 30, 2024, there was $81.7 million of total unrecognized stock-based compensation expense related to RSUs that is expected to be recognized over a weighted-average period of 2.2 years.Â The Company recognizes forfeitures as they occur. In the event that a PSU is determined to be improbable of vesting, the Company records an adjustment to reverse all previously recognized expense associated with the equity award in the current period. X - DefinitionThe entire disclosure for share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/718/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 29 R19.htm IDEA: XBRL DOCUMENT v3.24.3 INCOME TAXES 9 Months Ended Sep. 30, 2024 Income Tax Disclosure [Abstract] Â INCOME TAXES INCOME TAXESIn order to determine the Companyâ€™s quarterly provision for income taxes, the Company used an estimated annual effective tax rate that is based on expected annual income and statutory tax rates in the various jurisdictions in which the Company operates.Â Certain significant or unusual items are separately recognized in the quarter during which they occur and can be a source of variability in the effective tax rate from quarter to quarter.For the three months ended SeptemberÂ 30, 2024, there was $0.9 million in income tax expense, or approximately (4.2)% of pre-tax loss, compared to $0.1 million income tax expense, or approximately (0.2)% of pre-tax loss, for the three months ended SeptemberÂ 30, 2023. Income tax expense for the nine months ended September 30, 2024 was $0.4 million, or approximately (0.5)% of pre-tax loss, compared to an income tax expense of $2.2Â million, or approximately (1.0)% of pre-tax loss, for the nine months ended September 30, 2023. For the three and nine months ended September 30, 2024 and 2023, the Companyâ€™s effective tax rate differs from the U.S. federal statutory rate primarily due to the recognition of valuation allowances. Due to the Company's cumulative loss and the exhaustion of future taxable income from the reversal of taxable temporary differences, the Company's estimated annual effective tax rate for the current year includes a valuation allowance against the majority of the current year increase in deferred tax assets. X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for income tax. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12C -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12CReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12B -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12BReference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.5.Q1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/740/tableOfContentReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 21 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 11.C) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2 + Details Name: us-gaap_IncomeTaxDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 30 R20.htm IDEA: XBRL DOCUMENT v3.24.3 COMMITMENTS AND CONTINGENCIES 9 Months Ended Sep. 30, 2024 Commitments and Contingencies Disclosure [Abstract] Â COMMITMENTS AND CONTINGENCIES COMMITMENTS AND CONTINGENCIESThe Company is involved from time to time in various disputes, claims and legal actions, including class actions and other litigation, including the matters described below, arising in the ordinary course of business. Such actions may include allegations of negligence, product or professional liability or other legal claims, and could involve claims for substantial compensatory and punitive damages or claims for indeterminate amounts of damages. The Company is also involved, from time to time, in investigations by governmental agencies regarding its business which may result in adverse judgments, settlements, fines, penalties, injunctions or other relief. In addition, certain federal and state statutes, including the qui tam provisions of the federal False Claims Act, allow private individuals to bring lawsuits against healthcare companies on behalf of the government or private payors. The Company has received subpoenas from time to time related to billing or other practices based on the False Claims Act or other federal and state statutes, regulations or other laws.The Company intends to defend its current litigation matters, but cannot provide any assurance as to the ultimate outcome or that an adverse resolution would not have a material adverse effect on its financial condition, results of operations or cash flows.The Company assesses legal contingencies to determine the degree of probability and range of possible loss for potential accrual in its financial statements. When evaluating legal contingencies, the Company may be unable to provide a meaningful estimate due to a number of factors, including the proceedings may be in early stages, there may be uncertainty as to the outcome of pending appeals or motions, there may be significant factual issues to be resolved, and there may be complex or novel legal theories to be presented. In addition, damages may not be specified or the damage amounts claimed may be unsupported, exaggerated or unrelated to possible outcomes, and therefore, such amounts are not a reliable indicator of potential liability. As of SeptemberÂ 30, 2024, except as noted below, the Company has not recorded any material accrual for loss contingencies associated with legal proceedings or other matters or determined that an unfavorable outcome is probable and reasonably estimable in accordance with ASC 450, Contingencies. However, it is possible that the ultimate resolution of legal proceedings or other matters, if unfavorable, may be material to the Company's results of operations, financial condition or cash flows. Further, in the event that damages from an unfavorable resolution of one or more of these proceedings exceed the aggregate amount of the coverage limits of the Companyâ€™s insurance, or if the Companyâ€™s insurance carriers disclaim coverage, the amounts payable by the Company could also have a material adverse impact on the Companyâ€™s results of operations, financial condition or cash flows.Stockholder Derivative ActionsOn August 9, 2021, a stockholder derivative complaint was filed in the Delaware Court of Chancery against the Company's former President and Chief Executive Officer, Mark C. Capone, its former Chief Financial Officer, R. Bryan Riggsbee, its former Executive Vice President of Clinical Development, Bryan M. Dechairo, and certain of the Company's current and former directors, Lawrence C. Best, Walter Gilbert, John T. Henderson, Heiner Dreismann, Dennis Langer, Lee N. Newcomer, S. Louise Phanstiel, and Colleen F. Reitan (collectively, the "Individual Defendants"), and the Company, as nominal defendant. The complaint is premised upon similar allegations that were set forth in the securities class action lawsuit that was settled and then dismissed by the U.S. District Court for the District of Utah in December 2023 (the "Securities Class Action"), including that the Individual Defendants made false and misleading statements regarding the Company's business and operations. The plaintiff, Donna Hickock, asserts breach of fiduciary duty and unjust enrichment claims against the Individual Defendants and seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged breaches, or disgorgement or restitution, from each of the Individual Defendants, plus interest. Plaintiff Hickock also seeks legal and other costs and fees relating to this action. On November 19, 2021, this action was stayed by the Delaware Court of Chancery pending the resolution of the Securities Class Action. On January 18, 2022, a stockholder derivative complaint was filed in the Delaware Court of Chancery against the Individual Defendants and the Company, as nominal defendant. The action is premised upon similar allegations as set forth in the Securities Class Action and the Hickock stockholder derivative action. The plaintiff, Esther Kogus, asserts that the Individual Defendants breached their fiduciary duties and also asserts unjust enrichment and aiding and abetting breaches of fiduciary duty claims against the Individual Defendants. Plaintiff Kogus seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged breaches and claims, and restitution from the Individual Defendants. On behalf of herself, plaintiff Kogus seeks legal and other costs and fees relating to this action. On March 3, 2022, the Delaware Court of Chancery consolidated the Hickock and Kogus derivative actions and stayed the consolidated action. On April 19, 2024, the Court of Chancery ordered that Leo Shumacher be substituted for Ms. Kogus as a plaintiff in this consolidated action.On September 17, 2021, a stockholder derivative complaint was filed in the U.S. District Court in the District of Delaware against the Individual Defendants and the Company, as nominal defendant. The action is premised upon similar allegations as set forth in the Securities Class Action and Hickock stockholder derivative action. The plaintiff, Karen Marcey, asserts that the Individual Defendants violated U.S. securities laws and breached their fiduciary duties, and also asserts unjust enrichment, waste of corporate assets and insider trading claims against all or some of the Individual Defendants. Plaintiff Marcey seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged violations and restitution from the Individual Defendants, plus interest and, on behalf of herself, legal and other costs and fees relating to this action. On January 4, 2022, this action was stayed by the U.S. District Court for the District of Delaware pending the resolution of the Securities Class Action. On April 30, 2024, the parties across all of the foregoing stockholder derivative actions entered into a global stipulation of settlement to resolve the actions (the "Settlement"). On May 3, 2024, the parties submitted the Settlement to the Delaware Court of Chancery for approval. As part of the Settlement, (i) the Company agreed to adopt or implement certain corporate governance reforms; and (ii) the parties agreed that plaintiffs' counsel will apply to the court for an award of attorneys' fees and expenses not to exceed $0.95 million to be paid by the Company, and that the Individual Defendants and the Company will not oppose or object to the requested fee award. The Settlement contains no admission of liability, wrongdoing or responsibility by any of the parties. On August 6, 2024, the Delaware Court of Chancery held a hearing to consider the Settlement. The parties expect a ruling on or about November 26, 2024. The Company has accrued $0.95 million for the settlement of the stockholder derivative actions, which is included in Accrued liabilities in the Companyâ€™s Condensed Consolidated Balance Sheet as of SeptemberÂ 30, 2024.Other Legal ProceedingsFrom time to time, the Company receives recoupment requests from third-party payors for alleged overpayments. The Company disagrees with the contentions of the pending requests or has recorded an estimated reserve for the alleged overpayments. X - ReferencesNo definition available. + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for commitments and contingencies. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 405 -SubTopic 30 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/405-30/tableOfContentReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/450/tableOfContentReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 440 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 440 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 440 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/440/tableOfContent + Details Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 31 R21.htm IDEA: XBRL DOCUMENT v3.24.3 SUPPLEMENTAL CASH FLOW INFORMATION 9 Months Ended Sep. 30, 2024 Supplemental Cash Flow Elements [Abstract] Â SUPPLEMENTAL CASH FLOW INFORMATION SUPPLEMENTAL CASH FLOW INFORMATIONThe Company's supplemental cash flow information for the nine months ended SeptemberÂ 30, 2024 and 2023 are as

follows:Nine Months Ended September 30,(in millions)20242023Cash paid for income taxes$1.8Â $1.3Â Cash paid for interest1.3Â 0.8Â Non-cash investing and financing activities: Change in operating lease right-of-use assets and lease liabilitiesOperating lease right-of-use assets(0.3)8.7Â Operating lease liabilities(3.1)9.2Â Non-cash adjustment to right-of-use assets and lease liabilities from lease modifications3.1Â â€”Â Purchases of property, plant and equipment and capitalization of internal-use software in accounts payable and accrued liabilities2.5Â 9.1Â The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported on the Condensed Consolidated Balance Sheets that agrees to the amounts included in the Condensed Consolidated Statements of Cash Flows.September 30,(in millions)20242023Cash and cash equivalents$99.9Â $76.0Â Restricted cash9.9Â 9.0Â Total cash, cash equivalents, and restricted cash$109.8Â $85.0Â X - DefinitionThe entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/230/tableOfContent + Details Name: us-gaap_CashFlowSupplementalDisclosuresTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowElementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 32 R22.htm IDEA: XBRL DOCUMENT v3.24.3 LEASES 9 Months Ended Sep. 30, 2024 Leases [Abstract] Â LEASES LEASESThe Company leases certain office spaces and research and development laboratory facilities, vehicles, and office equipment with remaining lease terms ranging from approximately one to fourteen years. Operating leases are included in Operating lease right-of-use assets, Noncurrent operating lease liabilities, and Current maturities of operating lease liabilities in the Condensed Consolidated Balance Sheets. Finance leases are included in Other assets, Accrued liabilities, and Other long-term liabilities in the Condensed Consolidated Balance Sheets. Due to the increase in remote and hybrid work and the Company's need to ensure its facilities are designed to handle future growth, the Company has been executing on a multi-year strategy to reset its real estate footprint. As part of that strategy, during the nine months ended SeptemberÂ 30, 2023, the Company took full possession of the remaining phases of the west Salt Lake City, Utah facility and recognized an additional $5.9 million right-of-use asset and corresponding lease liability, net of tenant improvement allowance not yet received. Also during the nine months ended SeptemberÂ 30, 2023, the Company decided to cease the use of its former corporate headquarters in Salt Lake City and transition corporate support operations to its new facility in west Salt Lake City, and as of December 31, 2023, the Company had formally assigned the lease for its previous corporate headquarters in Salt Lake City to a third party.During the nine months ended SeptemberÂ 30, 2024, the Company terminated the lease for one of its Salt Lake City, Utah facilities. As a result of the termination, the short-term lease liability of $3.1Â million associated with the lease was removed from the Company's Condensed Consolidated Balance Sheets. The total net gain recognized in connection with the termination of the lease was $1.2Â million, which is included in Selling, general, and administrative expense in the Condensed Consolidated Statements of Operations.During the nine months ended SeptemberÂ 30, 2024, the Company also amended the lease for its west Salt Lake City, Utah headquarters to include approximately 63,000 additional square feet in anticipation of future operating needs. The lease has a term of 12 years, which is expected to commence in fiscal year 2026. Total future rent payments for the additional space are approximately $18.2Â million. X - ReferencesNo definition available. + Details Name: us-gaap_LeasesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/842-20/tableOfContent + Details Name: us-gaap_LesseeOperatingLeasesTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 33 R23.htm IDEA: XBRL DOCUMENT v3.24.3 ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) 9 Months Ended Sep. 30, 2024 Equity [Abstract] Â ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) ACCUMULATED OTHER COMPREHENSIVE LOSSThe functional currency of the Companyâ€™s international subsidiaries is the local currency. For those subsidiaries, expenses denominated in the functional currency are translated into U.S. dollars using average exchange rates in effect during the period and assets and liabilities are translated using period-end exchange rates. The foreign currency translation adjustments are included in Accumulated other comprehensive loss as a separate component of Stockholdersâ€™ equity.The following table shows the cumulative translation adjustments included in Accumulated other comprehensive loss (in millions):Ending balance December 31, 2023$(3.7)Period translation adjustments(1.5)Reclassification of cumulative translation adjustment to income upon sale or liquidation of certain foreign entities5.1Â Ending balance September 30, 2024$(0.1) X - DefinitionThe entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(21)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/220/tableOfContent + Details Name: us-gaap_ComprehensiveIncomeNoteTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 34 R24.htm IDEA: XBRL DOCUMENT v3.24.3 ACQUISITION 9 Months Ended Sep. 30, 2024 Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Â ACQUISITION ACQUISITIONOn February 1, 2024, the Company acquired from Intermountain Health select assets from its Intermountain Precision Genomics ("IPG") laboratory business, including the Precise Tumor Test, the Precise Liquid Test, and IPG's CLIA-certified laboratory in St. George, Utah for an immaterial amount (the "Precise acquisition"). In connection with the Precise acquisition, the Company recognized a gain of $2.2Â million, which is included in Other income in the Company's Condensed Consolidated Statements of Operations. X - DefinitionThe entire disclosure for asset acquisition. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 805 -SubTopic 50 -Name Accounting Standards Codification -Section 15 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480123/805-50-15-3 + Details Name: us-gaap_AssetAcquisitionTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_BusinessCombinationAndAssetAcquisitionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 35 R25.htm IDEA: XBRL DOCUMENT v3.24.3 DIVESTITURE 9 Months Ended Sep. 30, 2024 Discontinued Operations and Disposal Groups [Abstract] Â DIVESTITURE DIVESTITUREOn August 1, 2024, the Company completed the sale of its EndoPredict business to Eurobio Scientific ("Eurobio") for net cash consideration of $10.0Â million, subject to customary closing adjustments, plus contingent consideration subject to certain earn-out conditions. The transaction was accounted for as a sale of business. The Company recognized a total net loss, including transaction expenses, of $12.4Â million during the nine months ended SeptemberÂ 30, 2024 in connection with this sale. The loss is included in Goodwill and long-lived asset impairment charges on the Companyâ€™s Condensed Consolidated Statements of Operations. The recognized loss included the release of $4.4Â million of foreign currency translation adjustments previously included in Accumulated other comprehensive income (loss). As part of the transaction, the Company licensed the rights from Eurobio to continue to sell EndoPredict as a laboratory developed test outside of the European Union and licensed to Eurobio the right to sell Prolaris in vitro diagnostic kits outside the U.S. X - ReferencesNo definition available. + Details Name: us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/205-20/tableOfContentReference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -Name Accounting Standards Codification -Publisher FASB -URI https://asc.fasb.org/360/tableOfContent + Details Name: us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 36 R26.htm IDEA: XBRL DOCUMENT v3.24.3 Pay vs Performance Disclosure - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 Pay vs Performance Disclosure Â Â Â Â Â Â Â Â Â Â Â Â Net loss $ (22.1) $ (36.7) $ (26.0) $ (61.3) $ (116.1) $ (54.7) $ (84.8) $ (232.1) X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 402 -Subsection v -Paragraph 1 + Details Name: ecd_PvpTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe portion of profit or loss for the period, net of income taxes, which is attributable to the parent. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 60 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 323 -Name Accounting Standards Codification -Section 65 -Paragraph 2 -Subparagraph (g)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 815 -SubTopic 40 -Name Accounting Standards Codification -Section 65 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 11 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4Reference 17: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section 45 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(18)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(1)(d)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1A -Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1B -Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 60B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-04(22)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1 + Details Name: us-gaap_NetIncomeLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration XML 37 R27.htm IDEA: XBRL DOCUMENT v3.24.3 Insider Trading Arrangements 3 Months Ended Sep. 30, 2024 Trading Arrangements, by Individual Â Rule 10b5-1

Arrangement Adopted false Non-Rule 10b5-1 Arrangement Adopted false Rule 10b5-1 Arrangement Terminated false Non-Rule 10b5-1 Arrangement Terminated false X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_NonRule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrAdoptedFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 1 + Details Name: ecd_Rule10b51ArrTrmntdFlag Namespace Prefix: ecd_ Data Type: xbrli:booleanItemType Balance Type: na Period Type: duration X - ReferencesReference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-K -Number 229 -Section 408 -Subsection a -Paragraph 2 -Subparagraph A + Details Name: ecd_TradingArrByIndTable Namespace Prefix: ecd_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 38 R28.htm IDEA: XBRL DOCUMENT v3.24.3 BASIS OF PRESENTATION (Policies) 9 Months Ended Sep. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Basis of Presentation The accompanying Condensed Consolidated Financial Statements for the Company have been prepared in accordance with United States ("U.S.") generally accepted accounting principles (â€œGAAPâ€) for interim financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission (â€œSECâ€).Â All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. The accompanying Condensed Consolidated Financial Statements should be read in conjunction with the Companyâ€™s audited Consolidated Financial Statements and notes thereto included in the Companyâ€™s Annual Report on Form 10-K for the year ended DecemberÂ 31, 2023 (the â€œForm 10-Kâ€). The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. The Company has historically experienced seasonality in its business. The quarters ending March 31 and September 30 are typically weaker due to the annual reset of patient deductibles in the beginning of each calendar year and vacation schedules in the summer. The quarter ending December 31 is typically stronger due to increased demand as patients meet their deductibles throughout the year. Seasonal patterns were disrupted in recent years as a result of the COVID pandemic and certain other factors, but the Company believes it has experienced the impacts of seasonality in the third quarter 2024. Additionally, operating results for the three and nine months ended SeptemberÂ 30, 2024 may not necessarily be indicative of results to be expected for any other interim period or for the full year. Recent Accounting Pronouncements Recent Accounting PronouncementsIn November 2023, the Financial Accounting Standards Board ("FASB") issued accounting standards update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which enhances the disclosures required for reportable segments in annual and interim consolidated financial statements. ASU 2023-07 is effective for the Company for annual reporting periods beginning after December 15, 2023 and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2023-07 on its segment disclosures.In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires enhanced income tax disclosures, including disaggregation of information on the rate reconciliation table and disaggregated information related to income taxes paid. The amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact of ASU 2023-09 on its income tax disclosures. Reclassifications ReclassificationsCertain prior period amounts have been reclassified to conform with the current period presentation. The reclassifications have no impact on the Company's total assets, total liabilities, stockholders' equity, or cash flows from operations. Revenue The Company primarily generates revenue by performing genetic testing. Testing revenues are primarily derived from the following categories of products: Hereditary Cancer (MyRisk, BRACAnalysis, BRACAnalysis CDx), Tumor Profiling (MyChoice CDx, Prolaris, Precise Tumor, and EndoPredict), Prenatal (Foresight, Prequel, and SneakPeek), and Pharmacogenomics (GeneSight). Revenue is recorded at the estimated transaction price. The Company has determined that the communication of test results indicates transfer of control for revenue recognition purposes.Under Accounting Standards Codification ("ASC") 606: Revenue from Contracts with Customers, an entity recognizes revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company performs its obligation under a contract with a customer by processing tests and communicating the test results to customers in exchange for consideration from the customer. The Company has the right to bill its customers upon the completion of performance obligations and thus does not record contract assets. Occasionally, customers make payments prior to the Companyâ€™s performance of its contractual obligations. When this occurs, the Company records a contract liability as Deferred revenue, which is included in Accrued liabilities in the Condensed Consolidated Balance Sheets.In accordance with ASC 606, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts that are one year or less, as the revenue is expected to be recognized within the next year. Furthermore, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts wherein the Companyâ€™s right to payment is in an amount that directly corresponds with the value of the Companyâ€™s performance to date. In determining the transaction price, the Company includes an estimate of the expected amount of consideration to be received. The Company applies this method consistently for similar contracts when estimating the effect of any uncertainty on an amount of variable consideration to which it will be entitled. An estimate of transaction price does not include any estimated amount of variable consideration that is constrained. In addition, the Company considers all the information (historical, current, and forecast) that is reasonably available to identify possible consideration amounts. In determining the expected value, the Company considers the probability of the variable consideration for each possible scenario. The Company also has significant experience with historical discount patterns and uses this experience to estimate transaction prices. The estimate of revenue is affected by, among other factors, assumptions for changes in payor mix, payor collections, current customer contractual requirements, experience with collections from third-party payors, and changes in medical policies. When assessing the total consideration for insurance carriers and patients, revenues are further constrained for estimated refunds. The Company reserves certain amounts in Accrued liabilities in the Companyâ€™s Condensed Consolidated Balance Sheets in anticipation of requests for refunds of payments made previously by insurance carriers, which are accounted for as reductions in revenues in the Condensed Consolidated Statements of Operations and Comprehensive Income/Loss.Cash collections for certain tests delivered may differ from rates estimated due to changes in the estimated transaction price for contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met, settlements with third-party payors, or as a result of third-party payors disputing our bills or denying payment for tests that we have performed, among other reasons. As a result of this new information, the Company updates its estimate of the amounts to be recognized for previously delivered tests. During the three and nine months ended September 30, 2024, the Company recognized $8.6Â million and $17.3Â million, respectively, which resulted in $0.09 and $0.19 impact to earnings per share, respectively, for testing in which the performance obligation was met in prior periods, primarily due to a changes in the estimated transaction price. Additionally, during the nine months ended September 30, 2024, the Company recognized $3.0 million in revenue due to a retroactive coverage change by a payor for one of its prenatal products. For the three and nine months ended SeptemberÂ 30, 2023, the Company recognized $7.1Â million and $6.2Â million in revenue, respectively, which resulted in a $0.07 and $0.06, respectively, impact to earnings per share for tests in which the performance obligation was met in prior periods, primarily driven by changes in the estimated transaction price. The Company applies the practical expedient related to costs to obtain or fulfill a contract since the amortization period for such costs will be one year or less. Accordingly, no costs incurred to obtain or fulfill a contract have been capitalized. The Company also applies the practical expedient for not adjusting revenue recognized for the effects of the time value of money. This practical expedient has been elected because the Company collects very little cash from customers under payment terms and the vast majority of payment terms have a payback period of less than one year. Concentration of Credit Risk Concentration of Credit RiskFinancial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company limits its exposure to loss by placing its cash in financial institutions with high credit ratings. The Company's cash may consist of deposits held with banks that may at times exceed federally insured limits of $250,000 per customer. Substantially all of the Companyâ€™s accounts receivable are with companies in the healthcare industry, U.S. and state governmental agencies, and individuals. The Company does not believe that receivables due from U.S. and state governmental agencies, such as Medicare, represent a credit risk since the related healthcare programs are funded by the U.S. and state governments. Fair Value Measurements The fair value of the Companyâ€™s financial instruments reflects the amounts that the Company estimates it will receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels:Level 1â€“quoted prices in active markets for identical assets and liabilities.Level 2â€“observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.Â Â Some of the Companyâ€™s marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities.Level 3â€“unobservable inputs.All of the Companyâ€™s financial instruments are valued using quoted prices in active markets or based on other observable inputs.Â For Level 2 securities, the Company uses a third-party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application, and corroborative information. The fair value of the Companyâ€™s long-term debt, which it considers a Level 2 measurement, is estimated using discounted cash flow analyses based on the Companyâ€™s current estimated incremental borrowing rates for similar borrowing arrangements. X - DefinitionDisclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS). + ReferencesNo definition available. + Details Name: us-gaap_BasisOfAccountingPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for credit risk. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 942 -SubTopic 825 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -SubTopic 10 -Topic 275 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1 + Details Name: us-gaap_ConcentrationRiskCreditRisk Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities. + ReferencesNo definition available. + Details Name: us-gaap_FairValueMeasurementPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact. + ReferencesNo definition available. + Details Name: us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 205 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483504/205-10-50-1 + Details Name: us-gaap_PriorPeriodReclassificationAdjustmentDescription Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionDisclosure of accounting policy for revenue from contract with customer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20Reference 9: http://www.xbrl.org/2003/role/exampleRef -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (e) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Topic 606 -Publisher FASB -URI https://asc.fasb.org/606/tableOfContent + Details Name: us-gaap_RevenueFromContractWithCustomerPolicyTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 39 R29.htm IDEA: XBRL DOCUMENT v3.24.3 REVENUE (Tables) 9 Months Ended Sep. 30, 2024 Revenue from Contract with Customer [Abstract] Â Schedule of Total Revenue by Type and by U.S versus Rest of World The following table presents detail regarding the composition of the Companyâ€™s total revenue by product type and by geographical region, either U.S. or rest of world (â€œRoWâ€):Three months ended September 30,20242023(in millions)U.S.RoWTotalU.S.RoWTotalTesting revenues:Hereditary Cancer$78.4Â $12.1Â $90.5Â $75.1Â $11.4Â $86.5Â Tumor Profiling26.5Â 5.1Â 31.6Â 22.0Â 8.2Â 30.2Â Prenatal43.4Â 0.1Â 43.5Â 39.4Â 0.1Â 39.5Â Pharmacogenomics47.7Â â€”Â 47.7Â 35.7Â â€”Â 35.7Â Total revenue$196.0Â $17.3Â $213.3Â $172.2Â $19.7Â $191.9Â Nine months ended September 30,20242023(in millions)U.S.RoWTotalU.S.RoWTotalTesting revenues:Hereditary Cancer$235.6Â $34.5Â $270.1Â $203.6Â $35.3Â $238.9Â Tumor Profiling77.1Â 18.0Â 95.1Â 78.1Â 25.4Â 103.5Â Prenatal131.7Â 0.5Â 132.2Â 110.8Â 0.5Â 111.3Â Pharmacogenomics129.6Â â€”Â 129.6Â 102.9Â â€”Â 102.9Â Total revenue$574.0Â $53.0Â $627.0Â $495.4Â $61.2Â $556.6Â X - DefinitionTabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5 + Details Name: us-gaap_DisaggregationOfRevenueTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_RevenueFromContractWithCustomerAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 40 R30.htm IDEA: XBRL DOCUMENT v3.24.3 MARKETABLE INVESTMENT SECURITIES (Tables) 9 Months Ended Sep. 30, 2024 Investments, Debt and Equity Securities [Abstract] Â Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for debt securities classified as available-for-sale securities by major security type and class of security at DecemberÂ 31, 2023 were as follows:(in

millions)AmortizedcostGrossunrealizedholdinggainsGrossunrealizedholdinglossesEstimatedfair valueDecember 31, 2023Cash and cash equivalents:Cash$129.9Â $â€”Â $â€”Â $129.9Â Cash equivalents2.2Â â€”Â â€”Â 2.2Â Total cash and cash equivalents132.1Â â€”Â â€”Â 132.1Â Available-for-sale:Corporate bonds and notes8.4Â â€”Â (0.1)8.3Â Municipal bonds0.5Â â€”Â â€”Â 0.5Â Total$141.0Â $â€”Â (0.1)140.9Â X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 41 R31.htm IDEA: XBRL DOCUMENT v3.24.3 FAIR VALUE MEASUREMENTS (Tables) 9 Months Ended Sep. 30, 2024 Fair Value Disclosures [Abstract] Â Schedule of Fair Value of Financial Assets and Liabilities The following table sets forth the fair value of the financial assets and liabilities that the Company re-measures on a regular basis as of December 31, 2023:(in millions)Level 1Level 2Level 3TotalDecember 31, 2023Money market funds(a)$2.2Â $â€”Â $â€”Â $2.2Â Corporate bonds and notesâ€”Â 8.3Â â€”Â 8.3Â Municipal bondsâ€”Â 0.5Â â€”Â 0.5Â Contingent considerationâ€”Â â€”Â (5.4)(5.4)Total$2.2Â $8.8Â (5.4)5.6Â (a)Money market funds are primarily comprised of exchange traded funds and accrued interest. Schedule of Change in Fair Value of Contingent Consideration The following table reconciles the change in the fair value of the contingent consideration during the periods presented:(in millions)CarryingAmountBalance at December 31, 2023$5.4Â Change in fair value recognized in the Statements of Operations0.5Â Payment of contingent consideration(5.8)Translation adjustments recognized in Other comprehensive loss(0.1)Ending balance at SeptemberÂ 30, 2024$â€”Â X - DefinitionTabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_FairValueDisclosuresAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 42 R32.htm IDEA: XBRL DOCUMENT v3.24.3 PROPERTY, PLANT AND EQUIPMENT, NET (Tables) 9 Months Ended Sep. 30, 2024 Property, Plant and Equipment [Abstract] Â Schedule of Property, Plant and Equipment, Net The property, plant and equipment at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023 were as follows:(in millions)September 30,2024December 31,2023Leasehold improvements$78.2Â $91.3Â Equipment154.5Â 147.6Â Property, plant and equipment, gross232.7Â 238.9Â Less accumulated depreciation(117.3) (119.9)Property, plant and equipment, net$115.4Â $119.0Â The Company recorded depreciation during the respective periods as follows:Three months endedSeptember 30,Nine months endedSeptember 30,(in millions)2024202320242023Depreciation expense$4.8Â $3.4Â $14.5Â $14.8Â X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 43 R33.htm IDEA: XBRL DOCUMENT v3.24.3 GOODWILL AND INTANGIBLE ASSETS (Tables) 9 Months Ended Sep. 30, 2024 Goodwill and Intangible Assets Disclosure [Abstract] Â Schedule of Changes in Carrying Amount of Goodwill The changes in the carrying amount of goodwill for the nine months ended September 30, 2024 were as follows:(in millions)TotalBeginning balance$287.4Â Goodwill impairment(0.8)Translation adjustments(0.3)Ending balance$286.3Â Schedule of Amortizable Intangible Assets The following summarizes the amounts reported as intangible assets:(in millions)GrossCarryingAmountAccumulatedAmortizationNetAt September 30, 2024Developed technologies$603.3Â (316.9)286.4Â Internal-use software1.6Â (0.5)1.1Â Internal-use software (in-process)18.8Â â€”Â 18.8Â Customer relationships1.6Â (0.3)1.3Â Trademarks6.1Â (1.2)4.9Â Total intangible assets631.4Â $(318.9)312.5Â (in millions)GrossCarryingAmountAccumulatedAmortizationNetAt December 31, 2023Developed technologies$626.1Â (295.3)330.8Â Internal-use software0.8Â (0.1)0.7Â Internal-use software (in-process)11.2Â â€”Â 11.2Â Customer relationships1.6Â (0.2)1.4Â Trademarks6.1Â (0.7)5.4Â Total intangible assets$645.8Â (296.3)349.5Â Schedule of Non-amortizable Intangible Assets The following summarizes the amounts reported as intangible assets:(in millions)GrossCarryingAmountAccumulatedAmortizationNetAt September 30, 2024Developed technologies$603.3Â (316.9)286.4Â Internal-use software1.6Â (0.5)1.1Â Internal-use software (in-process)18.8Â â€”Â 18.8Â Customer relationships1.6Â (0.3)1.3Â Trademarks6.1Â (1.2)4.9Â Total intangible assets631.4Â $(318.9)312.5Â (in millions)GrossCarryingAmountAccumulatedAmortizationNetAt December 31, 2023Developed technologies$626.1Â (295.3)330.8Â Internal-use software0.8Â (0.1)0.7Â Internal-use software (in-process)11.2Â â€”Â 11.2Â Customer relationships1.6Â (0.2)1.4Â Trademarks6.1Â (0.7)5.4Â Total intangible assets$645.8Â (296.3)349.5Â Schedule of Recorded Amortization Expense for Intangible Assets The Company recorded amortization expense during the respective periods for these intangible assets as follows:Three months endedSeptember 30,Nine months endedSeptember 30,(in millions)2024202320242023Amortization of intangible assets$10.5Â $10.7Â $31.9Â $32.0Â X - DefinitionTabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life. + ReferencesNo definition available. + Details Name: us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1AReference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2 + Details Name: us-gaap_ScheduleOfGoodwillTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2 + Details Name: us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 44 R34.htm IDEA: XBRL DOCUMENT v3.24.3 ACCRUED LIABILITIES (Tables) 9 Months Ended Sep. 30, 2024 Payables and Accruals [Abstract] Â Schedule of Accrued Liabilities The Company's accrued liabilities at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023 were as follows:(in millions)September 30,2024December 31,2023Employee compensation and benefits$51.4Â $49.7Â Accrued taxes payable4.2Â 4.6Â Refunds payable and reserves19.2Â 20.1Â Short-term contingent considerationâ€”Â 3.1Â Accrued royalties6.6Â 5.3Â Legal settlements6.0Â 6.0Â Lease termination accrual 4.3Â 4.4Â Other accrued liabilities19.5Â 20.7Â Total accrued liabilities$111.2Â $113.9Â X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accrued liabilities. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 45 R35.htm IDEA: XBRL DOCUMENT v3.24.3 OTHER LONG-TERM LIABILITIES (Tables) 9 Months Ended Sep. 30, 2024 Other Liabilities Disclosure [Abstract] Â Schedule of Other Long-Term Liabilities The Company's other long-term liabilities at SeptemberÂ 30, 2024 and DecemberÂ 31, 2023 were as follows:(in millions)September 30,2024December 31,2023Contingent considerationâ€”Â $2.3Â Escrow liability7.5Â 7.5Â Legal settlements24.0Â 24.0Â Other2.8Â 7.5Â Total other long-term liabilities$34.3Â $41.3Â X - ReferencesNo definition available. + Details Name: us-gaap_OtherLiabilitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of other noncurrent liabilities. + ReferencesNo definition available. + Details Name: us-gaap_OtherNoncurrentLiabilitiesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 46 R36.htm IDEA: XBRL DOCUMENT v3.24.3 PREFERRED AND COMMON STOCKHOLDERS' EQUITY (Tables) 9 Months Ended Sep. 30, 2024 Equity [Abstract] Â Schedule of Common Stock Issued and Outstanding Shares of common stock issued and outstandingNine months endedSeptember 30,(in millions)20242023Beginning common stock issued and outstanding89.9Â 81.2Â Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plan1.1Â 0.9Â Common stock issued and outstanding at end of period91.0Â 82.1Â Schedule of Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations The following is a reconciliation of the denominators of the basic and diluted earnings per share (â€œEPSâ€) computations:Three months endedSeptember 30,Nine months endedSeptember 30,(in millions)2024202320242023Denominator:Weighted-average shares outstanding used to compute basic EPS90.9Â 81.9Â 90.5Â 81.6Â Effect of dilutive sharesâ€”Â â€”Â â€”Â â€”Â Weighted-average shares outstanding and dilutive securities used to compute diluted EPS90.9Â 81.9Â 90.5Â 81.6Â Schedule of Potential Dilutive Common Shares These potential dilutive shares of common stock, which may be dilutive to future diluted earnings per share, are as follows:Three months endedSeptember 30,Nine months endedSeptember 30,(in millions)2024202320242023Anti-dilutive options and RSUs excluded from EPS computation5.9Â 5.3Â 5.9Â 5.3Â X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the change in common stock outstanding. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 260 -SubTopic 10 -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 47 R37.htm IDEA: XBRL DOCUMENT v3.24.3 STOCK-BASED COMPENSATION (Tables) 9 Months Ended Sep. 30, 2024 Share-Based Payment Arrangement [Abstract] Â Schedule of Stock Option Activity A summary of the stock option activity for the nine months ended SeptemberÂ 30, 2024 is as follows:(number of shares in millions)NumberofSharesWeightedAverageExercisePriceOptions outstanding at December 31, 20230.7Â $13.38Â Options outstanding at September 30, 20240.7Â $13.38Â Options exercisable at September 30, 20240.5Â $13.38Â Schedule of Restricted Stock Unit Activity A summary of the RSU awards activity under the Companyâ€™s equity plan and inducement awards, including PSU awards, for the nine months ended SeptemberÂ 30, 2024 is as follows:(number of shares in millions)NumberofSharesWeightedAverageGrant DateFair ValueRSUs unvested and

outstanding at December 31, 20234.4Â $24.37Â RSUs granted2.5Â $22.46Â Less:RSUs vested(1.5)$23.77Â RSUs canceled(0.2)$23.62Â RSUs unvested and outstanding at September 30, 20245.2Â $23.63Â Schedule of Shares Purchased and Compensation Expense Shares purchased under, and compensation expense associated with, the Amended and Restated 2012 Purchase Plan for the nine months ended September 30, 2024 and 2023 are as follows:Three months endedSeptember 30,Nine months endedSeptember 30,(in millions)2024202320242023Shares purchased under the planâ€”Â â€”Â 0.2Â 0.2Plan compensation expense$0.5Â $0.5Â $1.6Â $1.7Â Schedule of Stock-Based Compensation Expense Stock-based compensation expense recognized and included in the Condensed Consolidated Statements of Operations and Comprehensive Loss was allocated as follows:Three months endedSeptember 30,Nine months endedSeptember 30,(in millions)2024202320242023Cost of testing revenue$0.3Â $0.4Â $1.0Â $1.1Â Research and development expense1.6Â 1.2Â 4.4Â 2.9Â Selling, general, and administrative expense10.5Â 10.0Â 33.5Â 26.3Â Â Â Â Â Â Â Total stock-based compensation expense$12.4Â $11.6Â $38.9Â $30.3Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of employee stock purchase plan activity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 48 R38.htm IDEA: XBRL DOCUMENT v3.24.3 SUPPLEMENTAL CASH FLOW INFORMATION (Tables) 9 Months Ended Sep. 30, 2024 Supplemental Cash Flow Elements [Abstract] Â Schedule of Supplemental Cash Flow Information The Company's supplemental cash flow information for the nine months ended SeptemberÂ 30, 2024 and 2023 are as follows:Nine Months Ended September 30,(in millions)20242023Cash paid for income taxes$1.8Â $1.3Â Cash paid for interest1.3Â 0.8Â Non-cash investing and financing activities: Change in operating lease right-of-use assets and lease liabilitiesOperating lease right-of-use assets(0.3)8.7Â Operating lease liabilities(3.1)9.2Â Non-cash adjustment to right-of-use assets and lease liabilities from lease modifications3.1Â â€”Â Purchases of property, plant and equipment and capitalization of internal-use software in accounts payable and accrued liabilities2.5Â 9.1Â Schedule of Cash and Cash Equivalents The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported on the Condensed Consolidated Balance Sheets that agrees to the amounts included in the Condensed Consolidated Statements of Cash Flows.September 30,(in millions)20242023Cash and cash equivalents$99.9Â $76.0Â Restricted cash9.9Â 9.0Â Total cash, cash equivalents, and restricted cash$109.8Â $85.0Â Schedule of Restrictions on Cash and Cash Equivalents The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported on the Condensed Consolidated Balance Sheets that agrees to the amounts included in the Condensed Consolidated Statements of Cash Flows.September 30,(in millions)20242023Cash and cash equivalents$99.9Â $76.0Â Restricted cash9.9Â 9.0Â Total cash, cash equivalents, and restricted cash$109.8Â $85.0Â X - DefinitionTabular disclosure of the components of cash and cash equivalents. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of supplemental cash flow information for the periods presented. + ReferencesNo definition available. + Details Name: us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of cash and cash equivalents restricted as to withdrawal or usage. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 8 -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8 + Details Name: us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowElementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 49 R39.htm IDEA: XBRL DOCUMENT v3.24.3 ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables) 9 Months Ended Sep. 30, 2024 Equity [Abstract] Â Schedule of Cumulative Translation Adjustments in Accumulated Other Comprehensive Income (Loss) The following table shows the cumulative translation adjustments included in Accumulated other comprehensive loss (in millions):Ending balance December 31, 2023$(3.7)Period translation adjustments(1.5)Reclassification of cumulative translation adjustment to income upon sale or liquidation of certain foreign entities5.1Â Ending balance September 30, 2024$(0.1) X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionTabular disclosure of the components of accumulated other comprehensive income (loss). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20 + Details Name: us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock Namespace Prefix: us-gaap_ Data Type: dtr-types:textBlockItemType Balance Type: na Period Type: duration XML 50 R40.htm IDEA: XBRL DOCUMENT v3.24.3 BASIS OF PRESENTATION (Details) 9 Months Ended Sep. 30, 2024 segment Organization, Consolidation and Presentation of Financial Statements [Abstract] Â Number of reporting segments 1 X - DefinitionNumber of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18 + Details Name: us-gaap_NumberOfOperatingSegments Namespace Prefix: us-gaap_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 51 R41.htm IDEA: XBRL DOCUMENT v3.24.3 REVENUE - Schedule of Total Revenue by Type and by U.S versus Rest of World (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Disaggregation of Revenue [Line Items] Â Â Â Â Â Total revenue $ 213.3 $ 191.9 $ 627.0 $ 556.6 U.S. Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Total revenue 196.0 172.2 574.0 495.4 RoW Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Total revenue 17.3 19.7 53.0 61.2 Hereditary Cancer Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Total revenue 90.5 86.5 270.1 238.9 Hereditary Cancer | U.S. Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Total revenue 78.4 75.1 235.6 203.6 Hereditary Cancer | RoW Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Total revenue 12.1 11.4 34.5 35.3 Tumor Profiling Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Total revenue 31.6 30.2 95.1 103.5 Tumor Profiling | U.S. Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Total revenue 26.5 22.0 77.1 78.1 Tumor Profiling | RoW Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Total revenue 5.1 8.2 18.0 25.4 Prenatal Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Total revenue 43.5 39.5 132.2 111.3 Prenatal | U.S. Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Total revenue 43.4 39.4 131.7 110.8 Prenatal | RoW Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Total revenue 0.1 0.1 0.5 0.5 Pharmacogenomics Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Total revenue 47.7 35.7 129.6 102.9 Pharmacogenomics | U.S. Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Total revenue 47.7 35.7 129.6 102.9 Pharmacogenomics | RoW Â Â Â Â Â Disaggregation of Revenue [Line Items] Â Â Â Â Â Total revenue $ 0.0 $ 0.0 $ 0.0 $ 0.0 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91Reference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 91 -Subparagraph (g) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479777/606-10-55-91 + Details Name: us-gaap_DisaggregationOfRevenueLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 41 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 924 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 11.L) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 30 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4 + Details Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: srt_StatementGeographicalAxis=country_US Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=us-gaap_NonUsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=mygn_HereditaryCancerTestingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=mygn_TumorProfilingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=mygn_PrenatalTestingMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_ProductOrServiceAxis=mygn_PharmacogenomicsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 52 R42.htm IDEA: XBRL DOCUMENT v3.24.3 REVENUE - Narrative (Details) - USD ($) 3 Months Ended 9 Months Ended 12 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Dec. 31, 2023 Revenue and Concentration Risk [Line Items] Â Â Â Â Â Revenue recognized $ 8,600,000 $ 7,100,000 $ 17,300,000 $ 6,200,000 Â Change in earnings per share (dollars per share) $ 0.09 $ 0.07 $ 0.19 $ 0.06 Â Revenue recognized due to retroactive coverage change Â Â $ 3,000,000.0 Â Â Capitalized costs incurred to obtain or fulfill contract $ 0 Â $ 0 Â Â Government Contracts Concentration Risk | Medicare | Revenues Â Â Â Â Â Revenue and Concentration Risk [Line Items] Â Â Â Â Â Concentration risk (percent) 11.00% 12.00% 11.00% 12.00% Â Customer concentration | Medicare | Accounts receivable Â Â Â Â Â Revenue and Concentration Risk [Line Items] Â Â Â Â Â Concentration risk (percent) Â Â 19.00% Â 12.00% X - DefinitionIncrease decrease in

earnings (loss) per share. + ReferencesNo definition available. + Details Name: mygn_IncreaseDecreaseInEarningsLossPerShare Namespace Prefix: mygn_ Data Type: dtr-types1:perShareItemType Balance Type: na Period Type: duration X - DefinitionAmount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 340 -SubTopic 40 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479483/340-40-50-3 + Details Name: us-gaap_CapitalizedContractCostGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 954 -SubTopic 310 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2 + Details Name: us-gaap_ConcentrationRiskLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFor an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 42 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20 + Details Name: us-gaap_ConcentrationRiskPercentage1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which increases (decreases) right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 + Details Name: us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification which increases (decreases) right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10 + Details Name: us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GovernmentContractsConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_MajorCustomersAxis=mygn_MedicareMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 53 R43.htm IDEA: XBRL DOCUMENT v3.24.3 MARKETABLE INVESTMENT SECURITIES - Narrative (Details) Sep. 30, 2024 USD ($) Investments, Debt and Equity Securities [Abstract] Â Estimated fair value $ 0 X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 54 R44.htm IDEA: XBRL DOCUMENT v3.24.3 MARKETABLE INVESTMENT SECURITIES - Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Details) - USD ($) Sep. 30, 2024 Dec. 31, 2023 Sep. 30, 2023 Cash and cash equivalents: Â Â Â Cash and cash equivalents $ 99,900,000 $ 132,100,000 $ 76,000,000.0 Estimated fair value Â 132,100,000 Â Available-for-sale: Â Â Â Estimated fair value $ 0 Â Â Total Â Â Â Amortized cost Â 141,000,000.0 Â Gross unrealized holding gains Â 0 Â Gross unrealized holding losses Â (100,000) Â Estimated fair value Â 140,900,000 Â Corporate bonds and notes Â Â Â Available-for-sale: Â Â Â Amortized cost Â 8,400,000 Â Gross unrealized holding gains Â 0 Â Gross unrealized holding losses Â (100,000) Â Estimated fair value Â 8,300,000 Â Municipal bonds Â Â Â Available-for-sale: Â Â Â Amortized cost Â 500,000 Â Gross unrealized holding gains Â 0 Â Gross unrealized holding losses Â 0 Â Estimated fair value Â 500,000 Â Cash Â Â Â Cash and cash equivalents: Â Â Â Cash and cash equivalents Â 129,900,000 Â Estimated fair value Â 129,900,000 Â Cash equivalents Â Â Â Cash and cash equivalents: Â Â Â Cash and cash equivalents Â 2,200,000 Â Estimated fair value Â $ 2,200,000 Â X - DefinitionInvestments And Cash, Accumulated Gross Unrealized Gain, before Tax + ReferencesNo definition available. + Details Name: mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax Namespace Prefix: mygn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionInvestments And Cash, Accumulated Gross Unrealized Loss, before Tax + ReferencesNo definition available. + Details Name: mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax Namespace Prefix: mygn_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionInvestments And Cash, Amortized Cost + ReferencesNo definition available. + Details Name: mygn_InvestmentsAndCashAmortizedCost Namespace Prefix: mygn_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_AvailableForSaleSecuritiesAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 103 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (aa) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 320 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 326 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1 + Details Name: us-gaap_AvailableForSaleSecuritiesDebtSecurities Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_CashAndCashEquivalentsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionSum of investments and unrestricted cash as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1 + Details Name: us-gaap_InvestmentsAndCash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_InvestmentsAndCashAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CashAndCashEquivalentsAxis=us-gaap_CashEquivalentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 55 R45.htm IDEA: XBRL DOCUMENT v3.24.3 FAIR VALUE MEASUREMENTS - Narrative (Details) - USD ($) Sep. 30, 2024 Dec. 31, 2023 Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Â Â Financial assets requiring fair value re-measurement $ 0 $ 5,600,000 Gateway Â Â Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Â Â Contingent consideration liability 0 Â Level 2 Â Â Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items] Â Â Estimated fair value of long-term debt $ 39,700,000 Â Financial assets requiring fair value re-measurement Â $ 8,800,000 X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB

-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479581/805-30-50-1Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value of asset after deduction of liability. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueNetAssetLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionThe fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (bbb)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_LongTermDebtFairValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_BusinessAcquisitionAxis=mygn_GatewayGenomicsLLCMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 56 R46.htm IDEA: XBRL DOCUMENT v3.24.3 FAIR VALUE MEASUREMENTS - Schedule of Fair Value of Financial Assets and Liabilities (Details) - USD ($) Sep. 30, 2024 Dec. 31, 2023 Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Total $ 0 $ 5,600,000 Money market funds Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Financial assets Â 2,200,000 Corporate bonds and notes Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Financial assets Â 8,300,000 Municipal bonds Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Financial assets Â 500,000 Contingent consideration Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Financial liabilities Â (5,400,000) Level 1 Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Total Â 2,200,000 Level 1 | Money market funds Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Financial assets Â 2,200,000 Level 1 | Corporate bonds and notes Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Financial assets Â 0 Level 1 | Municipal bonds Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Financial assets Â 0 Level 1 | Contingent consideration Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Financial liabilities Â 0 Level 2 Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Total Â 8,800,000 Level 2 | Money market funds Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Financial assets Â 0 Level 2 | Corporate bonds and notes Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Financial assets Â 8,300,000 Level 2 | Municipal bonds Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Financial assets Â 500,000 Level 2 | Contingent consideration Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Financial liabilities Â 0 Level 3 Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Total Â (5,400,000) Level 3 | Money market funds Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Financial assets Â 0 Level 3 | Corporate bonds and notes Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Financial assets Â 0 Level 3 | Municipal bonds Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Financial assets Â 0 Level 3 | Contingent consideration Â Â Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] Â Â Financial liabilities Â $ (5,400,000) X - DefinitionFair value portion of asset recognized for present right to economic benefit. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_AssetsFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3 + Details Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFair value of asset after deduction of liability. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueNetAssetLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionFair value of financial and nonfinancial obligations. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_LiabilitiesFairValueDisclosure Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_ContingentConsiderationByTypeAxis=mygn_ContingentConsiderationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member Namespace Prefix: Data Type: na Balance Type: Period Type: XML 57 R47.htm IDEA: XBRL DOCUMENT v3.24.3 FAIR VALUE MEASUREMENTS - Schedule of Change in Fair Value of Contingent Consideration (Details) $ in Millions 9 Months Ended Sep. 30, 2024 USD ($) Reconciliation of change in fair value of contingent consideration Â Beginning balance $ 5.4 Change in fair value recognized in the Statements of Operations 0.5 Payment of contingent consideration (5.8) Translation adjustments recognized in Other comprehensive loss (0.1) Ending balance $ 0.0 X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionFair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2 + Details Name: us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 58 R48.htm IDEA: XBRL DOCUMENT v3.24.3 PROPERTY, PLANT AND EQUIPMENT, NET - Schedule of Property, Plant and Equipment, Net (Details) - USD ($) $ in Millions Sep. 30, 2024 Dec. 31, 2023 Property, Plant and Equipment [Line Items] Â Â Property, plant and equipment, gross $ 232.7 $ 238.9 Less accumulated depreciation (117.3) (119.9) Property, plant and equipment, net 115.4 119.0 Leasehold improvements Â Â Property, Plant and Equipment [Line Items] Â Â Property, plant and equipment, gross 78.2 91.3 Equipment Â Â Property, Plant and Equipment [Line Items] Â Â Property, plant and equipment, gross $ 154.5 $ 147.6 X - DefinitionAmount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(14)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(13)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 360 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 4:

http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(8)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 360 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1 + Details Name: us-gaap_PropertyPlantAndEquipmentNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 59 R49.htm IDEA: XBRL DOCUMENT v3.24.3 PROPERTY, PLANT AND EQUIPMENT, NET - Schedule of Depreciation Expense (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Property, Plant and Equipment [Abstract] Â Â Â Â Depreciation expense $ 4.8 $ 3.4 $ 14.5 $ 14.8 X - DefinitionThe amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 360 -SubTopic 10 -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1 + Details Name: us-gaap_Depreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_PropertyPlantAndEquipmentAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 60 R50.htm IDEA: XBRL DOCUMENT v3.24.3 PROPERTY, PLANT AND EQUIPMENT, NET - Narrative (Details) $ in Millions 9 Months Ended Sep. 30, 2023 USD ($) Leasehold improvements Â Property, Plant and Equipment [Line Items] Â Accelerated depreciation $ 5.7 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A + Details Name: us-gaap_PropertyPlantAndEquipmentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan. + ReferencesNo definition available. + Details Name: us-gaap_RestructuringReserveAcceleratedDepreciation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 61 R51.htm IDEA: XBRL DOCUMENT v3.24.3 GOODWILL AND INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Goodwill (Details) $ in Millions 9 Months Ended Sep. 30, 2024 USD ($) Goodwill [Roll Forward] Â Beginning balance $ 287.4 Goodwill impairment (0.8) Translation adjustments (0.3) Ending balance $ 286.3 X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1 + Details Name: us-gaap_GoodwillForeignCurrencyTranslationGainLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2 + Details Name: us-gaap_GoodwillImpairmentLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_GoodwillRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 62 R52.htm IDEA: XBRL DOCUMENT v3.24.3 GOODWILL AND INTANGIBLE ASSETS - Narrative (Details) - USD ($) $ in Millions 9 Months Ended Sep. 30, 2024 Dec. 31, 2023 Oct. 01, 2020 Schedule Of Intangible Assets [Line Items] Â Â Â Goodwill impairment charge $ 0.8 Â Â Goodwill 286.3 $ 287.4 Â Pharmacogenomics Â Â Â Schedule Of Intangible Assets [Line Items] Â Â Â Goodwill $ 121.0 Â Â Percentage of goodwill 42.30% Â Â Percentage of fair value in excess of carrying value Â Â 12.00% Discontinued Operations, Disposed of by Sale | EndoPredict | Developed technologies Â Â Â Schedule Of Intangible Assets [Line Items] Â Â Â Intangible, net $ 13.1 Â Â X - DefinitionGoodwill, Percentage Of Record Goodwill + ReferencesNo definition available. + Details Name: mygn_GoodwillPercentageOfRecordGoodwill Namespace Prefix: mygn_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionSchedule Of Intangible Assets [Line Items] + ReferencesNo definition available. + Details Name: mygn_ScheduleOfIntangibleAssetsLineItems Namespace Prefix: mygn_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 10 -SubTopic 20 -Topic 205 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-10Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5BReference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 360 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482099/360-10-50-3Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-11 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(10)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_Goodwill Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 100 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2 + Details Name: us-gaap_GoodwillImpairmentLoss Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPercentage of fair value of reporting unit in excess of carrying amount. + ReferencesNo definition available. + Details Name: us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - Details Name: us-gaap_ReportingUnitAxis=mygn_PharmacogenomicsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_EndoPredictMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 63 R53.htm IDEA: XBRL DOCUMENT v3.24.3 GOODWILL AND INTANGIBLE ASSETS- Schedule of Intangible Assets (Details) - USD ($) $ in Millions Sep. 30, 2024 Dec. 31, 2023 Intangible Assets [Line Items] Â Â Gross Carrying Amount $ 631.4 $ 645.8 Accumulated Amortization (318.9) (296.3) Net 312.5 349.5 Developed technologies Â Â Intangible Assets [Line Items] Â Â Gross Carrying Amount 603.3 626.1 Accumulated Amortization (316.9) (295.3) Net 286.4 330.8 Internal-use software Â Â Intangible Assets [Line Items] Â Â Gross Carrying Amount 1.6 0.8 Accumulated Amortization (0.5) (0.1) Net 1.1 0.7 Internal-use software (in-process) Â Â Intangible Assets [Line Items] Â Â Gross Carrying Amount 18.8 11.2 Accumulated Amortization 0.0 0.0 Net 18.8 11.2 Customer relationships Â Â Intangible Assets [Line Items] Â Â Gross Carrying Amount 1.6 1.6 Accumulated Amortization (0.3) (0.2) Net 1.3 1.4 Trademarks Â Â Intangible Assets [Line Items] Â Â Gross Carrying Amount 6.1 6.1 Accumulated Amortization (1.2) (0.7) Net $ 4.9 $ 5.4 X - DefinitionIntangible assets. + ReferencesNo definition available. + Details Name: mygn_IntangibleAssetsLineItems Namespace Prefix: mygn_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAccumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section S45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-S45-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478859/928-340-50-1 + Details Name: us-gaap_FiniteLivedIntangibleAssetsGross Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -

Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5 + Details Name: us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_ComputerSoftwareIntangibleAssetMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=mygn_ComputerSoftwareInProcessIntangibleAssetMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_CustomerRelationshipsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TrademarksMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 64 R54.htm IDEA: XBRL DOCUMENT v3.24.3 GOODWILL AND INTANGIBLE ASSETS - Schedule of Recorded Amortization Expense for Intangible Assets (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Goodwill and Intangible Assets Disclosure [Abstract] Â Â Â Â Amortization of intangible assets $ 10.5 $ 10.7 $ 31.9 $ 32.0 X - DefinitionThe aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2 + Details Name: us-gaap_AmortizationOfIntangibleAssets Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 65 R55.htm IDEA: XBRL DOCUMENT v3.24.3 ACCRUED LIABILITIES (Details) - USD ($) $ in Millions Sep. 30, 2024 Dec. 31, 2023 Payables and Accruals [Abstract] Â Â Employee compensation and benefits $ 51.4 $ 49.7 Accrued taxes payable 4.2 4.6 Refunds payable and reserves 19.2 20.1 Short-term contingent consideration 0.0 3.1 Accrued royalties 6.6 5.3 Legal settlements 6.0 6.0 Lease termination accrual 4.3 4.4 Other accrued liabilities 19.5 20.7 Total accrued liabilities $ 111.2 $ 113.9 X - DefinitionLease Termination Accrual, Current + ReferencesNo definition available. + Details Name: mygn_LeaseTerminationAccrualCurrent Namespace Prefix: mygn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRefunds Payable And Reserve, Current + ReferencesNo definition available. + Details Name: mygn_RefundsPayableAndReserveCurrent Namespace Prefix: mygn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_AccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 8 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8 + Details Name: us-gaap_AccruedRoyaltiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionTotal of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_EmployeeRelatedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionCarrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LitigationReserveCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherAccruedLiabilitiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_PayablesAndAccrualsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionCarrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_TaxesPayableCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 66 R56.htm IDEA: XBRL DOCUMENT v3.24.3 LONG-TERM DEBT (Details) - Line of Credit - USD ($) 9 Months Ended Sep. 30, 2024 Dec. 31, 2023 Oct. 31, 2023 Jun. 30, 2023 ABL Facility Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Line of credit facility, commitment fee amount $ 48,800,000 Â Â Â Revolving Credit Facility Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Availability threshold amount 12,500,000 Â Â Â Revolving Credit Facility | ABL Facility Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Maximum aggregate principal commitment Â Â Â $ 90,000,000.0 Line of credit, increase in maximum principal upon request Â Â $ 25,000,000 Â Increase principal commitment Â Â $ 115,000,000 Â Long-term debt 40,000,000.0 Â Â Â Debt issuance costs $ 1,000,000.0 $ 1,500,000 Â Â Line of credit facility, borrowing base, percent of eligible accounts receivable plus certain cash held 85.00% Â Â Â Line of credit facility, borrowing base, eligible cash held $ 20,000,000 Â Â Â Line of credit facility, borrowing base, eligible cash collections, period 60 days Â Â Â Interest rate, weighted average percentage 8.40% Â Â Â Debt instrument, covenant, liquidity amount, minimum $ 60,000,000 Â Â Â Debt instrument, covenant, availability amount, minimum $ 25,000,000 Â Â Â Fixed charge ratio, minimum 1.0 Â Â Â Line of credit facility, commitment fee amount $ 10,600,000 Â Â Â Line of credit facility, commitment fee percentage 12.50% Â Â Â Borrowing base period 30 days Â Â Â Availability threshold amount $ 12,500,000 Â Â Â Debt instrument, maximum amount borrowing base period 45 days Â Â Â Revolving Credit Facility | ABL Facility | Minimum Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Undrawn fee (percent) 0.375% Â Â Â Availability threshold, percentage of maximum commitment amount 15.00% Â Â Â Revolving Credit Facility | ABL Facility | Maximum Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Undrawn fee (percent) 0.50% Â Â Â Availability threshold, percentage of maximum commitment amount 15.00% Â Â Â Revolving Credit Facility | ABL Facility | NYFRB | Variable Rate, Scenario One Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Basis spread on rate (percent) 0.50% Â Â Â Revolving Credit Facility | ABL Facility | Secured Overnight Financing Rate (SOFR) | Variable Rate, Scenario One Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Basis spread on rate (percent) 1.00% Â Â Â Revolving Credit Facility | ABL Facility | Secured Overnight Financing Rate (SOFR) | Variable Rate, Scenario Two Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Basis spread on rate (percent) 0.10% Â Â Â SOFR floor (percent) 0.00% Â Â Â Revolving Credit Facility | ABL Facility | Secured Overnight Financing Rate (SOFR) | Minimum | Variable Rate, Scenario One Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Basis spread on rate (percent) 1.00% Â Â Â Revolving Credit Facility | ABL Facility | Secured Overnight Financing Rate (SOFR) | Minimum | Variable Rate, Scenario Two Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Basis spread on rate (percent) 2.00% Â Â Â Revolving Credit Facility | ABL Facility | Secured Overnight Financing Rate (SOFR) | Maximum | Variable Rate, Scenario One Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Basis spread on rate (percent) 1.50% Â Â Â Revolving Credit Facility | ABL Facility | Secured Overnight Financing Rate (SOFR) | Maximum | Variable Rate, Scenario Two Â Â Â Â Debt Instrument [Line Items] Â Â Â Â Basis spread on rate (percent) 2.50% Â Â Â Revolving Credit Facility | ABL Facility | ABR Floor | Variable Rate, Scenario Two Â Â Â Â Debt Instrument [Line Items] Â Â Â Â SOFR floor (percent) 1.00% Â Â Â X - DefinitionDebt Instrument, Covenant, Availability Amount, Minimum + ReferencesNo definition available. + Details Name: mygn_DebtInstrumentCovenantAvailabilityAmountMinimum Namespace Prefix: mygn_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDebt Instrument, Covenant, Fixed Charge Ratio, Minimum + ReferencesNo definition available. + Details Name: mygn_DebtInstrumentCovenantFixedChargeRatioMinimum Namespace Prefix: mygn_ Data Type: xbrli:pureItemType Balance Type: na Period Type: instant X - DefinitionDebt Instrument, Covenant, Liquidity Amount, Minimum + ReferencesNo definition available. + Details Name: mygn_DebtInstrumentCovenantLiquidityAmountMinimum Namespace Prefix: mygn_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionDebt Instrument, Debt Default, Availability Threshold, Percentage Of Maximum Commitment Amount + ReferencesNo definition available. + Details Name: mygn_DebtInstrumentDebtDefaultAvailabilityThresholdPercentageOfMaximumCommitmentAmount Namespace Prefix: mygn_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionDebt Instrument, Floor Percentage + ReferencesNo definition available. + Details Name: mygn_DebtInstrumentFloorPercentage Namespace Prefix: mygn_ Data Type: dtr-types1:percentItemType Balance Type: na Period Type: duration X - DefinitionDebt Instrument, Maximum Amount Borrowing Base Period + ReferencesNo definition available. + Details Name: mygn_DebtInstrumentMaximumAmountBorrowingBasePeriod Namespace Prefix: mygn_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLine Of Credit Facility, Accordion Feature, Increase Limit + ReferencesNo definition available. + Details Name: mygn_LineOfCreditFacilityAccordionFeatureIncreaseLimit Namespace Prefix: mygn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine Of Credit Facility, Borrowing Base, Eligible Cash Collections, Period + ReferencesNo definition available. + Details Name: mygn_LineOfCreditFacilityBorrowingBaseEligibleCashCollectionsPeriod Namespace Prefix: mygn_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLine Of Credit Facility, Borrowing Base, Eligible Cash Held + ReferencesNo definition available. + Details Name: mygn_LineOfCreditFacilityBorrowingBaseEligibleCashHeld Namespace Prefix: mygn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine Of Credit Facility, Borrowing Base, Percent Of Eligible Accounts Receivable Plus Certain Cash Held + ReferencesNo definition available. + Details Name: mygn_LineOfCreditFacilityBorrowingBasePercentOfEligibleAccountsReceivablePlusCertainCashHeld Namespace Prefix: mygn_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionLine Of Credit Facility, Commitment Fee, Borrowing Base, Period + ReferencesNo definition available. + Details Name: mygn_LineOfCreditFacilityCommitmentFeeBorrowingBasePeriod Namespace Prefix: mygn_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLine Of Credit Facility, Debt Default, Availability Threshold + ReferencesNo definition available. + Details Name: mygn_LineOfCreditFacilityDebtDefaultAvailabilityThreshold Namespace Prefix: mygn_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPercentage points added to the reference rate to compute the variable rate on the debt instrument. + ReferencesNo definition available. + Details Name: us-gaap_DebtInstrumentBasisSpreadOnVariableRate1 Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(f)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.12-04(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 6: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 7: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69E -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69EReference 8: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69F -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69FReference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 11: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1BReference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section

50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1E -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1EReference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1F -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1FReference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1I -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1IReference 26: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1 + Details Name: us-gaap_DebtInstrumentLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionWeighted average interest rate of debt outstanding. + ReferencesNo definition available. + Details Name: us-gaap_DebtWeightedAverageInterestRate Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: instant X - DefinitionAmount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-1AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D + Details Name: us-gaap_DeferredFinanceCostsNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of the fee for available but unused credit capacity under the credit facility. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityCommitmentFeeAmount Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionThe fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used. + ReferencesNo definition available. + Details Name: us-gaap_LineOfCreditFacilityCommitmentFeePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionMaximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(19)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionThe fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility. + ReferencesNo definition available. + Details Name: us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - DefinitionAmount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -Topic 210 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 835 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69B -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69BReference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 55 -Paragraph 69C -Publisher FASB -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69CReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1D -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1DReference 7: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(16)(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4 + Details Name: us-gaap_LongTermDebt Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_DebtInstrumentAxis=mygn_ABLFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_CreditFacilityAxis=us-gaap_RevolvingCreditFacilityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VariableRateAxis=mygn_NewYorkFederalReserveBankRateMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: mygn_VariableRateScenarioAxis=mygn_VariableRateScenarioOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VariableRateAxis=us-gaap_SecuredOvernightFinancingRateSofrMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: mygn_VariableRateScenarioAxis=mygn_VariableRateScenarioTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VariableRateAxis=mygn_ABRFloorMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 67 R57.htm IDEA: XBRL DOCUMENT v3.24.3 OTHER LONG-TERM LIABILITIES - Schedule of Other Long-Term Liabilities (Details) - USD ($) $ in Millions Sep. 30, 2024 Dec. 31, 2023 Other Liabilities Disclosure [Abstract] Â Â Contingent consideration $ 0.0 $ 2.3 Escrow liability 7.5 7.5 Legal settlements 24.0 24.0 Other 2.8 7.5 Total other long-term liabilities $ 34.3 $ 41.3 X - DefinitionEscrow Liability, Noncurrent + ReferencesNo definition available. + Details Name: mygn_EscrowLiabilityNoncurrent Namespace Prefix: mygn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLegal Charges Pending Settlement, Noncurrent + ReferencesNo definition available. + Details Name: mygn_LegalChargesPendingSettlementNoncurrent Namespace Prefix: mygn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 805 -SubTopic 30 -Name Accounting Standards Codification -Section 35 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479613/805-30-35-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 805 -SubTopic 30 -Section 25 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479668/805-30-25-6 + Details Name: us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_OtherLiabilitiesDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of liabilities classified as other, due after one year or the normal operating cycle, if longer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_OtherLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionObligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(24)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(15)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_OtherSundryLiabilitiesNoncurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant XML 68 R58.htm IDEA: XBRL DOCUMENT v3.24.3 OTHER LONG-TERM LIABILITIES - Narrative (Details) $ in Thousands Oct. 23, 2023 USD ($) installment Sep. 30, 2024 USD ($) Dec. 31, 2023 USD ($) Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Â Legal settlements Â $ 24,000 $ 24,000 Raygen, Inc vs. Myriad Women's Health, Inc. Â Â Â Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Â Accrual, current Â 5,000 Â Raygen, Inc vs. Myriad Women's Health, Inc. | Settled Litigation, Contingent Payments Â Â Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Â Settlement agreement $ 21,250 Â Â Number of annual installments | installment 5 Â Â Raygen, Inc vs. Myriad Women's Health, Inc. | Settled Litigation, Contingent Payments | First Installment Â Â Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Â Settlement agreement $ 5,000 Â Â Raygen, Inc vs. Myriad Women's Health, Inc. | Settled Litigation, Contingent Payments | Second Installment Â Â Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Â Settlement agreement 5,000 Â Â Raygen, Inc vs. Myriad Women's Health, Inc. | Settled Litigation, Contingent Payments | Third Installment Â Â Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Â Settlement agreement 5,000 Â Â Raygen, Inc vs. Myriad Women's Health, Inc. | Settled Litigation, Contingent Payments | Fourth Installment Â Â Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Â Settlement agreement 5,000 Â Â Raygen, Inc vs. Myriad Women's Health, Inc. | Settled Litigation, Contingent Payments | Final Installment Â Â Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Â Settlement agreement 1,250 Â Â Raygen, Inc vs. Myriad Women's Health, Inc. | Settled Litigation, Non-Contingent Payments Â Â Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Â Settlement agreement $ 12,750 Â Â Number of annual installments | installment 3 Â Â Litigation settlement, outstanding Â $ 7,750 Â Raygen, Inc vs. Myriad Women's Health, Inc. | Settled Litigation, Non-Contingent Payments | First Installment Â Â Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Â Settlement agreement $ 5,000 Â Â Raygen, Inc vs. Myriad Women's Health, Inc. | Settled Litigation, Non-Contingent Payments | Second Installment Â Â Â Accumulated Other Comprehensive Income (Loss) [Line Items] Â Â Â Settlement agreement $ 2,750 Â Â X - DefinitionLegal Charges Pending Settlement, Noncurrent + ReferencesNo definition available. + Details Name: mygn_LegalChargesPendingSettlementNoncurrent Namespace Prefix: mygn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLitigation Settlement, Number Of Installments + ReferencesNo definition available. + Details Name: mygn_LitigationSettlementNumberOfInstallments Namespace Prefix: mygn_ Data Type: xbrli:integerItemType Balance Type: na Period Type: instant X - DefinitionLitigation Settlement, Remaining Amount Awarded To Other Party + ReferencesNo definition available. + Details Name: mygn_LitigationSettlementRemainingAmountAwardedToOtherParty Namespace Prefix: mygn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-4Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482765/220-10-50-5Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-17Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20 + Details Name: us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount awarded to other party in judgment or settlement of litigation. + ReferencesNo definition available. + Details Name: us-gaap_LitigationSettlementAmountAwardedToOtherParty Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap_LossContingencyAccrualCarryingValueCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: srt_LitigationCaseAxis=mygn_RaygenIncVersusMyriadWomensHealthIncMember Namespace

Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LitigationStatusAxis=mygn_SettledLitigationContingentPaymentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: mygn_LitigationInstallmentsAxis=mygn_FirstInstallmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: mygn_LitigationInstallmentsAxis=mygn_SecondInstallmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: mygn_LitigationInstallmentsAxis=mygn_ThirdInstallmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: mygn_LitigationInstallmentsAxis=mygn_FourthInstallmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: mygn_LitigationInstallmentsAxis=mygn_FifthInstallmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_LitigationStatusAxis=mygn_SettledLitigationNonContingentPaymentsMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 69 R59.htm IDEA: XBRL DOCUMENT v3.24.3 PREFERRED AND COMMON STOCKHOLDERS' EQUITY - Narrative (Details) - $ / shares Sep. 30, 2024 Dec. 31, 2023 Sep. 30, 2023 Dec. 31, 2022 Equity [Abstract] Â Â Â Â Preferred stock authorized (shares) 5,000,000.0 Â Â Â Preferred stock, par value (dollars per share) $ 0.01 Â Â Â Preferred stock outstanding (shares) 0 Â Â Â Common stock authorized (shares) 150,000,000.0 Â Â Â Common stock, par value (dollars per share) $ 0.01 Â Â Â Common stock issued (shares) 91,000,000.0 89,900,000 82,100,000 81,200,000 Common stock outstanding (shares) 91,000,000.0 89,900,000 82,100,000 81,200,000 X - DefinitionFace amount or stated value per share of common stock. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of common shares permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_CommonStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionFace amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 505 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13 + Details Name: us-gaap_PreferredStockParOrStatedValuePerShare Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionThe maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1 + Details Name: us-gaap_PreferredStockSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionAggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(28)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_PreferredStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant XML 70 R60.htm IDEA: XBRL DOCUMENT v3.24.3 PREFERRED AND COMMON STOCKHOLDERS' EQUITY - Schedule of Common Stock Issued and Outstanding (Details) - shares shares in Millions 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Common shares issued and outstanding Â Â Beginning common stock issued (shares) 89.9 81.2 Beginning common stock outstanding (shares) 89.9 81.2 Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plan (shares) 1.1 0.9 Ending common stock issued (shares) 91.0 82.1 Ending common stock outstanding (shares) 91.0 82.1 X - DefinitionStock Issued During Period, Shares, Share-Based Payment Arrangement And Employee Stock Purchase Plans + ReferencesNo definition available. + Details Name: mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans Namespace Prefix: mygn_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionTotal number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_CommonStockSharesIssued Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionNumber of shares of common stock outstanding. Common stock represent the ownership interest in a corporation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 2 -SubTopic 10 -Topic 505 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(16)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3 + Details Name: us-gaap_CommonStockSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_IncreaseDecreaseInStockholdersEquityRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 71 R61.htm IDEA: XBRL DOCUMENT v3.24.3 PREFERRED AND COMMON STOCKHOLDERS' EQUITY - Schedule of Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations (Details) - shares shares in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Equity [Abstract] Â Â Â Â Weighted-average shares outstanding used to compute basic EPS 90.9 81.9 90.5 81.6 Effect of dilutive shares 0.0 0.0 0.0 0.0 Weighted-average shares outstanding and dilutive securities used to compute diluted EPS 90.9 81.9 90.5 81.6 X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 16 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16 + Details Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10 + Details Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration XML 72 R62.htm IDEA: XBRL DOCUMENT v3.24.3 PREFERRED AND COMMON STOCKHOLDERS' EQUITY - Schedule of Potential Dilutive Common Shares (Details) - shares shares in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Equity [Abstract] Â Â Â Â Anti-dilutive options and RSUs excluded from EPS computation (shares) 5.9 5.3 5.9 5.3 X - DefinitionSecurities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1 + Details Name: us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_EquityAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 73 R63.htm IDEA: XBRL DOCUMENT v3.24.3 STOCK-BASED COMPENSATION - Narrative (Details) 9 Months Ended Sep. 23, 2021 shares Sep. 30, 2024 USD ($) day shares Jun. 01, 2023 shares Share-Based Compensation [Line Items] Â Â Â Unrecognized stock-based compensation expense related to stock options | $ Â $ 0 Â Options granted (in shares) Â 0 Â 2017 Plan Â Â Â Share-Based Compensation [Line Items] Â Â Â Shares available for grant (shares) Â 2,300,000 4,800,000 2012 Purchase Plan Â Â Â Share-Based Compensation [Line Items] Â Â Â Number of additional shares authorized (shares) 4,000,000 Â Â Maximum number of shares per participant per offering period (shares) 5,000 Â Â Shares issued under the plan (shares) Â 1,100,000 Â Options and RSUs | Non-Employee Director Â Â Â Share-Based Compensation [Line Items] Â Â Â Service period for award vesting (in years) Â 1 year Â RSUs Â Â Â Share-Based Compensation [Line Items] Â Â Â Vesting rights, average trading days | day Â 20 Â Unrecognized stock-based compensation expense related to RSUs | $ Â $ 81,700,000 Â Weighted-average period for recognition (in years) Â 2 years 2 months 12 days Â RSUs | Minimum Â Â Â Share-Based Compensation [Line Items] Â Â Â Service period for award vesting (in years) Â 3 years Â RSUs | Maximum Â Â Â Share-Based Compensation [Line Items] Â Â Â Service period for award vesting (in years) Â 4 years Â RSUs | Achievement Levels Based on EPS Targets Â Â Â Share-Based Compensation [Line Items] Â Â Â Vesting weight (percent) Â 34.00% Â RSUs | Relative Total Stockholders Return Â Â Â Share-Based Compensation [Line Items] Â Â Â Vesting weight (percent) Â 33.00% Â RSUs | Performance Based on Nasdaq Healthcare Provider Index Â Â Â Share-Based Compensation [Line Items] Â Â Â Vesting weight (percent) Â 33.00% Â X - DefinitionShare-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Average Trading Days + ReferencesNo definition available. + Details Name: mygn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsAverageTradingDays Namespace Prefix: mygn_ Data Type: xbrli:integerItemType Balance Type: na Period Type: duration X - DefinitionWeighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Namespace Prefix: us-gaap_ Data Type:

xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cost to be recognized for option under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionPeriod over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition. + ReferencesReference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe highest quantity of shares an employee can purchase under the plan per period. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of additional shares authorized for issuance under share-based payment arrangement. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionGross number of share options (or share units) granted during the period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares issued under share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionPercentage of vesting of award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_PlanNameAxis=mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_PlanNameAxis=mygn_EmployeeStockPurchasePlanTwentyTwelveMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=mygn_OptionsAndRestrictedStockUnitsMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_TitleOfIndividualAxis=mygn_NonEmployeeDirectorMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 74 R64.htm IDEA: XBRL DOCUMENT v3.24.3 STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details) - $ / shares shares in Millions Sep. 30, 2024 Dec. 31, 2023 Share-Based Payment Arrangement [Abstract] Â Â Options outstanding (in shares) 0.7 0.7 Options exercisable at end of period (shares) 0.5 Â Options outstanding (dollars per share) $ 13.38 $ 13.38 Options exercisable at end of period (dollars per share) $ 13.38 Â X - ReferencesNo definition available. + Details Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionThe weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - DefinitionNumber of options outstanding, including both vested and non-vested options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionWeighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant XML 75 R65.htm IDEA: XBRL DOCUMENT v3.24.3 STOCK-BASED COMPENSATION - Schedule of Restricted Stock Unit Activity (Details) - RSUs shares in Millions 9 Months Ended Sep. 30, 2024 $ / shares shares Number of Shares Â RSUs unvested and outstanding, beginning balance (shares) | shares 4.4 RSUs granted (shares) | shares 2.5 RSUs vested (shares) | shares (1.5) RSUs canceled (shares) | shares (0.2) RSUs unvested and outstanding, ending balance (shares) | shares 5.2 Weighted Average Grant Date Fair Value Â RSUs unvested and outstanding, beginning balance (dollars per share) | $ / shares $ 24.37 RSUs granted (dollars per share) | $ / shares 22.46 RSUs vested (dollars per share) | $ / shares 23.77 RSUs canceled (dollars per share) | $ / shares 23.62 RSUs unvested and outstanding, ending balance (dollars per share) | $ / shares $ 23.63 X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionWeighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan). + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - DefinitionThe number of non-vested equity-based payment instruments, excluding stock (or unit)

options, that validly exist and are outstanding as of the balance sheet date. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: instant X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionPer share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionThe number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionThe weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue Namespace Prefix: us-gaap_ Data Type: dtr-types:perShareItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 76 R66.htm IDEA: XBRL DOCUMENT v3.24.3 STOCK-BASED COMPENSATION - Schedule of Share-Based Compensation, Employee Stock Purchase Plan, Activity (Details) - 2012 Purchase Plan - USD ($) shares in Millions, $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share-Based Compensation [Line Items] Â Â Â Â Â Shares purchased under the plan 0.0 0.0 0.2 0.2 Plan compensation expense $ 0.5 $ 0.5 $ 1.6 $ 1.7 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 1D -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1DReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)(iv)(04) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 15: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 16: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 17: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(01) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 18: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(02) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 19: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(2)(iii)(03) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 20: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 21: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 22: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 23: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 24: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 25: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(ii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 26: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iii) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 27: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(iv) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 28: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (f)(2)(v) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionNumber of shares purchased for issuance under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (l) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward Namespace Prefix: us-gaap_ Data Type: xbrli:sharesItemType Balance Type: na Period Type: duration X - DefinitionAmount of cost expensed and capitalized for award under share-based payment arrangement. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (h)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1 Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_PlanNameAxis=mygn_EmployeeStockPurchasePlanTwentyTwelveMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 77 R67.htm IDEA: XBRL DOCUMENT v3.24.3 STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Share-Based Compensation [Line Items] Â Â Â Â Total stock-based compensation expense $ 12.4 $ 11.6 $ 38.9 $ 30.3 Cost of testing revenue Â Â Â Â Share-Based Compensation Expense [Line Items] Â Â Â Â Total stock-based compensation expense 0.3 0.4 1.0 1.1 Research and development expense Â Â Â Â Share-Based Compensation Expense [Line Items] Â Â Â Â Total stock-based compensation expense 1.6 1.2 4.4 2.9 Selling, general, and administrative expense Â Â Â Â Share-Based Compensation Expense [Line Items] Â Â Â Â Total stock-based compensation expense $ 10.5 $ 10.0 $ 33.5 $ 26.3 X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of noncash expense for share-based payment arrangement. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (a) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28 + Details Name: us-gaap_ShareBasedCompensation Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 78 R68.htm IDEA: XBRL DOCUMENT v3.24.3 INCOME TAXES (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Sep. 30, 2024 Sep. 30, 2023 Income Tax Disclosure [Abstract] Â Â Â Â Income tax expense $ 0.9 $ 0.1 $ 0.4 $ 2.2 Approximate tax rate (4.20%) (0.20%) (0.50%) (1.00%) X - DefinitionPercentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231 + Details Name: us-gaap_EffectiveIncomeTaxRateContinuingOperations Namespace Prefix: us-gaap_ Data Type: dtr-types:percentItemType Balance Type: na Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_IncomeTaxDisclosureAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 231 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 6.I.7) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Subparagraph (h) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Subparagraph (a) -SubTopic 20 -Topic 740 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(h)) -SubTopic 10 -Topic 235 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1 + Details Name: us-gaap_IncomeTaxExpenseBenefit Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration XML 79 R69.htm IDEA: XBRL DOCUMENT v3.24.3 COMMITMENTS AND CONTINGENCIES (Details) - USD ($) May 03, 2024 Sep. 30, 2024 Dec. 31, 2023 Loss Contingencies [Line Items] Â Â Â Pending settlement accrued Â $ 6,000,000.0 $ 6,000,000.0 Pending Litigation Â Â Â Loss Contingencies [Line Items] Â Â Â Pending settlement accrued Â $ 950,000 Â Pending Litigation | Maximum Â Â Â Loss Contingencies [Line Items] Â Â Â Settlement agreement $ 950,000 Â Â X - DefinitionCarrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details Name: us-gaap_LitigationReserveCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount awarded to other party in judgment or settlement of litigation. + ReferencesNo definition available. + Details Name: us-gaap_LitigationSettlementAmountAwardedToOtherParty Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type:

credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 720 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483359/720-20-50-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 27 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482395/460-10-55-27Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 9 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-9Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 4 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-4Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 460 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482425/460-10-50-3Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1 + Details Name: us-gaap_LossContingenciesLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 80 R70.htm IDEA: XBRL DOCUMENT v3.24.3 SUPPLEMENTAL CASH FLOW INFORMATION - Schedule of Supplemental Cash Flow Information (Details) - USD ($) $ in Millions 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Supplemental Cash Flow Elements [Abstract] Â Â Cash paid for income taxes $ 1.8 $ 1.3 Cash paid for interest 1.3 0.8 Change in operating lease right-of-use assets and lease liabilities Â Â Operating lease right-of-use assets (0.3) 8.7 Operating lease liabilities (3.1) 9.2 Non-cash adjustment to right-of-use assets and lease liabilities from lease modifications 3.1 0.0 Purchases of property, plant and equipment and capitalization of internal-use software in accounts payable and accrued liabilities $ 2.5 $ 9.1 X - DefinitionChange In Operating Lease Liability + ReferencesNo definition available. + Details Name: mygn_ChangeInOperatingLeaseLiability Namespace Prefix: mygn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionChange In Operating Lease, Right-Of-Use Asset + ReferencesNo definition available. + Details Name: mygn_ChangeInOperatingLeaseRightOfUseAsset Namespace Prefix: mygn_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionNon-Cash Adjustment To Right-Of-Use Assets And Lease Liabilities From Lease Modifications + ReferencesNo definition available. + Details Name: mygn_NonCashAdjustmentToRightOfUseAssetsAndLeaseLiabilitiesFromLeaseModifications Namespace Prefix: mygn_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionPurchases Of Property, Plant And Equipment And Capitalization Of Internal-use Software In Accounts Payable And Accrued Liabilities + ReferencesNo definition available. + Details Name: mygn_PurchasesOfPropertyPlantAndEquipmentAndCapitalizationOfInternalUseSoftwareInAccountsPayableAndAccruedLiabilities Namespace Prefix: mygn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_CashFlowOperatingActivitiesLesseeAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 23 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 740 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_IncomeTaxesPaid Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (e) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2 + Details Name: us-gaap_InterestPaidNet Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowElementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 81 R71.htm IDEA: XBRL DOCUMENT v3.24.3 SUPPLEMENTAL CASH FLOW INFORMATION - Schedule of Cash and Cash Equivalents and Restricted Cash (Details) - USD ($) $ in Millions Sep. 30, 2024 Dec. 31, 2023 Sep. 30, 2023 Dec. 31, 2022 Supplemental Cash Flow Elements [Abstract] Â Â Â Â Cash and cash equivalents $ 99.9 $ 132.1 $ 76.0 Â Restricted cash 9.9 Â 9.0 Â Total cash, cash equivalents, and restricted cash $ 109.8 $ 140.9 $ 85.0 $ 66.4 X - DefinitionAmount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashAndCashEquivalentsAtCarryingValue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 24 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4 + Details Name: us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(2)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 230 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(1)(a)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1 + Details Name: us-gaap_RestrictedCash Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - ReferencesNo definition available. + Details Name: us-gaap_SupplementalCashFlowElementsAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 82 R72.htm IDEA: XBRL DOCUMENT v3.24.3 LEASES (Details) ftÂ² in Thousands, $ in Millions 9 Months Ended Sep. 30, 2024 USD ($) ftÂ² Sep. 30, 2023 USD ($) Dec. 31, 2023 USD ($) Lessee, Lease, Description [Line Items] Â Â Â Operating lease right-of-use assets $ 57.4 Â $ 61.6 Short term lease liability 3.1 Â Â Gain on termination of lease 3.1 $ 0.0 Â Selling, general, and administrative expense Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Gain on termination of lease $ 1.2 Â Â West Salt Lake City Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Operating lease liability Â 5.9 Â Operating lease right-of-use assets Â $ 5.9 Â Area of real estate property | ftÂ² 63 Â Â Lease term (in years) 12 years Â Â Lease payments due $ 18.2 Â Â Minimum Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Remaining lease terms (in years) 1 year Â Â Maximum Â Â Â Lessee, Lease, Description [Line Items] Â Â Â Remaining lease terms (in years) 14 years Â Â X - DefinitionOperating Lease, Liability, Current, Terminated + ReferencesNo definition available. + Details Name: mygn_OperatingLeaseLiabilityCurrentTerminated Namespace Prefix: mygn_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionArea of a real estate property. + ReferencesNo definition available. + Details Name: us-gaap_AreaOfRealEstateProperty Namespace Prefix: us-gaap_ Data Type: dtr-types:areaItemType Balance Type: na Period Type: instant X - DefinitionAmount of gain (loss) on termination of lease before expiration of lease term. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 40 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479092/842-20-40-1 + Details Name: us-gaap_GainLossOnTerminationOfLease Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeLeaseDescriptionLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount of lessee's undiscounted obligation for lease payment for operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6 + Details Name: us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionRemaining lease term of operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7A -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7AReference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseRemainingLeaseTerm Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionTerm of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. + ReferencesReference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (a)(3) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3 + Details Name: us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix: us-gaap_ Data Type: xbrli:durationItemType Balance Type: na Period Type: instant X - DefinitionPresent value of lessee's discounted obligation for lease payments from operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseLiability Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - DefinitionAmount of lessee's right to use underlying asset under operating lease. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 842 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 1 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1 + Details Name: us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - Details Name: us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_StatementGeographicalAxis=mygn_WestSaltLakeCityMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MinimumMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 83 R73.htm IDEA: XBRL DOCUMENT v3.24.3 ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Details) - USD ($) $ in Millions 3 Months Ended 9 Months Ended Sep. 30, 2024 Jun. 30, 2024 Mar. 31, 2024 Sep. 30, 2023 Jun. 30, 2023 Mar. 31, 2023 Sep. 30, 2024 Sep. 30, 2023 AOCI Attributable to Parent, Net of Tax [Roll Forward] Â Â Â Â Â Â Â Â Beginning balance $ 740.5 $ 760.0 $ 783.2 $ 735.2 $ 835.2 $ 885.8 $ 783.2 $ 885.8 Period translation adjustments 3.9 0.2 (0.5) 0.1 2.0 1.5 Â Â Reclassification of cumulative translation adjustment to income upon sale or liquidation of certain foreign entities (4.4) Â Â 0.1 Â Â (5.1) (0.4) Ending balance 731.7 $ 740.5 760.0 $ 683.4 $ 735.2 $ 835.2 731.7 $ 683.4 Accumulated Foreign Currency Adjustment Attributable to Parent Â Â Â Â Â Â Â Â AOCI Attributable to Parent, Net of Tax [Roll Forward] Â Â Â Â Â Â Â Â Beginning balance Â Â $ (3.7) Â Â Â (3.7) Â Period translation adjustments Â Â Â Â Â Â (1.5) Â Reclassification of cumulative translation adjustment to income upon sale or liquidation of certain foreign entities Â Â Â Â Â Â 5.1 Â Ending balance $ (0.1) Â Â Â Â Â $ (0.1) Â X - DefinitionA roll forward is a reconciliation of a concept from the beginning of a period to the end of a period. + ReferencesNo definition available. + Details Name: us-gaap_AOCIAttributableToParentNetOfTaxRollForward Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - DefinitionAmount after tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 15 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-15Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 11 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 830 -SubTopic 30 -Name Accounting Standards Codification -Section 40 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481724/830-30-40-1Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 17A -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-17AReference 5:

http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 16 -SubTopic 10 -Topic 220 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-16 + Details Name: us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: duration X - DefinitionAmount after tax of other comprehensive income (loss) attributable to parent entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 19 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 20 -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1A -Subparagraph (c)(3) -SubTopic 10 -Topic 810 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 250 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 6 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 1A -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A + Details Name: us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(29)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(31)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10Reference 5: http://www.xbrl.org/2003/role/exampleRef -Topic 946 -SubTopic 830 -Name Accounting Standards Codification -Section 55 -Paragraph 12 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-04(19)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.6-05(4)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(4)(b)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(6)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Topic 946 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 3 -Subparagraph (SX 210.6-09(7)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SAB Topic 4.E) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2 + Details Name: us-gaap_StockholdersEquity Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant X - Details Name: us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 84 R74.htm IDEA: XBRL DOCUMENT v3.24.3 ACQUISITION (Details) - USD ($) $ in Millions 9 Months Ended Sep. 30, 2024 Sep. 30, 2023 Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract] Â Â Gain on acquisition $ 2.2 $ 0.0 X - DefinitionAsset Acquisition, Gain (Loss) + ReferencesNo definition available. + Details Name: mygn_AssetAcquisitionGainLoss Namespace Prefix: mygn_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - ReferencesNo definition available. + Details Name: us-gaap_BusinessCombinationAndAssetAcquisitionAbstract Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration XML 85 R75.htm IDEA: XBRL DOCUMENT v3.24.3 DIVESTITURE (Details) - Discontinued Operations, Disposed of by Sale - EndoPredict - USD ($) $ in Millions 9 Months Ended Sep. 30, 2024 Aug. 01, 2024 Divestitures [Line Items] Â Â Sale of business for net cash consideration Â $ 10.0 Total net loss, including transaction expenses $ 12.4 Â Foreign currency translation $ 4.4 Â X - DefinitionAmount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation. + ReferencesNo definition available. + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant X - DefinitionAmount of foreign currency translation gain (loss) in the disposal group, including discontinued operation, recognized in the statement of income as a result of the sale or complete or substantially complete liquidation of an investment in a foreign entity. + ReferencesReference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 830 -SubTopic 30 -Section 45 -Paragraph 20 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20 + Details Name: us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionAmount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal. + ReferencesReference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 944 -SubTopic 220 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-04(12)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 740 -SubTopic 270 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147477349/740-270-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 7 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3A -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3AReference 5: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5C -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-5CReference 6: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3B -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3BReference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-4Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147483499/205-20-50-1Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 205 -SubTopic 20 -Name Accounting Standards Codification -Section 45 -Paragraph 3 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483475/205-20-45-3 + Details Name: us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: duration X - DefinitionLine items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + ReferencesNo definition available. + Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration X - Details Name: us-gaap_DisposalGroupClassificationAxis=us-gaap_DiscontinuedOperationsDisposedOfBySaleMember Namespace Prefix: Data Type: na Balance Type: Period Type: X - Details Name: us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=mygn_EndoPredictMember Namespace Prefix: Data Type: na Balance Type: Period Type: EXCEL 86 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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Ÿ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`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{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|V6'I1K;&O*@QTU_!:6Z=;_:_U&MZBJA12:GFA8"3<'*XH M.>&RWG/PYW#JO*6$^>LEYVOLJLO87$3GKA(9JB.J$H=VB='@W9OF:?)^#_/V MEGE[`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{^^P.]W9 &-_\<,3##

1REQYH8F4RE"33VSWGMY(#@_T)8[TP5O8$+7%BE< M@^'9LF433'IB:AHG#9FR29^G3E3./+UKZ^N(G>;SA}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|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}[<{9C2GUQ1UF^2"74(?M+,,@=&RQ0D*X8 HC:\'MS* -Z1R?[X_H'SQWXK)B!B=* ,ES6PR"NP!R7+..V$>U^QT/?&X=7]:$\5_8 M'6SC ++.6%4>G"F#DLMF9=|,=?@_#NG!(?5Y X%\EN^-99<.^5CO0SIK0W,93 M]=Z4')?NIRRL)BTG/SNYDK:PL!4YIB?^D>49IMK>LQUC%X$?& 5_M0B> ^@31.NQ?P.BWWCL?K_ 1O)K=H+'68 3?P'E<6F,QA^K7F=@\+S&K +4<# M?XU6QFKJG[_/%.&)T3T?P]VIGJE8AH. +HU!O<$/)5\C9^=X%!MV70O80^ M7 -E6N!H ,P@?$ 3TS4'"178;1E7+A2]X9.,Q:,C)Y16NUASOXALX L#\M] MA9[_1#!C'.!1=8[TQ;3.DUX6A%'j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{(T5A+_ CH5 M [AWR:IX0968E@=)!K> O%MQR63"F8"),6@.,)G"/6=++KCE:$Y%U29MK$O!?(5QTC?.]"TFF"]10[?C+[][U=<4A4(005M6G"/&Q30J<>X M'KOPI"QA^4'=$1-W5#WZE5Z[52E3 U>L!1\A#F/Z?OHPB#OQYZ.9 YDI72C- M+,,)2.1T7G526H. E!F'W.#XO)4]X02 JC?U9. ^P?S6=4*9!6E!82BHBG2&[< M8[47VH]7_;#?JK]5=`O0@W! M<'KD(_3#-0_2B4B91B@TISTN=N0NIX?U"4: MWY*,$0P@_E/-[A4H3)8ND80=+ BW27=GP IW[#9W[_YO.L\HOW>HQL0\2,SM, MS"E"7_1VNC1/L5PC74`"A:0:H.P#C0:\G_\5?D?2XL$96ZIO4E]*VH81G/ MMP>VC?U(@JF\<.OY%'77$),]>I-PCTGE)9M<_ MRW4 %]SR/3AZRVT=??V@'U3;*6Y%!ZTM1[WV#=R0RU+;JLLUN\T_PJ1JC>_B MU0_&G.DUIT0(7)%J._R%B*.KIETMK"\HNUPJ2VW73S/ZST'M!.A\I.CHZX5S MT/PYC?\%4$L#!!0 ($5":%GLAQ?Q(@, /L& 9 >&PO=V]R:W-H M965>X4Q M]540Z*S BFE?UBCHSU]JBADZJDV@:X4L=T85#^(PO PJ5@IO,G*RA9J_9& X M*7"A0#=5Q=3S-7*Y'7N1]R*X+S>%&]0,JK9!A_0?*L7BDY!AY*7%0I=2@$* MUV-O&EU=IU;?*7PO<.OWJF C64GYRQX^Y6,OM(208V8I_J/E$6^0Q,L,F(R6WHI*PV MH=F "]59$[E2V*(\&$5_2{(SD\7]E\7L?OGS A:?I _E3.>W,/OZ[=/B;C9?M7L!\MH2S)5MQU.>CP)!#:Q9D._#K%CQ^!WP(=U*80L ,Y)@?V@=$M&,;O[*] MCD\"/F#M0Q)>0!S&Z0F\!(L^<7C)>]$KNMW*/%/TG D#3.0P^]V4 5T[ ]_ M5]HHNC?-'@N]14Z/(]M>NM(URW#L4,-H5(H3?I\((H,/Y[@G7:\TU/HDP?] MS,SA"'(-(.V.@"]Y(QOXOD_G'VRP*&[IS5G3/&L$L8,4(24,5BM479F0UD1GT>TOC5\@/[4/5BM4479F0UD1GZR5\6HE_HJB-*^?[F7JR/T+V"CI-80)[`J^_`Y(O$K L:ZJ&,X,Y M-3PE)"N9@4=3WDW.[#OWA^2_!"YJQ'R"*>G[JUJ$?@DWJC:Q[]IYIQF52 MY6^=Y(TJQ08,*5(l:G1C#,A/*7-]D,%EH1*A:EL.,)R! 4 X !D !X;"]W;W)K M&UL[5=M;^(X$/XKHVRU*M(52 *!=@$).*]7JN6RB6RR"IE:8IL80A?%/:=.17!K%_?!.^]\6.V%9,H53D7Y-(AT/G,X#$:[8)M6/8OL;MEGBZQEXH4F5_85O(!AT'PHW2(BN5*8(LX<4 >RYYV%/HMX\H>*6"9^,N'-DH MKYEFHX$46Y\&FJR9@85]M2FXA)%NDS+6DU83T].CVRY?KKW?W]S"\>7 MW=Y-[F]@/)_?+.9POF#+%%5CT+DS*BTPM+PI##L'3%\"0\%U[&^QYA]%:_ M14%6D7?[2"=>K<$YYDWPV[^ U_8Z-?;\"KEO[?G'D L1;9,T!<8CN...\75" M6&&L%&H%UXD*4ZVN!A5)I2?7SUR$:"B^=PUY,3UVIG(4X=*AI%,HG=$8?`M/[A!^U,-ADZ%H5-G?32G'HTV%+18P30F!*@@X3!E4KXD?`WC3&RX-JL[M(<0 MU/HXC& (1X2O#K69[IRRRNEZ1S%M'E:&DVW(BKI 4Q=6=68+5%9[84M$N=, MD5)*6X:Z@G/RD)$9Z+5@(70+(4)KA/.C;LE2QD)$<[Z_>.G0HI)%G.$DD, MB(;S=K-/FIQE,)B XC^1N8RB]JL^@U3IS^:'YH^U&2I6V6I>W*6*"2-2)]]-M5[TOND/)J35]/#D%>090L=TFWRE3)@5%=A1MJ#E%0AE@)H-5(,P&\B/GMU(H M!>,PW&0;(I"T9G1>C/6A]%WC$VWU. -MDN&.H0$E9^C%1B$HL=);1@7@-@.3F&Z+1NX1&0KR(IR,HHCHC*,S$)R=.XVO09TFI=EG,VC!@+? MI. MC+Z!X;M>LWLJ7]<8EG2YEBZ_AB[/Q$^O,NN"28,?)_*^.@59H5 N0T: M]4ZBBX"^TF4F]71YA]f..'[K(6P.Z9N$(702DTZ7@+\"@<!.*Y),[J.BNH.BLX MN;.F@E^P_]I=M>9_=M?/[OH_=E>OZ[{>R=WUB*&0YL#>`6#V%+UYIL>!0GN^MG]1OM0Z/]M4T%G.7XB[,@]V'P66440,:5K2]"%IYV@O_)"C3$2D=G<0DGM/`MX_YM8Q%+ .&2,GMW;7E;D+18S;,V]CM[P1 0>RIU+'5C\J4S>7.H+^O.:[8/9 M.^W=\]Fr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{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e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|\T:O7L$A0F5[R-?Z20FU,\ZPIDC#*\0?D)/C*E#@7+(?\? M[VMOQ<+PI' 6WB1,H1F@47""PB -(FPE,@EU@W245SZRO*,KOM18D,^8.,< M=VC.F>24Y-CU\LO+PU1H#4F9#VA)&&89P12FV@&40-IGNIA&ZMGY=NR@D8M7Q9@QFTB&YQ|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

\MKH4PKU553OXC MW1:VL)RW+R0U=U/&(AX->E7Z%)47L=3I"!2=4(>6,+,<.@W"'VAC>P[&-M-SL+O)-[L]WO6-LM%'+?93U:S*@LB.6FIL\RXX4WA7L-!E0>.]2:TZ&?=-/ M0AR%(-[Q9? #CQ2^LY6WG&'MUU,(>'?6K^%$)$DO-39XE2-IO&78]?E3}]}2Z-M%+]%-0JC7/,[H/L*&!;UJCG6,K3MJ89"'>]FL6H,(DEIK;J+(PR>#]PLXK8%C'-MU'W6EUF$],(MV#$:[[52@K8-)3HL-=>GQ3[6K[8L0^5%+/+#4W>8W.[,^V9E'! MKE)S-OC'/0SRVP,9K:JRCLO?6$Y;U_*]C%O58O_JZ#)46L=3(IC>&E\&//U[ZPEK>/^\YQCY>9&$OZE??-T(E2"PU-WF6 M(%/#^ZPA+=AO[Y09'D#@GFN~7702?T+BWJ;.\8N7M3X.5^_.2"8L<4 MD27*"!D##.MXN][M .,^,"l,OHBZM7]8Z>%2LPU)S?5H"C/K5~HU0T1%+S4V> M1+]ZOQR5&;'4 MW.199N2'JWYA"6_#N[W?/27/+;SQ+EU?YKL.AE6]C1UC%X},ZN/]ZOIR5%[$-M4G.39WF1'[UA26\#7?N^O+&'1Y=NKZLV](7UO*VKZ\M1X1%+-MS4V>A4=^>-<7EO VW+GKRRW%\2Y=7^.YZH5%O7T=8QN/6PSD_>KZVW5FG'FBU+N_XO5=;JU7Y\%$*,QN*$\SK2V7.J#HH,B*N,Q)?_@)02P,$% M-@-14)H6:7B7FOH-@-4P<-!D !X,"]W;W)K&ULE55K;]W?fb/TK5E9-K,22D/):!Y&-4JW26!$IW6P9[?30F-M-I,'*1_MY>.9X5!!PB8Q$H_NU-@"Q="H%-GN6,N#U3# M5/(:+#);)R!DX) (8UW7*SE/NO4.,3M7B1Y#K_)?ORK.>0:*N-3,M@5) R4?S3 MI]*'HP#??R? +PA7'=!E*N\HH8&0R7W1-G3B&8'>;IY-(ICPEY*:!3N,HPS MP?7X9DGNQ]}6,S*?C\]W MQ;H4AN&,.':H60R*YF:? 7H&AC.LS.1).9B"%^'>]BKE7"_B'AB=\(&$+6(A?>)^)[?H>LPBMR>G+6@'M1&7F1-MXUZ\@N$2(J(<588@.9$E6EK:]KN8%KT8EIT;%J=.05GIY[3?K"7.J,1C!S\ M/C6H'3C!QP_MGO>E(:..E5&G"3V8P(8)@4JQ[#D5$=0)+!"IZ.81M +N@V^L.#"8<.*9U%.B)ZP=]GH3S8ZV+ M1YUHBZM7]8Z>%2LPU)S?5H"C/K5~HU0T1%+S4V> M1+]ZOQR5&;'4 MW.199N2'JWYA"6_#N[W?/27/+;SQ+EU?YKL.AE6]C1UC%X},ZN/]ZOIR5%[$-M4G.39WF1'[UA26\#7?N^O+&'1Y=NKZLV](7UO*VKZ\M1X1%+-MS4V>A4=^>-<7EO VW+GKRRW%\2Y=7^.YZH5%O7T=8QN/6PSD_>KZVW5FG'FBU+N_XO5=;JU7Y\%$*,QN*$\SK2V7.J#HH,B*N,Q)?_@)02P,$% M-@-14)H6:7B7FOH-@-4P<-!D !X,"]W;W)K&ULE55K;]W?fb/TK5E9-K,22D/):!Y&-4JW26!$IW6P9[?30F-M-I,'*1_MY>.9X5!!PB8Q$H_NU-@"Q="H%-GN6,N#U3# M5/(:+#);)R!DX) (8UW7*SE/NO4.,3M7B1Y#K_)?ORK.>0:*N-3,M@5) R4?S3 MI]*'HP#??R? +PA7'=!E*N\HH8&0R7W1-G3B&8'>;IY-(ICPEY*:!3N,HPS MP?7X9DGNQ]}6,S*?C\]W MQ;H4AN&,.':H60R*YF:? 7H&AC.LS.1).9B"%^'>]BKE7"_B'AB=\(&$+6(A?>)^)[?H>LPBMR>G+6@'M1&7F1-MXUZ\@N$2(J(<588@.9$E6EK:]KN8%KT8EIT;%J=.05GIY[3?K"7.J,1C!S\ M/C6H'3C!QP_MGO>E(:..E5&G"3V8P(8)@4JQ[#D5$=0)+!"IZ.81M +N@V^L.#"8<.*9U%.B)ZP=]GH3S8ZV+ M1YUHBZM7]8Z>%2LPU)S?5H"C/K5~HU0T1%+S4V> M1+]ZOQR5&;'4 MW.199N2'JWYA"6_#N[W?/27/+;SQ+EU?YKL.AE6]C1UC%X},ZN/]ZOIR5%[$-M4G.39WF1'[UA26\#7?N^O+&'1Y=NKZLV](7UO*VKZ\M1X1%+-MS4V>A4=^>-<7EO VW+GKRRW%\2Y=7^.YZH5%O7T=8QN/6PSD_>KZVW5FG'FBU+N_XO5=;JU7Y\%$*,QN*$\SK2V7.J#HH,B*N,Q)?_@)02P,$% M-@-14)H6:7B7FOH-@-4P<-!D !X,"]W;W)K&ULK571;MHP%/T5*ZNF5EI)2*INA"I!;8BT;4* MNCU,>S#)!:PZ<68;-/}^MI-FH81H#WL!.[GCY)QC^SK<,_XL-@ 2O:0T$P-K M(V5^,=LBWD"*18?ED*DW*\93+-64KVV1<\") .*74=AVG;Z>89%84FF>// K9 M5E*2P2-'8INFF+_> F7[@=6UWA[,R'HC]0,["G.\ACG(I_R1]YE=L20DA4P0 MEB$.JX%UT[T>!KK>%'PGL!>U,=).EHPJZ\DD&5B.%@048]D9L/K,P1 HU41* MQN^2TZH^J9'U\1O[%^-=>5EB 4 &?Y!$,@;6E8426.$ME3.VOXJ94=ZPSAT_SQ8P* MXOV9:UCH7@K)$M+L%*0DJSXQRJE#C5-US\!<$N ^ZI KP1XQFBAS @:88FC MD+,]XKI:L>F!R<.@E1N2Z56<2Z[>$H63T;)ME20&R%'N0&-)]R;'VY)ZB*<%+0HDD(#Y""0F5%PHS- | MA, [/+M 9(AFZ)Y2JU1*A+958_4D[++H7=%L+<$\+FD'>0YWQ"KN/Z#?!A.WP$ ML8)W#=P[A-LJHBHGM\K)-7S>J9P*]S7/(R)BRL26 _IYLQ22JQWY]\EG0>PW M$^M3>BUR',/ 4L=0 -^!%7WAT.T[GYM<.&=pRRl*@.OC3T.LDR2, V91+%. M4Y(Q_HL-IDNF*X,D>2MRN&)[5W=25'1KU6X':^],1 #H5P1)5H%C$6L$+5?I MM4E8P1+4/AMT>N^DM= <<2.M5TGJMTJ.PQA0)D)*'.H*R\404%+UZ)/X[..TE M!\KZE,) ^JS*SLYO4](J2<+#M7[^0,R?-KNZD0>USD=X^VC%WKI?H>N\=\33*!**P4S.D$*GM>W W%1++ < MM-&PO=V]R.W-H965TW.2*T3A:!:2!=+9()$.ELW.QV@LW,1!-$K..*5-I?.PZ(8U0Q 4,T M!_-FX34C.8_NU?9(W3CI+QK^G,TH%^A%'9L++ M1W%IP-)/#)A M/"9"[O)!9US2H(^([JV+8OZC$)$ZO7R7] [X+T.6X@H3.@#1^DBC@E_[=.(M+,N68[W)\!A.9R+[H=[KS,F4CJGX.G_@4H(PIDD:L@1Q.NE.GYTKS[W(M O(S_@SI,EW,1EE3GAG[GNT,@ZY£9S6B$?5%AB#RWPL=T"C*2+(>_Q10]RPS M"US??J__R1LO&_,4CI@T;#U&Y^B.<$ZRCD$?/2I(&*6?T <4)NAIQA8I28*T4Q>R M%AFK[A.9,1[U)<;1:Z9CZE+>4F-<:HQSKKN#^]GW%_$B(H(&Z%[,*$<# M%LM9.LNFC]1VF/@LEA*/6'%0 -6LDP]%0T#C}>YNZJ[(:\\Q>TL15.B<'>[5]R\A93R%VKU?0W%N;!_W Z8K),P#@FD.NZ7&KHG>&]$IB5!*A8AH-HBV#DPCHJT M*U@[AV79]:6'& [9M=^HOZYKL.TMK;*-L,,,/8V$?R.J7)639PT$M.0[>O("0! M^B9'4?),BFXHB<0L/US,)H,17E4&2)@'!-$;9.B-D\X2YN0&D)"/'"'8IO%% MJ?&%<>!*C?F"1&?RRL,Y]E3?-Q*J*K>"-=>F7W-SC@*5]"G2*A5I04UE]"\- MY_DM0*.0A%.2W3B=R5&.B#"1$($>R.O.W&>L1E59(6$>$$R3OUW*WS[AI&]# M.@P)X!@FL.7[<;?QB$^+B_*B$PYI3ON\?J7FY=*!S???=:.!L;RJL@#!-%D<* M6]UZVT9A[A.QLQOQ;(()DLBTN'X3G,K9;KXG[A=T+;F]$=!W<@:J[0~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

*M:422.@[6HDTY0(IY0&(&LI,2V4D[G=P))$Y(,0}(S, Y+'$.K2TPPRD06:LQ MFSQ&%*GI89ZHZ,"2HU;11C"'KW(4NSW]]R)37]_7'YKW&0A.2P2G;R4A1M,5 M]Y>J4>W-1]M&TR>&%/.Q QV3]^:$_;:R<="%X@HJ)H'I68RW9EG.]86>;.* M'RE';(Y($(2:)HF*$1.1E5PRGLU); E:U& D2Z\FJ2,V4!J# U(SP>$*'+:" MNR9/8;R*45("+*BEZBPE7(9^F.J^+H@[:Q [42AMDO><>I&!ZAJ35R5 M67#L;F${R25)@.YF#WK>?\.2P\LXC=@SI<@+E9N0C-<2 S4#H&H>E))M,(. MSJ"EX0741H"J>5!}M/*=#AVUS%3BJ%/M_V>GO&1#>$!6E,A=8>H#=HS)7Q/ M?H,:DS=B=;) :B&VX4*,\T 01G&^TJ"A=0-0]*$61:&1QL M-S@_.6NTJS06.0H!X'2LV$6WD+1@4L_7[7:VARW2S7>'Y*KZ266:DW^R.V_M,#=0E9I*G/CVIU"D=!WV@'J;4WW3)((S;1C7+(HH,1$W%&YXK5KA7;MQL! M5VB@U$RNE:UQ<4M[E$#=#]B:!Z5F,MW9]F5?]6F4R[!{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{28H{!%,'C0&F:IRQ?D!.L&Y)31'RCKR M6N>AN]ZU=#AF3VFG5MHY2BD\@DR8HC/L8ZH)Y*EIYP(D$RDY.,"[TZ"I^TSW-M00G_68IN;,#[^E*D@G,JE?%7UJ316DG\:<=:.V@%%_,_2MJ3W6O5MU[@[(< M9Z-WE(V#>EY,(W?GH#67W-V5"X9V.,R1'IL6DR,+BZ-<:%'8LW&PO=V]R:W-H965TD9-F-92=-=U_$0YR9,X8<@ M,*'RK1:[2^\EDDLL0"+"T!6A5(=?CCRE<8U1+VO0IC5:> !MB*XX4TN)+ED.M^:_RGG:S]3?<,H7111Y+]#H1_&Z!7R-IAU<\1*U8SLA:B Q:NJV(&/ MP@0LI5!9,J8:XFX-)@G/9(DS&#LZRR2(%3C)Z[^"OO_~\L7'M=*)RVFMTKNI=Q*S'.E$E4IW"%N\0S-8$,9T5Q]TBED&Z$T=FK?H9V>0:H[JFP-KT]P" MJR1VXY&WZ@=#MM:"]T$7 C/#^2R(WAY$Z/:Z(?HM1/]IB"96SV+H[S&.S>D>9N\0Y;"E'!{-OV_V M$M: DQ4(_:B@C^8((7TS OJ B4!?,:V@"V;X/V1EX&\O8?_SLN<4X]%1*6^ M;FR(3:RW5UKG;5LS#'=3)':C07?(@YT7)/B-7'T)6/-$1,MDH1OW#Y"%6[+P M^0G\$K"P RQR!X=*MGTM?R\W_.5&=E"=7WK_5!+ P04 M "!%0FA9[8X AL,* M"N &0 'AL+W=O 2,7):B(&525GV;5LD$>18=%@) MA5J9,YYC]:9\88N2 TX-**>VZSCG=HY)886!L5WS,&!+24D!UQR)99YC_GL$ ME*T'5M?:&F[((I/:8(=!B17*4#R]$; @J)U Q8O58P!DHUD=K&KYK3:D)IX.YXR_{1 M:%=:9EC F-%O)))79P'IOH13F>$GE#5M_@EJ/V6#"J#!/M*Y_0L+)4LA65Z# MU0YR4E1OO*GSL -0/.T MP:X#P!^ 8!7 [SG1O!K@/_<"+T:8*3;E7:3N A+ M' :(, MO4-WTPB=GIRA$T0*-"&4JK**P)8JD,:2FK!"9@@[;8/+10H!"SXZ MCK\\@&>5UD:PNQ4\(7(MLKB]^4Q3&+OBV+5&6!C>]H(MH!*47&< M&*[Y RX7<;UC-Y.,W39.?_ID_.?I&,CKU">Q8OL|<+?C^A9!PIC%3 M/YHVO93M-LN:[^NI*EB$ X<^H KE/3K#MV_.Q]Z'IHR_IECPFF+35Q+,V)MN MO3?=7>KEWB@HJKL:PY)N@ 2=(!1T;9MV113L64%3I.Z'7M^]7T_U7Q%!B3A9 M1[3\3,(O7$ +_MKVCXLZL*&2 M09(WU_'W,7? VO'IYOOZ)S%(I)&>]20&2%0DZBI_.%4"1& M2Y*). /OO <9*R+|+Q6^BCSY^^H$\HR=%-DJ;"D,U,+H8K.S6C MYN5S@_UORROMVO),.M)HZK>,Y;O VFT#*!K#AG[IO\ M C_LQLOZ>,Fv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{1 M:%=:9EC F-%O)))79P'IOH13F>$GE#5M_@EJ/V6#"J#!/M*Y_0L+)4LA65Z# MU0YR4E1OO*GSL -0/.T MP:X#P!^ 8!7 [SG1O!K@/_<"+T:8*3;E7:3N A+ M' :(, MO4-WTPB=GIRA$T0*-"&4JK**P)8JD,:2FK!"9@@[;8/+10H!"SXZ MCK\\@&>5UD:PNQ4\(7(MLKB]^4Q3&+OBV+5&6!C>]H(MH!*47&< M&*[Y RX7<;UC-Y.,W39.?_ID_.?I&,CKU">Q8OL|<+?C^A9!PIC%3 M/YHVO93M-LN:[^NI*EB$ X<^H KE/3K#MV_.Q]Z'IHR_IECPFF+35Q+,V)MN MO3?=7>KEWB@HJKL:PY)N@ 2=(!1T;9MV113L64%3I.Z'7M^]7T_U7Q%!B3A9 M1[3\3,(O7$ +_MKVCXLZL*&2 M09(WU_'W,7? VO'IYOOZ)S%(I)&>]20&2%0DZBI_.%4"1& M2Y*). /OO <9*R+|+Q6^BCSY^^H$\HR=%-DJ;"D,U,+H8K.S6C MYN5S@_UORROMVO),.M)HZK>,Y;O VFT#*!K#AG[IO\ M C_LQLOZ>,Fv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

("!@1$! 'AL+W=O% $ M>&PO=V]R:W-H965T&UL4$L! A0#% @ 14)H6:%TL#G6 @ + @ !D M ("!3QT! 'AL+W=O&PO=V]R:W-H965T M&UL4$L! A0# M% @ 14)H66 ;^@79 @ K < !D ("!K"T! 'AL+W=O M&PO=V]R:W-H965T&UL4$L! A0#% @ 14)H6=_8 M8G8Q P ; D !D ("!/SH! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 14)H61"H!@ ;B\ !D M ("!140! 'AL+W=O&PO M=V]R:W-H965T&UL4$L! A0#% @ 14)H6:ST#%$ P ,0D !D ("! MI%$! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% M @ 14)H6=E'SN[G @ 6@T !D ("!!%P! 'AL+W=O&PO=V]R:W-H965T&UL4$L! A0#% @ 14)H66\KO;#9 @ J@< !D M ("!.G,! 'AL+W=O&PO&PO7W)E;',O M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " !%0FA9AJ9C2 P" !A*P M$P @ ':@@$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 .4P!3 +P6 7A0$! end XML 87 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 88 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a{ display: block; font-weight: bold; } .report table.authRefData p{ margin-top: 0px; } .report table.authRefData .hide{ background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover{ background-color: #2F4497; } .report table.authRefData .body{ height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited{ color: black; text-decoration: none; } /* table */ .report{ background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr{ border: 1px solid #acf; } /* Top labels */ .report th{ background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void{ background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl{ text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a{ cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a{ width: 200px; } .report td.pl a:hover{ background-color: #ffc; } /* Header rows... */ .report tr.rh{ background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc{ background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu{ background-color: #def; } .report .reu td{ border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou{ background-color: white; } .report .rou td{ border-bottom: 1px solid black; } .report .rou table td, .report .reu table td{ border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn{ white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump{ text-align: right; white-space: nowrap; } .report .nump{ padding-left: 2em; } .report .num{ padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text{ text-align: left; white-space: normal; } .report .text .big{ margin-bottom: 1em; width: 17em; } .report .text .more{ display: none; } .report .text .note{ font-style: italic; font-weight: bold; } .report .text .small{ width: 10em; } .report sup{ font-style: italic; } .report .outerFootnotes{ font-size: 1em; } XML 90 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.3 html2412981false670false8 falsefalseR1.htm0000001 - Document - CoverSheethttp://www.myriad.com/role/CoverCoverCover1 falsefalseR2.htm9952151 - Statement - Condensed Consolidated Balance Sheets (unaudited)Sheethttp://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunauditedCondensed Consolidated Balance Sheets (unaudited)Statements2 falsefalseR3.htm9952152 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)Sheethttp://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunauditedParentheticalCondensed Consolidated Balance Sheets (unaudited) (Parenthetical)Statements3 falsefalseR4.htm9952153 - Statement - Condensed Consolidated Statements of Operations (unaudited)Sheethttp://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunauditedCondensed Consolidated Statements of Operations (unaudited)Statements4 falsefalseR5.htm9952154 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited)Sheethttp://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLossunauditedCondensed Consolidated Statements of Comprehensive Loss (unaudited)Statements5 falsefalseR6.htm9952155 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited)Sheethttp://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquityunauditedCondensed Consolidated Statements of Stockholders' Equity (unaudited)Statements6 falsefalseR7.htm9952156 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)Sheethttp://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunauditedCondensed Consolidated Statements of Cash Flows (unaudited)Statements7 falsefalseR8.htm9952157 - Disclosure - BASIS OF PRESENTATIONSheethttp://www.myriad.com/role/BASISOFPRESENTATIONBASIS OF PRESENTATIONNotes8 falsefalseR9.htm9952158 - Disclosure - REVENUESheethttp://www.myriad.com/role/REVENUEREVENUENotes9 falsefalseR10.htm9952159 - Disclosure - MARKETABLE INVESTMENT SECURITIESSheethttp://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIESMARKETABLE INVESTMENT SECURITIESNotes10 falsefalseR11.htm9952160 - Disclosure - FAIR VALUE MEASUREMENTSSheethttp://www.myriad.com/role/FAIRVALUEMEASUREMENTSFAIR VALUE MEASUREMENTSNotes11 falsefalseR12.htm9952161 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NETSheethttp://www.myriad.com/role/PROPERTYPLANTANDEQUIPMENTNETPROPERTY, PLANT AND EQUIPMENT, NETNotes12 falsefalseR13.htm9952162 - Disclosure - GOODWILL AND INTANGIBLE ASSETSSheethttp://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSGOODWILL AND INTANGIBLE ASSETSNotes13 falsefalseR14.htm9952163 - Disclosure - ACCRUED LIABILITIESSheethttp://www.myriad.com/role/ACCRUEDLIABILITIESACCRUED LIABILITIESNotes14 falsefalseR15.htm9952164 - Disclosure - LONG-TERM DEBTSheethttp://www.myriad.com/role/LONGTERMDEBTLONG-TERM DEBTNotes15 falsefalseR16.htm9952165 - Disclosure - OTHER LONG-TERM LIABILITIESSheethttp://www.myriad.com/role/OTHERLONGTERMLIABILITIESOTHER LONG-TERM LIABILITIESNotes16 falsefalseR17.htm9952166 - Disclosure - PREFERRED AND COMMON STOCKHOLDERS' EQUITYSheethttp://www.myriad.com/role/PREFERREDANDCOMMONSTOCKHOLDERSEQUITYPREFERRED AND COMMON STOCKHOLDERS' EQUITYNotes17 falsefalseR18.htm9952167 - Disclosure - STOCK-BASED COMPENSATIONSheethttp://www.myriad.com/role/STOCKBASEDCOMPENSATIONSTOCK-BASED COMPENSATIONNotes18 falsefalseR19.htm9952168 - Disclosure - INCOME TAXESSheethttp://www.myriad.com/role/INCOMETAXESINCOME TAXESNotes19 falsefalseR20.htm9952169 - Disclosure - COMMITMENTS AND CONTINGENCIESSheethttp://www.myriad.com/role/COMMITMENTSANDCONTINGENCIESCOMMITMENTS AND CONTINGENCIESNotes20 falsefalseR21.htm9952170 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATIONSheethttp://www.myriad.com/role/SUPPLEMENTALCASHFLOWINFORMATIONSUPPLEMENTAL CASH FLOW INFORMATIONNotes21 falsefalseR22.htm9952171 - Disclosure - LEASESSheethttp://www.myriad.com/role/LEASESLEASESNotes22 falsefalseR23.htm9952172 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)Sheethttp://www.myriad.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)Notes23 falsefalseR24.htm9952173 - Disclosure - ACQUISITIONSheethttp://www.myriad.com/role/ACQUISITIONACQUISITIONNotes24 falsefalseR25.htm9952174 - Disclosure - DIVESTITURESheethttp://www.myriad.com/role/DIVESTITUREDIVESTITURENotes25 falsefalseR26.htm995410 - Disclosure - Pay vs Performance DisclosureSheethttp://xbrl.sec.gov/ecd/role/PvpDisclosurePay vs Performance DisclosureNotes26 falsefalseR27.htm995445 - Disclosure - Insider Trading ArrangementsSheethttp://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsider Trading ArrangementsNotes27 falsefalseR28.htm9954471 - Disclosure - BASIS OF PRESENTATION (Policies)Sheethttp://www.myriad.com/role/BASISOFPRESENTATIONPoliciesBASIS OF PRESENTATION (Policies)Policies28 falsefalseR29.htm9954472 - Disclosure - REVENUE (Tables)Sheethttp://www.myriad.com/role/REVENUETablesREVENUE (Tables)Tableshttp://www.myriad.com/role/REVENUE29 falsefalseR30.htm9954473 - Disclosure - MARKETABLE INVESTMENT SECURITIES (Tables)Sheethttp://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIESTablesMARKETABLE INVESTMENT SECURITIES (Tables)Tableshttp://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIES30 falsefalseR31.htm9954474 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)Sheethttp://www.myriad.com/role/FAIRVALUEMEASUREMENTSTablesFAIR VALUE MEASUREMENTS (Tables)Tableshttp://www.myriad.com/role/FAIRVALUEMEASUREMENTS31 falsefalseR32.htm9954475 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET (Tables)Sheethttp://www.myriad.com/role/PROPERTYPLANTANDEQUIPMENTNETTablesPROPERTY, PLANT AND EQUIPMENT, NET (Tables)Tableshttp://www.myriad.com/role/PROPERTYPLANTANDEQUIPMENTNET32 falsefalseR33.htm9954476 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)Sheethttp://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSTablesGOODWILL AND INTANGIBLE ASSETS (Tables)Tableshttp://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETS33 falsefalseR34.htm9954477 - Disclosure - ACCRUED LIABILITIES (Tables)Sheethttp://www.myriad.com/role/ACCRUEDLIABILITIESTablesACCRUED LIABILITIES (Tables)Tableshttp://www.myriad.com/role/ACCRUEDLIABILITIES34 falsefalseR35.htm9954478 - Disclosure - OTHER LONG-TERM LIABILITIES (Tables)Sheethttp://www.myriad.com/role/OTHERLONGTERMLIABILITIESTablesOTHER LONG-TERM LIABILITIES (Tables)Tableshttp://www.myriad.com/role/OTHERLONGTERMLIABILITIES35 falsefalseR36.htm9954479 - Disclosure - PREFERRED AND COMMON STOCKHOLDERS' EQUITY (Tables)Sheethttp://www.myriad.com/role/PREFERREDANDCOMMONSTOCKHOLDERSEQUITYTablesPREFERRED AND COMMON STOCKHOLDERS' EQUITY (Tables)Tableshttp://www.myriad.com/role/PREFERREDANDCOMMONSTOCKHOLDERSEQUITY36 falsefalseR37.htm9954480 - Disclosure - STOCK-BASED COMPENSATION (Tables)Sheethttp://www.myriad.com/role/STOCKBASEDCOMPENSATIONTablesSTOCK-BASED COMPENSATION (Tables)Tableshttp://www.myriad.com/role/STOCKBASEDCOMPENSATION37 falsefalseR38.htm9954481 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION (Tables)Sheethttp://www.myriad.com/role/SUPPLEMENTALCASHFLOWINFORMATIONTablesSUPPLEMENTAL CASH FLOW INFORMATION (Tables)Tableshttp://www.myriad.com/role/SUPPLEMENTALCASHFLOWINFORMATION38 falsefalseR39.htm9954482 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)Sheethttp://www.myriad.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTablesACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)Tableshttp://www.myriad.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS39 falsefalseR40.htm9954483 - Disclosure - BASIS OF PRESENTATION (Details)Sheethttp://www.myriad.com/role/BASISOFPRESENTATIONDetailsBASIS OF PRESENTATION (Details)Detailshttp://www.myriad.com/role/BASISOFPRESENTATIONPolicies40 falsefalseR41.htm9954484 - Disclosure - REVENUE - Schedule of Total Revenue by Type and by U.S versus Rest of World (Details)Sheethttp://www.myriad.com/role/REVENUEScheduleofTotalRevenuebyTypeandbyUSversusRestofWorldDetailsREVENUE - Schedule of Total Revenue by Type and by U.S versus Rest of World (Details)Details41 falsefalseR42.htm9954485 - Disclosure - REVENUE - Narrative (Details)Sheethttp://www.myriad.com/role/REVENUENarrativeDetailsREVENUE - Narrative (Details)Details42 falsefalseR43.htm9954486 - Disclosure - MARKETABLE INVESTMENT SECURITIES - Narrative (Details)Sheethttp://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIESNarrativeDetailsMARKETABLE INVESTMENT SECURITIES - Narrative (Details)Details43 falsefalseR44.htm9954487 - Disclosure - MARKETABLE INVESTMENT SECURITIES - Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Details)Sheethttp://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIESScheduleofFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDe INVESTMENT SECURITIES - Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Details)Details44 falsefalseR45.htm9954488 - Disclosure - FAIR VALUE MEASUREMENTS - Narrative (Details)Sheethttp://www.myriad.com/role/FAIRVALUEMEASUREMENTSNarrativeDetailsFAIR VALUE MEASUREMENTS - Narrative (Details)Details45 falsefalseR46.htm9954489 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Fair Value of Financial Assets and Liabilities (Details)Sheethttp://www.myriad.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueofFinancialAssetsandLiabilitiesDetailsFAIR VALUE MEASUREMENTS - Schedule of Fair Value of Financial Assets and Liabilities (Details)Details46 falsefalseR47.htm9954490 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Change in Fair Value of Contingent Consideration (Details)Sheethttp://www.myriad.com/role/FAIRVALUEMEASUREMENTSScheduleofChangeinFairValueofContingentConsiderationDetailsFAIR VALUE MEASUREMENTS - Schedule of Change in Fair Value of Contingent Consideration (Details)Details47 falsefalseR48.htm9954491 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET - Schedule of Property, Plant and Equipment, Net (Details)Sheethttp://www.myriad.com/role/PROPERTYPLANTANDEQUIPMENTNETScheduleofPropertyPlantandEquipmentNetDetailsPROPERTY, PLANT AND EQUIPMENT, NET - Schedule of Property, Plant and Equipment, Net (Details)Details48 falsefalseR49.htm9954492 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET - Schedule of Depreciation Expense (Details)Sheethttp://www.myriad.com/role/PROPERTYPLANTANDEQUIPMENTNETScheduleofDepreciationExpenseDetailsPROPERTY, PLANT AND EQUIPMENT, NET - Schedule of Depreciation Expense (Details)Details49 falsefalseR50.htm9954493 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET - Narrative (Details)Sheethttp://www.myriad.com/role/PROPERTYPLANTANDEQUIPMENTNETNarrativeDetailsPROPERTY, PLANT AND EQUIPMENT, NET - Narrative (Details)Details50 falsefalseR51.htm9954494 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Goodwill (Details)Sheethttp://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetailsGOODWILL AND INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Goodwill (Details)Details51 falsefalseR52.htm9954495 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Narrative (Details)Sheethttp://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetailsGOODWILL AND INTANGIBLE ASSETS - Narrative (Details)Details52 falsefalseR53.htm9954496 - Disclosure - GOODWILL AND INTANGIBLE ASSETS- Schedule of Intangible Assets (Details)Sheethttp://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofIntangibleAssetsDetailsGOODWILL AND INTANGIBLE ASSETS- Schedule of Intangible Assets (Details)Details53 falsefalseR54.htm9954497 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Schedule of Recorded Amortization Expense for Intangible Assets

(Details)Sheethttp://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofRecordedAmortizationExpenseforIntangibleAssetsDetailsGOODWILL AND INTANGIBLE ASSETS - Schedule of Recorded Amortization Expense for Intangible Assets (Details)Details54 falsefalseR55.htm9954498 - Disclosure - ACCRUED LIABILITIES (Details)Sheethttp://www.myriad.com/role/ACCRUEDLIABILITIESDetailsACCRUED LIABILITIES (Details)Detailshttp://www.myriad.com/role/ACCRUEDLIABILITIESTables55 falsefalseR56.htm9954499 - Disclosure - LONG-TERM DEBT (Details)Sheethttp://www.myriad.com/role/LONGTERMDEBTDetailsLONG-TERM DEBT (Details)Detailshttp://www.myriad.com/role/LONGTERMDEBT56 falsefalseR57.htm9954500 - Disclosure - OTHER LONG-TERM LIABILITIES - Schedule of Other Long-Term Liabilities (Details)Sheethttp://www.myriad.com/role/OTHERLONGTERMLIABILITIESScheduleofOtherLongTermLiabilitiesDetailsOTHER LONG-TERM LIABILITIES - Schedule of Other Long-Term Liabilities (Details)Details57 falsefalseR58.htm9954501 - Disclosure - OTHER LONG-TERM LIABILITIES - Narrative (Details)Sheethttp://www.myriad.com/role/OTHERLONGTERMLIABILITIESNarrativeDetailsOTHER LONG-TERM LIABILITIES - Narrative (Details)Details58 falsefalseR59.htm9954502 - Disclosure - PREFERRED AND COMMON STOCKHOLDERS' EQUITY - Narrative (Details)Sheethttp://www.myriad.com/role/PREFERREDANDCOMMONSTOCKHOLDERSEQUITYNarrativeDetailsPREFERRED AND COMMON STOCKHOLDERS' EQUITY - Narrative (Details)Details59 falsefalseR60.htm9954503 - Disclosure - PREFERRED AND COMMON STOCKHOLDERS' EQUITY - Schedule of Common Stock Issued and Outstanding (Details)Sheethttp://www.myriad.com/role/PREFERREDANDCOMMONSTOCKHOLDERSEQUITYScheduleofCommonStockIssuedandOutstandingDetailsPREFERRED AND COMMON STOCKHOLDERS' EQUITY - Schedule of Common Stock Issued and Outstanding (Details)Details60 falsefalseR61.htm9954504 - Disclosure - PREFERRED AND COMMON STOCKHOLDERS' EQUITY - Schedule of Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations (Details)Sheethttp://www.myriad.com/role/PREFERREDANDCOMMONSTOCKHOLDERSEQUITYScheduleofReconciliationofDenominatorsofBasicandDilutedEarningsPerShareCo AND COMMON STOCKHOLDERS' EQUITY - Schedule of Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations (Details)Details61 falsefalseR62.htm9954505 - Disclosure - PREFERRED AND COMMON STOCKHOLDERS' EQUITY - Schedule of Potential Dilutive Common Shares (Details)Sheethttp://www.myriad.com/role/PREFERREDANDCOMMONSTOCKHOLDERSEQUITYScheduleofPotentialDilutiveCommonSharesDetailsPREFERRED AND COMMON STOCKHOLDERS' EQUITY - Schedule of Potential Dilutive Common Shares (Details)Details62 falsefalseR63.htm9954506 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)Sheethttp://www.myriad.com/role/STOCKBASEDCOMPENSATIONNarrativeDetailsSTOCK-BASED COMPENSATION - Narrative (Details)Details63 falsefalseR64.htm9954507 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details)Sheethttp://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetailsSTOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details)Details64 falsefalseR65.htm9954508 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Restricted Stock Unit Activity (Details)Sheethttp://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetailsSTOCK-BASED COMPENSATION - Schedule of Restricted Stock Unit Activity (Details)Details65 falsefalseR66.htm9954509 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Share-Based Compensation, Employee Stock Purchase Plan, Activity (Details)Sheethttp://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofShareBasedCompensationEmployeeStockPurchasePlanActivityDetailsSTOCK-BASED COMPENSATION - Schedule of Share-Based Compensation, Employee Stock Purchase Plan, Activity (Details)Details66 falsefalseR67.htm9954510 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense (Details)Sheethttp://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetailsSTOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense (Details)Details67 falsefalseR68.htm9954511 - Disclosure - INCOME TAXES (Details)Sheethttp://www.myriad.com/role/INCOMETAXESDetailsINCOME TAXES (Details)Detailshttp://www.myriad.com/role/INCOMETAXES68 falsefalseR69.htm9954512 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)Sheethttp://www.myriad.com/role/COMMITMENTSANDCONTINGENCIESDetailsCOMMITMENTS AND CONTINGENCIES (Details)Detailshttp://www.myriad.com/role/COMMITMENTSANDCONTINGENCIES69 falsefalseR70.htm9954513 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION - Schedule of Supplemental Cash Flow Information (Details)Sheethttp://www.myriad.com/role/SUPPLEMENTALCASHFLOWINFORMATIONScheduleofSupplementalCashFlowInformationDetailsSUPPLEMENTAL CASH FLOW INFORMATION - Schedule of Supplemental Cash Flow Information (Details)Details70 falsefalseR71.htm9954514 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)Sheethttp://www.myriad.com/role/SUPPLEMENTALCASHFLOWINFORMATIONScheduleofCashandCashEquivalentsandRestrictedCashDetailsSUPPLEMENTAL CASH FLOW INFORMATION - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)Details71 falsefalseR72.htm9954515 - Disclosure - LEASES (Details)Sheethttp://www.myriad.com/role/LEASESDetailsLEASES (Details)Detailshttp://www.myriad.com/role/LEASES72 falsefalseR73.htm9954516 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Details)Sheethttp://www.myriad.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSDetailsACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Details)Detailshttp://www.myriad.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables73 falsefalseR74.htm9954517 - Disclosure - ACQUISITION (Details)Sheethttp://www.myriad.com/role/ACQUISITIONDetailsACQUISITION (Details)Detailshttp://www.myriad.com/role/ACQUISITION74 falsefalseR75.htm9954518 - Disclosure - DIVESTITURE (Details)Sheethttp://www.myriad.com/role/DIVESTITUREDetailsDIVESTITURE (Details)Detailshttp://www.myriad.com/role/DIVESTITURE75 falsefalseAll ReportsBookAll Reports mygn-20240930.htmmygn-20240930.xsdmygn-20240930_cal.xmlmygn-20240930_def.xmlmygn-20240930_lab.xmlmygn-20240930_pre.xml http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024http://xbrl.sec.gov/ecd/2024truetrue JSON 93 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "mygn-20240930.htm": { "nsprefix": "mygn", "nsuri": "http://www.myriad.com/20240930", "dts": { "inline": { "local": ["mygn-20240930.htm"] }, "schema": { "local": ["mygn-20240930.xsd"], "remote": ["http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"] }, "calculationLink": { "local": ["mygn-20240930_cal.xml"] }, "definitionLink": { "local": ["mygn-20240930_def.xml"] }, "labelLink": { "local": ["mygn-20240930_lab.xml"] }, "presentationLink": { "local": ["mygn-20240930_pre.xml"] } }, "keyStandard": 265, "keyCustom": 33, "axisStandard": 28, "axisCustom": 2, "memberStandard": 39, "memberCustom": 27, "hidden": { "total": 16, "http://fasb.org/us-gaap/2024": 11, "http://xbrl.sec.gov/dei/2024": 5 }, "contextCount": 241, "entityCount": 1, "segmentCount": 67, "elementCount": 604, "unitCount": 8, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 720, "http://xbrl.sec.gov/dei/2024": 29, "http://xbrl.sec.gov/ecd/2024": 4 }, "report": { "R1": { "role": "http://www.myriad.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["span", "div", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited", "longName": "9952151 - Statement - Condensed Consolidated Balance Sheets (unaudited)", "shortName": "Condensed Consolidated Balance Sheets (unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:MarketableSecuritiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "unique": true } }, "R3": { "role": "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical", "longName": "9952152 - Statement - Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)", "shortName": "Condensed Consolidated Balance Sheets (unaudited) (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockSharesOutstanding", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true }, "uniqueAnchor": null }, "R4": { "role": "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunaudited", "longName": "9952153 - Statement - Condensed Consolidated Statements of Operations (unaudited)", "shortName": "Condensed Consolidated Statements of Operations (unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:CostOfGoodsAndServicesSold", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "unique": true } }, "R5": { "role": "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited", "longName": "9952154 - Statement - Condensed Consolidated Statements of Comprehensive Loss (unaudited)", "shortName": "Condensed Consolidated Statements of Comprehensive Loss (unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "unique": true } }, "R6": { "role": "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited", "longName": "9952155 - Statement - Condensed Consolidated Statements of Stockholders' Equity (unaudited)", "shortName": "Condensed Consolidated Statements of Stockholders' Equity (unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-12", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-14", "name": "us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "unique": true } }, "R7": { "role": "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "longName": "9952156 - Statement - Condensed Consolidated Statements of Cash Flows (unaudited)", "shortName": "Condensed Consolidated Statements of Cash Flows (unaudited)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DepreciationAndAmortization", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "unique": true } }, "R8": { "role": "http://www.myriad.com/role/BASISOFPRESENTATION", "longName": "9952157 - Disclosure - BASIS OF PRESENTATION", "shortName": "BASIS OF PRESENTATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R9": { "role": "http://www.myriad.com/role/REVENUE", "longName": "9952158 - Disclosure - REVENUE", "shortName": "REVENUE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:RevenueFromContractWithCustomerTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": ["div", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R10": { "role": "http://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIES", "longName": "9952159 - Disclosure - MARKETABLE INVESTMENT SECURITIES", "shortName": "MARKETABLE INVESTMENT SECURITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": {

```
"contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R11": { "role": "http://www.myriad.com/role/FAIRVALUEMEASUREMENTS", "longName": "9952160 - Disclosure - FAIR VALUE MEASUREMENTS", "shortName": "FAIR VALUE MEASUREMENTS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R12": { "role": "http://www.myriad.com/role/PROPERTYPLANTANDEQUIPMENTNET", "longName": "9952161 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET", "shortName": "PROPERTY, PLANT AND EQUIPMENT, NET", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R13": { "role": "http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETS", "longName": "9952162 - Disclosure - GOODWILL AND INTANGIBLE ASSETS", "shortName": "GOODWILL AND INTANGIBLE ASSETS", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R14": { "role": "http://www.myriad.com/role/ACCRUEDLIABILITIES", "longName": "9952163 - Disclosure - ACCRUED LIABILITIES", "shortName": "ACCRUED LIABILITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R15": { "role": "http://www.myriad.com/role/LONGTERMDEBT", "longName": "9952164 - Disclosure - LONG-TERM DEBT", "shortName": "LONG-TERM DEBT", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DebtDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R16": { "role": "http://www.myriad.com/role/OTHERLONGTERMLIABILITIES", "longName": "9952165 - Disclosure - OTHER LONG-TERM LIABILITIES", "shortName": "OTHER LONG-TERM LIABILITIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R17": { "role": "http://www.myriad.com/role/PREFERREDANDCOMMONSTOCKHOLDERSEQUITY", "longName": "9952166 - Disclosure - PREFERRED AND COMMON STOCKHOLDERS' EQUITY", "shortName": "PREFERRED AND COMMON STOCKHOLDERS' EQUITY", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R18": { "role": "http://www.myriad.com/role/STOCKBASEDCOMPENSATION", "longName": "9952167 - Disclosure - STOCK-BASED COMPENSATION", "shortName": "STOCK-BASED COMPENSATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R19": { "role": "http://www.myriad.com/role/INCOMETAXES", "longName": "9952168 - Disclosure - INCOME TAXES", "shortName": "INCOME TAXES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R20": { "role": "http://www.myriad.com/role/COMMITMENTSANDCONTINGENCIES", "longName": "9952169 - Disclosure - COMMITMENTS AND CONTINGENCIES", "shortName": "COMMITMENTS AND CONTINGENCIES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R21": { "role": "http://www.myriad.com/role/SUPPLEMENTALCASHFLOWINFORMATION", "longName": "9952170 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION", "shortName": "SUPPLEMENTAL CASH FLOW INFORMATION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CashFlowSupplementalDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R22": { "role": "http://www.myriad.com/role/LEASES", "longName": "9952171 - Disclosure - LEASES", "shortName": "LEASES", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:LesseeOperatingLeasesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R23": { "role": "http://www.myriad.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS", "longName": "9952172 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)", "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ComprehensiveIncomeNoteTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R24": { "role": "http://www.myriad.com/role/ACQUISITION", "longName": "9952173 - Disclosure - ACQUISITION", "shortName": "ACQUISITION", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:AssetAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:AssetAcquisitionTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R25": { "role": "http://www.myriad.com/role/DIVESTITURE", "longName": "9952174 - Disclosure - DIVESTITURE", "shortName": "DIVESTITURE", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R26": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "26", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true }, "uniqueAnchor": null }, "R27": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "27", "firstAnchor": { "contextRef": "c-7", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "ecd:Rule10b51ArrTrmntdFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "ecd:Rule10b51ArrAdoptedFlag", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ecd:NonRule10b51ArrAdoptedFlag", "ecd:Rule10b51ArrTrmntdFlag", "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R28": { "role": "http://www.myriad.com/role/BASISOFPRESENTATIONPolicies", "longName": "9954471 - Disclosure - BASIS OF PRESENTATION (Policies)", "shortName": "BASIS OF PRESENTATION (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "28", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R29": { "role": "http://www.myriad.com/role/REVENUETables", "longName": "9954472 - Disclosure - REVENUE (Tables)", "shortName": "REVENUE (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R30": { "role": "http://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIESTables", "longName": "9954473 - Disclosure - MARKETABLE INVESTMENT SECURITIES (Tables)", "shortName": "MARKETABLE INVESTMENT SECURITIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R31": { "role": "http://www.myriad.com/role/FAIRVALUEMEASUREMENTSTables", "longName": "9954474 - Disclosure - FAIR VALUE MEASUREMENTS (Tables)", "shortName": "FAIR VALUE MEASUREMENTS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock",
```

```
"unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R32": { "role": "http://www.myriad.com/role/PROPERTYPLANTANDEQUIPMENTNETTables", "longName": "9954475 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET (Tables)", "shortName": "PROPERTY, PLANT AND EQUIPMENT, NET (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "32", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R33": { "role": "http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSTables", "longName": "9954476 - Disclosure - GOODWILL AND INTANGIBLE ASSETS (Tables)", "shortName": "GOODWILL AND INTANGIBLE ASSETS (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "33", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfGoodwillTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R34": { "role": "http://www.myriad.com/role/ACCRUEDLIABILITIESTables", "longName": "9954477 - Disclosure - ACCRUED LIABILITIES (Tables)", "shortName": "ACCRUED LIABILITIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "34", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R35": { "role": "http://www.myriad.com/role/OTHERLONGTERMLIABILITIESTables", "longName": "9954478 - Disclosure - OTHER LONG-TERM LIABILITIES (Tables)", "shortName": "OTHER LONG-TERM LIABILITIES (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "35", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R36": { "role": "http://www.myriad.com/role/PREFERREDANDCOMMONSTOCKHOLDERSEQUITYTables", "longName": "9954479 - Disclosure - PREFERRED AND COMMON STOCKHOLDERS' EQUITY (Tables)", "shortName": "PREFERRED AND COMMON STOCKHOLDERS' EQUITY (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "36", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R37": { "role": "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONTables", "longName": "9954480 - Disclosure - STOCK-BASED COMPENSATION (Tables)", "shortName": "STOCK-BASED COMPENSATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "37", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R38": { "role": "http://www.myriad.com/role/SUPPLEMENTALCASHFLOWINFORMATIONTables", "longName": "9954481 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION (Tables)", "shortName": "SUPPLEMENTAL CASH FLOW INFORMATION (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "38", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R39": { "role": "http://www.myriad.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables", "longName": "9954482 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)", "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "39", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R40": { "role": "http://www.myriad.com/role/BASISOFPRESENTATIONDetails", "longName": "9954483 - Disclosure - BASIS OF PRESENTATION (Details)", "shortName": "BASIS OF PRESENTATION (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": null, "uniqueAnchor": null }, "R41": { "role": "http://www.myriad.com/role/REVENUEScheduleofTotalRevenuebyTypeandbyUSversusRestofWorldDetails", "longName": "9954484 - Disclosure - REVENUE - Schedule of Total Revenue by Type and by U.S versus Rest of World (Details)", "shortName": "REVENUE - Schedule of Total Revenue by Type and by U.S versus Rest of World (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-92", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:DisaggregationOfRevenueTableTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "unique": true } }, "R42": { "role": "http://www.myriad.com/role/REVENUENarrativeDetails", "longName": "9954485 - Disclosure - REVENUE - Narrative (Details)", "shortName": "REVENUE - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R43": { "role": "http://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIESNarrativeDetails", "longName": "9954486 - Disclosure - MARKETABLE INVESTMENT SECURITIES - Narrative (Details)", "shortName": "MARKETABLE INVESTMENT SECURITIES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true }, "uniqueAnchor": null }, "R44": { "role": "http://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIESScheduleofFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails", "longName": "9954487 - Disclosure - MARKETABLE INVESTMENT SECURITIES - Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Details)", "shortName": "MARKETABLE INVESTMENT SECURITIES - Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "unique": true } }, "R45": { "role": "http://www.myriad.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "longName": "9954488 - Disclosure - FAIR VALUE MEASUREMENTS - Narrative (Details)", "shortName": "FAIR VALUE MEASUREMENTS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:FairValueNetAssetLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-152", "name": "us-gaap:BusinessCombinationContingentConsiderationLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "unique": true } }, "R46": { "role": "http://www.myriad.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueofFinancialAssetsandLiabilitiesDetails", "longName": "9954489 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Fair Value of Financial Assets and Liabilities (Details)", "shortName": "FAIR VALUE MEASUREMENTS - Schedule of Fair Value of Financial Assets and Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:FairValueNetAssetLiability", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": [ "span", "div", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-138", "name": "us-gaap:AssetsFairValueDisclosure", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "unique": true } }, "R47": { "role": "http://www.myriad.com/role/FAIRVALUEMEASUREMENTSScheduleofChangeinFairValueofContingentConsiderationDetails", "longName": "9954490 - Disclosure - FAIR VALUE MEASUREMENTS - Schedule of Change in Fair Value of Contingent Consideration (Details)", "shortName": "FAIR VALUE MEASUREMENTS - Schedule of Change in Fair Value of Contingent Consideration (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "ix:continuation", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R48": { "role": "http://www.myriad.com/role/PROPERTYPLANTANDEQUIPMENTNETScheduleofPropertyPlantandEquipmentNetDetails", "longName": "9954491 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET - Schedule of Property, Plant and Equipment, Net (Details)", "shortName": "PROPERTY, PLANT AND EQUIPMENT, NET - Schedule of Property, Plant and Equipment, Net (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R49": { "role": "http://www.myriad.com/role/PROPERTYPLANTANDEQUIPMENTNETScheduleofDepreciationExpenseDetails", "longName": "9954492 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET - Schedule of Depreciation Expense (Details)", "shortName": "PROPERTY, PLANT AND EQUIPMENT, NET - Schedule of Depreciation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:Depreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:PropertyPlantAndEquipmentTextBlock", "body", "html" ], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true,
```

"unique": true } }, "R50": { "role": "http://www.myriad.com/role/PROPERTYPLANTANDEQUIPMENTNETNarrativeDetails", "longName": "9954493 - Disclosure - PROPERTY, PLANT AND EQUIPMENT, NET - Narrative (Details)", "shortName": "PROPERTY, PLANT AND EQUIPMENT, NET - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "c-157", "name": "us-gaap:RestructuringReserveAcceleratedDepreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["ix:continuation", "span", "div", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-157", "name": "us-gaap:RestructuringReserveAcceleratedDepreciation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["ix:continuation", "span", "div", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R51": { "role": "http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails", "longName": "9954494 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Goodwill (Details)", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Schedule of Changes in Carrying Amount of Goodwill (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillForeignCurrencyTranslationGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfGoodwillTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "unique": true } }, "R52": { "role": "http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails", "longName": "9954495 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Narrative (Details)", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:GoodwillImpairmentLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-158", "name": "us-gaap:Goodwill", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "unique": true } }, "R53": { "role": "http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofIntangibleAssetsDetails", "longName": "9954496 - Disclosure - GOODWILL AND INTANGIBLE ASSETS- Schedule of Intangible Assets (Details)", "shortName": "GOODWILL AND INTANGIBLE ASSETS- Schedule of Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R54": { "role": "http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofRecordedAmortizationExpenseforIntangibleAssetsDetails", "longName": "9954497 - Disclosure - GOODWILL AND INTANGIBLE ASSETS - Schedule of Recorded Amortization Expense for Intangible Assets (Details)", "shortName": "GOODWILL AND INTANGIBLE ASSETS - Schedule of Recorded Amortization Expense for Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R55": { "role": "http://www.myriad.com/role/ACCRUEDLIABILITIESDetails", "longName": "9954498 - Disclosure - ACCRUED LIABILITIES (Details)", "shortName": "ACCRUED LIABILITIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R56": { "role": "http://www.myriad.com/role/LONGTERMDEBTDetails", "longName": "9954499 - Disclosure - LONG-TERM DEBT (Details)", "shortName": "LONG-TERM DEBT (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "c-186", "name": "us-gaap:LineOfCreditFacilityCommitmentFeeAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-186", "name": "us-gaap:LineOfCreditFacilityCommitmentFeeAmount", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R57": { "role": "http://www.myriad.com/role/OTHERLONGTERMLIABILITIESScheduleofOtherLongTermLiabilitiesDetails", "longName": "9954500 - Disclosure - OTHER LONG-TERM LIABILITIES - Schedule of Other Long-Term Liabilities (Details)", "shortName": "OTHER LONG-TERM LIABILITIES - Schedule of Other Long-Term Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R58": { "role": "http://www.myriad.com/role/OTHERLONGTERMLIABILITIESNarrativeDetails", "longName": "9954501 - Disclosure - OTHER LONG-TERM LIABILITIES - Narrative (Details)", "shortName": "OTHER LONG-TERM LIABILITIES - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "c-3", "name": "mygn:LegalChargesPendingSettlementNoncurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-202", "name": "us-gaap:LossContingencyAccrualCarryingValueCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["ix:continuation", "span", "div", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "unique": true } }, "R59": { "role": "http://www.myriad.com/role/PREFERREDANDCOMMONSTOCKHOLDERSEQUITYNarrativeDetails", "longName": "9954502 - Disclosure - PREFERRED AND COMMON STOCKHOLDERS' EQUITY - Narrative (Details)", "shortName": "PREFERRED AND COMMON STOCKHOLDERS' EQUITY - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "59", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PreferredStockSharesAuthorized", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R60": { "role": "http://www.myriad.com/role/PREFERREDANDCOMMONSTOCKHOLDERSEQUITYScheduleofCommonStockIssuedandOutstandingDetails", "longName": "9954503 - Disclosure - PREFERRED AND COMMON STOCKHOLDERS' EQUITY - Schedule of Common Stock Issued and Outstanding (Details)", "shortName": "PREFERRED AND COMMON STOCKHOLDERS' EQUITY - Schedule of Common Stock Issued and Outstanding (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "60", "firstAnchor": { "contextRef": "c-4", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "mygn:StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "unique": true } }, "R61": { "role": "http://www.myriad.com/role/PREFERREDANDCOMMONSTOCKHOLDERSEQUITYScheduleofReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDe "longName": "9954504 - Disclosure - PREFERRED AND COMMON STOCKHOLDERS' EQUITY - Schedule of Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations (Details)", "shortName": "PREFERRED AND COMMON STOCKHOLDERS' EQUITY - Schedule of Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "61", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:WeightedAverageNumberOfSharesOutstandingBasic", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "unique": true } }, "R62": { "role": "http://www.myriad.com/role/PREFERREDANDCOMMONSTOCKHOLDERSEQUITYScheduleofPotentialDilutiveCommonSharesDetails", "longName": "9954505 - Disclosure - PREFERRED AND COMMON STOCKHOLDERS' EQUITY - Schedule of Potential Dilutive Common Shares (Details)", "shortName": "PREFERRED AND COMMON STOCKHOLDERS' EQUITY - Schedule of Potential Dilutive Common Shares (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "62", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R63": { "role": "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "longName": "9954506 - Disclosure - STOCK-BASED COMPENSATION - Narrative (Details)", "shortName": "STOCK-BASED COMPENSATION - Narrative (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "63", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R64": { "role": "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails", "longName": "9954507 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details)", "shortName": "STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "64", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R65": { "role": "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails", "longName": "9954508 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Restricted Stock Unit Activity (Details)", "shortName": "STOCK-BASED COMPENSATION - Schedule of Restricted Stock Unit Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "65", "firstAnchor": { "contextRef": "c-212", "name": "us-

gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-212", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R66": { "role": "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofShareBasedCompensationEmployeeStockPurchasePlanActivityDetails", "longName": "9954509 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Share-Based Compensation, Employee Stock Purchase Plan, Activity (Details)", "shortName": "STOCK-BASED COMPENSATION - Schedule of Share-Based Compensation, Employee Stock Purchase Plan, Activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "66", "firstAnchor": { "contextRef": "c-216", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-216", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward", "unitRef": "shares", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R67": { "role": "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails", "longName": "9954510 - Disclosure - STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense (Details)", "shortName": "STOCK-BASED COMPENSATION - Schedule of Stock-Based Compensation Expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "67", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R68": { "role": "http://www.myriad.com/role/INCOMETAXESDetails", "longName": "9954511 - Disclosure - INCOME TAXES (Details)", "shortName": "INCOME TAXES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "68", "firstAnchor": { "contextRef": "c-7", "name": "us-gaap:IncomeTaxExpenseBenefit", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-7", "name": "us-gaap:EffectiveIncomeTaxRateContinuingOperations", "unitRef": "number", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "unique": true } }, "R69": { "role": "http://www.myriad.com/role/COMMITMENTSANDCONTINGENCIESDetails", "longName": "9954512 - Disclosure - COMMITMENTS AND CONTINGENCIES (Details)", "shortName": "COMMITMENTS AND CONTINGENCIES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "69", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:LitigationReserveCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "ix:continuation", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-232", "name": "us-gaap:LitigationReserveCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-4", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "unique": true } }, "R70": { "role": "http://www.myriad.com/role/SUPPLEMENTALCASHFLOWINFORMATIONScheduleofSupplementalCashFlowInformationDetails", "longName": "9954513 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION - Schedule of Supplemental Cash Flow Information (Details)", "shortName": "SUPPLEMENTAL CASH FLOW INFORMATION - Schedule of Supplemental Cash Flow Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "70", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxesPaid", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:IncomeTaxesPaid", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } }, "R71": { "role": "http://www.myriad.com/role/SUPPLEMENTALCASHFLOWINFORMATIONScheduleofCashandCashEquivalentsandRestrictedCashDetails", "longName": "9954514 - Disclosure - SUPPLEMENTAL CASH FLOW INFORMATION - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)", "shortName": "SUPPLEMENTAL CASH FLOW INFORMATION - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "71", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:RestrictedCash", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock", "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "unique": true } }, "R72": { "role": "http://www.myriad.com/role/LEASESDetails", "longName": "9954515 - Disclosure - LEASES (Details)", "shortName": "LEASES (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "72", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:OperatingLeaseRightOfUseAsset", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "mygn:OperatingLeaseLiabilityCurrentTerminated", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "unique": true } }, "R73": { "role": "http://www.myriad.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSDetails", "longName": "9954516 - Disclosure - ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Details)", "shortName": "ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "73", "firstAnchor": { "contextRef": "c-60", "name": "us-gaap:StockholdersEquity", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-238", "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "unique": true } }, "R74": { "role": "http://www.myriad.com/role/ACQUISITIONDetails", "longName": "9954517 - Disclosure - ACQUISITION (Details)", "shortName": "ACQUISITION (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "74", "firstAnchor": { "contextRef": "c-1", "name": "mygn:AssetAcquisitionGainLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "td", "tr", "table", "div", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true }, "uniqueAnchor": null }, "R75": { "role": "http://www.myriad.com/role/DIVESTITUREDetails", "longName": "9954518 - Disclosure - DIVESTITURE (Details)", "shortName": "DIVESTITURE (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "75", "firstAnchor": { "contextRef": "c-240", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-240", "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": ["span", "div", "ix:continuation", "body", "html"], "reportCount": 1, "baseRef": "mygn-20240930.htm", "first": true, "unique": true } } }, "tag": { "mygn_ABLFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "ABLFacilityMember", "presentation": ["http://www.myriad.com/role/LONGTERMDEBTDetails"], "lang": { "en-us": { "role": { "terseLabel": "ABL Facility", "label": "ABL Facility [Member]", "documentation": "ABL Facility" } } }, "auth_ref": [] }, "mygn_ABRFloorMember": { "xbrltype": "domainItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "ABRFloorMember", "presentation": ["http://www.myriad.com/role/LONGTERMDEBTDetails"], "lang": { "en-us": { "role": { "terseLabel": "ABR Floor", "label": "ABR Floor [Member]", "documentation": "ABR Floor" } } }, "auth_ref": [] }, "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AOCIAttributableToParentNetOfTaxRollForward", "presentation": ["http://www.myriad.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSDetails"], "lang": { "en-us": { "role": { "terseLabel": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": ["http://www.myriad.com/role/ACCRUEDLIABILITIES"], "lang": { "en-us": { "role": { "terseLabel": "ACCRUED LIABILITIES", "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": ["r79", "r82", "r86", "r1013"] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Accounts payable", "label": "Accounts Payable, Current", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } } }, "auth_ref": ["r79", "r779"] }, "us-gaap_AccountsReceivableMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableMember", "presentation": ["http://www.myriad.com/role/REVENUENarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accounts receivable", "label": "Accounts Receivable [Member]", "documentation": "Due from customers or clients for goods or services that have been delivered or sold." } } }, "auth_ref": ["r712"] }, "us-gaap_AccountsReceivableNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsReceivableNetCurrent", "crdr": "debit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Trade accounts receivable", "label": "Accounts Receivable, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current." } } }, "auth_ref": ["r931"] }, "us-gaap_AccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 }, "http://www.myriad.com/role/ACCRUEDLIABILITIESDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.myriad.com/role/ACCRUEDLIABILITIESDetails", "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Accrued liabilities", "totalLabel": "Total accrued liabilities", "label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r82"] }, "us-gaap_AccruedRoyaltiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedRoyaltiesCurrent", "crdr": "credit", "calculation": { "http://www.myriad.com/role/ACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": ["http://www.myriad.com/role/ACCRUEDLIABILITIESDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accrued royalties", "label": "Accrued Royalties, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r82", "r733"] }, "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": {

```
"http://www.myriad.com/role/PROPERTYPLANTANDEQUIPMENTNETScheduleofPropertyPlantandEquipmentNetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": -1.0, "order": 1.0 } }, "presentation": [
"http://www.myriad.com/role/PROPERTYPLANTANDEQUIPMENTNETScheduleofPropertyPlantandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "Less accumulated depreciation", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services." } } }, "auth_ref": [ "r39", "r163", "r608" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AccumulatedOtherComprehensiveIncomeLossLineItems", "presentation": [ "http://www.myriad.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSDetails",
"http://www.myriad.com/role/OTHERLONGTERMLIABILITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r180", "r181", "r508", "r509", "r510", "r511", "r512", "r513" ] }, "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": {
"http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [
"http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label":
"Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source." } } }, "auth_ref": [ "r22", "r23", "r99", "r169", "r605", "r634", "r635" ] }, "us-
gaap_AccumulatedOtherComprehensiveIncomeLossTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AccumulatedOtherComprehensiveIncomeLossTable", "presentation": [ "http://www.myriad.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSDetails",
"http://www.myriad.com/role/OTHERLONGTERMLIABILITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]", "label": "Accumulated Other Comprehensive Income (Loss) [Table]", "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)." } } }, "auth_ref": [ "r180", "r181", "r508", "r509", "r510", "r511", "r512", "r513" ] }, "us-
gaap_AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AccumulatedOtherComprehensiveIncomeMember", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ],
"lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r2", "r13", "r23", "r467", "r470", "r527", "r630", "r631", "r908", "r909", "r910", "r919", "r920", "r921", "r922" ] }, "us-gaap_AccumulatedTranslationAdjustmentMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AccumulatedTranslationAdjustmentMember", "presentation": [
"http://www.myriad.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accumulated Foreign Currency Adjustment Attributable to Parent", "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]", "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent." } } }, "auth_ref": [ "r3",
"r13", "r23", "r97", "r98", "r181", "r182", "r509", "r510", "r511", "r512", "r513", "r908" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": {
"role": { "terseLabel": "Additional 402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": [ "r844" ] }, "us-
gaap_AdditionalPaidInCapitalCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock",
"crdr": "credit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0,
"order": 1.0 } }, "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": [ "r91" ] }, "us-gaap_AdditionalPaidInCapitalMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [
"http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital",
"label": "Additional Paid-in Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r643", "r919", "r920", "r921", "r922", "r1018", "r1083" ] }, "ecd_AdjToCompAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": {
"role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": [ "r857" ] }, "ecd_AdjToCompAxis": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": {
"en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } }, "auth_ref": [ "r857" ] },
"ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote", "label":
"Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": [ "r857" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": {
"terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO Compensation, Footnote [Text Block]" } } }, "auth_ref": [ "r857" ] }, "us-
gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit",
"presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": [ "r47", "r48", "r401" ] }, "us-
gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [
"http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] },
"ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel":
"Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": [ "r890" ] }, "ecd_AggtErrCompAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": {
"en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r816", "r826",
"r836", "r868" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": [ "r819", "r829", "r839",
"r871" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember",
"presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate Pension Adjustments Service Cost [Member]" } } }, "auth_ref": [ "r891" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel":
"All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": [ "r857" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ],
"lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": [ "r864" ] }, "ecd_AllIndividualsMember": {
"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": [ "r820", "r830",
"r840", "r864", "r872", "r876", "r884" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "All Trading Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": [ "r882" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.myriad.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] },
"us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr":
"debit", "presentation": [ "http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofRecordedAmortizationExpenseforIntangibleAssetsDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Amortization of intangible assets", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [
"r10", "r291", "r298", "r743" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [
"http://www.myriad.com/role/PREFERREDANDCOMMONSTOCKHOLDERSEQUITYScheduleofPotentialDilutiveCommonSharesDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Anti-dilutive options and RSUs excluded from EPS computation (shares)", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r219" ] }, "us-gaap_AreaOfRealEstateProperty": { "xbrltype": "areaItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AreaOfRealEstateProperty", "presentation": [ "http://www.myriad.com/role/LEASESDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Area of real estate property", "label": "Area of Real Estate Property", "documentation": "Area of a real estate property." } } }, "auth_ref": [] },
"mygn_AssetAcquisitionGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "AssetAcquisitionGainLoss", "crdr": "credit",
"calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-
gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 18.0 } }, "presentation": [ "http://www.myriad.com/role/ACQUISITIONDetails",
"http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gain on acquisition",
"terseLabel": "Gain on acquisition", "label": "Asset Acquisition, Gain (Loss)", "documentation": "Asset Acquisition, Gain (Loss)" } } }, "auth_ref": [] }, "us-
gaap_AssetAcquisitionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionTextBlock", "presentation": [
"http://www.myriad.com/role/ACQUISITION" ], "lang": { "en-us": { "role": { "terseLabel": "ACQUISITION", "label": "Asset Acquisition [Text Block]", "documentation": "The entire disclosure for asset acquisition." } } }, "auth_ref": [ "r1016" ] }, "us-gaap_AssetImpairmentCharges": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetImpairmentCharges", "crdr": "debit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited":
{ "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 16.0 } }, "presentation": [
"http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "verboseLabel": "Impairment of goodwill and long-lived assets", "label": "Asset Impairment Charges", "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill." } } }, "auth_ref": [ "r10", "r37" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-
```

gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r135", "r147", "r167", "r195", "r221", "r223", "r230", "r231", "r270", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r462", "r464", "r502", "r602", "r670", "r737", "r738", "r779", "r807", "r978", "r979", "r1037"] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": ["http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrent", "crdr": "debit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total current assets", "label": "Assets, Current", "documentation": "Amount of asset recognized for present right to economic benefit, classified as current." } } }, "auth_ref": ["r159", "r171", "r195", "r270", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r462", "r464", "r502", "r779", "r978", "r979", "r1037"] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": ["http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Current assets:", "label": "Assets, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.myriad.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueofFinancialAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_FairValueNetAssetLiability", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.myriad.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueofFinancialAssetsandLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Financial assets", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": ["r478", "r479", "r767"] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIESScheduleofFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": -1.0, "order": 1.0 } }, "presentation": ["http://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIESScheduleofFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Gross unrealized holding gains", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r243"] }, "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIESScheduleofFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIESScheduleofFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross unrealized holding losses", "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r244"] }, "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis", "crdr": "debit", "calculation": { "http://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIESScheduleofFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIESScheduleofFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"], "lang": { "en-us": { "role": { "totalLabel": "Amortized cost", "label": "Debt Securities, Available-for-Sale, Amortized Cost", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r240", "r279", "r601"] }, "us-gaap_AvailableForSaleSecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesAbstract", "presentation": ["http://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIESScheduleofFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Available-for-sale:", "label": "Debt Securities, Available-for-Sale [Abstract]" } } }, "auth_ref": [] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "http://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIESScheduleofFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": { "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIESNarrativeDetails", "http://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIESScheduleofFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Estimated fair value", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r241", "r279", "r478", "r595", "r767", "r771", "r932", "r1022", "r1023", "r1024"] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": ["r879"] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": ["r880"] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": ["r875"] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": ["r875"] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Method", "label": "Award Timing Method [Text Block]" } } }, "auth_ref": ["r875"] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Considered", "label": "Award Timing MNPI Considered [Flag]" } } }, "auth_ref": ["r875"] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing MNPI Disclosure", "label": "Award Timing MNPI Disclosure [Text Block]" } } }, "auth_ref": ["r875"] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Timing Predetermined", "label": "Award Timing Predetermined [Flag]" } } }, "auth_ref": ["r875"] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": ["http://www.myriad.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Axis]", "label": "Award Type [Axis]", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": ["r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429"] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount" } } }, "auth_ref": ["r878"] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name" } } }, "auth_ref": ["r877"] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures [Table]" } } }, "auth_ref": ["r876"] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]" } } }, "auth_ref": ["r876"] }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccountingPolicyPolicyTextBlock", "presentation": ["http://www.myriad.com/role/BASISOFPRESENTATIONPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Basis of Presentation", "label": "Basis of Accounting, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [] }, "us-gaap_BusinessAcquisitionAcquireeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAcquireeDomain", "presentation": ["http://www.myriad.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition, Acquiree [Domain]", "label": "Business Acquisition, Acquiree [Domain]", "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree." } } }, "auth_ref": ["r292", "r293", "r294", "r295", "r296", "r458", "r762", "r763"] }, "us-gaap_BusinessAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessAcquisitionAxis", "presentation": ["http://www.myriad.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Business Acquisition [Axis]", "label": "Business Acquisition [Axis]", "documentation": "Information by business combination or series of individually immaterial business combinations." } } }, "auth_ref": ["r49", "r50", "r292", "r293", "r294", "r295", "r296", "r458", "r762", "r763"] }, "us-gaap_BusinessCombinationAndAssetAcquisitionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationAndAssetAcquisitionAbstract", "lang": { "en-us": { "role": { "label": "Business Combination, Asset Acquisition, and Joint Venture Formation [Abstract]" } } }, "auth_ref": [] }, "us-gaap_BusinessCombinationContingentConsiderationLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiability", "crdr": "credit", "presentation": ["http://www.myriad.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration liability", "label": "Business Combination, Contingent Consideration, Liability", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination." } } }, "auth_ref": ["r53", "r130", "r459", "r480", "r481", "r482"] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.myriad.com/role/ACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 8.0 } }, "presentation": ["http://www.myriad.com/role/ACCRUEDLIABILITIESDetails"], "lang": { "en-us": { "role": { "terseLabel": "Short-term contingent consideration", "label": "Business Combination, Contingent Consideration, Liability, Current", "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r53", "r130"] }, "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.myriad.com/role/OTHERLONGTERMLIABILITIESScheduleofOtherLongTermLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.myriad.com/role/OTHERLONGTERMLIABILITIESScheduleofOtherLongTermLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration", "label": "Business Combination, Contingent Consideration, Liability, Noncurrent", "documentation": "Amount of liability recognized

arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r53", "r130"] }, "us-gaap_CapitalizedContractCostGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalizedContractCostGross", "crdr": "debit", "presentation": ["http://www.myriad.com/role/REVENUENarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Capitalized costs incurred to obtain or fulfill contract", "label": "Capitalized Contract Cost, Gross", "documentation": "Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer." } } }, "auth_ref": ["r939"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://www.myriad.com/role/SUPPLEMENTALCASHFLOWINFORMATIONScheduleofCashandCashEquivalentsandRestrictedCashDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 1.0 }, "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0 }, "http://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIESScheduleofFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited", "http://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIESScheduleofFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails", "http://www.myriad.com/role/SUPPLEMENTALCASHFLOWINFORMATIONScheduleofCashandCashEquivalentsandRestrictedCashDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents", "totalLabel": "Cash and cash equivalents", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": ["r29", "r161", "r730"] }, "us-gaap_CashAndCashEquivalentsAtCarryingValueAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValueAbstract", "presentation": ["http://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIESScheduleofFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash and cash equivalents:", "label": "Cash and Cash Equivalents, at Carrying Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashAndCashEquivalentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAxis", "presentation": ["http://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIESScheduleofFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Axis]", "label": "Cash and Cash Equivalents [Axis]", "documentation": "Information by type of cash and cash equivalent balance." } } }, "auth_ref": ["r161"] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIESScheduleofFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": { "parentTag": "us-gaap_CashAndCashEquivalentsAtCarryingValue", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIESScheduleofFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Estimated fair value", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r1020", "r1021"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.myriad.com/role/SUPPLEMENTALCASHFLOWINFORMATIONScheduleofCashandCashEquivalentsandRestrictedCashDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.myriad.com/role/SUPPLEMENTALCASHFLOWINFORMATIONScheduleofCashandCashEquivalentsandRestrictedCashDetails"], "lang": { "en-us": { "role": { "periodStartLabel": "Cash, cash equivalents, and restricted cash at beginning of the period", "periodEndLabel": "Cash, cash equivalents, and restricted cash at end of the period", "totalLabel": "Total cash, cash equivalents, and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r29", "r112", "r192"] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "totalLabel": "Net (decrease) increase in cash, cash equivalents, and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r0", "r112"] }, "us-gaap_CashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashEquivalentsMember", "presentation": ["http://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIESScheduleofFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash equivalents", "label": "Cash Equivalents [Member]", "documentation": "Short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r161"] }, "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowOperatingActivitiesLesseeAbstract", "presentation": ["http://www.myriad.com/role/SUPPLEMENTALCASHFLOWINFORMATIONScheduleofSupplementalCashFlowInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Change in operating lease right-of-use assets and lease liabilities", "label": "Cash Flow, Operating Activities, Lessee [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CashFlowSupplementalDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowSupplementalDisclosuresTextBlock", "presentation": ["http://www.myriad.com/role/SUPPLEMENTALCASHFLOWINFORMATION"], "lang": { "en-us": { "role": { "terseLabel": "SUPPLEMENTAL CASH FLOW INFORMATION", "label": "Cash Flow, Supplemental Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental cash flow activities, including cash, noncash, and part noncash transactions, for the period. Noncash is defined as information about all investing and financing activities of an enterprise during a period that affect recognized assets or liabilities but that do not result in cash receipts or cash payments in the period.\"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period." } } }, "auth_ref": ["r108"] }, "us-gaap_CashMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashMember", "presentation": ["http://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIESScheduleofFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash", "label": "Cash [Member]", "documentation": "Currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits." } } }, "auth_ref": ["r161"] }, "mygn_ChangeInOperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "ChangeInOperatingLeaseLiability", "crdr": "credit", "presentation": ["http://www.myriad.com/role/SUPPLEMENTALCASHFLOWINFORMATIONScheduleofSupplementalCashFlowInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liabilities", "label": "Change In Operating Lease Liability", "documentation": "Change In Operating Lease Liability" } } }, "auth_ref": [] }, "mygn_ChangeInOperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "ChangeInOperatingLeaseRightOfUseAsset", "crdr": "debit", "presentation": ["http://www.myriad.com/role/SUPPLEMENTALCASHFLOWINFORMATIONScheduleofSupplementalCashFlowInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Change In Operating Lease, Right-Of-Use Asset", "documentation": "Change In Operating Lease, Right-Of-Use Asset" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote [Text Block]" } } }, "auth_ref": ["r855"] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]" } } }, "auth_ref": ["r852"] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]" } } }, "auth_ref": ["r850"] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": ["http://www.myriad.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount" } } }, "auth_ref": ["r856"] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Company Selected Measure Name", "label": "Company Selected Measure Name" } } }, "auth_ref": ["r856"] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": ["r87", "r139", "r603", "r657"] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": ["http://www.myriad.com/role/COMMITMENTSANDCONTINGENCIES"], "lang": { "en-us": { "role": { "terseLabel": "COMMITMENTS AND CONTINGENCIES", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": ["r122", "r310", "r311", "r713", "r965", "r970"] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": ["http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Common stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": ["r798", "r799", "r800", "r802", "r803", "r804", "r805", "r919", "r920", "r922", "r1018", "r1082", "r1083"] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": ["http://www.myriad.com/role/PREFERREDANDCOMMONSTOCKHOLDERSEQUITYNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [

```
"r90" ] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://www.myriad.com/role/PREFERREDANDCOMMONSTOCKHOLDERSEQUITYNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock authorized (shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r90", "r658" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://www.myriad.com/role/PREFERREDANDCOMMONSTOCKHOLDERSEQUITYNarrativeDetails",
"http://www.myriad.com/role/PREFERREDANDCOMMONSTOCKHOLDERSEQUITYScheduleofCommonStockIssuedandOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock issued (shares)", "periodStartLabel": "Beginning common stock issued (shares)", "periodEndLabel": "Ending common stock issued (shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r90" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunauditedParenthetical",
"http://www.myriad.com/role/PREFERREDANDCOMMONSTOCKHOLDERSEQUITYNarrativeDetails",
"http://www.myriad.com/role/PREFERREDANDCOMMONSTOCKHOLDERSEQUITYScheduleofCommonStockIssuedandOutstandingDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (shares)", "verboseLabel": "Common stock outstanding (shares)", "periodStartLabel": "Beginning common stock outstanding (shares)", "periodEndLabel": "Ending common stock outstanding (shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r14", "r90", "r658", "r676", "r1083", "r1084" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Common stock, 91.0 and 89.9 shares outstanding at September\u00a030, 2024 and December\u00a031, 2023, respectively", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r90", "r604", "r779" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": [ "r861" ] },
"ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": [ "r860" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": [ "r862" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": [ "r859" ] }, "us-gaap_ComprehensiveIncomeNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTax", "crdr": "credit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [
"http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": [ "r24", "r177", "r179", "r184", "r597", "r615", "r616" ] }, "us-gaap_ComprehensiveIncomeNoteTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNoteTextBlock", "presentation": [
"http://www.myriad.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSS" ], "lang": { "en-us": { "role": { "terseLabel": "ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS)", "label": "Comprehensive Income (Loss) Note [Text Block]", "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income." } } }, "auth_ref": [ "r96", "r183", "r596", "r613" ] }, "mygn_ComputerSoftwareInProcessIntangibleAssetMember": { "xbrltype": "domainItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "ComputerSoftwareInProcessIntangibleAssetMember", "presentation": [
"http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Internal-use software (in-process)", "label": "Computer Software, In-Process, Intangible Asset [Member]", "documentation": "Computer Software, In-Process, Intangible Asset" } } }, "auth_ref": [] }, "us-gaap_ComputerSoftwareIntangibleAssetMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComputerSoftwareIntangibleAssetMember", "presentation": [ "http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Internal-use software", "label": "Computer Software, Intangible Asset [Member]", "documentation": "Collection of computer programs and related data that provide instructions to a computer, for example, but not limited to, application program, control module or operating system, that perform one or more particular functions or tasks." } } }, "auth_ref": [ "r725", "r729", "r953", "r954", "r955", "r956", "r958", "r960", "r962", "r963" ] }, "us-gaap_ConcentrationRiskBenchmarkDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskBenchmarkDomain", "presentation": [ "http://www.myriad.com/role/REVENUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Domain]", "label": "Concentration Risk Benchmark [Domain]", "documentation": "The denominator in a calculation of a disclosed concentration risk percentage." } } }, "auth_ref": [ "r34", "r35", "r56", "r57", "r235", "r712" ] }, "us-gaap_ConcentrationRiskByBenchmarkAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByBenchmarkAxis", "presentation": [ "http://www.myriad.com/role/REVENUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Benchmark [Axis]", "label": "Concentration Risk Benchmark [Axis]", "documentation": "Information by benchmark of concentration risk." } } }, "auth_ref": [ "r34", "r35", "r56", "r57", "r235", "r637", "r712" ] }, "us-gaap_ConcentrationRiskByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskByTypeAxis", "presentation": [ "http://www.myriad.com/role/REVENUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Axis]", "label": "Concentration Risk Type [Axis]", "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender." } } }, "auth_ref": [ "r34", "r35", "r56", "r57", "r235", "r712", "r895" ] }, "us-gaap_ConcentrationRiskCreditRisk": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskCreditRisk", "presentation": [
"http://www.myriad.com/role/BASISOFPRESENTATIONPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration of Credit Risk", "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for credit risk." } } }, "auth_ref": [ "r60", "r149" ] }, "us-gaap_ConcentrationRiskLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskLineItems", "presentation": [
"http://www.myriad.com/role/REVENUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue and Concentration Risk [Line Items]", "label": "Concentration Risk [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r712" ] }, "us-gaap_ConcentrationRiskPercentage1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskPercentage1", "presentation": [ "http://www.myriad.com/role/REVENUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration risk (percent)", "label": "Concentration Risk, Percentage", "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division." } } }, "auth_ref": [ "r34", "r35", "r56", "r57", "r235" ] }, "us-gaap_ConcentrationRiskTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTable", "presentation": [ "http://www.myriad.com/role/REVENUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk [Table]", "label": "Concentration Risk [Table]", "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk." } } }, "auth_ref": [ "r33", "r34", "r35", "r36", "r56", "r133", "r712" ] }, "us-gaap_ConcentrationRiskTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConcentrationRiskTypeDomain", "presentation": [ "http://www.myriad.com/role/REVENUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Concentration Risk Type [Domain]", "label": "Concentration Risk Type [Domain]", "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration." } } }, "auth_ref": [ "r34", "r35", "r56", "r57", "r235", "r712" ] }, "us-gaap_ContingentConsiderationByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContingentConsiderationByTypeAxis", "presentation": [
"http://www.myriad.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 3", "label": "Contingent Consideration by Type [Axis]", "documentation": "Information by type of contingent consideration." } } }, "auth_ref": [] },
"mygn_ContingentConsiderationMember": { "xbrltype": "domainItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "ContingentConsiderationMember", "presentation": [ "http://www.myriad.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent consideration", "label": "Contingent Consideration [Member]", "documentation": "Contingent consideration." } } }, "auth_ref": [] }, "us-gaap_ContingentConsiderationTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContingentConsiderationTypeDomain", "presentation": [ "http://www.myriad.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Contingent Consideration Type [Domain]", "label": "Contingent Consideration Type [Domain]", "documentation": "Description of contingent payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice", "crdr": "credit", "presentation": [
"http://www.myriad.com/role/REVENUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognized", "label": "Contract with Customer, Asset, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price", "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which increases (decreases) right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained." } } }, "auth_ref": [ "r751" ] }, "us-gaap_ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"ContractWithCustomerAssetCumulativeCatchUpAdjustmentToRevenueModificationOfContract", "crdr": "credit", "presentation": [
"http://www.myriad.com/role/REVENUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Revenue recognized due to retroactive coverage change", "label": "Contract with Customer, Asset, Cumulative Catch-up Adjustment to Revenue, Modification of Contract", "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from contract modification which increases (decreases) right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time." } } }, "auth_ref": [ "r751" ] }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateDebtSecuritiesMember", "presentation": [
"http://www.myriad.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueofFinancialAssetsandLiabilitiesDetails",
"http://www.myriad.com/role/MARKETABLEINVESTMENTSSECURITIESScheduleofFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Corporate bonds and notes", "verboseLabel": "Corporate bonds and notes", "label": "Corporate Debt Securities [Member]", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment." } } }, "auth_ref": [ "r759", "r761", "r767", "r780", "r796", "r1079" ] }, "us-gaap_CostOfGoodsAndServicesSold": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfGoodsAndServicesSold", "crdr": "debit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunaudited": { "parentTag": "us-
```

gaap_CostsAndExpenses", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Cost of testing revenue", "label": "Cost of Goods and Services Sold", "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities." } } }, "auth_ref": ["r101", "r102", "r560"] }, "us-gaap_CostOfSalesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostOfSalesMember", "presentation": [
"http://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cost of testing revenue", "label": "Cost of Sales [Member]", "documentation": "Primary financial statement caption encompassing cost of sales." } } }, "auth_ref": [] }, "us-gaap_CostsAndExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CostsAndExpenses", "crdr": "debit", "calculation": {
"http://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total costs and expenses", "label": "Costs and Expenses", "documentation": "Total costs of sales and operating expenses for the period." } } }, "auth_ref": ["r107"] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "us-gaap_CreditFacilityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": ["http://www.myriad.com/role/LONGTERMDEBTDetails"], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Axis]", "label": "Credit Facility [Axis]", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r319", "r976"] }, "us-gaap_CreditFacilityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": ["http://www.myriad.com/role/LONGTERMDEBTDetails"], "lang": { "en-us": { "role": { "terseLabel": "Credit Facility [Domain]", "label": "Credit Facility [Domain]", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing." } } }, "auth_ref": ["r319", "r976", "r977"] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": ["http://www.myriad.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Current Fiscal Year End Date", "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "us-gaap_CustomerConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerConcentrationRiskMember", "presentation": ["http://www.myriad.com/role/REVENUENarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Customer concentration", "label": "Customer Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer." } } }, "auth_ref": ["r116", "r235"] }, "us-gaap_CustomerRelationshipsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CustomerRelationshipsMember", "presentation": ["http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Customer relationships", "label": "Customer Relationships [Member]", "documentation": "Customer relationship that exists between an entity and its customer, for example, but not limited to, tenant relationships." } } }, "auth_ref": ["r52", "r953", "r954", "r955", "r956", "r958", "r960", "r962", "r963"] }, "us-gaap_DebtDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureAbstract", "lang": { "en-us": { "role": {
"terseLabel": "Debt Disclosure [Abstract]", "label": "Debt Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DebtDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtDisclosureTextBlock", "presentation": ["http://www.myriad.com/role/LONGTERMDEBT"], "lang": { "en-us": { "role": { "terseLabel": "LONG-TERM DEBT", "label": "Debt Disclosure [Text Block]", "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants." } } }, "auth_ref": ["r123", "r193", "r303", "r304", "r305", "r306", "r307", "r318", "r319", "r329", "r335", "r336", "r337", "r338", "r339", "r340", "r345", "r352", "r353", "r355", "r514"] }, "us-gaap_DebtInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": ["http://www.myriad.com/role/LONGTERMDEBTDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Axis]", "label": "Debt Instrument [Axis]", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities." } } }, "auth_ref": ["r20", "r81", "r82", "r136", "r138", "r197", "r330", "r331", "r332", "r333", "r334", "r336", "r341", "r342", "r343", "r344", "r346", "r347", "r348", "r349", "r350", "r351", "r745", "r746", "r747", "r748", "r749", "r778", "r917", "r966", "r967", "r968", "r1032", "r1033"] }, "us-gaap_DebtInstrumentBasisSpreadOnVariableRate1": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentBasisSpreadOnVariableRate1", "presentation": ["http://www.myriad.com/role/LONGTERMDEBTDetails"], "lang": { "en-us": { "role": { "terseLabel": "Basis spread on rate (percent)", "label": "Debt Instrument, Basis Spread on Variable Rate", "documentation": "Percentage points added to the reference rate to compute the variable rate on the debt instrument." } } }, "auth_ref": [] }, "mygn_DebtInstrumentCovenantAvailabilityAmountMinimum": { "xbrltype": "monetaryItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "DebtInstrumentCovenantAvailabilityAmountMinimum", "crdr": "debit", "presentation": [
"http://www.myriad.com/role/LONGTERMDEBTDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, covenant, availability amount, minimum", "label": "Debt Instrument, Covenant, Availability Amount, Minimum", "documentation": "Debt Instrument, Covenant, Availability Amount, Minimum" } } }, "auth_ref": [] }, "mygn_DebtInstrumentCovenantFixedChargeRatioMinimum": { "xbrltype": "pureItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "DebtInstrumentCovenantFixedChargeRatioMinimum", "presentation": ["http://www.myriad.com/role/LONGTERMDEBTDetails"], "lang": { "en-us": { "role": { "terseLabel": "Fixed charge ratio, minimum", "label": "Debt Instrument, Covenant, Fixed Charge Ratio, Minimum", "documentation": "Debt Instrument, Covenant, Fixed Charge Ratio, Minimum" } } }, "auth_ref": [] }, "mygn_DebtInstrumentCovenantLiquidityAmountMinimum": { "xbrltype": "monetaryItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "DebtInstrumentCovenantLiquidityAmountMinimum", "crdr": "debit", "presentation": ["http://www.myriad.com/role/LONGTERMDEBTDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, covenant, liquidity amount, minimum", "label": "Debt Instrument, Covenant, Liquidity Amount, Minimum", "documentation": "Debt Instrument, Covenant, Liquidity Amount, Minimum" } } }, "auth_ref": [] },
"mygn_DebtInstrumentDebtDefaultAvailabilityThresholdPercentageOfMaximumCommitmentAmount": { "xbrltype": "percentItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "DebtInstrumentDebtDefaultAvailabilityThresholdPercentageOfMaximumCommitmentAmount", "presentation": ["http://www.myriad.com/role/LONGTERMDEBTDetails"], "lang": { "en-us": { "role": { "terseLabel": "Availability threshold, percentage of maximum commitment amount", "label": "Debt Instrument, Debt Default, Availability Threshold, Percentage Of Maximum Commitment Amount", "documentation": "Debt Instrument, Debt Default, Availability Threshold, Percentage Of Maximum Commitment Amount" } } }, "auth_ref": [] }, "mygn_DebtInstrumentFloorPercentage": { "xbrltype": "percentItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "DebtInstrumentFloorPercentage", "presentation": ["http://www.myriad.com/role/LONGTERMDEBTDetails"], "lang": { "en-us": { "role": { "terseLabel": "SOFR floor (percent)", "label": "Debt Instrument, Floor Percentage", "documentation": "Debt Instrument, Floor Percentage" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentLineItems", "presentation": [
"http://www.myriad.com/role/LONGTERMDEBTDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument [Line Items]", "label": "Debt Instrument [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r197", "r330", "r331", "r332", "r333", "r334", "r336", "r341", "r342", "r343", "r344", "r346", "r347", "r348", "r349", "r350", "r351", "r354", "r745", "r746", "r747", "r748", "r749", "r778", "r917", "r1032", "r1033"] }, "mygn_DebtInstrumentMaximumAmountBorrowingBasePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "DebtInstrumentMaximumAmountBorrowingBasePeriod", "presentation": [
"http://www.myriad.com/role/LONGTERMDEBTDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt instrument, maximum amount borrowing base period", "label": "Debt Instrument, Maximum Amount Borrowing Base Period", "documentation": "Debt Instrument, Maximum Amount Borrowing Base Period" } } }, "auth_ref": [] }, "us-gaap_DebtInstrumentNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": [
"http://www.myriad.com/role/LONGTERMDEBTDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Instrument, Name [Domain]", "label": "Debt Instrument, Name [Domain]", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities." } } }, "auth_ref": ["r20", "r197", "r330", "r331", "r332", "r333", "r334", "r336", "r341", "r342", "r343", "r344", "r346", "r347", "r348", "r349", "r350", "r351", "r745", "r746", "r747", "r748", "r749", "r778", "r917", "r966", "r967", "r968", "r1032", "r1033"] }, "us-gaap_DebtInstrumentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTable", "presentation": ["http://www.myriad.com/role/LONGTERMDEBTDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Long-term Debt Instruments [Table]", "label": "Schedule of Long-Term Debt Instruments [Table]", "documentation": "Disclosure of information about long-term debt instrument or arrangement." } } }, "auth_ref": ["r20", "r41", "r42", "r59", "r125", "r126", "r197", "r330", "r331", "r332", "r333", "r334", "r336", "r341", "r342", "r343", "r344", "r346", "r347", "r348", "r349", "r350", "r351", "r354", "r745", "r746", "r747", "r748", "r749", "r778", "r917", "r1032", "r1033"] }, "us-gaap_DebtSecuritiesAvailableForSaleTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleTable", "presentation": [
"http://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIESScheduleofFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt Securities, Available-for-Sale [Table]", "label": "Debt Securities, Available-for-Sale [Table]", "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)." } } }, "auth_ref": ["r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250"] }, "us-gaap_DebtWeightedAverageInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtWeightedAverageInterestRate", "presentation": [
"http://www.myriad.com/role/LONGTERMDEBTDetails"], "lang": { "en-us": { "role": { "terseLabel": "Interest rate, weighted average percentage", "label": "Debt, Weighted Average Interest Rate", "documentation": "Weighted average interest rate of debt outstanding." } } }, "auth_ref": [] }, "us-gaap_DeferredFinanceCostsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredFinanceCostsNet", "crdr": "debit", "presentation": [
"http://www.myriad.com/role/LONGTERMDEBTDetails"], "lang": { "en-us": { "role": { "terseLabel": "Debt issuance costs", "label": "Debt Issuance Costs, Net", "documentation": "Amount, after accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs." } } }, "auth_ref": ["r981", "r1031", "r1032", "r1033"] }, "us-gaap_DeferredIncomeTaxesAndTaxCredits": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredIncomeTaxesAndTaxCredits", "crdr": "debit", "calculation": {
"http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 14.0 } }, "presentation": ["http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "verboseLabel": "Deferred income taxes", "label": "Deferred Income Taxes and Tax Credits", "documentation": "Amount of deferred income tax expense (benefit) and income tax credits." } } }, "auth_ref": ["r115"] }, "us-gaap_Depreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Depreciation", "crdr": "debit", "presentation": ["http://www.myriad.com/role/PROPERTYPLANTANDEQUIPMENTNETScheduleofDepreciationExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Depreciation expense", "label": "Depreciation", "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation." } } }, "auth_ref": ["r10", "r38"] }, "us-gaap_DepreciationAndAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": {
"http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": ["http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization, Nonproduction", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production." } } }, "auth_ref": ["r10", "r38"] }, "us-gaap_DevelopedTechnologyRightsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DevelopedTechnologyRightsMember", "presentation": ["http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails",
"http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Developed technologies", "label": "Developed Technology Rights [Member]", "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property." } } }, "auth_ref": ["r129", "r953", "r954", "r955", "r956", "r958", "r960", "r962", "r963"] }, "us-gaap_DisaggregationOfRevenueLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": ["http://www.myriad.com/role/REVENUEScheduleofTotalRevenuebyTypeandbyUSversusRestofWorldDetails"], "lang": { "en-us": { "role": { "terseLabel":

"Disaggregation of Revenue [Line Items]", "label": "Disaggregation of Revenue [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r389", "r752", "r753", "r754", "r755", "r756", "r757", "r758"] }, "us-gaap_DisaggregationOfRevenueTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTable", "presentation": ["http://www.myriad.com/role/REVENUEScheduleofTotalRevenuebyTypeandbyUSversusRestofWorldDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disaggregation of Revenue [Table]", "label": "Disaggregation of Revenue [Table]", "documentation": "Disclosure of information about disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r389", "r752", "r753", "r754", "r755", "r756", "r757", "r758"] }, "us-gaap_DisaggregationOfRevenueTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueTableTextBlock", "presentation": ["http://www.myriad.com/role/REVENUETables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Total Revenue by Type and by U.S versus Rest of World", "label": "Disaggregation of Revenue [Table Text Block]", "documentation": "Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor." } } }, "auth_ref": ["r982"] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": ["http://www.myriad.com/role/STOCKBASEDCOMPENSATION"], "lang": { "en-us": { "role": { "terseLabel": "STOCK-BASED COMPENSATION", "label": "Share-Based Payment Arrangement [Text Block]", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": ["r399", "r403", "r431", "r432", "r434", "r765"] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement [Abstract]", "label": "Share-Based Payment Arrangement [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsAndDisposalGroupsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations and Disposal Groups [Abstract]", "label": "Discontinued Operations and Disposal Groups [Abstract]" } } }, "auth_ref": [] }, "us-gaap_DiscontinuedOperationsDisposedOfBySaleMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DiscontinuedOperationsDisposedOfBySaleMember", "presentation": ["http://www.myriad.com/role/DIVESTITUREDetails", "http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Discontinued Operations, Disposed of by Sale", "label": "Discontinued Operations, Disposed of by Sale [Member]", "documentation": "Component or group of components representing strategic shift that has or will have major effect on operation and financial result, disposed of by sale." } } }, "auth_ref": ["r7"] }, "us-gaap_DisposalGroupClassificationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationAxis", "presentation": ["http://www.myriad.com/role/DIVESTITUREDetails", "http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Axis]", "label": "Disposal Group Classification [Axis]", "documentation": "Information by disposal group classification." } } }, "auth_ref": ["r157"] }, "us-gaap_DisposalGroupClassificationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupClassificationDomain", "presentation": ["http://www.myriad.com/role/DIVESTITUREDetails", "http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Classification [Domain]", "label": "Disposal Group Classification [Domain]", "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration", "crdr": "debit", "presentation": ["http://www.myriad.com/role/DIVESTITUREDetails"], "lang": { "en-us": { "role": { "terseLabel": "Sale of business for net cash consideration", "label": "Disposal Group, Including Discontinued Operation, Consideration", "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation." } } }, "auth_ref": [] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationForeignCurrencyTranslationGainsLosses", "crdr": "credit", "presentation": ["http://www.myriad.com/role/DIVESTITUREDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Foreign currency translation", "label": "Disposal Group, Including Discontinued Operation, Foreign Currency Translation Gains (Losses)", "documentation": "Amount of foreign currency translation gain (loss) in the disposal group, including discontinued operation, recognized in the statement of income as a result of the sale or complete or substantially complete liquidation of an investment in a foreign entity." } } }, "auth_ref": ["r58"] }, "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssets", "crdr": "debit", "presentation": ["http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Intangible, net", "label": "Disposal Group, Including Discontinued Operation, Intangible Assets", "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of." } } }, "auth_ref": ["r1", "r63", "r74", "r120"] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsDisclosureTextBlock", "presentation": ["http://www.myriad.com/role/DIVESTITURE"], "lang": { "en-us": { "role": { "terseLabel": "DIVESTITURE", "label": "Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]", "documentation": "The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } }, "auth_ref": ["r62", "r118"] }, "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain", "presentation": ["http://www.myriad.com/role/DIVESTITUREDetails", "http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Disposal Group Name [Domain]", "label": "Disposal Group Name [Domain]", "documentation": "Name of disposal group." } } }, "auth_ref": ["r762", "r763"] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": ["http://www.myriad.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Period Focus", "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": ["http://www.myriad.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Fiscal Year Focus", "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": ["http://www.myriad.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported, for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": ["http://www.myriad.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": ["r811"] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": ["http://www.myriad.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": ["r843"] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": ["http://www.myriad.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]" } } }, "auth_ref": ["r854"] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": ["http://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Basic (dollars per share)", "label": "Earnings Per Share, Basic", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": ["r185", "r203", "r204", "r205", "r206", "r207", "r208", "r212", "r214", "r216", "r217", "r218", "r220", "r456", "r461", "r475", "r476", "r598", "r617", "r734"] }, "mygn_EarningsPerShareBasicAndDilutedEPSAbstract": { "xbrltype": "stringItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "EarningsPerShareBasicAndDilutedEPSAbstract", "presentation": ["http://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Net loss per share:", "label": "Earnings Per Share, Basic And Diluted EPS [Abstract]", "documentation": "Earnings Per Share, Basic And Diluted EPS" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": ["http://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Diluted (dollars per share)", "label": "Earnings Per Share, Diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": ["r185", "r203", "r204", "r205", "r206", "r207", "r208", "r214", "r216", "r217", "r218", "r220", "r456", "r461", "r475", "r476", "r598", "r617", "r734"] }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Effect of foreign exchange rates on cash, cash equivalents, and restricted cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r505"] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "presentation": ["http://www.myriad.com/role/INCOMETAXESDetails"], "lang": { "en-us": { "role": { "terseLabel": "Approximate tax rate", "label": "Effective Income Tax Rate Reconciliation, Percent", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": ["r439", "r766"] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.myriad.com/role/ACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.myriad.com/role/ACCRUEDLIABILITIESDetails"], "lang": { "en-us": { "role": { "terseLabel": "Employee compensation and benefits", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": ["r82"] }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": ["http://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation Expense [Line Items]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype":

"durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [
"http://www.myriad.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Weighted-average period for recognition (in
years)", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over
which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D'
represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r433"] }, "us-
gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation":
["http://www.myriad.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized stock-based compensation expense
related to RSUs", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to
be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": ["r1011"] }, "us-
gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr":
"debit", "presentation": ["http://www.myriad.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized stock-based
compensation expense related to stock options", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation":
"Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": ["r1011"] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Employee Stock Option", "label": "Share-Based Payment Arrangement,
Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of
shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "mygn_EmployeeStockPurchasePlanTwentyTwelveMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.myriad.com/20240930", "localname": "EmployeeStockPurchasePlanTwentyTwelveMember", "presentation": [
"http://www.myriad.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
"http://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofShareBasedCompensationEmployeeStockPurchasePlanActivityDetails"], "lang": { "en-us": { "role": {
"terseLabel": "2012 Purchase Plan", "label": "Employee Stock Purchase Plan Twenty Twelve [Member]", "documentation": "Employee Stock Purchase Plan Twenty Twelve
[Member]" } } }, "auth_ref": [] }, "mygn_EndoPredictMember": { "xbrltype": "domainItemType", "nsuri": "http://www.myriad.com/20240930", "localname":
"EndoPredictMember", "presentation": ["http://www.myriad.com/role/DIVESTITUREDetails",
"http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "EndoPredict", "label": "EndoPredict
[Member]", "documentation": "EndoPredict" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": ["http://www.myriad.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel":
"Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } },
"auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown",
"presentation": ["http://www.myriad.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town",
"documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": ["http://www.myriad.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel":
"Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] },
"dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince",
"presentation": ["http://www.myriad.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or
Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": ["http://www.myriad.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity
Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is
commonly abbreviated as CIK." } } }, "auth_ref": ["r809"] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": ["http://www.myriad.com/role/Cover"], "lang": { "en-us": { "role": {
"verboseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other
units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple
classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest
[Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType",
"nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": ["http://www.myriad.com/role/Cover"], "lang": { "en-us": { "role": {
"terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all
reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were
required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most
recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": ["http://www.myriad.com/role/Cover"], "lang": { "en-us": { "role": {
"terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company
criteria." } } }, "auth_ref": ["r809"] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber",
"presentation": ["http://www.myriad.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation":
"Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain
1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": ["http://www.myriad.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity
Filer Category", "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-
accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent
filing containing the related disclosure." } } }, "auth_ref": ["r809"] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri":
"http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": ["http://www.myriad.com/role/Cover"], "lang": { "en-us": { "role": {
"terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing
the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024",
"localname": "EntityInteractiveDataCurrent", "presentation": ["http://www.myriad.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Interactive Data
Current", "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File
required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such
files)." } } }, "auth_ref": ["r893"] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityRegistrantName", "presentation": ["http://www.myriad.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity
Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref":
["r809"] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [
"http://www.myriad.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that
is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": ["r809"] }, "dei_EntitySmallBusiness": { "xbrltype":
"booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": ["http://www.myriad.com/role/Cover"], "lang": { "en-us": {
"role": { "terseLabel": "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } },
"auth_ref": ["r809"] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname":
"EntityTaxIdentificationNumber", "presentation": ["http://www.myriad.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number",
"label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-
digit value assigned by the IRS." } } }, "auth_ref": ["r809"] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "EqtyAwrdsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards
Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]" } } }, "auth_ref": ["r848"] },
"ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel":
"Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table
[Member]" } } }, "auth_ref": ["r889"] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"EqtyAwrdsAdjsMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Equity Awards Adjustments", "label":
"Equity Awards Adjustments [Member]" } } }, "auth_ref": ["r889"] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": {
"en-us": { "role": { "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair
Value of Equity Award Amounts Reported in Summary Compensation Table [Member]" } } }, "auth_ref": ["r889"] }, "us-gaap_EquipmentMember": { "xbrltype":
"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquipmentMember", "presentation": [
"http://www.myriad.com/role/PROPERTYPLANTANDEQUIPMENTNETScheduleofPropertyPlantandEquipmentNetDetails"], "lang": { "en-us": { "role": { "terseLabel":
"Equipment", "label": "Equipment [Member]", "documentation": "Tangible personal property used to produce goods and services." } } }, "auth_ref": [] }, "us-
gaap_EquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Equity
[Abstract]", "label": "Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "EquityComponentDomain", "presentation": ["http://www.myriad.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSDetails",
"http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Equity Component", "label":
"Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred,
treasury stock, retained earnings, etc." } } }, "auth_ref": ["r14", "r156", "r180", "r181", "r182", "r198", "r199", "r200", "r202", "r207", "r209", "r211", "r222", "r271", "r272",
"r301", "r371", "r445", "r446", "r453", "r454", "r455", "r457", "r460", "r461", "r466", "r467", "r468", "r469", "r470", "r471", "r474", "r508", "r509", "r510", "r511", "r512",
"r513", "r515", "r517", "r527", "r613", "r630", "r631", "r632", "r643", "r696"] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"],
"lang": { "en-us": { "role": { "terseLabel": "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]" } } },
"auth_ref": ["r858"] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"ErrCompAnalysisTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Erroneous Compensation
Analysis", "label": "Erroneous Compensation Analysis [Text Block]" } } }, "auth_ref": ["r816", "r826", "r836", "r868"] }, "ecd_ErrCompRecoveryTable": { "xbrltype":
"stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": {
"en-us": { "role": { "terseLabel": "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]" } } }, "auth_ref": ["r813",
"r823", "r833", "r865"] }, "mygn_EscrowLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.myriad.com/20240930", "localname":
"EscrowLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://www.myriad.com/role/OTHERLONGTERMLIABILITIESScheduleofOtherLongTermLiabilitiesDetails": {
"parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.myriad.com/role/OTHERLONGTERMLIABILITIESScheduleofOtherLongTermLiabilitiesDetails"], "lang": { "en-us": { "role": { "terseLabel": "Escrow liability",
"label": "Escrow Liability, Noncurrent", "documentation": "Escrow Liability, Noncurrent" } } }, "auth_ref": [] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType",

```
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Executive Category:", "label": "Executive Category [Axis]" } } }, "auth_ref": [ "r864" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://www.myriad.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r478", "r479", "r492", "r767" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://www.myriad.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r478", "r479", "r492", "r767" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "presentation": [ "http://www.myriad.com/role/FAIRVALUEMEASUREMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value of Financial Assets and Liabilities", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]", "documentation": "Tabular disclosure of financial instrument measured at fair value on recurring or nonrecurring basis. Includes, but is not limited to, instrument classified in shareholders' equity." } } }, "auth_ref": [ "r767", "r1020", "r1021", "r1026" ] }, "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems", "presentation": [ "http://www.myriad.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_FairValueByBalanceSheetGroupingTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByBalanceSheetGroupingTable", "presentation": [ "http://www.myriad.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value, by Balance Sheet Grouping [Table]", "label": "Fair Value, by Balance Sheet Grouping [Table]", "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities." } } }, "auth_ref": [ "r54", "r55" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://www.myriad.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.myriad.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Axis]", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r343", "r392", "r393", "r394", "r395", "r396", "r397", "r477", "r479", "r480", "r481", "r482", "r491", "r492", "r494", "r531", "r532", "r533", "r746", "r747", "r759", "r760", "r761", "r767", "r771" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "terseLabel": "Fair Value Disclosures [Abstract]", "label": "Fair Value Disclosures [Abstract]" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://www.myriad.com/role/FAIRVALUEMEASUREMENTS" ], "lang": { "en-us": { "role": { "terseLabel": "FAIR VALUE MEASUREMENTS", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r487", "r489", "r490", "r491", "r494", "r495", "r496", "r497", "r498", "r593", "r767", "r772" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://www.myriad.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r343", "r392", "r397", "r479", "r492", "r531", "r759", "r760", "r761", "r767" ] }, "us-gaap_FairValueInputsLevel2Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": [ "http://www.myriad.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.myriad.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, "auth_ref": [ "r343", "r392", "r397", "r479", "r480", "r492", "r532", "r746", "r747", "r759", "r760", "r761", "r767" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://www.myriad.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r343", "r392", "r393", "r394", "r395", "r396", "r397", "r479", "r480", "r481", "r482", "r492", "r533", "r746", "r747", "r759", "r760", "r761", "r767", "r771" ] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationCalculationRollForward", "presentation": [ "http://www.myriad.com/role/FAIRVALUEMEASUREMENTSScheduleofChangeinFairValueofContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Reconciliation of change in fair value of contingent consideration", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock", "presentation": [ "http://www.myriad.com/role/FAIRVALUEMEASUREMENTSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Change in Fair Value of Contingent Consideration", "label": "Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability." } } }, "auth_ref": [ "r483", "r488", "r493" ] }, "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementPolicyPolicyTextBlock", "presentation": [ "http://www.myriad.com/role/BASISOFPRESENTATIONPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements", "label": "Fair Value Measurement, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities." } } }, "auth_ref": [] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "crdr": "credit", "presentation": [ "http://www.myriad.com/role/FAIRVALUEMEASUREMENTSScheduleofChangeinFairValueofContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Change in fair value recognized in the Statements of Operations", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings", "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r484", "r493" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInOtherComprehensiveIncome", "crdr": "credit", "presentation": [ "http://www.myriad.com/role/FAIRVALUEMEASUREMENTSScheduleofChangeinFairValueofContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Translation adjustments recognized in Other comprehensive loss", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Other Comprehensive Income (Loss)", "documentation": "Amount of gain (loss) recognized in other comprehensive income (OCI) from liability measured at fair value on recurring basis using unobservable input (level 3)." } } }, "auth_ref": [ "r485", "r493" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements", "crdr": "debit", "presentation": [ "http://www.myriad.com/role/FAIRVALUEMEASUREMENTSScheduleofChangeinFairValueofContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payment of contingent consideration", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements", "documentation": "Amount of settlements of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r486", "r493" ] }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "crdr": "credit", "presentation": [ "http://www.myriad.com/role/FAIRVALUEMEASUREMENTSScheduleofChangeinFairValueofContingentConsiderationDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability Value", "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r483", "r493" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://www.myriad.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.myriad.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fair Value Hierarchy and NAV [Domain]", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r343", "r392", "r393", "r394", "r395", "r396", "r397", "r477", "r479", "r480", "r481", "r482", "r491", "r492", "r494", "r531", "r532", "r533", "r746", "r747", "r759", "r760", "r761", "r767", "r771" ] }, "us-gaap_FairValueNetAssetLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueNetAssetLiability", "crdr": "debit", "calculation": {
```

```
"http://www.myriad.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueofFinancialAssetsandLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.myriad.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails", "http://www.myriad.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial assets requiring fair value re-measurement", "totalLabel": "Total", "label": "Fair Value, Net Asset (Liability)", "documentation": "Fair value of asset after deduction of liability." } } }, "auth_ref": [ "r1020", "r1021" ] }, "mygn_FifthInstallmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "FifthInstallmentMember", "presentation": [ "http://www.myriad.com/role/OTHERLONGTERMLIABILITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Final Installment", "label": "Fifth Installment [Member]", "documentation": "Fifth Installment" } } }, "auth_ref": [] }, "us-gaap_FinanceLeasePrincipalPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinanceLeasePrincipalPayments", "crdr": "credit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payment on finance leases", "label": "Finance Lease, Principal Payments", "documentation": "Amount of cash outflow for principal payment on finance lease." } } }, "auth_ref": [ "r521", "r523" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [ "http://www.myriad.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueofFinancialAssetsandLiabilitiesDetails", "http://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIESScheduleofFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument [Axis]", "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r265", "r266", "r267", "r268", "r273", "r274", "r276", "r277", "r278", "r280", "r281", "r282", "r354", "r369", "r472", "r499", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r614", "r740", "r767", "r769", "r771", "r772", "r773", "r774", "r775", "r776", "r777", "r780", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r933", "r934", "r935", "r936", "r1019", "r1022", "r1023", "r1024", "r1025", "r1027" ] }, "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r165", "r283", "r297", "r743" ] }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseTableTextBlock", "presentation": [ "http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Recorded Amortization Expense for Intangible Assets", "label": "Finite-Lived Intangible Assets Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of amortization expense of assets, excluding financial assets, that lack physical substance, having a limited useful life." } } }, "auth_ref": [] }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": [ "http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails", "http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": [ "r290", "r292", "r293", "r294", "r296", "r297", "r299", "r300", "r561", "r562", "r725" ] }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross Carrying Amount", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r283", "r297", "r562", "r743" ] }, "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain", "presentation": [ "http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails", "http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]", "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company." } } }, "auth_ref": [ "r290", "r292", "r293", "r294", "r296", "r297", "r299", "r300", "r725" ] }, "us-gaap_FiniteLivedIntangibleAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsNet", "crdr": "debit", "calculation": { "http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofIntangibleAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Net", "label": "Finite-Lived Intangible Assets, Net", "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": [ "r561", "r960" ] }, "mygn_FirstInstallmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "FirstInstallmentMember", "presentation": [ "http://www.myriad.com/role/OTHERLONGTERMLIABILITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "First Installment", "label": "First Installment [Member]", "documentation": "First Installment" } } }, "auth_ref": [] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r820", "r830", "r840", "r872" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount", "label": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r820", "r830", "r840", "r872" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount", "label": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r820", "r830", "r840", "r872" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Forgone Recovery, Explanation of Impracticability", "label": "Forgone Recovery, Explanation of Impracticability [Text Block]" } } }, "auth_ref": [ "r820", "r830", "r840", "r872" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Forgone Recovery, Individual Name" } } }, "auth_ref": [ "r820", "r830", "r840", "r872" ] }, "mygn_FourthInstallmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "FourthInstallmentMember", "presentation": [ "http://www.myriad.com/role/OTHERLONGTERMLIABILITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Fourth Installment", "label": "Fourth Installment [Member]", "documentation": "Fourth Installment" } } }, "auth_ref": [] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]" } } }, "auth_ref": [ "r853" ] }, "us-gaap_GainLossOnTerminationOfLease": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GainLossOnTerminationOfLease", "crdr": "credit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 17.0 } }, "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.myriad.com/role/LEASESDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gain on termination of lease", "terseLabel": "Gain on termination of lease", "label": "Gain (Loss) on Termination of Lease", "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term." } } }, "auth_ref": [ "r518" ] }, "mygn_GatewayGenomicsLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "GatewayGenomicsLLCMember", "presentation": [ "http://www.myriad.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gateway", "label": "Gateway Genomics, LLC [Member]", "documentation": "Gateway Genomics, LLC" } } }, "auth_ref": [] }, "us-gaap_Goodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Goodwill", "crdr": "debit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited", "http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails", "http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill", "periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Goodwill", "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r164", "r284", "r594", "r738", "r742", "r768", "r779", "r942", "r949" ] }, "us-gaap_GoodwillAndIntangibleAssetImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetImpairment", "crdr": "debit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Goodwill and long-lived asset impairment charges", "label": "Goodwill and Intangible Asset Impairment", "documentation": "Total loss recognized during the period from the impairment of goodwill plus the loss recognized in the period resulting from the impairment of the carrying amount of intangible assets, other than goodwill." } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETS" ], "lang": { "en-us": { "role": { "terseLabel": "GOODWILL AND INTANGIBLE ASSETS", "label": "Goodwill and Intangible Assets Disclosure [Text Block]", "documentation": "The entire disclosure for goodwill and intangible assets." } } }, "auth_ref": [ "r940", "r952" ] }, "us-gaap_GoodwillForeignCurrencyTranslationGainLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillForeignCurrencyTranslationGainLoss", "crdr": "credit", "presentation": [ "http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Translation adjustments", "label": "Goodwill, Foreign Currency Translation Gain (Loss)", "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) asset representing future economic benefit from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r287" ] }, "us-gaap_GoodwillImpairmentLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillImpairmentLoss", "crdr": "debit", "presentation": [ "http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails", "http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Goodwill impairment", "terseLabel": "Goodwill impairment charge", "label": "Goodwill, Impairment Loss", "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized." } } }, "auth_ref": [ "r10", "r285", "r286", "r289", "r742", "r768" ] }, "mygn_GoodwillPercentageOfRecordGoodwill": {
```

```
"xbrltype": "percentItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "GoodwillPercentageOfRecordGoodwill", "presentation": [
"http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Percentage of goodwill", "label": "Goodwill, Percentage Of Record Goodwill", "documentation": "Goodwill, Percentage Of Record Goodwill" } } }, "auth_ref": [] }, "us-gaap_GoodwillRollForward": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillRollForward", "presentation": [
"http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofChangesinCarryingAmountofGoodwillDetails" ], "lang": { "en-us": { "role": { "terseLabel":
"Goodwill [Roll Forward]", "label": "Goodwill [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_GovernmentContractsConcentrationRiskMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "GovernmentContractsConcentrationRiskMember", "presentation": [ "http://www.myriad.com/role/REVENUENarrativeDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Government Contracts Concentration Risk", "label": "Government Contracts Concentration Risk [Member]", "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. Risk is the materially adverse effects of termination of a significant contract or group of contracts or from future loss of a significant portion of business with a specified political body or unit thereof, such as Department of Defense, US Navy, New York City." } } }, "auth_ref": [ "r116" ] }, "mygn_HereditaryCancerTestingMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "HereditaryCancerTestingMember", "presentation": [
"http://www.myriad.com/role/REVENUEScheduleofTotalRevenuebyTypeandbyUSversusRestofWorldDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Hereditary Cancer",
"label": "Hereditary Cancer Testing [Member]", "documentation": "Molecular diagnostic hereditary cancer testing." } } }, "auth_ref": [] }, "us-
gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": {
"http://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } },
"presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Loss before income tax", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": [ "r100", "r141", "r146", "r599", "r610", "r736", "r737", "r924", "r926", "r927", "r928", "r929" ] }, "us-
gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeLossFromDiscontinuedOperationsNetOfTax", "crdr": "credit", "presentation": [ "http://www.myriad.com/role/DIVESTITUREDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Total net loss, including transaction expenses", "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal." } } }, "auth_ref": [ "r64", "r65", "r66", "r67", "r68", "r76", "r158", "r450", "r611" ] }, "us-
gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role":
{ "terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
"presentation": [ "http://www.myriad.com/role/DIVESTITUREDetails", "http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Disposal Group Name [Axis]", "label": "Disposal Group Name [Axis]", "documentation": "Information by name of disposal group." } } }, "auth_ref": [
"r762", "r763" ] }, "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems", "presentation": [
"http://www.myriad.com/role/DIVESTITUREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Divestitures [Line Items]", "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-
gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
"presentation": [ "http://www.myriad.com/role/DIVESTITUREDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]", "label": "Disposal Groups, Including Discontinued Operations [Table]", "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component." } } },
"auth_ref": [ "r12", "r18", "r21", "r63", "r69", "r70", "r71", "r72", "r73", "r75", "r77", "r78", "r121" ] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://www.myriad.com/role/LEASESDetails",
"http://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Axis]", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r302", "r308", "r309", "r484", "r488", "r493", "r627", "r629", "r681", "r725", "r770", "r1052" ] }, "us-
gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain",
"presentation": [ "http://www.myriad.com/role/LEASESDetails",
"http://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Income Statement Location [Domain]", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r308", "r309", "r484", "r488", "r493", "r627", "r629", "r681", "r725", "r770", "r1052" ] }, "us-gaap_IncomeTaxDisclosureAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Income Tax Disclosure [Abstract]", "label": "Income Tax Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://www.myriad.com/role/INCOMETAXES" ], "lang": { "en-us": { "role": {
"terseLabel": "INCOME TAXES", "label": "Income Tax Disclosure [Text Block]", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r196", "r437",
"r439", "r440", "r441", "r442", "r443", "r444", "r447", "r449", "r451", "r452", "r642", "r766" ] }, "us-gaap_IncomeTaxExpenseBenefit": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": {
"http://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunaudited": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } },
"presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunaudited", "http://www.myriad.com/role/INCOMETAXESDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Income tax expense", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r148", "r153", "r210", "r211", "r221", "r228", "r231", "r438", "r439", "r448",
"r618", "r766" ] }, "us-gaap_IncomeTaxesPaid": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaid", "crdr": "credit",
"presentation": [ "http://www.myriad.com/role/SUPPLEMENTALCASHFLOWINFORMATIONScheduleofSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role":
{ "terseLabel": "Cash paid for income taxes", "label": "Income Taxes Paid", "documentation": "Amount, before refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": [ "r30", "r114", "r915", "r1014", "r1015" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": {
"http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight":
1.0, "order": 8.0 } }, "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel":
"Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } },
"auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInAccountsReceivable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 15.0 } }, "presentation": [
"http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Trade accounts receivable", "label":
"Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": {
"http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight":
1.0, "order": 2.0 } }, "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel":
"Accrued liabilities", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r9" ] }, "mygn_IncreaseDecreaseInEarningsLossPerShare": { "xbrltype": "perShareItemType", "nsuri":
"http://www.myriad.com/20240930", "localname": "IncreaseDecreaseInEarningsLossPerShare", "presentation": [ "http://www.myriad.com/role/REVENUENarrativeDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Change in earnings per share (dollars per share)", "label": "Increase (Decrease) In Earnings Loss Per Share", "documentation":
"Increase decrease in earnings (loss) per share." } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInInventories": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInInventories", "crdr": "credit", "calculation": {
"http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight":
-1.0, "order": 3.0 } }, "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedLabel":
"Inventory", "label": "Increase (Decrease) in Inventories", "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities." } } }, "auth_ref": [ "r9" ] }, "us-
gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": {
"role": { "terseLabel": "Changes in assets and liabilities:", "label": "Increase (Decrease) in Operating Capital [Abstract]" } } }, "auth_ref": [] }, "us-
gaap_IncreaseDecreaseInOtherNoncurrentAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInOtherNoncurrentAssets", "crdr": "credit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 } }, "presentation": [
"http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Other assets", "label": "Increase (Decrease) in Other Noncurrent Assets", "documentation": "Amount of increase (decrease) in noncurrent assets classified as other." } } }, "auth_ref": [ "r913" ] }, "us-
gaap_IncreaseDecreaseInPrepaidExpensesOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"IncreaseDecreaseInPrepaidExpensesOther", "crdr": "credit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, "presentation": [
"http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Prepaid expenses and other current assets", "label": "Increase (Decrease) in Prepaid Expenses, Other", "documentation": "Amount of increase (decrease) of consideration paid in advance for other costs that provide economic benefits in future periods." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInPrepaidTaxes": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidTaxes", "crdr": "credit", "calculation": {
"http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight":
-1.0, "order": 10.0 } }, "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedLabel":
"Prepaid taxes", "label": "Increase (Decrease) in Prepaid Taxes", "documentation": "Amount of increase (decrease) of consideration paid in advance for income and other taxes that provide economic benefits in future periods." } } }, "auth_ref": [ "r9" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [
"http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited",
```

```
"http://www.myriad.com/role/PREFERREDANDCOMMONSTOCKHOLDERSEQUITYScheduleofCommonStockIssuedandOutstandingDetails" ], "lang": { "en-us": { "role": { "verboseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Common shares issued and outstanding", "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "mygn_IncreaseDecreaseInUnrecognizedTaxBenefits": { "xbrltype": "monetaryItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "IncreaseDecreaseInUnrecognizedTaxBenefits", "crdr": "debit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits", "label": "Increase (Decrease) In Unrecognized Tax Benefits", "documentation": "Increase (decrease) in unrecognized tax benefits." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Individual:", "label": "Individual [Axis]" } } }, "auth_ref": [ "r820", "r830", "r840", "r864", "r872", "r876", "r884" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]" } } }, "auth_ref": [ "r882" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]" } } }, "auth_ref": [ "r812", "r888" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted [Flag]" } } }, "auth_ref": [ "r812", "r888" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]" } } }, "auth_ref": [ "r812", "r888" ] }, "mygn_IntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "IntangibleAssetsLineItems", "presentation": [ "http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets [Line Items]", "label": "Intangible Assets [Line Items]", "documentation": "Intangible assets." } } }, "auth_ref": [] }, "us-gaap_IntangibleAssetsNetExcludingGoodwill": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsNetExcludingGoodwill", "crdr": "debit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Intangibles, net", "label": "Intangible Assets, Net (Excluding Goodwill)", "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges." } } }, "auth_ref": [ "r290", "r960", "r961" ] }, "us-gaap_InterestExpenseNonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Interest expense", "label": "Interest Expense, Nonoperating", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": [ "r227", "r912" ] }, "us-gaap_InterestPaidNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestPaidNet", "crdr": "credit", "presentation": [ "http://www.myriad.com/role/SUPPLEMENTALCASHFLOWINFORMATIONScheduleofSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Cash paid for interest", "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities", "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount." } } }, "auth_ref": [ "r188", "r190", "r191" ] }, "us-gaap_InventoryNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InventoryNet", "crdr": "debit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Inventory", "label": "Inventory, Net", "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer." } } }, "auth_ref": [ "r170", "r731", "r779" ] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Interest", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r221", "r226", "r231", "r737", "r911" ] }, "us-gaap_InvestmentsAndCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsAndCash", "crdr": "debit", "calculation": { "http://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIESScheduleofFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": { "parentTag": "mygn_InvestmentsAndCashAmortizedCost", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIESScheduleofFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated fair value", "label": "Investments and Cash", "documentation": "Sum of investments and unrestricted cash as of the balance sheet date." } } }, "auth_ref": [ "r1048", "r1050" ] }, "us-gaap_InvestmentsAndCashAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsAndCashAbstract", "presentation": [ "http://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIESScheduleofFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Total", "label": "Investments and Cash [Abstract]" } } }, "auth_ref": [] }, "mygn_InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "InvestmentsAndCashAccumulatedGrossUnrealizedGainBeforeTax", "crdr": "credit", "calculation": { "http://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIESScheduleofFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": { "parentTag": "mygn_InvestmentsAndCashAmortizedCost", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIESScheduleofFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Gross unrealized holding gains", "label": "Investments And Cash, Accumulated Gross Unrealized Gain, before Tax", "documentation": "Investments And Cash, Accumulated Gross Unrealized Gain, before Tax" } } }, "auth_ref": [] }, "mygn_InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax": { "xbrltype": "monetaryItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "InvestmentsAndCashAccumulatedGrossUnrealizedLossBeforeTax", "crdr": "debit", "calculation": { "http://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIESScheduleofFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": { "parentTag": "mygn_InvestmentsAndCashAmortizedCost", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIESScheduleofFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Gross unrealized holding losses", "label": "Investments And Cash, Accumulated Gross Unrealized Loss, before Tax", "documentation": "Investments And Cash, Accumulated Gross Unrealized Loss, before Tax" } } }, "auth_ref": [] }, "mygn_InvestmentsAndCashAmortizedCost": { "xbrltype": "monetaryItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "InvestmentsAndCashAmortizedCost", "crdr": "debit", "calculation": { "http://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIESScheduleofFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIESScheduleofFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" ], "lang": { "en-us": { "role": { "totalLabel": "Amortized cost", "label": "Investments And Cash, Amortized Cost", "documentation": "Investments And Cash, Amortized Cost" } } }, "auth_ref": [] }, "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Investments, Debt and Equity Securities [Abstract]", "label": "Investments, Debt and Equity Securities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": [ "http://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIES" ], "lang": { "en-us": { "role": { "terseLabel": "MARKETABLE INVESTMENT SECURITIES", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": [ "r143", "r155", "r237", "r238", "r500", "r501", "r1046" ] }, "mygn_LeaseTerminationAccrualCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "LeaseTerminationAccrualCurrent", "crdr": "credit", "calculation": { "http://www.myriad.com/role/ACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://www.myriad.com/role/ACCRUEDLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease termination accrual", "label": "Lease Termination Accrual, Current", "documentation": "Lease Termination Accrual, Current" } } }, "auth_ref": [] }, "us-gaap_LeaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.myriad.com/role/PROPERTYPLANTANDEQUIPMENTNETNarrativeDetails", "http://www.myriad.com/role/PROPERTYPLANTANDEQUIPMENTNETScheduleofPropertyPlantandEquipmentNetDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements [Member]", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [ "r119", "r525" ] }, "us-gaap_LeasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "label": "Leases [Abstract]" } } }, "auth_ref": [] }, "mygn_LegalChargesPendingSettlementNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "LegalChargesPendingSettlementNoncurrent", "crdr": "credit", "calculation": { "http://www.myriad.com/role/OTHERLONGTERMLIABILITIESScheduleofOtherLongTermLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.myriad.com/role/OTHERLONGTERMLIABILITIESNarrativeDetails", "http://www.myriad.com/role/OTHERLONGTERMLIABILITIESScheduleofOtherLongTermLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Legal settlements", "label": "Legal Charges Pending Settlement, Noncurrent", "documentation": "Legal Charges Pending Settlement, Noncurrent" } } }, "auth_ref": [] }, "us-gaap_LegalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LegalFees", "crdr": "debit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Legal settlements", "label": "Legal Fees", "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings." } } }, "auth_ref": [ "r896" ] }, "us-gaap_LesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.myriad.com/role/LEASESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Line Items]", "label": "Lessee, Lease, Description [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r522", "r526" ] }, "us-gaap_LesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://www.myriad.com/role/LEASESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lessee, Lease, Description [Table]", "label": "Lessee, Lease, Description [Table]", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [ "r522", "r526" ] }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDue", "crdr": "credit", "presentation": [ "http://www.myriad.com/role/LEASESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Lease payments due", "label": "Lessee, Operating Lease, Liability, to be Paid", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease." } } }, "auth_ref": [ "r524" ] }, "us-gaap_LesseeOperatingLeaseRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRemainingLeaseTerm", "presentation": [ "http://www.myriad.com/role/LEASESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Remaining lease terms (in years)", "label": "Lessee, Operating Lease, Remaining Lease Term", "documentation": "Remaining lease term of operating lease, in
```

'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r526", "r1034"] }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": ["http://www.myriad.com/role/LEASESDetails"], "lang": { "en-us": { "role": { "terseLabel": "Lease term (in years)", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": ["r1035"] }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": ["http://www.myriad.com/role/LEASES"], "lang": { "en-us": { "role": { "terseLabel": "LEASES", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability." } } }, "auth_ref": ["r516"] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities", "label": "Liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": ["r20", "r81", "r82", "r83", "r85", "r86", "r87", "r88", "r195", "r270", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r463", "r464", "r465", "r502", "r656", "r735", "r807", "r978", "r1037", "r1038"] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total liabilities and stockholders\u2019 equity", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": ["r95", "r140", "r607", "r779", "r918", "r937", "r1028"] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": ["http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES AND STOCKHOLDERS' EQUITY", "label": "Liabilities and Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited"], "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": ["r83", "r160", "r195", "r270", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r463", "r464", "r465", "r502", "r779", "r978", "r1037", "r1038"] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": ["http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Current liabilities:", "label": "Liabilities, Current [Abstract]" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "calculation": { "http://www.myriad.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueofFinancialAssetsandLiabilitiesDetails": { "parentTag": "us-gaap_FairValueNetAssetLiability", "weight": -1.0, "order": 2.0 } }, "presentation": ["http://www.myriad.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueofFinancialAssetsandLiabilitiesDetails"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Financial liabilities", "label": "Liabilities, Fair Value Disclosure", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": ["r479", "r1020"] }, "mygn_LineOfCreditFacilityAccordionFeatureIncreaseLimit": { "xbrltype": "monetaryItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "LineOfCreditFacilityAccordionFeatureIncreaseLimit", "crdr": "credit", "presentation": ["http://www.myriad.com/role/LONGTERMDEBTDetails"], "lang": { "en-us": { "role": { "terseLabel": "Line of credit, increase in maximum principal upon request", "label": "Line Of Credit Facility, Accordion Feature, Increase Limit", "documentation": "Line Of Credit Facility, Accordion Feature, Increase Limit" } } }, "auth_ref": [] }, "mygn_LineOfCreditFacilityBorrowingBaseEligibleCashCollectionsPeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "LineOfCreditFacilityBorrowingBaseEligibleCashCollectionsPeriod", "presentation": ["http://www.myriad.com/role/LONGTERMDEBTDetails"], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, borrowing base, eligible cash collections, period", "label": "Line Of Credit Facility, Borrowing Base, Eligible Cash Collections, Period", "documentation": "Line Of Credit Facility, Borrowing Base, Eligible Cash Collections, Period" } } }, "auth_ref": [] }, "mygn_LineOfCreditFacilityBorrowingBaseEligibleCashHeld": { "xbrltype": "monetaryItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "LineOfCreditFacilityBorrowingBaseEligibleCashHeld", "crdr": "credit", "presentation": ["http://www.myriad.com/role/LONGTERMDEBTDetails"], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, borrowing base, eligible cash held", "label": "Line Of Credit Facility, Borrowing Base, Eligible Cash Held", "documentation": "Line Of Credit Facility, Borrowing Base, Eligible Cash Held" } } }, "auth_ref": [] }, "mygn_LineOfCreditFacilityBorrowingBasePercentOfEligibleAccountsReceivablePlusCertainCashHeld": { "xbrltype": "percentItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "LineOfCreditFacilityBorrowingBasePercentOfEligibleAccountsReceivablePlusCertainCashHeld", "presentation": ["http://www.myriad.com/role/LONGTERMDEBTDetails"], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, borrowing base, percent of eligible accounts receivable plus certain cash held", "label": "Line Of Credit Facility, Borrowing Base, Percent Of Eligible Accounts Receivable Plus Certain Cash Held", "documentation": "Line Of Credit Facility, Borrowing Base, Percent Of Eligible Accounts Receivable Plus Certain Cash Held" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityCommitmentFeeAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCommitmentFeeAmount", "crdr": "debit", "presentation": ["http://www.myriad.com/role/LONGTERMDEBTDetails"], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, commitment fee amount", "label": "Line of Credit Facility, Commitment Fee Amount", "documentation": "Amount of the fee for available but unused credit capacity under the credit facility." } } }, "auth_ref": ["r80", "r84", "r319"] }, "mygn_LineOfCreditFacilityCommitmentFeeBorrowingBasePeriod": { "xbrltype": "durationItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "LineOfCreditFacilityCommitmentFeeBorrowingBasePeriod", "presentation": ["http://www.myriad.com/role/LONGTERMDEBTDetails"], "lang": { "en-us": { "role": { "terseLabel": "Borrowing base period", "label": "Line Of Credit Facility, Commitment Fee, Borrowing Base, Period", "documentation": "Line Of Credit Facility, Commitment Fee, Borrowing Base, Period" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCommitmentFeePercentage", "presentation": ["http://www.myriad.com/role/LONGTERMDEBTDetails"], "lang": { "en-us": { "role": { "terseLabel": "Line of credit facility, commitment fee percentage", "label": "Line of Credit Facility, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for the line of credit facility regardless of whether the facility has been used." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityCurrentBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityCurrentBorrowingCapacity", "crdr": "credit", "presentation": ["http://www.myriad.com/role/LONGTERMDEBTDetails"], "lang": { "en-us": { "role": { "terseLabel": "Increase principal commitment", "label": "Line of Credit Facility, Current Borrowing Capacity", "documentation": "Amount of current borrowing capacity under the credit facility considering any current restrictions on the amount that could be borrowed (for example, borrowings may be limited by the amount of current assets), but without considering any amounts currently outstanding under the facility." } } }, "auth_ref": ["r80", "r84"] }, "mygn_LineOfCreditFacilityDebtDefaultAvailabilityThreshold": { "xbrltype": "monetaryItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "LineOfCreditFacilityDebtDefaultAvailabilityThreshold", "crdr": "debit", "presentation": ["http://www.myriad.com/role/LONGTERMDEBTDetails"], "lang": { "en-us": { "role": { "terseLabel": "Availability threshold amount", "label": "Line Of Credit Facility, Debt Default, Availability Threshold", "documentation": "Line Of Credit Facility, Debt Default, Availability Threshold" } } }, "auth_ref": [] }, "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityMaximumBorrowingCapacity", "crdr": "credit", "presentation": ["http://www.myriad.com/role/LONGTERMDEBTDetails"], "lang": { "en-us": { "role": { "terseLabel": "Maximum aggregate principal commitment", "label": "Line of Credit Facility, Maximum Borrowing Capacity", "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility." } } }, "auth_ref": ["r80", "r84"] }, "us-gaap_LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage", "presentation": ["http://www.myriad.com/role/LONGTERMDEBTDetails"], "lang": { "en-us": { "role": { "terseLabel": "Undrawn fee (percent)", "label": "Line of Credit Facility, Unused Capacity, Commitment Fee Percentage", "documentation": "The fee, expressed as a percentage of the line of credit facility, for available but unused credit capacity under the credit facility." } } }, "auth_ref": [] }, "us-gaap_LineOfCreditMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LineOfCreditMember", "presentation": ["http://www.myriad.com/role/LONGTERMDEBTDetails"], "lang": { "en-us": { "role": { "terseLabel": "Line of Credit", "label": "Line of Credit [Member]", "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars." } } }, "auth_ref": [] }, "srt_LitigationCaseAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseAxis", "presentation": ["http://www.myriad.com/role/OTHERLONGTERMLIABILITIESNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Axis]", "label": "Litigation Case [Axis]" } } }, "auth_ref": [] }, "srt_LitigationCaseTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "LitigationCaseTypeDomain", "presentation": ["http://www.myriad.com/role/OTHERLONGTERMLIABILITIESNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Litigation Case [Domain]", "label": "Litigation Case [Domain]" } } }, "auth_ref": [] }, "mygn_LitigationInstallmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "LitigationInstallmentsAxis", "presentation": ["http://www.myriad.com/role/OTHERLONGTERMLIABILITIESNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Installment [Axis]", "label": "Litigation Installments [Axis]", "documentation": "Litigation Installments" } } }, "auth_ref": [] }, "mygn_LitigationInstallmentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "LitigationInstallmentsDomain", "presentation": ["http://www.myriad.com/role/OTHERLONGTERMLIABILITIESNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Litigation Installments [Domain]", "label": "Litigation Installments [Domain]", "documentation": "Litigation Installments [Domain]" } } }, "auth_ref": [] }, "us-gaap_LitigationReserveCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationReserveCurrent", "crdr": "credit", "calculation": { "http://www.myriad.com/role/ACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.myriad.com/role/ACCRUEDLIABILITIESDetails", "http://www.myriad.com/role/COMMITMENTSANDCONTINGENCIESDetails"], "lang": { "en-us": { "role": { "terseLabel": "Legal settlements", "verboseLabel": "Pending settlement accrued", "label": "Estimated Litigation Liability, Current", "documentation": "Carrying amount of reserve for known or estimated probable loss from litigation, which may include attorneys' fees and other litigation costs, which is expected to be paid within one year of the date of the statement of financial position." } } }, "auth_ref": ["r87", "r971"] }, "us-gaap_LitigationSettlementAmountAwardedToOtherParty": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationSettlementAmountAwardedToOtherParty", "crdr": "credit", "presentation": ["http://www.myriad.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.myriad.com/role/OTHERLONGTERMLIABILITIESNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Settlement agreement", "label": "Litigation Settlement, Amount Awarded to Other Party", "documentation": "Amount awarded to other party in judgment or settlement of litigation." } } }, "auth_ref": [] }, "mygn_LitigationSettlementNumberOfInstallments": { "xbrltype": "integerItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "LitigationSettlementNumberOfInstallments", "presentation": ["http://www.myriad.com/role/OTHERLONGTERMLIABILITIESNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Number of annual installments", "label": "Litigation Settlement, Number Of Installments", "documentation": "Litigation Settlement, Number Of Installments" } } }, "auth_ref": [] }, "mygn_LitigationSettlementRemainingAmountAwardedToOtherParty": { "xbrltype": "monetaryItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "LitigationSettlementRemainingAmountAwardedToOtherParty", "crdr": "credit", "presentation": ["http://www.myriad.com/role/OTHERLONGTERMLIABILITIESNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Litigation settlement, outstanding", "label": "Litigation Settlement, Remaining Amount Awarded To Other Party", "documentation": "Litigation Settlement, Remaining Amount Awarded To Other Party" } } }, "auth_ref": [] }, "us-gaap_LitigationStatusAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationStatusAxis", "presentation": ["http://www.myriad.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.myriad.com/role/OTHERLONGTERMLIABILITIESNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Litigation Status [Axis]", "label": "Litigation Status [Axis]", "documentation": "Information by status of pending, threatened, or settled litigation." } } }, "auth_ref": ["r966", "r967", "r968", "r971"] }, "us-gaap_LitigationStatusDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LitigationStatusDomain", "presentation": ["http://www.myriad.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.myriad.com/role/OTHERLONGTERMLIABILITIESNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Litigation Status [Domain]", "label": "Litigation Status [Domain]", "documentation": "Status of pending, threatened, or settled litigation." } } }, "auth_ref": ["r966", "r967", "r968", "r971"] }, "dei_LocalPhoneNumber": {

```
"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.myriad.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "us-gaap_LongTermDebt": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebt", "crdr": "credit", "presentation": [ "http://www.myriad.com/role/LONGTERMDEBTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "label": "Long-Term Debt", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation." } } }, "auth_ref": [ "r20", "r138", "r342", "r356", "r746", "r747", "r778", "r1049" ] }, "us-gaap_LongTermDebtFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtFairValue", "crdr": "credit", "presentation": [ "http://www.myriad.com/role/FAIRVALUEMEASUREMENTSNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Estimated fair value of long-term debt", "label": "Long-Term Debt, Fair Value", "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission." } } }, "auth_ref": [ "r1020", "r1022", "r1023", "r1024" ] }, "us-gaap_LongTermDebtNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongTermDebtNoncurrent", "crdr": "credit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Long-term debt", "label": "Long-Term Debt, Excluding Current Maturities", "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation." } } }, "auth_ref": [ "r168" ] }, "us-gaap_LongtermDebtTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeAxis", "presentation": [ "http://www.myriad.com/role/LONGTERMDEBTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt, Type [Axis]", "label": "Long-Term Debt, Type [Axis]", "documentation": "Information by type of long-term debt." } } }, "auth_ref": [ "r20", "r966", "r967", "r968" ] }, "us-gaap_LongtermDebtTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": [ "http://www.myriad.com/role/LONGTERMDEBTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Long-Term Debt, Type [Domain]", "label": "Long-Term Debt, Type [Domain]", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }, "auth_ref": [ "r20", "r40", "r966", "r967", "r968" ] }, "us-gaap_LossContingenciesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesLineItems", "presentation": [ "http://www.myriad.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Line Items]", "label": "Loss Contingencies [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r312", "r313", "r314", "r317", "r435", "r744", "r972", "r973" ] }, "us-gaap_LossContingenciesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingenciesTable", "presentation": [ "http://www.myriad.com/role/COMMITMENTSANDCONTINGENCIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Loss Contingencies [Table]", "label": "Loss Contingencies [Table]", "documentation": "Disclosure of information about loss contingency. Excludes environmental contingency, warranty, and unconditional purchase obligation." } } }, "auth_ref": [ "r312", "r313", "r314", "r317", "r435", "r744", "r972", "r973" ] }, "us-gaap_LossContingencyAccrualCarryingValueCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualCarryingValueCurrent", "crdr": "credit", "presentation": [ "http://www.myriad.com/role/OTHERLONGTERMLIABILITIESNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Accrual, current", "label": "Loss Contingency, Accrual, Current", "documentation": "Amount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r312" ] }, "srt_MajorCustomersAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": [ "http://www.myriad.com/role/REVENUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Axis]", "label": "Customer [Axis]" } } }, "auth_ref": [ "r235", "r754", "r790", "r794", "r982", "r1051", "r1053", "r1054", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1080", "r1081" ] }, "us-gaap_MarketableSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesCurrent", "crdr": "debit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Marketable investment securities", "label": "Marketable Securities, Current", "documentation": "Amount of investment in marketable security, classified as current." } } }, "auth_ref": [ "r906" ] }, "us-gaap_MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MarketableSecuritiesRealizedGainLossExcludingOtherThanTemporaryImpairments", "crdr": "credit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 19.0 } }, "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Net realized losses on marketable investment securities", "label": "Marketable Security, Realized Gain (Loss)", "documentation": "Amount of realized gain (loss) on investment in marketable security." } } }, "auth_ref": [] }, "srt_MaximumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": [ "http://www.myriad.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.myriad.com/role/LEASESDetails", "http://www.myriad.com/role/LONGTERMDEBTDetails", "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum", "label": "Maximum [Member]" } } }, "auth_ref": [ "r313", "r314", "r315", "r316", "r398", "r435", "r482", "r559", "r626", "r628", "r636", "r648", "r649", "r701", "r703", "r705", "r706", "r708", "r723", "r724", "r739", "r750", "r764", "r771", "r772", "r776", "r777", "r791", "r980", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044" ] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Measure:", "label": "Measure [Axis]" } } }, "auth_ref": [ "r856" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Measure Name" } } }, "auth_ref": [ "r856" ] }, "mygn_MedicareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "MedicareMember", "presentation": [ "http://www.myriad.com/role/REVENUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Medicare", "label": "Medicare [Member]", "documentation": "Medicare" } } }, "auth_ref": [] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://www.myriad.com/role/LEASESDetails", "http://www.myriad.com/role/LONGTERMDEBTDetails", "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Minimum", "label": "Minimum [Member]" } } }, "auth_ref": [ "r313", "r314", "r315", "r316", "r398", "r435", "r482", "r559", "r626", "r628", "r636", "r648", "r649", "r701", "r703", "r705", "r706", "r708", "r723", "r724", "r739", "r750", "r764", "r771", "r772", "r776", "r791", "r980", "r1039", "r1040", "r1041", "r1042", "r1043", "r1044" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value [Flag]" } } }, "auth_ref": [ "r875" ] }, "us-gaap_MoneyMarketFundsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": [ "http://www.myriad.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueofFinancialAssetsandLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Money market funds", "label": "Money Market Funds [Member]", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }, "auth_ref": [ "r984" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement [Text Block]" } } }, "auth_ref": [ "r883" ] }, "us-gaap_MunicipalBondsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MunicipalBondsMember", "presentation": [ "http://www.myriad.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueofFinancialAssetsandLiabilitiesDetails", "http://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIESScheduleofFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Municipal bonds", "verboseLabel": "Municipal bonds", "label": "Municipal Bonds [Member]", "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments." } } }, "auth_ref": [] }, "srt_NameOfMajorCustomerDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": [ "http://www.myriad.com/role/REVENUENarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Customer [Domain]", "label": "Customer [Domain]" } } }, "auth_ref": [ "r235", "r754", "r790", "r794", "r982", "r1051", "r1053", "r1054", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1080", "r1081" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote [Text Block]" } } }, "auth_ref": [ "r857" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r189" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:", "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash provided by (used in) investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }, "auth_ref": [ "r189" ] }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:", "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r112", "r113", "r115" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": {
```

```
"http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 }, "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 4.0 }, "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunaudited": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited",
"http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited",
"http://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunaudited",
"http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "totalLabel": "Net loss", "terseLabel": "Net loss", "netLabel": "Net loss", "verboseLabel": "Net loss", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r103", "r115", "r142", "r158", "r175", "r178", "r182", "r195", "r201", "r203", "r204", "r205", "r206", "r207", "r210", "r211", "r215", "r270", "r320", "r321", "r322", "r323", "r324", "r325", "r326", "r327", "r328", "r456", "r461", "r476", "r502", "r612", "r678", "r694", "r695", "r806", "r978" ] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [
"http://www.myriad.com/role/BASISOFPRESENTATIONPolicies" ], "lang": { "en-us": { "role": { "terseLabel": "Recent Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "mygn_NewYorkFederalReserveBankRateMember": { "xbrltype": "domainItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "NewYorkFederalReserveBankRateMember", "presentation": [
"http://www.myriad.com/role/LONGTERMDEBTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "NYFRB", "label": "New York Federal Reserve Bank Rate [Member]", "documentation": "New York Federal Reserve Bank Rate" } } }, "auth_ref": [] }, "mygn_NonCashAdjustmentToRightOfUseAssetsAndLeaseLiabilitiesFromLeaseModifications": { "xbrltype": "monetaryItemType", "nsuri": "http://www.myriad.com/20240930", "localname":
"NonCashAdjustmentToRightOfUseAssetsAndLeaseLiabilitiesFromLeaseModifications", "crdr": "debit", "presentation": [
"http://www.myriad.com/role/SUPPLEMENTALCASHFLOWINFORMATIONScheduleofSupplementalCashFlowInformationDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash adjustment to right-of-use assets and lease liabilities from lease modifications", "label": "Non-Cash Adjustment To Right-Of-Use Assets And Lease Liabilities From Lease Modifications", "documentation": "Non-Cash Adjustment To Right-Of-Use Assets And Lease Liabilities From Lease Modifications" } } }, "auth_ref": [] }, "mygn_NonEmployeeDirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "NonEmployeeDirectorMember", "presentation": [ "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Employee Director", "label": "Non-Employee Director [Member]", "documentation": "Non-employee director." } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]" } } }, "auth_ref": [ "r856" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-NEOs", "label": "Non-NEOs [Member]" } } }, "auth_ref": [ "r820", "r830", "r840", "r864", "r872" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount", "label": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r847" ] },
"ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [
"http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r846" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Non-PEO NEO", "label": "Non-PEO NEO [Member]" } } }, "auth_ref": [ "r864" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": [ "r883" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": [ "r883" ] }, "us-gaap_NonUsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonUsMember", "presentation": [ "http://www.myriad.com/role/REVENUEScheduleofTotalRevenuebyTypeandbyUSversusRestofWorldDetails" ], "lang": { "en-us": { "role": { "terseLabel": "RoW", "label": "Non-US [Member]", "documentation": "Countries excluding the United States of America (US)." } } }, "auth_ref": [ "r1085", "r1086", "r1087", "r1088" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total other income (expense), net", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r105" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [
"http://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other income (expense):", "label": "Nonoperating Income (Expense) [Abstract]" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": [ "http://www.myriad.com/role/BASISOFPRESENTATIONDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of reporting segments", "label": "Number of Operating Segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise. (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r738", "r925" ] }, "us-gaap_OperatingCostsAndExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingCostsAndExpensesAbstract", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Costs and expenses:", "label": "Operating Costs and Expenses [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": {
"http://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunaudited": { "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Operating loss", "label": "Operating Income (Loss)", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r146", "r736", "r924", "r926", "r927", "r928", "r929" ] }, "us-gaap_OperatingLeaseLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiability", "crdr": "credit", "presentation": [ "http://www.myriad.com/role/LEASESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease liability", "label": "Operating Lease, Liability", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease." } } }, "auth_ref": [ "r520" ] }, "us-gaap_OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Current maturities of operating lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } }, "auth_ref": [ "r520" ] }, "mygn_OperatingLeaseLiabilityCurrentTerminated": { "xbrltype": "monetaryItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "OperatingLeaseLiabilityCurrentTerminated", "crdr": "debit", "presentation": [
"http://www.myriad.com/role/LEASESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Short term lease liability", "label": "Operating Lease, Liability, Current, Terminated", "documentation": "Operating Lease, Liability, Current, Terminated" } } }, "auth_ref": [] }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": {
"http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Noncurrent operating lease liabilities", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } }, "auth_ref": [ "r520" ] }, "us-gaap_OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited",
"http://www.myriad.com/role/LEASESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Operating lease right-of-use assets", "label": "Operating Lease, Right-of-Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } }, "auth_ref": [ "r519" ] }, "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense", "crdr": "debit", "calculation": {
"http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 13.0 } }, "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Non-cash lease expense", "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction", "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease." } } }, "auth_ref": [ "r914" ] }, "mygn_OptionsAndRestrictedStockUnitsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "OptionsAndRestrictedStockUnitsMember", "presentation": [
"http://www.myriad.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Options and RSUs", "label": "Options And Restricted Stock Units [Member]", "documentation": "Options and Restricted Stock Units." } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]", "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [
"http://www.myriad.com/role/BASISOFPRESENTATION" ], "lang": { "en-us": { "role": { "terseLabel": "BASIS OF PRESENTATION", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r61", "r131", "r638", "r639" ] }, "us-gaap_OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.myriad.com/role/ACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://www.myriad.com/role/ACCRUEDLIABILITIESDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other accrued liabilities", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r82" ] }, "us-gaap_OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": {
"http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 6.0 } }, "presentation": [
"http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } }, "auth_ref": [ "r166" ] }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri":
```

```
"http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax", "crdr": "credit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Change in foreign currency translation adjustment, net of tax", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss) Arising During Period, Net of Tax", "documentation": "Amount after tax, before reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature." } } }, "auth_ref": [ "r3", "r97", "r98", "r99", "r503", "r504", "r507" ] }, "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationNetOfTax", "crdr": "debit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://www.myriad.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSDetails", "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Reclassification of cumulative translation adjustment to income upon sale or liquidation of certain foreign entities, net of tax", "verboseLabel": "Reclassification of cumulative translation adjustment to income upon sale or liquidation of certain foreign entities", "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, Net of Tax", "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation." } } }, "auth_ref": [ "r5", "r6", "r99", "r174", "r506" ] }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent", "crdr": "credit", "presentation": [ "http://www.myriad.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSDetails", "http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive income (loss), net of tax", "verboseLabel": "Period translation adjustments", "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent", "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity." } } }, "auth_ref": [ "r8", "r13", "r132", "r176", "r179", "r207" ] }, "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax", "crdr": "debit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Reclassification adjustments for losses included in net loss, net of tax", "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Net of Tax", "documentation": "Amount after tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities." } } }, "auth_ref": [ "r5", "r99", "r174", "r269" ] }, "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax", "crdr": "credit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofComprehensiveLossunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Change in unrealized loss on available-for-sale debt securities, net of tax", "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax", "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale." } } }, "auth_ref": [ "r172", "r173", "r269" ] }, "us-gaap_OtherLiabilitiesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Other Liabilities Disclosure [Abstract]", "label": "Other Liabilities Disclosure [Abstract]" } } }, "auth_ref": [] }, "us-gaap_OtherLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesDisclosureTextBlock", "presentation": [ "http://www.myriad.com/role/OTHERLONGTERMLIABILITIES" ], "lang": { "en-us": { "role": { "terseLabel": "OTHER LONG-TERM LIABILITIES", "label": "Other Liabilities Disclosure [Text Block]", "documentation": "The entire disclosure for other liabilities." } } }, "auth_ref": [ "r82", "r86", "r964" ] }, "us-gaap_OtherLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 4.0 }, "http://www.myriad.com/role/OTHERLONGTERMLIABILITIESScheduleofOtherLongTermLiabilitiesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited", "http://www.myriad.com/role/OTHERLONGTERMLIABILITIESScheduleofOtherLongTermLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other long-term liabilities", "totalLabel": "Total other long-term liabilities", "label": "Other Liabilities, Noncurrent", "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r86" ] }, "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncurrentLiabilitiesTableTextBlock", "presentation": [ "http://www.myriad.com/role/OTHERLONGTERMLIABILITIESTables" ], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Other Long-Term Liabilities", "label": "Other Noncurrent Liabilities [Table Text Block]", "documentation": "Tabular disclosure of other noncurrent liabilities." } } }, "auth_ref": [] }, "us-gaap_OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunaudited": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Nonoperating Income (Expense)", "documentation": "Amount of income (expense) related to nonoperating activities, classified as other." } } }, "auth_ref": [ "r106" ] }, "us-gaap_OtherOperatingActivitiesCashFlowStatement": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherOperatingActivitiesCashFlowStatement", "crdr": "debit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Other non-cash adjustments", "label": "Other Operating Activities, Cash Flow Statement", "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)." } } }, "auth_ref": [] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Other Performance Measure, Amount", "label": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r856" ] }, "us-gaap_OtherSundryLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherSundryLiabilitiesNoncurrent", "crdr": "credit", "calculation": { "http://www.myriad.com/role/OTHERLONGTERMLIABILITIESScheduleofOtherLongTermLiabilitiesDetails": { "parentTag": "us-gaap_OtherLiabilitiesNoncurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://www.myriad.com/role/OTHERLONGTERMLIABILITIESScheduleofOtherLongTermLiabilitiesDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Sundry Liabilities, Noncurrent", "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are expected to be paid after one year (or the normal operating cycle, if longer), from the balance sheet date." } } }, "auth_ref": [ "r86", "r137" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount", "label": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r818", "r828", "r838", "r870" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Compensation Amount", "label": "Outstanding Recovery Compensation Amount" } } }, "auth_ref": [ "r821", "r831", "r841", "r873" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Outstanding Recovery, Individual Name" } } }, "auth_ref": [ "r821", "r831", "r841", "r873" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]" } } }, "auth_ref": [ "r845" ] }, "us-gaap_PayablesAndAccrualsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PayablesAndAccrualsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Payables and Accruals [Abstract]", "label": "Payables and Accruals [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PaymentsForProceedsFromTenantAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForProceedsFromTenantAllowance", "crdr": "credit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Tenant improvement allowance received", "label": "Payments for (Proceeds from) Tenant Allowance", "documentation": "Net cash outflow or inflow from monetary allowance granted by the landlord to a tenant to entice tenant to move into landlords building which will enable the tenant to prepare the leased premises for tenants occupancy." } } }, "auth_ref": [ "r25", "r109" ] }, "us-gaap_PaymentsForSoftware": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsForSoftware", "crdr": "credit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Capitalization of internal-use software costs", "label": "Payments for Software", "documentation": "The cash outflow associated with the development, modification or acquisition of software programs or applications for internal use (that is, not to be sold, leased or otherwise marketed to others) that qualify for capitalization." } } }, "auth_ref": [ "r110" ] }, "us-gaap_PaymentsOfDebtRestructuringCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsOfDebtRestructuringCosts", "crdr": "credit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Fees associated with issuance and refinancing of revolving credit facility", "label": "Payments of Debt Restructuring Costs", "documentation": "The cash outflow for cost incurred in the modification of term of existing debt agreement in order for the entity to achieve some advantage." } } }, "auth_ref": [ "r28" ] }, "us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsRelatedToTaxWithholdingForShareBasedCompensation", "crdr": "credit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedTerseLabel": "Payment of tax withheld for common stock issued under stock-based compensation plans", "label": "Payment, Tax Withholding, Share-Based Payment Arrangement", "documentation": "Amount of cash outflow to satisfy grantee's tax withholding obligation for award under share-based payment arrangement." } } }, "auth_ref": [ "r187" ] }, "us-gaap_PaymentsToAcquireOtherProductiveAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireOtherProductiveAssets", "crdr": "credit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited" ], "lang": { "en-us": { "role": { "negatedLabel": "Capital expenditures", "label": "Payments to Acquire Other Productive Assets", "documentation": "Amount of cash outflow for the purchase of or improvements to tangible or intangible assets, used to produce goods or deliver services, classified as other." } } }, "auth_ref": [ "r110" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": {
```

"terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]" } } }, "auth_ref": { "r855" } }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": { "r855" } }, "us-gaap_PendingLitigationMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PendingLitigationMember", "presentation": ["http://www.myriad.com/role/COMMITMENTSANDCONTINGENCIESDetails"], "lang": { "en-us": { "role": { "terseLabel": "Pending Litigation", "label": "Pending Litigation [Member]", "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process." } } }, "auth_ref": { "r971" } }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": ["r847"] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO", "label": "PEO [Member]" } } }, "auth_ref": ["r864"] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name" } } }, "auth_ref": ["r857"] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount" } } }, "auth_ref": ["r846"] }, "mygn_PharmacogenomicsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "PharmacogenomicsMember", "presentation": ["http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails", "http://www.myriad.com/role/REVENUESScheduleofTotalRevenuebyTypeandbyUSversusRestofWorldDetails"], "lang": { "en-us": { "role": { "terseLabel": "Pharmacogenomics", "label": "Pharmacogenomics [Member]", "documentation": "Pharmacogenomics" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": ["http://www.myriad.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofShareBasedCompensationEmployeeStockPurchasePlanActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Axis]", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": ["r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010"] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": ["http://www.myriad.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofShareBasedCompensationEmployeeStockPurchasePlanActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Plan Name [Domain]", "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": ["r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008", "r1009", "r1010"] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]" } } }, "auth_ref": ["r848"] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]" } } }, "auth_ref": ["r892"] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]" } } }, "auth_ref": ["r847"] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": ["http://www.myriad.com/role/PREFERREDANDCOMMONSTOCKHOLDERSEQUITYNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": ["r89", "r358"] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": ["http://www.myriad.com/role/PREFERREDANDCOMMONSTOCKHOLDERSEQUITYNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock authorized (shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": ["r89", "r658"] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": ["http://www.myriad.com/role/PREFERREDANDCOMMONSTOCKHOLDERSEQUITYNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Preferred stock outstanding (shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": ["r89", "r658", "r676", "r1083", "r1084"] }, "mygn_PrenatalTestingMember": { "xbrltype": "domainItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "PrenatalTestingMember", "presentation": ["http://www.myriad.com/role/REVENUESScheduleofTotalRevenuebyTypeandbyUSversusRestofWorldDetails"], "lang": { "en-us": { "role": { "terseLabel": "Prenatal", "label": "Prenatal Testing [Member]", "documentation": "Molecular diagnostic Prenatal testing." } } }, "auth_ref": [] }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses and other current assets", "label": "Prepaid Expense and Other Assets, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r907"] }, "us-gaap_PrepaidTaxes": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidTaxes", "crdr": "debit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Prepaid taxes", "label": "Prepaid Taxes", "documentation": "Amount of asset related to consideration paid in advance for income and other taxes that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": ["r732", "r741", "r938"] }, "us-gaap_PriorPeriodReclassificationAdjustmentDescription": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PriorPeriodReclassificationAdjustmentDescription", "presentation": ["http://www.myriad.com/role/BASISOFPRESENTATIONPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Reclassifications", "label": "Reclassification, Comparability Adjustment [Policy Text Block]", "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error." } } }, "auth_ref": ["r904"] }, "us-gaap_ProceedsFromDivestitureOfBusinessesNetOfCashDivested": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromDivestitureOfBusinessesNetOfCashDivested", "crdr": "debit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": ["http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from the sale of business, net cash sold", "label": "Proceeds from Divestiture of Businesses, Net of Cash Divested", "documentation": "This element represents the cash inflow during the period from the sale of a component of the entity." } } }, "auth_ref": ["r26"] }, "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions", "crdr": "debit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from common stock issued under stock-based compensation plans", "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised", "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised." } } }, "auth_ref": ["r4", "r17"] }, "us-gaap_ProceedsFromLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromLinesOfCredit", "crdr": "debit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": ["http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from revolving credit facility", "label": "Proceeds from Lines of Credit", "documentation": "Amount of cash inflow from contractual arrangement with the lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": ["r27", "r917"] }, "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities", "crdr": "debit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Proceeds from maturities and sales of marketable investment securities", "label": "Proceeds from Sale and Maturity of Marketable Securities", "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period." } } }, "auth_ref": [] }, "srt_ProductOrServiceAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductOrServiceAxis", "presentation": ["http://www.myriad.com/role/REVENUESScheduleofTotalRevenuebyTypeandbyUSversusRestofWorldDetails"], "lang": { "en-us": { "role": { "terseLabel": "Product and Service", "label": "Product and Service [Axis]" } } }, "auth_ref": ["r232", "r560", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r727", "r752", "r789", "r791", "r792", "r795", "r797", "r974", "r975", "r982", "r1051", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1080", "r1081"] }, "srt_ProductsAndServicesDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ProductsAndServicesDomain", "presentation": ["http://www.myriad.com/role/REVENUESScheduleofTotalRevenuebyTypeandbyUSversusRestofWorldDetails"], "lang": { "en-us": { "role": { "terseLabel": "Product and Service", "label": "Product and Service [Domain]" } } }, "auth_ref": ["r232", "r560", "r619", "r620", "r621", "r622", "r623", "r624", "r625", "r727", "r752", "r789", "r791", "r792", "r795", "r797", "r974", "r975", "r982", "r1051", "r1053", "r1054", "r1055", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1080", "r1081"] }, "us-gaap_PropertyPlantAndEquipmentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentAbstract", "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Abstract]", "label": "Property, Plant and Equipment [Abstract]" } } }, "auth_ref": [] }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": ["http://www.myriad.com/role/PROPERTYPLANTANDEQUIPMENTNETNarrativeDetails", "http://www.myriad.com/role/PROPERTYPLANTANDEQUIPMENTNETScheduleofPropertyPlantandEquipmentNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Axis]", "label": "Long-Lived Tangible Asset [Axis]", "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale." } } }, "auth_ref": ["r11", "r525"] }, "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentDisclosureTextBlock", "presentation": ["http://www.myriad.com/role/PROPERTYPLANTANDEQUIPMENTNET"], "lang": { "en-us": { "role": { "terseLabel": "PROPERTY, PLANT AND EQUIPMENT, NET", "label": "Property, Plant and Equipment Disclosure [Text Block]", "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections." } } }, "auth_ref": ["r118", "r150", "r151", "r152"] }, "us-gaap_PropertyPlantAndEquipmentGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentGross", "crdr": "debit", "calculation": { "http://www.myriad.com/role/PROPERTYPLANTANDEQUIPMENTNETScheduleofPropertyPlantandEquipmentNetDetails": { "parentTag": "us-gaap_PropertyPlantAndEquipmentNet", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.myriad.com/role/PROPERTYPLANTANDEQUIPMENTNETScheduleofPropertyPlantandEquipmentNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of

physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r119", "r162", "r609"] }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": [
"http://www.myriad.com/role/PROPERTYPLANTANDEQUIPMENTNETNarrativeDetails",
"http://www.myriad.com/role/PROPERTYPLANTANDEQUIPMENTNETScheduleofPropertyPlantandEquipmentNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r525"] }, "us-gaap_PropertyPlantAndEquipmentNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 3.0 },
"http://www.myriad.com/role/PROPERTYPLANTANDEQUIPMENTNETScheduleofPropertyPlantandEquipmentNetDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": ["http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited",
"http://www.myriad.com/role/PROPERTYPLANTANDEQUIPMENTNETScheduleofPropertyPlantandEquipmentNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Property, plant, and equipment, net", "totalLabel": "Property, plant and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": ["r11", "r525", "r600", "r609", "r779"] }, "us-gaap_PropertyPlantAndEquipmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": ["http://www.myriad.com/role/PROPERTYPLANTANDEQUIPMENTNETTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Property, Plant and Equipment, Net", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r11"] }, "us-gaap_PropertyPlantAndEquipmentTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": [
"http://www.myriad.com/role/PROPERTYPLANTANDEQUIPMENTNETNarrativeDetails",
"http://www.myriad.com/role/PROPERTYPLANTANDEQUIPMENTNETScheduleofPropertyPlantandEquipmentNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Long-Lived Tangible Asset [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": ["r119", "r525"] }, "us-gaap_ProvisionForDoubtfulAccounts": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProvisionForDoubtfulAccounts", "crdr": "debit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 20.0 } }, "presentation": [
"http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Bad debt expense", "label": "Accounts Receivable, Credit Loss Expense (Reversal)", "documentation": "Amount of expense (reversal of expense) for expected credit loss on accounts receivable." } } }, "auth_ref": ["r186", "r275"] }, "mygn_PurchasesOfPropertyPlantAndEquipmentAndCapitalizationOfInternalUseSoftwareInAccountsPayableAndAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.myriad.com/20240930", "localname":
"PurchasesOfPropertyPlantAndEquipmentAndCapitalizationOfInternalUseSoftwareInAccountsPayableAndAccruedLiabilities", "crdr": "credit", "presentation": [
"http://www.myriad.com/role/SUPPLEMENTALCASHFLOWINFORMATIONScheduleofSupplementalCashFlowInformationDetails"], "lang": { "en-us": { "role": { "terseLabel": "Purchases of property, plant and equipment and capitalization of internal-use software in accounts payable and accrued liabilities", "label": "Purchases Of Property, Plant And Equipment And Capitalization Of Internal-use Software In Accounts Payable And Accrued Liabilities", "documentation": "Purchases Of Property, Plant And Equipment And Capitalization Of Internal-use Software In Accounts Payable And Accrued Liabilities" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]" } } }, "auth_ref": ["r845"] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/PvpDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]" } } }, "auth_ref": ["r845"] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": ["http://www.myriad.com/role/COMMITMENTSANDCONTINGENCIESDetails",
"http://www.myriad.com/role/LEASESDetails", "http://www.myriad.com/role/LONGTERMDEBTDetails",
"http://www.myriad.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]" } } }, "auth_ref": ["r313", "r314", "r315", "r316", "r391", "r398", "r426", "r427", "r428", "r435", "r482", "r534", "r543", "r559", "r626", "r628", "r636", "r648", "r649", "r701", "r703", "r705", "r706", "r708", "r723", "r724", "r739", "r750", "r764", "r771", "r772", "r776", "r777", "r791", "r800", "r969", "r980", "r1023", "r1040", "r1041", "r1042", "r1043", "r1044"] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": ["http://www.myriad.com/role/COMMITMENTSANDCONTINGENCIESDetails", "http://www.myriad.com/role/LEASESDetails",
"http://www.myriad.com/role/LONGTERMDEBTDetails", "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]" } } }, "auth_ref": ["r313", "r314", "r315", "r316", "r391", "r398", "r426", "r427", "r428", "r435", "r482", "r534", "r543", "r559", "r626", "r628", "r636", "r648", "r649", "r701", "r703", "r705", "r706", "r708", "r723", "r724", "r739", "r750", "r764", "r771", "r772", "r776", "r777", "r791", "r800", "r969", "r980", "r1023", "r1040", "r1041", "r1042", "r1043", "r1044"] },
"mygn_RaygenIncVersusMyriadWomensHealthIncMember": { "xbrltype": "domainItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "RaygenIncVersusMyriadWomensHealthIncMember", "presentation": ["http://www.myriad.com/role/OTHERLONGTERMLIABILITIESNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Raygen, Inc vs. Myriad Women's Health, Inc.", "label": "Raygen, Inc Versus Myriad Women's Health, Inc. [Member]", "documentation": "Raygen, Inc Versus Myriad Women's Health, Inc." } } }, "auth_ref": [] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]" } } }, "auth_ref": ["r813", "r823", "r833", "r865"] }, "mygn_RefundsPayableAndReserveCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "RefundsPayableAndReserveCurrent", "crdr": "credit", "calculation": {
"http://www.myriad.com/role/ACCRUEDLIABILITIESDetails": { "parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [
"http://www.myriad.com/role/ACCRUEDLIABILITIESDetails"], "lang": { "en-us": { "role": { "terseLabel": "Refunds payable and reserves", "label": "Refunds Payable And Reserve, Current", "documentation": "Refunds Payable And Reserve, Current" } } }, "auth_ref": [] }, "us-gaap_RepaymentsOfLinesOfCredit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RepaymentsOfLinesOfCredit", "crdr": "credit", "calculation": {
"http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": -1.0, "order": 3.0 } }, "presentation": ["http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited"], "lang": { "en-us": { "role": { "negatedTerseLabel": "Repayment of revolving credit facility", "label": "Repayments of Lines of Credit", "documentation": "Amount of cash outflow for payment of an obligation from a lender, including but not limited to, letter of credit, standby letter of credit and revolving credit arrangements." } } }, "auth_ref": ["r111", "r917"] }, "us-gaap_ReportingUnitAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReportingUnitAxis", "presentation": [
"http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Reporting Unit [Axis]", "label": "Reporting Unit [Axis]", "documentation": "Information by reporting unit." } } }, "auth_ref": ["r288", "r289", "r742"] }, "us-gaap_ReportingUnitDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReportingUnitDomain", "presentation": [
"http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Reporting Unit [Domain]", "label": "Reporting Unit [Domain]", "documentation": "Level of reporting at which goodwill is tested for impairment." } } }, "auth_ref": ["r288", "r289", "r742"] }, "us-gaap_ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ReportingUnitPercentageOfFairValueInExcessOfCarryingAmount", "presentation": ["http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Percentage of fair value in excess of carrying value", "label": "Reporting Unit, Percentage of Fair Value in Excess of Carrying Amount", "documentation": "Percentage of fair value of reporting unit in excess of carrying amount." } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": {
"http://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Research and development expense", "label": "Research and Development Expense", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": ["r436", "r725", "r737", "r1045"] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [
"http://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Research and development expense", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date:", "label": "Restatement Determination Date [Axis]" } } }, "auth_ref": ["r814", "r824", "r834", "r866"] },
"ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Restatement Determination Date", "label": "Restatement Determination Date" } } }, "auth_ref": ["r815", "r825", "r835", "r867"] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": ["http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "Restatement does not require Recovery", "label": "Restatement Does Not Require Recovery [Text Block]" } } }, "auth_ref": ["r822", "r832", "r842", "r874"] }, "us-gaap_RestrictedCash": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCash", "crdr": "debit", "calculation": { "http://www.myriad.com/role/SUPPLEMENTALCASHFLOWINFORMATIONScheduleofCashandCashEquivalentsandRestrictedCashDetails": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.myriad.com/role/SUPPLEMENTALCASHFLOWINFORMATIONScheduleofCashandCashEquivalentsandRestrictedCashDetails"], "lang": { "en-us": { "role": { "terseLabel": "Restricted cash", "label": "Restricted Cash", "documentation": "Amount of cash restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits." } } }, "auth_ref": ["r905", "r916", "r1047", "r1050"] }, "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": [
"http://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIESScheduleofFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Cash and Cash Equivalents [Domain]", "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": ["r161"] }, "us-gaap_RestrictedStockUnitsRSUMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": [
"http://www.myriad.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails",
"http://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"], "lang": { "en-us": { "role": { "terseLabel": "RSUs", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met." } } }, "auth_ref": [] }, "us-

gaap_RestructuringReserveAcceleratedDepreciation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestructuringReserveAcceleratedDepreciation", "crdr": "debit", "presentation": ["http://www.myriad.com/role/PROPERTYPLANTANDEQUIPMENTNETNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Accelerated depreciation", "label": "Restructuring and Related Cost, Accelerated Depreciation", "documentation": "Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan." } } }, "auth_ref": [] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": ["http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r92", "r127", "r606", "r633", "r635", "r641", "r659", "r779"] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": ["http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Accumulated deficit", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": ["r156", "r198", "r199", "r200", "r202", "r207", "r209", "r211", "r271", "r272", "r301", "r445", "r446", "r453", "r454", "r455", "r457", "r460", "r461", "r466", "r468", "r469", "r471", "r474", "r515", "r517", "r630", "r632", "r643", "r1083"] }, "us-gaap_RevenueFromContractWithCustomerAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerAbstract", "lang": { "en-us": { "role": { "terseLabel": "Revenue from Contract with Customer [Abstract]", "label": "Revenue from Contract with Customer [Abstract]" } } }, "auth_ref": [] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunaudited": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": ["http://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunaudited", "http://www.myriad.com/role/REVENUEScheduleofTotalRevenuebyTypeandbyUSversusRestofWorldDetails"], "lang": { "en-us": { "role": { "terseLabel": "Testing revenue", "netLabel": "Total revenue", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": ["r144", "r145", "r221", "r224", "r225", "r229", "r231", "r232", "r233", "r235", "r388", "r389", "r560"] }, "us-gaap_RevenueFromContractWithCustomerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerMember", "presentation": ["http://www.myriad.com/role/REVENUENarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revenues", "label": "Revenue from Contract with Customer Benchmark [Member]", "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation." } } }, "auth_ref": ["r235", "r894"] }, "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerPolicyTextBlock", "presentation": ["http://www.myriad.com/role/BASISOFPRESENTATIONPolicies"], "lang": { "en-us": { "role": { "terseLabel": "Revenue", "label": "Revenue from Contract with Customer [Policy Text Block]", "documentation": "Disclosure of accounting policy for revenue from contract with customer." } } }, "auth_ref": ["r154", "r380", "r381", "r382", "r383", "r384", "r385", "r386", "r387", "r726"] }, "us-gaap_RevenueFromContractWithCustomerProductAndServiceExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerProductAndServiceExtensibleList", "presentation": ["http://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Revenue from contract with customer, product and service, extensible enumeration", "label": "Revenue from Contract with Customer, Product and Service [Extensible Enumeration]", "documentation": "Indicates product and service for revenue from satisfaction of performance obligation by transferring promised product and service to customer." } } }, "auth_ref": ["r752"] }, "us-gaap_RevenueFromContractWithCustomerTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerTextBlock", "presentation": ["http://www.myriad.com/role/REVENUE"], "lang": { "en-us": { "role": { "terseLabel": "REVENUE", "label": "Revenue from Contract with Customer [Text Block]", "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts." } } }, "auth_ref": ["r154", "r372", "r373", "r374", "r375", "r376", "r377", "r378", "r379", "r390"] }, "us-gaap_RevolvingCreditFacilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevolvingCreditFacilityMember", "presentation": ["http://www.myriad.com/role/LONGTERMDEBTDetails"], "lang": { "en-us": { "role": { "terseLabel": "Revolving Credit Facility", "label": "Revolving Credit Facility [Member]", "documentation": "Arrangement in which loan proceeds can continuously be obtained following repayments, but the total amount borrowed cannot exceed a specified maximum amount." } } }, "auth_ref": [] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]" } } }, "auth_ref": ["r883"] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": ["http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"], "lang": { "en-us": { "role": { "terseLabel": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]" } } }, "auth_ref": ["r883"] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": ["http://www.myriad.com/role/ACCRUEDLIABILITIESTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Accrued Liabilities", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock", "presentation": ["http://www.myriad.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cumulative Translation Adjustments in Accumulated Other Comprehensive Income (Loss)", "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]", "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)." } } }, "auth_ref": ["r23", "r1029", "r1030"] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": ["http://www.myriad.com/role/PREFERREDANDCOMMONSTOCKHOLDERSEQUITYTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Potential Dilutive Common Shares", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": ["r32"] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems", "presentation": ["http://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIESScheduleofFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Available-for-sale Securities [Line Items]", "label": "Debt Securities, Available-for-Sale [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": ["r239", "r240", "r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250"] }, "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock", "presentation": ["http://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIESTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Fair Value for Available-for-Sale Securities by Major Security Type and Class of Security", "label": "Schedule of Available-for-Sale Securities Reconciliation [Table Text Block]", "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock", "presentation": ["http://www.myriad.com/role/SUPPLEMENTALCASHFLOWINFORMATIONTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Cash and Cash Equivalents", "label": "Schedule of Cash and Cash Equivalents [Table Text Block]", "documentation": "Tabular disclosure of the components of cash and cash equivalents." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock", "presentation": ["http://www.myriad.com/role/SUPPLEMENTALCASHFLOWINFORMATIONTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Supplemental Cash Flow Information", "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]", "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfCommonStockOutstandingRollForwardTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCommonStockOutstandingRollForwardTableTextBlock", "presentation": ["http://www.myriad.com/role/PREFERREDANDCOMMONSTOCKHOLDERSEQUITYTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Common Stock Issued and Outstanding", "label": "Schedule of Common Stock Outstanding Roll Forward [Table Text Block]", "documentation": "Tabular disclosure of the change in common stock outstanding." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": ["http://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements." } } }, "auth_ref": ["r46"] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": ["http://www.myriad.com/role/STOCKBASEDCOMPENSATIONTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Stock-Based Compensation Expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": ["r46"] }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "presentation": ["http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Amortizable Intangible Assets", "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": ["r743", "r959"] }, "us-gaap_ScheduleOfGoodwillTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfGoodwillTextBlock", "presentation": ["http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Changes in Carrying Amount of Goodwill", "label": "Schedule of Goodwill [Table Text Block]", "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule." } } }, "auth_ref": ["r742", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951"] }, "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock", "presentation": ["http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Non-amortizable Intangible Assets", "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment." } } }, "auth_ref": ["r743", "r961"] }, "mygn_ScheduleOfIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "ScheduleOfIntangibleAssetsLineItems", "presentation": ["http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Intangible Assets [Line Items]", "label": "Schedule Of Intangible Assets [Line Items]", "documentation": "Schedule Of Intangible Assets [Line Items]" } } }, "auth_ref": [] }, "mygn_ScheduleOfIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "ScheduleOfIntangibleAssetsTable", "presentation": ["http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSNarrativeDetails", "http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofIntangibleAssetsDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Intangible

Assets [Table]", "label": "Schedule Of Intangible Assets [Table]", "documentation": "Schedule of Intangible Assets [Table]" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": ["http://www.myriad.com/role/PROPERTYPLANTANDEQUIPMENTNETNarrativeDetails", "http://www.myriad.com/role/PROPERTYPLANTANDEQUIPMENTNETScheduleofPropertyPlantandEquipmentNetDetails"], "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation." } } }, "auth_ref": ["r11", "r525"] }, "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock", "presentation": ["http://www.myriad.com/role/SUPPLEMENTALCASHFLOWINFORMATIONTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Restrictions on Cash and Cash Equivalents", "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]", "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage." } } }, "auth_ref": ["r19", "r134", "r1050"] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": ["http://www.myriad.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails", "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofShareBasedCompensationEmployeeStockPurchasePlanActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": ["r400", "r402", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429"] }, "us-gaap_ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationEmployeeStockPurchasePlanActivityTableTextBlock", "presentation": ["http://www.myriad.com/role/STOCKBASEDCOMPENSATIONTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Shares Purchased and Compensation Expense", "label": "Schedule of Share-Based Compensation, Employee Stock Purchase Plan, Activity [Table Text Block]", "documentation": "Tabular disclosure of employee stock purchase plan activity." } } }, "auth_ref": ["r45"] }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": ["http://www.myriad.com/role/STOCKBASEDCOMPENSATIONTables"], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Restricted Stock Unit Activity", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": ["r128"] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": ["http://www.myriad.com/role/STOCKBASEDCOMPENSATIONTables"], "lang": { "en-us": { "role": { "verboseLabel": "Schedule of Stock Option Activity", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": ["r15", "r16", "r128"] }, "us-gaap_ScheduleOfWeightedAverageNumberOfSharesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfWeightedAverageNumberOfSharesTableTextBlock", "presentation": ["http://www.myriad.com/role/PREFERREDANDCOMMONSTOCKHOLDERSEQUITYTables"], "lang": { "en-us": { "role": { "terseLabel": "Schedule of Reconciliation of Denominators of Basic and Diluted Earnings Per Share Computations", "label": "Schedule of Weighted Average Number of Shares [Table Text Block]", "documentation": "Tabular disclosure of the weighted average number of shares used in calculating basic net earnings per share (or unit) and diluted earnings per share (or unit)." } } }, "auth_ref": ["r31"] }, "mygn_SecondInstallmentMember": { "xbrltype": "domainItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "SecondInstallmentMember", "presentation": ["http://www.myriad.com/role/OTHERLONGTERMLIABILITIESNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Second Installment", "label": "Second Installment [Member]", "documentation": "Second Installment" } } }, "auth_ref": [] }, "us-gaap_SecuredOvernightFinancingRateSofrMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredOvernightFinancingRateSofrMember", "presentation": ["http://www.myriad.com/role/LONGTERMDEBTDetails"], "lang": { "en-us": { "role": { "terseLabel": "Secured Overnight Financing Rate (SOFR)", "label": "Secured Overnight Financing Rate (SOFR) [Member]", "documentation": "Interest rate at which bank can borrow U.S. dollar overnight while posting U.S. Treasury bond as collateral." } } }, "auth_ref": ["r1017"] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": ["http://www.myriad.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": ["r808"] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": ["http://www.myriad.com/role/Cover"], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": ["r810"] }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": ["http://www.myriad.com/role/LEASESDetails", "http://www.myriad.com/role/REVENUEScheduleofTotalRevenuebyTypeandbyUSversusRestofWorldDetails"], "lang": { "en-us": { "role": { "terseLabel": "Geographical", "label": "Geographical [Domain]" } } }, "auth_ref": ["r233", "r234", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570", "r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592", "r645", "r646", "r647", "r702", "r704", "r707", "r709", "r711", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r728", "r753", "r781", "r782", "r783", "r784", "r785", "r786", "r787", "r788", "r793", "r800", "r982", "r1051", "r1053", "r1054", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064", "r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1080", "r1081"] }, "us-gaap_SellingGeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunaudited": { "parentTag": "us-gaap_CostsAndExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": ["http://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunaudited"], "lang": { "en-us": { "role": { "terseLabel": "Selling, general, and administrative expense", "label": "Selling, General and Administrative Expense", "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc." } } }, "auth_ref": ["r104"] }, "us-gaap_SellingGeneralAndAdministrativeExpensesMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SellingGeneralAndAdministrativeExpensesMember", "presentation": ["http://www.myriad.com/role/LEASESDetails", "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Selling, general, and administrative expense", "label": "Selling, General and Administrative Expenses [Member]", "documentation": "Primary financial statement caption encompassing selling, general and administrative expense." } } }, "auth_ref": [] }, "mygn_SettledLitigationContingentPaymentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "SettledLitigationContingentPaymentsMember", "presentation": ["http://www.myriad.com/role/OTHERLONGTERMLIABILITIESNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Settled Litigation, Contingent Payments", "label": "Settled Litigation, Contingent Payments [Member]", "documentation": "Settled Litigation, Contingent Payments" } } }, "auth_ref": [] }, "mygn_SettledLitigationNonContingentPaymentsMember": { "xbrltype": "domainItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "SettledLitigationNonContingentPaymentsMember", "presentation": ["http://www.myriad.com/role/OTHERLONGTERMLIABILITIESNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Settled Litigation, Non-Contingent Payments", "label": "Settled Litigation, Non-Contingent Payments [Member]", "documentation": "Settled Litigation, Non-Contingent Payments" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } }, "presentation": ["http://www.myriad.com/role/CondensedConsolidatedStatementsofCashFlowsunaudited", "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofStockBasedCompensationExpenseDetails"], "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "verboseLabel": "Total stock-based compensation expense", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": ["r9"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": ["http://www.myriad.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Service period for award vesting (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": ["r765"] }, "mygn_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsAverageTradingDays": { "xbrltype": "integerItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRightsAverageTradingDays", "presentation": ["http://www.myriad.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails"], "lang": { "en-us": { "role": { "terseLabel": "Vesting rights, average trading days", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Average Trading Days", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Award Vesting Rights, Average Trading Days" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": ["http://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails"], "lang": { "en-us": { "role": { "negatedLabel": "RSUs canceled (shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": ["r420"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": ["http://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "RSUs canceled (dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": ["r420"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": ["http://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails"], "lang": { "en-us": { "role": { "terseLabel": "RSUs granted (shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": ["r418"] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",

```
"presentation": [ "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "RSUs granted (dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": [ "r418" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "presentation": [ "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "RSUs unvested and outstanding, beginning balance (shares)", "periodEndLabel": "RSUs unvested and outstanding, ending balance (shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": [ "r415", "r416" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": [ "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": [ "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "periodStartLabel": "RSUs unvested and outstanding, beginning balance (dollars per share)", "periodEndLabel": "RSUs unvested and outstanding, ending balance (dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": [ "r415", "r416" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": [ "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Date Fair Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": [ "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "negatedLabel": "RSUs vested (shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": [ "r419" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "RSUs vested (dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": [ "r419" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails", "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofShareBasedCompensationEmployeeStockPurchasePlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Share-Based Compensation [Line Items]", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r400", "r402", "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberOfSharesPerEmployee", "presentation": [ "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Maximum number of shares per participant per offering period (shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Maximum Number of Shares Per Employee", "documentation": "The highest quantity of shares an employee can purchase under the plan per period." } } }, "auth_ref": [ "r43" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized", "presentation": [ "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Number of additional shares authorized (shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Additional Shares Authorized", "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares available for grant (shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r43" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options exercisable at end of period (shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r409" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options exercisable at end of period (dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r409" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r411" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options outstanding (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r407", "r408" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Options outstanding (dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r407", "r408" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod", "presentation": [ "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares issued under the plan (shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Issued in Period", "documentation": "Number of shares issued under share-based payment arrangement." } } }, "auth_ref": [ "r43" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward", "presentation": [ "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofShareBasedCompensationEmployeeStockPurchasePlanActivityDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Shares purchased under the plan", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award", "documentation": "Number of shares purchased for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r1012" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails", "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofRestrictedStockUnitActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Award Type [Domain]", "label": "Award Type [Domain]", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r404", "r405", "r406", "r407", "r408", "r409", "r410", "r411", "r412", "r413", "r414", "r415", "r416", "r417", "r418", "r419", "r420", "r421", "r422", "r423", "r424", "r425", "r426", "r427", "r428", "r429" ] }, "us-gaap_ShareBasedCompensationAwardTrancheOneMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheOneMember", "presentation": [ "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Achievement Levels Based on EPS Targets", "label": "Share-Based Payment Arrangement, Tranche One [Member]", "documentation": "First portion of award under share-based payment arrangement differentiated by vesting
```

```
feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheThreeMember", "presentation": [
"http://www.myriad.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Relative Total Stockholders Return", "label":
"Share-Based Payment Arrangement, Tranche Three [Member]", "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting
feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationAwardTrancheTwoMember", "presentation": [
"http://www.myriad.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Performance Based on Nasdaq Healthcare Provider
Index", "label": "Share-Based Payment Arrangement, Tranche Two [Member]", "documentation": "Second portion of award under share-based payment arrangement
differentiated by vesting feature, including, but not limited to, performance measure or service period." } } }, "auth_ref": [] }, "us-
gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-
gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage", "presentation": [
"http://www.myriad.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting weight (percent)", "label": "Share-Based
Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage", "documentation": "Percentage of vesting of award under share-based
payment arrangement." } } }, "auth_ref": [ "r985" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1", "crdr":
"debit", "presentation": [ "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONScheduleofShareBasedCompensationEmployeeStockPurchasePlanActivityDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Plan compensation expense", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount", "documentation":
"Amount of cost expensed and capitalized for award under share-based payment arrangement." } } }, "auth_ref": [ "r430" ] }, "us-gaap_StatementEquityComponentsAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [
"http://www.myriad.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSDetails",
"http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components", "label":
"Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r14", "r90", "r93", "r94", "r156", "r180", "r181", "r182", "r198",
"r199", "r200", "r202", "r207", "r209", "r211", "r222", "r271", "r272", "r301", "r371", "r445", "r446", "r453", "r454", "r455", "r457", "r460", "r461", "r466", "r467", "r468",
"r469", "r470", "r471", "r474", "r508", "r509", "r510", "r511", "r512", "r513", "r515", "r517", "r527", "r613", "r630", "r631", "r632", "r643", "r696" ] },
"srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": [
"http://www.myriad.com/role/LEASESDetails", "http://www.myriad.com/role/REVENUEScheduleofTotalRevenuebyTypeandbyUSversusRestofWorldDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": [ "r233", "r234", "r563", "r564", "r565", "r566", "r567", "r568", "r569", "r570",
"r571", "r572", "r573", "r574", "r575", "r576", "r577", "r578", "r579", "r580", "r581", "r582", "r583", "r584", "r585", "r586", "r587", "r588", "r589", "r590", "r591", "r592",
"r645", "r646", "r647", "r702", "r704", "r707", "r709", "r711", "r714", "r715", "r716", "r717", "r718", "r719", "r720", "r721", "r722", "r728", "r753", "r781", "r782", "r783",
"r784", "r785", "r786", "r787", "r788", "r793", "r800", "r982", "r1051", "r1053", "r1054", "r1056", "r1057", "r1058", "r1059", "r1060", "r1061", "r1062", "r1063", "r1064",
"r1065", "r1066", "r1067", "r1068", "r1069", "r1070", "r1071", "r1072", "r1073", "r1074", "r1075", "r1076", "r1077", "r1078", "r1080", "r1081" ] }, "us-
gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [
"http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Line Items]", "label":
"Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information
associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r198", "r199", "r200", "r222", "r517", "r560", "r640", "r644", "r650", "r651",
"r652", "r653", "r654", "r655", "r658", "r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r671", "r672", "r673", "r674", "r675", "r677", "r679", "r680",
"r682", "r683", "r684", "r685", "r686", "r687", "r688", "r689", "r690", "r691", "r692", "r693", "r696", "r801" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows
[Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]",
"label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of
Comprehensive Income [Abstract]", "label": "Statement of Comprehensive Income [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel":
"Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [
"http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Statement [Table]", "label":
"Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash
flows, and shareholders' equity." } } }, "auth_ref": [ "r198", "r199", "r200", "r222", "r236", "r517", "r560", "r640", "r644", "r650", "r651", "r652", "r653", "r654", "r655", "r658",
"r661", "r662", "r663", "r664", "r665", "r666", "r667", "r668", "r669", "r671", "r672", "r673", "r674", "r675", "r677", "r679", "r680", "r682", "r683", "r684", "r685", "r686",
"r687", "r688", "r689", "r690", "r691", "r692", "r693", "r696", "r801" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us":
{ "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": [ "r817", "r827", "r837",
"r869" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Stock
Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined
number of grantor's shares during predetermined time period." } } }, "auth_ref": [] },
"mygn_StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans": { "xbrltype": "sharesItemType", "nsuri":
"http://www.myriad.com/20240930", "localname": "StockIssuedDuringPeriodSharesShareBasedPaymentArrangementAndEmployeeStockPurchasePlans", "presentation": [
"http://www.myriad.com/role/PREFERREDANDCOMMONSTOCKHOLDERSEQUITYScheduleofCommonStockIssuedandOutstandingDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plan (shares)", "label": "Stock
Issued During Period, Shares, Share-Based Payment Arrangement And Employee Stock Purchase Plans", "documentation": "Stock Issued During Period, Shares, Share-Based
Payment Arrangement And Employee Stock Purchase Plans" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueShareBasedCompensation", "crdr": "credit", "presentation": [
"http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Issuance of common stock
under stock-based compensation plans, net of shares exchanged for withholding tax", "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
"documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)." } } }, "auth_ref": [
"r44", "r89", "r90", "r127" ] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity",
"crdr": "credit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
"weight": 1.0, "order": 3.0 } }, "presentation": [ "http://www.myriad.com/role/ACCUMULATEDOTHERCOMPREHENSIVEINCOMELOSSDetails",
"http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited",
"http://www.myriad.com/role/CondensedConsolidatedStatementsofStockholdersEquityunaudited" ], "lang": { "en-us": { "role": { "totalLabel": "Total stockholders' equity",
"periodStartLabel": "Beginning balance", "periodEndLabel": "Ending balance", "label": "Equity, Attributable to Parent", "documentation": "Amount of equity (deficit)
attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r90", "r93", "r94", "r117", "r660", "r676", "r697",
"r698", "r779", "r807", "r918", "r937", "r1028", "r1083" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "StockholdersEquityAbstract", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": {
"terseLabel": "Stockholders\u2019 equity:", "label": "Equity, Attributable to Parent [Abstract]" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [
"http://www.myriad.com/role/PREFERREDANDCOMMONSTOCKHOLDERSEQUITY" ], "lang": { "en-us": { "role": { "terseLabel": "PREFERRED AND COMMON STOCKHOLDERS'
EQUITY", "label": "Equity [Text Block]", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r124", "r194", "r357", "r359", "r360", "r361", "r362", "r363",
"r364", "r365", "r366", "r367", "r368", "r370", "r371", "r473", "r699", "r700", "r710" ] }, "us-gaap_SupplementalCashFlowElementsAbstract": { "xbrltype": "stringItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowElementsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Supplemental Cash Flow Elements
[Abstract]", "label": "Supplemental Cash Flow Elements [Abstract]" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": {
"terseLabel": "Tabular List, Table", "label": "Tabular List [Table Text Block]" } } }, "auth_ref": [ "r863" ] }, "us-gaap_TaxesPayableCurrent": { "xbrltype": "monetaryItemType",
"nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxesPayableCurrent", "crdr": "credit", "calculation": { "http://www.myriad.com/role/ACCRUEDLIABILITIESDetails": {
"parentTag": "us-gaap_AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://www.myriad.com/role/ACCRUEDLIABILITIESDetails" ], "lang": { "en-
us": { "role": { "terseLabel": "Accrued taxes payable", "label": "Taxes Payable, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred
and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within
the normal operating cycle if longer)." } } }, "auth_ref": [ "r81", "r82" ] }, "mygn_ThirdInstallmentMember": { "xbrltype": "domainItemType", "nsuri":
"http://www.myriad.com/20240930", "localname": "ThirdInstallmentMember", "presentation": [ "http://www.myriad.com/role/OTHERLONGTERMLIABILITIESNarrativeDetails"
], "lang": { "en-us": { "role": { "terseLabel": "Third Installment", "label": "Third Installment [Member]", "documentation": "Third Installment" } } }, "auth_ref": [] },
"srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": [
"http://www.myriad.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Axis]", "label": "Title and
Position [Axis]" } } }, "auth_ref": [ "r930", "r1036" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [
"http://www.myriad.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Title of Individual [Domain]", "label": "Title and
Position [Domain]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Total Shareholder Return Amount",
"label": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r855" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": {
"role": { "terseLabel": "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]" } } }, "auth_ref": [ "r862" ] }, "us-
gaap_TrademarksMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TrademarksMember", "presentation": [
"http://www.myriad.com/role/GOODWILLANDINTANGIBLEASSETSScheduleofIntangibleAssetsDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Trademarks", "label":
"Trademarks [Member]", "documentation": "Rights acquired through registration of a trademark to gain or protect exclusive use of a business name, symbol or other device or
style." } } }, "auth_ref": [ "r51", "r743", "r953", "r954", "r955", "r956", "r957", "r958", "r960", "r961", "r962", "r963" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role":
{ "terseLabel": "Trading Arrangement:", "label": "Trading Arrangement [Axis]" } } }, "auth_ref": [ "r882" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType",
"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": {
"role": { "terseLabel": "Trading Arrangements, by Individual", "label": "Trading Arrangements, by Individual [Table]" } } }, "auth_ref": [ "r884" ] }, "dei_TradingSymbol": {
"xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.myriad.com/role/Cover" ], "lang": {
"en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref":
[] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [
```

```
"http://www.myriad.com/role/FAIRVALUEMEASUREMENTSScheduleofFairValueofFinancialAssetsandLiabilitiesDetails",
"http://www.myriad.com/role/MARKETABLEINVESTMENTSECURITIESScheduleofFairValueforAvailableforSaleSecuritiesbyMajorSecurityTypeandClassofSecurityDetails" ],
"lang": { "en-us": { "role": { "terseLabel": "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that
imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a
contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r239", "r240",
"r241", "r242", "r243", "r244", "r245", "r246", "r247", "r248", "r249", "r250", "r251", "r252", "r253", "r254", "r255", "r256", "r257", "r258", "r259", "r260", "r261", "r262",
"r263", "r264", "r265", "r266", "r267", "r268", "r354", "r369", "r472", "r499", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539",
"r540", "r541", "r542", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r614", "r767", "r769", "r771",
"r772", "r773", "r774", "r775", "r776", "r777", "r780", "r897", "r898", "r899", "r900", "r901", "r902", "r903", "r933", "r934", "r935", "r936", "r1019", "r1022", "r1023", "r1024",
"r1025", "r1027" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Adoption Date", "label": "Trading Arrangement Adoption Date" } } },
"auth_ref": [ "r885" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Arrangement Duration", "label": "Trading Arrangement Duration" } }
}, "auth_ref": [ "r886" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate",
"presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Expiration Date", "label": "Trading Arrangement
Expiration Date" } } }, "auth_ref": [ "r886" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName",
"presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Name", "label": "Trading Arrangement, Individual
Name" } } }, "auth_ref": [ "r884" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle",
"presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Title", "label": "Trading Arrangement, Individual
Title" } } }, "auth_ref": [ "r884" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "terseLabel": "Aggregate Available",
"label": "Trading Arrangement, Securities Aggregate Available Amount" } } }, "auth_ref": [ "r887" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role":
{ "terseLabel": "Termination Date", "label": "Trading Arrangement Termination Date" } } }, "auth_ref": [ "r885" ] }, "mygn_TumorProfilingMember": { "xbrltype":
"domainItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "TumorProfilingMember", "presentation": [
"http://www.myriad.com/role/REVENUEScheduleofTotalRevenuebyTypeandbyUSversusRestofWorldDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Tumor Profiling",
"label": "Tumor Profiling [Member]", "documentation": "Tumor Profiling" } } }, "auth_ref": [] },
"mygn_TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember": { "xbrltype": "domainItemType", "nsuri": "http://www.myriad.com/20240930",
"localname": "TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember", "presentation": [
"http://www.myriad.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "2017 Plan", "label": "Two Thousand Seventeen
Employee Director And Consultant Equity Incentive Plan [Member]", "documentation": "Two Thousand Seventeen Employee Director And Consultant Equity Incentive Plan" }
} }, "auth_ref": [] }, "us-gaap_TypeOfCostGoodOrServiceExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"TypeOfCostGoodOrServiceExtensibleList", "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunaudited" ], "lang": { "en-us": {
"role": { "terseLabel": "Cost, product and service, extensible enumeration", "label": "Cost, Product and Service [Extensible Enumeration]", "documentation": "Indicates type of
cost from product sold and service rendered." } } }, "auth_ref": [ "r983" ] }, "country_US": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/country/2024",
"localname": "US", "presentation": [ "http://www.myriad.com/role/REVENUEScheduleofTotalRevenuebyTypeandbyUSversusRestofWorldDetails" ], "lang": { "en-us": { "role": {
"terseLabel": "U.S.", "label": "UNITED STATES" } } }, "auth_ref": [] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": {
"role": { "terseLabel": "Underlying Security Market Price Change", "label": "Underlying Security Market Price Change, Percent" } } }, "auth_ref": [ "r881" ] },
"mygn_UnrecognizedTaxBenefitsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "UnrecognizedTaxBenefitsNet", "crdr":
"credit", "calculation": { "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } },
"presentation": [ "http://www.myriad.com/role/CondensedConsolidatedBalanceSheetsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Unrecognized tax benefits",
"label": "Unrecognized Tax Benefits, Net", "documentation": "Unrecognized Tax Benefits, Net" } } }, "auth_ref": [] }, "us-gaap_VariableRateAxis": { "xbrltype":
"stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateAxis", "presentation": [ "http://www.myriad.com/role/LONGTERMDEBTDetails" ], "lang": {
"en-us": { "role": { "terseLabel": "Variable Rate [Axis]", "label": "Variable Rate [Axis]", "documentation": "Information by type of variable rate." } } }, "auth_ref": [] }, "us-
gaap_VariableRateDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VariableRateDomain", "presentation": [
"http://www.myriad.com/role/LONGTERMDEBTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate [Domain]", "label": "Variable Rate [Domain]",
"documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index." } } }, "auth_ref": [] },
"mygn_VariableRateScenarioAxis": { "xbrltype": "stringItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "VariableRateScenarioAxis", "presentation": [
"http://www.myriad.com/role/LONGTERMDEBTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate Scenario [Axis]", "label": "Variable Rate Scenario [Axis]",
"documentation": "Variable Rate Scenario" } } }, "auth_ref": [] }, "mygn_VariableRateScenarioDomain": { "xbrltype": "domainItemType", "nsuri":
"http://www.myriad.com/20240930", "localname": "VariableRateScenarioDomain", "presentation": [ "http://www.myriad.com/role/LONGTERMDEBTDetails" ], "lang": { "en-us":
{ "role": { "terseLabel": "Variable Rate Scenario [Domain]", "label": "Variable Rate Scenario [Domain]", "documentation": "Variable Rate Scenario [Domain]" } } }, "auth_ref":
[] }, "mygn_VariableRateScenarioOneMember": { "xbrltype": "domainItemType", "nsuri": "http://www.myriad.com/20240930", "localname":
"VariableRateScenarioOneMember", "presentation": [ "http://www.myriad.com/role/LONGTERMDEBTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate,
Scenario One", "label": "Variable Rate, Scenario One [Member]", "documentation": "Variable Rate, Scenario One" } } }, "auth_ref": [] },
"mygn_VariableRateScenarioTwoMember": { "xbrltype": "domainItemType", "nsuri": "http://www.myriad.com/20240930", "localname": "VariableRateScenarioTwoMember",
"presentation": [ "http://www.myriad.com/role/LONGTERMDEBTDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Variable Rate, Scenario Two", "label": "Variable Rate,
Scenario Two [Member]", "documentation": "Variable Rate, Scenario Two" } } }, "auth_ref": [] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": [ "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us":
{ "role": { "terseLabel": "Vesting [Axis]", "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } }
}, "auth_ref": [ "r985", "r986", "r987", "r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004",
"r1005", "r1006", "r1007", "r1008", "r1009", "r1010" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"VestingDomain", "presentation": [ "http://www.myriad.com/role/STOCKBASEDCOMPENSATIONNarrativeDetails" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting
[Domain]", "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r985", "r986", "r987",
"r988", "r989", "r990", "r991", "r992", "r993", "r994", "r995", "r996", "r997", "r998", "r999", "r1000", "r1001", "r1002", "r1003", "r1004", "r1005", "r1006", "r1007", "r1008",
"r1009", "r1010" ] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel": "Vesting
Date Fair Value of Equity Awards Granted and Vested in Covered Year", "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]" } }
}, "auth_ref": [ "r851" ] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "calculation": {
"http://www.myriad.com/role/PREFERREDANDCOMMONSTOCKHOLDERSEQUITYScheduleofReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDe
{ "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [
"http://www.myriad.com/role/PREFERREDANDCOMMONSTOCKHOLDERSEQUITYScheduleofReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDe
], "lang": { "en-us": { "role": { "terseLabel": "Effect of dilutive shares", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "documentation":
"The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": [ "r923" ] }, "us-
gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": {
"http://www.myriad.com/role/PREFERREDANDCOMMONSTOCKHOLDERSEQUITYScheduleofReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDe
{ "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunaudited",
"http://www.myriad.com/role/PREFERREDANDCOMMONSTOCKHOLDERSEQUITYScheduleofReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDe
], "lang": { "en-us": { "role": { "terseLabel": "Diluted (shares)", "totalLabel": "Weighted-average shares outstanding and dilutive securities used to compute diluted EPS",
"label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in
calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r213", "r218" ] }, "us-
gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"WeightedAverageNumberOfSharesOutstandingBasic", "calculation": {
"http://www.myriad.com/role/PREFERREDANDCOMMONSTOCKHOLDERSEQUITYScheduleofReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDe
{ "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [
"http://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunaudited",
"http://www.myriad.com/role/PREFERREDANDCOMMONSTOCKHOLDERSEQUITYScheduleofReconciliationofDenominatorsofBasicandDilutedEarningsPerShareComputationsDe
], "lang": { "en-us": { "role": { "terseLabel": "Basic (shares)", "verboseLabel": "Weighted-average shares outstanding used to compute basic EPS", "label": "Weighted Average
Number of Shares Outstanding, Basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or
units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in
that period." } } }, "auth_ref": [ "r212", "r218" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasicAbstract": { "xbrltype": "stringItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasicAbstract", "presentation": [
"http://www.myriad.com/role/CondensedConsolidatedStatementsofOperationsunaudited" ], "lang": { "en-us": { "role": { "terseLabel": "Weighted average shares outstanding:",
"label": "Weighted Average Number of Shares Outstanding, Basic [Abstract]" } } }, "auth_ref": [] }, "mygn_WestSaltLakeCityMember": { "xbrltype": "domainItemType",
"nsuri": "http://www.myriad.com/20240930", "localname": "WestSaltLakeCityMember", "presentation": [ "http://www.myriad.com/role/LEASESDetails" ], "lang": { "en-us": {
"role": { "terseLabel": "West Salt Lake City", "label": "West Salt Lake City [Member]", "documentation": "West Salt Lake City" } } }, "auth_ref": [] },
"ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "terseLabel":
"Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year
that are Outstanding and Unvested [Member]" } } }, "auth_ref": [ "r849" ] } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-
45-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "SubTopic": "20", "Topic":
"205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-10" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-
45-10A" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)",
"SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r4": { "role": "http://fasb.org/us-
gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "15", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-
45-15" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "SubTopic": "10",
"Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-16" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name":
```

"Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-1B" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r10": { "role": "http://fasb.org/us-gaps/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "SubTopic": "20", "Topic": "205", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(3)", "SubTopic": "10", "Topic": "810", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "SubTopic": "10", "Topic": "360", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "205", "SubTopic": "20", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "14A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "220", "SubTopic": "10", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "360", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "470", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "20", "Section": "55", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-14" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "20", "Section": "55", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-20" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "805", "SubTopic": "30", "Section": "25", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479668/805-30-25-6" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "830", "SubTopic": "30", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "470", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "942", "SubTopic": "825", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205-20/tableOfContent" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3A" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-3B" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-4" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5D" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205",

"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r83": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r84": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r85": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r86": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r87": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r88": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r89": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r90": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r91": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/220/tableOfContent" }, "r97": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r98": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r99": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r100": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(10))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r101": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r102": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(2)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r103": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r104": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r105": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r106": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r107": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r108": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/230/tableOfContent" }, "r109": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r110": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13" }, "r111": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r112": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r113": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r114": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r115": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r116": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "275", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r117": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r118": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/360/tableOfContent" }, "r119": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1" }, "r120": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r121": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A" }, "r122": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r123": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "470", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/470/tableOfContent" }, "r124": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r125": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r126": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r127": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r128": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r129": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r130": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479613/805-30-35-1" }, "r131": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r132": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r133": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21" }, "r134": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r135": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r136": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r137": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r138": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r139": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r140": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r141": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r142": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r143": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/942-320/tableOfContent" }, "r144": { "role": "http://fasb.org/us-

gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r145": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r146": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r147": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "SubTopic": "20", "Topic": "740", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "SubTopic": "360", "Topic": "958", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h))", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Topic": "606", "Publisher": "FASB", "URI": "https://asc.fasb.org/606/tableOfContent" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1403", "Paragraph": "b", "Publisher": "SEC" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5C", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(13))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-17A" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "15", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-04(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7",

```
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r211": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" },
"r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph":
"16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-
10-45-2" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45",
"Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r216": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r217": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-
50-1" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r223": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-
50-22" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r227": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-
50-30" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r231": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32",
"Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r232": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-
50-41" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "Name": "Accounting Standards
Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/320/tableOfContent" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-10" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r240": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-
10-50-2" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r244": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r247": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-
50-3" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r251": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-
10-50-5" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r255": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-
10-50-5" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r259": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r260": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r261": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-
50-5A" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-
10-50-5B" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r268": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-
50-3" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65",
"Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r272": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5",
"Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r273": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" },
```

"r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480265/350-10-S45-1" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-2" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-3" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name":

"Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1E", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1F", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":

"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477349/740-270-45-3" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef",

"Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481839/830-10-45-9" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482014/830-20-35-3" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "230", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "40", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481724/830-30-40-1" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-12" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/842-20/tableOfContent" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "40", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479092/842-20-40-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-

```
20-50-3" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r532": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r533": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r534": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r535": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r536": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r537": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r538": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r539": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r540": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-
50-7" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r544": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r545": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r546": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r547": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r548": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r549": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r550": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r551": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r552": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r553": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r554": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r555": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-
50-50-4" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r559": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "926", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483154/926-20-50-5" }, "r562": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "928", "SubTopic": "340", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147478859/928-340-50-1" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "220",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1" },
"r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r565": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r566": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18" }, "r567": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932",
"SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-
235-50-23" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "23", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r571": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r572": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r573": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-
235-50-31" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "31", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r577": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r578": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r579": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31" }, "r580": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r581": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-
50-5" }, "r582": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r583": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r584": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-5" }, "r585": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-
50-5" }, "r586": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6" }, "r587": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-7" }, "r588": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-
50-8" }, "r589": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "8", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r590": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8",
"Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8" }, "r591": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "280", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1" }, "r592": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "932", "SubTopic": "323",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1" },
```

```
"r593": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r594": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(10)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r595": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r596": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r597": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r598": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r599": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r600": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1" }, "r601": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r604": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r605": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r606": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r607": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r608": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r609": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r610": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r611": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r612": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r613": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r614": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r615": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r616": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r617": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r618": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r619": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r620": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r621": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r622": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r623": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r624": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-17(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2" }, "r625": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E" }, "r626": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r627": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r628": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r629": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r630": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r631": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r632": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r633": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r634": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r635": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r636": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r637": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "825", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r638": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r639": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r640": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r641": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r642": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r643": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r644": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r645": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r646": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2" }, "r647": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r648": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r649": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r650": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r651": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r652": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r653": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
```

```
"Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r654": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r655": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r656": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r657": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r658": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r659": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r660": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r661": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r662": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r663": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r664": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r665": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r666": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r667": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r668": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r669": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r670": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r671": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r672": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r673": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r674": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r675": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r676": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r677": { "role",
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r678": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r679": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r680": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r681": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r682": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r683": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r684": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r685": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r687": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r688": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r689": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r690": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r691": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r692": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r693": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r694": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r695": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r696": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r697": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r698": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r699": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-
50-2" }, "r700": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r701": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r702": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r703": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r704": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r705": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r706": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r707": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r708": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6",
"Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r709": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6",
"Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r710": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r711": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "948", "SubTopic": "310",
```

```
"Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479628/948-310-S99-1" }, "r712": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "310", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2" }, "r713": {
"role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r714": { "role": "http://www.xbrl.org/2003/role/disclosureRef",
"Topic": "970", "SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r715": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970",
"SubTopic": "360", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column B))", "Publisher": "FASB",
"URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r716": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column C))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r717": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column D))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r718": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column E))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r719": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column F))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r720": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column G))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r721": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column H))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r722": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "970", "SubTopic": "360", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-28(Column I))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478979/970-360-S99-1" }, "r723": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-
50-1" }, "r724": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r725": { "role":
"http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r726": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards
Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "235", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483426/235-10-50-4" }, "r727": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification",
"Section": "55", "Paragraph": "13H", "Subparagraph": "(a)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-
55-13H" }, "r728": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "13H", "Subparagraph": "
(b)", "SubTopic": "40", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r729": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "38", "Subparagraph": "(b)", "SubTopic": "20",
"Topic": "805", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479876/805-20-55-38" }, "r730": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic":
"210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r731": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" },
"r732": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r733": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "8", "Subparagraph": "(c)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147483467/210-10-45-8" }, "r734": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r735": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r736": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r737": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r738": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r739": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r740": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r741": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r742": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r743": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482640/350-30-55-40" }, "r744": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "460", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "27",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482395/460-10-55-27" }, "r745": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r746": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r747": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r748": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69E", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481568/470-20-55-69E" }, "r749": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "69F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F" }, "r750": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r751": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479806/606-10-50-10" }, "r752": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-
55-91" }, "r753": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "91", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r754": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r755": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r756": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-
55-91" }, "r757": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "91", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r758": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91",
"Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r759": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r760": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
}, "r761": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph":
"17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r762": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715",
"SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480576/715-80-50-11" }, "r763": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-
50-6" }, "r764": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r765": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic":
"718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r766": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r767": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r768": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r769": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r770": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r771": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r772": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r773": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r774": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r775": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-
10-55-107" }, "r776": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r777": { "role":
```

```
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r778": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482949/835-30-55-8" }, "r779": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting
Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r780": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r781": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235",
"Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17" },
"r782": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph":
"21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21" }, "r783": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932",
"SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477215/932-235-50-29" }, "r784": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3" }, "r785": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2" }, "r786": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932",
"SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477916/932-235-55-4" }, "r787": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5" }, "r788": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "932", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "6",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6" }, "r789": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944",
"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479401/944-
30-55-2" }, "r790": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "13H", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H" }, "r791": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r792": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r793": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-
40-55-9C" }, "r794": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "9C", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r795": { "role":
"http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9E", "Publisher":
"FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E" }, "r796": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80",
"Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-17" },
"r797": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph":
"18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18" }, "r798": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946",
"SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r799": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-
210-50-6" }, "r800": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55",
"Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r801": { "role": "http://www.xbrl.org/2003/role/exampleRef",
"Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r802": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r803": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r804": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r805": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name":
"Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r806": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name":
"Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r807": {
"role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r808": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r809": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r810": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r811": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form
10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r812": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F",
"Section": "16", "Subsection": "J", "Paragraph": "a" }, "r813": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section":
"6", "Subsection": "F", "Paragraph": "1" }, "r814": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6",
"Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r815": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F",
"Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r816": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r817": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence":
"C" }, "r818": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1",
"Subparagraph": "i", "Sentence": "D" }, "r819": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6",
"Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r820": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r821": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r822": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r823": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r824": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F",
"Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r825": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section":
"19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r826": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F",
"Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r827": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form
40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r828": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r829": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r830": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r831": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r832": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Form 40-F", "Section": "19", "Paragraph": "b" }, "r833": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a" }, "r834": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a",
"Subparagraph": "1" }, "r835": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a",
"Subparagraph": "1", "Sentence": "i" }, "r836": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18",
"Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r837": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR",
"Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r838": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form
N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r839": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r840": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r841": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r842": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r843": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name":
"Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r844": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r845": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC",
"Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r846": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r847": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2",
"Subparagraph": "iii" }, "r848": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r849": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1",
"Subclause": "i" }, "r850": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r851": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1",
"Subclause": "iii" }, "r852": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r853": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1",
"Subclause": "v" }, "r854": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r855": { "role": "http://www.xbrl.org/2003/role/presentationRef",
"Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r856": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2",
"Subparagraph": "vi" }, "r857": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
"Subsection": "v", "Paragraph": "3" }, "r858": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229",
"Section": "402", "Subsection": "v", "Paragraph": "4" }, "r859": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K",
"Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r860": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher":
"SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r861": { "role":
"http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5",
"Subparagraph": "iii" }, "r862": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402",
```

```
"Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r863": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r864": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r865": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r866": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r867": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r868": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r869": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r870": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r871": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r872": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r873": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r874": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r875": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r876": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r877": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r878": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r879": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r880": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r881": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r882": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r883": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r884": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r885": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r886": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r887": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r888": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r889": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r890": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r891": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r892": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r893": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r894": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18" }, "r895": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "SubTopic": "825", "Topic": "944", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B" }, "r896": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(6))", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r897": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r898": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r899": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r900": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r901": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r902": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r903": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r904": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "205", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1" }, "r905": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r906": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r907": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r908": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r909": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r910": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r911": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r912": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r913": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r914": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r915": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r916": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r917": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(f))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r918": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r919": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r920": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r921": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r922": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r923": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r924": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r925": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r926": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r927": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r928": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r929": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r930": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r931": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2" }, "r932": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1" }, "r933": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r934": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r935": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r936": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r937": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
```

```
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r938": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r939": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340",
"SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479483/340-40-50-3" }, "r940": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-20/tableOfContent" }, "r941": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r942": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r943": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-
50-1" }, "r944": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r945": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r946": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r947": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r948": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r949": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r950": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1A" }, "r951": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482573/350-20-50-2" }, "r952": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-30/tableOfContent" }, "r953": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482686/350-30-45-1" }, "r954": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350",
"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r955": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-
30-50-1" }, "r956": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "1", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r957": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r958": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1" }, "r959": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r960": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r961": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r962": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r963": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-2" }, "r964": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/405/tableOfContent" }, "r965": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting
Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
"Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-
50-1" }, "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r969": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r970": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI":
"https://asc.fasb.org/450/tableOfContent" }, "r971": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting
Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1" }, "r972": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r973": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r974": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r975": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r976": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r977": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6" }, "r978": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r979": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A",
"Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r980": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r981": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r982": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r983": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "606",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "91", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147479777/606-10-55-91" }, "r984": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "715", "SubTopic": "20", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-
20-50-1" }, "r985": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r986": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r987": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r988": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r989": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r990": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r991": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r992": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r993": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r994": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r995": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r996": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r997": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r998": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
```

```
"Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r999": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1000": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1001": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1002": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1003": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1004": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1005": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1006": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1007": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1008": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1009": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1010": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1011": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1012": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r1013": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r1014": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482685/740-10-50-22" }, "r1015": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r1016": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "805", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "15", "Paragraph": "3",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480123/805-50-15-3" }, "r1017": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815",
"SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "6A", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480682/815-20-25-6A" }, "r1018": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-
40-65-1" }, "r1019": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r1020": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1021": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1022": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1023": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1024": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r1025": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r1026": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r1027": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-
50-6A" }, "r1028": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "2B", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-2B" }, "r1029": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r1030": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "830",
"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-
30-50-1" }, "r1031": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section":
"45", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-1A" }, "r1032": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2" }, "r1033": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "835",
"SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482900/835-
30-50-1" }, "r1034": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section":
"50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1035": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3" }, "r1036": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r1037": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852",
"SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r1038": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-
50-7" }, "r1039": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50",
"Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1040": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1041": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r1042": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1043": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1044": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4",
"Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r1045": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r1046": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "940",
"SubTopic": "320", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/940-320/tableOfContent" }, "r1047": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.9-03(1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r1048": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1049": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(16)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1050": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.7-03(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r1051": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r1052": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3",
"Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r1053": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1054": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r1055": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C",
"Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r1056": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944",
"SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI":
"https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r1057": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name":
"Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r1058": {
"role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1059": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
```

```
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1060": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1061": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r1062": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1063": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1064": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1065": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1066": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1067": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1068": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1069": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r1070": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1071": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",
"Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1072": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",
"Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1073": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",
"Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1074": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1075": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A",
"Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r1076": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1077": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1078": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r1079": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1",
"Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-1" }, "r1080": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1081": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2",
"Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r1082": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4",
"Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r1083": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1084": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r1085": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1",
"Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r1086": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2",
"Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r1087": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3",
"Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r1088": { "role":
"http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6",
"Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" } } } ZIP 94 0000899923-24-
000057-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0000899923-24-000057-xbrl.zip M4$L#!!0 ( $5":%FN.5B.N0< $HH > 97AH:6)I=#,Q,2UC97)T
M:69I8V%T:6]N;V8N:'1M[5IK;]LX%OV^OX*;8ML$L!W+CSAUT@!MFAEDL=O. MM 5F]}.'%]F(B"1J2,J.Y}?ON:3D1^Q.760Z=8(IT"02+R_OX^C<2TKGJ?'X?K\V"]R/M%B?
G$NU)0I\>1 #:.D.^KV>2+D MZ2*) ^J>"#T=1?.*?)*.7O2[_7W2 J1 /!%[TX3W3AL)[!_/!G4+.IC)L;Z'.Z'$<]:'+RSK5YIFZ*L??Q M(*AJQ&.=:3^UO7_SFBDG?!
<9?/QBT\JEY:}DS/V0>>|>-&RO+!M*XU*@!5 MOTG8B$7\Y2RX,(*>3!6R<2GJD1-7=ZF:*,?Z42=:]V WVV,$7YKO9/S'UQ_> MO'YW],'].C__NOHO^WAU^>GZ_3O6[_8.^1&{O/KPZ?
J'Z\O7=-'7W{ZY)X.M MGERWV$^\RM@_.^RMXK^U6"R-4\FOD4DM3;NR2]X1:I M01+R.;LM]"R3XD:V0[[# D-$PJ-QA,>X99C.07].![D-@4+&TEINYB22\UN)=5=T6MP3,
9+9KY080T2B)5! M88)8@>FP1$C#9JF^4V8K^K&#F%.,$F!Q7P_!4(-A_/!"4++%$%DDQX62:U!?Q!',-F95P5"5B$.P4]JHBS M2D G@+.2P19 IXAY2N2=($M0SK(E)FLXV^M+__9"D>
(62509! !$#;3XY:RW M)^8V94FF9[9!J9$WRCK#L1"GF\%N6-E. 9MMC-FP]JG@;;!W>/NTEISGSTY[ MT>C,UHBJ6P.B")TD"I>'JLAG[HIQ(SU&D',UR23EDDD @.* W1KV ,B6+VI?
AE*+ZFW,*[O[%"I\$\D6*X52]BL# M!>"GJ,*>]2 E"Z^&N8E7ZYRKI$9]SBK:^D2*ZV:CVE0@3MAB]69$GYG:JN) M54)QH\@!%2J^KP(%::HL56'_9%I?LCU':BMA$/:D?
E*)AE+%5<:)VN&6-V)9 MS3$C] :K+0W^FD@2!/MBOA0/8-N]PO%D?W!\TCD9;>)X9\+;@//N5+"S61%<: M4U\Z[F]'RLJ4P+3U#4D<:R.\ ,Y%O<$^R*!+F=.(+.F9(1&TWP&^>+94"?
9^ M*@".JP? #1'+*<[JSU:479DDZ!'5%'FQ6WJ]13NQ _N&R^WMG\-FEZ<_\(UI& /1YNM, 3@)S8'\@M.#-D M+!CKGEQM)O9'TI\1T/%!42UL.0J6I-PN^@KB.@]Q*7P1\-
[7!#UGF;J567U@ M<$^^]8" /!#0>[7E&CZ=+9<_05P\#:TE'Q$]KJ)S24V$L]_H,C;ZU85U'#VK MT\8N"KN_ 95YKIR3\G?(?
Z+1.M"X4+#/*SD$DL&UEK@"TSX*S[D4Q!0A#R]@*!=ZBSMLJ!SX0 M)>],73FV!4J3*^AUL?JM:) 6VTD';IR0[ \2?1-<):H?RI8JJSJ:0:6/";
M^D#=U/PI\S+3/FCS,0=YGQ^5@5/F!^TEFM:Z*=TSFI.YM2 4#/4+_U]( *P_4KX9.H M<_)R2&^%G<%_T2Q^T"$0"# M!5_LV#L ,Y\ FZI?RY4@\!J^>/QN -OW/M>\&'@C'/P!/-
='Z8EPB+G2,RIJ /)(0 M^ZJ[]BNLCRIR!@THJ5]^M[M,E4S8U9V,*SH08N_#_NFOD'Y-2 ]_"J>H:(4V M(GGTH% >^XYG2S]U[\.W4EO_@GD 97AH
M:6)I=#,Q.BUC97)T:69I8V%T:6]N;V8N:'1M[5IM;]RX$?[>7\$Z;&(#VO5J M7_RR=@PD/]=P<4W:),"UGPI*'*T(4Z*.1:]_?6=(:5]\6XN&_C2K(T+$-N2 MAL-Y>?C,D-
)E[@IU=9D#%U=_NOQSI\-^TFE=0.E8:H [$*RVLIRP7P38.],1 M-%+?NIH;. M'\A^<@YG_=YIW!ND0P"1C.!T&&>CDU2[V_''C1]\M,EP[G,S@^_!G4;"KC9H+ZG*[&<1\U M.;AW':
{DI:Q[%P^"JE8\U4J,\8N>_W=!3SH9+Z2:CU]]E@58]AYF[*,N>/DJ MLKRT'0M&9D'0RO\"VHB3^,M9<.$4]2A90NM2W"WU M&[JYJV_?
W9/A5D]N(_8IUOAB=7>RNIHR###&4=MRF0I,%WC#MWY08[&W=:)___LZV$9G'9]&&Y9SJ? #$PES)") M7"XM^[7F!G&MYGB_TL8Q7;)WVA0LJG7^R73&_H[$Q
7[*Y3@9&HC=ENF74S2 M^7-(4G_ODO266TP-)]&8L[M2SQ2("40A5TV&A$832HTE!6?@LF2\G+.Z="8& MJ "+C*\WF#K."KS"]"F6\11O&:8+I$"G@]R&0 DI6,O-G$0*?@(/Q?&Q
M67DNRPQ9A#N)>F29JE]@3@3.2@8C!)TDYJDP[P19@K)22TPV<+ /D;8'TF*.M(Y*H%0H@$#6BQ4]GO3TIMSG+E){9%J4&)M(ZPW$B3C>#W6AEM (VVQJS8>US
MP=MP[_#V>2TY+U^<]>/3"]L@JFD-B")TEDF\/+1'/G.WC!OP&,&G&[B M>&?"VH#S[E2W,ZIQ)4RE(+!RJFTM.G,XM IT:2T(P-Z)%$^);\D0JZ>94X+=- M2VO+ \]C*BR+-
=&5QM27COO&H:HV%6+:.^H8D3;41W@#?HDYP'V2P2YG3$ZAH MS9 (MM\!OKBV9(7L_5P G.X/@%LBABE7M6P,NHR-?G5A'<>>U6EC%X7=WT"512&=_@-
\D\TM@[T7$BTSRLY1"0CUUKB MH/%8[^V%E]MX).AS[4&TH$&VUF:5N<2D!H-$5Y ML<.9 ;^C*AMZ,U]G?5?ICS;; Z!O ERS&0E'"5M(C0L<:&'!:5\$9].+XA!$
M&+:,42CU%NN\K0O$!T;).]-4C]U'9<^IC._AUH>]=6:0-B),.WBR0^#XD^@& M85$H?[*<:C4%]H$EGS0'Z];A1R@J!>> 3V>Y#HS(U_"+>-O2#BR@LC,VN[N@ M("38^=C6?]
^4$7C:Y$.Z<+4G@#N# T4[^N=C#H]LL=U)[[ ,1@H'AMA4O7Q^<'+0#&CB.^]4]B]?? M*Q_"T:\D$(H^$'K]B=<"K[8L?<(S")!,)Y%_KN$!1R;."P<'6PXVB,W'P2G
ME6EG&P;D[J{G^XAN3=WFF*>0NK?S]2[EZY%X"EZ]?#%$VO0_-[X=>"0D?P=, M-63K'W*%L:&C5-8&Y8F$V7_ELW^A?4K1N\XE9.S=HHA_"#NG/X+X+4$\_$_[I=YR"$]P\===N
M<\A7OIUK?H8O^8[]%X3_ U!+ P04 " !%0FA9E^K917<$ !5%P`'@ M &5X:&EB:70S,C$M8V5R=&EF:6-A=&EO;G!U+FAT;>U8;5,;-Q#^WE^Q-=/$ MS-
CF[OR"WV"FA:33IHLW2.1C1W?:\VF03Q=)AW%^?5'TPP9/_QI^G.[#<>86T@T,HL<2B/R&;SG:,Z@W5YY M':EBJ<4LLQ %40_>*WFSTEEEM\)*/*SC3/>J[^F>GV0:*[X\G')Q#H(?-$00
MAZ-D.,!TU([]R8"S)!D$$4^3?9:&/(K_#1LTE-RK,<8N)1XTYB)O9^CF'_>B MSGZ_1).%X#8;AT'P2\.['DY3E5N:3]/XZL\JS&8PIF<4SZIB'$84R>*%;3,1
M9OG80VQ4H6KW1$FEQSN!_YDX2SMEG8HX&7N$"WJDYRY^W#,M-VZ 6 M;>5HQ$>D'&D2_[FH(.Q3'"ERK"&%D0/QXB(3L,#0C3KA.H*[Y9X0^.@?*/DC
MU%;D(F%6J'QKJH\EVS>E-B6C>:V"$TQ5+&ID)DH,EV@>4W4K5D(MARWX)Q>N"YQ8:@:&UCW'W;NJ\MC[MU:3?._J@-E-LYTML\96LL:6O8FM%B!+
MLGKV,N>H#>F"O%1**X2^G.UO:J>,P^^8HQ6):<$?>=)I 8-CE&S!-$*B=*&T M7U#0=*&>[0RC*)@X?[$ MP%FN%A+Y#,DE8_;93G\X>>3U/27L,TNFB7^YA'=(K% )LJF9%!6LIG6
LQ"5[+2\|YRAR MPC*OBIX0,TPXX8C<&Z\ 9L)Q46@T+H&6\V!2 HTDCIFD]$Q!&9F6'YB*G.6) M^S_%Y,)'=S.25RFK_%6!E=;,9PQT[]*.OA>'93$MBV4U5IJ4WR:12%88'-=_
M3+@PA63+LH,1[VMUJ 3;K7=%+77Z_0&T1>%O=DV&.[?>[)?D8+N MG<++N^:)5A2-I&)+:06/0J <4C',ZAHZCX@+']7..Q'1#'94P'J@_'=.B\WT4
M7JESWW!@6+6:RZ6S8N,2:'<#:.!@-JYQ_:8YN58%F^0\!<2_+=?WTNTE7W7& M5:\C7&"4%!SJ')(;G_S>K;3HU:.%PUO6"GASPX<"_Q/I3_0P=/ O6&#DX2
MRL0)X2],4XGZ]A7_Q3UN+CB7^$"8[UOO3Y.%[Z;:=%@6W#V4N9/S428PI,;\ MG>NM.$=X75VSOE\95(2\O+QH7$?(-Z4&03@+ OI# ]>0<@<=[/F+WY5KY=8' MW"\M7SL_>@
ME_&5VK%$R5X.-5^%/>ZW?9(-/0UA,NVU1-X?<\I"\^ET]:^_Y MY_3_ %!+ P04 " !%0FA94T1O&(4W 0 #8Q$ $0 &UY9VXM,C R-# Y M,S N:'1M[*WK=^)(DN_W_2MTF;W;5>
<82@^>KF[NH?RH]MTJVV-B1&?&+R(C(B,A?_\_KV)*>]>N9 MCOW;+TI-_D6BMNX8IOWTVR^]_L7-S2_!_L?O_ZO:O5_OCQ\DRX=?3]FMB]=
MN)3XU)!>3'\D^2,J_>FX/\UG(MU;Q!\ZJKA:#6Z[<"9SUWP:^9(JJ_7HLNA7 M]UQN-36YHVC5MF$,J_4&U:N=>J=5):HR5-3F@ YE>O9T+A-#UY1.IZKI35*M
MU]M&M=TRZE59'3:.JC)0==HY,\X'>D?5&YV!/!RH=778AC\4>5!7.TWXU*@W MV'M'/LP9YFU[Y^,K;Y61[T_./WUZ>7FIO0YM?M//]6?GT/]^_]?41'9.J:7L^L75:F;_$CW_+X@6?2)?
8'M*-^_) M>'(PJRJBAH]A.K&_"'L 1[5:T_.\R?X 2^O1Q=Z[N)M0^(-V)O@RY6+7N'% M/^.F B3N?&*_1I>.9T_VRI5CX"J3M3VW=G\9,/?UR9F^DY=55IO3..\(HY,>'\{W+W_ 3?
S7,U0&% M%S<_!3\NL;X*8UUY>#3V]{BO-*IRNZHIT7,,:L83 'Y8F?S4JSX1,EE'0/C# MZL6^NW':G4_P*[OPW!*@#*K4KO[H5[J_CB@QNK^.J4\DO+5*_YJ:S[]5+AS; M!\50?9Q-
@%!Z\.FWBD]?_4^,G9^Z__$?__&K;_H6[2*FJA%X?OT4?/GKI^#1 M-\>8=7\US&?)\V<6_:UBF-[$(K-5V[$1#,!\/<<+]1O\:1H&M=F?\/LM:"?7 MU(/WQ_H/=/A;1:\"&6TRQB=1\[P'^LM
'79MD:>*%%#]MPIPZGQHOE*C.B06 M0M0$>1M6U4:ER[fX]=/*&U*\\_]&^T*UUD=U8ON(?+'6/U%9U*]^_I"-B(7A#*QOD#?:,VE%Z[ MSACA[!+=_Q/6MXNIYSOP@'O7,:.ZW[.-/G6?
39U>O0+(/7-@T6^FYT\JQ92/5UPAVL$NDJ6T&(_/H M$RKCRCH #:J;8U@O?ZOS/"K MW@MQ#?;/'P%Q@M5&B8;61 5_K_TC%2=537L[MF_4\RB=T^(;A3$\@/]@VM&G
M1^J.H[>VVD"0>V7]K9J6C2"7#BE8 CKU8FPW-,#//>:EP+@D9N>?^X 18*DY MGEAHXK+O1BX.>\5,J[UZ!AAQ['V+EX3O})RIRSXQ6_H<@<+&[2%QO4KT_1AF M-751-
_@4_/CK]7?HL_XC+7G36$;,Q\66O/G/_J7:9\%G&7LGS\3K$[3H,N7 M,CH3WW%W?.W:_?CE);6=L6G'/38I:58>\6EUJ._.A+=M^]%7I^'Z8BH\V$ M>@.+)_!GJJ'!K[2.?Z0Y$FA8F/
M0YT9?4^9GQ!] D;"YZ%)78D)+(WU(2]N_GO5?WA[\WP$JT^?,)4620**NCYZ M"\Q(K\H*_%]TW^*W^3"-I4L[573@5G^)/D"-#/3D9,E31[4.3(9Q-
8(,$'PUXV>O$,G73#UP4R3#'Z.HX]I*1[\.4 M\)ZKOZ88.0-+W[*1K>B]FF!{11?!]V/'[ON._C-R=V)?,:?&?"3H])"-G1[J M%)SD/<,PT>$BUCTQC1O[@DQ,L-Z*0GY%+CK]=7TZGEJX4W?
GCZB+U[ETA$]I MIC>V[HQI87AQ<$/YP+QXH#ZX]M2X(BXZ^%YA",^9:9[EU YNFY^*?MW#&-66 MF+6/^:'PX&[P0(>#.R>%5X0\<.G@OM,IF@X\,.[@WMZ)N#EO:+[7.EQTU_(8
M?DZ6]"^\GWED/R=#?JA%]SES]7.R)#P/.S$'FMK!7;A3T:]O#9!Z<@.DF=5. M& \;1CS0X>#^7N$5(0]<*KHWRH6?W\_)C!=%]5GS]G.R(KQV< >S^%,K^A[AT?
R<(V35:$5W2O.W!X_!I<)O MD?)@WQ^#<45WGK.T![-*B-4*[PP?Q[[/C/Y%]VDYL.\SXT71?=V\[?O,"]P M)_=X4RNZSYC?FI99CER]Z/N1QUG3L]-_X7W:HZ]IV?%"N*Q'(GSAO="C!';2
ME7)FE4%7YRY1]TAT*+HWF'. ZTA<$CYC01E7= @GETB6;WP&ZA'< :R M!'1'>!C.P,9\]}1=,S<])FD%7SRZ#KL%=HNZ1 MZ%#TG<;\_9QC<*GHWB@?7?
LXQ&%=T!S5'/R>K1+)&T7W+(_DYF=&_\'[F\?V< MS'A1=)\S;S\G*\(W.4O4S7)]A=_4/):?^SXS^:?^5=1.,#O,^-%T7W=O.W[S C/G9/KN?Z" MZ%*-I\^22R")
M:^Z;XTE.:^GSK'>PO_Y,2Z_.6.;E D@I.@OSMU.LF#.@CG1 M6")B*YQD8Z9KS9D9_T6(10"! :%HD992,4<$7#CAOY:<_QFNTHHL B\""0$2 MBA: *1=W3C 0LR\ \DZD/\+ZK,BG'/81
```

*$@"Z#3&5G2M'B3:>FC8^U"A*UP&D4J55WVLI;AHD:H33JP^%@2X#%H)MG 9 M2BJ53C{6:ERT>-4)Z^1C08#+R%7IV:)R&4XZ>KG+,,99'M6@QI)SK78[^DZ*%*
M=_(I>#F*IN(RSL*)>!R+)UQ&6;Z3?SGNQ=3SG3%UO:4E_3LU@#WNMD.*MKYD M<0:8K<.P7(*'4CV8WL|OL|?9A*ZR_ZOS3%T;AP^7P{6Z[ZW==|`!?:&V/AH3
MJ^?;XX.>J3VEUZXSCH;UI^F/(JJ=J#;G,C0DX%H N!ZAV%91N0QC",CR#M?C ME+\]*I?A/0'7 L#U*+8KES%)ON :#80#C/9IYMIZ#U2GYC,96#FYX!<1>,N#IR6U$L_%H?
JW$5ZX(XI>FS:Q=9-8-S _=XIWOSV*WITXH*OH M)1WX?:I/7=;W:8%(SUOD-S'IOT]M>,*$6%S;^'GO FNSR~ZL2=3WV-7J :?E0X9GH2L:=P')+/F@9&6.;1=# MQZ:SI[V"<4?]Z6BA!Y"
[$EZ<@"@ H&G=!LRP!H D ; 4 =V&H$M"=6Z#&L5:?0N/ VXC+L5:A N/ WYC0(5:%PH:%:GS&XLH.SG-A:'.1FF_419TH@'3PSV)9=W1ME>[(;K,F-\#FL01W#@-C)W0G X
M,*0^4SAP&Z<[(3AL6Z,X@@.W4,O#PH$C#10ZAL?U]+^FIF>BME]:#[X2G[Z0V=>PVOW;MXO"9%$TN(W;W+L.S,2? MW5LPN9YM8&+9594>UGW.E G<1D\X9T*FRH?;
M&$8}>LQ_+[ZN8T6<$CX3!'/K5_.H]KAH>ZJP:WK_$ GCHN.\0_;']M'!0H MK<2MC\P%}>6J{B\)P%ZD;O+K!IM 8OK-?*;&C0T3?=(%NUY'O6]++[.@KLLB
MWIIJCDMTND!_&8]4'JF.Y3S-'LRGT5:=E'A4-[;NC.F\>\H78N&)9OT1I:@K M>X;+[_!-B?9>;CG>U*4P6O@P<3QB?76=Z<2#1UA3 S*$U[!HUI0:=Y,PD+5<
MI'9E&\X]'IVF;UO8$H]_92B,@, FG2R>*<(X9P&V_8B2$7SG@R]:G;=X;^''W'IFSN+PQ9N8Q*IV!)N%,SE'=BV M.O6\PC*\'VUC%,C(3ED,_4"M874;FI$ *C-N8Q4[,>'2)0;%.O$ *0>X]=.Q
M-N1MZC!32;TOWZZ);EHPV*RB-!<8]/&CIZXU/7.L9]-^6KTHJU=_<^PGT*]C MG&Y,O-^TZ=TP>/.!,24WL[(36]R&&@2F\L64(F>FI[B-DPA,Y8FI+/W9%K?A
M'8&IG/54=O84MU$[@:F*8QJ'O] M,H-T>0'0/>\XUHG887,!B-C?]0T?G:77 MQ?U\9V?7F?0$\]-XC-S-',NP[2=&=F=XHD>VM+0.*M.U G MJ6K<13&*W^=9U;@+*-"
5Y\OX5^H\N60R,O65K/@_J>?WB>5_(S_IQ?;^NON1 M6\N2W-Q%";@C=Z;HYM;%GY,*-S#9%S'IO-ZZ7DJG*Y/QU,+KF7IN9X5&+7&
MOZ:>CW<7)MM0X]9AYY837/A[W/K]W++M0*JL5JWG?6EZ$\ 1UA1=D/B1+Z2MPGN-IW)N<=N S'5R66"03'%<$./Z M>Q>Y>,9E='U \>%25=UQ[+(Q*/GT1^?#0")168@SY9ITRJ[
MZ7/X](^C^\Z8O>"9NCZ:YN%+V/N"GV/Y=C]U=D/@#*3M 6]^(7AQ2HP;4^+3^ M?:===Z\CQ/DUA7W_B3W/C7X,B:U-_ J[!R:"A/JMHE7>S#4M<0D%@=DK%IS03)]]1;^B(}.&-
B_W+F@5U0]0"[P^!"S_PW/5>.:\;V\268; N>P[@33EY1 M$5L_;F\>KRZE_F/O\;J_"I=$J#OJX/M7%S\>;AYOKOI2[_92NOJ?B]][MU^O M(N{[]O^OV;NUM^9J0FFM&?
Q!LJ'S'/L,N:Q*?2?^7 M9&);+A-K)YK8]=W#=^E74(^V8]].Q_070I7B0C_W-D%#>0.->BPTfDO^WZ=@C%+7FCW0B>/Z%6GHN&/B M@Z7XZI\/S5=J5'UW.E<..J?{7W_KM.K-
SQOU@V\<@<)> >PM&>,E[._>@^/ M5P_?_B$]7-W?/3Q*]$\>C]ZMX_2XYTS;_HC+R-R2HDEW#Y+2^&\!E.ZNI&Y
M9[=?!6[.*O@,,^*8ZAD>,\+:J06;5&25NE=H1PL.C$#]Q)33Z3T(':9=WB MB<1W#T*K"ZV^IU9GD5@6+-FLUH?$\N9ZO1[}?I)Z_7'A]YM_X9I;Z'88Q6[M/P=.I-
F'KC.6H@D>:&CLB>>F#X30MPXVII)E!=2>(Z9U/8>UQ\2K$L-*4/^_V M[X'G^"[Y)=\I%8V+(A87SGAL>ABDEH8FK*OV%&V-\Y4I)5;.5RQ>? W/N66/
MB71OH]*5]VJS65>%SYWWQ-1D$TO+Y ?ZQ')>;1^KZB-&-RO=[_]XN.E=2E^O M;]\>;R[Z9]+-[46MZ&S_K#,FT)=/W)'W$ M?(=$P0N>9KD_N-=LYJ7?WECD \O1?
\883J'=76_6ZATE\<[+$>GVWDJ25]IP M>]"=A]BNX07SM3VW=F%8ZPZCS!6'??9?#0$6Q[6=(SL)K;%6ZE]0B+\2EA1<\M1@0);#<'€'#=7 7M?4-3W%_OL$SE C,
[4I74U7I%GR\D:2]LBQA*N%;7)^EB,RLO!)S$>_<1^=E M+CV=2A<3%27,5)3PY\S>Q;!\Y]Z#P (0%ML1A^W!(?'KA)C\EH-EH56359:__LS[M8'7S2#+V(=\&0/ M?
W\)4LNV!#V2UYLP_R9(EUDUY,$#:KM5E>N=>D-1%1ZT-[6'6K\FA:V@7&EU MZJ!U:GM,<7%I("74[?<.GMGT_\Q)8,J$:%(!375%:18>2# Q"6<6J]^^P?1*
M=^'4 -))/K7H9.3844S@#*V7(/-, LN2 .<>G[HH,Z.(\0=@/BNX MU ^7F,^VBLJ*59^K!ZU[!%^,Q1H0=)MM.M5K2G+NZ'^R1%>;AUP@^>82HBQ M8&YD-EDBR8=K*9
Y0=.O[!^?SE[DIW8\NES3&IU4FY&;OV^HZ9ZT:5!*'1[U?\)H_H-"2C?? MW[;=?:\UD/^W7 X8?"2MP$X-0F&@1!}).F;)I]@,G6?=G@0I7(*C9;9Z?S8> M.-.'}5^U9,2X#>/<#!;T-
5@&)?"'7D8F?+/0L^O;PIM%(U2/J$^! 1+G6*:Q MELF=F#Z'V&)/MN D-P'#I6FFJ ,F:7,3L!'LNP%!6>_A, ^D_0;$KTH2XTC.Q MHINCMGOCL'Q,"
4[D.DY!]A&U=:,0>CLT7X5ZHM@7_#ME@5]D]7=."NSM?DL\ M@_PE?;6<-,'_8+/ 9),P"9BN17IWRT31>#)9\9K*?%;AZ+/!UCSXN)BD!L^!HY2S=44S[^=R MS6+/(.13VPP(ZHV(2\$
626R6@'DZ2;8*-YOE9O;ZYC-0I,)P1(Y^NP1=U.? M*1A@_RH/[.FX:C@L91D?""LF+/(P+'G.D7JEVU'.9*UQIFKS[.!HJ%TI&"+. M]TW""$H*II-X.
K)60P@45!M4SUZ(6)J1>L\^5[^J192D0+N4R,ORMJ.%VP5 M<&^3IU3O#07XV]4 ZX^9_RPVV RWEU?_@SUK6+_'H%UC81*U.\V:W%#3:K)V M3=:R"9ZWM5JSE5%*=*W3SB0.?W
7.K?,N;?E)7$ 2]\VZ1ZTV@%C%:EZ5"V) M$2^2_RO)}XUKK *3"VSDD8L&X-\2M!.7@:6]AT?I1J!*UW-W\\8.3#_6J("\ M74M2Q#SCK9?..];+@8-;AV@WQZ@BT)8 ;>"TW?AT+*FUG6
EN'(HKBQ$?WZ\ M@U=.R3_00K41BL-A?L!8+H2/ ^CQQH("J4VL/8$,8R.PE^L,H'M,H:'D4CL M-!(/.ULY0VF]_2$+<,FD>OBMPK{5I]3FTP-$0{I,1?%%&.VN$@J8;4DQD%] M
Z.$WA%Z)W.]T]FH=Q;+)2]5%DKKLQ2<9LM4%/(-L{0D B?T:WGT*<^"])??2K MT*]Y]9=V4M./>"/IVG)>O-/0IT*+GK(6!52WA1;E4HN>H@.M*:P%*(S)=Z0-
MZC1N5TSHE6+I%>1SY\3TBM@'/P12.DJ8G: >.3M!J/%T3/M.;/++$M/,OGG1I M>OHT.!,,3<&>3:R99S)[>*'.4=\']3AXS0/UIM;;#1RAVXLAL>JJ;00+Y7Z0
M_3D\K8%I=TUH]\)H=\.UOV-IH^FS*A&FK^$+*_]ZMYRO"F6%O4&SC3JO"D] MF-Y/H<,+(IB:)12XP$H"K#1^)5X72KQ 2CS8$/1=8 Q3X/>NHU,#=;,;0T 61 MNI/3T*
(@B5.PM:.*)"Q)NF--%D0YDC G#H$U5>&D'DF8$RFY]HT^$2PN(UC? M:&%(%$7>-!&O$UA)@15ZI)M[0CD72#D#VS#T)ET3W7=+(FM"+PNL),)* M2^R2$3?J
MJYBJM%7I/K(#AEBS4(!F?.O_747R< "//T%JVVDF;U5#0L1KE>TT"!>6*JXB MYUHSEBK!5R:VF_'/JWC1D>@4YKUO.D RKO5-S$%<":G73$"]_#5DQD>0\32) MWNVEU/_QI7]S>=-
[N+G]\SO^-&4JV2D/*ZV8BC7!#Z8MP6,M;#62:/"\G [7 MJ;4;6MK3X5IRK=5N9W*FFZ+6FLUT)\UM_EYK-[(;U/N;KC3&^2^7[GL,=K MH97VC,PTQQ:-*8YA/REJ++!\
[$Q%##6R'&%HP,B/[SR77 R*N&8]9U2L&^//"1 MJ=FN3/W^U6_ 08VSC;4<>S4SXDOL=6!G6V[?K#MCG3<]?X4(TO-ZB'[']Z>L MWK"(3UT?Q%-BG@>K}?
E./'\S[=2<.=3]&8FJQ/ZKUM0&[[S$7L*8&:[C'_2O MJ?E,K,!57.5J&@+(4A%@_)[!3?'SVW A5W/;>*#\U#/>GB:O+9\F7VU$A\E/ MO>H3(9-S1$C)-O
_5PM\/P+XKHS(_9!)3HVOAD=&X^YD&!4=M8.C _+MT'UH'\E78AYDLV((^3A5":@?1@*42E?1U)K"B0AD9)H49FD+&L8Q+]ZTGZOG M8[!+\192ZC?8+6HZFL3*>K$%8LN2L*#LHD
A- HK4A"3 ;UBOOKG0_.5&M5_ M4]>)$0^UTF6GPZB?]Q60=X!ZB#4BB>TI,+!%J;Z+H36L:)5NN];F!"=E\Q$> M76)0B>@ZS,GW))?J%!9!X-Q.&C2IM51L]&_1H+V0F]S6MY2?
S/AZV!)}(U:.MBQ-+(LOPBX#*%D69$BH-@(I2KVF<0*5L1N<-6)JV[@S85WNJAOG) 2FJS9K*B2T@;,8<5>$69+0 &6I-Y@099,,2[UTZ(:0A^>1U1]^Z',O}%NT7
MDOS$1J1B#\38L[ZW],2X,00Z1L47[;4%&ARMDE,WNB[0?>9U@2E/0,W2*C%BCUCK9_M$" 5&PI@()<63]MBJ%OPA%UA%*W6Y!Y/94@O#_,JM)\DBQ*2HPD56=8G<*'
M_8WHTLK(%IT|)_LWI/H#ON1N^ /L)J1XC,S4*]U&*S,[Z?@J."..3N[3PVJ*" MT*K4>DVE?TU\L'A518#G>LEX]YU %[^[$R"J=O^&8N^8#+S!'.^SB2,^B(B
MO7O<)2#N/9(6O.BKB*ZQNS#U)FY -_9?&$2(FD.H,(VXI()*"'Z'2.,68-=>: M\L;VB?UD#BSJ[:X6RQ%=W}JF$%$R\"X!XE>ONC5%DGQU'./%M*P8S+?1U51K
M#4[BBR(@G6O^PDZ0Z> I/AUN(%,&@S+BAK :=U6/F_:'H M M^!A8*PR""B)S!Y*%6EJ @$A/VC)PNMI5O'5O?M,O04,'=:7*$C O+++L_H M9T*(: "1#&(G?
%EZ1=K;C]>%!]QWY8X.J8O"$T[^=&0]4?+":B&L/1U7#8?U M=,3[8B0?2[S.Y+:2F5E_!VU/7HI"($]DT ERMY("U!8"">FU#,PN$161P,] MP;[=]+/[=Q7__?O?M\NJA_XMT]?3U!)W-&"!
MX4RQ\4,TKV/WF4HYNC*$Y*(N8I9)!],%ZO]W:R6649.WS.\O6PE$5*@L3<@L MKCO WAXB=S-.OK+'3?%TUN^$S0[N UQL3,-L8&EO){.<'PX") +RIPKYA$T; MMD(>:Y8;HK/-
\98L=TJ-91M$[/CMH>:1F-\6M-P,>RQC5I3,"C@XB&@(G*30 MC8EQ@D7-BL9-%]&RF?21CS;&X[@8J_ T&>=-@<:^VK,<.T2IRB\BX9AM%(VF MC-U%Q6[B26(E52U%
JPH;,>9EYY)12^9X'Z H{QJZ^'"T7E=?,+4!*KK(F) M+(WL>@QRO5,10+7_>14(5"SUI9&9J2]VZ_9A_@_;I;KS9,,MK*,-* V*9JB M\CI+G3N>P226*?U(7K^$=
(XMF&K6L7A$U%P+8+VO=],#"X]PEC-S$$2U]4GO MW'JS[*>J3]TQ@&\@"JMWM[6!CH] QDN@XGM9P8T3\72EH5[H=^90R2 1<]@R*OPN7#L ENOY6G&1?
M<*TT@XI#:VY!EC+S0CY$ >)2D.T]S+=D["8@BJ]/$B=)JA"3XD2I=.O952-Q M8E 6:<A7@YXK_/#:#3)_= M?S?U/1_4)5
H9H%K5HX)=6:'@BG8E"/LM*F"%FKTFUW8K)*I.#EDK.X6R*^_MU*<3GXX'U_U69DT^DU19K,-Y7%)]^2>%_:2=2?"B6G/E-K<>PG0\7IAS*R
MMLJ7N/L'L5"MKW&T?>G*W%0$B/A%CD9V G\'T>)'VC!L)#>Q)#QXVK: MDDXFID]VZZ-9CFV-;55U TEO{N H$NBD+(Q2AL+1\[J08W]0!BFRS/-MZKO,\:0P/"D-;F]1CN
1,\.'U"%Z\^QP+7!_-HCU39/QU.+^'1^$*DSGKAT M1&T/3%7),#]'16[Y*B->C0U,VRG:IQ$(WZ M0'T';S*NB&L#/;PE,E\&5(Z1@7]EVU+BLAN22X$P:GE$35(UNA-J*PY-?Z
MC=Q14_3Z!NX'F&K54QNU%N^K3Y KXBWM[?P2[NHN0IL188QD7!-?907+H(ND20&M+,"81M%H K78.9\\?)9WDI++VV*:A MMW'7?<3~LGV"-<6V$]V,L[NB9NM5DA@0Z'963/
NR9QMQ"BA=,+B=V3$&F3.5 MTQZP0]R%6!\R'343L>YD=I@"%V+-[))//K;FC38_EC9QQL1,NW@U>JJ-.D4 MF. >*X&/4HGHN(M#[!GP*]F.#T_W'>G"L0UJ>]3
OQBI6#3RVK2)K9M@E?1] M^((E0]96]WR6IAV^JZX&3N_$\=A&X;E++8+))39]?3,,?154I2S>&3)07MY ! M#&+[;[YEB<0=CBAR,Q#,"Z3!6CRA@WI*?BO}>>;.MP]EF$@Z'!R-A,
/0{P[68@(20/*IBU?!< -@W8Y%&+JK1OVUG)GA;CZ@FL.\I M)A&C"/WZB73C@(\"W\$W)DJM?ZXU<]@DCC^5?L.'FYZE]+7]JNKQVN+_IER+G<]\SO^37F\L=I#J,:1
&%Y,UP@?9C. M9&J8<,W'HDWU@VE++\%@+YW$FT5>=PNH.,PNR<24R9EWS$TVKL4GKL65]L38Q M,P+F9Y&)1\^C/SY'<6/39J-D-WT.'Q\N:/B&-R8$>V'P\'T{SU^1 .X>!CO#-
MX<\U^.G3^O>-->JW>:,3^)->4V.\W;I3:[345$_:_+W6KHLQY3RFUKM/VA)" M>S<:VUF[+,9!#!>D7!RA=B)}_@BK,Y7&<-W(DRCH1N/?@?NI.T_-ES3Y+$"% MRBF2YA:^24.9?
="S%,[6F_(-_&PD"-)I=/6V9:&7-J^8G:=1!$#V@-#W.H6Z_0 MP$'A'FOVYM)G:D\'?QV^]QJQDK@X^'@MBMJZXK_$.#KVG7&&'O")_YI^,+ M<6'6+_75GKBF3!
Y+A_XS8O.!.'=2PDD'SB2)TZQ?B)<1K(5[-,/0+SQGO M*4XMT"(EQ"O3,5+R4.\FIB;WXU>J=5LNKLM?]MG+/MX2HVENOZ&R[M0I&W1M,460DD"],3_-U#8FF*1TZ\/F1+/ B)?3?
\ZC@&R^JD[K.I4Z_O6,;Z MRJ[(*EC.&1P0+-H*< B4+9&-=$#1P 9L96B""J#P!)0M/GHZH-0QU*4*E7*2 M2-GB;J9#"@9%6W5N=$K96I(4(|25Q\QE|< D\QR)IA)&KD_)>M/DNF67$!9
MD('+!5VO K+&24*STE4S.)=-="7A$"M;]Y=28J4%6*GO'^H66.$0*ULW2U)B M!7S\MB):.>)XD5K9&_E-BI5/I-EO[-R/)I\?1R07K^M2"+Y_.I"=J4Y=89\PJ
M(\;8M$W/=UEMY5Z&63G\DRV&64CEKP&-031Z*P3>++I*]D/6.C&M-X576W$4 M,#'1=D<-=CW6F@(U)XF:+<,:[JA1*]U2%*BK.^0 V']-EHMRV&@<U14][#W?GL MK_Z-
/F'C1>K[5E"EO4 #(>0V6+49:R 5(4W!91E8EM=*\II M)_I:.<|^"6UE/I B0<$!GN&L>DXWTA5P;S3,F@OD98;!?"HRXRL!!4*VY"E M ;(:.F;Y<)9IX&L!"4-VY#%C@E4LFYF+Y!5<&0E*
('8AJP&GLZD[E_XD >R MLDS$*X+Q&+;0MI]6S[[.\GB\(DI{JG,XUPS&#>>=PSFF].+HX3ERP.D*.6>%3 M'UK,=5\7 .-V=+,,]H-6J=)N9'*@NH%5X.*V9C/M!"VLOZGL=%RR@=2K06K,9
MJX-6!Q9$MZ=N8U5SDX[^\62WV(^(&6X MW7+KV$[0^:OHY+Z#KLD_O-(FN?1Y'L-,)2@03 DNT57!$@X1$D6VVL5'*!M 3:F]-@X$2'@R583*Q5(L%
<7#¥]D;$$L%I@M6>CJ,#0T2,AEE >>Q>8V!%I[M7PM+>)X\ B;QOGMJP'00,.MMQP1@N -,AL96:IC4Y7B](L):?&+E,-OCJ5&C
M5+H:#\J%EVXX:IUE8!ZU,,>)W34_DVSJ[]\=Y]0RDP]BU:42(;.?L%Z9G=J'-M$?GO)X*RI*9@*I2Q_8@,PBD"9?RB+$/[,16V6-!_[QZ< F#< ^P@1F0)N8B@3DZ>]:TIT"8,,/9L;TO
MC"'|=8 DE7I7KJ'V+@+"T3=S9C4_"H@>OMUU6$_4=[0ZK@;LY\^5*1+M3P6B M2>W3G*&*148"H@*B:4J_ +)UG3&Q"!1,ZD^&R#A$"1;TGD3T3+I$$S7_F,7$F+4=+P]E8Q:K*.=
;,5!$*,N$*3$*.,,U2VB1&6H6G\6W5; MO#K#]"86F>$$ZZ&:Q*^-5@G"(=Q)-*F+X@C2A+]2-R(NW:M!W9(&T$#XFF#L. MXQW!U%CZE5@QA6 >?
6X["68C8\&L[R:8.P[C'<%L8*)*FT?!%&Z:,;,*1_ ME@-4D B,BCS1(%3G2<[4]WQBLWF(@R5.Z'X1/RM7?[Z-JV,@Z"D+!2)UT0NT MQ>UT/*#NW9
MCM[=0F>LKM>+/<%F,Z<1A2OUVL#BQM2]=#MQ-0VBZ|=8Q-6DJ0>MG4,&B\HOP)KEF)++7:?2;2L"XZ7!^)8RC?TOWGHO5IGEF!)CO*4P/9X@:"DP M?
A(8WU)ED@'kWOP{93FFY!C7F!Y?/XV)$XR+6,,^L89//AE8-"IC7FJF.2;N MDVD'^6_JJA3K%,O6CR2P?4HEHNO.&-X]]Q(MN/#TWU'NG!L TN[#/R+Y>L1 MC#)';?
A##D0=UM=.$3XUZXV|JZK'@H$;S6 "^JDI^*^IYYO#V682##H<'(V$P#M#)3M 7XAR4'G7Q*A@.X68L MTLC%!>1OVYD)WNHC]@G)&:)L^2A"OWXBW3B@\(3O5BR^I>__>+CI74I?
KVZO M'F\N^F?2S>W%9HW Z3QZMY=2_|>?_LWE3>_AYJK/[_CCM?3'YVC!-VTV%G;3Y_#QX7*%;WAC6;$7!C\O]O&Y-#G1OX=>%;PY_KL%/
MG]:_;]1K]48C]B>YIL1^O^E1G5]CI:9ZTN;OM79=C"G%_7>?=(6"_Y=K[2S M=EF,VQE(?3Y^9SN1]GZ$M9=*8[AN$Y$D4-*QZ\#]!,;M!+0?^&>2)!EV ,[M1=++I9B(BG*??
BFGRIC=NOV[=,D$RX3T;1]Y>U$Z2+ M#>81;7 M4>\KZGT/T,2E)9JX"#$JKQAEU<2E)9JX"#$JKQAEU<2E=6)-7(9#>:BG%*/@ MGO**4=KYGY 89=7$195%$Y>4?
#AB\W/V7CS2)2ZMF7TV<:?$/Z]VUH/U1T7'-MQ8C83WC0$,#"I3"@?U,C:, !2"'/Q+1PQZ$Z=-RJ!SP&=-R-!U2?NJ9O4H^= M@XF[/+L>452.QK9;DI'92,$K^V2!YN(8(0UWPT?R6I&
;V/B_U8Q7_WSH?E*C>]_]>O$*6R[TOVOO[55 M1?W;2=Z++"L>! *W) H?#H'K2&/=&];]%(&RX],LR3GJ^:-"L+8NS!$X595N2 M9?-$+8 EN~NIXX7N,U^8&KV%[8I'-
L%P).'B2VU]ODN/-=BV7(2,3#!:O.1 M]K96BYLC?Y#0_B9)NP[8<1%RXQ&9$;RV9QN/"]9$ IA2Z-@)(.M"5\36%0)U MZ2/A1T*=%F]0"-05&W5)
\=\0EV]TE4*I>LV!YR3H6[U_@*A+@<+]L:8:[#N M;7N7A*US\-B1V2(8LP]4MXCGF4,8T!NSU4/[E@5EX76FK5M3@QIH]MIAOHZ(MPAXR"HN2])8{O3ES\!S9WMW%#O/E2"!
M@1<#&.Q9?3J>!C7[&R*ZV#/ #,YUGT[@%Y.C@,;R^=<4JU&CYP ER%*<&.[< MG+Z0_C#XXH>\HP*HR G]6"W"_Q#N)?S`C.)-_]MN#Y.Z+?D2O=^O[G1XM@
M'H_!O\VS'#A!IB(BS 4!99X!9D[J5:ZC?V=1(%0#&A:A87. 4+9!ATO"WL9 MFH"O=G9)53@:SC;,[0X;F<2'NK?{!HM%XH,!1@K&DS$8J28$-.HF@%9 M=#(Q??B^!{31PUS-L->[@[D"
5V6HP_LF[B=XI*2R:!#4S?]DE+C^\PUB2%] MI3.%(7E@<]MZ+3@J8-W&8]}39N>=3F/N3B++\$OO6^_VXJHO]1ZERZN+J^]? MKAXD33F35%E5,^M+R5,4.1E=LFN-RD6,.-
FDT2(V^_GPRY+6>+!%Q<6#VYA7 MM=X0=;>\JN/OT!RBL[0G9,3G4YZT5DN>;.GXZKAL!@;/B-.KK &Z4QM9E!Z M*62+*YB54K,2)1K(";DH*.EOL7+Y-
3ZO/TB%UH6B6P6'88,WF?=5FBWX6WJ.SR!:Z)Z9Q8U$ M*4),JPW>:K4'S&WP3)_YJ?MLZC10@P4=YY[A2F$>-T7Z/2;>W?S$Z@3>@" MP1W!*9ZYLY\|>GQ-W>1)4Y<@)'P;-
L@_E:;X.7C>!?.O!7<$=P1WRL*==!&H MC XS5^56I=NHQYR,DSJZ) #"%4"2ABBW J3-"T!*4 S!N!**U5%80OX4SS> M4WBM@CN".J$$%/9H,!^U7+IW7-
;XV/=/SCUQJ>W'+2W9G%0BP'1$ M77 GR_!A][*NR#R)>@FB@\MEN=!]#Q>_1S6U6F99 R>>.YXZ^]>C'K8<)HHH M?5Q1,BFM3JL@6;+&@&R%;=_UQK(65"RKB9=[HXYUHM
M^S[%@HJ&F]CXY+QDEVHD)$E($I^22I&9:MZY@TK{J'S1M6FVM49,X3]'QET)N8X+\'=O\R?.Y',*^!|_"JKC$++1I\315$HT21.# M?6NKE&:E]|88*0)S)X,YH44$1P5'^>9HJG5A2Y5:-
NM"JQCK0@EV,A/7W(KZ M!Y&B6R0]ML6^/4(-E]*N=!4ELXB#@)M0!H({@CM<9. MEA'$ XBZQ1.HER ^N%QQ^W]_W%Y)FIRRX%:D}]FG56C$.G1
A(4+%$:$T$J2M5:3O(CCM2K>511FMR.4_^1K: M;?W2!0Q2BI,*3XVCJ8P0;:T3P2%/*@23IZO&:%.J.3BH4P!.J1'!4SCDV@+&%/.]K0PDV*0]23%O8!$^-1H,TS=_:SH:6Q/-Y:DY.>YP)N
M0AD({@CN"%U5;\EX.8:F5KG2U"6(XNS:T4ZK^".X({@SEP])V>Q%KCHDP%M)36MTFTJ->WX1Y,*@!PC+KD5'W5>\%&"R*(XNE8XK8{(@CM'B?[F7EVG-;#D M9KU%@P 3EV
2HLXS=$*,'AY TIL\27H)8H/+=;3]J_O'J^]?KA[2%]/NG]S! M&V&R.WG15//%MQQKG2A?7&OE+:,3,(:PH!X@~+0H"V"M!:KX=]!*@N@P!UVD*$ MA @56H122=!:/X==!$>I=)MM+:.1
V\67!@HB480DJT)HK%)LMZ-NRT)X&+(M&HS+<*8#BZZ.>E$)MF:7(VJ75Q=A0$T1W>E$ X8M:\9."Y-=U@P5 M VK\Z4HFI<(V5H.ALDZ9%YF30@JK1KX 'K_ ZI<%1P
ME&^.IEL*EHK"G>T,W:/W/*W+ETE@_,!!=R$ M,A#<$=SAF3O[F90]54-F2M578)(L&A)/UIL">X{@CNG 9WT@6>UBIA=VP_ MUE J7;6YUXE] B + B1I9'(K0%1>)))W;-
$PG[EI4H>&7FR+.C9(&6H4_JO@ MCN!.5FM'TD8 V3>R:FA8AY-!AJ9 E)#W$G/G,+;B >2]SHF\ER!@N%QA^[WW M*UM=$"-&I"M$. MW4W25=LVFD&U;?OPO2&%E
DIX]2<76L(1 4_58*-5Z=8/>B2PD"0A27Q*4F.M M/<1>DM2N=)N-N$800I:$+!:50EE*)TI:SGY-)4*?2;37E_;.L\A"C$I0"<%Z, MNUYOO:G17'$"FWN%G1-2H@ 1Z9/B:2H]NM82Y
"%5DVYTE4/T;!*H(X?U E- M(G@]>,.H_3U.M#EMJV+)9'92"K XEV-,)2#%N83-$18(W$)5]TJ0H5742UT ME?K^>-D_32@#P1W!'9ZYDZ7-
>0Q5K7&EJDL0"=ZK&+>P6:8B!UAP1W!'<.?T MN),N32*K6LLFMOAO9M'C7P"$*X D[2&[%2 -7@!2@MAB7!VNR;@36XDK{HS"

M;17<$=S))JBPY:3[["OQFDTLSLGJU'L!)B'J}>9.EO'# XAZBR=1+T%T<+GR M]O_^N+V2-#EEX:TXNJET1ST^_06%`&%)2% 6P4HTPKUEE+I M-COJ7C7J0H2X0E,I12B-!#77*M-W$1RUTFW5X]J/\6;!E6'WC?-:VFT5TP4, M4HJS"T^-HZF,D.9:1X)#GEW8TBI=+8LNX@)X'-)/J!+!4<%1OCF::G%8BY\> M=&VH<[\VE&"34IQK]*SB|*=_>S[5@IV6I5NJI.4XY_M:JD R#*BDEOQT>8%'V4^U?;=:EIQKJWP7P5W!'>R# 3G7FC7ZN#&5E;5-P)_M0M1+S)T, XG92WI,YDG22Q F7"ZI[5_=/UY]_W+UD+ZN=C5Q()C06A]N<5I3 M)L0Y&>W27.OWM4/R>5LYP&&X^_+H2 $.(9Y"/#,4SRV]<_8Q_FVKK/BWVLBL MB8:07R&_IRR_Z78!UCT2[%,>V=9PHDY7#A+EX7%/K%07K3#"}/$(QX3}\FT MV:L;JX*A4R"JFS6[%3E960:E$M%QWY38,ZQ@MAT?GNX[TH5C&UB88>!?C%+$ MAP_7IDULW226U/?A"Y8N65O=5UV:=?BNNEIKX:PGCL?R(<]=:A'??*:??TS# M'\%@&?:6;@P9*"]N(0,8Q-3??,L2A3L<4;CU9M-YZ5\L"$!J3$SUAS.-I-P.#P8"8-Q@*9Q7)9M>|\Y*]O&]& [A9BS2R$6U M^+?MS&Q5NH^H)3 IX0(U*HC0KY](-PXH/.& [%8OO[_]X.E=2E^O;J\>;R[Z M9]+-[<5FA<#I)'JWEU+_QY?^S>5[-^'FJL_O^..5S 0S&TG7EO/B M21^F-ID:)ESSL6A3_6#;C6 NGS$@'V^L4F5I.:5ZL> PTP!F89&)1\^C/SX; MIC>QR.S'JQ2^X8U9P%X8_+Q0MS4Y4+GAWEGXYO@G&OST:?W[M5KW64;78G^2:$OO]IDDC]=MM_"--(,+1IY$04T8OP[<3V#X34 U#*B+NYH; MJR&.2>XE'S>%V=<)F(IAT+H<4JO8^GWT6O_[MT_>WNS[YT_7#W M7;JIOWKH/=[T]VZB!4T NTGBO:U5(]=T8[U M8AH7!4$7M75L@ZH(-A.#E-H(PMT<0^J23@!&9M)B]B&1,;8 M&/YO]D6Y>A3L986LJN-EJO9LH[=$TSCEW*YTZ\W]FW#P8X\(H&Q*

\368JWDN_V4%ZORM)L*<:<^O856:16)1XM)S]%C-<7.XB>^X;DO,!7W(W M_.'1GN=1?UF#7 6CED';G2C3MF6Y0&%AX\VP[6S0 \2]7;KC6Y!H^P_9.D M7AVB(VXIK+HM&CIQ9^B.6NE][NRH!R&:K$?$-VM#V1A+9F#;=5Z{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{&?+K"$)XTX-HL12!76\T$C&9N1 MM(Z8%/U?EV+B>B+B9;,L]HOKU@2\"2R4+&U*)/8*=5]CK@(!?D(SWH UJ M9&28?K$V2*X?)PFEN]<'ERR:T^=,I&9#;H7U/S&:-!I%9&"B#;]O4,8:& M%^QCK)^2V!YDF0AX=3>|"CGT RZLU&F\?^O%JQYF#,%?^C9QNH72U?&2,]: MD1=P_/4D(_^@M,!,VF\S)V!J&3D>)[KX%-@E^6"$[<>QO#/X"SLU[[+PE*@-MS4$6F;VD]A[FX1CK/>7##/EE_1#HC#@QKS-+@)PY(!L\XUX*[A M3+%/6#33_1IV\+9J_N<1Z7,RZDS+69MAOWNYDUFOS^Q8>B072\BTD.G,9;J= MLU!W*MUV(^O=-:YD>@\#YQ/K^Q?%]N"?Z.HQ<<&/"Z:AKHHE-G"@;M9(4^1$ M4.M3*A$=R]V)/4,OTW9P*\UW1 O'-JB-Z1;P%R,[2S\/]V"))?5]^(*EWM16 M0Y1+TP[?55=KK0:,9^)X)H+EW,5*7O.9?GXQ#7\&G]?OC$$A+RXA0@@$%-_M\RU+).YP1.'VFWCOTK\X>0KN.? MV*@^O&GD1C.8D"=:';B4_*R2{4SPG%@O9.8A&?)) C1YPX;T%/S7U//-X6PS M'8?#@$Y?=?H.,=E5=WGK%T#7@7#(=R,11JY}'_MV9X.0)LL.^X !-67'N^DB[O;RZO;_M4E_M6_^W9SV7N$#V';L]XW MJ?\(7WR_NGWL2Q]^W/9^7-[[Q_7=4="D:A7MNC9-FJ<8(6HHNT3?+..ZN K M$}6=?U[%BXY$2F6N2(.U]78ZA@?IZ]LCJTO\G?M$[/"PF86NA@^PM-^#[PG3 M8A_OAG/EO=#=EZ:G6XXW=>DCO.*+Y>@_YVM]4PZL#=.>4J/GA]_A "C8!1,8 M@N].Z5&(]8:QW-W.,9"U @[&4XQ:#9 MRWSJ566C,Y46"_F>Y(W M'7BF81+7I* 51AZP$$F5/U\$]S_[I'R6'#?Z(7AT^/U'R?0D@1GE+'ERR:T^=,I&9

*M;94]N\B#Z;4/TIOD_@#M$0X_V67:NT&&5BK[K":?,'=JEW%:N)@]T:5)1Y,B<'9 PO%KA=*B@%]W:$"0IF\4 _@6,F"V& .U=F[2!Q[4UA'_M9XQR!S >;$O?)APS\P67?F'Z57^$I>+BWS)\U3@NL+IAB,\K+,8OD#'4PV MZ[13B\L%<32DU{G&1U!9S.;9 9'=I&X&E@ @SMA/U]O.8@7(X>WEGEGH#)2? MV=WL@4JO8X+AO!/LI'MVT>LD"(9?:'H3^O"" F[OG)O2G0'H_<+|QH.VAP?=8 M/5/YV2FRQ21WR>D$DPL63$66+BV!>A1*9"6 98PX/>2@W.SD)>8DF$2><+3 M,;~'4W&(%$@%V!3=J8" D-&KZNJ.=H[W2T 03$}\I-W #!7=53^%21?_ Z7 M/2**TX4-B>*6M%S%7 ""TE@PV!4:J'HB(!<^LI\|QB!-X>89(#/VR8%W@+8L MBMC_*1NN;*T$8/K1G E@2;!+9$$T^04;PGD\EF_H-P3GQOR#:S=M@*2IP]NEOUW9<#2'DA I1&0\%H\I23&S+,\[A3'#% '^ B\EY.* QPK81:< MD[P #6M%P_YXT:\^(J_,I%B0V#1-8)YZ4)!:!R!XF-7^FXK5Q14NZFUV*.MQ4PH]I1(? 3WD(W':HXES"SA?V""G3+CT*<-YK\!#7F1-IQ"2/#5=AS8>1IT0 ML?C910")=?)LX, [,;2:9))ED%6ZQF01X1/),45PKFN8E4,3"Y";!L3F6;=1< M/!ZHF*ZN2G,9Z$.6D/U92%O>LKF8#4;QV;YDY;+TC&CY)G:;D3;R3OA-KX=E6 M]&-[TI0>$'6_P<@--B_*F\9%0WA>80 F0T5UY0Q4/!03* Q+,!]KBGC0I%; >D M@<E\ J!-:"R+7G&A7^%;%<=3FDO$/J;,#5CHI\:(P9.6J}CXIQMSIQ70G#0 MM&:IY;Z$HA1<+6@B+-T\P M)L.)LW\9F[A)4]/\$?#7792L02LC.5BSER9LXG>P))?7WE(Q=\5+S/ UY_4$ ME\)Z61^SQ!(F7T?4LCSJ>8BU>O#'OY/@WRPE&>,.T /X'[#H&S1)UB%!J5'Q M1(W.,)[?TADF9/ELN;JOQ52)##K-0:]S^)UT#FU1@XR6475&S8&.Y:/&YY0, M[AD0] (%;$>4U\C@HF(2:"WO \#L)GRA(;MP^*./ PL6KHDV5R[9)U4/JQ;L(V:8N5#<\6KU\?9 3=-AA3:<-. M.J.SBT&K6UK@M@+3&FH"."0"*);:M ,%A#2\L'*71!/CLXMN>U"%:1 U.9P8 M.;P5-23W-.'-2*-M?OP/M9IE}4_ RP:==J=WVKLJK$KCSP>5(H9G8+)>YF8-5?;O!NP/J. "QLA/*QM MWD/"EX(V[_8(4\#F'56D"+C&GJPFQ09B[,R=X\QUC9O_LQ2/_F\MFTW(!& MV^DMQ&JOA8T8=W;OU,9'-<7}]@B37ZSV*!H1K]HZQ.CSD6//6R%/LECM=7#;-M4CQ-X30LU_? HOM7Q&P_&2S%VZ,"U[U"VATTXY3N@>UT0TMUVV5WMWKQ=R=L-.M2CKN[D$[S6DYTNY!Q,6C/?C]XY3,P]R\T4ZY>8=/M+50>4>ADJ*+]1$Q.V7/ M!WN? #ECI6IQ7"PH,9.G(?"A7Y6CWE?0Y.]NIG]$2F.'26].#ZQD)S1#)7UF M1B=U6ACO+9#^ZX!^K:O<#[*@O)*]JOI3N/^3]E]-3G4V%!E>9#BIA^=772[0,'CCH@]MT[Y8QL;G&? >M\B<,* M414>Q](>#,O7AL;)XS;JK/]JXDM!Y6%[A,FO//1;B$)Q=;K.^J\<]KP5\B3+ MVCZ-]AE6A~\]?.D6I(VN=;]E .%%B.$C*$^6XC=/L[S2]8ODP8XK:-C)U5->Z'Q*^%).1 M.R!, 9DZ3O81'F(<^LBQYZV0)UFF#EIG%_UC:TS.#[!3[/0K+5\SZMW+]&AK MU<7$Y4#G>'A(^2WO!FW05WK]TL+?)9W9(5,^U_1Z$O1:2&-\BY:#@PYF+@[* M.#4I04V]-O<=- O6]#O"GZ>O?LHML;OTT_A/U2:TJ7@&@7@/@WA2:B;V*.(8%X M]7/)#)NEC$;'OIV'.03]TES FU>2A>7I*LXZ#VU:8GS7DNI.<(XT'-UB]H(I MV%-!6L)K3=7&B@#G^!-? %3!4"ZN2TQ0Q45VI%IU+N6:!\];&[AFR*@]7LVA(R*.M/!7&!X$%>4>QEU'OS9^!V+"N3);X^.,XDSR= TX1+C6N5N],ND7$1((I.INU M9LIAM?H(VU'FK+0H3C8^'+?G*,? ^C\5B4>^.:Y>_(4P2-]_!"UQ3ZPE1:T;)?%]'1"UEE7'5W5JK4F])E8.E/9 M)#7$9M&[3^XX$)*]!6!-K6](K1EC=HI3*_.,Z31;AT"M.3N:QSN8XUZS^S]C M%=7&R%D;,7&Q"4'$H\1@&0*U.1F.),:.*)8U:R6V#8] ZP4,!VHBC82-.^ MEU<((IFAPC>6RJ0;39YJNN9HS/ZB8N!VJZ5%*L=<{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

WUWE;G)9#&BU8V8#T//N[<_:!6?4\+#S-4W^)XR,,/.R?!54L#IO<.\Z& M^42%*&PXIR*3W!6W;O&\,VB.AWOD\Y7G8QPXWJR, .(EGM3Q&1TUZ=>D_Y9A MBGRD/T+2[Y;=N>3-23]W2_=P67N!-@FCHVN3,-JN3<(7-G4VM4$8);1!&%6Y M#<++-W>WOYT]7#}^D+U>?GS{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`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`M%!*R?"(MAH1-/@)8ODLX\W9-U(#ZK M&U-&;\QUT'0B%!*B3@F-5+;0<0%:*K!,Y%D2US8Q><8 02FQOS%ED?PI#G>Z r+T1*R&6V9"81LX8U+;R>O!-\!R;A-(C7^G@HZW H49MBL!P*\-^"7RT^W_ M?GWX3#IQ_;2PVC;(<'"A679M@.\UT4 &@;39CTM8J7!G_F.,R{OOKV=J(R- MSRZ21GG\(2RYNV%YK?!;B8J8@(((S0(I<>[KP]\;Q_ >%?9#$X_^CIYNO' M+7<[W-]N!ZU6LNGVRYH#]\'W6](>4.E;+G5-(7KC- (893PC(I+T+++S+T3YW MV4[;)6@)A5B9O;>"=\3-$=]"'A1./&2;98];!4-/" M 9#PA:W]\(8=?A#,1; 3]GL>_@;*L] 0MR2146N?1])%AA"O?%TCD60NL&^R M&67Y^G?:>0 ,H[+(9M39YTK[N-)\9%,>L33\(XP2&FFFQS["T,F8@-W(Y96 M%"A?\17"[P!{23$(W5H?3"I:.(]^V7WRIS^4,DMH3E-Z7O*:YR_ 8.#HPW ML:. XR],7M+%ZS/@B2,\Q1='=,.!7V[I M^2:UA@:ZQQ&(0QZ$H.-8-F(H-- HBUNDN!Z*.B4!!1(4,4@&_"^9_+Z@LZ_)K2 MGZ8..\0WXV\H);R=6C3 B6\O_6L H&KF#C6# 7U3"'"-NQ_%;0"D97KTXU8 M9RP2C0O05 (E__P$2\'"J1:60- +.3AP'2QGTF_M1I274,QGB0Y=N(>[5?$@ M7F4+G;4TJP+/;93;3T'M)'EWX;*.CA\4,&?0CAUZK,1D98[.1%"$$|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}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{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}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{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`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

*Z%FHK=B+NLS[YT!<#EF\3D;X%L#WQ#N(KU'0)MK<0W'|G0Y(G2H233=4@M(WT)(VL!G0#E8-@(7_%*C ,?/)=? MT,V%]UK(+;R+N0Z&!XFK!%*'%W)N8G@TPBF1T-P,^JTC,Y'MN33#;NJ'?6*H_M_N'_/18TX!/0RNCIL!(DD+!KS#=>)ZY MNJ^!>]:$+'%3CK1^H&S3BK$[>([\"&'ZTO9? RD&;!IL$5OPL%F*Q8 F"IR)0 M?+SUT76&?)I>=#M8F0Q8(T%F80K1'GA3V_N+[\"&I_$_Q0I@+!218)0R:X%UFF MSG[BPPU@D;I (%P#YH'_ +_7;0R4JFM2P1.8 ^# D'ES,$FS;F88\CULH_!I? M,I)@A5]!*-CN$DPB!U?'?LK/S^3@6XD;-1B?501+5]+)#FP'$;%]ID[8A7H/B M -%AV> ^8M%,CU57E3@STE_83P5 ^ONP"4 0]G+,Ff1!. M/&> 3,Y5B(D)D*A83>)!*-DOQZE@#'G3 E^.+*FSRAW1*@^#(KC&37\ N#ITO M*E)^I@,Q#;!(323;E2!/?J:X1E@YL7]:Q.3Q4NKU 09[CDS2$_/W(8\8=,U] M+V[C4OXP7]$U 1R,HE<^9=%I1(1G2$("GF4?+SQR%C[,AD?F/D;%7"V)0K.1 M))*GTU;7PW0T_^!2DSWA\B92V-?R*[LDT&&>L%A.JHAWEY4A#C'M_@#FA M-N%_;[OQ!1Y3K]VT!Q?S5WW<8&VRM44\B%[&1?!5BW@P!;9>L0T_?=P"O8X M'>BPM"^P(,*$S4TA,D?75!H-KN0J3=*MCZ8/-ZA.@ZE;&O94J"C<,&9N;.F9P?&%DBJ/W9<(=$0>GA-T9TL1]AB5(8U!*\ MV@U.DPC4O0WV2.HVZQDY4DYQI>I'%05XWBNJK92D M\!8|_AXXM89N;SI:.ZZQF73UDRDNO?%N!I8!2LEOLO5#NFQ*E_(2A%Z#&U?\ M"?R>KSYG]^JY;$J?K16 }&%[?K:G+'L\)(_X?+0.G#M _"?,4X=M^5T)&^)A MWYKPK3*7-)%ZI;J"I<@/L1GZE KNZC/HA WI7[*. M:2; .:SIHP_#YG^;OCF"S,.4(-NT"B% M/=^ S7K;1.1 -12^>&O*-Z:K@<"\AP,!3&.BDL,[_^O3>F! ?8,T@<% MOZ)0C;*

{B8OKLVO=BP9O0S0%FFGWVT3=?O.TVN)Z.;D9=.$3@2NZ;"M"&M&*V MT-"IY,)!@O$'"U;$9RYU<2ML!+N M.52$1JJHAL!K\;U"TZ!XW!=L)*2!%L&QU@M+^5_#D7YW9'H]G#F/"6(84/A MP'D.EG-)B3]W9<(=s0>GA-T9TL1]AB5(8U!* MV@U.DPC4O0WV2.HVZQDY4DYQI>I'%05XWBNJK92D M\!8|_AXXM89N;SI:.ZZQF73UDRDNO?%N!I8!2LEOLO5#NFQ*E_(2A%Z#&U?\ M"?R>KSYG]^JY;$J?K16 }&%[?K:G+'L\)(_X?+0.G#M _"?,4X=M^5T)&^)A MWYKPK3*7-)%ZI;J"I<@/L1GZE KNZC/HA WI7[*. M:2; .:SIHP_#YG^;OCF"S,.4(-NT"B% M/=^ S7K;1.1 -12^>&O*-Z:K@<"\AP,!3&.BDL,[_^O3>F! ?8,T@<% MOZ)0C; M+N B0KLVO=BP9O0S0%FFGWVT3=?O.TVN)Z.;D9=.$3@2NZ;"M"&M&*V MT-"IY,)!@O$'*"U;$9RYU<2ML!+N M.52$1JJHAL!K\;U"TZ!XW!=L)*2!%L&QU@M+^5_#D7YW9'H]G#F/"6(84/A MP'D.EG-)B3]W9<(=s0>GA-T9TL1]AB5(8U!* MV@U.DPC4O0WV2.HVZQDY4DYQI>I'%05XWBNJK92D M\!8|_AXXM89N;SI:.ZZQF73UDRDNO?%N!I8!2LEOLO5#NFQ*E_(2A%Z#&U?\ M"?R>KSYG]^JY;$J?K16 }&%[?K:G+'L\)(_X?+0.G#M _"?,4X=M^5T)&^)A MWYKPK3*7-)%ZI;J"I<@/L1GZE KNZC/HA WI7[*. M:2; .:SIHP_#YG^;OCF"S,.4(-NT"B% M/=^ S7K;1.1 -12^>&O*-Z:K@<"\AP,!3&.BDL,[_^O3>F! ?8,T@<% MOZ)0C; {B8OKLVO=BP9O0S0%FFGWVT3=?O.TVN)Z.;D9=.$3@2NZ;"M"&M&*V MT-"IY,)!@O$'*"U;$9RYU<2ML!+N M.52$1JJHAL!K\;U"TZ!XW!=L)*2!%L&QU@M+^5_#D7YW9'H]G#F/"6(84/A MP'D.EG-)B3]W9<(=s0>GA-T9TL1]AB5(8U!* MV@U.DPC4O0WV2.HVZQDY4DYQI>I'%05XWBNJK92D M\!8|_AXXM89N;SI:.ZZQF73UDRDNO?%N!I8!2LEOLO5#NFQ*E_(2A%Z#&U?\ M"?R>KSYG]^JY;$J?K16 }&%[?K:G+'L\)(_X?+0.G#M _"?,4X=M^5T)&^)A MWYKPK3*7-)%ZI;J"I<@/L1GZE KNZC/HA WI7[*. M:2; .:SIHP_#YG^;OCF"S,.4(-NT"B% M/=^ S7K;1.1 -12^>&O*-Z:K@<"\AP,!3&.BDL,[_^O3>F! ?8,T@<% MOZ)0C;*

*M,52$1JJHAL!K\;U"TZ!XW!=L)*2!%L&QU@M+^5_#D7YW9'H]G#F/"6(84/A MP'D.EG-)B3]W9<(=s0>GA-T9TL1]AB5(8U!* MV@U.DPC4O0WV2.HVZQDY4DYQI>I'%05XWBNJK92D M\!8|_AXXM89N;SI:.ZZQF73UDRDNO?%N!I8!2LEOLO5#NFQ*E_(2A%Z#&U?\ M"?R>KSYG]^JY;$J?K16 }&%[?K:G+'L\)(_X?+0.G#M _"?,4X=M^5T)&^)A MWYKPK3*7-)%ZI;J"I<@/L1GZE KNZC/HA WI7[*. M:2; .:SIHP_#YG^;OCF"S,.4(-NT"B% M/=^ S7K;1.1 -12^>&O*-Z:K@<"\AP,!3&.BDL,[_^O3>F! ?8,T@<% MOZ)0C; {B8OKLVO=BP9O0S0%FFGWVT3=?O.TVN)Z.;D9=.$3@2NZ;"M"&M&*V MT-"IY,)!@O$'*"U;$9RYU<2ML!+N M.52$1JJHAL!K\;U"TZ!XW!=L)*2!%L&QU@M+^5_#D7YW9'H]G#F/"6(84/A MP'D.EG-)B3]W9<(=s0>GA-T9TL1]AB5(8U!* MV@U.DPC4O0WV2.HVZQDY4DYQI>I'%05XWBNJK92D M\!8|_AXXM89N;SI:.ZZQF73UDRDNO?%N!I8!2LEOLO5#NFQ*E_(2A%Z#&U?\ M"?R>KSYG]^JY;$J?K16 }&%[?K:G+'L\)(_X?+0.G#M _"?,4X=M^5T)&^)A MWYKPK3*7-)%ZI;J"I<@/L1GZE KNZC/HA WI7[*. M:2; .:SIHP_#YG^;OCF"S,.4(-NT"B% M/=^ S7K;1.1 -12^>&O*-Z:K@<"\AP,!3&.BDL,[_^O3>F! ?8,T@<% MOZ)0C;*

{B0KLVO=BP9O0S0%FFGWVT3=?O.TVN)Z.;D9=.$3@2NZ;"M"&M&*V MT-"IY,)!@O$'"U;$9RYU<2ML!+N M.52$1JJHAL!K\;U"TZ!XW!=L)*2!%L&QU@M+^5_#D7YW9'H]G#F/"6(84/A MP'D.EG-)B3]W9<(=s0>GA-T9TL1]AB5(8U!* MV@U.DPC4O0WV2.HVZQDY4DYQI>I'%05XWBNJK92D M\!8|_AXXM89N;SI:.ZZQF73UDRDNO?%N!I8!2LEOLO5#NFQ*E_(2A%Z#&U?\ M"?R>KSYG]^JY;$J?K16 }&%[?K:G+'L\)(_X?+0.G#M _"?,4X=M^5T)&^)A MWYKPK3*7-)%ZI;J"I<@/L1GZE KNZC/HA WI7[*. M:2; .:SIHP_#YG^;OCF"S,.4(-NT"B% M/=^ S7K;1.1 -12^>&O*-Z:K@<"\AP,!3&.BDL,[_^O3>F! ?8,T@<% MOZ)0C;*

*M7"WO7U%@6"JN$Q6?M>8BBVIU8G4#INMVE+:?!263$Z6?E.EN"Y3??$O&VDS M9\SNH^/HQ6.8[;71E7_DHSAQ+K$!F&)MUS27-SFH@F'D(;|_VN^WF\8JB<@&^_M'T-4;M@6W5&TMYJ~]-J~W'3;A!6'$K\ABU.2W;1_=37K;?HU+G)0/=!ROJ;S4 MW-&G*G'OL4L:[IN'!H/NS5V3V3R+6GD7R7@S\$ZO-L>&=U:)ZD'CnXI7UC7/R-MC(4N12+_7-0*XR>L>:*@^2K1@ M:T&BJG-S=N[:D;Q6_FLH"V,K=\"}R;^7D-AF:27Q(2YONCQJ7&74NLM&}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

*6'0=L&4C%='CN^7PUM4"@ [[!6)^>]*LM&6(.%L#&I>#C4 V? M+.D)5(8UF]RJ.3P U(;9Z^#%H&N\.O/HN Z6)]"8/_6)CXWR>,W2KQ/ [UQ0MZCK#O2C?P#'D6SH6@B MMP#;2K _Q7PVX!OI/ A*.3YL,." X R>COEKT@<#8HO 5?GV5>/A]>7?03 MW,WI XGBS(LG'I@6G[ZFQAD0G(7!.+(P TLYM 4FG_)1C)FI1*UX!QRP@7.|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|**|+)C"\AP?O0\QB[F'S9[&4G66]1(M|))SHT$@(NQ%%B:&2]=$Y.^FJ;[":WEZ 19WZ5BL(4!-#@@S2*GGS('}H(E M.D9B\D5184H+'AT\7YNW,%XFS')3X-ZCI>H2I$Y\(Z<2BA!6?B(G6P&R0)7GKP*\O4198L07WK1',N45$U^-DP0BHKT R6-]R:\%Q-WZAS60CFL MZ\'QK7)8,3>]SF&M[%"%,"N-MKW9%3C4Q9'UE:R0&>3TVFO>7GBI%USO0?=F:I#RX(HQH!M@>@$=U&4&W#7]R#[V5!WC_1'_-?Y3: "FR$%7V'T-6G %1?#&+31AO0003S_[B|R" M/X$*_%WA D:8:DTG"N(M"Y+H7X:?SI?'"1ZGY%X9 X M[[^>2W=W<<%5Y(X;SN!)G.8@VW#/6)X*1(O]?4.ZZYN?PC"76?5 B@C1*R!" MT=*%.M,A+N2*]NM2<=T 'H. 1X/$%T!|/U-,,S$_]27"FKAEK*Q#H0:'PK6(M BSB;QA7R[_))F1Y"]1VC0CBAQ$+)6Q;+,"?E1^X$", M0?B(VT5?"7-T^.7S; M0.X^,\)Q35?)7'2R:@7A[*'ER6YMZ07XBKY$QW()^)0V1K];@8ZZ&:\#0 W<0!1;C|_3INA$,V/-Z"AGN"P8E8EBN$(=I2P)HQ9.NAXL$RXGT,Q "#1+B MTGZ3AP ;4-+P,B\G@RM.Y.-3L3Q 9XB1)0V#PR6\Y1O2"R|<8BR4!/KP!MH8 MN FYK(V0,;Z!Y_C^"=^+@[XVLG4'_+X!@(%31.17PQ#>???-48T)[M#N6>@XB](N16C)E@ ^:{E GP#-A)3V3 5$R;48E+, +9A7!)EBMD.0;1@;2[3 MUPB+L/GY=#[B0PD#0@SUD9]HR2,3+7STY3 SRJ.XNIE4(U"=SLCLK0T$BXU MLY%L^[GM*DP+T_SGK>Y,3TY>'L+GJESTI!@(HI?I] MBH==Y3L/#85I+]FE5?T^,#'[\"D5/I%@7SU*MD? R53_Y,_#6(W-+^F#F:L(%(C M-J"5-`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|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|FC:.Z8?\"R\->MAR4T8TQ%:SC?G'M28>Y$P5T%KY'>=\'G%$QTHSCG$"_)&\N"HW'V>Z*2LQ+=*2P)9Z^6H+@Y*E, M2OLX<\@FIP%U3*;$:ZSVSLX2CZ G7OE)SS4LW< %=V'EW2UV/H%M2=0/M_G=H0C+G%N#BC)SWG&6%AG!!W*%GB=$O[)HUT]W2"YHC(&M7O#1]#:-V M 3'.V_A<0EB%F.Z"ZGWO7\ !#_3HK=ZW75Q]*69E0=2G_U4%D4/_=IJ=HRT7 M2E,)?E6AM,K&6TX=Y/#SM;9H;HUFQV_5WLY:S2/.Y5UGDXJ E]|L"EQ9>=W* M7"WO7U%@6"JN$Q6?M>8BBVIU8G4#INMVE+:?!263$Z6?E.EN"Y3??$O&VDS M9\SNH^/HQ6.8[;71E7_DHSAQ+K$!F&)MUS27-SFH@F'D(;|_VN^WF\8JB<@&^_M'T-4;M@6W5&TMYJ~]-J~W'3;A!6'$K\ABU.2W;1_=37K;?HU+G)0/=!ROJ;S4 MW-&G*G'OL4L:[IN'!H/NS5V3V3R+6GD7R7@S\$ZO-L>&=U:)ZD'CnXI7UC7/R-MC(4N12+_7-0*XR>L>:*@^2K1@ M:T&BJG-S=N[:D;Q6_FLH"V,K=\"}R;^7D-AF:27Q(2YONCQJ7&74NLM&}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

*6'0=L&4C%='CN^7PUM4"@ [[!6)^>]*LM&6(.%L#&I>#C4 V? M+.D)5(8UF]RJ.3P U(;9Z^#%H&N\.O/HN Z6)]"8/_6)CXWR>,W2KQ/ [UQ0MZCK#O2C?P#'D6SH6@B MMP#;2K _Q7PVX!OI/ A*.3YL,." X R>COEKT@<#8HO 5?GV5>/A]>7?03 MW,WI XGBS(LG'I@6G[ZFQAD0G(7!.+(P TLYM 4FG_)1C)FI1*UX!QRP@7.|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|**|+)C"\AP?O0\QB[F'S9[&4G66]1(M|))SHT$@(NQ%%B:&2]=$Y.^FJ;[":WEZ 19WZ5BL(4!-#@@S2*GGS('}H(E M.D9B\D5184H+'AT\7YNW,%XFS')3X-ZCI>H2I$Y\(Z<2BA!6?B(G6P&R0)7GKP*\O4198L07WK1',N45$U^-DP0BHKT R6-]R:\%Q-WZAS60CFL MZ\'QK7)8,3>]SF&M[%"%,"N-MKW9%3C4Q9'UE:R0&>3TVFO>7GBI%USO0?=F:I#RX(HQH!M@>@$=U&4&W#7]R#[V5!WC_1'_-?Y3: "FR$%7V'T-6G %1?#&+31AO0003S_[B|R" M/X$*_%WA D:8:DTG"N(M"Y+H7X:?SI?'"1ZGY%X9 X M[[^>2W=W<<%5Y(X;SN!)G.8@VW#/6)X*1(O]?4.ZZYN?PC"76?5 B@C1*R!" MT=*%.M,A+N2*]NM2<=T 'H. 1X/$%T!|/U-,,S$_]27"FKAEK*Q#H0:'PK6(M BSB;QA7R[_))F1Y"]1VC0CBAQ$+)6Q;+,"?E1^X$", M0?B(VT5?"7-T^.7S; M0.X^,\)Q35?)7'2R:@7A[*'ER6YMZ07XBKY$QW()^)0V1K];@8ZZ&:\#0 W<0!1;C|_3INA$,V/-Z"AGN"P8E8EBN$(=I2P)HQ9.NAXL$RXGT,Q "#1+B MTGZ3AP ;4-+P,B\G@RM.Y.-3L3Q 9XB1)0V#PR6\Y1O2"R|<8BR4!/KP!MH8 MN FYK(V0,;Z!Y_C^"=^+@[XVLG4'_+X!@(%31.17PQ#>???-48T)[M#N6>@XB](N16C)E@ ^:{E GP#-A)3V3 5$R;48E+, +9A7!)EBMD.0;1@;2[3 MUPB+L/GY=#[B0PD#0@SUD9]HR2,3+7STY3 SRJ.XNIE4(U"=SLCLK0T$BXU MLY%L^[GM*DP+T_SGK>Y,3TY>'L+GJESTI!@(HI?I] MBH==Y3L/#85I+]FE5?T^,#'[\"D5/I%@7SU*MD? R53_Y,_#6(W-+^F#F:L(%(C M-J"5-`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

*MNXGV=JO;/*H_WG<3.2]/FX%K4Y]AL']U/<|E^CUH]T7&VIN92 MS>I>'+<3-KMKX MG;9UN6P3.EK|{7*Y'+K)R/7B@8CB4>!-#0G>NL@C=L:OVH4O>CT73W)?*
*T(LD"_2[H2GZ<8IF_6O=R)6\[FI[W4-#9;L7S MN'/2;-W/S_Q *J'B_J!\Z@MWUF^.SHZ7MEEN1-\9YG#.L==8#EI-0_WD3=V M/DZ'359LW2+\;&XN:N\][#3/,&*
(Z#A,J@'CFT1P,\;BB]>+9Z4,)3^YBEO< M'L ^S^;?,K)9'Y?];\IO7G1BYIDKQG^'B5K-V!V(@UXBW)\';A\6^\8-,]Q) MBF1E;A'V5P'IZM"XLW%=Q_]HX.!U^,+N2'A&V*
+D>!5L!QW;]_+8>#!/1__>S M?]S=%_,$+&I]>!?WG0MX(5!:^_]+&I]>!?WG0MX(5!:^_]+%AGNNZ'G>E'=N6=&>]{5VD-[CQ9P[8YL M-9<-XQP>ZML>T!|T0|X#8Q
F.K@$7\^L)YD-F3Z_7BVMCLR4NI ++*. M6-7^;%>NW=JW;0!UOP90&@B/5HL"F'GZS9\ZI2?M X%-[KU$;Z=QG=KU;3= M&N[EM[:H_TN3AD[8469$E=[6T98/H?M).*
(IM!=RTE\,NS5[9# MPF8Z)&R.&X]:]TS4]9-"9!7@OOH>[X'14TOQNU]1U,XIP)NO\MX<4W9/5\U2 MKJ%.9%7@ M^]W:FJ2&^:RF$V^U'48&W/Q1"M39WQ#^-64(<6IJBND]V\5:1"
MF07M1OOP.9++=R>+]Q'5[KVBL|:Q8R2,]PZ=U?DF:7NS\U-WMH<3)F>IR5 MGNCN.\^QR$'-@EQMD+<7C\8NC8^Z;,4'0EG#,N+?8>2BS!O.X 3LJTH^],3
M/L.)X^<";P$8F(/E\7(7T.X.A)XL#0^C[%#'J9(X3:JZZ&"/NQ([1Q?+7> 7^-K1VZ&MX=NQB ? MP[5!G*<(41$&UX)0 5?R#JK866%W0;N\688>,/24EWG^,'JS*G6"N\LP/(@*
*MJV[6;ESZ5#Q^)H,50RN>@,L*WCH]4:+<^:P5(8*/7BR@\Z93-?EG;K3HM/1$ M&RU$"F[9:7=?+"U1&HK,@6118 1N6$@F0W+@,Q09^]/ *O$VKHW7BQR(8(T< ML%(6*
*O8/>/SM6'@@L89NMA#.3C]{X43D[0$CN@=L$!X.!9W.#< =:<'T!8# M*H.!#8%<8[']7FSB_1P'\]9MPPVSH :#_B4_'/#?%L?"*7T4DKI#">7M>+,%' M10Q.0)%8&8G$ WC1ZX,*
(^#3P<_@H;N>55>O"0/E\#H&Y@'BDLWXVT>C>^HD_(M'4Z[M0IW3@%8N5D"Q424D8;.GJI9P\QABNM*P04NY.OD8ACCR7CQ_M;D MC1!$+Q*2GP!14A&Y14@<'_P(.)-*
*[8_($USCC*>5-IUE1'R[\\0R?OG$ M:1f?&P-=P.EYV88BW8,IE%;SY'|Q&<,*91JK%K0\7)G&$Q1\;')[*Q=UNDX5 MBBTV> DA^>;S9DA);4K*]D24K,F\MMOX@Y2'|?JOOK1H3V4AX*
MKJ2+9>5YI:L&ZY8J.]C%=BXK[W^]/;7ML\Y]IY\M#8+'|++)O)GYON6-/N./D M\+[C";:=_:=A%=)P5D:%B>KXG)39-T\VT0FR-9I/1Q^>4&_+.K'^OA)LYL=
*M$MY:>>##6HFS&\uL++=N8]2C=M> ;+==#2W9KWUS,E8YX87RDP9(32\"#4F1P/.MQ)Q1SGO KZJARH8S%0[G**@__W&4?R=B0-]%"F#SAK3!]X"W.!YC\HCSX78L*
*MHE38L%!=XB8V+&3#0C8L9,-"_BRTXZBP8;'-A(4V5B=3TM%0T<3LW0T&RK:.M+V?X[<[*W35?N(T46>98=QK3R7UGYFX[W,A'@24-36ZMYW1FH MNG=1"DPD*
*_/RTV=8!-3,]ORP>33S^M#MX3B@.)DH8*5-Y\)\B{OA 195R7QVWM30N@"K6Q&@>LH]W8 5QV %>-(MA7(L12U0:5_"9NR+'Z M'78.5W8]UR2*
*9Z/;ECO6YH[3K0P.VO#VVB2\5,QF1^L=2W7QXV MCUZMIQG5M27V*IJ1#3Z7$WV>=*C_,@8!;?#91,7)B4UZL'GQY+P1M=-.R*[M4GQZ,J)<;J'9=[T@Q"I4,OJ;IK$74"O8FR ;4F-*
JN#;$WK'8 #D>9\$H^)MC MO;1>,9@LU?!XV^-(G\4 MGDELBSD]MDV6%27:(H-%ME@D0T6V6"1#1;M."H. ML&C_@D6LEZ7S]#(;$=HOG_?_^<=I#[UYNYM>;QL3LORQ[C3)=O-T-
*[ECWTEX MKV-"1-=[&A6:4H%LZ&=MCG.1G^6'UZ*0^Z<&_Q/%#OA ME%R7Q6O+!'::SO2QL$)@]*NJ!.%'.$;>&WIC4?B'UT3'HV /A8-'16&-HK&*
*G(D&_QK%/(P@Q.OHCHU",'J%9 _&[Q+I+MFI&:1"Z=N'2Q;4QI56&A4+FE40:%1 M>:,TJOT+\;3VU87=DHVD:NW!+6/QSE@S=OO_!XCNEQ^TAG5,=:SLIR^*
M_C#]&.VG@QSGR.F==3(/A6\ 6D?QO"F=%88AWLF7.//,RYQ> MGL("TK3IE(-57IPD(AW"'/.9OWRS%Z-\O-&+<1?B0]]@3XGS?)BV.E+V5KN M50->F.U!*,C6#-5A>[9FR-*
8,,3(P8VN&,,W0=J#"U@QMK&9H$UHW*V>!5,Z$ M5LXB0SG;NWC2?I=$K)ZDN57A)%LN9'GC\>HJNLVS=6L[GRQ[\2[SX5"A\W6 MM,Y3.[_A*
*BW&F*RR4A^@U>;08^-^6HG.0O.5YI[G138@&+LV@\>]!!!OSG9B? M\5'TDMQ-)OQ2U_LK#WA "CH#+ ^'Z@#K7!4*.FC$FRO23>. 1\0CUZ!(2:X?_ M$VZ8#=7ZRE-*
@L',2.1[G>;O9U:M#WZ=J> 1@ MA&\G8/7A3F7!93#Z-T]K-I M:05(-)C0WXKNSZDW'QKCG[%R&\>.[T=CD]HJD:5F2>V22VY&D^&]YHB6S$ZO8RQA+[N9=A@,1U M8#OD??
R]>=5T^L+'\&1F.T%=[H,+.^C>Y=$9^A;>4!$4E]^ZV!W#*VZ#$7P. M)TZW>?BBZ5P 86&$*068!'T@L0@6D#AYE*A;+OY;*&VT5RF>X(E8*7-ZXJ?.\9438$*HXEV0;9G0MG8 OF]S1*
*MK_?R+K_<#'O>]7*4A4!>SL=5MH@/Q=^V&'MUW#",;]S($VG3>=<_7XW}?)2'/)B&PJHJ-BIN MARY2%C^FGV=Y0NND0YD0[U*+#I,4E@AUH3(:P ,XSC!8#%O2N"K&08"GCNB*
*M,31N%.4E$: AH1'!0K+4N)8U,5CR.&-CCHMAZS2C^:T;NGW&"/"(F<5*K7;J-R M?'&++H] YO)ICU_/94-+^B=;Y@E'(<)8!@6P<<7STHWRM!E[G(%[8%B MD6?S;S%8_FR6-W9#'-*
]M57R-QG\IQ!8'_[V=!SSOK>$=GO5;_USGL|$_ACW:K M=[@Y.X9/1X=!'_Z_=.GZF[AKJ;D9C=R .>H":GP=N'[;XQ@UOW$F)ZO\&(!* M!1&KP-!.L=GO/QH0>1T^<&I")/P&-*
1X%6P''=KUN(,$]'_][-_W(W-DV?O M?A#3 [-=P NYD[_[;A:ES$F&.-W,J38[N/ Y^"L/?)0> XOW#'&!)WQ@D_Y MI7H"KDINCZZ8\6DQD9I*2C6$Q39!N--IX*9#J=C*
'P)^(F+V)2&TY9#^4V M_=P"N2N/JACT%IZYH9%G#-&!+E$]8%R1PR,#9A>U- UJO[0>KE*>8X|00\ NZ@-ME"#X[=H-0J(CE/Y@AR7Q#2B1)*T*
*)+//SU*DO(#)PZO\?=YL4,U\>28;R!TX&W#C09KF^,P>?:],PYA2 MMD@5!4BZ8+8(4F\3D<4-1QY5Y[H\=C[*-32=T\ M.VN>E2L_22EF,/%>&3;5UI-J"4^72?*
*QJ34;4]*IIB[W#4ZX#GVD# ME@>Z"%!(GD0.Y8[A HEY"'C-I=*IMDZ.E,AL2.TGN//$R+TE@@)!$WG!&+X! M)7$49 Q*ZD)*
*[I.9I2]P@,N3R$R4%IHQ4X*EDP/YIB"L0.&%'P.0Z,0G@GV! M-(, [79RAU^]Y4]@68/07,02T@<.>,(79RAU^]Y+]Q4@KZ5F\)]@ M>=+E[Y;0[S:,72LT. ?V\%ROA3!(&*
*(,"LUX*U$/(IHU$GNNT:!>;=%.!1>3F+:.M!V5P6&"3T! MX.KW R] 2"!5"\%W@O#\D]4+J4[0PRH<5!]>$L(!P<;>1$ NA/FN!\-!5* MQ-0"&LXPOD%3%07!!%>"Q)6X(TCY-*
*0$;O#IT'!50G$&'Y760P>]O!'LS&(3 MN^[2>1)X?-R -<2(>C+?6H5!RHC9 3VGH;9"+ T05 M&.*L98'PRH(!&\%D@*)H&O49RQ4$#)-Z%UN[V8L 0L&@ OIMC8&U=("=BL*
*MW>&>$M32FLZG(@6;&(!\9061%L,C%U%2]&9E'B%GF1?GH< O8^U-L@(\ 2"! M7Q1UI]8 Q_5B#PIOZK9QGJ2Y4L?Z .S! VC">ONX2C^.7G?/PW.Q$@ZRP5E*75*
MH"^UWBJEXG7T$:)(@)Z-W9\CZ,!+&OHHD+I>;@1G,A;[+$/T)H+,D2HA'0> ML0<%M V0?'B$5)^!XA?>,,ZDJR49I8QE.G\(99)0 <4>UP7X0")"ZF'^>KH MBL8;!&
*(G(F"A1T>2(J;TLRL(),/09PH^D@M)\KYJA2Z<-)4C6DMC*0"W&_Q M2UI$6&;]2D3DPP (D(XV:)62+P 9*VXK M%V3J9 >G<"[@70WG]\P=2I&#SL-*
*"P_"XVP#PEAR6_I4C$,;A6&+IE!\O55U@ M-5*P.N1)'}B41>DA7%,M F$@RY)U3=' +7Z\(RP3P&.5N<8GDUJL]P_UZ>X MD_*L!W-9 $<6#'-4/&^?%AIL^E'?*
*+)\SI9F(&R:3#VTW!X02PD6B6!^MRAP@ M*Q/E8(IBP1.%7&I,&Y)2K@[AO>@M%WB0DAXV)M6P+ \R,.8!YG\PWE#=EO#*-.TGV@=P37]HBK"2R_S^AJEUL&P%T'*
MTB,#:.^#^D^]AA]^4D.9Z=!!6@YK_@V!AGQ:K&#XM>;84S B02>6.@APLC MF$_0$NAO2.I515]I&EY$P%* #T(M#-2=TMOO2- 7F$7^@M6$H'^7!!1@UFM(E4(IN33BV&1I*
*M!\S0:VZ@I$#-\GD%43_D(P4%"Q@L#7G>3HJ##9;(2Z!:."5'94$;J7DW0N11 ML\EV!K8;\DZXH="2]&'//A:!!9S$KWZB?2J3RC>@U+(KZ" MPWM=[/|P8!HE_*
M@)Z\"4K=,"EIYOQLOEVKT-N0:Q4]Y!0 TR!Q1Z!"YZ@%[;D9T,.]! M-.SH >2 (P8Q!>LBY+4J9+BY4UFKS>0 T>&DG=35]$R#,HRXBEMW- X% MN7>.^PI.HS-*
*I69O_O40"'+]>4$F3R,;M^T-@9$89 *,9A@#6B6/8Y=).1Z\7(M\R D--%GL:'+*_US)B!'P!S! =X)(2B=-.8C2W2%>_.H5?KQ"2J2?&I(QZ&+!)%7$3?_C1E28R^ X(NP8H>;*RE!R*
*MC5"E+S6-I=T5Z[N.PUQ%>;>AJUP84B^\8^&T8#.Q(B0;_D;$UTL,P_IC&(1"MVZ$9]5W$]HI>I>EH_AZ^4B.Q/K?:?J2/7 9M%4!>;U)AETJABRU ,XGX?;69: M/!{?*CIQ[*N*
<2/"M!,ND6R8: 7P(=H) :N']=]HG.0O.5YI[G138@&+LV@\>]!!!OSG9B? M\5'TDMQ-)OQ2U0+4&^ ,"UZM?Y4$@68/07,02T@<.>,(79RAU^]Y+]Q4@KZ5F\)]@ M>=+E[Y;0[S:,72LT. ?V\%ROA3!(&
<@6V9T,VFO M;RH%%?TKES_JSG{}XS]I[>W<%%GZW0#4/07Q2"&YN;U[M95 MMF2_IB71Y9X.O>3ULJ7ZZQ?D[V^%^7OA26BV-31MM?U>]1N|F)>=9;N-[F'*?VK,Q_ M'*

*[LQ"RN>GB^ZA9'N^3Y6 MT:B7J"01$ %5';3]{(:ROQ%*S|^,?E(S'R>+?/ YV*AB&(<^9W?=ZDNP"05U M-,*DKG@TPC*7+/9^\HP@^'*O7W.#)9+M+F*L&T)D7IC-*
!2A,_!&3\PFQ]TS.6YW1^5\X8$#W94SOIY=ZT''94$0U/;6GK;_6DY=<3& M'J;PM1XLA:]6KO263N'C3G6DA8,@*KK+%!TK|C>AK[6O"1]\,%QN5T)'SOA MV+:,47?*
*&.#K>MDPHF\=GJ??)C:\=6;&Y? ^@<,GN">2G?2FUKU=&H];YZM?N MYA*Q<#U^Z[$J-K%OPP*IN[) VD*T[R9N7AZ>-<^V++;5OUXSOV6>!;N&Y[EDP M*
*SAUH;ZS56:ZS2:'",.Q=QSCW;9J&UYGM.\F;EX>KC1B\8*PL@IVP0?9-+&/ M60[P0U0T!^.&<_&\[),&,%;79DF@IX_LF\7006L5-N86JH|4851=#HRXBEMW- X% MN7>.^PI.HS-*
*6K;FM0#E+FX#N5Y$5P_E>JJRU5_,S$Q>?#=SM[2'GA==29$'A7$&4K 2"'M36NAFS4^=HLYI=]PL]NDLJ^X1/=6B=;Q/;[8.3,+MR<>4@Y;B;GQ V"**)^ MPWUCY/2>V3?*
*WJ87:0IW76CDKXOWXN'E8?[3O)FY.#IM'F\'-OL1&5CPJ1.0O M/B26/-QGE|>U=JJV'T:8M@BTK^[<,N$<,>'IT MWR!@[?G/,HEEDN4@TSFLYR&U=^ =N>)*Z"7K]LK&F!_I*
*0>]OW^IDMGS]?S M=>]2Z/V'X%(@G%4N!RO%R(GC.NWNBR)84D5QXFX-\+#3 M%Z6Z?VI[D HYIQ >BC5].D^3 H]>4K-\Z MC@8'(74&P"%<&NQYG1B;#*QP:.$LF5POM3@*
MP[HQ^2>=H%UC)I_9\:)P((LBG%0(M#\&>)W$*4YS5"U5R!6>!Z%_$,>4)81C)_L\'-U8>P',)5N.U(WY/NJ.V-UF MOEF9OT_.?+J-#M ;#<4LTfN><>F<__+9^"2N>%XP!';-*
*#!4^;5QH=0Y2FNUE6'9 M2J/U5T9 ,9.; ^G.!<#BSM.F<1R5%N?RSXN=^3@/G\?&SMQ&2M1TZ.J$ MV!fBL^%(*08O&:52B++#F?H/-Q")]G=HTP"D/E\&CF_//-#N!]5VW.W1V*ZX^*
*M\/_]L.X9H>W6V4J\+&5:?-4G\NEFGJXYD!905\?3RS>>%^<1R?W_%-EJ<#$6N^[=;|_P $0UBYWM.N/ES01.*7T(CY5JD:R_XU=E*@,=!= M/)==#2PZ&*
*(M%:/1FTFAW^>X\6T(_M2, M*3^_!^()XY2L]G.B2)[!XWP/TI^U$S-_".(:<0LJCF(ZVDT"N]$*7IP ;EGO M12^@XIJB9RF8K?*
*UWU/8BJ1@D:99T1L1IJJ6B5T>WL0H:L+'+&42;CDH2[NF M;1G =:-\\&P4(Z5PDN"QK":F\ZWRC>DU;O. -3Q(^]S,] 3(!)#&U"6\3SC? MX?L&??[ZOQ^__R(_2V7[*MU<<,CX0'&@V.%:*
*J"(,$"W4V#!!X+5!T9Z3VGWKHMH],P MWA_>1+X'IW"S]+=#BR%(X^,@5+Z\]-6]AL^5:DAW9H3TAHIE67]H$D_TP]!)< M1D70FU1F0!(D\/Q*Q.!-Z YYB#KN_X:#@#0%>Z\-3]CX]*
3' W@.$>!$R M24CU\,,1$A4>RR#]Z4/&[JS?FU=-Q\?.O G:X6-XW"V=NW#IZ0LE:G2$9B5' M%[Z\\KJ8-(!BMV8T"7[^CPLH1%V$: VG#O#R1CO8.6@W7!1H?IK-\R%4EO,
*M>QUE7"KUR]BF9 2[\R!DG;,Y8',_L(80%#T4%& "NV'*5KM&BA'BJFQ4Y$G, MDO;])DC11PH\C1 &H UF@(*52>-Y"#RIP^$F*.87@XQPP] \)$QW?"F.IDF@ M)Y 5*\O3?*
*D$/\"IEAN)EP!H1\'T6#%6+< M3!TFN+/U5)ZCRXOWGW^DKPJ%'(]14--<\N0L MO/,<[GR%RE/*C@F.77#=H#RS96@V)U;1IZEVK'!*P(=;H!),L],\TF>R7O-*
MSTVGW3X]Z'0:>))SWY3"|FTX[6-N6?>J-8&%$QDQFL>@-+rJ$Y2VC-EQPM. M//9TNBA^U3YZ46!(HZ4)&F5A\A440%I3RFX<+D>_S>;@'1%"X"Y#^YR^4MIB MQ9+5E9[?W*
*08NJL-W!^J)*I"LD2O@03!'83&7$U.-O(/E:0#56;JA&L9]XR5 M0P@M:-G;L'@B^\XH/5@E=!,A8L]UW^4F3BFNOZVWQ1T'W72[S91;KO)+DK1D M[I8-"CS*#Y!-RGX\#-*
*DI.E+++7[S1]QTS#8#D)$>HG2B%V_ =@>@F44EQ MJ?:1?A\R\^;#;XC$WPG5>B5(8>=">!0#M*AQ$8)B$67M .(.E[QG*0KRI6& M%5AKH78]IU5';=\A*_"DJ9ARM3ONEJPC5*79[#-*
.:Y5CE#/[%7.01V1K%|: M_X_9QA<%=+'S1JHPX>;9$(RIOTO9W.:+_A^DXSQC#T>/3T[NE.$KKSS%(6' M)ER&Y3/D6&52(/_%VJ5BAH(SY4$()IJ PC;'8 U-04W3D*
*{4H[=OLR(3%FS*4PF0LPQ#X&GHVF>_W 9:1PHUC-_|+WGKBDB*\77IFS#A>_MT>N#8WCLI*#X.39+I1M5N I3+BAEO=2;U W!R/ GNMMI$B5A+;E&,79)-'&L1+FG(\0()*"U>5H!SP]*
*;F 94:4>55'3#J_+JT0^& MZM7T+;1"DRI^P?,-WH@6*E TT4'$W>;04:+)FK]-R'D*1W.#:1]IN\R+ M*BM%G73LX>J5U'#F#&Z)((4H<<+,/F\R7X&@;0:|(C&(LT %2[D_L,HXF H>*
*MH=*0D,*#Z$CCD+@B),]M2F=\) ,'M9+'78UN%GG*T>ERPRTE',%, I3+Y:K$L9J11+G$##*GCY.2XQ0)X?)]96/:R\/RGIMF4E6G&AV=L5]R>@68*%@VBUD@9RQ.TAG5J?
AG\.JW%D>0#(I'(3 M>)G0TC =KLQ(H^"V(?^4LH3%O_(:>H!NL (3S2UY10XVS@LD:7QG'FL+YLQ M%HLI^;I!%_^,,$/7L#H?%!0V'76U2,IEXQ50FU*HGT53[!BE)QL>|\"K_@0:\.*
MG0GI5Q69;CB<8LR?LNN:(*8L>+,0#@!U<2WNXNL2#\FT(T_U( ]K(%S-35*4Y&N+7IN4?<8-_%9 M3(\"LGA&NGD\KA5#0,6&L\R&&3'!@E1L.V1DD:&A0%,&'U OB$$;X(@4=I3:)*
MNW"F:.&6 ^Z@[-0@M!)\^$*AE=^5\+0B1BP0G3YO:9%@&G.#N=1IGV[ZQ+ MG2Q5G17"Y58I3@WG-#PD>EWM+HXO)/THX>;2QWFXXC\)469>A60 1&!0*
ME:Z'2\'2R^CO9F)3;H&F$M%>%W4-]M& MYUCVPDP$#":J(K3AOP18L-(_EC M5I:@?EJ'HXR:/%1*.JN'X^SBCZDCBA V8K@Z86<8K0@L%Z1SR"^~M"\D)\K'#CLL+(X=)V#*
*<@@3%O;+GH.]RK#[N7%^\O?7N'21GDX(#5 M)00E8H %W.@5I;8IQGD^\/FO=05Y C(,+X1N6CEQXX M='U3@>3Q+E)?!9@/@QZF-93O*4U8T;8HZ2R(+*6:F9N0Z[ )6C(RZ-S#,U"Z*
ME^2AOP)DSU.5J$3>A7G FY@1M6(5I#PZ4 L'E+'O10M$EK\DST%H+$_&@TIK M_&9R@ PB=!JJ08+O_(DM"}77QHBT7.3\."ZZ9)P#XX-"Z/P6AU2IYKR%T%N
*MCE]AQDJ">6IHB8Y53=4#(265"%W6>Z ZV5(%&HE*O$>-3H*)0AN85T,A'3$+!' MM-^2UXW12SEG0+?OO7"@<89$ PI-1*W0\ Hl=/3*RN:A;[F-QUWSX,D4?9:1BBL(*F*
*>GR7(@RBMG;6;!.[<_!9A)8HH664M0XE4ZV[ER:M7K52VSZYDUP)DJZY5-U21|K>D3@;.HB@F^;G^#'CJ55P;'*2RV,"_QRD;*BJ*
*M?;HS@1^D:4XM0:0]BI"AV+V,C2=:|'}R,&S:2RR9HA=A 7SRX:%8H%4$=K0 MBC^3;4V0[@\}'!4:%:5!$V MBIK52&JYC9&TJ/E]GAJ@C(S2.,SP8 M2T 7%84>,& :%%,[*I/W5_5*
*P]JC?2*4A#11\X3^/@L:15[7@=B)OI;=Q@I)K*''TB2>D'BY2,TACWR.%-%F*X5H5R"\I)+ MF3,<=(?5-%$IUODJ4UR"*1,T>#+CUI>RH '+(;@?MNMI=U1LJ]?%E43,6CP$NG'LS2E7*
D_>$JBZ=4T738 M:78K[G/5P<_@K&R&QO[Q1C4G-'',Q*V3NJ Y.4=BR3H&75^U!'IED!:LU9>T. MWHI\TCXP>,]!VAJ5)5,H')^'6;F<^40(5+-T5Q'.LU.7XF1)^,QLOYB3W>P7*
MTYG;:^CW$'5,Z/@Z952T3^ E 4,P6C?*&C(N!@18C MB(\\3!C<_9>MU%S6GBZ?XVC6=TQEZ3Y;FLW:7[^)*WCN^2,/D=]9LKL#|'-MCA3XWTK5^3$)H+N;!#[_KL(7"%-RY?*
8%\+TQ.:J.B,^,= E;$KV"Z@-G]==-!|-%8U3_4-KJ.7A4!(','UTT'9^)-RR]&+=#>=>?P>V;(Z^Y\A0NY1]#V^P[H)W:+SC'Q M0BS[IN-5WG3_GUFXL&5(?*
Z|!V\1/SK=>EM!U,|K'P/OHQ!DPDI=#O^F%ON MIYSE@OD,NDR-\@L3->M!+#R]Q/>KQGV:)K+B.6]I0OH'-"CW<;29[*0!FZH MO;!I82/[% QN&,(1C!2D2-J?*
L,L&ED=BY1]K5_HT2-!PK9L\)+#Y.W6CF|7OHR^::[KN^;_$.$X&HSDR!.QYO2G]O M-]N:"C/_@?;#E,/]Y.KU*UE5>J23!',DV\WOD"I9\OU=-OM TQ0I$(JO#+N M-X<9@/;"_)*
(FI3DS9,"$27.Y&_Y*R*N^F\=(M!!]HN0S$I"HI; MG>8,M1V)I)\INGRB5FM5FM8UEMFUFMLQ*K30_7LJRV%4=:QGVI6UGG(5Y;K'NKT:K?:S4I?KQZ1L3:QJF]D%3G_MIY?*
*OGYU/$>=T:.]C+Z<(_8$L<);?^^]W=>?DE$3E49%H^=<[NCZ'EOH?,3D MU9]PW#9EHSTGLP=R+R944_X?GD"H;D@|;YF">AU)=V-XAF|^KBMPT=*T|&*
*MPC_<6U!;11.B/Q"UUAJYF],:.R0,-TY1%^>?]Y"B+MS04ZZ^ST'T$UO^6?IZ M#/IZ_^'C'M+7>\[,M.3UV.3U^?R7/22OSVY/A):R'I6R+K]_V$/*NN1$_3TX*
M&3=IAA[N(F7]&,L,=&=,N>AZ1@^60D23?]XQ&5"]D^>D,W#84;>9T9-P,+Z> MR6AN0=US:?4UQ0_7-&Y8[C84V,4W152W]HTNY,'2;,[/+)=C;-,L,4/CME MXNK3KU_/?*
*_S^,;2\-5S:V!C?:HRE!=)/1!4.5"TFG=/NL>IZ^=2S! M^_%E:LXI*FLM3R=G4'$*@BC,$ M&"!5W4|SA"U-4\;B93L)\!^M'5[;!X$42(5/N.?U0'6S=];O:KA;_^O?GA8,> M"?*
J#!'_IR@[XS_H(\8#1SL3QE?U.N?)5F3+5>G'#Q>G5V<7!4^V/:U?OB=6_>KRZF,=GY]-S\X_3,CTE+R=79]BV[HXN[fJ M7U@?(=X[.3\|/3LY/?[KLC6;06E76H^V.K]/.$.W'YBQ-X/<$>
MB8LO5C-WJ(=Q9;G(^OIU<7IW%9X$0+>%/7\|%KK7G,/[_]JR7QSK) MQ/L3>_^"3NNG9_7SLZ0HVU^3)>6VPE?IJ2HA9S73R_|%F(+(IGU.\X%/V@+E M.5+%@2.AD?!XAJ*
7;HE!);A)!#($BV"B1>^YC/B-_#"^(ML464+OS|"T*.*UTL M&?>1FR*<8F\B%?:X+\Ej*(R!+K.P+T,2GJQ-U+E3XCC>_"K#K_>/7MV[41? M:N#59Q@OC20G:4+IT1,3#8K"*$N-
3!+X58_IZO"H?G8ND-Y,ATTU,=,AIGNA M#IDU(P\4%:?!\;U4C77=,58CHC12(O":V(1$P (ITT$>L1Z-V./)Q8+7)^O
*M=*I#%DG\PZ0:,#&S"361'1>'/_:622S;1&9<'/(D(E=E_F2'IY$SY9+ZDY9 M^$ \@KIR'5>8(9G&37^-]\XOZ.)%S7HW(MZ+IE\286YPYI+CPR9*S)>$^)5ZR MJY,.YIQ,:YK0!|:CEOI?*
2TI>"4WB(BD!V[4>7@L)Q!-]A;2WNS$H9@&!?U/S M! X."5U49OMM,C6U7Y!0E_Y?6._@B:GU@H0X?WK#+>R8&BY(K,#9)^]!?"S> M(VK?U)L,#-YK^)X]##MY(RDL,2P,\XJY;
*<+O\ZG\]PS5-Z/\.I)4OYJLEMWA MGC]KN?Y=^[%3HBCHH4$.ZX1)MNNP9EDD4/8]<5.M2UB2N(Q1>P_@C(1KR1]=B#E*Q3R*

M1V_6$OYV1#+++\0/;A9USXE.A^<%AW>:NQ/C\11BC-UL2*X_YVID>F_9%LRYU M/$@U5G%68GVAA_5&#F)3M)%TK-G96#390E@X%V7H(^DR[^!@%PA08GZY#^9; M-A%(/&?#JZ$(2DI(IB?-L8=4;]!F#8&K5ZX\:XT^_I89A%J.3H M(TQXJ&%U:Z^=.NFR/*"CGVOC\!M1VOABVI&_U8.DF5:QX707#>"#)".4Y%0A$;#_J U^/\^Z#9$ MT!Nf;_WSH3,*

)_1:8STL"CDH(3G;A21F!Q9)ADAP1&N6,Y%@6B%TOO3[=]\[M7>&(NPXX]TM'-!R-T;BE6U&&"BQ.=_%)N8F0=GP0R'#"N'2;#;'#ZV(,]=Q MV^D;="<9=$H4+G91B)B@!)<*N;[.fWT9MX;W=ZU;S09JBT+I[LM===P-Y'>@1 M,*B0I_OCKZUA[#SC4,"E5B+P?AVP-3DJ8/1!{HBM![!Y"QBC)^:\HY%TAT*3Y8H;; M D49%4A'#H]8;B8_=VFVWPE"90>3TVV0VHD MR2OD9:CSG7".+)N6WKC3^]+]-;4[C2(&2A12<^T$MZA)2O"K$"RCA\&@*V>V MC6ZS,?K:[O;_=WKM_O#>1#52,%'!\S$U^4YR1, 2 4^48%HAC&!6IEM+HK)* MCZ?*

*FUB%AA;PJIDH/IP_=QKAU)P>1T/L-6U!%!]CYU@H;Z6Y_1#]YTV*FQ"4U MKTYPC@:[6[SC[N0-L*_2RD2C*<;+HXY^(Y4D4,*0,;%>4U?(R7<=2$-WQ@]# MS36()('2R:GI=*

*(Z0DL6"H;,(=:E'A[K[6M&12#<'F9[@=@RU!S0FYACE=]8 M:%\LC">;+A;:)$K6B!H\Z]"3E4R=O%ZVDF(&AQ4F*3Z@~4ZW-5!"USMS.!2(,/$]=4VE:]DE=%R 9I6Y$P04.1 I9*X!8OM[U41K/1ZG0E&N=1*:%(IW(PUORKBD;>H9(**@H<2FU2RMV!\]HH8Z:PNF?5- MVOR4V*52Q-IK5E5$,GL!R@2[0@XJM#ZE,\8Y"UF5!*3*:18I&46BT62%H#,$=/C[X=T{A1H@4*2R6[']P]S.%X MYR/9!_$4L1+&5)9D_^:.627A*,[G[H>2(4\E>*F,B3);?$2U"(%-@]G&E'_# M3D"FC#<>A9=@"""^'F&'C(@5< JW@TQ6]_C?XF'X(&Y7FP[VX)OH]/2 $?*]*

M^BFC+94$THBV9%< .B.I-!*;HK7:=?&K#HJCC>;0.TC=XV>)CD/J+_%QJ^J M&,F9:QC[-4MZK)3QD4I$Y2V,5+T1RO1W1MT6?U(7NQ;%3L/SB. ^)Z.]2/&. MK",OQWA_F]BJ KW<.1.Q$4:H*HNQ-+kW70#ECZ5C*&B]=4-J(/P M&K35P,"'4M>&FR>6<$)!C_A&P7,X<\AYDX Q6[)15(1V>;1.51$=QO*^& M3"Z&=T18*5IL$-IZ7L)E%Z\0*052E &22B8:!TA2.HK$'T-B!ZS1[)&^)50 MIS*16E!?>VQ;L(JCM[?WJ-L4OE]?K6Q@&M[V?0+8_83=1PCT \K4AD5[<2E M8IMQU0#"@_%%K D*58&WL3+'T-G&<;_6P(2A5O94HE,)^[;$A4-,*#@S449G3B*

*MD"'"=OAZGR=!B;?A;K+M6KZ1&L||CR&0 1"06(S;Q!:-(/?I?Y)CLBGCKQ\@ M^\E7AD]V6G42\1*H:16Z[$B9#^/$9;]G|$H0/+)E?BFDI69.QHK"$GR=A(C M,+*

((E3"THT3;MYM4$H&\#:&;_GJ_OSPGO,G@4C8"X7607OFL;QY:^XVLM;D](4[EVXHAKO:86F?K)+Z)D5TX|'-R)7?I M;@\]^0]T&))"=8(L%<<'ASQU/"XB-7,!:*

^/!1+O@6W\%#P5BR,E0RHU-EF8)/'4,*"6L, %Q+=%A2]TA8^ZR!76QS[C!K?8HY;PY1UU M 1 8+2D13Z4@<\|+57VTE.WQ30V4HX'^$J0U M+.$ETVV5+^"O1%G[>L.=:AR.*

*<$*A*)9Z1#\#'3@;P*DE/\@A?/8@!+]*%&C(M449#*J^H&0T;V5%@@/1C6!166NCMQ#@+OMFR@.QZF/M?+!VV(D1Z<1!P.RY*

*MP$Z>UVDX7]:#,IQ2^5'=Q@7TJDO%4%*SMRC6+0$6#NYV>GM,>"4Q40:I#VV M.1U$DBIXSO3/*V?T3!G!4^G-3HD+>(V@SJ!!3 I=*JB;O[ZVD|PLNXC5"0X:/*

*M$IU45K3P7M]*PJ4XP9]HZ(+ETI^?/L-_(6UCCME?&&^1?W00I6!D,IV:EPP ML-/2)C39?/@-)90YAD\1DN R.-$F_@=:;M!^Q U_1$T\VPVEX|SIA9"A<&4ZI MI*1Q.,D(DD?*

*DX(^$4O)A8HHAWU$-,] M/R8\E7BEDG2&EXM4$M;UO=2&T*7HE/!DW#RW9E))YR?NJS9R?@:=TOFI9%;" MR?*

^[\W\]=2:N\7))QO5@,GH2_79>%NLM'X@D)AV\2FL5JYOJKP>7+8C\.7_H?8 M8_Q\2URA@,_UB%]#>")ZZ8&SY-[4I=CQ20RY>D)M:$8E+'7E(_J;F\'T!0/$^X MOZ^7A%-F@{(W->K"NK@?

OYI@![N6>&YQ8E/QV N$5.H'Ii/47SH+E32TL27VR MJ"%?,@F?+)@K,.6KCG@#S&LGN6;NKL?*]<[&9KEV,&I$QB;-#FT(K3;AH/:" M'83'.8WLA?&0.l.PMN,;V)(O83_[[@YF.5B;,#!Q-@=S&TR>3W(Y3[EAB5& ME9ZL3U\P=>%3]+DVYQ.\P,37#>NO1+(7A9L@CH_%F"%F$R#U93 C/BV0%T<&# MU_9Y'?|RS]'VMMA!.U3!L'"P8'W*

*V18[2GNRRI3!CP(F+Q619"Y>Q\'EFC BTW8+54*U=,M_QA$2;?_(.55.ZP.Q2TK6, HDMA"G.=.M'XP=_ 3ZIELX,41$7'VS8'W.91W(F9@$4'4U?B^>UP+&D@?1&;/^!5EZCU[7:; MQ6U=?*

*OE2M'tY-[,4VZ0@*H5A<2ZTGSHV*J^ S3--278 XVS_>BY**|04 HN^W(,TQ$^]& MAT'C-[G-I@ZI0?MHB. RE*K5>L"F93'J8%/_"08>KI@J6,3S=F!1-2=F7,H0 MO,8A6^) '9)IX-K> *]*

*BX95H\P(I*7A596>?F?\1YO 0.,)@NP6NS^& M8FQ5;)$6.1EL;-P.VPYC7_70=]DR:/X-8VA/GE#$.T MLJG0SQ./?S"TRM+Q3CK$Q*J8HJPH|5U%[5$0E=6N\1.SMRM!5 :[8'C0GS9E*

*MOQ"WR:*_$2- (:A-L!_ ."E,-77I@A;T6N:D-(-Z1*0ZSSGQYLRP>U0S^W/4")4=R03F M/7Z&^-[@'I8!FK7F()+*,.[:-BM2-530I&J9LOGYE:KE64*M^/*N58^YEB+A*

*M5D!1V@$DF6$G;-3U$>43,BOA\6TS9!9F[ZL#ACBU8RB8D+Y37[,[5Y7N@W. M(":2SE6#'GXM7Q;-5$P[E6&J4 -E=ZM.9E+59'QW@E5$\+K;8@$$94*X[&O-E*

ML&0$]TO9Vj:D%B^#+>,YY?JFY)4N@R5M%G#HB70#+*]X*6RA4O-3$ZI,HZ#$W<8GD70$\8SH/"6]$V-[5$ XT&Y_ I# FG:^=>V9(?-Z\E M[K6VADB]--P87DGE-9('F=

*<7(BF&>']TI1C!S;W]-Q13BQ?M1!?0% *@\9/ M,#QG 9Q_'\'WMGU"4@K#AER!3^!_]80#XOY*S*Q$6?HHPT_1.1]00BEIAG2V5S,:QX)QS,R*

MYEA>%HQ7!:WEZTHI493OV\/PS5)L!==)/$.S$W2E/2@{0LXV6#_,PC/.HS9#EK0"6Z90XG7YEPAG!STZI1M%5[H^>N>PPHI; ,#$C:,?W_X$;"/Q"5!YD&1)?3@U(E64N\ )=

[$C7+'91!SO MQ=CL3Y4;-DGR&\YIOf?*U+:\/XNVML1=OPN_D&:RCVD>;5+T=WEM"W1#MYX M;R_)7W719U#6&]9U6O:GGI*5MRMXUES,/C__\E|02P,$% @-14)H60ZJ-M'F!G'P

NB,! 4 !M>6=N+3(P,C0P.3,P7V-A,"YX;6S=75E76TF2?N!? MX?&\3I1S7^IT]1P,N)HSV'@ =\T\Z>1JTM(|)6$S?SZB;Q"+&834EZX=I]] M#$+H?IGQ96P9&?

*G7__QV,GIUEKI<#+ ^[37]A,Q^E<9A$H?CS[^] G3\#LSK M__S;?_]RUW\#^)^\VA_NO=B9A?I+[55>1!+OL^;,.UU!P-0YB>349Q$*B?#8P-\MWO[YX^[=;[__* MVW?*

C\^V;]K>7:YT.[WHC?BQ[\S_O|X_"EW3B8##B>SMPXE =,A[l.VQ?W)\'- MVEE_%-:>K>]I1?H+EVZ"\!)0!H[|\F\;7?_O+]U>+Z6@FHW28\]ORIZ?#O1N;/

M/$'IN/A+F)R;]^LST9QS2>IHC?J">C82QB?NM&!?_1EY1FT_G8S>,07\?A MM!_.S]-O[V>#D].IVGYVIGYQ_'D.1.[&<%%#__I2/?W,U@N!&83Y] M)VP??]YX2*

*'W^:SZT4A|L2;NI;!EP\< W-%/?I-%LNGREG?UVYE?%M)CV!<>\ M/3DY&"4"*IX2C)GKQU-E8?[-M >R;((U&L:TFO)HT."6H$E^_~_U]*^KK0O@MLK@FWN'=S95Z\X\UT?G+2?B8@*

MR4Z6?Y^;R4F'3)E-NA')@@(XM$TYK QX;(C MA 3*@Y$Y5!{C"K#Z9/{6Y\3W++\MCVJTWW;3+!\7ZXC]E]9VY46N/9]NN:<[1 M'Q_#C>9I@ ,VDCNTO[BB03@O<8$+*'9Q'C"E3*

M\=HS7$W&[UW59YHY/TI'*NYO"),Y6IG#%!):'_2&^F>)R-GL;=(X-.%+-C3P M@LU X@F]<4ZCC-6]X0?PK$(}<-1HIH$NLF'!&2Y\ )TB=_%]0@@(92$"@OC MP;=QD\+D\WCX?

ZFIHV+=IG()P-BWVU0:/(J 1B#:N++#% MQM@(BMNIHK/ I4OE8IOB19_0IGEE7H$NJUIS.+EBZ"'V*$ZG6SL<"4Q-4B= 0C MG2D_!NJ\\IZRI[CZ'!WU CF\M01?:,ZKR?S@-

#6NI(OWDYNF):KS#Y-QN(#% M-`)0V6(_,W157B>P1F5P@C.K(^5.U\|H/PJJ3P%++,4E40|@I3TRK4Q7L,3 MD0Y[YPPAZ))F=AIHL]1&T(X%X3J+7M3>W]D?3I_BF&B7JS'T] S$9?

SY.S]RB\> M;"-C'@>4 PZ-HT[2U$/,G&>C D.>/O,6SQHA6XS#(E(W^NB&<6^\|4Z',S(0[@B,. C"6""2&0%CU#-WCJ/KD$6_(C5LQ7%V1 MU,OR7P%8)(^U$99*CLO:>X(HA //K$-0DJ6QE SU-[GOL?0)_^X,@TVFNJ[M0C|,,S<(40CG30FFFSK*X]fP?3)T:JO*RH(IH')Q(3[;!\-[!)45A@')!ATP\QV FLMC),'IHXJ:0 M[*VNKCVY'9FSPS)O!_G3-*

*+70!EDG&454H'A9,I)S<%&6*B2'0S.*!UI;W@\" MZI,QJR#,>1-?L01L@#]FYQ!:CS,&L<2M9R6DQIEEQ?C$RVTYPB!9A!6.HQ0 MG05?HE'!3?62L/OQI,F*56!#M.FO6/,Y<^//0W2Y%\-*

#(+O?PFA>CF/^ M/IG$K\/1:&"S9-0X1,8"#MEJ!EYZ!SP'],(-CNK;Q>2KX.I3&J "..J+HAD) M+[_J0F)HH(203(0-$MD)"!\NI-"")J(KAT)/T78SU!JN)&PUYK2NCOH%RR[MV1

*CF2;N32D\\OJ$*D7G5A) MYF;(+B4O+9T[P32OQ+ S5R C2?[.IG_]WTTPZ_MVX8I9G.Z=HYFZFIVW*4^: MBX1U6PJ_^VW6.%R\P[%KSO=P_MO%@'^)*

*+H!>'^*7P0N59!=D+&6U">&|?##@6DS2:^J;DVN PZDK9L4+" M0D?&A,Q@N(C!^/)*1)5?],o=,#8O%SA+X4WE:KM;&A=D?P]F7[?ETAD]H+N.,_MXJ;@?Z7V>T"4429Z"E3%B"*

(@'IQ.!@CUZ+MDPJFL?51^#9A]4K"\|\N=V14&W M4[M8@C1M^WQ<+.+I@"8]'CO9L :TJOVH+%L4UN8KE0 M(_2=0BV^-1,LU)'1,H9#@]1&9DUUY2GVF2Z%TR?MH#Z2]DZDNS.

3#,%?X M!)#5(#2Z[B9Q#H$CZ56R@E3OL?.P [",SSQ-.#6E6\<..F*C2;M3LYQFKKAP MN&S!.QY+'R,*1[@ C&9CHL)!FMJ1X8. ^J2'-V++#;2>XEACJ'3I)[4+ ^'6/5*

*MQHT0V%8\&3Z'TUE9CV>$?SC&CUY4L!L+;. ,3)H@_@N;/ L\:$)XY$94ILAJR M/BG8JES!0#'55>1!+OL ^;,.UU!P-0YB>349Q$*B?#8P-\MWO[YX^[=;[__* MVW?*

*V'Y\#YMHE<5]WK36WW/'(?SW<;^WLFI&S;%B VT,^7HD $3@T#> M&0T^$@\&?;22^ O)UTZQK8*K3WOM53E172C(S)D)=-]3$1JR+&>&:.9HK P#*

*MZ616@?,02.U$R(J1V3H)HS,,?,HL+S[V,A3BN#(%);41>RAGQZT!IQP#8]QQ M6K*8G*B>[;D;2Y\ 8D*[MG"D0F@)U3G.NZV^_W0NG5QGEK]A11QAU*Y7N'ZM2W*;*

44/[H##@\A8[Q4X ME"O/C!OC:A/D841!\IZ[H4A%B;QD7=.-@Y4EO]=M>=.#CWN&]=5!UNIV.F. M0ZN7!U:#M(2$;" 8G4!X0\!DCR0A5B9.6?:I?F+P7CA5U-,]9W3?31!/% MV8]P?*

MRX\=2%5A>,8_O30M'*8S<=#K,P\7U+%OQG_,%>2XIYZV#[W#Y$:E M(!NGT\GXR(W20;,__->\B!G??CFSSNMRMMQA<%/*22UMSTH2B(XA<",M2K7W*

*M7'LT_">Z,=T;YUH+X$[=VX_Y?A++=ZKH#=TS]H/_W0W"9;*VFN$43=?,O,&O M'U,SG,2K(_7!1B*E!Y5+7^;2G(&)6%H>)BF--E]1ZONJW0^K7SG?YUT>+!6. MSFE?*

VG4NUNK?J2/VG,C%"[&5ZV"QI-C.C&QD@RG(K,0CMKYTHHU<&9*% M]*:3?GD:C*5/GO-S$_Q9>5 OYW6CBM3Y0'7P$F*BH;2/8V!Y"H"Q)8D,5QO-M=L]/% 3_]*)\&*

[XL_Z,=Z["]+'71/4Y*U'D]]H?3DQ AG,LW' ?4GS>X9S MHDOV*B6?,A4FI^HGF;L.S!,S\#^?-_M\5'C1)(2;?GDWFSOM.OEP^S'/D71X M9'#U3E:5)WUL)F=#_ +2WYY\0T]*

[XW7#LQI$41Z.C=[9H>A]=UMPK 88H"8)) M"=XY 3SPZ+Q25LG:^ZRKHZMPK#^D%-LZM;WI=%XN',7%\<4U:?H)YIG!Q86" MP556=K_+RV]=

*IV3DKAKQ5^.I4_Q;8N]K;SV<%I6^0V8&@0F,\1LG"R1'L< M$(*#D 47FF<90^V=RDX'U*M=GFX8?$?S@9X0I%XK"W?>*IO#U';..YZ@\B\G M)+XLO:B(NXVM%VN_=IV>B;K/*

*M(=>*O5A/+_ >9+2@"?_9;A);O '17G$OS D1/,*PB+()691VD ZQ;&E<[9CF M7C!/C{]_"A[5D4QU=7602 ^OTPS2=-?,P: ^/QMLP%(S*K?;0&.-<$1 ZD=//T M0*BTF27JB:I=,?*

*H8IB>&Q3\%;,K*J1I[%F_,?.ICX@E#$]+!*_(%U<'A3MB2 MA*=2&Q Q4C!:,.<@D6ANB$ZKZ77X/ N15!/M.O*DGH9K-OBZ=OIL:,&0;K><)*

MM&88N;/!Q,B=H09DROELLE"^=I^%>|'TJ>/+"WCCZPNF9B[VKE%?GER[/FH3 M2:8T@A0\1E.P'B?(1*237 AYNIW[*R.KFY.FM-@HM8;F'6HYW&-@O4A@XI$*

*M6QH3M#;Z[BGY1!?,$K=E"$/IZB?(H"-QYJ,HL)WTN+?O?MCK,#EZB+1!F0 M.>MRZX,&PUP$K700GA*E56UJK(*K3]N\S\28ZN+]D$C+*Z\;2,,/*8(I"HB(*

*M(4J26I6[8X)7EB53MI4[9] U0#|"@-@]=]:54-T-LCO&N4RG7Z;8!US;**L M-PA[7F|@\^!E48[6B9P32R353F>O#*Y/NZG/Q*5N!%<]^?!NTESW/8_3N/2B M'2'*$KL,1/#,6\]? V1!*

*)%^B%/R.&"VL,+RHG5F3*A&C:(@*"M?O"N6EX$W.J)*55;SVHF)%:$],>K*1C5A=0V MIE1[]?1M9/=<1CV@SLC,-8- 2R+%R@R>,PN:&NZ#0K+S[P+0>R[V7OF1JS!%*

M_QS6K$-9=!N@7;\-& LFM:,,&@F&=U!F]'H0K A>LL"HU37WM|[%-0)#(_ M!XFZ$52]_AUW;QX{I0*4(@/)Y8"\)H%9.MO^=]?BRD5 M1-*

A>OG8!%,WC&U!IP$GT;I$)62ET7O7J/>\RA2RTYXG22FZ]HWKENN(5LH2-MDI_>D5E;2-6(LY-.T4H.W<7)@JY323,,_M^"R48GX6U4X"WU.%;&P2;C(1') M"->NNKWI#P*

*9R7*_&29Y5K2Z5[/+'M=M*[Y@1*>J1 M(92F1X8$9WGM>1.G8ER)9.]VHOZ9.HE=RK&BM@LW: ^?(I& X5Z;[+;.+;N%9BT<^6BZXNL+H7L%XU\-K& M4/(S#M9SX:S- ICFJ?*

3O0J6H&,%04E.OI-!1U^Z'<#>2E>CRPN5-M=E202;U MOO%'H8|3LW)<-Q.TT%NC>M >-<\D#WVY8; S-876I#&*4*G+0$/?O P6FI(07/(A&9 MR.HMIA_"LU*9(OFV7*)]JG7DAQ'7?*

Y?KJ$^]"_%V?$5FT${Z)SWBCB%0!N+<+1!,)K% $T&%'1>>C"KEVNX5T?6I M1O[!I^>FXN^:GG<=W+)*"'",HA\"X+.VN&)C(!J(Z:!*XEE^Q M5@!_6>)?6INAI-*

*Z[TG9@=GZ0[\1.#&*V7 1#@2%4JF_+463&"%@5B/#$B*Q] M)YF>#+)/P4!'3'OH;'=]058_$70\:1.P36]36@@^5D/;!FIQ%$'*XK/1#$1E MM)8Z1H0ET%H26[I-RC)4OXEW-*

60_0F>DZM2J+!,N3I@=3?+LJVO2@!!)C!$,_M$C&QG"QH@%(A,P'YL/GE?O.G$;QH!PM+4KIJPKC4Y:D.P.VT&B+DP'^>U\M6AI?3"\:=Y)6?*

P^Q0&)5C//+,2442$;50[^$YP(KP0WAF2=:8>6;56W3)?O?#\='N-O[9\=[NT5'XDN)\ ME",YG1LV_M"C>;G:>>O,#4?%7.=%P]DKJ^W/WIM_XHN+%/Z/$;<;Q^3M2MW:R M[$I[OH.V?

*CB:WAS<:GU=7O#MYNUA^S+5M:ZT641.W\5+6[CBFN8<%U<[A$&. MBAK'*6BF. A6<@HZ[\RN#Y%(O7Y=.NZVTYD5]]H;[G6+_IX METY[U^X]6!0YE]-@T1E;-*

QU:!\KK8!B&2%KBA B=/#B)ULM3(U+FH=8^QSY M4S%V|"=4DHP#3E11\NHE M&!XO0^;'%(GQ1WE417]W^)-10\DX=XIV4$'C?$BZ^EQ?.P9NC4_:ZAAY?BPB7.5!]>[H7G[\0

*CG52)(D?S(J3#P-V%"(E2 MGJ0B@LK:U1RW4?3!>Z\NZ/NOYEYK\CMC\HH*72%3;2K=/'@NJ\XL,-%%H$K3 MQ&@01JEU.?IC6.3.6/*,TGE^)MUT9F-*

*F*3*JP!.NRYE$#EY8*4FP2+/A.GU? M0%.|24\.1SK?,^@/E=873X?YW'=;>X?_V-K_M/M^=^OHT^%NFV2\(I>(WRI*_M@-OHL4'FQM>[PVZ0HZV,8/.\,Y=34BF7>HGA0UJTFUL^]WSO.Z),XD>(<\@ M@BB'O;(1WW$U!/5U4O$!T=3Y5SJG1FW@)/(*0F01:F/--J@=THUFG@I0I""_M\%R[>?2]8/K@5U5FQIV'43<61+4(]-HRNPL3JD_+J#*'E|7\9J2G7%XZ\/.IG]_VOM8 M-*

*/R'W>,K?>QF9RF9G9>;FN;H5HOZ?_38N5QRC8P=?4>OKF5ZV@B*AFX&_=.MNOG<@<0I9H<$=1Q#.<'*K;NAI&F=R\2]Y$D7-?OWXMG8R%UYC-<;;.'WHW1*

*MIZU|H0RH9<;?HNP/IF9GKUB;W_?>[F-P=;1[/;#;*Q;F\|"/+DHP-S"T&SUO<|M:-M;[BUX17A&/FY5PKY6PW'UL(F$AR.B0+TE$&0@0&QF<%66N"+I_P+-;VEQ|&*

*M5.&BQ_I^?;$N'!?$"5JZ_!-<37H6G%4Z0NK(RC]H+-!22NK5[!=!V;C$ZTHU.EY2A>W=-\Q6F&(M#]$%,,2@IR\E 9=U@L2C|D9&)USM*OY'0?7)4M7AR:V#H57E4LU*M9U'+^Y] M6*

+AV69?0!2RH $*Q5 26'P8%'C49>L-+6# CM@|"G6ZH82F\|YG>U@M*KS M<5SB6!Q$3LW9)2*K)2&s:'2BEXU+|.QAY%?CH8;SI@<6\C$CLJ|#>E4^555?*

MU:>YX{':/BYG9#OT#@<%$D0O+H.PEK!7AK)/J2*%>*>9BC(>3Z,4*9H\\11XAD!&&H!U\N_8VB|(QED9>FQ+W0'GB MI8_(^-JR*#NW:?WCU.AM8HL6PQZ3(!R528XQRT8)*

[7SC!@J:O?J?1A1G^ZM MJX8>%252QX=HFP)?:Q/<8G.C\|6>6/1E;$IH6U+V8.E D>=B-.<6_RE6,F% M>/@Y?;H0L ,/HN(D5],-R^/%VY,3?P%K>S(N!YM+?_')>#J,,9^\DA>X] BX*

*MJ'295REP#:C*RF66PB!>YH PA\HL6\U"[>RBNJ4&F[^T.W3\4'7BG=MGCFU,.N M;K,=1,HLH5E EBXA889(1L]]#Q2OOt7WDD56_X>A>-*

*%7!8!J2(SML]]4.,Q3'U*MU7BR9T^4BVQO*2]O 99B."B M3!ET8J;<7Z,.!*U!"A-H9CP34;M*:2/ ?4KA=42SYQ-H'4]]=XK3]O4N+%G[M3(@F0&EI=[XH*

4.4P%E@B8>D4XAA)2?}WD?I<-7F0X5Y[961/890X/%!3\? MT9PC(8_2,#@*;870%3+&O&<|>HA*;M2",H+G.8"C-%+|GTQL-.FO^_ ^9?.Z MX$ 7\|YI[?+NN]W#P|V=K0\[VP?*

OWQ]\.#H^V/ZOOQ_L[^P>'I4"WN|_O7(C M#U/ $>'LM4^=Y)TTGK31Z*293GGY2!S<..X.1 -9BKNN&>/H2_ _5J=MQ @RU^ZO_$2(F_IY]SSNUG-0+V]

*MEE9HM/L>70#4-@YG1IC("-]T",)I50IE\Z3*I23-)[0VB4O:T+M4Q#QXN2K M+-D./8NC3Q_]K<'7;?VM[>_OYN_^"/O0_O#@[?;QWOH?[#>;#W>2M!BB)^9QM _Q7+H)@\FPDJ%^2-*

*EH)9V(I';!QJM*5^^*>/S M\&ZU9HV;R+"':V;\YX $.D%C-,.G>A-%D2 :=$&J .9N2M(ED4=N:WT30)R/I M M'R(^ !&!0,2__X^_KOJ_?(AJ-<,_N-OI,_T:[_(#:I-[CXC|]I.7M'I-_^*

MOW_^V[ ]^_]#R/I&?_2 +AE[=-O\?'P?B7PR'X:,1?_NR-+W)VC4K)_2^ M^5\'-]_TX-|,K0OYS\L\,FZ_?AfV+R_$OG'(_jK\X?_H$8+ZI@#@-J5,I0(< MG'2&>,XRXSI IO#_7?R#^A0%

*[7R=_>?'746_1%?"S|[7]|_'.+ ^'*DIY@-/.#>/L"?'T: MW_S#NVC4K],_Q*^.>O\83?[]AR;Z\41!*X?PRI)OE-_(_&ND?$08)X+|_:1*

*M^MM__MLOOTPEYX=QV/3A!/(OLQ^_G+Q_C+0W&/^;>E>_SK[S?^_W$?'D">/O M7^$__C;]77WMP_RSRR'DI>CG0RZ@5(*S_Y.G_;HUIDL$,HS7 0A^"H-"\8H8*

M%SU[>\PWSR()LK_NCRLB?OSLJGB;[^K*>!*CZZ_=O(<@<57 88UH=Y[[AV< MVD944>CA;_&@,_^:+f)S4/TFWOM2ORRAS8W.^SY ?_+I^?6(7'C_]?SF MW3@*>*

(_CLZIM48:GXBAG!+)&!"/&Q0!HZ-15BB@^C%C1G,&9C$\[,7O%K M8>^OT!^/YI],%#)1QG(44U%7&>9WTX=X]S1"TE1E-)9*,.,*$X=ZK8(W3 MB86VQC1<'\|M^0Y&,Y'-*

*INM&VTZ>=A<5=7GN*DFQJFF$/3??FF&2&>TL_"O-M0DO(/V*_P3GP'W\;#Z_AJL-F,$96'_4G+\3Y#!?EAVLF$ZGP^;J;5.HD^W@ MK]HG'DCD^2**)$$D9%EXK(#8E!H5M+1*

*XUM$6,1H(H|><(0>((WSU#T,LYL M+?!%%-J2#0\PO9UL86N!.G|@FE1BPT) %5FPU+1Z@@/;*ZYI2^J=42**#5N 3 M+I@:;@,@@+/$B6L)%MHS2F*QW+Y<*|ZS6W3-A$V&WP*

*"$<[4,)];?GXQ>ZX< M0/#)@DQ@$1PKNN<1!YN-EH*R,"7DRMI_!**FYA=Y_(_57D$Y34W)/E8UW5;5 M!RE-A.C{GWTOO1<^^J^|L>_/P"%/08 T1 >A0=F>$#]\X#E4ZGZ/E461?6>U/*

M GH-%@G\19F_D&,UU?7_>*%'@\|O85@&/H3+LDQ^@_<#!-M@!0%!(1DCCP M :UHB2)0+!*TA9BG-H*UM3V(M<&]"IJTHHG'E.;4N8$QCA62$=^,.@-+D9S*

*M{JML;9:9>#2.B;34X]B#)@I"3$QE'WUMKWDQDM=-A@HR?JQYL.WFD85#\"-X M"|/_?S|X'*TY.?K]=\WP3S],YR|BVN:L(R8X=*(DHP3-HT B4A17N^BR3I4I*

ML2'$[KE2.3{1IDL:L#X>@SN706EEO2=9BTRD1UB>$Y[7FZ,:>^:,299=4#$]1 M=,,^#5A7W'"'QE=1,,#LFB-Z/1M>#)%KH 0=0WEX(<87[#,->DW|W_6LXO?1#>,.>K MK{C_30[!SF-T'"'TC18PQ.'E+'%&A*'%%DP_!_4C\INBO(X%%[6FO!5CE(M,94]&D^.%LZ;)8;X!'EXB/P$4'2CWAA.8?BM%V$ZU!.(S<54I9-1GT?+0)O_MB$H>YY&ED90*

(4G&,AZ"9UK6=YC:'=/KYO!>,:(%&^T3C?.PH=F-#]7TAIA M."-)9C08/<_O&XN/5_6CQ4OMU7\,]>Q8$.@Q_G, M__6Y&4ZD/QX/>^%Z7$XZ5IK/2/;!^%PP9@,7B?*

*@@T0I5Z+A89@2A2<<@I8OX MAS(TQ_W M7QI[*KVQ/YZ7OW%/R\|O1IR!)>AR7?>AR6<,B$6\ T&UQ"^GZ&_'"%[UI.*

M2[[=]>@$1N,F_ZL9]M-/XN7W1_)XJCPUJUS.6J[/O%)&Q]O>R%]<#.%BLFL?MYQF@6W\;F LI,4%D8H9(C3/#4VI)-%IGE20Z0K7#$JLP;3O:ECQ_>I:=JKC)!JO+@X>I<3>"

[SA(9#F?;8BSU9-\"1VC(P1IR&0+1EN!+J9""O99WMEI;7Y'ET]/1-Y%I1V<5D M//\G#"'UQG[X_;#<0QB>H076&US,3I/0-XE:H7>"GBD0M,0C"9RAZVJRHU(% MG;A.98>N?*

*DUW7EI^/32M"'+'B>@-Q:0R2%;43(7R\&PY #$ MX@?%/$5/&%8(KKTPRL?FPL8-%>],#^P9\'B/X$ MX8$I7'T'+?O8*W%UO&&'H9Y,WY_&_07*

*S]U\M> M]/VI:0#*28%0$]J.I'-,,x@0+!*%F6K%Q<,Y^2P#:2F 5^45U1%SQ5D|.35U MI>]"FEON:X"JZ!HM=*]:U1)44U;4]][\RT?%KG4F6=-<C(??S[^^/+P>C9LK&![]%?*

O7I5C%P6@$^_]TYO\ZCSEG9RP:H3+@ MJ@1)$;N8(6# 0P"O?/4$!6? [/0NM5SD+85M731]'^"^\D/ARBB;[#]L>RC M1]4Z:WT:8Z4#5%1DA*++2=93;_3'+56X\]C[*

(0&7.JEMX$&!0N^HQ1D2-G MU8\2EZ/9_M;;@R?/KOY28T%G2A@.B$B#BVG("CFJ.=?>)MQ;OKP|&E0WDSR6Z0&,_E]\=3IDE0"E=/Y0/QWGKB"?, #+tPTHFVZ*

MW,+959"@AK)7|>>90F_EON5#T>{_G%E@Z/3T#KZ2K&]$!V'7 2.R.**-<5$Y%H6EE@JR/KGL/IH2 MFTXTTD@8^Y/+8.'$@A:Q$",+=466F4S2(}*!-QJ>/B=IY_BL@O1Z6U)1]*

MY6CU1_!?S7";,UI;)(s1RM%(-"W73YSQ:&QI3:Q1V:$UKYU2ZS!A19CZ|9M? M@>590:253Z0^^2LXSO0 326K&,G&^2@M"]EJ'$5UK/,GC|(Z4?DF4JV=!?014B_ZX;S"1Y1

MA>:X/SE!B?0B$BLU)\"XS]%'8.+!7:PE:2/WG|OM(44E23=UQ-2&4?;8AWD# M@WAYY8=_3!T9)QD8QI"4Z+Y(EA0.@4B%(X?@G?:US:C5V%Z!;MT^)OX2;N M8WQS=/-*

*(Q1KXNNH4/<"V-^&B+32ZDBX5U-%%X.@A3F69>X(+%,#-Z'<XL MD**W/ 2C?$[M!YR|H.OF(:0.V,*)%BKH/J?)%%H9G=++BBQKM2JU!21PNN80. MD8'161JWH/9YFT?*

B>Q,7K;;64LV;&\L-+//B-]X.CT;AWY<=HX|_6"$CT,)?AfV(IPKS[*-MW! ;H 3PRX$QSXYX9JFPCJEH:U^P;GE(>T#,#[4.Y?=&];6O0SVNSC$OGUA]-M9GR&X:2NSSE/@M(D+

{G<,2(%.)80$'B?/;12]7X@XN.2YSK]=[WX]G3EFSW M;6'IV*1>!L59EMS\4>?4;"F#*4'1FC2ZJ#AXW@"#0|!3,;2> Q]HA2T,X\6S M<%]4W$*1NEG5L=[_F73%F4 Z;$;CWX:EJE3V*4JK/;'"EJM5^(?GC)&W7NH:VC?M_!_K(40MH2^M[58Q9?GCP//AZ/VGWX].SSX>?3H[M/3K$?W:V_NCTMB+3.]\;3LH2YF9X\;WW^L4)P9]/?1].(5X/$0>,PQ=)E'IV MP;QPTV"?CTI#KMFG6V1%[Q#MUHG7^R+I6NW.9H"APW(=P]!WLXG#S;H8"2! MI$JR!,6I9(PA_2!PF2(<4[UKV"8 MRZ,!6%^:]B'+YP>422]G&%9$H62*.7T M0MD&/%%">YL-^C.^]@:,\!]S.VJFUQI=%;4JZV)OFLC3(>@YB-<;^$'L^?[[8KENCA@DZ72 ME,2E8ZIT32R1GI1RQXZ6P.K72<<%#8+6]L"507]N=$?R/+03'R>,N63\$]N. M]087QWD!VE&)IHP6_]7L,'^=L;1D--< M9F&4P6T_&X.0-*7$FYP(6 N<9LJGZT9%4+46U8,=_O!Z@ M8+[Z_IMFD&[L40%&,1-)L.")E$$1'R4EB9;^1SQ%'6O?0UV$XP?FS-9J:',.U!]J5(PD]PY7]VQSDC" OE%@!.'>)B$B0XKW5DC.? =T&G'21. MM*?'U$,X%Y4:ZQ(G*I7I EAIW6NE(\U9662KE.;6U0Z2;X]Q>T;5UO,*&E554O>DBG&.)@UIDNGZ93"$;1+L;RCK M-R5A#4]D5]NB\QIG',M'-MT\45+^I>]:44TK0DS=IU-MNQ@6]<"Q0H*_<-*A^&2%.L,94-P0^5H"**Q%;>]=D.PJME1PL;Z&"%6--D MLC9(=^/1C(^&%9,I$AN,)BG0)%!2G/OUND(^&*/QYOG:Z %H_4Q\'.P-O$8 M(G$YIG)5U1!7&G(Q]74&PS3-M:NW/$;QXFE12##U^.:AX= MG'XY.9I<2*S1NV:]!V]!H? (9^"O=?;PY.'CC^Z63\^DE0+GP??VU-!BX.8Z_M:?MWZ+.^6L=TQ5XW2Q>OP).>,5+#2$\=C)MJ&S)@RX!]NV!LGH6Z)>>M\W)OW M?U^&8)IVJAR38 & (2C@Q)@7[K529I$B=URY(D6N?;;R#JZL[DIWRZE';;FT% M[$\AVE2=>GQ#+&5=+,6U<))A#^PB^'!%?W3LZOL$[S[A: VQ+B>$; =U1 MYG<+&EI&J#;4M7..\5+5.E)+A$7'4TK*0@12(!$R_F,2+3VZ>T><&KM5KO:^ M46L3+;.5)?;+K]?CT40^?)>#K]?CT40^?)>0Q.F<@W6F8=5X>L1 MZ#& <[GV^%A6YC#):.J&%L.C@_C?U[W15.)EAHC.!4V;$FY*!A3C M:$.]D8B2!CU@!4/TM2_2+!H'R:@V?&])OX71]$;SRXQ!NNA^M ; EZV8EN-U8 M-%54N08]MM=#"WO.,J":24Y!>V(L18HF@1-8D>,N(\M9' M%:S'D.]U^+#L#=T;%)4UT=068POFPX<&=T(87I5\BIL-|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f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|>D0\%Y"#0($071HIRM*.6(#1"(,[0FM(Q MG8+EI7W1O\!H\]B8<7$T>1-S0*1H.A4)G8.L<6%;5+FTP\.|>(!/(@7890NVSB M:X@E;T2'9T23-U/+CD*\ZT#*|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|_1OT[H^23P-)V0N M>LZL=)&AY2@$D8Y.XBP>\)SVAN%_(-:NT-K-R%Z=8;6'A&CAZO1&@#_YJWEL M;1W875AMZT/>C2VWCRQZ:HMOF0)M&XH;P*?L/FYQLQ.QECAPZ7]N M%8D*I|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{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{XXE=+!BC]B7L"+9X=IGP#[MKO<7;GN7?GA1#.5>,X?JK+%6HHZ/7OEI. MU!#S D9L?>UWD2ETS_B9=5E61E"6LB.E#"&1C!6'.V5"';,ET5=14=N171/. MRZ9,FWI8P)=GAU;7QGG'6#.X^5'M#;&IN-P2*'"*>]{.1,,3")+7+NZW ,P? MA#?U,<"[M2/O-X# ^O#]- UWZE*Y7Y7*S[]XZWE05](4-U[!WBD@JKMA6V"KZN,/*WR MZ*%7UJ"=MW#IUPZI#H2N9ATG#O$I7=R%/2YR2XURZ%EZR]!ED>K#'^

*$=LDOEB:W*MT"LJ#T0KF_{QG7B-Z;= Y #(N]^XS_G M9=40PlNEHO25/Q)>+K)8;@%$$LB-!.?*Z%*8U ,=-Nl:1FP/?[4ZUD@-W MX IX&93(V*X>8=V0.=H:>58T/"?*
56_0X^8Z8Y55DO;N0<|^JG.*E^ KQ]5S MR=O=R:?5(\X+S=W)6RR&5>=<$"OHC?lOJSMO19E&; M(R*L-:,8GRWW'"\XEf|\O^>=+5>8N77$5/;CE]+MN%C.]]V?-21:]_*>4*^&M1 M$LHU&0P"@3*41(+DX||C!DE$HE0Y1Y)%GLG:Z, M.[$NF-/Z-NN=,PU\LQL.P/.&!?"P6JKCZV9_8;KJN9D4S8W";!C;AZVW_)R! M#;]0TH:*8_G9EDO03L263Z 8/0.D854MUPIW "ZA<^7T, ^%3!P[0:KW3 MGG$4Y#3AD(D MH:6SCOZU?1<BWL2 M>A>&P>A<&P>A<BWL2 M%Y44Y8\0.2;Y,]J?OTOFYGLM2V1%%JG@L/,.A3U$ 4>(1F 4!AUF8IC+%#>9ZQ-M5E6/83(3K]DM7;!<$S:X-W OF7IWHFYHGH$M52=B&UR8<"*^W94) M*QC,+D^_2C=X?>+XV_-=H!B58.<*Q?C3=L(]IJ#7QU555^<%N_BN#K/[-15]-M+ ^9IP&#((A\BGD8PBW@&/1P+05C,XRPTV3:,4IQZ"Z'(-C=!>4?8L-#A.&1Z MGHA3(,SLU+9RX!;--?5)*@AJR^K(1FG-ZOWH2W^6]=#_T5+|2_O<9'_JS'O M'U=%M5KFK$UD*=BU_*M3?^5^)P7N*
*Y7JR5FV^_#;^9W"CI65PY.S/4|/L+$1E'E\#M+^1O 8?S2?.0##37446-'3?I E.X?%HR>AH^1^F->.%B7VVX59[R7+5|?$N5 MU%_R!
[G7RE|X>W%P6R_Q;VVYTU!P7JC2B5=%K\ABF5&9[HXD8G3H T|;.RHM^!=FF,X5R MX'E515?<*Z=?7 ^5-YYU8S1W6#S!=ACNMCY=G0*LH;:\$ M;2<$4%)T?2PV%6FW?0?.!;RN^.V1NW4"+O:>TW%YKQ[L(G!WMN+34W/\E,(MW6.3.?K%()'SX'O3]7%[@_$N?U1]N>)/'?'&=M3DHF?UUA[T1Y[W1<$R@O4L. M1Q^T.!4^__#E,Z,-.4^7]"1"&L8$^Q"+-)/^ V$P)1Z%@B41BSW3^2S5/@W> M&WD55_2 VN"!D>A^RAHG/R>))NA:O7$LJE.MR^2P!'O27+,:>UI3:/94>Y1 M*0:/VQY\R7VE:O4|E>G>-1.KGI-Q1W:@ITL,:, M4ZT/R3V^OIXHLJ&3;"VMTAR'F/EQ$$'B>0%$GLA4VK0/LY2Q+$EQD 3,1&F'R4VLN%\NSF\O M#(/K(_CH.:.\[J*,"N)Z8C71XA-JL^ZPG^5JE\?N*!1F=$8PP\@3?IQFT/-46?94(IJ)((0X M\GS"62PB+ ^W O"@T;S6YA7)-5AO(BQ;L.5'4&\)=X6*V@'>]>=:M;MY:P7,ZW M#!W>5M00T-6EO2%2\|Y=U!!ZJP]CSCNV/;I7E'-6?9:,JG, Z>[_Q;4Z8GF]-M$E]Q^0]>JW/![,'+ (O9$$@51(%=R'DNCBE.81@A@*&<8LS' <^&9'WL8<3+R\ MK_D!:=M1-N+B)-ML2-7I=$:*&)]AA|WC(%\U'[*6F;M@DWG04|$S(IMF9V91=6 MQ4P#Z)H=A>F6H=
*[AM,O>Y)9@.&M@;DI_9B{GEO#LMT*W'6CF4L;?GE4(_TJT M-K7?:?47^6Z]X%D88Q$1&,:1UNO9ZC.+$AGE+'*PVX=9E4XMB?3/?V!,=1U'/R#%QLQ:O@D]GTUU M:=U85-<788_2>Y^+L&/B'!T(._JBG4&XX2^\>,:,*#?VX*!J3]I_G] M/?::.NA,)4'$*8S\1+IY*4DA]@,?1IY@-* D#O1:#1K2G=@X=%RTVZTU"^ / MR0A8AX([,AR[568Y((11O38GIZY:O,OFM MZ95"IKX7L#1+5!4-3]W!8)#PE,,@091'0N#$,W(G=H>?.LHE?SNE?O0;++#3# M4=82&L::](4SCR(=E,%5B&AW\'GC/P<%VPON"!*3*&:2EOEZ^+7VP5#C&=[M%,(H0:IU%,M@)M($B^+ _7J-[M|%_@/7'V[_HJ4I/RF'UL,/=3"5 ^_M_79Y=_$)W-Z=WPWDHVAKPS}+OF+W<,.M G2_;+_]O:%F^;,OL[[^CA_XB]U" M\7>>WS_4G)V-2 _WGK?]WD_Y\EE^MG> L[U M?8CPGC E*'U6T 7VY0HT! M/\V\B'(1I:G1T8HE'Q-KT(40G#;7_9AB)7_A71*%V0ID"[+>4C4#=&8*O&8(M=!SM1_1Z#)V!CM6SWOT\=VO@B> X6BQMN9AU53T1]K?+]ZG#65Q:^I(7_$1\ M+#G+Z_7E!W4@G3BK@UU[$6X@(I7Y",?2B"$&$,@&S-"(P MRI(0Q9SX.-3*O+;F8&(;MJ$(B JW/0VW$'0$ZK#EF@4J,YNEN %7 K3\;"X9 MJ0I/:Y,
9Y4MNH7S0Q.0&YG)Z A/@VM94^J=W-K*GS-+G)EN=@LW@?3"%&=)=2^A+9 E>[M,G:*W#NWRDX.Z(2"&,=5Q>NJ%]J/F; ^2(D.H$O A*BA7A2Q\R B-!#ZW$NU
M:A,/4IG8,K=WMW!#U**6Q!XFFL<=ITIJ>,31"-G2F^A08T@@ET43]FC,7,'@-MF)@'RQ4AV=S>N)CBR M.BR"L_M5^-W*.1\6;/_^U;&G+&LYD5>|R_Y"V>7TO.OIG.RY.WR\DNYJJ%
M]+;W@5V!SV5S\"&6=#G%FS8/0/KR5ES#'IIL-\4%]I:ZX%!&^6E-F1T".D6W M9A?LO5\,9X?@#O9W=DG'SH9_717\M;W"\OFY8.NVDP%EB1[@!'FD+' "(1"0> M3F$4ARA+
YHDR#=QV Z3F=A:-XAV|]N 4&3-[.81;/2LW^D2F|FP5MB6&@H M3M"5N11R\M@=?+E4!4-Y(WS+'6$_O)T;.5!O.L8:3#;9:7753FQL,YE23;B]R8B(Q& ML0>ISRA$F8<@P4+^A+P
9]0+_2Q>U*K^FYX)TB=M9'\V#&BKDF0$4%6_[5E= M1\R+WATEO.'!S/ 8P*IG=:8!R\SD*)R:.G=K+M1-SI]^;4'IPCP< M!#Q*C:XLF+,PL=/S\?SV;^#SEZN_WX+/-U=?
P=7UQ6W7|#YQIO+WR|O M+B|N#7N#6L#LVOA,?V1D880F.5^RQV1VN_0^YU3V-G;*4?G77?X.Z^N\:NZ M_VQRZIA:>('-$(0"R&4SY.1"KT"9M+O">/$|\)]_[]
(V)+K\YSN@Y^A]&0+@!RY'Q%&43"QY#X D$F0A;& M<9:E3.M&WP"-B>W@6Z(&ES*.8#)LC!O):F9@WM*S:?M5H=]#2R:G2VUWC41
MBLWNA0R+,WCSX\BK\]WM&.9]Y_;&R*-6-^[]_+Z9PLNBJO%RV39A^)Y7"^[C MF(;$AQ%##""2I3!+N(\HSZGL:!>K&]/CM.9V*;TR('?%3T3/1M 1\.RN)'9 MS+IL:8(^4:.>B&]UE+
MLI7-T&/1%?'/Y_8RY].JV-C] M+,RXP#R!B:>R3]C<'1 P)3 568H0H3A,50(10]0F5]^6)-C2- QL# *E&;9P M);Z9!NY)[EP3M01S%3X8I#5O<$!'[+VMO]9+=M#\\?BT7+UR?
LO+EYSR(_5O ME\V$R^NQ V?VX%"\:]N+VM_7%5U6733SH4D>"$9C"'FB8]H(782S+IQ). MI3@*!3);31WS-W5@15@QZRX#1Z^\2P3I6=_WA%^PS#JH?+@VI+-9^L98%WO
MQ:>\;KNPK]N>,NXN/C& CBRC:.^YFM:430?O6^D%QKRK\KIG^U=>/ZS8]@1$ ML[/RD==>G/D-65,%=_]@R+%K2^OV4CTD\,+P<"6MF@](Z;@O(985]V5CXTY
M6WOE$:'Z+9;"C57]KL2- 7$RO+#ZV?!FE,378TZ].[$ZM21[*]MU9E*:)+T M\Y>OV4CX]^]ANG2]VF6)]2-P=A3K2L2'QK!3LX("S:=>0.'W5&GS.(M+_ M&RYS-<:-W+S<4E](7U=W?
ZRZHZ.$8R]+$(&"<@%12 A,D?"AAU@6IP(;'1X. MDII8(=>T@2)^!M;D@:1O$/T>![DLC|N\, C/E')#>Y1QO& :#"\!"]X^6R8\:F_ MH%%X$8@IQ=+Y^KC[RL<5ZHM6/6_\25;^,,07
M44I#$Z4!A2CRI(<$$(J2'T22AL3^NBD*I,,)5B%C4!N94 M"T|'<S8E8.E. MA>(S5:*8-IW"!, =_P!W H!R(P%XDB(V1K0WMJD%*<6(K7Q6IK\'@_P'2: MF7';-.6S(K7Q6IK\'@_P'2: MF7';-.6S(K,\4JZ-AO+_ 3!
[<>8O1-K+<\\BX[+,<\T MFZ>7;78(LW%E9Q>TWI?XLT/T1NM#NZ1E6[EVJ"W1 H7"RZ($PQCY!*(P\F$;.MJ [*J(NE_N5NLM\Q. RZ+*Y9=_,-Z MM9|MO:$0?K6/F.?'/8W?
2L9_JF^OVC-M0;*O8N<[X MLX72#83M1]9-7K-,:%53S%FEFD1^RE!X)=5%3OB5^/!<21*J*MPW+M=0M3RV M?^=L$?N$BR!B,&&17,4XB2$1G$,$"'"&!7.
"813!LF%BXAWDFJ6V_6G]P&& MVZMVI./1#!3K6B[52GF&OJ<$TLR^,/,Y45!N.3H#]M:\"NE2]\%RS TP107*7YVK P,$5P"2#M10V?,1:=%%6R(0R[E)0A[&TEB9%)%Z2\#
(!)F7BKI3KP"]B#:K<5>5SC"7> \5/2MR MBJQF%N+C1U"+,0&-U?Z8%(Y4>F_X6=7UF'!O5?'H%Q %# MQ)B &2$IS'@8!2@."4J-ZGN-DYQ##- QK'36Q7=(F*] MD1LP%"0G%
(UY,]VHL(.4S^TI765]#%.<-YT#VT]A(]]-^T#+"UQOAN[O\1$FUE(3[!!$[G%?V(W(9NK8HPG61*=SD,%ZWO M2FL\?4)WIB,EZPZU-
U+U!.5&MV"]ZI22HR6NJDW;T^WN206JSZ\^7MP]G;O MKT]R_<=+?E5^R>56:5=4E7(^@Y_7P388Y@=#)(891!Y,88D8!YD-"64^B)F
MV+/H+O<#B:BEER]94X^\6O=!_C.E9A%D8A8Q2U4M+0"3WDY#XD0>%1{) M4!ZA4.AE$OV TDV>MO0>W[M_W^^:GL_] W$\H5,Q5ESW6#_'5MIF:]"OEKSW
M1>S%\YHCU]#TNYA0=>@]0>[^&N\=%'^R? M._":Q:GH_7W]\;&XORZ]XC>\O"QNGQ\?VXUP51=W9"GMV/G3DBS_=]E=4=<|
M.C4=>_J3G_O[LMG|@8\/LB&.NVXEL\K_^4W=07X;7>"#[S@0MW)D_[+^7(-MKI6%E]|@ZDRJ:SY/[I)N.^,IR?#;D,V=?B,9N%G0.->=<<@H,CYK> WV"'3Y/ M@M/N^-F8VGQGU+9
[!QD6PIB>]_I]A$OE^L,DX6'PXQA/X$9S3!$THV!.&81 M1(D?1DS=/0ZUBB0=&7]B:],=W6E(;K*33>\N[0(R;\$0LQ#ZA,:^"+*&#&JEF[)MQ]2[BX\?;WZ]^
2^7)Y_N/S2]*DU3"BSA%?/9LP FN%^8%TNH>-HFXDBS4N/ M*,#ERG&I44?0N,I3L^1BWN2UTZ#;RV@[<3CS8,?'U2U?G>&+!A<2!^X(PPZRL89,0?E'H\?
G"]RF4FPE=9H#$\DDM4V_>"L^%$A\3I M;]8'GS/3HZ]LMIT:?N&K^QC/->04+YLXMQ^'$2)9 +'O^1!%W(>1?&TQ%MKG[!#%C6],7E>XO)+7M5OF@7K%O8^-
L#$VM71!8KPF6F4_+C4 MXZN9$X'-M*LOZR2]C+7DLBOH?734^.IZCPFV4]I[&&[;\ZRO^X*NJ\N%?' M^%UZ]D=:>00 1C@3,DMB#(8YB'Q'DQ7YLLM/5 M)SWUYK:E?
9H2\YL9VN H-YF=AI-9I]#D@:[>>%B/8F8_/,"^,X2Z+I^>Z^]"=&$7[O59PC/AQ9!3$4'D>QBF M 8](F$0AES:-9)G1I:H!6A,,B(84"WLPA_T>H, DP8Z M^2>(@FN(Z$C9ARC-JMT.
(K|59YU7+#N!'FZ%M>W3\N%U^7C7E*UIX/-E4U M<,TLSU%<>^RHD$'^P0VK;NFZ?,G#C-7S5!/9VC>CJG. -OKJ^IN9#0[>5FH MBFEM4_"J!Ij"QIC07Q.1 $,I=L3(5]NDU@**94?
>F$0LHFl*Q5UG1 M> #S$XF+?!.OYV^4K)WA\|@R*E#+#E)O\]5^D[U2#3^K';2A 9~WG>L[3[L] #LW9_3< $\/$CD8GP-,;STT+K^ Z !6)6QR\[=&8[D+$0OG]$8 /Z:95?)0&2
M%\VW81/MK>5/3:WZYN-U]M'K^@@"I93CP*?0HR&!2*0>S+P0P\#/2)1D+",.! M4=:R/2N31VFD]D#YXB.@&X;4CUN.[.K$6H"NYQ/- Z69\=I4ENTQ=;8|&*K!
M#E]GF]3&UPG.B4['QW$U6@M&WJ5,K3U@Q^K7GC"BY3%UX\5]49N83[RB9?[4 M$EE'/R.:1)@E%'(4QQ ED8#$HSZD623M&F,ACHWN;X_0F_R\25%7.Y"F'UN/ M@Q-
BS&.0.AY.NP&\$3Z1$S,CZ7U)'5U%CU";=X#:#W1]TZ=-5^S^/JB#YP] M+_F5.-X3=OMM9IAX<2HM@$=X'E&4,D@H(S!F<9IB0E.,A4;G4B;4IW9M.Z.
M.\4[C8R;0DA;ADXYD3)"6_/P:2H,S2R)1C/HIJ4Z2; !P=6AD1'O>\R$;6/:. M@]P&L,XK|N8>Q]K3#$ +@BP6,*/R'Y0TNP%,%0"))%29+PU"CGY2BE.5+B M.+,/&!^'*$D|[*?
8@SQATE6+/0PS/Y,_IB():.IG/A8FS8#<0&3;%0A/!Y2> M474BOF%$; _|>VP3;O5'!W%U-.T)G[LMGP^(>N%XV\H*E<9/[.98OGU7|Q:WI MO/A.E\^.,U6T2\6UGUMOFTU?B
I>%W/I5U[QLCMK;\6JRTH$Y02R-$T@XDD(-M"9.&D"4$H35E7N@:;]QU_>!+W9@[!81-X)E7A!S:Q:+0; MC;DA,J=/!G>9BD4J1^K=7!>)_ .OC#U5)9 7W ME1-%8YB*
(%%|.*)$_D Q(@Z2+@_1GMSS?.CY2YOLUR2Z5J!-]9.*]VSF'2[O M>6WH9)E]fF7G08P.Y-W.:-RF_QV!CI6@.1E@N1M"PRFS8 \2/E'2'4<@D0S
MIW%P",L\[I"SO/Z,:1.HIYH=!@$**);N6IH$/D0A01#'L0\S1*GPL@AQ;I3. M?8C(U-E1#4FPIFG9%_(@.GK&X5295:R L;CFZ4H#\KC*3#[$8MXDI $A]_*- MAIZU3VI4_U>Y(^]XJ;
(E;WA5E!FJ.]# ^<%ZPW0|Z3RYX|&5>1%,8!\Y!T!S#W M<-9A"L,LIDDD@<I 0GGCB9;YBMS4N:7N=/84GDR_\6\Z,DOC.VM!O?$OZK-ET ME1O.V@=P#0B_PSOEN35=)^3"'V!
(VSX6TGRG?0QYB.(,^*AZ! B1@AGD* YQ* MNYO10%60:-FZ*-@/.4]KOJ::)2X_?K_Y\6D6>&$"D1[G$"5)*M<_CF&<49HB MWVTC371H|\/^
M&VY3CD\&RF$:LCTOLZU+6M*ZK]S=4N L_,77N)(?EE()UN2 MN\$U7X@DR[B72B5*$5\":-.AH@PU:BKK+4J=:8CHK M=3I,;>92IUJB(Y)T*;Z>L;^<9C M>9]"LA5]5I'")L0TK<
[!DQ/K+9-&JI6M+;E>(NS&)11OMV>0DCPH\A$9A"E(4!Q&E"81*G29BR-&'4]CW$)6I MPX4MM>ZVY%\-#'V /P])YH'JJL(8'I VY3;,&)-1'T5R=79YD,.\9Y%#8NZ=
M+0X^,*>-OZQ6[(|\N5R0-"$^#2G,TCB$*& 9S#|&T!/4(Q$/ TX]$P5<#SRQ MSJW)F"G,1NHD#2CBE,,I"AE$ H409S2"?HR9ARF**4W,PYTVLEM'+C]L0I$$
MRS]0PPW(!@$_-0/0NFK(2;_(A'D# ?P52Z;:%/P@P'PC2>;_^$<6CPHFT+ M?AH&>N;61BHS"SOZK3:ViV]Y=F1"-\/..C7?"O/64.[!W6)|\SD7[<-E4=5X MN53N9N?H(I9Z*6,QC-)
M0FGTF#XD8 QXVF&$Y($3*L0Q "_B2WFY[S 2]"C M:N#['P%%8YMSNJAF&M30ZTMIL]4Y(J[!9N=TL>YV.MC;DA,J=/!G>9BD4J1^K=7!>)_ .OC#U5)9 7W ME1-%8YB*
<-;SGUWJSO_>]Y_?"P6JIE2UTR>]BQL6"93W 8 MR9691"J2FA'II*GRN4&0\1"'*?7C1=&4!F!W^AZ:+3]:W]ZL_?;N<:7]#5ZG M(:GS._P=_*$8XTO6]#FD]\=`U:V]7M%_@+RJ5
[Y%*>=O\,'=NRJF@.')KK-F8U0TZ M%:RW;M/)XYG7PI%CWJ*?L/IZH67KY^>^=WJ4U||\ODO-XU!FI;=79O3RJ 1 MC+4M@S1-@SQS4*_"6+67UE!*N.1O-)?<#[++AF@-30R=O*CB-
2MV< M@HE5S1LK@K,5OSD%CGX5G)&,6_5\O(EI[$J4C4]1$22J{T> M$@RB-(I@FL848AHE LWR1++[".NWZCD.S;#!<":PH1NS M+ZO#5%8MH4[HV7-\[-
EZ]HR*U^_9, ZPW6]IXO%N7KE_%9Y]%^-%3C|FGBC M@TRL;FNZH"$,6LIFNX_C\NMM+YR(;]9XH[=(KKHR*\XOD(P*ZVA?<)S.K([_MFJYAOG?QSP+:WW-
[62VC[*BY\1'R$2099I)+!B @@#K$'D1^*D(C0BU*C M&V8:-"26;JVZ'PTCAC=%=.#4TW{'0G9 1?X6.6&:4KL,#]LC.+L.6*:$!S* M$]-]=>8&(6U-4Q6,+9M >'55/_#R[@$7K2&K?N-
5S=EE<=T<'+[)=FM*I:I* MJ9O6)XN812+*5/^@.$E5B;< 9LA#T N)%RV!EX8E M\|-,+9>XK%3>*V@*#AC6&_AA0)NZW\E[3K*]^V;5-N5L77^X)RUHQ 6UE+=S
M_^1ZT@LZA&W0A_(@Y8XO@'>,4RU72^=T<7YW+]'++W]ZG?67F8S!T]+%_M;]3YE\ZXG#A$O8E+$L@$OA#Q/P4XB#U(,??!>)07X=V44C>]. M]9#0W1?,R6>Z =Y2<;G#W>?
=V5;V-_3,>]9]H?8WIP>>,,'-[*>\|HLM5]2QG M<9-LGZ(P"#$/59!*@P9$3#-@OF$4U)!FFS*[/[%B40\T;]N"\(CK9.J;MPZ:G>;[_-.$>OSL.] ,"_BZ!>TA4N_3@W9 Z*--(?
>L5/OK[C\!Z]5M&H, MS%I70?5"'@4^\6'F"P$14O48$DKERBF")$PRC\1&VCU :V+EWE*66^AU2SQ0 M,;@PT^TAS/14VQ$29IK= Z$?:G9>/59#.$=:/411$]76$/FM3NN\8I&$WI0
MN./E8]Y.XV?^&7!5T\]\A+7%D10 MRKTX@F$6$0AB+/<:0>9#P;E8@Z3LO(?ID7@-JA#*139]H6=@-E M/2?
$D>QFAFM7]8J^.F+%/_/9T"2[O)/S\]Y796[]E7H%KK%;+T5#>EZ/?Z"92CQN[*?<*(9X@.C4P<,U24 43<-8X2%0,/$(CP6'-$D\B*(H@!BQ!",$ MPTF6>!%+@\4++\EJ+ECZQ-
X1&,WHZ8G"&H9--U(VY",(Q1^2QU6D|!")>4.D M-T+NQ4.'GK4(BOZ--_8-EZ]?5:F;\HY7];82'V4A20D5$/N^=#PX|F"*I..! M<'2=$8&]--6ZK39..F)#M:4-6N(&,LDP" 9Q
M4&=@V(5!O\I7Z?,2EX#E^+Y82>(4/&R1HBU2=&V:FB_%\T9T-O5Y|P\]\?$;?N2+),*Q'X4>9#1F$*&,P2P1"22> M/_LDB>(LPCH&ZQB!BW3Z5'+.KXC=^]OKM$Q?X>5EWEVN;
(/F=1+52Y;6N-^U#KL17_#U_ M?%9]8A_S)K6O:Z[L^6GF4Q)(0HI1',$5I"&F*,^QQPGVFY2A/P]|4BMQC M"]1KOLYZ?5=4\/VQY.TI$-@R!{!:X:R))DXCWO^NTW&B(]%\T+&[N>O?
3M3= M=]*V/(,K 3JNP99MHPIG$TV404SD72?,+H|R3A-G%G;9#-?!4(U[JO.%=R9# M,"8+\-$V, MTFT&J4V\|FUHM^=235FS8E6;IOD/ X8P3^,4A] +XQ0B2BC$ 17*8&@[+\X8%T-
4X;E*7-M=:W$B;|K; NF1=*KO18 I*GKOMLCRW08KME#"C,S@!I>%/IT+,.@:^#+SX*R MG<\^)=IFCOQ)(TZX/;CS^=HGXS CD-]^FBG57#Y\+$?+[XOVD@M]O2MQ42V;
M+^18#9 M?S]W\V!?[T4#2#U'<1IXS*S[FHZ>B_O",?KR.ZXGHT^X M7:2G_7K\]VEVS;9_W"/88@D&888@P)3!%F$&&DTC$
M@=R.QZ%VI'JF,^3#N^E<%KI[?RNEN=TW\^YR5OJO)UI?#S M%]YV:EU@(3)?) AZ"0X@HDSZ3B20&^O$(QF2&VT_X^N-M9X+14?88@]M&%[# M3WF-
EVW9+I;7JH2+77.M$03U/"'>`])S2.*M2-WL[#K]ZIU<>0,N$^U99>D{[M;HPU0O1=VF#I 7&LZ97FVR>6'?O*L:IWI"B]SE]_%BM2\?)%)>Y<%D_/JO>6 MDCI?
MM7.,E1\L,R+'R;5YTO>G,.LG;,+@BZ?F;K^V3!X'K$(HP]YD50+#G(M&$213R\&:0(3CCD.L_^1,U?3,&Y)WF=+'*$HIQ7W1!%;DEJ=5.GIBL8/W^S;H MF=-
_BSDVL]#;.G!GH"=5TU82].4"K6!@5!(SL)&MS9L\ QOQSQH[8,-6;,M>5[6:7XWW*YKW7=\VMR?=N#/UH726^K8]VU\%-KYYSB##R M/9]#$3#IT N60NRS$(K(!U*/1S[VTQ^C=
<0A]B=>0K\]JR-,%1%I*RS|* TA M#LZDWDKXX\Z/V?(W7VN'C5SRQS??A\DJCK_/+/WP'1L.,O__D[8,0Q,S7^^% M02YL"TFMGGA9OUY+_:W/BX:')T7\&Z]7:2 0\H0'?>ZKY2?
((^%Q"'FA82RW M:P1E@DN ^QB",(_!A! M'#("19C)Y9LA$]?(-'>,^#,*<^V]-6Y>W#3#;X[0, RZ;8'%W@!QL07BVP 0 M%B6WQB5T5F]K>-3,Q;;&A=ZOM*7QCIUE7&\N
F#YP|KSD5Z+)++F[3C)1"ON!E$_%6F_H[_KW<^(%G\MQR*. A**0.I4@-*5[9/"-""]GPPB))$_QHE6.6T[\A.I&VMEF@IMDHIFM6A^.MZ"%DN&$U@=SPSD9:
(8;1AV\NB:N0/$#&H9<,NJLD"'U*3,C/N^FR@J8O4V1 MW2@S1^FZ?=:,%=U!2O%(LO6EPU_V%7YSFPIG 3A++\M:-&AY715,A M^AJ75^5MK?*BFD.Q:UXV#"Y02C.!LPS2{$ 0Q2*
)/!"F&&!DI"&-##$SD35H M3KPXM#RT==S/P!,NP4O3+>W]D4 '3CU:|A@,D,SO4D M#ZT5+ME-
05=B=U1=1BG.W=U!%X(#71ZT7S4S%9RRQ65++M_^B;_PY:}}L5^T3907!,5RQTL32$.>0B3DACBC)(}1F*9!$*9!Z&[_[A,Y+I\;O1S=0U;$=5!/&6ZA#;E_UA]=,W:X3V(,I2V+HT=1G
M)$@0,NL^Y8RS&:/^;:"$# 94]FU$A>Q'5+IPMV$)27>S:']",-/-@W\|H&J$WNE:V[?K7$P6?+KE]#@.FZ M8XY@,"7'CB P07DM+1&=.61#M&9VR#3$WG?(=%XR#_OG8Y65C4S[A
M6J3OJU%W)U:0+3'P:.B0./VQ0N!S=FOC-UZK#(/KA'{J5R3V.R0)JS,/79R_GWW]#G M+U=_OP6?,ZZ^@LMOOUWP90K\OE;+X,ILCXFCQ=]"@5E7<'N-WBIK
M)XQT6IFT\T*2]>6W+Y:?[@86P*>\HLN5NB6YT2'LA6G"4@8991E$0>C#+*0> M#&D6X8P0P1.CB*L1]8FMU)J7)O"XY:.K9P&V_.CHF .L]>S59 B:F2JGX%E7 M5#, "P7%1-3W:
[U)7S0B68Z75S :Q,T973UPY8L7|%XZE^JYO6;?EW.I%R*@O M$IK"A*$4(A8)B'E$88(H12$E,,.QB?49)C>U4|12 8^X7A>L7@FP6K,$EHHG M^PL4(U#J&1=W
)E9DPU=T!#>*3+/=G//2$=&0M1HC-:A[T!'K#%3?3:LH@\ MJ!#4=3=!2U:CFV1=G#_6VK&'@V|/K,/M:);<>57##I3871CU>:F37B$><++9A M1,)28K-HQ*!0=O&
(PT/.%Y$8%&DG>C'\Y,DYGV-@LNJ>N9L$7(;B#0)8"A\ MINX+,XB9:DPK&/:0_#!F1E6SCM"9>BGMY7:"O*$(?FIR.0=*#QGA)#{N]$S':!3<|'M'4^''7B'RGNE
!\2=2#M]^#CYH!7O3_KU;,_ M2E:=L__^7!@G\OYY?>]3G!9.3W.H?8'S;2E#5=)!5:LF2/K^US$$QATP!*; MJ9^&W!.DU8Z(;>63'1MS-J=L1*B^5S;VJ&VIAT)=3-
T]P6W;R!U8E>7]#W6^ MBY_D7^K7A8A9'"$F021<^FH\|6"&TAAZ8>+[/*,LI4;1#Q/B$^ORNMDBOK\O MFS+-X*G,"YH_R/W&ML6I:04) VSUEMJ$#,S
(J+YKKZ;C[&V:9EY887L&;& M9:I*S2X]-;'I7/FL@^OFMEO'Q=ZWNGT$,>3-0,,%6EYU&;M#O4!W18_Z>#RKW.":;:QD9/RH/MD]"-",/)BWHIX^ MJ^-
R1+2WOLJOO|S%.CYN]O:?.6]/$!?<#SA-(Q^&619(/0L#F*5!!E.!LUB@ M)*"^T?413;H3Z]|ZTTI;3;O8;-]WX0T@. ?8X.#8%%G|(,>)>#F*;VRY)(-M9R?.EH)/&-4X1/7= OH#4.C$,H9>-
S^QN"RJ7#YY5[+KU3*G.:^NRQ4]9ZNG MFK//2WRO>W8Q.M#$=J&C#]8W/=9<-'F4BA7.5,\YT'&D?Z(QCM#XV893<,R, M"$NX':%CJ.S#FVQK4X]QD>?[?Q#6]#^28C^2W9^0J|
[^"?^5'+;.-N"1/RJY M<\FU?^K^;SHX6X%R0ED<<2=3;?,8BR*(^9QAD62C",,IP%*1F32E= ML,:E-]>TK?S"'ZDI6VX|Z[%KYEPXFPXJV/-6B*TL4X]#T&?Q#&R8;(O4G\TS M*:
{_]EN%7|W3HQK_!QY.<[8FM4-<@WF6S_)^?B.6[\4JZJ;J']*D4TV%!0 M'$/$0@)3Z@E(TRSSD9_ZF!KU ALF-[&_-=)5Y+XT;G(Y@IZ>V7.'B9DQ&^DM

M\LL@',ZZB^Q(.75_D9;8C]%A9$=P[1XCNV_9*?TG3NIMQR>U8[NL^6.U\/, M(A;',$T3'R("S?P>Q-4;"@;WMD[MAI.>7CN0WDRAK00W5N01L1QI\/#$JLZKNB*AO=7;L-03)#"J2VO55AC M?/39PAK;@O;#&OHO35#)M#M=0RS!0F#E7!»)ZO&509RF%":!\%B,&*)8*S7# M@.;$.C]C55/#8EI.D3'3_K$*IY-4UM*6=XZ"I^]394L; J/BITX.1_?N=)P_ MUP^K,O\79PN/!UZ2>2%,14Q4E6-E%,@/?1Q3C_DH[LRJ''_0FM@:[-S3PQNJ MKJY-]3#3LP*.D##3_D/7I\"6\(0WJ/:EF^H658_2^]ZDVA=Y]#;5@5=<5];Y M?'S"»=E$Q3D>4)8 H/0%Q!Q3\ 493&,#GA&K&6JY2"6:Z* M>]B4'A4#6'$\\@7:Z#;$]I\TWK6FBA]J^KK$RLP.#%?/ EH,YJN3LRSMY<9P> MR1^D)LX^"/E< Z\: ^D(X,]A\V3#D*>->OV0^U$*49A0N2](($$2,L@AQ$G&" MC=;]S=!3+ _.2D.%2OI5:<^6VDL5PH5;5]]R]XONLUJ%MP//N^CN";2WQNX_ M8:<='W"55U?BG%*5/Y07]TT*PFO[!S;VX_,H#7RI*BR4ZH,(]F$6<$^UQ_1B MP,&@]=&)E1[9B;6]84+EQ5W+A]8Y[&9]H@F?G@]Z!\5,/3=X;#DX:],$7L'O MW7\G:=AK)K@CY=8D.]OBFP'QUB@8OFUG,_ZT4?SVK(S0E?B4+Y_EIZW#?_5< M5W(Q5VEF"X\)E"8TA!PEI8S+_QG5PS&D/_6I6$0VE3U#V[50]T&/C#'0.NK/TED X.OFFU&>U,9:0O%T$;(:=5]?]F_(:7)KGB T-,:+B_?K'N=I-?0;3@-8E7NMA9]6G_]'Z(.03)L M*1RB86813(!PFA.N(:W5L>G0N+,=F&H(US\]U7G<,O?[ZN/E>5V7.7FN59^B MN]4U5E5%O_'Z2MSA[S>KY5(25*6/%G'HLR 6,>10$$*4)!%,*4M@&-/8HQD1 M66OT3\R]L3:KC@!?5;4K] R'=(60UA>4ET5]U)C'U4;UYT!EWI&X.1#'1"8V*8HDO),T@2)Z!A19\+LB M;&@W#@*D9R!.%=O,$MA(;'YE=$ D5_=##Y&8]S+H@)\]-S^'GK53R_O>RN" [Y$\Z95'Q>+5*$8AY&'%+F(XB\(%"9RP'T21IB@BG#?F)VRVN8 MH-8W]I2[6QTQ4"MJ9LHY I6>FCH0W_+&9TL/_+2F_&>0%V-_O]T@',,:JR>E M(QT>(3:K-NL)_E:O-=^RT_F^: (M=EZUU4T7$<@-]pIJXK,(9AP%TAWQ\]'.#"O17X;0@[*D]L,T -,T(/P(/2* F\3*@%(8;(]Q-(1.3# M-*', 4'+/!-BXV[,>VSK@K7]ZL_VF2FFEG=<RT=:5QCN< MV,4*-%'5W%$XQ\IP<[&&]>.@+=^]B]+%"$KF&PPCH5WM-?2(SKOM,)B;P=B M]K:=#;F]'WASCZ7D#W(X.>YE05>/_.NJJM99YM>]$O>].)2(OO"\E$78X[Y M$D11)O!M4_AYT==;#69$U&R9;+_.7.YR!R^Y[_;7]7F_O$*EB M$PV/D^>O.<+++T0IS*C>S+CV.H'N()KD:UKI#C@H15S><\OQ%#2QI?GPN&Q7D M)$H031E4]Q\A8M(9IY'(!&$,DSB0)#0Z%KD +&I$U1*S+AJ8l.P ,H-!\8= M;(]#M-1*0WCR&8";FO1L(Q#+H)\ ML^<>R-^VKL&106=1K6&!UEHU\]1MB%A^_M0\0S'0)EHNUA^_M0\0S'0)EHNUA^,]4?6X;'SY*;? +@\)JVW?W9(9QT@\.GR6X9&>Z$[JB> M@3Y=ES'A4>&/R54V,)ZXLVVUUKX-'$"Z4:XXP@B%!" M(8D1@M+++)B%EB!!N=#5^@-:,,8&/#_(O[BSE$]ND.XZAF$]=
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l.P ,H-!\8= M;(]#M-1*0WCR&8";FO1L(Q#+H)\ ML^<>R-^VKL&106=1K6&!UEHU\]1MB%A

*MF#Z;RZ^MEKK"#=S"RR4Z[91_6"OFR85'45!=\9:*JOUY,\|5+O,LJN95N<;-MY8RKGJ;/ZM;TRZHL-O+3B(NXP%QD1'JQGO1B U?P%_A"I$F< Q->3Y-TOVVV M#%RT1\}YFU6JW9>*,@F,-+/5<7;L(@7?<<\|$!^\#Z\EKRAS4(CNH;ZP.PZR<# MGC2,42X|DZZ_Q(&7D"+E,8XC%6;,O1#G5$C_.0AB+G@1J*PB2)AQCX3K2.%J M^KNYLA_ 13,:=Y;TP(<3%#S@?;N%/4 @;<92W]2$0<^;9!)=U>)&6WHJ*$; MR-9G7S!.Y(X;$AP%N;J?SGR1$+Y6/.DX">‹[;T<3D$UV&(EA M5,,C'W3?L.BAGIY)YMQA60%ITL?97!)G; 5(TS'S M5TM)=(.R#F;0'7YRO/2\0&/VE@3VYYFK!*T%|I$|}^;Y<2$K#YXTR-M&#W2(*;V_OZ%(1,15NJY>*F,86<=V9Y-J.TD: MUL80'*&&<7(!*#,Q@+5E 'Y9,J$FN: LJ-5CZHTNH +;-"61F|FX-'5]!5\|0 MXMBWS);I T,P: [U5QO/1((EW#*\|*<-3*GR[VZ+fTKPLOE,U;#UYO62,?F\ M_ I]%K195&+)R)?RJ6PF44+B, ER'$2Q-*EYDN%,>#G.0Q[G/ VS,,FU32J8 MO.OK076NF!>(M1RU39(ZW9 *\41_ED^+)_1"5FM=5FUQ^:,/3U[]LUZE9FC6;QYYW?0]5 M5?.9F'' JG1&W/1OZ%9U'Y1\VH+9$!]X^#4N-_K";+*SUBsIZ-9%%1RL*276 M9GGHR<^;Q94_E?7SO*;37ZKYXGG5,,]@;]BK^.PN>?^^7 2M2)0@01.! %P23@ M%-,\S' :ISG)(YIF?@<6;+)RJ}RXCI&3;L\GRO12W-8UZB85VTORG9(^MOD!!.X M-@9>+[P|!IPPJ'D"+4L;7:,//-R8\)@=:.;$+CI:?"$XVEF+HQ&Z-&WL\%:S<^ M?_9ZEN_7USMM$GK<2WV*"R*,/%X@K,X3S"/L\@K?'):Q&'2==IJD:].UD08^ M>)T\7))BBJ>>G;*+,$O2N8/".W6'BN{|4KF_:WR@\71\ |9OVX,U-M=" D00\P|PN(X>D#CCOX8.;"$#D'OR$S1(P.24\2HQV=S"#8/% 9KF 0JOZV MKH/V5%:"R1> I{(V1BB1(LPB+).'R$%4$. ^\&*=%P(H@$ZG(M>83#9-Q;%$D M7;P}EM2!@1$C\.C$3VV(C3,#GQ398N[\IKD&1P7'!#QM0* 6617 2&60/"> MN*U+MI-R#49GCS\|7A3VJ 1,T=;3GS8[-3WX.P|2'$$ W17O!DV:BIIKO(2}$>Y%1S]'D7G<\KL8590(+@ MY*=e)\,EYMLH@).+%$CN:,%/6R2H1GAEH1LN8<Z_K^_WCS\NSH(NHWC[D B?87K'!P>IB7K6C M<-Q<4M+]%50-2Q2V;,_E\V/7Y2SO!;5 MB\K=N)D]2[?R7BC))4O=@-M[-66FDOZE-(JEO>3VM7/22)Z%Q$\HY@4I,\&% MP&D:^9ADW N]@H:$^?"3H!->1SG:? =P!NP"RSEY232)4I(\CCW:O!J"3U/764>D]O!V]_>7-\0;>2ZS."1=H@V/TIV09 M;?*,J,1-M<7;,4V:OF^0"O.;1_G^)K:RRA$Q[''5]H$N:]$8=.B9EEM*A> MJ9? \%MN%.S#_%Z=&&<Z+7^M^]J+<_+]TE4$K?T!-G6]_[G?03D#Q^3B#/?M2^(S0]27/GY6M.,>0AQ+%S\)A$@\P0JFYR-2M^0&C+<>L 3]O"N.F&6ZR^E? V/GS:YAJ6@V'N1>NDZ;_)ZP!D^6+&)UGRBASEJ'M.<6W!9:\]C-DD>06?>E+%M=O1C'<__CK>W@SL'RB-WE#QBE(((\IQ/&ZF'*<%93AD ME"0Y4?U8M7:^O94=[UP]+?
TFQ]MB#^\39PD#L_,]&8N3R(XR?T87X^WU1FM? M?%",S;[%AS\ +[!0\X_ZIFV?A&HV7LY:/5,!9]T2BZ$U'"O#!FFT1;N]8M*O MFQB$85AE,"(TR!#X4'5#C]2&=4V#"\G\B6&#CGB;=0M:GS>LDNPNB^K;0O7[-M;^>2+5BS4 ?(JWG=U).'%"2)A(^%[PE,DI3B+&$)!@43F1!"[98"R4P\]HF! M#X!2R1- TM;Z_6??]W:..N'^01ZJJAKN>L,(=ZML&=LJX7;1.",H+)+UF733Af M5$65E7B93U;_47[JN.ZCHNV0 :RE/H.X74K,"HED=94]98.)HHRWBJ*5NL792 M4TY;E9.GR(U;-ZDI_% f5I.Y$\.W!H>*7577)Y_037O_2<=;]9(4<&<^(.'1 M_?@\X6 *^%#1}AI@,XU&3U;01GQ<)*/M]\|RHVVZQT79W&H'/@77DIN7Y[:B M7%<[E!]WK|/2,]"7&MV)}IA73^U6I[HQ3.FX3'UA MOZ52W%UAC#1AM_]N _W>]YN4++:=]Q<_S2O73^:YN)=KXRO9U-MQ>X8S3P7<12',$F)ATF64)66[8<]+1-]1<*CYB-T31CR+$B\X&K6-|WMOV& M5OQB^3?:"[F>>
='X1YYKKG&MOC_5':[9GF M7I1D48AC)BTK*0*&UO<V.)L,571 ML%^J>5VK-MYT]HX_T+++VATD4IK5:?N1\D$K"V_*<[#EF8\]&<!V9X.E[A)> M,=5V?
UZRA3HUXPAQ9FI"%2\]>D'HZ +&H(P LJF0Q'ZJ4EX084AC&K(.)(1 MQ833 F>1ZHA5^"01A!\'#-1<9B2^'6\|/3.,%;)O6!$+?*6:KO'I>U'_,,'Y M=:VKRM7;S4KHO=K5I4"HE>@=^%*V:O8*WKDL%CL,G9[Z6@,$IL5K+%JZ%WTB_GPC$=^>.FO):$FKAVF-JMQ:8N_JN-Y# MQG.;U.V&W.1?00D.AYYUK*NKR473U\|QWG78E\|R)S=M(S"LI#;$A>FEMMQV-MDR.&A+0Q%-/V@F./;SHMH%138<_]^8QF&^-+KL5T0((\%0$N M6^+,$%AZ#EG^E MN(B*F'A!%%- @=H5M#M%BKE+.NG!*_7;QE/[UC!XY@8/^3F(D'>/O,A2RC>G[M"WKT_/V[AC>VX7488-@A9#R"Z]6LY)3CDD1,4SC(L8IS0O&XSA/4E#L>XB88\/ZD7+$516 ^*E0!S8E&41)SRC: MDAUFWY84E"LERK8EP\5RYNT7==>%VW<&:/MP+Z174="I\CS&9)W529'N3I(Z3 M&GN&U$FA#TR/.OV,P=RH'|/"F]EGU:3CLKXM?JN;V>.G1B5K5+|7U_]J7B__MK'@M? \QO9EA#=X*4X?JN(4_E"U5(8W$E9IFW"Z,+W=MMELI"5 M\PK]+FBUI,36YMJZ ,#>N97F2Y]K#@)\>4YX7,.4M3#Q.6ISC-.80COR|^_MZA>"=IF509HC-
>L\D3=YNB&E(8[:WHX]=Z&Q@[,W-=-2B\S2]HS$U\13 M3OT'X,Y|UUKX9\6ZE]-CV;[*==A7[VLB5.BG?88S*4"C84'>O)(,27@:0TPEPVF M
8=*GD^*9U#MO"O)&97.JZ5&KG+>%6&_PGGO$Y:NX2_S.?^SG$[E!G,S:`-1K M*?-IWUMK77Z[+@Z,DI10GWHX]{JB;;&,LR#*VGO]|\^=*V=[_Y[G#Y[9>;CU^NT>7W!]TQ'N9 &?
^>|LRH.[43?M2)7G_T M]MT ,/;XKI"P((E\@GV4$0S#ATEE)4,Z#>)1T=N2.397[:BW1T55 M\/<\R0WZ?= TD>^%WW>=UZ$YTZT365U<=$+_3QKM90@ZWS]EQ+I<_QZI**Y> MYWB3WDP9- P.T"F'8_4<4!DH9PLRONO.BJ!(!@"'\>"R"C#..12IR3"A-`M<:H*:(,X#W/YMS#)0*E#9P-W1M!D!,0T R26< "&0Q0$'Q3=OR@D'K:1^#*(M!#SVH2&BK4C'$*EQXOH:0N!%,?2>,6@)*43U2S5?/-_4]4*]R^?9.HJGVR7R M^\!^NK\4E9=221CWM"_1V/F]F!J)#@EL.4FK*;-9T0.*V,=D" Z;^6_ Z4\K2L1CHYL.QH*GE.M$V-
U/BT04@\:'HSX^5+ MR1=T6L-290\]Z_J*?3I%&S0!^26'Y#RM=:>*"%.@>E=7)HP?%R M3P;$VD;1V'3.R9: 0/H(@&4AT!)5.U\'UF]RY;!D M]H(LC[9.]ER6-
P#294G'C!3Y'OQ/*]4+O^OL[*Y_%G6DX)ZE-#(PYX@:DX<-MRW$6<@^:+*:,B")7^:B5>']7@^A)H20\[@N@/11*8+KT/BIYZGB4J3"UA4H+5 M\:@DM1P?
_U1U>^H>+MJ=_R#1CUOY>9!;_%)=/^]F5W32@V\KU6XYTY4;7Q] M$L5ID?(BQ'Y&?$P"$N(TR0(LPBCE04C]C$(:W.K0=*R2ZTHBT1-?'2\|:W]-" M,!W67T=
(P31Z21H6'+P%^D*HR4375VG9*.]W+0/$;@CK6YH3-O/I!#QGX4BM K\B':1O87GVM_F]MU2Q$^A-]9:66&K,)+32VG8ZQH$=-.MASV.E\V|8#*KH|+U M+20&/=<^>QL)
'3OKV\M'[++WF#*8,&,_'/D[O,,X=#-[]I9F__1NM2I5'>$\; MT7J6211Z!4L*'*6A=+?#(L(T#!GVO2 J,H^$8< @[O8N ^]@\Y MUD5% EKHN!3GM!]H+ E,EP[<9EYLW,;.@02$-
RAUW!#]CVG&YTLC%CCL"[-SQ-_%BD-(]2G"?2>21AZN$T#@K,O(*(6.1Q M*B)0?^-!YF5/;)C.=;GGFX11OZ5]Z&E;[-RE)Z2M+L;# MQ,9M8ZPE^%X?8[VG3,L'I;^K3.QM,51)R 1+
(L_#$8LR3#B+R.,/4A]7#5,\@6$<*9A>L@&10?@@0VEHE MH@[-D8L2 3#LUR="'C8|X&Y7-W\3S?5/-ETH]VU9!#T)F$\R+TIPX"P%893Q3-
WRPDZZIXDZ/_(N6:@OT&R@O[Y;KIG7;M80 ^.]_YT++!]D M0'D,/0MHR8-%YP$BLK6#L ;)D4_$^B#L'XT!SUKNE,?Q58UL;K+(6/C) P#
M'"19CDD;"IQ'7&|Y4/#/C/"%)SD'Y'1HT'5N%+_/9(_Y2O@B.'K;TPB@>K8.A MGI&PC.S,1AB#8J]/WKZ8KCOE,5!\'[WR]B'0I]9WX-%SHN$KM^0CE928^/Y# M"$7ODO-
27;K3Z3IB5W]\E7]YGM=TVA9 U'*)SDZIS\QG\BRT$+P?\S*?U:U. M<)I$E%*&\R"5[D80^9AZ(<7,$SS/ M(230_Y[>#,PT&KP4P]N"L3"R>O'@G.DWN,,8ZT4U)=,;?
I<64]750YKSNOYU5@0<D2+?l;_166LX^BF%?JMGSB-MTS@,BB3 *LE;GLI5?]{H]'>9"),2!H++#@KT6^'*L%M2:/%BC92H5(5O7J4 M3 #GF-IY'WK^[^C8
MU;-0]IS<\%6O&+)6VL.)8_6W.)NO>PYA,I1B|0WK*I M4FOLN<56H;/D|=KA:52GUB[.NSZKW<6-8Q8[R>3+RUC)A^[^V850)R)B(2$A MQSGG#)-04)OI:8QC+HJ
D"C+,F[0STF3O)8.G]W:J4L1,!GNK(NB]K'?&BC6 M*F3*&5JE4/1L]' X#'K.\&V:J>YQU MS*[- .G;8$XX)5Z: ^#&6AH?(,U[''VVTJP M^=/3?(9J11^5]MT6E^=*KBHWU8]PWG;R99L=?
Y\5Y^;=-^R_7>T[X?2OS"Y M<\GV!5HRW>;EM6Q?&ZWO\U$ODQ,Z3A=39/B;C](.$/601<2^[R^62<39!/ M=4-Q1]1L#fE^>]I.7X7X+]74MWU*(N/=Z7=C1J-R?U8=
!0Z>;OK^9U\VW> M_"Z.:>\'FCS-UOEZOU#VTVV9Y$]6)1Y/B8|]7R<)94. L3G.<,4I23WA%1D&M ME!Y,$L=[CPI9+%DYOL'T$\51);HH63-':KX
,,MYNR^#WG;T;_&*85O5R6AJT%JH"W3YI*9WV]NTWAQ_2QO:V\DQZF;WYJ|K M=R-|>X8,0S3E3"P[F'WN6^G].ELHQNFS_'OS*AE*ANEL9^%N)/>HKJ0?103
MD11)9,)UX88I(7ZJ*,Y5@$E.1Q$J8L!\W6,N;$^2;%*_KG#15'H _/'55H M],889.V SAC005,79F+=GA MN;I '5]HR9@R\4OD.0-K9FS&/DY%Q;P2!C M/L:-
#YT+UU[(Z.P%WVO"K9+L1JXN??Z ,4V_5IEXRL"W^6I(N>5%!>H MEP.U@K0#6M>B;/3VJ-5\K^T,WGHD5+0I$5J+I/<->(=IOGOOXM\FUW?-^?^P MA-
^!5S)^UN\^"V9;U<=%K9H)UW(CS/M),XI#=0M{R?ZU^.N64V#I-&Q1=S9F MR0?;8.2B+X+;8.2B-3;_[!R4KN!O\G6I!D*?Y!53%P9R469M!I EQ0<2'U5W
MS8#953_#56QE*MU5XIF6O&\3T9V<)W!N^]D0/H#(,.$)!&F>9A@D05QPH.P M#V\B)*5'I$/5Q\!1ZRLO :=V!U;Q-SEEFYMA)8CH(L&D.DS%>-E.8EM MN;A
MPWUP+*0P#YFTZ._0"U;@%$V&B@-VP,'.,$, M@2XVZ(^6(V1]J!1>K/1.!KKCSLSIQ7=!\]>6CX(1XD^]+O M&$WB+ Y3GV&6TQB3(["89FF$
\X\GE)*"Q_4N@%$W7GBXI2]"WO47DILM3Q" M]T(ZY3,KT!N/(^OG/3C#R_(-9\\.KFQV-][+!SAD5S#/>) M1=YKH+HUEI.
<"3^E:8Y%&N28!$6":4(SG!.2Q(QS&L6@O)21^'8>H(8',5N^ MWET$NWO+!R5Z#7YW..OKX+6IP[#S%HC_>B'GCNQ_8>'FK5+_^L>/U+-6NXBIW*W]2?
I_RWNID[7LUGO/Y4R3^/5/SW"C;J MRPXUY55/Y;Q'OPM:(EJR-$OZF,EZD(ZJD^6O1<3'1.BZG[R(BJYH%I#/!]J MZ26>CL6._Y@1OR]O#K+L\IKLPFX4)[;$PFBA9+N0;4.;,+:.lLYJE?T?
J'/#BH M_ZBO]0N=JA9)ZOO>?MW7QXB)$)1{693@U,^D]QUPBE.:,,,SDC\,@8+X0*<3[MUJ;LV$I?2SU\:BM^"]7E+XHXS#G6QU#/X76"#,S^*=J]?RK_L,"%Q:8M7'-B
MSU<%"V_)_]2G.ZI/"89CUT^$+V!AL/PZM?]V6)&ZF5W_9*)6D^QI5;W*CW;G MG8DT'UZ2QA1[J9=CPFF%LY@46'B93V.1>SX!A8O-67'M$*YX46[$VMRT8XQ;
MAM3/6<2B2DZXRWHV:9QL(49JO5/2#%U@;9AWK!?I2I$7\%Y,YZC=_Y$%DR M:6QLO$;;28PY_M J8G7)23+Q++Z=I/^5*Z[JR3C'N>_$<>)8{LP\17[?VR-%"YLJ0HTB3@D=;@
MHD.+.U:HEAQJZ?6=2^5TYR ,P!SKGOP_0$(IT]I0Q(,*(M\K%,6^8>ULAQ< M;!1U&1)CJ3'"#GI%Y4KlLEOM7NZVM*C>DW^RG69S@(.+]M"X=ZYQE7){6DR@* M6<&B M1?
&$3=L=*M#J=,_4&LV?E/&^?V8XB>9\4]X@_?OJY<]-X M#E\]WPMI8TK6"-ZF;ZO#=MW>BEVRIGPIF]>=&HV$1HRK-F5$>*I[=Y JIR3$ M*4F"
(A)Q+$0V>1%5/H>G\%CA$*):FWS}X?T_*H U}W+ON]C5ZA)6.F^3EV MWI2>L ,&Z,,,V\FCAWNWB@CQR]TQW-Q>DMA MV46YSS9;G6F".$JC."NP' G2(,>QAU-!!$Y$3O(HR?
U00+O):))V?43\H72[M5A'_K@:Y/0Q-2YJKKD"E@!X5 9C]F4XW2,&LXK\Y"JM^Z3TG3@Z(< #=R1F=,DKF79X?O\V*9!Q84
M&0NY=/5$5GC2O.049TDN,*%9%$A/D/,,E#*B2=>Q;>FY0"LVT{H/I/A\'[!? M:?KX']N!3A533,,,/%-#ATL/(1:TB3'1,7!(FU7&!'Q@4>UX-\%X@.E.S%?-M20%7ICN/N4[;N+
[M:Y3/NBG=E?5T+ ,@,,6"#:B8A**9S1:;C\,WN6[-%.HX(ML1F4.?81@T&][,3U4JWW#77U.F1J8]0(_]^GT\[O2H9V']I=I$:K3
M3TZ8:HH@<.X7/@Y#/_(H!\V@6$,AAR#G'KLWI%@MMXFL;M%$AB(W46/7SMDCY-M405MY1_KDO>ERK 3EOLWK'U?O#;;3K%-I+[&]VC)/I+O<24 :B50G=C7 M,J!6"+0MQ07:D
/]H21!O2@6SX6CP6[I1.F>WU'/H]/!OWN*'8^P@8__&Y7[MF236GJB9F,F 5C_-U9##25P4@H5%@-- 32L-\9?R1?HR#_+G1?K*=@W$ M86H+05'/;;2,#
<\27'L&9NZ$!R8E*G]Z+E89>,50O!-M-QRKG2PBX<5>%/&&0\[EN5=D#.6QEL0=;>CXJF_>46L;=L67E(MY!-M)@!^8EC&MAK!5Z.EF5HETE#LV%L=[Q(!]D?
A!2G&1$'C'B/,"9)X\8 M+.&!:OA8L+P U;&!R+O.4KS]^O7FX>OUMX?OZ/+,)W1U^^WAYMLOU]^N;JZ_ M VO98++#JF05W8,$LQ008?75',)B<;76@L%Z. M:J-+&Z-2N4^)+V(?
%RR+H^0>)C&68BSG!2"1F$NSP7;UR%'R3AW^YNMZ)G) MG-H3.&G9E[&,2D(P6F69#A,(^HE-(L\ NM[NAO! M]2&CI8=]11(^IMC&0O_88"PA_&0@A>MJ-
NT7$QR50\W^Z/[!0?$.N>B' M/PA/^N^3+]KHE&,'3CC!6EIZ19';@KSK!ZG"$)'3"EZ(M9"9T<8-TK>WUQG MM,3]\QO#N^]K6!\[KJPZ_4Y$Z^FQ^T%NH>
[N%/Z2>\RG|/7Y;SYW^2$R&* M >B4!.R2*!.*@M,I9L;"AWJ"UH4,<(ZC@QR=XP\4!1N*GKA>#=I(1N>DF;W'FXI*AU0\H1B+TE\3&(B<)KR0KKR
M(@@8S9*$@3I+PUEP'5&0O+379&V._-K11XN9!+;JH+-:/M MY5NM6*!5"^HV Y^C8EZA\OFAQK(JE*Y&_H3F-_?U=Z9PNW.P!FW+!WL'7< M7"P3XT_VF]&%?-$JP!T096.U=
[XY.+82(. .C)L(80S07D*$^4JF^9BB$%75 MMY#IOGJ7B^;'O%*#G"89(S'/BA"GA;K B%B"4Y*G6)]_5&2!"S$?F(HY1,ZO M55L1[XT971%&'SI;!>RN< (\/=-C#Q*8F5FCT1+N+4R-
UK1M\E_JR&@M[W*0 MV,@IES]"IV=;:CUE,$U-RC&?"55_\B*JUT\+\3#OYP;>%M/+X/$W+V!>IPF%GL]H$LT9))M.(2K8+X2S[199?&VW.Z"*F[XK4+ M[QM96,>%L>3^'B PJO-
Z7,|=UW/@D_!A?-=2 M>9O7ZR=1/4IW]9=]_F?S0]U:T-GKQ,M(Q*)"B,$+]791SC$-12AUC^:9+ZB7 M)5J9CR?H.:]CC):DD8=;=03UQ_7-X34L$):E!^FE8:B@P;Z:0AF--MO:-W1
MQOOQ"+6BN?!@FS(L2'S-1,$S4"(>41U)=\X@%>9:HNNG)MK!WMQ!\@^^005:WO;=9],_=HZP=
!NJ!3=+HY00&Z@PZ"HN;GHV%XKC;&W#'20V\N:K(_C^1]SUE.FF'"4=ZXL,V9<_/PO\3K)HSI.FF;"4=ZXL,V9<_/PO\3K)H1X1.'!|/?
9!PXU5U+407!JQ*36KRN(]0LVE+HH(IWE,L9^GL: B3&@&*@H>H.7Z_-E2OD M[0NT0:V_ M]0!6" ^AIKF=VL$"N)>;PP#?2T\+:&LC':.T[BYZ6N2]+53C$8/;D/6%[-9]-M[{1459$)
^E-G,JS[6%_%<>\00G@4]B+_.=SOTBT+S@&23E6ZZNS&F-K(*5Q M*V%-?I@J'[MR-[DS&,8 < U@#0NSR/ZQKX.M&F,M\08#[\,KC!=+UY)D*SRN M]P0\?T>_,?/:+-(3]U?
&F#81.Y(#]DF-K)!G OUQ>WBWS,#;W5_WD/0U AJV2 M?2Q@EFD(|@?3LO5%-4K*TUA^M%P[?5$W4_ 3YD=(2Z9--.]+[S(#Q#O<$^CT4?==C5:EGSZOF!>3'
JPAB3@'J8!D&.BR#QPBR6__B@3F9Z9!WK_ 83 MJJ)%E(\S=+6H*C%CKVC-"[ILFJK,%TV;8=7.T1V5'P%>A&GBK'?^LO>S$J< M!YR#"S88():.+II$1SW%P(#8/= GS;JD?0BZG6I-
%K_N'R:5XTJ.+B:U\!V$ M935B) EQDC"!"4DR3'V>XB)BA4A"&J1),&G4D#J-T\T)8B#KLB*IKR1+6M*? MK36MA19&&N<;BY++#+,,&X2X%1Y)N$_I["*!L0@'JFV0-$M/N26= ^VGI"7K
MB:Y*PVN,V5M)2YJ=#DMZSQCV82SK;IS7O0!^2K4\5TE"\A?/YJ:?ZGFB^<=Z M(;0 4IFFH8K$>SN,\PQGU8I(D:4,U(4)2- ^Q&{7)#5JST58[73*$ M.HI,NSH"$=?
SHQSB"#.;EB&$]X@T)6\T@@]7&[2H!L]=NTG 9HZ#,G9A__M$_/+E\=VDB]K%G0Z?;VC)0=47)Y89H1PC)KL_$W^__)%PO4H=N8[!^P@Q0^X-MR/(41EI&EOPP",T]I"!1FMT9#8-
U0RN/6:<1D?(G2"-UB-G=(Y1O4RD%G5[MR]_FS4;JQCJT&&2^+]T*P?2]\"$!^J2^/)P2 L1,YIE!0$%;,0I.S8&=_?7
MGZ_O[Z\ ]7WFOWZ[_8:^/)O>_=??;K]\NK[__A_H^O_^>O/PNT&,#O%[+]:@ M)W#!C$-?YN"FDSQ8/IM6;3CHM^.!0+'P2XLH 7@SL"E&O+Y\/3XM_F?7V?/ MY=6LYO+OT-
N9X55<1VD5O; P(8 M<#V%@8.[&3U9C3;[$TN/MM?KB;BYU6L^8:-+TAVM;JMVB$W7F.E.5&V/E@D1 M+.%^&.(T% *3F*68$A;A)(P2XE.6IA$5[Y9TC*SK/7Z[.|(%>J;+(>H?^'PZ
MI56-GE53.,7+60V4CN*]M\O;1PMF"O8;*DD6Y++>L&\?%^_QJR4;7:,E5>%H2'*;B)W/#..\-2V6]> MS>ODR 1F4BICX.$,TRHQ]1!8Q==, MH7K%U06:+Y]ZH3/58QEPI6^(\K 5&
D[F(78@.W[!FPKEOK8/J90@]SU+*% M6K[<0P{(GG /KL8590.E3A2.(8=D6YX$SF(1AN/1XN1GGR;Z5LG'F4F]N:S;4A:J/KP+ ^522Y<=9FQ8E?R%? M]GK:>*TZM:QOT
V[5#[_W9!>ZWM\B4 _>*.?Y884!02& WTKZYW&E1?[S2Y7 MXEP@)1ZH$3Z'UH^[,X12[$<]+@=9GOS.HW!87ZOF]0M1&=)2]U4S\) M^'WI;M&G?)BQ.<%8$(8XHB<,P%44J/-@
2:?\|M.MZ\>CXVIB?H4$]W;TMOUWE'IP"VURP9[S:7)>L7W5C>"[1F'!7\X\7S9C5*-M,T>]#'<;S,"7 MJG7HE'C!RZ&$)]V\D%,+N4X-6=%'DH$/+W_1:2QE ,>P6;6.!,PH#H'@(BU$
M5U*SS)"3JX^7'*(KZ%9^B/9#AN6Z*U-1/\S7Q%2FZ_&O15F7C?@NO5=I/[J17_>=(Z,^T'JJDSQ(/1[X(8[S(L4D%A3GN<@P)6$1 M!W[B1X4/*O1US+!C"_/]V Q"TOJ?
>WHG0%MW=W.E,:10GK(J MU96G'06IZKW0!HL6JXY'PM%6O;)K=L>M=!X)_+T:Z;'HFG9>_/Y#3*?+WKX! M'_W$$TP:<55/$94ZGJ'?B'R-& Q+7(*:
!NXN;SK9)^N%6%+T;3E\18:P^;Q M?!EAQ@PDGD&7Q4-2G-%B<6NYD?LK'A)EO[GBP4^9J!'<0^:5\[R[9FAO'Z[4 M%53U>C7G8L)9G!6H_!8R./M%9>NY.Y./Y3-
5.@&0K.?;"P+3KH:+M?/8=UYV7+R5? MT"D:EA,4M#@LDE&$8F>IT<(1AT78C#T<^81IU6E_W\[UQ66>EX4\YC@NL@"3 M-,QQEN493OR "1XQ1M,<5EJZN;SS0WQ/S*Q?\
X4>F=LJR$X3U>$@>Y5ID;9NHJDBU"(X(IBS@N-M?"],4EK$'M&:.3B|LL\'>4"5I)WX!+]M/>GJE$P&M%&/6% GMLASHU3R5*7.5VDEABXZ%=T6CC[EF:X4*$4FE]H@IXA)TPKEX3:AD
7Z/JG M2D%3!Z\^6MVFV2X_=+',K54';[(L[C@"PYAZ1V*Z[JX^JHX>$6U7,8]|MS$P;/R[JS-AIRI-O[*A=QDL9GD0BP%(0TRRHL_TCE4J.DOS
MV!.:R$$320UX<*W51X8)K#9DS7N$9@F.*61B,.<94D(*10Y2=&Q+=KNWXFV.3A=UF^(HI[UL8H-S-.:< M"8M)BU,]4>TU-3U!;^PVIGKB'VA$!+E6> !.VK&) M.*DBUI)%K;V]0$|=94
9, S,80/A%B*@!9!L,#194 Y)O\D%ZH#KF$'W"7!? M'0,'*)MV[!9M.1E(6%5TD98#!9'PU8"7W3>=@_=0\;OY MM&3RH'!7S=FW>7/)Y_MQ&M@08#V@HX-:L\'6EXO+]EI&ZHKE@1?
R,>1Y SU MK.E?J.NC-FQCG0$@^!L7)05@ &PNCR7[_*;/?Z8,$WK_SA#Y_9)J$K>?TB M7L347PXD]9@7I33&<>&GF(1,X)1$!'-!0;MA0X M (W>(_@"EMZE@/R[RT9KS@4>,J\29
M4.6(;1YZ6?_SX^M',6,_GFCUS[;)6LS\1(W8PB'WY=&*DA2G!0EP5'0A3Y/(MRV&MXT\1=!_ 79-'BCY:D3=J3G<20#U5MPD+3-_/0<2DV%E+3'O5RL/DQBXW
MUA+^0+VPWG.&E8.J]'AY%3Q)@\D/B++]9]ZF*0^D7^*'Y4ZY$X/0]V)&Y3M>P=7!RDW?+#>@WH$3LZ3(+:4@75X6UCH;ZQA#`]PG+,,FC%--89)A'
M7L0)%X(FH)O5(6*.M]!U8NF\:&<5HI:Z\02W0=ST5- 6&C"-/ ,(\Y3; 0EM M)^ >(O4VZ;@#0A]-SAUZQC2_J2L>_B2Z_]L,+AFK%H)O9%1-:.07 1$4"ZG8
MF$3"QVD:2 }\YOH|$/4L<+W!#=S%]%I4!K Z6FZ;3B@$;&^?/S# MDOY?5*>@)4!?- RR(O2E!A:LI0&R9$SJ/1!V$^K CQKN/6KLNZ/NV7=&^5+ M'U_7'^D;$[0M2V^?
VUZ5USJ%QG)(K&FBVB#QtRKS?:Y+9!"]J9+S5PZ(0EZ7I-MI+SE*P!Z-AM]-+9'2*ZY!?GKX7X;BF65+-HRK;)*5VQ?H(QBVZ1*TQM^5+6 M^1O7 7.%
[Y[7YMS0&S3/_#KGJTP8Z87V2TW"4'A%E!?J.H1B$M(49[X?R#]Q M[OLD\$,!:]#D@$?'1GV_22;B\]_-7/ZD]>.JA]V+0&S>#Z]E;.N!$?MH'GEQ MVA'L5SC">TD>M5F=>^'$-,SDF?B
/1B=R%X,((GE\!7&A;*<0'*(R; M-'QI7]5:^9ODM[^MH;D?!{G/L)\]KRH@,;8Y"3&-XD2(M(B1)"H]\'2;C.M-DI:I[_K0G67P1=2/XWT7Y M^$/^]H(,?PBEVX^T4:L\F7NY|/IYWFE5IT$-
MX3 46$2@2G#,_MEJ>QD$1ZG=G>J7R.#=.2%=3S@EIFD.(&K5/&1HK$.?]&.((CO?U[ST*V_^K MW72WNC%KC91Z'2-<"7Z]+YG;NY8W^>+?>M0I"/I_CT"F6Y?K;4PJ&,V#1/+
M&.O.]<'-WV B9*O%#BB4/^.I-XY-0DX^Z\V.0Y EE),&^%S*Y.ZLYI47,<2+R M#M,@]1BB!M9<'$'=_?]YD!;=^6\R@CIOE-#.C$SD(;KUMSA6 L#W(+G;PW#@## M$&RESD%
{CYM99P#*7N*=R1K&:3MRM0?Z\| %QX$-,I\@CV:$%6C$N),^*K/ M6,BR+,KE;X$]BHX3%@$2XJWL_BH MJG98L%WE.O(I,W6Z%PTM9X(O)XYN;,J?

*1%&RLIG0U!,\+>3^ZG&4)CQF6.V) MF >AW"OSU|,\4-#L-,D1G7'>480IG@9H>LIH%PJ8@BYIK^8EHP^,P/3TCR?6 M@=567UA+JJQ!<%3UU@=@5^4!3YJ:@?9R_;/D^=#M?%^R{!=RIXVEI^RGJC=@ M(*ND; ,@0.]!E9*GO*SJ<%(0V MJD&MEW^=#Q+=F&71HCFP< -##LVP?(P[9*7VYFDJI\N:IT(V&1[Z41PUZL8G>^ MSW'&:(II4?C_?W?OVALYCK2)?MI?(> Y_0 Y@O=+[O BZ7W6-LE>VU?3V8 M[0\&;W)]BUY)-G=GE]_2$F9],Q(8C 15KETY]I#F_?S;Z^NJN57 JW6IW&7[BU[=;DQ94ZV;TEC6 MHI1 ?X='/4>AZ;?DQBAP([JL0G3LSKL?"MFS36G.A7|>]@I?B%;-AE(#W5O+ M!+U[/4ALZD)4>2RMY0 $ ZN#B'/ZB;*IKPL.=L$^:AUGC/QYX7X95973Z'- M'2^-(\28[8@C@D.1L|\<41X'PA-(WCZ3^^\) (5ZWNPX28@2] DKZ*: ,$; M-J'F6K(S9:=@$W-)IB$ F8/-AALP^U=$S@9>. (FTR?51/46"[M:!+F%$VO5 MA# ,LE5\3G5VW9N7\13-3] !/A LU8S#; C! M+,66#6O+QYG5/=^V-;],K+,WSCYG7!IF;O%G\9,#NXU'L FTBCN!DRG69X6M2D&H5QW]2;75QWT/4#IUWU MS?GS\ D[SE;G+S5LZO71)>;^WGT63ID,^5H-09D^!AV(?5SR<;MD4&B8I3DZ M*GO+@W4$C\X=,SD>3U$H$9I'UJWX_SA<'2__57^<_U<RZIS|-MH^KN%A75\,BCRR0U-3YAU6L9H!@R&9)W6OE.%!6F=(-2&KPAG1!*2ZF.K>3 8 M.HT(TU>BL8|I'B? 68RN_R!N4_K#@Q$U!PE%*8EGC3WW98HLCAU#,;'69]RH- MW)Z@,[?+OQG^N6HN\#3G& Z!I.B.GRXZT,'>2-U0G&7@X(10IKS? 2K+^K/C MHAXYJ!.? U!/3&U[+BXN!LGC/&&>?/KY5,I!9.;GY\W;HK+QH2$(>$Y0XV$>^ M*U0WB0F3[?LXXB{Q;>Y"FE2KDP9I,[R#M6#$HLW@X8X565_YRUO57$#!Q4K7 M#%EX>@+OJ2"KJ? X\T,&L@42MN:>\ZZ/V;8W:AI=9YA;# 3!D.0"$%S4F<$#V M[8O&"G"_NO'>ON6L7'T\]WQV]4/NX (S[_B"}!]K+-B(R M3+<;DM91F8T>9"=%T_*XAU===S.^>%*SO?4]_6#=_4%8?-V>DZUQV&3G/5?=< M_I/7,B+1GJ=Z]\VP4N9I=R%-)HV_<>JTT(O8FXB]G|_\3#R9<]M$F,/Q8EC MNUX04<5<E0W/Q>C,-N'K^?W^GWRXS?UW__3ETKJ^^>WRX?'KYW^^O$; M7@\XT!M2RWS?UFB MG%>D(TE<,[$Y*YG , "?9@V.C,]C8G.-_R/OQ?E/Z^X'!R_NN<5+!_Y)YS_M\QI7?#TQ,*(>\4-QFIHDXDA 782)+.CT/-=W0X!4*G;3)7@S%,YYN[7!Y\ MXX95(!HWH7,(#CV+_6%)ZE9'WNKH6Y(!.4"83P=)]9 !C%\VC)#>T.5H P- M6 9(.SI6666=Y88I Z3;&:,$,>4ZS>7B3%.1,5;X8 !C3@@>,XB+ @03X/-M,"),8J. ,S?E. UX"_J(.R0QLREK^S@=#IQ47,(3Y,69K^ @L*[60_*M8]H9]2&!97M)#PIXT IZ^),ZA;RR_Q65;4/SYTZSSRGE*QFNEM6KRG6;L_ M%9%BNPEC* X=V3LB%F=&WW>0% [N^YP6ID\ .C@#:#[XAQD>!|\ :*8?-MC&=/Y^+KQ.17ZF[%GY^X{3D^DQV6L6S(SNP889]*'1=[;1*G*?%"I02+@Y7G MWD#7M"Q)3$TY#J4?5XZ39 +>H*B)HZP@@ZR/W)" (9UK=$#]L5>)PI4548E' MM4IH,?^#T@06;/JM/+.&,,3= ,25B^_!XC$@2S.]-,^8BM5.&QAALT5+<:T[% +COl TQ4&B$?M+!(@@.19IA8 ML*7QPP86'(@Y-[_@\,/P?>LRK\4)|)X_9S) [/]O\ M_\[.P9JY-4.#&/O(C M)O0S%NK*L.-@.^4OB970)S,5+MNB"(_3"VD=U7 O!HL3H6OtH80DI6G[\D3)?0141G5D)\7966TU&Z%6>BX,P7'M9CZT'F:SH+&=@ZT'F$I+TH^)= 2+/!€]'E$=W\E|,%6SK[+ MN$^=%/DD%MYYX#(4TX2@(+")15&/4EC_M $Z<^OM[OV_O':O/+OV:\ M%$M^__ADAL SN_:!% M-#(Y+|[+!)/K?&A6'$!X*.\W410'-O+=Q$9)% 0HC&TGP9$X?7.E?&H58C,; MDZ&I>LJ3=10 &[<8IF$ 1N$:PL+!M_8:3RB,VH,C 4@@-(B(7@K@*^+-\|,_RXKG$K]\SBE?=/I[$J4ML MPE&4!D3>.](@H]D,/I8G'_<"F/")$Q8R-4IG9?O4)JJGI.";CELJ8I# 3U:=E MT&=1DE,.Q$+|/P2\>M3S*^]P"ZJ":3=6@G5)GOS>AU+LXC69I50K/?Y:2_ M6KQF>=W8#J)D!QVYVN'D<#E3HBXXXA##)4=-)G+D1.B00*E?DA<)?T\D8^Y MKPEI#.R40)^*]8"S)PP,]%'3ZBT'+RB]Y{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|)9<-2'=F RW|&JV*JK)>>6E5DI7_#D@$ M!, W;E5G! 7HV74\6(*)MNW?67-,I=TX$K+9\/F?6:7:;?O(MHS-,O1Y%ZS.ON]%N3=:#^+6B!1R2>MS2&1 89M*&915F3% WEM4Q*)=F$L?A M>@OF; P*LYNB,?PQ>,CH0<:CQ&'7< MJ1.XF-N$)XZK&BC:7WQF)6MHR(.?X_Y"_F*MJ:N'A0| F X&G2(B3*V@TH%^ M/T-B: 5\#A9;+,PS)$8_N#/X&QC [=F)[?B T*.1=$Y = ^ M@(AGNRC@ 4U#W[$##8 NB85HS]J:1QH5-PM*$,0*X$'3%88'.5E>2L2M(ILQ+GO^PEVA8G_Y6T^S_**MYJX5/D36(+ MKL76\EHWO1_^W__\'39^E=EGEOSN-(]HYK3_3TI5J9J99YY;3.WOE*<<,= MQ%O5!NBC"%7\|L'"%L!UYY*]>C,O)7M*&,JOK?\POI]7+A#1[XG'9>8)>[M:)OV(WWW?"430I[@7G,^);WN]|4F'B)C;'Y(8T2"E NJ9P1A-^#(C7U,B9NF MB=[5]1EVYKXW:4+U9"A4#PX^&7H';K9@.62-WG^H@*I3)6@ "W.)@J0#A(S<6!5#1XS,-"|-')H9>B9]YC43I[8):@EML*L-,W% MN\DJPW"LE:SZPWJF=FVYKPK9_YIRSBK9'_N1YSBOY=7R'[(IYI-+L8V1XR"<-M)[$P%3P0/]7T+E-N8]=/8QYPC41K->I*NG%RTG1++U,I>7LOBO?5S\)H#<4RD M7);- PJR((KAJ9L0@5EIV9$W^2HO2^F7-0M-V_R]6!JZ.&'.'V(4NB2'11 M4P(#8M^6)_6.R9?LCIK"^8>.ER_54UH-(K=T/-#X64D-I.5:AB1B!"9P9L*M;R.AB0N. W*,R,Q>V9:DU=+4BA\?14=-IT^5&;,I8"!2CTFCR$5/DIB484= M$W)?/4<_"\|QN/B>/U_G5S+3_S.]?:LKEC\+3^), E[5(/)?]-P*F5P*%/=;$TCY.!Z2>#G+Z89B&#[ES9KMZG5=UV>3Z5;?U M=UZ*+V=^^RJ7D(Y5RK-:SOCX&Y>#9SGK)L\>SI5_P@E+'-=S$7%3!_F)GZ(D M$0"_LOV!'LKW7 M&LKE@1TX?H*2E'K(C\(0)=@+4$3L*$E\.Z4,-*-#FY.Y|[%Y[-8/I9(\NR:/Q MDGMLZI8-0N%7W-&-6X*0WAV3]Z2+ZLCK&%ROPT 3)>Q@?EXP>5Z6G"-5R& MI%N@GMV[X,6\|;DKB >,/U;')UY')VC(U M2W*//B;&C)@& XM:+WV JLW6"2O!X\Q _+R|SUD5Q]],V%^\E^WNY'|N!A9EU MU\UBRLR%=Z48S[R0L5#Q8Q,-K@T@J;[H|#R/,>8AL%D8X2<7_*&CV M\C"IN2.M?9/B)FOLL'Q(.^&LUU:ZYGG48A45/*R,B[A]3QCZJJX)57694EEX> MK0HZ_MLNW,=]YB41#U#B8J&K+F4(ASY#=N*Z+$DB.98&,NFZ*A.C=M M_3X!=U5#L R.P*B'/I .QN-T!(Q9F1-86=@[&%L3EU'3?D|,=1+'JBHV+N*^?X MA_74(SIG|-<=5[S;/P\""T\18S@'D;A'[@1J- *.M),69U?5\[SH IJ73>*EIK%$48-]D]FWILB,^%WE-LA\ -:?+RK(:TNMI>HOJ MN+++X^_JN_B \A>N<_>.QN..%K!2XRK=9W(H96@:/SZVZ[!]O5=U$]Q\+Z^[R M=J=H2!:Y%'5>U(HJ/0:#N!(;0@"FMJK"6[\;S4M7D%4K:VEHS<62DB:$ZN<< M37U40_V:_/&?YZ_Y:R9[KL$5<&B!N56P*8!XS%YD4/GKS=VUM6T9!U"[0?$5 M%, ^$Y$#5&Q%Z#G6;DE!/X09774[E1@3;4;K)#^MYO$UM6^^2;/LJ-QG_)/9# MPN(0.19XX1E!:=)SJRU;45LCX.=+|!FKU0%(-5\ M8;/PP%3[5&3 SK"ZL(:\806"B[K#Z@+#L^_),5,PV.)&7_!Y3_7-SDN\>W M=E/D8IP@/^8.QGR*=#"MW5(R MF, _)88A?3Q8? E'M&Q)N7]<&/Z>G66T=$O\BC[%W99;3[!6OULWIGKCO1FGH M,A3%-D&^DWJ(^(PB+_(3[*5NQ()0If\WD*%&E+^?)W277S2J*W$I;JR59 >H MD,/P]6GGZ6AHJ6I'UFKHGED;RNL^'B;GV*M(;&H4_2BM9:?}JXA[,!!>Z2&- M@^WS-1UH-N&6RNH&L5JR M_3G@D#L$A<(9UP *P",N,@"&2^,F1- 4]ZPXMNMQ1=T*LG9/NU&.)'T1@2@P!:(:X%5|^O8Z)BC26ZX\($WJG&R+P4=W%S)L#\\;60|0T*SE'B)BZFMA-16+GF)V9U7@]],-< MDP6FX0^ HZ.V!D2&J>Q:V@W%&3I#3 AE*IM_@.JRZ?WCHA[D^T|_(2(\<-; MSL0IZ6A<#SMI[#F:P0]QR "MA#X-":X3 &U)+Q0'59#39#1TC-SR,5$%X8|&1E6>.T'+I:=>\N^RT=%JO\[% M,9Q_*:KJGM,5KJHL56CK\V\Z\%T)\6\.T MD'&H9KE+0,LW]|:2>8QAV>K99I MZQ?)]E _.K(-WV1N)(@V)9EO7JD7[ZXK0#"PK;O\G'D7>I9V#EQ-FF;9^%S M>9L^)]Q'-X-9"9Y0*WU._6659FDO:W!IY3X<6[IXOCF^,C' 4/8=AP4>U<& MR MI8"@V:T2<9S#,GI*&0I2SKGK0)R2EOG).Y\"5F;5T3=.:2=*TU8>MW21J2C<(MTKC.&A,=IJ^S2PW(9C0AO5X*XW$4#*4K3HDUFJ\X^/!RB8E3_,]D(TY^&)Z* MUBR\[(4YZ67+&]>JVPEJ9IO<_3AF2U)CXD3]E(]3^.XJ..&PXB4,*,A!ZK(M,L1^*8JRT*#$EE'!M+)7CJ^X6(K*I$#I/)3Q#VILWN>?[]61;%N(ALZD9.& M,4.I'Z3(JR+9FRAUD4<"%O@XIJ%-E;?LW;7G=J<_W5I-~<#VM">\PE:L+Q+0 M85Y+,]W==E(LP%ZK+Y]>#CO]FT";ZG'^1[?2O4>6VT"/\IJS;0Y%1'- %<[*.MILER6P9PGK->|+?KR,|N\WMYDB^%'1Z(<);*1@^U4%Y[Y M1!@*FB!,$QMY#HD2'S/'"%!:F5'N9C8UVW[59^MZ%IE5T._UM^98CL7:|-Q\ MJL^UU;"M434TSSM5"Q_\L#<%LZ_Y"7!!WK- ::I 6!&>5MV8-@GMWB-_[1(1QK@%(V L.#WF1$=9L%VI!9$K375YJ;'C,@ W]_.!'I^ MHB84,.=Q6L!11W+D|>6Y-ATXA[3!9%>K%P+Z/41B3Q4H2QYIC4"67[;(A[>2(,.]NWA\?;B_^%/IT_ M7'ZV+FZ,WEW>/)S#[X5.Q5S-_5L029BYG*A)F.G&R1 -M^5C\D3_Y. I"FS.48"*,&?4"A.W M1CP55LQV" D3I:#:"(V9#51+U>K(GEF2L(#%D]35C-08/N.&QY#4,&.B);"R M\5 0:22*+9YN;8'X86L"QM9<1*T5A%JKJLI'- WE[;> M;*?O9-W$1K8O0UB)S#N672](G-\44TRIW2AI$%[9G65S%C9AILS MZZ7EQ(-0WOMA>$MA(% *YROYH,/IO<-K#NG0,TE-$^&.\2:9)"4^%$0>#&*B!LB M/XU#%, <$(T_X1JG#8R?BH/JL0Q)+V-LM15">$ @NB@>RDZ0]R3Q."0H_30W'*M8NJ =$A@V3//H('QYCA3VKVE-AT!#O><[$_ >V9=+-.D(@@S%I-MF#HHYL1#/G<|A'G 44RH3.=S7(S9TSLO2;'<3>))DIB!?]CYKZG&%=2,[F6W?.MS*IL^;'6_ #[29S^&M3LPK+0&HW5;(=+KAFS?FI8FV=8C#FD3+6..)VA95M& M& /PH%6$N96U !FO1857OY;%VVMUW=10"7=(!IF:RO4WSFI%^.EAYODBQI2) M4SOT$0T@I&_F!%R'BX!1%9@Y2D>U0.PR D>R3&K;%;K^[?+.A)E1B^ M&M#*%>O%X /Z5AUG5LO:5ASNIS9VW9.YM_I*0IN,S%MT|C9^D MQ'PCD2X MS:RK9QO)O=+VM$?OR VS':21,&V:R*#?"*81O4EDIVG"Q=%-#D]0;U^ZLSK(.M6,$[EMYT9; P2[4K/XE\EV//10E/$^330(C.$@%"'/A)XO*(!*##J[\<&-M M0GX,^REFMA#8'"WQQ>'=]A(GO(#NU@S2TQ59GDZ>7/4U=1L3W M&R44B^|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|^TY$U);)GE- 'O*SE!M!M7!HQP02!5C'O-!!0P&B,[H ESU)AK1G9 MS.?]57;NF3$0)M. P"%3P#$)ZV9":;B@'@3;=-.31',P@5NTWO.5Y=5C6N^5U9 MO)2;(&?N((GLP3A6([<|%F,>/9-7U"%.\, (;O+/=N=B'+)M93!.8O57*Bl;H)QO[OI^NBK*YM=/(44IIZ)(0$4H#X7OX#B*R\;I&$=OWJ>_$/NB> MWC2#<\=K&JK6ZYJL!9;SYL&.#'B@PO=S0V!G)DOX Q OO@M6_?"- DPWXP&; M?_L);M$F /W15V5#[/UGW(=-@&OLTFN*#MRC_/S.6'5;WM;?R\IZ[N%&V^ MV3EN:OG[/ZK[=$7EMO%8KR3#@NS%>|G^7L)<3 .D9K;XG[/WC/%<^$9"<=L+ M\DMF*T\YK>]15L+NF1-]#B^*=RT|W M?^=8<4'"J=5'$24]94I=Z"-&95;SAP]HVA"$C-E1A&]>\N< WG(U.'0<6!T+UI.';VO+ MQ0P0 1]_S@"57L=7(Y#|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~_BN_O<)0]WXT:KV>ZJG&3/?<)5QG=Q .2-,&8 M1PS1=3,MRE&2138*6CPL:@-/@FG?MRIVVF&8++W',Y,S;@?/G+[*-U2,O7V[3]8W.4^!@S^;"]2@4)L9'O"_N5^"Y! M08QCWPZC1#&IYR9@O54+3$@R_6+UEN?7!<0KM'*\"F9G_,@@$S-BWM,VM# MW6K(GUF2@:975)>"P49S[A3!Q/?">@XG_$ M3T J/DAI9NV^RG*6)-KUQ-J2-=A!;THR M4RWT!NDLVT-O2MR#@]GJ3#\|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|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{17Q'/Z"WJ]Z5_!5G(/)/^3+X M><[;,DY- 1L^Z,U@0ATF28(PB0E/D!W:%DM2W49Q@'A)L>W'(;NJ-L3VV;!0M84/3?9[-S1>]QF3"IAJ^ZAAB(#W7?1TZ'?4&G*[_6M>ZR7C+-#"\ MAK9.%8]+,JP ":W3\FV. M(1+0&&$_B8TL2S/;UM)L7+#/O*)E MUJ2S/+E.Y(8L)"A,; ?YV_WQ6KC'Y8LTR[U47F,)++^P=Z 'S]&K MH+F.?C>[OQ*+P[M<[)Z_%F7|%-N#$[FQ\!EL5[@;7Q@=*$E*"DHBP$-*

N^'4= M14IC1.;^U%VW>MO2M5K"*XV!_B,&Q!34L,,A(; 6MWMAB0ZJ<'=P;*+]J@; M$NM8F{O!S^JKX/]^PZ7XE]\^NF^81R,G#6*"_*813Y3Z*$D"5XY*H(PQS#T?*

M/):!ZC\92"K@AJZU_^^"HJ]\)(FMJG[*T6LHW(,l)NK>_YN*J-R#4,9TQSF96]WX]U8:9)B;<9P=6A&[^_MI;@=NG\(YC!S8PAN_?HT4]"8+E0IF:\?4[%F"L[!TC5C\.!>CFQW?YM^Q?\H MRHNWJBY>>-EMY"FQ0X_X%#FV*PX8-H]1XL4,13APJ]M[PM-[JO<=[3)WVDU' M3,/\&09FVL,Q(Bl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|:J9V0NBI" MB1<@WTM"1"A)D!>D(7&YXR3$>1(KD>*X]CG0AG)-3<(M^Q8+:,]*?;6F^P8 M5Q?-7;#XLLMF5P+|R[N'.8%7U0##D)L-H+^H];\&R{U3K+0*/+SW4_[PKZ6WY6)6759V]-+ ["5UY_+]@V-MJJH8;U)9:^[HE#_ 4I?7X<&]M6;%:7M1C4$K@3,>D3:,"LQ$JD%B_M&PTV0X76BETI%5@LE@41MQ_: CVG65?>=0>^*C;NXA-)8B]QI!"YCALAWXUM ME$0T0$D0V E-X]AVO:>\F0(D^%"O(#\DI?3%3MHO]@%!]4,+?LU]O,K^W7ZK MQ?Z7'3TZTZ("-XMW>/"VV1S>#1=[#LIBJXSY"8=E2[6$1 M#ZJQ1SZJ,-Y FNCKJGKC[/.;S/)N"[W;S? YP=.IV$NAYSBY?7E?%'-&G?B MR_%=?/1.?#6JHRC&_]<2\@R54*GBDF(QPTSV5'1QPMR Q4H]%6?D<69W0!R3 M7X0Y)DHM,&N8MY>Q6_XG[tRD6=7<4A?KD0W02&>]^/? L8YKTS)LM1Q;_M+;:=ZGRE]1MLV/_Q:PXR4,"OT'-T1,_]$T"AU;,.MBO'X>(MY2"\X"&-6['9'9LQ+2F:,_\Q)O1UY?E&\\QP+!]15%^S M/"MY>WD*& UC[+K(#M,0^7;$Q/X=ABB@?A 3AZDFG)U9 M7V='#[!%S8BBWMYC&DW8;J()Q^@V 5US.?NO*>V.8===0S?3?GT2.#:#;_(< MLX(0LQ@]W# CF8_29VS8_URY]COPC/S.HS]?]9+5O6[Y(Q MJ^,,F$X(19[;D1NF@0>PH7WR[F'B"/]8)[PAEF21%2IV^ "N)\0F6IO;,O0 M5-/-?'NW-R^^:n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l[__\7N8COXXF7[^ ME5,J?KWY[3]<__KW)[__NUC\-KI?,;KXZ>VOSH.K?A$?RW[!S_?OSN,7N/1D M.)[-_3B6%)R&?YHMOOEN$OU\(?47Z? KEV=\H7Y&;7R/E6X1Q(M@?O_2' [M M7WJY92F.Z60$9Y[_*?]^.CMY\,I+U(Y/?XR3RU_+CW]]/4$X(*&+/YS_^I_M_L-L>/EU!#??^S*% ,.<_7/!X|"9%H]0)6E!W?R__\-> [MWZ=P@RALN#R"7[C M-N_+6]:E +[/89Q@R=/-\T>3^,"714D6BD]N_'/D H\5W!PF&@\53C\)L/O5Q M/O#:.)1U2ZGL1O?-BKO WQU$QFFVS!' SXB,.A+O$Q %^#GCCAF?]R+[M_ML>4GU?FT?3^,MDFF"*)N/F=7X:GVCV(5BO?^/7KWZ*#R+QRW"4;OXZ3R>7 M-70UGU20W%(M2.X??D&N,TRGD-XMM?(L8 M#B?I>)S>X.8[$,$;]CB0+'DBN"4FXD$C/XAH; [P.7-DJ@'CPVHW@(-[P^ZR M; 0,%U;_G@V+X*\|:015,@E/O L*>>">,.^"& >?U&4+&M0Z6&,)L R5%* M](+9|3_OAF-@ X'^D)94$*L :;*31O>96@(N2Y.!% N\ D!6O'HC<+C6P;&O M3%L"QFO\|'1Z,?E|/(B0N94Z$ RHT0!FQ+,G5F'$K;E)22:M=3U8W+U\LZ,K M^I,@8D>!MH2)Q=9X.OTXG7P;CB,Z5#%R*F5$H^<-&KW@B;4|$L.55%$DP7T-MUW3UVS=+1\,GF[5$VQ)$/DYF&_D)D#518'.B M-E,3*EJ.!^_>#!X-'WA6$FO/\A6[W@*?D$WF)114E)SKZ^&4ROCF|'+@85D M4.):(M_(-;"'1"+F]!*#%9KO=WS]X'6;*;[A8\O=A=? (HC_^'K_X\6=8G+?2 MZ)443)+ &:)694\7TV+N)89 MN)\U;'5;! 4#QL)HE'2207"CT8K1'7$#"\D=$]L13N@FP"!^>7?C1Z=34;CF$V&Z24A3+,$$]Y0/)(^@)CN13 M0:5CX+RI@(,'+]T,/\V?-NXNR"9P<'P)T\^XY?TVG?P^__)ZC4O-S=*9#U(7&7.$,V0C".2>O224TK(5PFQ 'RD50*0-31L!P&.M3R7,$ZEN,B#-8*2;%S)O&5. FA!M%?1!9TR MA_V.*Q^\,C.P-'Q6N;OPVC 62/G4CTI&",[_.P8L,R$HM(0E'3%YQCTN$E^N MF0 D"M8#UQ&2OO1>3<,'E_L+L^]\Y3)$?Cn<13_Z, +3FRL%&!?E(%0@ MD4>T7R9H@EC.Z AQIV.R)KL|!Y@']^;-,-'P0685D39R2^..B;?XG=G BPQ@M%;I^A7]DKT4?67&B;71%5DP&M1AD;.M-\3Q#!)^.IN,AJG?WI;D8^>_]UL*B4*U YS6^'8WSK$/$R65[XNH5A9"SR9"4!SO21C&N$88K$ MZ! R"(D 6I=ZS'X6%@8Y?NER.<)H/KOYSMVZW(;N7II)+10+/"'1+FR8*6CA#F!?A>/F:9N,/.(D'ZALX]F5X)D'S$W@)77 M? O;E:)S*/\? [3%@E|&Q<6 M8V@L DZZUT0#$WOOIWV'NPPBN*UR&<",T@8W__'$IEUD?B@\;M'DIW*2X!8P_@,O$(T:T+RG?:VM;0TT^+ MC>Y>Q<53$WV#>=H/P-J9Y,?R +@Z!]1.8Y"H=B2!@_*$RLRNHA&RI!]3EZOJSC: M!3?WW]|/WXVN<+*S;!O Q<T9,*:.3IH0.AI5[X-P9 MXX2+J38N|K^_GTX%B9|FV@XOC|U_+T0?Z9]?S+S:]([*-!XH&7TR\'7C& MK90AU#-H$CWC,5DF6%Q7EK0'7-.1U4|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|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

Q_ABK>B6[^SW@GU-I'0I[8,S$K.!M8["EE0XF5I*;FC)99) M32 (!YK3Q*HI[5RL)Z>=PJU.53VK+OT$07YB?7/)92 MO!&<#'"%PYB+Q29;K; $-N\!% X$&F< (16I? O]F)T'ZO'G;A0'6OKY\-E -! MJ52E'S-(E*3$<)3XR"TN;I=B5,!E]4SU5@3VFS$Z &#V@>A6VFL7FM?6?\7M M.!F8+9/?;$EO2%&Z^7#CB$TQ@ R6.58[W;0EB?VFH)]!9Q4--@#0%VXU? 9Q. MTE63E HHS\0%1F@12/8^M@4N4Z>H>YT:$;0;_G^'I>9'V%_*37OA]TLBH'EMW>_E[SND-< M^4V_]M+98@ M7O1B?=(Z[&ZT(HVQE/83:4HJU!>;((DAWB"YYJA^UB[">66)-;- /1BM-5A(MI$Q)\)3]<>F^C%D&OLXR%XIF7],XON>>]J M>_/|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{!B=C+^AT"=3W#0&1D=PR7OB9&G"2B,G M3L1 =-#4!.9C_4*,M02U=I7P0$#;526-(NS:;B^RH0/)I6", M$L8(ROA"(^_M44YDX!DYRAY=WT-MJ0N*6KLF>-BM=\NE-_JRA2_P 5WF15OT^>) !D#D,I+ M3:PMZ4Z++- JL!0$'(63!4H#N#=I*TEJ!'G@@V.VOIG9SLITSDC M0}J5SOH7,/,(V0@<C>C^,Z",(E+@-R$TVR!QR0X(4R"%*CPEM//>U;,@99:U= M#.P$@ATHJ1T$/N^C(MM+!U4'Y(Q.PKE"|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`6!H:=)SPZT MU*;1>7]T]N_%T>OWAV??/CK\?G%>_2CSH]?XY]=G!R?[V*+7GAB!1.U#R8GBY^4*8XR:U'(Y]5\]^"SQ?$N!"!6)*RT@IHR!6J$AH3BSZ;(27]1O. M;4K=_AT,;M]T,KY^UUUU-Y.WCM-KE,]:2V!3GW1C%*F$31-M++;O(*5!(3+!L.16BOI=AKKAI>_&3T/.d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{\]_Z[5A8F1VX<1@;(L$Z,2%O" ^T],2Y9ZW14 M4M=V^3>EK5\35AT[]YH\5%=1FS:K%#/NYG-=_V6-.H 5-%0R- (L&CG>@*!<[MN4B46%TBIDQI*=/-1"6#VXNP(IC:%3@/*=C7>+PKPYW@=N3G\N'W!YYJ3XV/ MQ 6+H#>>$HPR'(F262^5"19]^S[K*>K74.RA_<BFQR<2L TRT @ ME3GDOAKB)5@2##>)9^5PZV@Z!U>..*?P!<;SX3=8DG>4K,\=Z 63NOR',*Z! MR&@YP>4$)#C<:;-+&FCM05#\RPU%1/VBI.V*TC7 M_NID7${@\ =?S)S,_^FTZN? IZKSLY%PKU&8GG&+Y*C@%R4!U&X--CK, G':0 M<-Z"Q HI^7M/O>V$NYJ*E7W$HLT\H$}?:EN(3 X#!RL3$5H)9:.7R?=0Y,7 MS?TGY;O"X(L:6]'KI\N-D- "PG[;L8O'6/ZZ9!YVIJFVK4F7C*$;0B MEODR\P,],^?0\\;M4>126^M<[9+*)AIUOO*SX>PT7]^=PH6UT-6/Y<=[7H(V M.F:0)'M6O*-*(WX]2&:6:N^<8]QVWY;-*/MG:*JY#?8>F\<.]-? ((4A/L] MCJ:3.7X:EU);S1\:\UBF!V(${DO)!&-HY!GZQIGI3+456M2?O[T=C?U.R.P? MJ9WJM`.?IP.)\]E=(8SB",_FPWS,"YEG/[[:MDY[0W.XG2X&&.[<,$D'@(E M7&ODSY9+9<%9(B63T3,*OE+]X9G;T=CO3,W^_A=N3AO [+_M=3Q^OR"_L38(Z M0B-N(#('32P5AF2C P/C56"UG;3M*.QWM<+_`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``2]QUVIV4HIPK6)B#91DFDD+RT MP^($5YV/F6>)&WAG9S-/R/F9YG5L@YKG3U[VTI@##8<0=*Y^^X^$<7EA,V9QMP=Z#8FL]\@H \P=]/!ID!Z@KM+ MWIA-BT%\Z?%%/ 971#JB#-.D""XS!Q*\-7G/>U(:K^%@7Y M3M--@#8>ZOV%'RG5_7;AQ_+TTP^:?99G8SOZO(<9891ZI"HL&!(UY=TGA&$.D?&HS/:)1U!I9J8 MS:EK=U37-GA9DPJNJ9TV+=%S-P8+;.(Q@+UH7;UWH$F\GR8C$LV!%7U_$]P"O=>XQ11G)9)5#:4.764 M1)>R5$;+H#H9RL,!;]DO)@93Z>]^FA[7M$]AM&&6.%H.;V3&'1SP2YN4E$Y(ZU5WQV]$MM4 M@[%M,/.\A]6ENAHXNKAC]&\]P_/QE#NGH&TS]9_AP=1E@>IH7(SH>FV]CF0.) M^X'@@*:.:14TPSG:()*U)2^"K-U)c>?#-!Q=S8??M[E6WG\OW6L@+2\:7'Z]NKGV=.RG8UR4LX]^7LW:VRN_%.]ZE8^C)?ETW'(JY M7-Z/3XVl*6._%$E>AI+5CL1K(XC)6@@:,W>Y=CG8_E3WW]3M0"A]WJP>1.$[MFU"T6,*DNJ^PFNN^XZ#!L<('P",PEH66N?C^R,@O}>LP-KX4NH=!4!'G+.*$R_#2.L MEL;1:/'(ZPOEL'G>T1CV|TX.Y'M748H6XT HDIYS1U0]V#,;,6I#HZ4V!3KD%ALXS8W/RJR?"P] M& 1RQ",)D3LBI5+$EEI4%L," NWMF!S'XCKD/"LAO%M>D;;C@W;J*.MX2U>-<+A)>

Scanned with CamScanner

{C&\NKQ;! MW*+V.\6PMG>3V9/]+^ A<%6ZP87%D!-/O&296*\U9R@5FVI7^.Q)I.}/ K1BZ\@;F?CBJ-2'FYFG=#(A926M3\V$<%TFJ8!"4%(BT-)! M!27,)\N BVO%[6BOB?DP-^4YMZ-QS^'SX@4#DW29WA0(%S&A5Q-BL<%XXKRD-MD$U(4+W=\;/$_#-,@=D&84]F:U314INF[;IY\(V-G^2+'3K'U^U3PX\+)-J/ M4_CQZ?P;DG$U*W[M)/]M,AVE/4Q@A;?*

*6;YQ9VBPX)**3U>A,,$Y\=$"$`1^E "9D;,;7T?-S M]%;>!BO;I%;>2AL]GJS,IO/27"A=Q?GH|#JK<_1],!NXR)*3DD)H'262:.VOYOAY"D!_8"ECDZ? F1/ ?>(MDN++#/X"BX$K?OKC-3J<,+UQP#=PO=0_,0!!4\&UL]6LOKB:I-E=R&XPS=0Y,= -MN1\4)ZY>?DWO@-A7A'.!-HW-TZN+B=3E% >CNX8,#E@?&5,!,AQ:(CD ML?@-8B7-T4#(P?&-$+'JZ?*

*UD>CH"PM[BZUO_&)&./481#Q&8 M?)[ZKU^&T8^6KA,H)P62GAC%/8R5NZ"''!0)1RTRUXN*Q+=C)DWR6@-X+P>N'*

M'76$W3=BEH>*]UFX7D;12N!;9Y{US>ALXP<7,SK;WCG)0@2C:\2HSQ+0GZM9 M2;&3VE+N$2]+&<_3'X-/YP,69#+H Q-(I?H:I$-S] !CLJAQR5B&4=@:7,P@ M_O'SY-NOUT]

<0N/ZBSMDW+V1D4=ID+PDV4!?T83+'-+,7Nl2MST(20\O> MFC40S\"2E !0OJ;.UZGWNOIR_HJ(N%?27; "B>V5'?#<=+P@L9S-@#F0DI, M$)f8P5TU4>+<-*

"1TEF5AF^=NG$2S3U?@&GK@_2B2H:@-8+V87E?;PR3V<1;[@Y^6!/TWV#\U_>11]?+-ZZD\=!+96*J,|*<' R61GTQ)7|WW+PMZ$P)S$D2:=!?"+G4@VO.M7=)*

M\^I=#E=3\L DCK? QXMSZK?!?0 .,X!,N7BTJ0O91|)2,>LHT"4]AG58^$,.^M M+!V]3>&8^N@M;$&I6= ZK=9GVX7TAV/"US:V#9V7NJ(-B>8?'\ M7\)Y?L##];11-

(-4$5<+I>@".$!GP"I&LG$^2@M"IAJIL&<)Z"\'LJ]&)[7% MVW>9Q7M(PXABN[9Z40(5FIP|^45SQ)\;G*.MKZ2E21V1M>]./ T-7L$X?KGTT[\OXP,G&1C&< %@5"!92B3H%(A0"|*

*(WNGJ MXRI!+2=A0>+=E= Dj&ZXN5ELEAE>5I5(B*17CMH80X&X/"[>>NU(58ZHZ]>'7'2C'9%<2>)PD1)J3,I&9FE< M|>NO&Q'6&M#VP<)%)<2=*

VH[BHK9E=@81AM^*K;_9Z3WUM+1H%"QQ7)).M$!\<)=]ZI(YGE7M|A'/T=)8F%434U7$WP",G@C1+C'-,;S@47I\@\0%X.T@ M(88RFXXQBMX$9]4O7SY/3;^-*

@_A7.TF^#8@]#2G6:COEXV$!E^@]=^'K|\ M^GJ4_AM_7LY++R;71OGU%S_^#"?CX]E|>.GG& 5=3/UXAH]#L7R<#B,,E"]M MF+DA-*

*D!)!11)\.KR(9Y8*ZYB*MG;;NF.6&MMK=T3>4T W X.^SRM.QG$*?@90 M8/DO,G8]MJ3TS+B7+@2906MI9$]AB1 A1Q+*#@0|HSB=@9PV@G@ ML7:I7@=L-*

;'$TH#AK#N%A#OOP[G?E1Z:M^P4+I[_S;%53S(/D5IM2=6V'*S M##]XSG@Y^E9)A42%V.@Z_C;074-/8YYH)0S64D +8'HL(MP'RC?\9V"#2-'R M6YE*=W9-I)2-U[;V.*-*

UI&P$)O6S@:F6 MILH_7^Z.S?CR^. M7KTI(/OGPU^/SB]}F_OSX-?Y9F>M=HRYYRS=4%?>AZ=*5U_;@*R?QIAO M@Y\GUSDK]Z>%,&CE,*

*()%VEY+Z0)PB3M2F=R<;;D^32,Z^S0G;PV$5'MH^_/4 M\'P_LJBGT365,30)Y>&G.Q^KO7:5%(*?"D.'I=9&$8 11(2?K8]:. M5[\(=C=:I*4&T\M2WW'+-T#H1+UPF63#*

M#9'!.)YL'1E6_K|:C1@M3VOE80TXLP?! N3VHH %VWA'^ ^,)% ;NA#\1 MY'@CA<'''9I$]E6K? M3_BI$KV'A!M=-@2,C?++*%W;DT HEV96VPII2H6MQL9*E=M2YPPA7325D0-*

M4> MF+6&G$9P5A\$&V2#=]%(H^"Z26Q[RY7@T9!89B=+2TMG#AZ(\3;]J'5RLG85 M\;ZE!MV?&O4"KETTTBBXQ#4K@2FN7'2$N2#1W)?IW%Q$PK6RUH&STG=6)OJ4

MG$;.?'H!URX.=1<33'E3#$5JAAN1FR4CM 0#:XL ''U!$IV_ M2^3Q<^YK@=F SB.VHD;Z+8H|AYL;C^'D[$SSSA3'<7,K$9D^)3MX*3:V7C|N-M/5,9L_8U3;)E5WU..A%N*

*Y;HN:;WP(-5,5&B7&E.(3]00-N"8@$"])-BE6O M&MVYCBD7WGE;_9V85M-0 V*IV'1<\Q*R<(LG36"Y!1>(%4X0E 5%RZGFL? 6 MN8#(049*H?9?X|64_|--M|@*&8^G@>ROI@;*

MGY&!X60/#.49 ^62 V.*XU M 1V83EH"X[7G6^P_6.7G&'2Q#_3]*6UG!'Z#;9AT.5I%,,.Y,;%(!8@,&KV; MS!,Q0@2%THK*U=Z2=QZMTIG'V SB]E91$T"KX8"_NZUU2U(I# ^AU*

{"EYYY+ MR+XU!#UP;]}!X>3.-@_!-!OBY1&@!'>$-' WK_D>55;?,>(()\=E;15@.PNR? E=Q(G:(3FB!;FAB:><%&75L\;>>HI_.U(@!7UUD[LC5W(ESRCG('A+|02$5%1G(*

M.G$^,PX6W>GN]O?=K]TT?7)9!X25]%6M4>@A[P*_N+'GV$XOE?__DS^H+O; M -O3T/U]@#WE_?'20&P'KS[+SZ?-1^=O9HPIS>V9;W@:/FC'/DFC-5DL$1_2OG@0#C0J!8#B?

I?.ZG\UX7T3.2/V]2[_EDW$<7>%F?S(^]M,Q M_MILH'++WB85 %$LHGHCBL28R$B5/0J5(C.B=Y#@8" ,,9<-("A8ED4J[:@F26)T-4U(;=#?:.7FOWN&DD)O_?L+AV*

MQ5"#!TU=6G0^3+8OIY<(H]? &/>;_@XC!AX#A-$$0B'"PEDDE6CEL4_?M(3NM_PY+L"($_)ZWW@M/3*NL*"6:E>M3)F3BLM4D..*N*

M]R9'WMEMR8/';^K_7V+](&?/^.UXG+HZW/YX=OKQ^.SBOSZ^,_IP8[W&J7>_E%8ZS.Y)$ MI7/L!^\]NO?>N[&3$+@#,"0+:8BTZ(JY[#QOV6DJ Q.-U;X]^2)1^]K\NX&(

MS[Y]66W"G,B6H5' 9^!>II)&YKDAAH.C!]0VMC;SF]+6|\E:7=P\MJR=Z$1W/2OB@$6B(P4-@X'5U.IO/A/Q;??Y;Y@4^: M1QDJ;O<*]X*D)0DB6@+&./1==1*ZMMM5B_9&-*

*JHZ<.U^P?OF1KNOFLA[@A#1 MV>B9)LF:@-Q(0R$1+CTW#M01N#'30B/?WE_M>9&VW@\OON/O M7V$\VV<_^=[O(P\BN85.^#Y9B4$8*Z;DBB6&T(6/P)"B-*

*@49IQIM!6E^]9[*S M%,-](0\2+A]-RJP[HWS)Z442,#:$0[(*P'\;]]RN__^1IV_G?3_V)+M+."3))6HD M*"?$^V^",\>@+3- DT&8R/DV[DD4!9,.9HRI;9VH/I/D^#< C<()SBWT4\#*

ML>LFB1,J4F ^:W0[,6^1263B ;^,^&T6O,L0:@^(^^=)<&Z%AQT2G-LHIV6\ MW3L2ES(%[5PHU5T8)6NKB9,AD> %8' #.H;:(S/^*1<6T%AAP3G-GII &KK M$FOHL680Z+:*1$N?=*

*'$:99)$"$RP:QCLGH7BY\YP;F5ZK=(<&ZCAP8@M<$A M3_;>FBPUH5"N/V3)B$V6$LHT8HB?4C*F;[__@9(:J(X;)+8 N13]>"R92=V M#!\"$8% A$TA-*

*WSSBDM)$[.E;]KW(^1^W8@,L9OHZ8BVTQV_G9]__?G+U]. MOG[\G/,#OWW^\.7LY/+R[*7'C^E@=&HGD_0<<.=OXW'X.S <'I$/-M*4M @81)CQ(IE%%Y^*

*9@_W.N5;\9@+\%=M IZ;C;Q&"5,)7)%*S"'.<[\^*R2R M7)%'$!!?<)PS_5WH(Z%X$'FM6'S[V_%$)CD):F7MO:@WI$IN$-.4,>9N<'M8R*

*M@4M/LUI#1ETSV1]*5BWFL1HHX&Q^8.%;N$BIYQA%F_M).R61"Q\%BL"#Y& MM2_J8OKAVVW Y6 E;@#%7A)MIAW&_ 40XMC!9.Y6_1 MQ?/'AZ>\UY%%H9('WF+N)*

(H%R,O!D&2YY80H(:QF/<%I-W5\URR_Z@EAAK;1T M='&LC\:[2MQ[@)@0,KG0/;Z^C]K0] ,T?7(A)M!R7PEH"F MQ(7V/LOW&YZ]R77V?FZUSH66_APBP0?*

*I['"'I#LK*ZWZU?*N@(MK&U?+]2\&>TP9C1'"$>)1BB;0&'R\Q M(@,,2@-,;X>L%NZBBT*@.[P.T$<; //S;M=W,9S_6#:ZGB[8A)^D# ->7=AB7 MUZ&:2F^5YN!V1I"^9F%W"#1>*

*Z\?/36 P46? MKTM0U?SR_8.=V1&/E]|CS/=A)RS,,K-V^*SU|(?!%^)>MA$;C&[6RVF^]RTE MFIL<"%L&X8_!&AF-'8I&6D7@?]&7SJ*_#6=ULF>]'^4-PJ*!S;(7@U_M[4.)*

*M#':,41P"BD7+U"P"98FB:R>MY0(;C2Z#^0U+IFO$74,?-'>II) [.GQ9Z_P M_@:?/'B'[@$VOT*D.J+ O,_%"0ZY* 7RU L;M#=\|:WIAO#|U=(-.^0U!;7-< M3+0-F_[7V<

*L97*8H/|[_;_OI/YN[?HJN.3=HFG!"E)M=L\8"<'VL;>$V//=JFD)F"B!,(@-,1E O:PP$AP M%|U1F.18? S8?B16'__>#U2Z0.)HO34 RX_Q9QR.?^2+7_]|-!Z,;^XO!C?? M'PN9)>$NLA*

*052DBC@-'U@D+!C]99ZT/U19^$;N#I&9A=SP<7KTH+:>;!J!V M$7_D7A*CFS] A(N''=(Y[HE"40 M*=>.]KY]MY-;Z\0I84FNH*

MZP2(#A^K,ZF@MQ.E%QDW.<,!L+;$O<.2=P$)BG6>;JZ0UAR#G#3UOE';>EW M;D>4MK[U/?N!VNY6Y[]/Z!L"T#750"")#MGLC'.O,3(/1";9TMZ-H]|>:S!(>AXX^1-R*

+7GATSUGZWK&TS^?1V=\^3J?GZ>53 MNVL6/;>!^2E!%YE47P_$ MZC\?T"(QI5) 5LF@C%,=5%(HXMP.!#QA9 2ER DNE(_:*E[ZZ"U=T5#G6<%>F#BBHF$?!;6- MO;57H<*

!39QQA#E6X#5 1. ^2P4@9$I6@(AA1,K/VRU8T[65(RL:]M%,[#<.M?6ON G:6(BISCV>C#@*$;N2C|#)B0K0JWP+|%ZHIV L,>UD=_#71I7$G;K1>"QT!S=B|P+/"'"2?

$YA1EV^S6PGPNKVSA+ MV)774^T\!VN.ODW&,;>TGK4@H@TBY2KQW-4H*0(+$W@T##O) T^D-0IA-CO MNW5;9[P%POI61@M&[FXZ&[_&R45<[>9?A_\>++#?)L&^,,8C\#I

*9)$[H(_ MN3T-_)44W!2?2KV%G+K=-]{4H!7220/PNIK8$&_MY-^/|$<.&\!H%$+DB#LF MD%9&@(N:Y8<(9{(L?EZLTU$G[U@#24=*O?0AN3HPKG+"422+ALDB25\AQ\"B=*

MCC$99ATOW3IN'%?D4^?IV'"IBH+R,."F;-E!BT&,B4@A @3-/C'"",.UO^IG# MR"8XB),+RM+2W0UWT50Q_U5(|!W3#/LKH6U0/9NC^'Q>XK6 XS81;?(+38$X MR$WIA)+

*(4'#S).%,%2\,VI_*BL:LS8%70E'M=%CGLA-4"1RAJB7N2EW M1/$Y&F&3<>"2PTE'2A>&;*>H8CG2FR-M7P6T.;ZRTf?QHO+JY8Y.3G-,X\E; M7Z(?1LU;7:$7D%65"WCB(IL"*A1B9/F-*

"4,.P@3D2'!,@;_ZZN1^)LT3W^N MC]=^[,6.VG "1D(2 ^>+#H3';|XHHXT9):AVEI>L/ME/TGN[JJ\'.JPG5Y?32 M9B'2R>GIQ1]G'!|\/OGP^<@HM6Y,,&VR%"D.+LY L^/&.>Y*

*M/(#DP+K|<# ;O.FB.?/L6CC+ _,&214QXB&*W)4K(,,XUR =^I*/WO<253E MT3>%T+%];LK]HH&@|P+0,?*NW9*%8ZMNU%XX "DLQS\|, +E=89 A(!^ ,O(">D\[Q9*

M30+C4F'/4MAU2G7Y4-V;P]+H"[;!BS+A[LIQ-#3Z>GXU@U&<]6]O8%\)*R+T!^'P![^]FKHP5B)/49.2H6(U%Y;*90M/J]^ M$RV= "3?&X"*2+ZV/S6?$7P5){=+*

{!N4T..9[(&2sELY5Y$$$$_X,*8@)"8 MJ9H&%G"W/B7;O|,(;JJ *2T8!NP.N>$%=2QV[8W&RM)4K@ Z_=>1!23!L2KZ, K M|& X8S(A!(@L"AL:[93U E0^KT]@GK?<4@R[PU)963?*

YIW@E_.OOUV=7?S^|>S#U1&YZG7+%,A2[Z2N M4'[Z8W2S-7<=(@C+' 64")OR^%B,=[%M(DK'(PB>+77=(")>LH.?X5C9M|*

*M'N4)X$]C[(46*40E@2_%X5!UP)R'DY5BGHPSQ*OB55-KR*C<=/MXO,]^%'.< MJ!LX:TYS5_#9) ^OGF8+Y"S5!A+%*><19OIK3+B"M@@(!4>NC-9+YTO'1:RK] M8^4HQ:Y6?*

*1\GY>9PLJQ?))08B1L%D4U^>4T@-1J"(R)8@TG*K29F4=*76Q M@Q$80YCK[&50 M2D3I_-U6@E]'SR'Z?M7-J)3P&T#22T,\WUQ$;.Q2)$@RG1O7RC",=!HI'UPB*

*MA#+!BD^_>T5%W3O0TL?3D5)N#B?/N!AC80'4&!'31X@P)E5B(=(Q.W@L7 M^O5\6^E1<*R.MT+F0(7SO&>?/BR8AZ%H,"V-"A"0(\XA C>1C#!TN97Q8%9*

*MZ59:#&Q(Z[Y;NB7M'ZJN<3'9-6 ROHQ'-I#;,1;-%?PWB^X>,,S@> MP[S-,E,(I$2](OA87KK%Q#HZZA91E#Y>CI9T@VAYG,A%-,%YC!:WX.E;#RY; M3C1+,*841ZD%*YTU6D])7?-*

RO(9W0.8 <;< FL$HGJ>%'IXTD@1<>$LA%@2'>#H3';!XHHXT9):AVEI>L/ME/TGN[JJ\' JPG5Y?32 M9B'2R>GIQ1]G'!|\/OGP^<@HM6Y,,&VR%"D.+LY L^/&.>Y

*!'9S:FKO2CNLJ#74+J$J?0D=)N#&$//0/P)*S MB!VX,+F'Z_P=KN,4.2Z(-LHS*4N_$WQ-15UC^QK_^-9[\ M^U;,%8##9>W-!SOZ=^9G:1:Y]TG-.PU+,;I>MDJCS.?*

3P0@FLW0Y3l,E65XE[K4'-M<4G^%XW=+&8$Z2B]RRW.0\"%;4Q'TNKFX K!JT]UU+9'}Q\N/@W'XP?2G3$F M.0KQ0,2Y5[Z72%,&#IXP1&'E,*

*FJD^EYN6[=6+FDE3E"7A55/9W.KB_LZ&9Q M_%+L.0)8((5-SBFFA Q>:9M!QK3XGM5XGUF*N\!/3V;BQ0?KEF"7\E$/-MEV$+BE_B56EAC&/Y\0NAP#@#!QGG"^6HI$/"^. F=O-*

*$NJJ_I8!RAK%5U'R'Y MR@K_?3 :W-[=+@G7#B+L0(?QI;DXVPZ,'H7 '4?*J6-8Z6XS07:H_,5'*RO] M$)6-2\BOMN+MW\\|*

*(M\8;"\A'3!&-,/'9#=$)88G!":8GT(LD5$G(\>;"73A@0G'!*16HA8DT,PD;8(C]N_Q@^9#)<2EG"0$IN?DR;/D,$6(V53U,Z%D.SAX'C\ M3,4>B6\%CL-$VD *\N4!^^6QL1\C@2AC!4I. <:U!*

*<%X9\!7XA(+XVG I7N3 M;R"E[O/+?LO\#I-W |#Y\%NRR|$$;>%=?QV\M@N^=-'+$E^WOOV=-'+$E^WOOC@%N63&Q@#HI!E8N85.^#Y9B4$8*Z;DBB6&T(6/P)"B-*

MELJ3CX/5&XB^49.V?'?Z>M/8P#0SVB-N7'8!)466"HHBAA^:G)_HH7]%=_I. MJEWLSZ05T4X+R!N/;JZ6Q5C7X)/.1-'1'N<&P2!_QBD0,HH*8A+*ND^JAD?*

MOM]2O5$AY!PJW0.0\)7'YV<5-=#P=3Q>]L6U^%PNL(\Z5 8 'D$=T D6;C&'; M$4=*%P1L(*6EN![\R>"DA\Q;]$+EL!PE-^-9M,+ MZ./@9PYSO@WOIJ=Q,H-8^=1.O_\C#L,U)IC0?

*;>14D@"&*0)M2C)+$#]5)€ MB3[8FRI 8$O)ZIY\KK=68_-0?F#]D3L9C(F,&N2=TQ"C2Q WD0%%AP&$AH&5 M+P32U4"WE*IX"_@=)?IW!:S3\7*

*8_7Q8'.RYP3A<*YL(<$j04%"'5!D!5AG/ MU0=:&T.(C[@\RE[14;>75%W(';>4)MR|Y^(#]@;32Z#%AO/1\R0SN39WC54 M(*+R$(`0\W =*

*@9;8*D)UTF'TCW,N]}6MP55/PY@#UJ|;>U>,C4O<5PZ#_8F M7CNL6'"*(T)T=@ALKIWR'GBC+!>8:](OV.V!3/=$]WX/6"EL$P;L$7K+,\? MH[M!#]IE=/O[>U@-*

*F,"LV9IM(@X1/.=R($N> 9PCY?D\KD#2X]BUU5I N)S;6..;7Y8;M\?@4=">6. ^3@"/_@"-R^U>[>A=)/+[E7B; M4#KY:0?#Y0" E[R11+4FSJ'(&9A>Q< YT)*B8#3Q2DE-.Q;>*

|/GA;H/Z%_GI MWN7>]J0^:#ZG&D_V[G=SD&0P?N#,.*4UA|"75.OVD7D6J\";HB3+D6"I3L" M41L^VP/R+_W#,&W"@UGF*+WS#Q5ZY%HIAS]9N4\BXH3D+$I(""NB\VL(*

M@5GI;$-'TKK|{5TD^/M4RGO VK,X1,'YCJ7-(RGF(RXC1D9HBX2*?MG '*>E MNPGN05XWS+V+K'|?RJE|8NID;_7R+,:>,HTS!^%SP%BQ%,F K! I]_F$'S-K MDST\D;_KZ[W],

[S]T4UT"+$YEW-8{)WPQ>>YQ6@9?I|/ S7 0PU-VG>3 F\ M Y+R*!5OP793%:R10OINL>,A7^\&L7>1H7\;#=2&V$N)(6+MR52?IV6-[].& M6_H.1A/(6@&\YU;&;L ?]I(*ADOJ+!4!XK]*

*:%! =*Z%[21]:1T5&@=B*TR45*9=+=&K_M|MQOFWL4=0-]2;W/| M^_G5/\XN?D\/>\NH?NF_QW WC,,TGT?U4/C(;(0$1-WCO]H@?D\A3DO.,UG M\SO7&Z?=Z,PN7\FN&?*

\>"8MUH8CH1SP8QZ0&VDN# M@@-#FEQ4Q)2NU=A%4]V73SV?:T45T@K UG/"I9',$U_FQ#LE-QWE /$!\ MHIY373)9^:,Z9FKK/H]X"5,+0(M4 @>?8@413-_6X=Q\]'..41

*5B$R/K>KN4CPQ/OIV[OAG86P_QC$%;_KY' MB"-^YE?RX]OX93R=+M}8{IE='G>C\S=[&1D(_%!D*8A)B.#<*+T]><^]#4? M]^V#H#6CIOM15.5.D5] 6#>+,-9.%TU2/40A2AB%M-*

4$\<1S81TVR#M@16QG6>UBWS!Y;H ZD_#XV+B;@LS\:$.QXI0CPH@"E2>RYRE8TF"766< M7>T=5P RM>W\31#!;_H3U!$;_SWV.?\+6&4W_>5:[7

MA+.;$9=@0T0)H5BB[UW#A-E2.HNBH ZZWD*\?-!5105NH6FR0SI/I'6P.M]IRQ23(D\E4"CYXBQ^%W$6/"L.7.%)^"NX&4NG-'^[1%\XBZ1<0\/Y$35I$1 M.

(SS.SF0CP.W3G&&,5..Z*XE*5CMFWTU'!T:VB=V#A7ZP0#Z&2=N7#>)]-2) M\9DX%IL()/%,(CTGF?:FXXV24,?)IY\DE<^Y32$52KGC$16\$ M-62U WQC2.K/(S^)=AH_QL7_?UZ(-;*

<8!H,Z'~-,%>#€\-)[OZTHNPYI$F07 . M0E2.21@R&O9FI'{$88BSO5!1F>$!ZFTIC|8./5:/8IVI;/&B7_D)/# .(HHCZ M_#;=:H\T\0%9OWN%H6G+-->D-2K^KOZ+OMHXN#(?*

5CWEP:@HW)K'\/3I$(.MD:IVB(4(4B*:{JU$0%0HPCF<#\++WGHC8XU&K+3E:%6:J4ZSA9//YZ6ZP/[6AZ M33SC$AN"IF?%O*."BL38LI%*1C!ONLS\E[HJYMZ?0NXMJ+K, M&PKQ6"*

(2Z0 "QA$3'[6*$!=V 8\YH'O+X[9P0. ^CBR,-Y]DHO,'Q+)352A%$ M F%Y++")#&N$37_.MZCA]C/Q;>[O/YY,QPGL_\"#=#X.AG>S&,[L)-=Y3A_2Y+GNZFY!|S@RI3*

M_.9YG7YEWD\&)@4B=$"'9VIB.0$KJOPV19S1H+VWO#2 479#-#'2:!.OE7 M5F N_FM&+ E2:I18+AATX*YK@0UB205!C0#TEFZ6M1>!365_]L'&JD'N3RT% M<^2%4;?=3S:*

I#M9CHBQ&(@_@YII$0<'A I#X%RPF)C!0?^'H@ MJ4W5/15'8F%5-1#N;-APFQB]EE:DF%_N"F?R&UZJD&,X(A*59Y$IV7!PY[%HMA4H50/MK"(;MH<(;"?W_1M#)]-

;&"":.?!G]W63>5/_L;S^\ M V%|@OW_S _,3ZON^7(F^3$\@?5GB@\$UPZCBQL5Z0,4R1%,80I'> 7(;PI MOW(?++UJ"/#F:FSS6<_<9GPXN3S+-N3;V=?+DZO/YU]+/.3IN'(!2W@(#X6L*

MV!,PC?-0$W#R;B#6*FH4 M.^AN{A:4PS^>=^$,.MCK@0I$<"L_PVQBEOD8[(@9\MGXC],1H\=B\'_UM*:S4FTTMW)MA)4L:=T>>6/(^!)$Y%B M%!JFRM%

*D$]$(*YDA%UG'8J$"XE3*Z; [AC+-S:C]>]D*GK_)712&N0^N=@ M]GT>O.4]^7WPXV!-IH-9O=+$^\334$KBX@$:?$9++)2&$0#5\R0$&W1]'1] M7[!M)ZO>R+D" -@&IX+:J.V!?*

1V/'NHX/PXFT<,.75K@!QS+(&?(,.OW$!N M&L,?805XJ+7H%PI'(>440 M-W#@:YX,4HE80{)BY1^G/_M\W;O>-C(;A\]C'2 M-Y9EP@8"U!+%26XWCI%C M3"-*

B1"0I&$)CZ;O\"%P34#?<.5N-Z.!P@TP8 L6$?S3<[*78;^>CN#2:Q%D:.M-00$%ENPPYIR!,$ 1@0G%Z+T1K'2-5%[D<-$F X!0;>TU-*

*$;>1=0N+%V^4^.S[==^LM>&H'ZR/AK#T.*K66!6Q M1@JI"&+0%0S\ + @CF,/!QRA+%[*T=.MWN"8W0.(I=9.%H\%0HP^OIO:4;B, M/T%H,;Y*;YR,8)N-IG?#F1W-*

%M5\GT<^%Z;^G#\.?KPYD$P9"'> QH0XBQ(9 M A)D2F%!8F*!K:3'-TW=*T93& @CF!!;C^CJJ#7*URT7V1.8&W,"M+(L41? U+XU.5!9J^H^O'*5%?[!8#2XO;M= M$IZ8!{3 Y0R@[C-

*10F:<11T-,J#<=/&%5#YBX]65OHA*AN7D%]MQ=N_GQ&. M%8M.Z(*BMF#DC.5PMF&'A*=|.1\(QIVJ)WD[W1#'_J&53>!V\^ZV\7Z1>UWD]]8Y]6AOXK5,GA-K M!6(B]*

*{^7,$%8Z36B4G@9'4\E)|-U LCE4O4&M@65:%1.Q==Q# L)+#L W.U MLˆ>V__9^>JUBL,PQAPB-I)MD&#*40OBI0 $:2&:FU>]E)-C7,[9/,RI>_=,:9 M8H|OXO#^{DY\#'|?*

+YNMX|//8C@L)3|RNZ'G?Y^?JW\=S_X59[EMXLTH M#_V:WT LWRA=*V^DE4PCHR*&PY-)E-^UH12BL"_X&&AI+ ^I-&*M\.U#W'&D/.M.@WLIX-ULN1W'G%-/X\6;N=OD_%T>FTI-*

*H81G;-Y((*H+-+4&"0@$C/6)(_ M25)M9J-RU]H!GZLB+-[SSGA(3YR$,_C_B1TN$Q5/ R959$(D!;RI8,%(Y$-7 M<68^\9G7]/Q<&)?&VDPD28B M[TR 8,T[!".6R'++A<V?!^6*&QAWS M7.(H W(@>\2QH\@$%Y'#ACO/1#*\F?-D'0.=]H3YSYXH#(4&]D%_0=GC2HO_ MZ'SV/4ZNOMO10Z &/F=T(K?^)'D>AY4<;<(8LE)A@UWB0G2]NFDBQM_!;+=[M1OR+;K#W@;%?>3,N;-.G\63YH_SOR+4C02^B_OSVL; M/9E%T@2V"4<2"XHX20ZYY#@*-A GM VA^&B?RCV9C\P//ALYL0CIKET240F2 M$)$T/R&!/>R"!DA%"(A@[.D5+AR?%F:A;S?6.]\-Q8A+(!+B0&99."FFJ&&(^0>CE4[*DF7+'_5BK M6_+UCO=.'!#Y!?;4.Y.R52P(>OO0%OB_O:43F{0DL(I6(&@Q6WF&.G'$2 M<>$% T0:34N;LU!E6I*A$'5Q)5 06B%N8T+.18N48]C@Y*3IU@-ZGY(@/].2 M]L1L?].2]E%__[1RR$JR5"C/T% M@JW3DO;12 -P.EQP6P:G.)Z$]RK/\(T"I&D\,AC^:#FW@04J52H]#:0//EJ: MEK07K-YB6M(^.FX Y]N'IB1LL<9!($E" F8HQ,@\Y@I>99,'WJ@LW;^VP?$U M[>!EKXDW^RBO 206N*UF$%%ID6>E$0+&0,*1Y?*L7V^QQ-XX&FCI.0+'4_VK MS-8YQE5X8]V_9]0_=%>$G7\WU\]fT=%C1<7%>#C\-) ID_^A:>8V%91d)/>& MT\"0%3GCJ1P'2$M";>E>JV_+8>.G0V'EMH^_8/I\966U\2X92T98HBP2GH MT 2.C/4)1<4QX4:G\F4@:\;<.]U@X&#PM]^.!#MX'WX8UY1=SFSDUGCN_'E MF\/KP"*V5(#FJ)"($XZ1M22!#DV(T4DA7>E)0&_%VSOMDO,K[<4CP/9+'XE_ MSO7W*!?K-;&"$R1-+LH5$-UJ+PT*CG*6A%&20!^_|RO5H[0GSZ^T"8\ V_Z; MT"PVX2C>Y#N^ M[+W3]D" TF8\#G*_^'Y<==VY%M@+;E$B(KON7"$3<[2O/>&,,A_\&\WE]A0I MMM=DZ%?:B\]?[;=3Y;E*LO<'QEPXXNXOO6E$]P%IK%'D> MNNX=Q.>1&42"H,8H1YU]A^G9G7S_\IG;_C9.@T9@+Q3_C\OZ[A9?[@ROK#/(M2Y\S=X/^C+$&?>/ZE'8&7R< .=I2%&%*> M)&A \|R YDV*%@F:[\X\!CM;>IAQ.\S_\KGK7\-0] (GG7]H0+!.1=X#JW5(S MD4$<*"UB).99.7E]C %249U<&.0RZM)/6+\/Y[\QOP7, &\[<7F7WO|Q%)> M)<<9HX@Y9?+8=8VT$!ZE#E*GG OL'5U%\X(O.<,_2^P]WM"<=`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|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}WU?UP__1OEKUV MY\P\<30*WX9VI*S*]JS.>R&Q;B.8M6!8?0G=HV8; -]9[8_A^#[&^8/0\WFS MZ)VF_*!NCAN_4[>C8Y_;7>WQN$O4#,=^"1GX#XS_[;&?ODQU,_K3#NP*]M6;-F)QTU4)BP61R5E?5R9]___N_9'$JGWTO4BJ7@[B"Y0BW<1_?AGG-R?IU??>@6&@W#?Z0-';-GE M]@^?.?ZV;NV"U2X;]M'/\]VZ32R5C6R.5I85SOD,./K6;MUZU?2U5>[C3D+X M'WV?VHMWTE4I_[E)_<]-ZE2Z^9I[*(]+*.7E2O4]#[.)>KR#\]8;.E3A[FLN= M[6NQ ^;5PM6,V]&>01S)5-'9YM>+E6M(OQ0;.T7167]/! TLL/[MZ6\:IMAQXZ+5JL./]+TWBJ>R]BYG__XV\>>3]^GD;#H;W-K%77.Y9S.=/E"M M=/Q0K>XCMLH;/K^;o8T? V4>9!4WIVE6KU9(?JLN=`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`0DMI<=NZU3S.0ZWK;AE5WXOCJ`;#DL\WUM=]UJ7E(/WW%I9 MU-?0B9_=V>`P_IL=A$**6K=ÐM7XHA^MKBV1[UU3E*W>@(IR'MS2E[9B%**G'=O?.BQ30 MY19AM6!*TDM;E WKERO,<@Q=G67H*K?^=P-9O=YM,E"E!#>W,!'=7T<)" F M K>EM+OGI^KU"3E0W8>)LG;8N&)F_IS.#Y'YW+?OXR\(^6)6*I+<[U/U6HP< MG+L[1)3-Z?]KG'T>~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|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end XML 95 mygn-20240930_htm.xml IDEA: XBRL DOCUMENT 0000899923 2024-01-012024-09-30 0000899923 2024-11-04 0000899923 2024-09-30 0000899923 2023-12-31 0000899923 2023-01-012023-09-30 0000899923 2023-07-012023-09-30 0000899923 2024-07-012024-09-30 0000899923 us-gaap:CommonStockMember 2022-12-31 0000899923 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000899923 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000899923 us-gaap:RetainedEarningsMember 2022-12-31 0000899923 2022-12-31 0000899923 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-03-31 0000899923 2023-01-012023-03-31 0000899923 us-gaap:RetainedEarningsMember 2023-01-012023-03-31 0000899923 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-012023-03-31 0000899923 us-gaap:CommonStockMember 2023-03-31 0000899923 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000899923 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000899923 us-gaap:RetainedEarningsMember 2023-03-31 0000899923 2023-03-31 0000899923 us-gaap:AdditionalPaidInCapitalMember 2023-04-012023-06-30 0000899923 2023-04-012023-06-30 0000899923 us-gaap:RetainedEarningsMember 2023-04-012023-06-30 0000899923 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-012023-06-30 0000899923 us-gaap:CommonStockMember 2023-06-30 0000899923 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000899923 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000899923 us-gaap:RetainedEarningsMember 2023-06-30 0000899923 2023-06-30 0000899923 us-gaap:AdditionalPaidInCapitalMember 2023-07-012023-09-30 0000899923 us-gaap:RetainedEarningsMember 2023-07-012023-09-30 0000899923 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-07-012023-09-30 0000899923 us-gaap:CommonStockMember 2023-09-30 0000899923 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000899923 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0000899923 us-gaap:RetainedEarningsMember 2023-09-30 0000899923 2023-09-30 0000899923 us-gaap:CommonStockMember 2023-12-31 0000899923 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000899923 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000899923 us-gaap:RetainedEarningsMember 2023-12-31 0000899923 2023-12-31 0000899923 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-03-31 0000899923 2024-01-012024-03-31 0000899923 us-gaap:RetainedEarningsMember 2024-01-012024-03-31 0000899923 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-012024-03-31 0000899923 us-gaap:CommonStockMember 2024-03-31 0000899923 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000899923 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000899923 us-gaap:RetainedEarningsMember 2024-03-31 0000899923 2024-03-31 0000899923 us-gaap:AdditionalPaidInCapitalMember 2024-04-012024-06-30 0000899923 2024-04-012024-06-30 0000899923 us-gaap:RetainedEarningsMember 2024-04-012024-06-30 0000899923 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-012024-06-30 0000899923 us-gaap:CommonStockMember 2024-06-30 0000899923 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000899923 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0000899923 us-gaap:RetainedEarningsMember 2024-06-30 0000899923 2024-06-30 0000899923 us-gaap:AdditionalPaidInCapitalMember 2024-07-012024-09-30 0000899923 us-gaap:RetainedEarningsMember 2024-07-012024-09-30 0000899923 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-07-012024-09-30 0000899923 us-gaap:CommonStockMember 2024-09-30 0000899923 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0000899923 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-09-30 0000899923 us-gaap:RetainedEarningsMember 2024-09-30 0000899923 mygn:HereditaryCancerTestingMemberus-gaap:NonUsMember 2024-07-012024-09-30 0000899923 mygn:HereditaryCancerTestingMember 2024-07-012024-09-30 0000899923 mygn:HereditaryCancerTestingMembercountry:US 2023-07-012023-09-30 0000899923 mygn:HereditaryCancerTestingMemberus-gaap:NonUsMember 2023-07-012023-09-30 0000899923 mygn:HereditaryCancerTestingMember 2023-07-012023-09-30 0000899923 mygn:TumorProfilingMembercountry:US 2024-07-012024-09-30 0000899923 mygn:TumorProfilingMemberus-gaap:NonUsMember 2024-07-012024-09-30 0000899923 mygn:TumorProfilingMember 2024-07-012024-09-30 0000899923 mygn:TumorProfilingMembercountry:US 2023-07-012023-09-30 0000899923 mygn:TumorProfilingMemberus-gaap:NonUsMember 2023-07-012023-09-30 0000899923 mygn:TumorProfilingMember 2023-07-012023-09-30 0000899923 mygn:PrenatalTestingMembercountry:US 2024-07-012024-09-30 0000899923 mygn:PrenatalTestingMemberus-gaap:NonUsMember 2024-07-012024-09-30 0000899923 mygn:PrenatalTestingMember 2024-07-012024-09-30 0000899923 mygn:PrenatalTestingMembercountry:US 2023-07-012023-09-30 0000899923 mygn:PrenatalTestingMemberus-gaap:NonUsMember 2023-07-012023-09-30 0000899923 mygn:PrenatalTestingMember 2023-07-012023-09-30 0000899923 mygn:PharmacogenomicsMembercountry:US 2024-07-012024-09-30 0000899923 mygn:PharmacogenomicsMemberus-gaap:NonUsMember 2024-07-012024-09-30 0000899923 mygn:PharmacogenomicsMember 2024-07-012024-09-30 0000899923 mygn:PharmacogenomicsMembercountry:US 2023-07-012023-09-30 0000899923 mygn:PharmacogenomicsMemberus-gaap:NonUsMember 2023-07-012023-09-30 0000899923 mygn:PharmacogenomicsMember 2023-07-012023-09-30 0000899923 country:US 2024-07-012024-09-30 0000899923 us-gaap:NonUsMember 2024-07-012024-09-30 0000899923 country:US 2023-07-012023-09-30 0000899923 us-gaap:NonUsMember 2023-07-012023-09-30 0000899923 mygn:HereditaryCancerTestingMembercountry:US 2024-01-012024-09-30 0000899923 mygn:HereditaryCancerTestingMemberus-gaap:NonUsMember 2024-01-012024-09-30*

*0000899923 mygn:HereditaryCancerTestingMember 2024-01-012024-09-30 0000899923 mygn:HereditaryCancerTestingMembercountry:US 2023-01-012023-09-30 0000899923 mygn:HereditaryCancerTestingMemberus-gaap:NonUsMember 2023-01-012023-09-30 0000899923 mygn:HereditaryCancerTestingMember 2023-01-012023-09-30 0000899923 mygn:TumorProfilingMembercountry:US 2024-01-012024-09-30 0000899923 mygn:TumorProfilingMemberus-gaap:NonUsMember 2024-01-012024-09-30 0000899923 mygn:TumorProfilingMember 2024-01-012024-09-30 0000899923 mygn:TumorProfilingMembercountry:US 2023-01-012023-09-30 0000899923 mygn:TumorProfilingMemberus-gaap:NonUsMember 2023-01-012023-09-30 0000899923 mygn:TumorProfilingMember 2023-01-012023-09-30 0000899923 mygn:PrenatalTestingMembercountry:US 2024-01-012024-09-30 0000899923 mygn:PrenatalTestingMemberus-gaap:NonUsMember 2024-01-012024-09-30 0000899923 mygn:PrenatalTestingMember 2024-01-012024-09-30 0000899923 mygn:PrenatalTestingMembercountry:US 2023-01-012023-09-30 0000899923 mygn:PrenatalTestingMemberus-gaap:NonUsMember 2023-01-012023-09-30 0000899923 mygn:PrenatalTestingMember 2023-01-012023-09-30 0000899923 mygn:PharmacogenomicsMembercountry:US 2024-01-012024-09-30 0000899923 mygn:PharmacogenomicsMemberus-gaap:NonUsMember 2024-01-012024-09-30 0000899923 mygn:PharmacogenomicsMember 2024-01-012024-09-30 0000899923 mygn:PharmacogenomicsMembercountry:US 2023-01-012023-09-30 0000899923 mygn:PharmacogenomicsMemberus-gaap:NonUsMember 2023-01-012023-09-30 0000899923 mygn:PharmacogenomicsMember 2023-01-012023-09-30 0000899923 country:US 2024-01-012024-09-30 0000899923 us-gaap:NonUsMember 2024-01-012024-09-30 0000899923 country:US 2023-01-012023-09-30 0000899923 us-gaap:NonUsMember 2023-01-012023-09-30 0000899923 mygn:MedicareMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GovernmentContractsConcentrationRiskMember 2024-01-012024-09-30 0000899923 mygn:MedicareMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GovernmentContractsConcentrationRiskMember 2024-07-012024-09-30 0000899923 mygn:MedicareMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GovernmentContractsConcentrationRiskMember 2023-07-012023-09-30 0000899923 mygn:MedicareMemberus-gaap:RevenueFromContractWithCustomerMemberus-gaap:GovernmentContractsConcentrationRiskMember 2023-01-012023-09-30 0000899923 mygn:MedicareMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember 2024-01-012024-09-30 0000899923 mygn:MedicareMemberus-gaap:AccountsReceivableMemberus-gaap:CustomerConcentrationRiskMember 2023-01-012023-12-31 0000899923 us-gaap:CashMember 2023-12-31 0000899923 us-gaap:CashEquivalentsMember 2023-12-31 0000899923 us-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000899923 us-gaap:MunicipalBondsMember 2023-12-31 0000899923 us-gaap:FairValueInputsLevel2Member 2024-09-30 0000899923 us-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember 2023-12-31 0000899923 us-gaap:FairValueInputsLevel2Memberus-gaap:MoneyMarketFundsMember 2023-12-31 0000899923 us-gaap:FairValueInputsLevel3Memberus-gaap:MoneyMarketFundsMember 2023-12-31 0000899923 us-gaap:MoneyMarketFundsMember 2023-12-31 0000899923 us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000899923 us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000899923 us-gaap:FairValueInputsLevel3Memberus-gaap:CorporateDebtSecuritiesMember 2023-12-31 0000899923 us-gaap:FairValueInputsLevel1Memberus-gaap:MunicipalBondsMember 2023-12-31 0000899923 us-gaap:FairValueInputsLevel2Memberus-gaap:MunicipalBondsMember 2023-12-31 0000899923 us-gaap:FairValueInputsLevel3Memberus-gaap:MunicipalBondsMember 2023-12-31 0000899923 mygn:ContingentConsiderationMemberus-gaap:FairValueInputsLevel1Member 2023-12-31 0000899923 mygn:ContingentConsiderationMemberus-gaap:FairValueInputsLevel2Member 2023-12-31 0000899923 mygn:ContingentConsiderationMemberus-gaap:FairValueInputsLevel3Member 2023-12-31 0000899923 mygn:ContingentConsiderationMember 2023-12-31 0000899923 us-gaap:FairValueInputsLevel1Member 2023-12-31 0000899923 us-gaap:FairValueInputsLevel2Member 2023-12-31 0000899923 us-gaap:FairValueInputsLevel3Member 2023-12-31 0000899923 mygn:GatewayGenomicsLLCMember 2024-09-30 0000899923 us-gaap:LeaseholdImprovementsMember 2024-09-30 0000899923 us-gaap:LeaseholdImprovementsMember 2023-12-31 0000899923 us-gaap:EquipmentMember 2024-09-30 0000899923 us-gaap:EquipmentMember 2023-12-31 0000899923 us-gaap:LeaseholdImprovementsMember 2023-01-012023-09-30 0000899923 mygn:PharmacogenomicsMember 2024-09-30 0000899923 mygn:PharmacogenomicsMember 2020-10-01 0000899923 us-gaap:DiscontinuedOperationsDisposedOfBySaleMemberus-gaap:DevelopedTechnologyRightsMembermygn:EndoPredictMember 2024-09-30 0000899923 us-gaap:DevelopedTechnologyRightsMember 2024-09-30 0000899923 us-gaap:ComputerSoftwareIntangibleAssetMember 2024-09-30 0000899923 mygn:ComputerSoftwareInProcessIntangibleAssetMember 2024-09-30 0000899923 us-gaap:CustomerRelationshipsMember 2024-09-30 0000899923 us-gaap:TrademarksMember 2024-09-30 0000899923 us-gaap:DevelopedTechnologyRightsMember 2023-12-31 0000899923 us-gaap:ComputerSoftwareIntangibleAssetMember 2023-12-31 0000899923 mygn:ComputerSoftwareInProcessIntangibleAssetMember 2023-12-31 0000899923 us-gaap:CustomerRelationshipsMember 2023-12-31 0000899923 us-gaap:TrademarksMember 2023-12-31 0000899923 us-gaap:RevolvingCreditFacilityMembermygn:ABLFacilityMemberus-gaap:LineOfCreditMember 2023-06-30 0000899923 us-gaap:RevolvingCreditFacilityMembermygn:ABLFacilityMemberus-gaap:LineOfCreditMember 2023-10-31 0000899923 us-gaap:RevolvingCreditFacilityMembermygn:ABLFacilityMemberus-gaap:LineOfCreditMember 2024-09-30 0000899923 us-gaap:RevolvingCreditFacilityMembermygn:ABLFacilityMemberus-gaap:LineOfCreditMember 2023-12-31 0000899923 us-gaap:RevolvingCreditFacilityMembermygn:ABLFacilityMemberus-gaap:LineOfCreditMember 2024-01-012024-09-30 0000899923 us-gaap:RevolvingCreditFacilityMembermygn:ABLFacilityMemberus-gaap:LineOfCreditMembermygn:NewYorkFederalReserveBankRateMembermygn:VariableRateScenarioOneMember 2024-01-012024-09-30 0000899923 us-gaap:RevolvingCreditFacilityMembermygn:ABLFacilityMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrMembermygn:VariableRateScenarioOneMember 2024-01-012024-09-30 0000899923 srt:MinimumMemberus-gaap:RevolvingCreditFacilityMembermygn:ABLFacilityMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrMembermygn:VariableRateScenarioOneMember 2024-01-012024-09-30 0000899923 srt:MaximumMemberus-gaap:RevolvingCreditFacilityMembermygn:ABLFacilityMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrMembermygn:VariableRateScenarioOneMember 2024-01-012024-09-30 0000899923 us-gaap:RevolvingCreditFacilityMembermygn:ABLFacilityMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrMembermygn:VariableRateScenarioTwoMember 2024-01-012024-09-30 0000899923 srt:MinimumMemberus-gaap:RevolvingCreditFacilityMembermygn:ABLFacilityMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrMembermygn:VariableRateScenarioTwoMember 2024-01-012024-09-30 0000899923 srt:MaximumMemberus-gaap:RevolvingCreditFacilityMembermygn:ABLFacilityMemberus-gaap:LineOfCreditMemberus-gaap:SecuredOvernightFinancingRateSofrMembermygn:VariableRateScenarioTwoMember 2024-01-012024-09-30 0000899923 us-gaap:RevolvingCreditFacilityMembermygn:ABLFacilityMemberus-gaap:LineOfCreditMembermygn:ABRFloorMembermygn:VariableRateScenarioTwoMember 2024-01-012024-09-30 0000899923 srt:MinimumMemberus-gaap:RevolvingCreditFacilityMembermygn:ABLFacilityMemberus-gaap:LineOfCreditMember 2024-01-012024-09-30 0000899923 srt:MaximumMemberus-gaap:RevolvingCreditFacilityMembermygn:ABLFacilityMemberus-gaap:LineOfCreditMember 2024-01-012024-09-30 0000899923 mygn:ABLFacilityMemberus-gaap:LineOfCreditMember 2024-01-012024-09-30 0000899923 srt:MaximumMemberus-gaap:RevolvingCreditFacilityMembermygn:ABLFacilityMemberus-gaap:LineOfCreditMember 2024-09-30 0000899923 us-gaap:RevolvingCreditFacilityMemberus-gaap:LineOfCreditMember 2024-01-012024-09-30 0000899923 srt:MinimumMemberus-gaap:RevolvingCreditFacilityMembermygn:ABLFacilityMemberus-gaap:LineOfCreditMember 2024-09-30 0000899923 mygn:RaygenIncVersusMyriadWomensHealthIncMembermygn:SettledLitigationContingentPaymentsMember 2023-10-232023-10-23 0000899923 mygn:RaygenIncVersusMyriadWomensHealthIncMembermygn:SettledLitigationContingentPaymentsMember 2023-10-23 0000899923 mygn:RaygenIncVersusMyriadWomensHealthIncMembermygn:SettledLitigationContingentPaymentsMembermygn:FirstInstallmentMember 2023-10-232023-10-23 0000899923 mygn:RaygenIncVersusMyriadWomensHealthIncMembermygn:SettledLitigationContingentPaymentsMembermygn:SecondInstallmentMember 2023-10-232023-10-23 0000899923 mygn:RaygenIncVersusMyriadWomensHealthIncMembermygn:SettledLitigationContingentPaymentsMembermygn:ThirdInstallmentMember 2023-10-232023-10-23 0000899923 mygn:RaygenIncVersusMyriadWomensHealthIncMembermygn:SettledLitigationContingentPaymentsMembermygn:FourthInstallmentMember 2023-10-232023-10-23 0000899923 mygn:RaygenIncVersusMyriadWomensHealthIncMembermygn:SettledLitigationContingentPaymentsMembermygn:FifthInstallmentMember 2023-10-232023-10-23 0000899923 mygn:RaygenIncVersusMyriadWomensHealthIncMembermygn:SettledLitigationNonContingentPaymentsMember 2023-10-232023-10-23 0000899923 mygn:RaygenIncVersusMyriadWomensHealthIncMembermygn:SettledLitigationNonContingentPaymentsMember 2023-10-23 0000899923 mygn:RaygenIncVersusMyriadWomensHealthIncMembermygn:SettledLitigationNonContingentPaymentsMember 2024-09-30 0000899923 mygn:RaygenIncVersusMyriadWomensHealthIncMembermygn:SettledLitigationNonContingentPaymentsMembermygn:FirstInstallmentMember 2023-10-232023-10-23 0000899923 mygn:RaygenIncVersusMyriadWomensHealthIncMembermygn:SettledLitigationNonContingentPaymentsMembermygn:SecondInstallmentMember 2023-10-232023-10-23 0000899923 mygn:RaygenIncVersusMyriadWomensHealthIncMember 2024-09-30 0000899923 mygn:TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember 2023-06-01 0000899923 mygn:TwoThousandSeventeenEmployeeDirectorAndConsultantEquityIncentivePlanMember 2024-09-30 0000899923 srt:MinimumMemberus-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-09-30 0000899923 srt:MaximumMemberus-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-09-30 0000899923 mygn:NonEmployeeDirectorMembermygn:OptionsAndRestrictedStockUnitsMember 2024-01-012024-09-30 0000899923 us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheOneMember 2024-01-012024-09-30 0000899923 us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheThreeMember 2024-01-012024-09-30 0000899923 us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedCompensationAwardTrancheTwoMember 2024-01-012024-09-30 0000899923 us-gaap:RestrictedStockUnitsRSUMember 2024-01-012024-09-30 0000899923 us-gaap:RestrictedStockUnitsRSUMember 2023-12-31 0000899923 us-gaap:RestrictedStockUnitsRSUMember 2024-09-30 0000899923 mygn:EmployeeStockPurchasePlanTwentyTwelveMember 2021-09-232021-09-23 0000899923 mygn:EmployeeStockPurchasePlanTwentyTwelveMember 2024-01-012024-09-30 0000899923 mygn:EmployeeStockPurchasePlanTwentyTwelveMember 2024-07-012024-09-30 0000899923 mygn:EmployeeStockPurchasePlanTwentyTwelveMember 2023-07-012023-09-30 0000899923 mygn:EmployeeStockPurchasePlanTwentyTwelveMember 2023-01-012023-09-30 0000899923 us-gaap:CostOfSalesMember 2024-07-012024-09-30 0000899923 us-gaap:CostOfSalesMember 2023-07-012023-09-30 0000899923 us-gaap:CostOfSalesMember 2024-01-012024-09-30 0000899923 us-gaap:CostOfSalesMember 2023-01-012023-09-30 0000899923 us-gaap:ResearchAndDevelopmentExpenseMember 2024-07-012024-09-30 0000899923 us-gaap:ResearchAndDevelopmentExpenseMember 2023-07-012023-09-30 0000899923 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-012024-09-30 0000899923 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-012023-09-30 0000899923 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-07-012024-09-30 0000899923 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-07-012023-09-30 0000899923 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2024-01-012024-09-30 0000899923 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2023-01-012023-09-30 0000899923 srt:MaximumMemberus-gaap:PendingLitigationMember 2024-05-032024-05-03 0000899923 us-gaap:PendingLitigationMember 2024-09-30 0000899923 srt:MinimumMember 2024-09-30 0000899923 srt:MaximumMember 2024-09-30 0000899923 mygn:WestSaltLakeCityMember 2023-09-30 0000899923 mygn:WestSaltLakeCityMember 2024-09-30 0000899923 us-gaap:AccumulatedTranslationAdjustmentMember 2023-12-31 0000899923 us-gaap:AccumulatedTranslationAdjustmentMember 2024-01-012024-09-30 0000899923 us-gaap:AccumulatedTranslationAdjustmentMember 2024-09-30 0000899923 us-gaap:DiscontinuedOperationsDisposedOfBySaleMembermygn:EndoPredictMember 2024-08-01 0000899923 us-gaap:DiscontinuedOperationsDisposedOfBySaleMembermygn:EndoPredictMember 2024-01-012024-09-30 shares iso4217:USD iso4217:USD shares mygn:segment pure mygn:installment mygn:day utr:sqftfalse0000899923--12-312024Q3http://www.myriad.com/20240930#TestingMemberhttp://www.myriad.com/20240930#TestingMemberhttp://www.myriad.com/20240930#TestingMemberhttp

26000000.0-26000000.0-500000-500000900000141880000-4200000-65550000076000000.025000002500000145000001450000-36700000-36700000200000200000900000143580000-4000000.0-692200000740500000-3000000.0-3000000.012400000124000000-22100000-22100000390000039000009000001445200000-100000-7143000007317000000-84800000-232100000464000004680000067000008600000389000003030000-3000000.0-17000001200000280000-80000000-15000001360000003100000022000002000000.03000000.046000001800000127000001370000049000005000000.0100000-20000020000002000000-16300000580000022000000-135000008660000-15300000-562000001540000053200000840000066000008800000900000.0103700000-6000000.043900000300000.00122000007300000100000000.040000000.010000000.000160000030000010000-95000003100000.0-300000-100000-311000001860000014090000066400000109800000850000000.0BASIS OF PRESENTATION Myriad Genetics, Inc. (together with its subsidiaries, the "Company" or "Myriad") is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower health care costs. Myriad provides insights that help people take control of their health and enable healthcare providers to better detect, treat, and prevent disease. The Company currently operates as a single reporting segment. The Company's principal executive office is located in Salt Lake City, Utah. The accompanying Condensed Consolidated Financial Statements for the Company have been prepared in accordance with United States ("U.S.") generally accepted accounting principles ("GAAP") for interim financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission ("SEC"). All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. The accompanying Condensed Consolidated Financial Statements should be read in conjunction with the Company's audited Consolidated Financial Statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 (the "Form 10-K"). The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. The Company has historically experienced seasonality in its business. The quarters ending March 31 and September 30 are typically weaker due to the annual reset of patient deductibles in the beginning of each calendar year and vacation schedules in the summer. The quarter ending December 31 is typically stronger due to increased demand as patients meet their deductibles throughout the year. Seasonal patterns were disrupted in recent years as a result of the COVID pandemic and certain other factors, but the Company believes it has experienced the impacts of seasonality in the third quarter 2024. Additionally, operating results for the three and nine months ended September 30, 2024 may not necessarily be indicative of results to be expected for any other interim period or for the full year. Recent Accounting Pronouncements In November 2023, the Financial Accounting Standards Board ("FASB") issued accounting standards update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which enhances the disclosures required for reportable segments in annual and interim consolidated financial statements. ASU 2023-07 is effective for the Company for annual reporting periods beginning after December 15, 2023 and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2023-07 on its segment disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires enhanced income tax disclosures, including disaggregation of information on the rate reconciliation table and disaggregated information related to income taxes paid. The amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact of ASU 2023-09 on its income tax disclosures. Reclassifications Certain prior period amounts have been reclassified to conform with the current period presentation. The reclassifications have no impact on the Company's total assets, total liabilities, stockholders' equity, or cash flows from operations. The accompanying Condensed Consolidated Financial Statements for the Company have been prepared in accordance with United States ("U.S.") generally accepted accounting principles ("GAAP") for interim financial information and pursuant to the applicable rules and regulations of the Securities and Exchange Commission ("SEC"). All intercompany accounts and transactions have been eliminated in consolidation. In the opinion of management, the accompanying financial statements contain all adjustments (consisting of normal and recurring accruals) necessary to present fairly all financial statements in accordance with GAAP. The accompanying Condensed Consolidated Financial Statements should be read in conjunction with the Company's audited Consolidated Financial Statements and notes thereto included in the Company's Annual Report on Form 10-K for the year ended December 31, 2023 (the "Form 10-K"). The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of revenue and expenses during the reporting period. The Company has historically experienced seasonality in its business. The quarters ending March 31 and September 30 are typically weaker due to the annual reset of patient deductibles in the beginning of each calendar year and vacation schedules in the summer. The quarter ending December 31 is typically stronger due to increased demand as patients meet their deductibles throughout the year. Seasonal patterns were disrupted in recent years as a result of the COVID pandemic and certain other factors, but the Company believes it has experienced the impacts of seasonality in the third quarter 2024. Additionally, operating results for the three and nine months ended September 30, 2024 may not necessarily be indicative of results to be expected for any other interim period or for the full year. Recent Accounting Pronouncements In November 2023, the Financial Accounting Standards Board ("FASB") issued accounting standards update ("ASU") 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which enhances the disclosures required for reportable segments in annual and interim consolidated financial statements. ASU 2023-07 is effective for the Company for annual reporting periods beginning after December 15, 2023 and for interim periods within fiscal years beginning after December 15, 2024. Early adoption is permitted. The Company is currently evaluating the impact of ASU 2023-07 on its segment disclosures. In December 2023, the FASB issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, which requires enhanced income tax disclosures, including disaggregation of information on the rate reconciliation table and disaggregated information related to income taxes paid. The amendments in ASU 2023-09 are effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact of ASU 2023-09 on its income tax disclosures. Reclassifications Certain prior period amounts have been reclassified to conform with the current period presentation. The reclassifications have no impact on the Company's total assets, total liabilities, stockholders' equity, or cash flows from operations. REVENUE The Company primarily generates revenue by performing genetic testing. Testing revenues are primarily derived from the following categories of products: Hereditary Cancer (MyRisk, BRACAnalysis, BRACAnalysis CDx), Tumor Profiling (MyChoice CDx, Prolaris, Precise Tumor, and EndoPredict), Prenatal (Foresight, Prequel, and SneakPeek), and Pharmacogenomics (GeneSight). Revenue is recorded at the estimated transaction price. The Company has determined that the communication of test results indicates transfer of control for revenue recognition purposes. The following table presents detail regarding the composition of the Company's total revenue by product type and by geographical region, either U.S. or rest of world ("RoW"): <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="36" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-bottom:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">U.S.</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">RoW</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">U.S.</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">RoW</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#ceeeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Testing revenues:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Hereditary Cancer</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">78.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">12.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">90.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">75.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">11.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">86.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Tumor Profiling</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">26.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">31.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">22.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">30.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Prenatal</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">43.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">43.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">39.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">39.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Pharmacogenomics</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">47.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">47.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">35.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">35.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total revenue</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">196.0 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">17.3 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">213.3 </td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td

<table>
<tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt">

align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">102.9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none">

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In accordance with ASC 606, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts that are one year or less, as the revenue is expected to be recognized within the next year. Furthermore, the Company has elected not to disclose the aggregate amount of the transaction price allocated to remaining performance obligations for its contracts wherein the Company's right to payment is in an amount that directly corresponds with the value of the Company's performance to date. In determining the transaction price, the Company includes an estimate of the expected amount of consideration to be received. The Company applies this method consistently for similar contracts when estimating the effect of any uncertainty on an amount of variable consideration to which it will be entitled. An estimate of transaction price does not include any estimated amount of variable consideration that is constrained. In addition, the Company considers all the information (historical, current, and forecast) that is reasonably available to identify possible consideration amounts. In determining the expected value, the Company considers the probability of the variable consideration for each possible scenario. The Company also has significant experience with historical discount patterns and uses this experience to estimate transaction prices. The estimate of revenue is affected by, among other factors, assumptions for changes in payor mix, payor collections, current customer contractual requirements, experience with collections from third-party payors, and changes in medical policies. When assessing the total consideration for insurance carriers and patients, revenues are further constrained for estimated refunds. The Company reserves certain amounts in Accrued liabilities in the Company's Condensed Consolidated Balance Sheets in anticipation of requests for refunds of payments made previously by insurance carriers, which are accounted for as reductions in revenues in the Condensed Consolidated Statements of Operations and Comprehensive Income/Loss. Cash collections for certain tests delivered may differ from rates estimated due to changes in the estimated transaction price for contractual adjustments, obtaining updated information from payors and patients that was unknown at the time the performance obligation was met, settlements with third-party payors, or as a result of third-party payors disputing our bills or denying payment for tests that we have performed, among other reasons. As a result of this new information, the Company updates its estimate of the amounts to be recognized for previously delivered tests. During the three and nine months ended September 30, 2024, the Company recognized $8.6 million and $17.3 million, respectively, which resulted in $0.09 and $0.19 impact to earnings per share, respectively, for testing in which the performance obligation was met in prior periods, primarily due to a changes in the estimated transaction price. Additionally, during the nine months ended September 30, 2024, the Company recognized $3.0 million in revenue due to a retroactive coverage change by a payor for one of its prenatal products. For the three and nine months ended September 30, 2023, the Company recognized $7.1 million and $6.2 million in revenue, respectively, which resulted in a $0.07 and $0.06, respectively, impact to earnings per share for tests in which the performance obligation was met in prior periods, primarily driven by changes in the estimated transaction price. </div>The Company applies the practical expedient related to costs to obtain or fulfill a contract since the amortization period for such costs will be one year or less. Accordingly, no costs incurred to obtain or fulfill a contract have been capitalized. The Company also applies the practical expedient for not adjusting revenue recognized for the effects of the time value of money. This practical expedient has been elected because the Company collects very little cash from customers under payment terms and the vast majority of payment terms have a payback period of less than one year.<div style="margin-top:6pt;text-align:justify">The following table presents detail regarding the composition of the Company's total revenue by product type and by geographical region, either U.S. or rest of world ("RoW"):</div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.326%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.695%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.703%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="36" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended September 30,</td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="15" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">U.S.</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">RoW</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">U.S.</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">RoW</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Testing revenues:</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Hereditary Cancer</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">78.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">12.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">90.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">75.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">11.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">86.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Tumor Profiling</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">26.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">31.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">22.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">30.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Prenatal</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">43.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New

Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">43.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">39.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">39.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Pharmacogenomics</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">47.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">47.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">35.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">35.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none">

align:right;vertical-align:bottom">270.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">203.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">35.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">238.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Tumor Profiling</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">77.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">95.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">78.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">25.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">103.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom">Prenatal</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">131.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">132.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">110.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">111.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Pharmacogenomics</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">129.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">129.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">102.9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">102.9 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none">

and cash equivalents and accounts receivable. The Company limits its exposure to loss by placing its cash in financial institutions with high credit ratings. The Company's cash may consist of deposits held with banks that may at times exceed federally insured limits of $250,000 per customer. Substantially all of the Company's accounts receivable are with companies in the healthcare industry, U.S. and state governmental agencies, and individuals. The Company does not believe that receivables due from U.S. and state governmental agencies, such as Medicare, represent a credit risk since the related healthcare programs are funded by the U.S. and state governments.0.110.110.120.120.190.12MARKETABLE INVESTMENT SECURITIES<div style="margin-top:6pt;text-align:justify">At September 30, 2024, the Company had no investment securities outstanding. The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for debt securities classified as available-for-sale securities by major security type and class of security at December 31, 2023 were as follows:</div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amortized
cost</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gross
unrealized
holding
gains</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gross
unrealized
holding
losses</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Estimated
fair value</td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom">December 31, 2023</td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Cash and cash equivalents:</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">Cash</td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom">129.9 </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom">129.9 </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">Cash equivalents</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.2 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.2 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Total cash and cash equivalents</td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">132.1 </td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">132.1 </td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Available-for-sale:</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">Corporate bonds and notes</td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8.4 </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8.3 </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">Municipal bonds</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">141.0 </td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times

*New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:120%">(0.1)</td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">140.9 </td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify">The cost of a security sold, or amount reclassified out of Accumulated other comprehensive income or loss into Net loss, is determined based on the specific identification method. Additional information relating to fair value of marketable investment securities can be found in Note 4.</div>0The amortized cost, gross unrealized holding gains, gross unrealized holding losses, and fair value for debt securities classified as available-for-sale securities by major security type and class of security at December 31, 2023 were as follows:<div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:50.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Amortized
cost</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gross
unrealized
holding
gains</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gross
unrealized
holding
losses</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Estimated
fair value</td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom">December 31, 2023</td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Cash and cash equivalents:</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">Cash</td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom">129.9 </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cff0fc;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">129.9 </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">Cash equivalents</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.2 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.2 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Total cash and cash equivalents</td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">132.1 </td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">132.1 </td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Available-for-sale:</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">Corporate bonds and notes</td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8.4 </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8.3 </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">Municipal bonds</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom">Total</td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">141.0 </td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-*

align:bottom">$</td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom">140.9 </td><td style="background-color:#cff0fc;border-bottom:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 1299000001299000002200000220000013210000013210000084000000100000830000050000000500000141000000.00100000140900000FAIR VALUE MEASUREMENTS The fair value of the Company's financial instruments reflects the amounts that the Company estimates it will receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels: Level 1—quoted prices in active markets for identical assets and liabilities. Level 2—observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Some of the Company's marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities. Level 3—unobservable inputs. All of the Company's financial instruments are valued using quoted prices in active markets or based on other observable inputs. For Level 2 securities, the Company uses a third-party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application, and corroborative information. The fair value of the Company's long-term debt, which it considers a Level 2 measurement, is estimated using discounted cash flow analyses based on the Company's current estimated incremental borrowing rates for similar borrowing arrangements. The fair value of the Company's long-term debt is estimated to be $39.7 million at September 30, 2024.</div><div style="margin-top:6pt;text-align:justify">At September 30, 2024, the Company did not have any financial assets requiring fair value re-measurement. The following table sets forth the fair value of the financial assets and liabilities that the Company re-measures on a regular basis as of December 31, 2023:</div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="6" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top">December 31, 2023</td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div>Money market funds(a)</div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">2.2 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">2.2 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top">Corporate bonds and notes</td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8.3 </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8.3 </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top">Municipal bonds</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none">

*#000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(5.4)</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5.6 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>(a)</div></td><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Money market funds are primarily comprised of exchange traded funds and accrued interest.</div></td></tr></table></div><div style="margin-top:9pt;text-align:justify">The following table reconciles the change in the fair value of the contingent consideration during the periods presented:</div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Carrying
Amount</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at December 31, 2023</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5.4 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Change in fair value recognized in the Statements of Operations</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Payment of contingent consideration </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5.8)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Translation adjustments recognized in Other comprehensive loss</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Ending balance at September 30, 2024 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> For the Level 2 contingent consideration related to the acquisition of Gateway Genomics, LLC ("Gateway"), the Company reassesses the fair value of expected contingent consideration and the corresponding liability each reporting period using current financial or operating projections. As of September 30, 2024, the Company has estimated a fair value of $0 related to the Gateway contingent consideration as the achievement of the contingent consideration targets is not considered probable.</div><div style="margin-top:6pt;text-align:justify">The fair value of the Company's financial instruments reflects the amounts that the Company estimates it will receive in connection with the sale of an asset or pay in connection with the transfer of a liability in an orderly transaction between market participants at the measurement date (exit price). The fair value hierarchy prioritizes the use of inputs used in valuation techniques into the following three levels:</div><div style="margin-top:6pt;padding-left:36pt;text-align:justify">Level 1—quoted prices in active markets for identical assets and liabilities.</div><div style="margin-top:6pt;padding-left:36pt;text-align:justify">Level 2—observable inputs other than quoted prices in active markets for identical assets and liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Some of the Company's marketable securities primarily utilize broker quotes in a non-active market for valuation of these securities.</div><div style="margin-top:6pt;padding-left:36pt;text-align:justify">Level 3—unobservable inputs.</div><div style="margin-top:6pt;text-align:justify">All of the Company's financial instruments are valued using quoted prices in active markets or based on other observable inputs. For Level 2 securities, the Company uses a third-party pricing service which provides documentation on an ongoing basis that includes, among other things, pricing information with respect to reference data, methodology, inputs summarized by asset class, pricing application, and corroborative information. </div>The fair value of the Company's long-term debt, which it considers a Level 2 measurement, is estimated using discounted cash flow analyses based on the Company's current estimated incremental borrowing rates for similar borrowing arrangements.397000000The following table sets forth the fair value of the financial assets and liabilities that the Company re-measures on a regular basis as of December 31, 2023:<div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:2.262%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.999%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.602%"></td><td style="width:0.1%"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 1</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 2</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Level 3</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="6" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top">December 31, 2023</td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><div>Money market funds(a)</div></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">2.2 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">2.2 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top">Corporate bonds and notes</td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8.3 </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">8.3 </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top">Municipal bonds</td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-*

align:right;vertical-align:bottom">— </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="6" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:top">Contingent consideration</td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5.4)</td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5.4)</td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="6" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">Total</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2.2 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">8.8 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">(5.4)</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5.6 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> (a) </td><td colspan="24" style="padding:2px 1pt;text-align:left;vertical-align:bottom"> Money market funds are primarily comprised of exchange traded funds and accrued interest. </td></tr></table> 220000000220000008300000083000000500000005400000054000002200000880000054000005600000 The following table reconciles the change in the fair value of the contingent consideration during the periods presented: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Carrying
Amount</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Balance at December 31, 2023</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">5.4 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Change in fair value recognized in the Statements of Operations</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Payment of contingent consideration</div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(5.8)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Translation adjustments recognized in Other comprehensive loss</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Ending balance at September 30, 2024</div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 5400000050000058000001000000PROPERTY, PLANT, AND EQUIPMENT, NET The property, plant and equipment at September 30, 2024 and December 31, 2023 were as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.513%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Leasehold improvements</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">78.2 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">91.3 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Equipment</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">154.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">147.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Property, plant and equipment, gross</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">232.7 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">238.9 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less accumulated depreciation</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(117.3)

</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(119.9)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Property, plant and equipment, net</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">115.4 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">119.0 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The Company recorded depreciation during the respective periods as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine months ended
September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Depreciation expense</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4.8 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3.4 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">14.5 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">14.8 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> During the nine months ended September 30, 2023, the Company incurred $5.7 million of accelerated depreciation of leasehold improvements and equipment in connection with the Company's decision to cease the use of its former corporate headquarters in Salt Lake City, Utah, and transition corporate support operations to its new facility in west Salt Lake City. The Company formally assigned the previous corporate headquarters lease to a third party as of December 31, 2023. See Note 15 for further discussion.<div style="margin-top:9pt;text-align:justify">The property, plant and equipment at September 30, 2024 and December 31, 2023 were as follows:</div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.226%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.511%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.525%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.513%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Leasehold improvements</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">78.2 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">91.3 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Equipment</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">154.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">147.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Property, plant and equipment, gross</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">232.7 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">238.9 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Less accumulated depreciation</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(117.3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(119.9)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Property, plant and equipment, net</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">115.4 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-

serif;font-size:10pt;font-weight:400;line-height:120%">119.0 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The Company recorded depreciation during the respective periods as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine months ended
September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Depreciation expense</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">4.8 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">3.4 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">14.5 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">14.8 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
78200000913000001545000001476000002327000002389000001173000001199000001154000001190000000.048000003400000145000001480000057000000GOODWILL AND INTANGIBLE ASSETS Goodwill The changes in the carrying amount of goodwill for the nine months ended September 30, 2024 were as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Beginning balance</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">287.4 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Goodwill impairment</div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.8) </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Translation adjustments</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.3)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ending balance</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">286.3 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The Company recognized a goodwill impairment charge of $0.8 million during the nine months ended September 30, 2024 related to the goodwill allocated to the Myriad International reporting unit. The goodwill impairment charge is reflected in Goodwill and long-lived asset impairment charges in the Condensed Consolidated Statements of Operations. See Note 18 for further discussion. As of September 30, 2024, goodwill for the Pharmacogenomics reporting unit (formerly referred to as Mental Health) was approximately $121.0 million, which represents approximately 42.3% of total recorded goodwill. On November 1, 2024, UnitedHealthcare updated its medical policy for pharmacogenetic testing to no longer provide coverage for certain multi-gene panel pharmacogenetic tests, including the Company's GeneSight test, under its commercial and individual exchange benefit plans, effective January 1, 2025. The Company is still assessing the full impact of this policy change on its long-term forecasts; however, goodwill recorded in connection with this reporting unit may be at risk of impairment. The reporting unit was last quantitatively tested for goodwill impairment as of October 1, 2020, at which time the fair value of the reporting unit was in excess of the carrying value by 12%. As more information becomes available about the impact of the coverage decision by UnitedHealthcare, or if other adverse events occur, the Company may be required to record a goodwill impairment charge, which could have a material impact on the financial statements. See Item 2. Business Updates and Item 1A. Risk Factors for additional information. Intangible Assets Intangible assets consist of amortizable assets of developed technologies, internal-use software, customer relationships, and trademarks, as well as in-process internal-use software that is not yet being amortized. During the nine months ended September 30, 2024, the Company completed the sale of its EndoPredict business, including certain developed technologies with a net book value of approximately $13.1 million. See Note 18 for further discussion about the sale of the EndoPredict business.</div><div style="margin-top:9pt;text-align:justify">The following summarizes the amounts reported as intangible assets:</div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gross
Carrying
Amount</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated
Amortization</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Net</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">At September 30, 2024</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Developed technologies</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">603.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-

color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(316.9)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">286.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Internal-use software</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.5)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Internal-use software (in-process)</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Customer relationships</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.3)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Trademarks</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1.2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Total intangible assets </td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">631.4 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(318.9)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">312.5 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gross
Carrying
Amount</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated
Amortization</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Net</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">At December 31, 2023</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Developed technologies</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">626.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(295.3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">330.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"> Internal-use software </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.8 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Internal-use software (in-process) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Customer relationships</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.2)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Trademarks</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-

align:right;vertical-align:bottom">6.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.7)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Total intangible assets</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">645.8 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(296.3)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">349.5 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify">The Company recorded amortization expense during the respective periods for these intangible assets as follows:</div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine months ended
September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom">Amortization of intangible assets</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10.5 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10.7 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">31.9 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">32.0 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify">The changes in the carrying amount of goodwill for the nine months ended September 30, 2024 were as follows:</div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:87.204%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.596%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Total</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Beginning balance</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">287.4 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Goodwill impairment </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.8)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Translation adjustments</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.3)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Ending balance</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">286.3 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>2874000008000000-3000002863000008000001210000000.4230.1213100000<div style="margin-top:9pt;text-align:justify">The following summarizes the amounts reported as intangible assets:</div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gross
Carrying
Amount</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated
Amortization</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Net</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">At September 30, 2024</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Developed technologies</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">603.3 </td><td style="background-

color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(316.9)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">286.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Internal-use software</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.5)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Internal-use software (in-process)</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Customer relationships</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.3)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Trademarks</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1.2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Total intangible assets </td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">631.4 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(318.9)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">312.5 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gross
Carrying
Amount</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated
Amortization</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Net</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">At December 31, 2023</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Developed technologies</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">626.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(295.3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman';sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">330.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"> Internal-use software </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.8 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"> Internal-use software (in-process) </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Customer relationships</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.2)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-

serif;font-size:10pt;font-weight:400;line-height:120%">Trademarks</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.7)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Total intangible assets</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">645.8 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(296.3)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">349.5 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:9pt;text-align:justify">The following summarizes the amounts reported as intangible assets:</div><div style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gross
Carrying
Amount</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated
Amortization</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Net</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">At September 30, 2024</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Developed technologies</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">603.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(316.9)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">286.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Internal-use software</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.5)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Internal-use software (in-process)</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">18.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Customer relationships</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.3)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Trademarks</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1.2)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Total intangible assets </td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">631.4 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(318.9)</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">312.5 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Gross
Carrying
Amount</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Accumulated
Amortization</td><td colspan="3" style="padding:0 1pt"></td><td

colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Net</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">At December 31, 2023</td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Developed technologies</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">626.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">(295.3)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">330.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div>Internal-use software</div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.8 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div>Internal-use software (in-process)</div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">11.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top">Customer relationships</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.2)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Trademarks</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.7)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top">Total intangible assets</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">645.8 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(296.3)</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">349.5 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
603300000316900000286400000160000050000011000001880000001880000016000003000001300000610000012000004900000631400000318900000312500000626100

style="margin-top:9pt;text-align:justify">The Company recorded amortization expense during the respective periods for these intangible assets as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.192%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine months ended
September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom">Amortization of intangible assets</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10.5 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">10.7 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">31.9 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">32.0 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt

2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 10500000107000003190000032000000.0ACCRUED LIABILITIES The Company's accrued liabilities at September 30, 2024 and December 31, 2023 were as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Employee compensation and benefits</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">51.4 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">49.7 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued taxes payable</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Refunds payable and reserves</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Short-term contingent consideration</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued royalties</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Legal settlements </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Lease termination accrual </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other accrued liabilities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Total accrued liabilities</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">111.2 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">113.9 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The Company's accrued liabilities at September 30, 2024 and December 31, 2023 were as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.338%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Employee compensation and benefits</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">51.4 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">49.7 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued taxes payable</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">

height:120%">Refunds payable and reserves</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19.2 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Short-term contingent consideration</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Accrued royalties</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.6 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Legal settlements </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">6.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Lease termination accrual </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.4 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other accrued liabilities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">19.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">20.7 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom">Total accrued liabilities</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">111.2 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">113.9 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
514000004970000042000004600000192000002010000031000006600000530000060000000.060000000.0430000044000001950000020700000111200000113900000LONG-TERM DEBT On June 30, 2023, the Company entered into an asset-based revolving credit facility (the "ABL Facility") with an initial maximum principal amount of $90.0 million, with JPMorgan Chase Bank, N.A., as administrative agent and issuing bank, the other lender parties thereto, and certain of the Company's domestic subsidiaries (the "Guarantors"). On October 31, 2023, the Company entered into an amendment to the ABL Facility to increase the maximum principal amount of the available revolving line of credit by $25.0 million for a total maximum principal commitment of $115.0 million under the ABL Facility, which was effected through a new commitment provided by a new lender, Goldman Sachs Bank USA. The ABL Facility matures on June 30, 2026. The obligations of the Company are guaranteed by the Guarantors and the ABL Facility is secured by substantially all of the assets of the Company and the Guarantors. The Company had long-term debt of $40.0 million under the ABL Facility at September 30, 2024 and December 31, 2023, net of $1.0 million and $1.5 million of debt issuance costs, respectively. Proceeds from the ABL Facility were or will be used for the working capital needs and general corporate purposes of the Company and its subsidiaries. Availability under the ABL Facility is subject to a borrowing base, which is the lesser of (a) 85% of the Company's and the Guarantors' eligible accounts receivable plus certain cash held in a segregated and fully-blocked account with the administrative agent in an amount up to $20.0 million ("Eligible Cash") minus any reserves established by the administrative agent in accordance with the ABL Facility, and (b) the aggregate amount of cash collections from eligible accounts of the Company and the Guarantors for the 60 consecutive days most recently ended. Subject to certain conditions, the Company can freely withdraw cash from the Eligible Cash account, provided that any reduction in the Eligible Cash amount will have a corresponding reduction in the borrowing base under the ABL Facility. Loans outstanding under the ABL Facility will bear interest at a rate per annum equal to, at the option of the Company, either (a) the greatest of (i) the daily Prime Rate, (ii) the daily NYFRB Rate plus 0.5%, and (iii) the monthly Adjusted Term SOFR Rate (as defined below) plus 1.0% (the "ABR") plus an applicable margin ranging from 1.0% to 1.5% depending on the aggregate average unused availability under the ABL Facility during the prior quarter or (b) term Secured Overnight Financing Rate ("SOFR") for a tenor of one, three or six months (at the Company's election) plus 0.1% (the "Adjusted Term SOFR Rate") plus an applicable margin ranging from 2.0% to 2.5% depending on the average unused availability under the ABL Facility during the prior quarter, with an ABR floor of 1.0% and an Adjusted Term SOFR Rate floor of 0.0%. Under the ABL Facility, the undrawn fee ranges from 37.5 to 50 basis points based on the daily amount of the available revolving commitment. The weighted average interest rate for borrowings under the ABL Facility as of September 30, 2024 was 8.4%. The Company may elect to prepay all or any portion of the amounts owed prior to the maturity date without premium or penalty. The ABL Facility is also subject to customary mandatory prepayments with the proceeds of unpermitted indebtedness and upon the occurrence of an over-advance. Voluntary and mandatory prepayments and all other payments of the ABL Facility must be accompanied by payment of accrued interest on the principal amount repaid or prepaid. The ABL Facility contains customary loan terms, interest rates, representations and warranties and affirmative and negative covenants, in each case, subject to customary limitations, exceptions and exclusions. Covenants under the ABL Facility limit or restrict the Company and its subsidiaries' ability to incur liens, incur indebtedness, dispose of assets, make investments, make certain restricted payments, merge or consolidate, and enter into certain speculative hedging arrangements. The ABL Facility requires the Company and the Guarantors, on a consolidated basis, to maintain minimum liquidity of $60.0 million and minimum availability of $25.0 million at all times before achieving a fixed charge coverage ratio of 1.0 to 1.0 and thereafter, to maintain a fixed charge coverage ratio of 1.0 to 1.0 until achieving availability under the ABL Facility of greater than the greater of (a) $10.6 million and (b) 12.5% of the lesser of the maximum commitment amount and the borrowing base for a period of 30 consecutive days. As of September 30, 2024, availability under the ABL Facility was $48.8 million. In addition, the ABL Facility includes a number of customary events of default. If any event of default occurs (subject, in certain instances, to specified grace periods), the principal, premium, if any, interest, and any other monetary obligations on all the then-outstanding amounts under the ABL Facility may become due and payable immediately. Under the terms of the ABL Facility, if (i) an event of default has occurred and is continuing or (ii) availability under the ABL Facility is less than the greater of (a) $12.5 million and (b) 15% of the lesser of the maximum commitment amount and the borrowing base, the Company will become subject to cash dominion, upon which the administrative agent will apply funds credited to a collection account to first prepay any outstanding protective advances, second to prepay any revolving loans and third, to cash collateralize any outstanding letter of credit exposure. Such cash dominion period will end when availability has remained in excess of the greater of (i) $12.5 million and (ii) 15% of the lesser of the maximum commitment amount and the borrowing base for a period of 45 consecutive days and no event of default is continuing.
90000000.025000000115000000400000000.01000000.015000000.8520000000P60D0.0050.0100.0100.0150.0010.0200.0250.0100.0000.003750.00500.0846000000025000OTHER LONG-TERM LIABILITIES The Company's other long-term liabilities at September 30, 2024 and December 31, 2023 were as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Contingent consideration</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New

Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2.3 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Escrow liability</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Legal settlements</div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total other long-term liabilities</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">34.3 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">41.3 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> On October 23, 2023 (the "Effective Date"), the Company and Ravgen, Inc. ("Ravgen") entered into a settlement agreement pursuant to which the parties agreed to settle a pending lawsuit. Subject to the terms of the settlement agreement, the Company agreed to pay Ravgen a contingent payment of $21.25 million payable in five annual installments, with (1) the first installment of $5.0 million payable on the later of (a) 30 days after notification in writing by Ravgen of the successful conclusion in favor of Ravgen of all of Ravgen's litigations and patent reexaminations pending as of the Effective Date and (b) January 1, 2026 (the "Contingent Payment Date"), (2) the second installment of $5.0 million on the first anniversary of the Contingent Payment Date; (3) the third installment of $5.0 million on the second anniversary of the Contingent Payment Date; (4) the fourth installment of $5.0 million on the third anniversary of the Contingent Payment Date; and (5) $1.25 million on the fourth anniversary of the Contingent Payment Date. Additionally, the Company agreed to pay Ravgen a minimum of $12.75 million in three installment payments of which $7.75 million is outstanding as of September 30, 2024. The remaining payments will be made in two installments: (1) $5.0 million on or before October 31, 2024 and (2) $2.75 million on or before October 31, 2025. The Company has accrued $5.0 million in Accrued liabilities and $24.0 million in Other long-term liabilities for these payments in the Company's Condensed Consolidated Balance Sheet as of September 30, 2024.<div style="margin-top:9pt;text-align:justify">The Company's other long-term liabilities at September 30, 2024 and December 31, 2023 were as follows:</div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,
2024</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">December 31,
2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Contingent consideration</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">2.3 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Escrow liability</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Legal settlements</div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">24.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Other</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">7.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total other long-term liabilities</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">34.3 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">41.3 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
02300000750000075000002400000.024000000.028000007500000343000041300000212500005500000050000005000000050000001250000127500003775000050000000
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">PREFERRED AND COMMON STOCKHOLDERS' EQUITY The Company is authorized to issue up to 5.0 million shares of preferred stock, par value $0.01 per share. There were no shares of preferred stock outstanding at September 30, 2024. The Company is authorized to issue up to 150.0 million shares of common stock, par value $0.01 per share. There were 91.0 million shares of common stock issued and outstanding at September 30, 2024. Shares of common stock issued and outstanding <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td

style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Nine months ended
September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom">Beginning common stock issued and outstanding</td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">89.9 </td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">81.2 </td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plan</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.9 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Common stock issued and outstanding at end of period</td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">91.0 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">82.1 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Basic earnings per share is computed based on the weighted-average number of shares of common stock outstanding. Diluted earnings per share is computed based on the weighted-average number of shares of common stock, including the dilutive effect of common stock equivalents, outstanding. In periods when the Company has a net loss, stock awards are excluded from the calculation of diluted net loss per share as their inclusion would have an antidilutive effect. The following is a reconciliation of the denominators of the basic and diluted earnings per share ("EPS") computations: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine months ended
September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom">Denominator:</td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Weighted-average shares outstanding used to compute basic EPS</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">90.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">81.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">90.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">81.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom">Effect of dilutive shares</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Weighted-average shares outstanding and dilutive securities used to compute diluted EPS</td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">90.9 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">81.9 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">90.5 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">81.6 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Certain outstanding options and restricted stock units ("RSUs") were excluded from the computation of diluted earnings per share because the effect would have been anti-dilutive. These potential dilutive shares of common stock, which may be dilutive to future diluted earnings per share, are as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td

style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine months ended
September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom">Anti-dilutive options and RSUs excluded from EPS computation</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.9 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.3 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.9 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.3 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
5000000.00.010150000000.00.0191000000.091000000.0 Shares of common stock issued and outstanding <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom">Nine months ended
September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom">Beginning common stock issued and outstanding</td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">89.9 </td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">81.2 </td><td style="background-color:#cff0fc;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plan</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.9 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Common stock issued and outstanding at end of period</td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">91.0 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">82.1 </td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
899000008990000081200000812000001100000900000910000000.091000000.0821000000821000000 The following is a reconciliation of the denominators of the basic and diluted earnings per share ("EPS") computations: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine months ended
September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom">Denominator:</td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Weighted-average shares outstanding used to compute basic EPS</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">90.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">81.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">90.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">81.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-

height:120%">Effect of dilutive shares</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cff0fc;padding:0 1pt"></td><td colspan="3" style="background-color:#cff0fc;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cff0fc;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cff0fc;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Weighted-average shares outstanding and dilutive securities used to compute diluted EPS</td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">90.9 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">81.9 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">90.5 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">81.6 </td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>
9090000081900000905000008160000000009090000081900000905000008160000000These potential dilutive shares of common stock, which may be dilutive to future diluted earnings per share, are as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.753%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.449%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine months ended
September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom">Anti-dilutive options and RSUs excluded from EPS computation</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.9 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.3 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.9 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.3 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 5900000053000005900000053000005STOCK-BASED COMPENSATION On November 30, 2017, the Company's stockholders approved the adoption of the 2017 Employee, Director and Consultant Equity Incentive Plan (as amended, the "2017 Plan"). The 2017 Plan allows the Company, under the direction of the Compensation and Human Capital Committee (the "CHCC") of the Board of Directors, to make grants of restricted stock and restricted stock unit awards to employees, consultants, and directors. Stockholders have subsequently approved amendments to the 2017 Plan increasing the shares available to grant thereunder, including most recently at the Company's annual meeting of stockholders held on June 1, 2023, when stockholders approved an amendment to the 2017 Plan to increase the aggregate number of shares of common stock available thereunder for the granting of awards by an additional 4.8 million shares. As of September 30, 2024, the Company had 2.3 million shares of common stock available for grant under the 2017 Plan. If an RSU awarded under the 2017 Plan is cancelled or forfeited without the issuance of shares of common stock, the unissued shares that were subject to the RSU will again be available for issuance pursuant to the 2017 Plan. The number of shares, terms, and vesting periods are generally determined by the Company's Board of Directors or the CHCC on an award-by-award basis. RSUs granted to employees generally vest either ratably over three or four years or as cliff vesting after three years either on the anniversary of the date on which the RSUs were granted or during the month in which such anniversary dates occur. The number of performance-based RSUs ("PSUs") awarded to certain employees may be increased or reduced based on certain additional performance and market metrics. RSUs granted to non-employee directors generally vest in full upon the earlier of the completion of one year of service following the date of the grant or the date of the next annual meeting of stockholders following such grant. Options granted to the Company's President and Chief Executive Officer as an inducement to his employment expire on August 13, 2027. The performance and market conditions associated with PSU awards granted during the nine months ended September 30, 2024 include vesting that is based on revenue targets (34% weighting), adjusted earnings per share targets (33% weighting), and relative total stockholder return (33% weighting) measured against the Nasdaq Health Care Index (IXHC) using the 20-trading day averages at the beginning and end of the measurement period. The measurement period for the relative total stockholder return metric is January 1, 2024 through December 31, 2026, and the revenue and adjusted earnings per share metrics will be measured based on fiscal year 2026 results. The Company estimates the likelihood of achievement of performance conditions for all PSU awards at the end of each period. To the extent those awards or portions thereof are considered probable of being achieved, such awards or portions thereof are expensed over the performance period. The portion of the awards pertaining to relative total stockholder return represent market conditions and, accordingly, the estimated fair value of such awards is recognized over the performance period. Stock Options A summary of the stock option activity for the nine months ended September 30, 2024 is as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(number of shares in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Number
of
Shares</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted
Average
Exercise
Price</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Options outstanding at December 31, 2023</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.7 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">13.38 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span

style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Options outstanding at September 30, 2024</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.7 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">13.38 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Options exercisable at September 30, 2024</td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">13.38 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> As of September 30, 2024, there was no unrecognized stock-based compensation expense. There were no options granted during the nine months ended September 30, 2024. Restricted Stock Units A summary of the RSU awards activity under the Company's equity plan and inducement awards, including PSU awards, for the nine months ended September 30, 2024 is as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(number of shares in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Number
of
Shares</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted
Average
Grant Date
Fair Value</td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom">RSUs unvested and outstanding at December 31, 2023</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.4 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">24.37 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">RSUs granted</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">22.46 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom">Less:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">RSUs vested</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1.5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">23.77 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">RSUs canceled</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.2)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">23.62 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">RSUs unvested and outstanding at September 30, 2024</td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.2 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">23.63 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Employee Stock Purchase Plan The Company also has an Employee Stock Purchase Plan that was initially approved by stockholders in 2012 and was amended and approved by the Board of Directors of the Company on September 23, 2021 and the stockholders on June 2, 2022 (the "Amended and Restated 2012 Purchase Plan"), under which 4.0 million shares of common stock were authorized for issuance under the Amended and Restated 2012 Purchase Plan. Shares are issued under the Amended and Restated 2012 Purchase Plan twice yearly at the end of each offering period and the number of shares that may be purchased by any participant during an offering period is limited to 5,000 shares. The first offering period of 2024 started on December 1, 2023 and ended on May 31, 2024. The second offering period of 2024 began on June 1, 2024 and will end on November 30, 2024. As of September 30, 2024, 1.1 million shares of common stock were available for issuance under the Amended and Restated 2012 Purchase Plan. Shares purchased under, and compensation expense associated with, the Amended and Restated 2012 Purchase Plan for the nine months ended September 30, 2024 and 2023 are as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended
September 30,</td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine months ended
September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"> Shares purchased under the plan </td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom">0.2</td></tr><tr><td

colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Plan compensation expense</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">1.7 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> Stock-Based Compensation Expense Stock-based compensation expense recognized and included in the Condensed Consolidated Statements of Operations and Comprehensive Loss was allocated as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine months ended
September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cost of testing revenue</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.3 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.4 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1.0 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1.1 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Research and development expense</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Selling, general, and administrative expense</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">33.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">26.3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Total stock-based compensation expense</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">12.4 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">11.6 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">38.9 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">30.3 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> As of September 30, 2024, there was $81.7 million of total unrecognized stock-based compensation expense related to RSUs that is expected to be recognized over a weighted-average period of 2.2 years. The Company recognizes forfeitures as they occur. In the event that a PSU is determined to be improbable of vesting, the Company records an adjustment to reverse all previously recognized expense associated with the equity award in the current period.4800000230000OP4YP3YP1Y0.340.330.3320 A summary of the stock option activity for the nine months ended September 30, 2024 is as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:1.0%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.036%"></td><td style="width:0.1%"></td></tr><tr><td

colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(number of shares in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Number
of
Shares</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted
Average
Exercise
Price</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Options outstanding at December 31, 2023</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.7 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">13.38 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Options outstanding at September 30, 2024</td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.7 </td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">13.38 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Options exercisable at September 30, 2024</td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">13.38 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>70000013.3870000013.3850000013.3800<div style="margin-top:6pt;text-align:justify">A summary of the RSU awards activity under the Company's equity plan and inducement awards, including PSU awards, for the nine months ended September 30, 2024 is as follows:</div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:73.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.034%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.036%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(number of shares in millions)</td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Number
of
Shares</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Weighted
Average
Grant Date
Fair Value</td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom">RSUs unvested and outstanding at December 31, 2023</td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.4 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">24.37 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">RSUs granted</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">22.46 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt;text-align:left;vertical-align:bottom">Less:</td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">RSUs vested</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1.5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">23.77 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cff0fc;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom">RSUs canceled</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(0.2)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">23.62 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">RSUs unvested and outstanding at September 30, 2024</td><td colspan="2" style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.2 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">23.63 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 440000024.37250000022.46150000023.7720000023.62520000023.6340000005000110000OShares purchased under, and compensation expense associated with, the Amended and Restated 2012 Purchase Plan for the nine months ended September 30, 2024 and 2023 are as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.461%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.604%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended
September 30,</td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine months ended
September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"> Shares purchased under the plan </td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid

#000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.2 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom">0.2</td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top">Plan compensation expense</td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">0.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom">1.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="padding:2px 0;text-align:right;vertical-align:bottom">1.7 </td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 00200000200000500000500000160000001700000 Stock-based compensation expense recognized and included in the Condensed Consolidated Statements of Operations and Comprehensive Loss was allocated as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.603%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Three months ended
September 30,</td><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine months ended
September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cost of testing revenue</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.3 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">0.4 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1.0 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1.1 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Research and development expense</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.6 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">4.4 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Selling, general, and administrative expense</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">10.0 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">33.5 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">26.3 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">Total stock-based compensation expense</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">12.4 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">11.6 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">38.9 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;padding:0 1pt"></td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">30.3 </td><td style="border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table>

300000040000001000000.011000001600000120000044000002900000105000001000000.033500000263000001240000011600000389000003030000081700000P2Y2M12l
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">INCOME TAXES<div
style="margin-top:9pt;text-align:justify">In order to determine the Company's quarterly provision for income taxes, the Company used an estimated annual effective tax rate that is based on expected annual income and statutory tax rates in the various jurisdictions in which the Company operates. Certain significant or unusual items are separately recognized in the quarter during which they occur and can be a source of variability in the effective tax rate from quarter to quarter. <span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the three months ended September 30, 2024, there was $0.9 million in income tax expense, or approximately (4.2)% of pre-tax loss, compared to $0.1 million income tax expense, or approximately (0.2)% of pre-tax loss, for the three months ended September 30, 2023. Income tax expense for the nine months ended September 30, 2024 was $0.4 million, or approximately (0.5)% of pre-tax loss, compared to an income tax expense of $2.2 million, or approximately (1.0)% of pre-tax loss, for the nine months ended September 30, 2023. For the three and nine months ended September 30, 2024 and 2023, the Company's effective tax rate differs from the U.S. federal statutory rate primarily due to the recognition of valuation allowances. Due to the Company's cumulative loss and the exhaustion of future taxable income from the reversal of taxable temporary differences, the Company's estimated annual effective tax rate for the current year includes a valuation allowance against the majority of the current year increase in deferred tax assets. 900000-0.042100000-0.002400000-0.0052200000-0.010COMMITMENTS AND CONTINGENCIES The Company is involved from time to time in various disputes, claims and legal actions, including class actions and other litigation, including the matters described below, arising in the ordinary course of business. Such actions may include allegations of negligence, product or professional liability or other legal claims, and could involve claims for substantial compensatory and punitive damages or claims for indeterminate amounts of damages. The Company is also involved, from time to time, in investigations by governmental agencies regarding its business which may result in adverse judgments, settlements, fines, penalties, injunctions or other relief. In addition, certain federal and state statutes, including the qui tam provisions of the federal False Claims Act, allow private individuals to bring lawsuits against healthcare companies on behalf of the government or private payors. The Company has received subpoenas from time to time related to billing or other practices based on the False Claims Act or other federal and state statutes, regulations or other laws. <span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company intends to defend its current litigation matters, but cannot provide any assurance as to the ultimate outcome or that an adverse resolution would not have a material adverse effect on its financial condition, results of operations or cash flows. The Company assesses legal contingencies to determine the degree of probability and range of possible loss for potential accrual in its financial statements. When evaluating legal contingencies, the Company may be unable to provide a meaningful estimate due to a number of factors, including the proceedings may be in early stages, there may be uncertainty as to the outcome of pending appeals or motions, there may be significant factual issues to be resolved, and there may be complex or novel legal theories to be presented. In addition, damages may not be specified or the damage amounts claimed may be unsupported, exaggerated or unrelated to possible outcomes, and therefore, such amounts are not a reliable indicator of potential liability.
As of September 30, 2024, except as noted below, the Company has not recorded any material accrual for loss contingencies associated with legal proceedings or other matters or determined that an unfavorable outcome is probable and reasonably estimable in accordance with ASC 450, Contingencies. However, it is possible that the ultimate resolution of legal proceedings or other matters, if unfavorable, may be material to the Company's results of operations, financial condition or cash flows. Further, in the event that damages from an unfavorable resolution of one or more of these proceedings exceed the aggregate amount of the coverage limits of the Company's insurance, or if the Company's insurance carriers disclaim coverage, the amounts payable by the Company could also have a material adverse impact on the Company's results of operations, financial condition or cash flows.
Stockholder Derivative Actions On August 9, 2021, a stockholder derivative complaint was filed in the Delaware Court of Chancery against the Company's former President and Chief Executive Officer, Mark C. Capone, its former Chief Financial Officer, R. Bryan Riggsbee, its former Executive Vice President of Clinical Development, Bryan M. Dechairo, and certain of the Company's current and former directors, Lawrence C. Best, Walter Gilbert, John T. Henderson, Heiner Dreismann, Dennis Langer, Lee N. Newcomer, S. Louise Phanstiel, and Colleen F. Reitan (collectively, the "Individual Defendants"), and the Company, as nominal defendant. The complaint is premised upon similar allegations that were set forth in the securities class action lawsuit that was settled and then dismissed by the U.S. District Court for the District of Utah in December 2023 (the "Securities Class Action"), including that the Individual Defendants made false and misleading statements regarding the Company's business and operations. The plaintiff, Donna Hickock, asserts breach of fiduciary duty and unjust enrichment claims against the Individual Defendants and seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged breaches, or disgorgement or restitution, from each of the Individual Defendants, plus interest. Plaintiff Hickock also seeks legal and other costs and fees relating to this action. On November 19, 2021, this action was stayed by the Delaware Court of Chancery pending the resolution of the Securities Class Action. On January 18, 2022, a stockholder derivative complaint was filed in the Delaware Court of Chancery against the Individual Defendants and the Company, as nominal defendant. The action is premised upon similar allegations as set forth in the Securities Class Action and the Hickock stockholder derivative action. The plaintiff, Esther Kogus, asserts that the Individual Defendants breached their fiduciary duties and also asserts unjust enrichment and aiding and abetting breaches of fiduciary duty claims against the Individual Defendants. Plaintiff Kogus seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged breaches and claims, and restitution from the Individual Defendants. On behalf of herself, plaintiff Kogus seeks legal and other costs and fees relating to this action. On March 3, 2022, the Delaware Court of Chancery consolidated the Hickock and Kogus derivative actions and stayed the consolidated action. On April 19, 2024, the Court of Chancery ordered that Leo Shumacher be substituted for Ms. Kogus as a plaintiff in this consolidated action. <div
style="margin-top:6pt;text-align:justify">On September 17, 2021, a stockholder derivative complaint was filed in the U.S. District Court in the District of Delaware against the Individual Defendants and the Company, as nominal defendant. The action is premised upon similar allegations as set forth in the Securities Class Action and Hickock stockholder derivative action. The plaintiff, Karen Marcey, asserts that the Individual Defendants violated U.S. securities laws and breached their fiduciary duties, and also asserts unjust enrichment, waste of corporate assets and insider trading claims against all or some of the Individual Defendants. Plaintiff Marcey seeks, on behalf of the Company, damages allegedly sustained by the Company as a result of the alleged violations and restitution from the Individual Defendants, plus interest and, on behalf of herself, legal and other costs and fees relating to this action. On January 4, 2022, this action was stayed by the U.S. District Court for the District of Delaware pending the resolution of the Securities Class Action. <div
style="margin-top:6pt;text-align:justify">On April 30, 2024, the parties across all of the foregoing stockholder derivative actions entered into a global stipulation of settlement to resolve the actions (the "Settlement"). On May 3, 2024, the parties submitted the Settlement to the Delaware Court of Chancery for approval. As part of the Settlement, (i) the Company agreed to adopt or implement certain corporate governance reforms; and (ii) the parties agreed that plaintiffs' counsel will apply to the court for an award of attorneys' fees and expenses not to exceed $0.95 million to be paid by the Company, and that the Individual Defendants and the Company will not oppose or object to the requested fee award. The Settlement contains no admission of liability, wrongdoing or responsibility by any of the parties. On August 6, 2024, the Delaware Court of Chancery held a hearing to consider the Settlement. The parties expect a ruling on or about November 26, 2024. The Company has accrued $0.95 million for the settlement of the stockholder derivative actions, which is included in Accrued liabilities in the Company's Condensed Consolidated Balance Sheet as of September 30, 2024. <div
style="margin-top:9pt;text-align:justify">Other Legal Proceedings From time to time, the Company receives recoupment requests from third-party payors for alleged overpayments. The Company disagrees with the contentions of the pending requests or has recorded an estimated reserve for the alleged overpayments.950000950000<span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:5.5pt">SUPPLEMENTAL CASH FLOW INFORMATION The Company's supplemental cash flow information for the nine months ended September 30, 2024 and 2023 are as follows: <div
style="margin-top:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td
style="width:1.0%"></td><td style="width:74.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td
style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td
style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td></tr><tr><td
colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span
style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cash paid for income taxes</td><td
style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1.8 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td
style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1.3 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash paid for interest</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Non-cash investing and financing activities: </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">

Change in operating lease right-of-use assets and lease liabilities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom">Operating lease right-of-use assets</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(0.3)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">8.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom">Operating lease liabilities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3.1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Non-cash adjustment to right-of-use assets and lease liabilities from lease modifications</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Purchases of property, plant and equipment and capitalization of internal-use software in accounts payable and accrued liabilities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported on the Condensed Consolidated Balance Sheets that agrees to the amounts included in the Condensed Consolidated Statements of Cash Flows. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,</td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash and cash equivalents</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">99.9 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">76.0 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Restricted cash</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total cash, cash equivalents, and restricted cash</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">109.8 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">85.0 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> The Company's supplemental cash flow information for the nine months ended September 30, 2024 and 2023 are as follows: <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom">Nine Months Ended September 30,</td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash paid for income taxes</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1.8 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom">1.3 </td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash paid for interest</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">1.3 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">0.8 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-

color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Non-cash investing and financing activities: </td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom">Change in operating lease right-of-use assets and lease liabilities</td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom">Operating lease right-of-use assets</td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(0.3)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">8.7 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom">Operating lease liabilities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(3.1)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.2 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Non-cash adjustment to right-of-use assets and lease liabilities from lease modifications</td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">3.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">— </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Purchases of property, plant and equipment and capitalization of internal-use software in accounts payable and accrued liabilities</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">2.5 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.1 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> 18000001300000130000080000-30000087000000-31000009200000310000002500000910000 The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported on the Condensed Consolidated Balance Sheets that agrees to the amounts included in the Condensed Consolidated Statements of Cash Flows. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,</td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash and cash equivalents</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">99.9 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">76.0 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Restricted cash</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total cash, cash equivalents, and restricted cash</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">109.8 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">85.0 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported on the Condensed Consolidated Balance Sheets that agrees to the amounts included in the Condensed Consolidated Statements of Cash Flows. <table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.046%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.599%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom">September 30,</td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom">(in millions)</td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2024</td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom">2023</td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Cash and cash equivalents</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">99.9 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">76.0 </td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px

0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Restricted cash</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.9 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-left:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">9.0 </td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom">Total cash, cash equivalents, and restricted cash</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">109.8 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-left:1pt solid #000;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">85.0 </td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table> 999000007600000.099000009000000.010980000085000000.0LEASES The Company leases certain office spaces and research and development laboratory facilities, vehicles, and office equipment with remaining lease terms ranging from approximately one to fourteen years. Operating leases are included in Operating lease right-of-use assets, Noncurrent operating lease liabilities, and Current maturities of operating lease liabilities in the Condensed Consolidated Balance Sheets. Finance leases are included in Other assets, Accrued liabilities, and Other long-term liabilities in the Condensed Consolidated Balance Sheets. Due to the increase in remote and hybrid work and the Company's need to ensure its facilities are designed to handle future growth, the Company has been executing on a multi-year strategy to reset its real estate footprint. As part of that strategy, during the nine months ended September 30, 2023, the Company took full possession of the remaining phases of the west Salt Lake City, Utah facility and recognized an additional $5.9 million right-of-use asset and corresponding lease liability, net of tenant improvement allowance not yet received. Also during the nine months ended September 30, 2023, the Company decided to cease the use of its former corporate headquarters in Salt Lake City and transition corporate support operations to its new facility in west Salt Lake City, and as of December 31, 2023, the Company had formally assigned the lease for its previous corporate headquarters in Salt Lake City to a third party. During the nine months ended September 30, 2024, the Company terminated the lease for one of its Salt Lake City, Utah facilities. As a result of the termination, the short-term lease liability of $3.1 million associated with the lease was removed from the Company's Condensed Consolidated Balance Sheets. The total net gain recognized in connection with the termination of the lease was $1.2 million, which is included in Selling, general, and administrative expense in the Condensed Consolidated Statements of Operations. During the nine months ended September 30, 2024, the Company also amended the lease for its west Salt Lake City, Utah headquarters to include approximately 63,000 additional square feet in anticipation of future operating needs. The lease has a term of 12 years, which is expected to commence in fiscal year 2026. Total future rent payments for the additional space are approximately $18.2 million.</div>P14Y5900000590000031000001200000630000P12Y18200000ACCUMULATED OTHER COMPREHENSIVE LOSS<div style="margin-top:6pt;text-align:justify">The functional currency of the Company's international subsidiaries is the local currency. For those subsidiaries, expenses denominated in the functional currency are translated into U.S. dollars using average exchange rates in effect during the period and assets and liabilities are translated using period-end exchange rates. The foreign currency translation adjustments are included in Accumulated other comprehensive loss as a separate component of Stockholders' equity.</div><div style="margin-top:6pt;text-align:justify">The following table shows the cumulative translation adjustments included in Accumulated other comprehensive loss (in millions):</div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Ending balance December 31, 2023</div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(3.7)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom">Period translation adjustments</td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1.5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Reclassification of cumulative translation adjustment to income upon sale or liquidation of certain foreign entities </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Ending balance September 30, 2024 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-align:justify">The following table shows the cumulative translation adjustments included in Accumulated other comprehensive loss (in millions):</div><div style="margin-top:6pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:83.256%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.544%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div>Ending balance December 31, 2023</div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom">(3.7)</td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Period translation adjustments </td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">(1.5)</td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Reclassification of cumulative translation adjustment to income upon sale or liquidation of certain foreign entities </td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom">5.1 </td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"> Ending balance September 30, 2024 </td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom">$</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom">(0.1)</td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table> -3700000-150000051000000-100000ACQUISITION On February 1, 2024, the Company acquired from Intermountain Health select assets from its Intermountain Precision Genomics ("IPG") laboratory business, including the Precise Tumor Test, the Precise Liquid Test, and IPG's CLIA-certified laboratory in St. George, Utah for an immaterial amount (the "Precise acquisition"). In connection with the Precise acquisition, the Company recognized a gain of $2.2 million, which is included in Other income in the Company's Condensed Consolidated Statements of Operations. 2200000DIVESTITURE On August 1, 2024, the Company completed the sale of its EndoPredict business to Eurobio Scientific ("Eurobio") for net cash consideration of $10.0 million, subject to customary closing adjustments, plus contingent consideration subject to certain earn-out conditions. The transaction was accounted for as a sale of business. The Company recognized a total net loss, including transaction expenses, of $12.4 million during the nine months ended September 30, 2024 in connection with this sale. The loss is included in Goodwill and long-lived asset impairment charges on the Company's Condensed Consolidated Statements of Operations. The recognized loss included the release of $4.4 million of foreign currency translation adjustments previously included in Accumulated other comprehensive income (loss). As part of the transaction, the Company licensed the rights from Eurobio to continue to sell EndoPredict as a laboratory developed test outside of the European Union and licensed to Eurobio the right to sell Prolaris in vitro diagnostic kits outside the U.S. 10000000012400000-44000000falsefalsefalsefalse

"